<SEC-DOCUMENT>0001104506-24-000026.txt : 20240808
<SEC-HEADER>0001104506-24-000026.hdr.sgml : 20240808
<ACCEPTANCE-DATETIME>20240808070005
ACCESSION NUMBER:		0001104506-24-000026
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		102
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240808
DATE AS OF CHANGE:		20240808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INSMED Inc
		CENTRAL INDEX KEY:			0001104506
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				541972729
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30739
		FILM NUMBER:		241185933

	BUSINESS ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		908-977-9900

	MAIL ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INSMED INC
		DATE OF NAME CHANGE:	20000128
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>insm-20240630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c55c6bb2-e1ff-4fc1-8df4-decd904b3b6b,g:5264b7b4-c672-47ab-b9d7-1b1bb5962c46,d:b049349da60d4a3c9beace0bfd291454-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:insm="http://www.insmed.com/20240630" xmlns:dei="http://xbrl.sec.gov/dei/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>insm-20240630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001104506</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-26">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-27">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-28">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-29">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-100">http://fasb.org/us-gaap/2024#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-101">http://fasb.org/us-gaap/2024#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-102">http://fasb.org/us-gaap/2024#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="c-7" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-103">http://fasb.org/us-gaap/2024#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="f-108">http://fasb.org/us-gaap/2024#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="f-109">http://fasb.org/us-gaap/2024#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="f-110">http://fasb.org/us-gaap/2024#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="c-7" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="f-111">http://fasb.org/us-gaap/2024#ProductMember</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-222" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-847">25.5384</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-223" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-848">0.0255384</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-224" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-849">0.0307692</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-289" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-999">0.0255384</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-294" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-1000">0.0307692</ix:nonFraction><ix:nonNumeric contextRef="c-295" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1027">352</ix:nonNumeric><ix:nonNumeric contextRef="c-297" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1028">203</ix:nonNumeric><ix:nonNumeric contextRef="c-299" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1029">357</ix:nonNumeric><ix:nonNumeric contextRef="c-301" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1030">250</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="insm-20240630.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="reportingunit"><xbrli:measure>insm:reportingUnit</xbrli:measure></xbrli:unit><xbrli:unit id="sale"><xbrli:measure>insm:sale</xbrli:measure></xbrli:unit><xbrli:unit id="day"><xbrli:measure>insm:day</xbrli:measure></xbrli:unit><xbrli:unit id="days"><xbrli:measure>insm:days</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">insm:VertuisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">insm:VertuisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">insm:AdrestiaTherapeuticsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">insm:AdrestiaTherapeuticsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:AlgaeneXIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-04</xbrli:startDate><xbrli:endDate>2021-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">insm:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">insm:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">insm:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:PriorityReviewVoucherMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:PriorityReviewVoucherMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">insm:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:PriorityReviewVoucherMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">insm:ARIKAYCEGlobalNetSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">insm:ARIKAYCEGlobalNetSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">insm:BrensocatibGlobalNetSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:EuropeAndTheRestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:EuropeAndTheRestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:EuropeAndTheRestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:EuropeAndTheRestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:RedemptionOfThe2025ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:AdrestiaTherapeuticsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:VertuisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:VertuisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:A2019IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-12</xbrli:startDate><xbrli:endDate>2020-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:A2019IncentivePlanThirdAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-15</xbrli:startDate><xbrli:endDate>2018-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">insm:AdrestiaTherapeuticsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">insm:VertuisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="insm:TriggeringEventAxis">insm:MilestoneEvent1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">insm:VertuisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="insm:TriggeringEventAxis">insm:MilestoneEvent2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">insm:VertuisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-04</xbrli:startDate><xbrli:endDate>2021-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:AlgaeneXIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:AlgaeneXIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-24</xbrli:startDate><xbrli:endDate>2021-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncAndAlgaeneXIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:A2025ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-07</xbrli:startDate><xbrli:endDate>2024-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:A2025ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:A2028ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:A2028ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-02</xbrli:startDate><xbrli:endDate>2024-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">insm:VertuisBioIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:A2028ConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">insm:S.NicoleSchaefferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">insm:S.NicoleSchaefferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">insm:S.NicoleSchaeffer2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">insm:S.NicoleSchaeffer2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">insm:MartinaFlammerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">insm:MartinaFlammerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">insm:MichaelSmithMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">insm:MichaelSmithMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib049349da60d4a3c9beace0bfd291454_1"></div><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric> </span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June&#160;30, 2024</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-30739</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">INSMED INC</ix:nonNumeric>ORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.306%"><tr><td style="width:1.0%"/><td style="width:48.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Virginia</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">54-1972729</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. employer identification no.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">700 US Highway 202/206</ix:nonNumeric>,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Bridgewater</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-11">New Jersey</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">08807</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">908</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">977-9900</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number including area code)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section12(b) of the Act:</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.196%"><tr><td style="width:1.0%"/><td style="width:36.831%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Trading symbols</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">INSM</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.306%"><tr><td style="width:1.0%"/><td style="width:48.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">o</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">o</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Smaller reporting company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">x</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of August&#160;2, 2024, there wer</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">e <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">171,849,103</ix:nonFraction> shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">of the registrant&#8217;s common stock outstanding.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib049349da60d4a3c9beace0bfd291454_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTER ENDED JUNE&#160;30, 2024 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.783%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_10">PART&#160;I.&#160;&#160;FINANCIAL&#160;INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_13">ITEM 1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_16">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_16">Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_16">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_16"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_16">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_16">, 2024 (unaudited) and December&#160;31, 202</a>3</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_16">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_19">Consolidated Statements of Comprehensive Loss (unaudited) for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_19">and six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_19"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_19">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_19">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_19"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_19">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_19">, 2024 and&#160;2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_19">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_22">Consolidated Statements of Shareholders' </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_22">Equity</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_22"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_22">(Deficit) </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_22">(unaudited) for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_22">and six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_22">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_22">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_22"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_22">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_22">, 2024 and 2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_22">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_25">Consolidated Statements of Cash Flows (unaudited) for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_25">six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_25"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_25">June</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_25"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_25">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_25">, 2024 and&#160;2023</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_25">7</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_28">Notes to Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_28">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_82">ITEM 2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_82">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_82">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_100">ITEM 3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_100">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_100">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_103">ITEM 4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_103">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_103">48</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_106">PART&#160;II.&#160;&#160;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_109">ITEM 1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_109">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_109">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_112">ITEM 1A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_112">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_112">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_115">ITEM 2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_115">Unregistered Sales of Equity Securities</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_115"> and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_115"> Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_115">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_118">ITEM 5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_118">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_118">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_124">ITEM 6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_124">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_124">51</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_127">SIGNATURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_127">52</a></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise indicates, references in this Form&#160;10-Q to &#8220;Insmed Incorporated&#8221; refers to Insmed Incorporated, a Virginia corporation, and the &#8220;Company,&#8221; &#8220;Insmed,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Insmed Incorporated together with its consolidated subsidiaries. INSMED, PULMOVANCE, and ARIKAYCE are trademarks of Insmed Incorporated. This Form&#160;10-Q also contains trademarks of third parties. Each trademark of another company appearing in this Form&#160;10-Q is the property of its owner.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ib049349da60d4a3c9beace0bfd291454_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I.&#160; FINANCIAL INFORMATION</span></div><div id="ib049349da60d4a3c9beace0bfd291454_13"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="ib049349da60d4a3c9beace0bfd291454_16"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except par value and share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:62.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">1,246,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">482,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="f-32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">298,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">40,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">41,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-36">90,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-37">83,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">41,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">24,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">1,418,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">929,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-42">72,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-43">65,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-44">19,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-45">20,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-46">16,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-47">18,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-48">61,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-49">63,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-50">136,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-51">136,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-52">85,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-53">96,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-54">1,810,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-55">1,329,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">290,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">214,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">224,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">2,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">2,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">6,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">8,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">524,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">225,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, long-term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">946,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">1,155,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">158,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">155,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">101,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">84,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">25,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">27,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, long-term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">11,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">11,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">3,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">3,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-78">1,771,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-79">1,661,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-80"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-81">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-82"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-83">500,000,000</ix:nonFraction></ix:nonFraction> authorized shares, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-85">166,666,599</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-86"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-87">147,977,960</ix:nonFraction></ix:nonFraction> issued and outstanding shares at June&#160;30, 2024 and December&#160;31, 2023,&#160;respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-88">1,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-89">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-90">3,943,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-91">3,113,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-92">3,903,845</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-93">3,446,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-94">2,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-95">745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity (deficit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-96">38,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-97">331,923</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders&#8217; equity (deficit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-98">1,810,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-99">1,329,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the unaudited consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ib049349da60d4a3c9beace0bfd291454_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> INSMED INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Loss (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:53.085%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.913%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.913%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.913%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.915%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-100"><span style="-sec-ix-hidden:f-101"><span style="-sec-ix-hidden:f-102"><span style="-sec-ix-hidden:f-103">Product revenues, net</span></span></span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-104">90,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-105">77,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-106">165,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-107">142,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-108"><span style="-sec-ix-hidden:f-109"><span style="-sec-ix-hidden:f-110"><span style="-sec-ix-hidden:f-111">Cost of product revenues (excluding amortization of intangible assets)</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-112">20,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-113">16,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-114">38,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-115">30,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-116">146,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-117">196,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-118">267,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-119">324,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-120">106,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-121">84,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-122">199,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-123">164,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-124">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-125">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-126">2,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-127">2,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of deferred and contingent consideration liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-128">103,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-129">13,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-130">91,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-131">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-132">379,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-133">312,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-134">600,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-135">526,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-136">288,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-137">235,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-138">434,409</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-139">383,686</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-140">10,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-141">11,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-142">19,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-143">21,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-144">21,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-145">20,619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-146">42,309</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-147">40,622</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of interest rate swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="f-148">384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-149">1,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-150">2,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="f-151">349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-152">269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-153">488</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-154">1,369</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-155">599</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-156">299,771</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-157">244,279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-158">456,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-159">403,560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-160">838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-161">530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-162">1,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-163">1,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-164">300,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-165">244,809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-166">457,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-167">404,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-168"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-169">1.94</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-170"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-171">1.78</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-172"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-173">3.02</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-174"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-175">2.95</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average basic and diluted common shares&#160;outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-176"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-177">154,702</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-178"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-179">137,553</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-180"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-181">151,579</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-182"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-183">136,957</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-184"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-185">300,609</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-186"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-187">244,809</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-188"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-189">457,700</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-190"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-191">404,573</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-192">1,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-193">2,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-194">2,049</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-195">2,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-196">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-197">132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-198">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-199">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-200">301,803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-201">247,143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-202">459,785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-203">406,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the unaudited consolidated financial statements</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ib049349da60d4a3c9beace0bfd291454_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Sharehold</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ers' Equity (Deficit) (unaudited)</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:31.248%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.099%"/><td style="width:0.1%"/></tr><tr style="height:30pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated <br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-204">136,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-205">1,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-206">2,809,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-207">2,856,342</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-208">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-209">44,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-210">244,809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-211">244,809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-212">2,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-213">2,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options and ESPP shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-214">513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-215">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-216">7,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-217">7,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-218">2,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-219">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-220">37,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-221">38,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for vesting of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-222">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-223">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-224">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for asset acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="3" id="f-225">3431</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="f-226">34</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-227">72,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-228">72,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-229">18,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-230">18,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-231">142,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-232">1,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-233">2,945,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-234">3,101,151</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-235">1,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-236">155,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-237">148,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-238">1,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-239">3,138,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-240">3,603,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-241">1,636</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-242">464,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-243">300,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-244">300,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-245">1,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-246">1,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options and ESPP shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-247">3,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-248">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-249">68,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-250">68,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-251">14,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-252">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-253">713,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-254">713,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for vesting of RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-255">529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-256">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-257">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-258">23,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-259">23,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-260">166,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-261">1,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-262">3,943,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-263">3,903,845</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-264">2,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-265">38,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the unaudited consolidated financial statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Sharehold</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ers' Equity (Deficit) (unaudited)</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:31.248%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.099%"/><td style="width:0.1%"/></tr><tr style="height:30pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated <br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-266">135,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-267">1,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-268">2,782,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-269">2,696,578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-270">756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-271">87,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-272">404,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-273">404,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-274">2,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-275">2,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options and ESPP shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-276">595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-277">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-278">8,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-279">8,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-280">2,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-281">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-282">37,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-283">38,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for vesting of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-284">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-285">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-286">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for asset acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-287">3,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="f-288">39</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-289">81,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-290">81,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-291">34,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-292">34,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-293">142,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-294">1,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-295">2,945,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-296">3,101,151</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-297">1,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-298">155,745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-299">147,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-300">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-301">3,113,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-302">3,446,145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-303">745</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-304">331,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-305">457,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-306">457,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-307">2,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-308">2,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options and ESPP shares issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-309">3,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-310">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-311">72,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-312">72,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-313">14,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-314">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-315">713,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-316">713,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for vesting of RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-317">895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-318">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="f-319">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-320">44,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-321">44,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-322">166,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-323">1,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-324">3,943,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-325">3,903,845</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-326">2,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-327">38,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the unaudited consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ib049349da60d4a3c9beace0bfd291454_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows (unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:67.421%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-328">457,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-329">404,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-330">3,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-331">2,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-332">2,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-333">2,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-334">44,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-335">34,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-336">3,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-337">3,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Paid-in-kind interest capitalized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="3" id="f-338">12,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="3" id="f-339">11,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Royalty financing non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="f-340">9,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherNoncashExpense" format="ixt:num-dot-decimal" scale="3" id="f-341">3,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Accretion of discount on marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="insm:AccretionOfDebtDiscountMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-342">1,963</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="insm:AccretionOfDebtDiscountMarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Finance lease amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-344">1,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-345">1,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="insm:NoncashOperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-346">1,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="insm:NoncashOperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-347">7,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in fair value of deferred and contingent consideration liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-348">91,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-349">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Change in fair value of interest rate swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-350">2,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="f-351">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Vertuis acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="insm:NoncashAcquisitionRelatedExpense" format="ixt:fixed-zero" scale="3" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="insm:NoncashAcquisitionRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-353">10,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Adrestia acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="insm:NoncashAcquisitionRelatedExpense" format="ixt:fixed-zero" scale="3" id="f-354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="insm:NoncashAcquisitionRelatedExpense" format="ixt:num-dot-decimal" scale="3" id="f-355">76,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-356">1,080</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-357">2,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-358">8,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-359">8,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-360">17,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-361">155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-362">15,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-363">7,458</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-364">2,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="f-365">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-366">6,748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-367">5,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-368">306,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-369">269,095</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Purchase of fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-370">11,462</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-371">8,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:fixed-zero" scale="3" id="f-372">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-373">292,690</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cash acquired in asset acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="insm:ProceedsFromCashAcquiredInAssetAcquisition" format="ixt:fixed-zero" scale="3" id="f-374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="insm:ProceedsFromCashAcquiredInAssetAcquisition" format="ixt:num-dot-decimal" scale="3" id="f-375">3,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-376">300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-377">65,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-378">288,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-379">232,554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options and ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-380">72,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-381">8,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-382">713,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-383">38,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Payments of finance lease principal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-384">1,266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:num-dot-decimal" scale="3" id="f-385">1,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-386">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-387">1,218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-388">784,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-389">43,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Effect of exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-390">1,641</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-391">3,432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-392">764,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-393">461,154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-394">482,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-395">1,074,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-396">1,246,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-397">612,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Supplemental disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-398">16,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-399">19,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-400">1,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-401">1,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the unaudited consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ib049349da60d4a3c9beace0bfd291454_28"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div></div><div style="text-align:center"><span><br/></span></div><div id="ib049349da60d4a3c9beace0bfd291454_31"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-402" continuedAt="f-402-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.      The Company and Basis of Presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company's first commercial product, ARIKAYCE, is approved in the United States (US) as ARIKAYCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mycobacterium avium complex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis (CF). In March 2021, Japan's Ministry of Health, Labour and Welfare (MHLW) approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. NTM lung disease caused by MAC (which the Company refers to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's pipeline includes clinical-stage programs, brensocatib and treprostinil palmitil inhalation powder (TPIP), as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP) and hidradenitis suppurativa (HS). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH). The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, artificial intelligence-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in the Commonwealth of Virginia on November&#160;29, 1999 and its principal executive offices are located in Bridgewater, New Jersey. The Company has legal entities in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom (UK), and Japan.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements have been prepared pursuant to the rules&#160;and regulations for reporting on Form&#160;10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the US (GAAP) for complete consolidated financial statements are not included herein. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000110450624000008/insm-20231231.htm">Annual Report on Form&#160;10-K for the year ended December&#160;31, 20</a>23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any references in these notes to applicable accounting guidance are meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. The unaudited interim consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;The Company had $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-403">1,246.8</ix:nonFraction> million in cash and cash equivalents as of June&#160;30, 2024 and reported a net loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-404">457.7</ix:nonFraction> million for the six months ended June&#160;30, 2024. The Company has funded its operations through public offerings of equity securities, de</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bt financings and revenue interest financings. The Company expects to continue to incur consolidated operating losses, including losses in its US and certain international entities, while funding research and development (R&amp;D) activities for ARIKAYCE, brensocatib, TPIP and its other pipeline programs, continuing commercialization and regulatory activities for ARIKAYCE and pre-commercial, regulatory and, if approved, commercialization activities for brensocatib, and funding other general and administrative activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects its future cash requirements to be substantial. While the Company currently has sufficient funds to meet its financial needs for at least the next 12 months, the Company may raise additional capital in the future to fund its operations, its ongoing commercialization and clinical trial activities, and its future product candidates, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company&#8217;s commercial, regulatory and development activities. Any future financing will also be contingent upon market </span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.      The Company and Basis of Presentation (Continued)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-402-1" continuedAt="f-402-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><ix:continuation id="f-402-2" continuedAt="f-402-3"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiarie</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-402-3">s,  Adrestia Therapeutics Inc., Celtrix Pharmaceuticals,&#160;Inc., Insmed France SAS, Insmed Gene Therapy LLC, Insmed Germany&#160;GmbH, Insmed Godo Kaisha, Insmed Holdings Limited, Insmed Innovation UK Limited, Insmed Ireland Limited, Insmed Italy S.R.L., Insmed Limited, Insmed Netherlands&#160;B.V., Insmed Netherlands Holdings B.V., and Insmed Switzerland GmbH.</ix:continuation> </span></div><div id="ib049349da60d4a3c9beace0bfd291454_34"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-405" continuedAt="f-405-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.      Summary of Significant Accounting Policies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company&#8217;s complete listing of significant accounting policies is set forth in Note 2 of the notes to the consolidated financial statements in the Company's </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000110450624000008/insm-20231231.htm">Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">. Selected significant accounting policies are discussed in detail below.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-406" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, acquisition related intangibles including in process research and development (IPR&amp;D) and goodwill, fair value of contingent consideration, and accounting for research and development costs. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-407" continuedAt="f-407-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-407-1">The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for uncollectible trade receivables.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-408" continuedAt="f-408-1" escape="true">The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the six months ended June&#160;30, 2024 and their respective percentages for the six months ended June&#160;30, 2023.</ix:nonNumeric></span></div><ix:continuation id="f-408-1"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.116%"><tr><td style="width:1.0%"/><td style="width:33.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.936%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-56" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-409">34</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-57" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-410">35</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-58" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-411">32</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-59" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-412">36</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-60" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-413">18</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-61" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-414">17</ix:nonFraction>%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturers, or an adverse change in their business, could materially impact future operating results.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="f-415" continuedAt="f-415-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finite-lived Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Finite-lived intangible assets are measured at their respective fair values on the date they were recorded. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6 - Intangibles, Net and Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Assessment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by </span></div></ix:nonNumeric></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;2.      Summary of Significant Accounting Policies (Continued)</span></div></div><ix:continuation id="f-405-1" continuedAt="f-405-2"><ix:continuation id="f-415-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing the carrying value of the assets to the fair value of the assets.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="insm:BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock" id="f-416" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations and Asset Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for the Company&#8217;s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets&#8217; carrying amounts on the acquiring entity&#8217;s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. If the in-licensed agreement for IPR&amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as acquired IPR&amp;D expense in its consolidated statements of comprehensive loss. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable, unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. None of the Company's contingent consideration met the definition of a derivative as of June&#160;30, 2024. Upon recognition of a contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="f-417" continuedAt="f-417-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-lived Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Indefinite-lived intangible assets consist of IPR&amp;D. IPR&amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&amp;D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&amp;D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#8217;s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;2.      Summary of Significant Accounting Policies (Continued)</span></div></div><ix:continuation id="f-405-2" continuedAt="f-405-3"><ix:continuation id="f-417-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company&#8217;s outlook and market performance of the Company&#8217;s industry and recent and forecasted financial performance. The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-418" continuedAt="f-418-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-418-1">&#8212;Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#8217;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. As of June&#160;30, 2024 and December&#160;31, 2023, the Company continues to operate as <ix:nonFraction unitRef="reportingunit" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-419"><ix:nonFraction unitRef="reportingunit" contextRef="c-62" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-420">one</ix:nonFraction></ix:nonFraction> reporting unit. The Company performs an impairment test for goodwill annually as of October 1.</ix:continuation> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6 - Intangibles, Net and Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-421" continuedAt="f-421-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-421-1">Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.</ix:continuation> See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9 - Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtPolicyTextBlock" id="f-422" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Unamortized debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-423" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the UK, and Japan. The results of the Company's non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in total s</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hareholders' equity (deficit),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a component of accumulated other comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company realizes foreign currency transaction gains and losses in the normal course of business based on movements in the applicable exchange rates. These gains and losses are included as a component of other expense, net.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesPolicyTextBlock" id="f-424" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In the normal course of business, the Company is exposed to the effects of interest rate changes. The Company may enter into derivative instruments, including interest rate swaps and caps, to manage or hedge interest rate risk. Derivative instruments are recorded at fair value on the balance sheet date. The Company has not elected hedge accounting treatment for the changes in the fair value of derivatives. Changes in the fair value of derivatives are recorded each period and are included in change in fair value of interest rate swap in the consolidated statements of comprehensive loss and consolidated statements of cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="insm:InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock" id="f-425" continuedAt="f-425-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Cost of Product Revenues (excluding amortization of intangible assets)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Inventory is stated at the lower of cost and net realizable value. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;2.      Summary of Significant Accounting Policies (Continued)</span></div></div><ix:continuation id="f-405-3" continuedAt="f-405-4"><ix:continuation id="f-425-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. Inventory used for clinical development purposes is expensed to R&amp;D expense when consumed.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-426" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&#160;Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock (RS), restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="f-427" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three and six months ended June&#160;30, 2024 and 2023: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-428">300,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-429">244,809</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-430">457,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-431">404,573</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of basic net loss per share:</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-432">154,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-433">137,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-434">151,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-435">136,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-63" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-436">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-66" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RS and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-67" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-68" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-69" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-73" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-74" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-452">154,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-453">137,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-454">151,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-455">136,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-456"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-457">1.94</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-458"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-459">1.78</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-460"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-461">3.02</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-462"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-463">2.95</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-464" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of June&#160;30, 2024 and 2023, respectively, as their effect would have been anti-dilutive (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:66.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.553%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.555%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-75" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-465">23,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-76" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-466">21,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RS and RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-77" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-467">3,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-468">2,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-79" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-469">665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-80" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-470">666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-81" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-471">23,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-82" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-472">23,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-473" continuedAt="f-473-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements (Not Yet Adopted)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In December 2023, the FASB issued ASU 2023-09, Income Taxes&#8212;Improvements to Income Tax Disclosures, in order to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires greater disaggregation of income tax disclosures related to the income tax rate </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;2.      Summary of Significant Accounting Policies (Continued)</span></div></div><ix:continuation id="f-473-1"><ix:continuation id="f-405-4"><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reconciliation and income taxes paid. ASU 2023-09 will be effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of adoption of ASU 2023-09 on its consolidated financial statements.</span></div></ix:continuation></ix:continuation><div id="ib049349da60d4a3c9beace0bfd291454_37"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-474" continuedAt="f-474-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3.      Fair Value Measurements</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-475" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-476" continuedAt="f-476-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:36.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June&#160;30, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-477">1,246.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-478">1,246.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-479">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-480">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="f-481">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="f-482">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-483">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" scale="6" id="f-485">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="f-486">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" scale="6" id="f-487">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="f-488">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="insm:BusinessCombinationDeferredLiability" scale="6" id="f-489">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="insm:BusinessCombinationDeferredLiability" format="ixt:fixed-zero" scale="6" id="f-490">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="insm:BusinessCombinationDeferredLiability" scale="6" id="f-491">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="insm:BusinessCombinationDeferredLiability" format="ixt:fixed-zero" scale="6" id="f-492">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-493">169.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="f-494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="f-495">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-496">169.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3.      Fair Value Measurements (Continued)</span></div></div><ix:continuation id="f-474-1" continuedAt="f-474-2"><ix:continuation id="f-476-1"><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:36.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-497">482.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="f-498">482.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-499">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-500">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:MarketableSecurities" scale="6" id="f-501">298.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:MarketableSecurities" scale="6" id="f-502">298.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:MarketableSecurities" format="ixt:fixed-zero" scale="6" id="f-503">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:MarketableSecurities" format="ixt:fixed-zero" scale="6" id="f-504">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="f-505">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="f-506">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-507">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="f-508">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" scale="6" id="f-509">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="f-510">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" scale="6" id="f-511">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="f-512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="insm:BusinessCombinationDeferredLiability" scale="6" id="f-513">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="insm:BusinessCombinationDeferredLiability" format="ixt:fixed-zero" scale="6" id="f-514">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="insm:BusinessCombinationDeferredLiability" scale="6" id="f-515">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="insm:BusinessCombinationDeferredLiability" format="ixt:fixed-zero" scale="6" id="f-516">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-517">84.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="f-518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="f-519">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-520">84.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="f-521">300.0</ix:nonFraction>&#160;million of marketable securities, consisting of US Treasury Notes, matured. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. The collateral for interest rate swap and the interest rate swap are recorded in other assets and accounts payable and accrued liabilities, respectively, in the consolidated balance sheet as of June&#160;30, 2024 and December&#160;31, 2023. The collateral for interest rate swap is cash, a Level 1 asset. The interest rate swap is a Level 2 liability as it uses observable inputs other than quoted market prices in an active market. There were no transfers in or out of Level 1, Level 2 or Level 3 during the six months ended June&#160;30, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company held <ix:nonFraction unitRef="usd" contextRef="c-83" decimals="INF" name="us-gaap:MarketableSecurities" format="ixt:fixed-zero" scale="0" id="f-522">no</ix:nonFraction> available-for-sale securities. Marketable securities maturing in one year or less are classified as current assets and marketable securities maturing in more than one year are classified as non-current assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2) whether the security was rated below investment grade; (3) failure of the issuer to make scheduled interest or principal payments; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover. The Company has determined that there were no other-than-temporary impairments during the six months ended June 30, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred consideration arose from the acquisition of Motus Biosciences, Inc. (Motus) in August 2021. The Company is obligated to issue to Motus equityholders an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-523"><ix:nonFraction unitRef="shares" contextRef="c-92" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-524"><ix:nonFraction unitRef="shares" contextRef="c-93" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-525">184,433</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s common stock on each of the first, second and third anniversaries of the closing date, subject to certain reductions. During August 2022 and August 2023, the Company fulfilled the payments due on the first and second anniversaries of the closing date by issuing <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-526">171,427</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="c-95" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-527">177,203</ix:nonFraction> shares of the Company's common stock, respectively, after certain reductions. A valuation of the deferred consideration is performed quarterly with gains and losses included within change in fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss. As the deferred consideration is settled in shares, there is no discount rate applied in the fair value calculation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred consideration has been classified as a Level 2 recurring liability as its valuation utilizes an input, the Insmed share price, which is a directly observable input at the measurement date and for the duration of the liabilities' anticipated lives. Deferred consideration expected to be settled within twelve months or less is classified as a current liability within accounts payable and accrued liabilities. As of June&#160;30, 2024, the fair value of deferred consideration included in accounts payable and accrued liabilities was $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="insm:BusinessCombinationDeferredLiability" scale="6" id="f-528">12.4</ix:nonFraction> million.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-529" continuedAt="f-529-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following observable input was used in the valuation of the deferred consideration as of June&#160;30, 2024:</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3.      Fair Value Measurements (Continued)</span></div></div><ix:continuation id="f-474-2" continuedAt="f-474-3"><ix:continuation id="f-529-1" continuedAt="f-529-2"><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.111%"><tr><td style="width:1.0%"/><td style="width:21.989%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.159%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.460%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of June&#160;30, 2024 (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Observable Input</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="insm:BusinessCombinationDeferredLiability" scale="6" id="f-530">12.4</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed share price as of June&#160;30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-97" decimals="2" name="insm:BusinessCombinationDeferredConsiderationLiabilityMeasurementInput" scale="0" id="f-531">67.00</ix:nonFraction></span></div></td></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities arose from the acquisitions of Motus and AlgaeneX, Inc. (AlgaeneX) (together, the Business Acquisition) in August 2021 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16 - Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The contingent consideration liabilities consist of developmental and regulatory milestones, a priority review voucher milestone and net sales milestones. Upon the achievement of certain development and regulatory milestone events, the Company is obligated to issue to Motus equityholders up to <ix:nonFraction unitRef="shares" contextRef="c-98" decimals="INF" name="insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-532">5,348,572</ix:nonFraction> shares in the aggregate and AlgaeneX equityholders up to <ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-533">368,867</ix:nonFraction> shares in the aggregate. The fair value of the development and regulatory milestones are estimated utilizing a probability-adjusted approach. At June&#160;30, 2024, the weighted average probability of success was <ix:nonFraction unitRef="number" contextRef="c-100" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-534">42</ix:nonFraction>%. The development and regulatory milestones will be settled in shares of the Company's common stock. As such, there is no discount rate applied in the fair value calculation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company were to receive a priority review voucher, the Company is obligated to pay to the Motus equityholders a portion of the value of the priority review voucher, subject to certain reductions. The potential payout will be either <ix:nonFraction unitRef="number" contextRef="c-101" decimals="2" name="insm:ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage" scale="-2" id="f-535">50</ix:nonFraction>% of the after tax net proceeds received by the Company from a sale of the priority review voucher or <ix:nonFraction unitRef="number" contextRef="c-101" decimals="2" name="insm:AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage" scale="-2" id="f-536">50</ix:nonFraction>% of the average of the sales prices for the last <ix:nonFraction unitRef="sale" contextRef="c-102" decimals="INF" name="insm:NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders" format="ixt-sec:numwordsen" scale="0" id="f-537">three</ix:nonFraction> publicly disclosed priority review voucher sales, less certain adjustments. The fair value of the priority review voucher milestone is estimated utilizing a probability-adjusted discounted cash flow approach. This obligation will be settled in cash. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities for net sales milestones were valued using an option pricing model with Monte Carlo simulation. As of June&#160;30, 2024, the fair value of these net sales milestones were deemed immaterial to the overall fair value of the contingent consideration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities have been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the inputs to the valuation approach, the estimated fair value could be significantly different than the fair value the Company determined. Contingent consideration expected to be settled within twelve months or less is classified as a current liability within accounts payable and accrued liabilities. Contingent consideration expected to be settled in more than twelve months is classified as a non-current liability. As of June&#160;30, 2024, the fair value of the current and non-current contingent consideration was $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-538">68.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-539">101.5</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation of the contingent consideration liabilities is performed quarterly with gains and losses included within change in fair value of contingent consideration liabilities in the consolidated statements of comprehensive loss. <ix:continuation id="f-529-2" continuedAt="f-529-3">The following significant unobservable inputs were used in the valuation of the development and regulatory milestones and the priority review voucher milestone as of June&#160;30, 2024:</ix:continuation></span></div><ix:continuation id="f-529-3" continuedAt="f-529-4"><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"/><td style="width:25.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.290%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.350%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of June&#160;30, 2024 (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-540">161.8</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probabilities of success</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-105" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-541">14</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-106" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-542">97</ix:nonFraction>%</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority review voucher milestone</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-543">5.2</ix:nonFraction></span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-108" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-544">16.4</ix:nonFraction>%</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-109" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-545">16.4</ix:nonFraction>%</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the six months ended June 30, 2024 and 2023 (in thousands):</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3.      Fair Value Measurements (Continued)</span></div></div><ix:continuation id="f-474-3"><ix:continuation id="f-529-4"><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.391%"><tr><td style="width:1.0%"/><td style="width:38.143%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred<br/>&#160;Consideration <br/>(Level 2 Liabilities)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration<br/>&#160;(Level 3 Liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-546">7,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-547">58,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:fixed-zero" scale="3" id="f-548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:fixed-zero" scale="3" id="f-549">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" sign="-" name="us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" scale="3" id="f-550">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" sign="-" name="us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" format="ixt:num-dot-decimal" scale="3" id="f-551">3,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" format="ixt:fixed-zero" scale="3" id="f-552">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" format="ixt:fixed-zero" scale="3" id="f-553">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-554">7,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-555">61,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-556">5,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-557">84,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:fixed-zero" scale="3" id="f-558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:LiabilitiesFairValueAdjustment" format="ixt:fixed-zero" scale="3" id="f-559">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" sign="-" name="us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" format="ixt:num-dot-decimal" scale="3" id="f-560">6,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" sign="-" name="us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" format="ixt:num-dot-decimal" scale="3" id="f-561">85,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" format="ixt:fixed-zero" scale="3" id="f-562">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" format="ixt:fixed-zero" scale="3" id="f-563">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-564">12,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-565">169,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the convertible notes, which differs from their carrying value, is influenced by interest rates, the Company's stock price and stock price volatility (collectively, the Current Market Factors), and is determined by prices for the convertible notes observed in market trading which are Level 2 inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company's <ix:nonFraction unitRef="number" contextRef="c-122" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-566">0.75</ix:nonFraction>% convertible senior notes due 2028 (the 2028 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of June&#160;30, 2024 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-8" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="9" id="f-567">1.2</ix:nonFraction> billion, deter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mined using Current Market Factors and the ability of the Company to obtain debt on comparable terms to the 2028 Convertible Notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company's <ix:nonFraction unitRef="number" contextRef="c-124" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-568">1.75</ix:nonFraction>% convertible senior notes due 2025 (the 2025 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of June&#160;30, 2024 wa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="f-569">384.5</ix:nonFraction> million, determined using Current Market Factors, and the ability of the Company to obtain debt on comparable terms to the 202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 Convertible Notes. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10 - Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Synthetic Royalty Financing Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company entered into a revenue interest purchase agreement (the Royalty Financing Agreement) with OrbiMed Royalty &amp; Credit Opportunities IV, LP (OrbiMed). Under the Royalty Financing Agreement, OrbiMed paid the Company </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-6" name="insm:ProceedsFromRoyaltyFinancing" scale="6" id="f-570">150</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to <ix:nonFraction unitRef="number" contextRef="c-127" decimals="2" name="insm:DebtInstrumentRoyaltyStatedPercentage" scale="-2" id="f-571">4</ix:nonFraction>% of ARIKAYCE global net sales prior to September 1, 2025 and <ix:nonFraction unitRef="number" contextRef="c-128" decimals="3" name="insm:DebtInstrumentRoyaltyStatedPercentage" scale="-2" id="f-572">4.5</ix:nonFraction>% of ARIKAYCE global net sales on or after September 1, 2025, as well as <ix:nonFraction unitRef="number" contextRef="c-129" decimals="4" name="insm:DebtInstrumentRoyaltyStatedPercentage" format="ixt:num-dot-decimal" scale="0" id="f-573">0.75</ix:nonFraction>% of brensocatib global net sales, if approved (the Revenue Interest Payments). In the event that OrbiMed has not received aggregate Revenue Interest Payments of at least </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-574">150</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on or prior to March 31, 2028, the Company must make a one-time payment to OrbiMed for the difference between the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-6" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="6" id="f-575">150</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the aggregated Revenue Interest Payments that have been paid. In addition, the royalty rate for ARIKAYCE will be increased beginning March 31, 2028 to the rate which would have resulted in aggregate Revenue Interest Payments as of March 31, 2028 equaling </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-6" name="insm:ProceedsFromRoyaltyFinancing" scale="6" id="f-576">150</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The total Revenue Interest Payments payable by the Company to OrbiMed are capped at 1.8x of the purchase price or up to a maximum of 1.9x of the purchase price under certain conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company&#8217;s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective interest method over the life of the arrangement, in accordance with ASC 470, Debt and ASC 835, Interest. The Company will utilize the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and will update the effective interest rate on a quarterly basis. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11 - Royalty Financing Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further details.</span></div></ix:continuation><div id="ib049349da60d4a3c9beace0bfd291454_40"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-577" continuedAt="f-577-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">4.      Product Revenues, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of </span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">4.      Product Revenues, Net (Continued)</span></div></div><ix:continuation id="f-577-1" continuedAt="f-577-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract to determine which are performance obligations and to assess whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net consist of net sales of ARIKAYCE. The Company's customers in the US include specialty pharmacies and specialty distributors. In December 2020, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Europe. In July 2021, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Japan. Globally, product revenues are recognized once the Company performs and satisfies all five steps of the revenue recognition criteria mentioned above.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-578" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a geographic summary of the Company's product revenues, net, for the three and six months ended June&#160;30, 2024 and 2023 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:24.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.164%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.164%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.164%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.170%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-579">63,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-580">57,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-581">120,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-582">106,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-583">21,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-584">15,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-585">36,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-586">28,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe and rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-587">5,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-588">3,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-589">9,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-590">6,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total product revenues, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-591">90,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-592">77,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-593">165,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-594">142,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer credits: Certain of the Company's customers are offered various forms of consideration, including prompt payment discounts. The payment terms for sales to specialty pharmacies and specialty distributors for prompt payment discounts are based on contractual rates agreed with the respective specialty pharmacies and distributors. The Company anticipates that its customers will earn these discounts and, therefore, deducts the full amount of these discounts from total gross product revenues at the time such revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates: The Company contracts with certain government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accounts payable and accrued liabilities on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">4.      Product Revenues, Net (Continued)</span></div></div><ix:continuation id="f-577-2" continuedAt="f-577-3"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-577-3">The Company also recognizes revenue related to various early access programs (EAPs) in Europe. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.</ix:continuation> </span></div><div id="ib049349da60d4a3c9beace0bfd291454_43"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-595" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">5.      Inventory</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-596" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's inventory balance consists of the following (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"/><td style="width:49.266%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.258%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.261%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-597">24,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-598">24,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-599">36,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-600">33,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-601">28,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-602">25,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-603">90,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-604">83,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company has not recorded any significant inventory write-downs. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.</span></div></ix:nonNumeric><div id="ib049349da60d4a3c9beace0bfd291454_46"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="f-605" continuedAt="f-605-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">6.      Intangibles, Net and Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangibles, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finite-lived Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company's finite-lived intangible assets consisted of acquired ARIKAYCE R&amp;D and the milestones paid to PARI for the license to use the Lamira&#174; Nebulizer System (Lamira) for the delivery of ARIKAYCE to patients as a result of the US Food and Drug Administration (FDA) and EC approvals of ARIKAYCE in September 2018 and October 2020, respectively. The Company began amortizing its acquired ARIKAYCE R&amp;D and PARI milestone-related intangible assets in October 2018, over ARIKAYCE's initial regulatory exclusivity period of <ix:nonNumeric contextRef="c-3" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-606">12</ix:nonNumeric> years. Amortization of these assets during each of the next five years is estimated to be approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="f-607"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="f-608"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="f-609"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="f-610"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="f-611">5.1</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million per year.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-lived Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company's indefinite-lived intangible assets consisted of acquired IPR&amp;D from the Business Acquisition (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16 - Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Indefinite-lived intangible assets are not amortized.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-612" continuedAt="f-612-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the Company's intangible assets for the six months ended June 30, 2024 and June&#160;30, 2023 is as follows (in thousands):</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">6.      Intangibles, Net and Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Continued)</span></div></div><ix:continuation id="f-605-1" continuedAt="f-605-2"><ix:continuation id="f-612-1"><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"/><td style="width:24.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.210%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-613">32,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="f-614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-615">2,425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-616">30,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-617">29,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="f-618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-619">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-620">29,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-621">1,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="f-622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="f-623">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-624">1,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-625">63,704</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="f-626">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-627">2,526</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-628">61,178</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-629">37,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="f-630">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-631">2,425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-632">35,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-633">29,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="f-634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-635">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-636">29,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-637">1,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="f-638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="f-639">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-640">1,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-641">68,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="f-642">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-643">2,526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-644">66,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><ix:continuation id="f-605-2" continuedAt="f-605-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's goodwill balance of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-645"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-646">136.1</ix:nonFraction></ix:nonFraction> million as of June&#160;30, 2024 and December&#160;31, 2023, resulted from the August 2021 Business Acquisition. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16 - Acquisitions </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-605-3">for further details.</ix:continuation>&#160;</span></div><div id="ib049349da60d4a3c9beace0bfd291454_49"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-647" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">7.      Fixed Assets, Net</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-648" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"/><td style="width:33.916%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.398%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.401%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-161" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-649">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-650">24,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-651">22,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-163" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-652">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-653">6,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-654">6,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-165" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-655">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c-166" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-656">5</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-657">6,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-658">6,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-169" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-659">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-660">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-661">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-171" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-662">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-663">1,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-664">1,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-173" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-665">2</ix:nonNumeric>-<ix:nonNumeric contextRef="c-174" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-666">10</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-667">37,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-668">38,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-669">43,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-670">35,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-671">120,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-672">110,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-673">47,342</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-674">44,628</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-675">72,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-676">65,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div id="ib049349da60d4a3c9beace0bfd291454_52"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-677" continuedAt="f-677-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">8.      Accounts Payable and Accrued Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-678" continuedAt="f-678-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consist of the following (in thousands):</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">8.      Accounts Payable and Accrued Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Continued)</span></div></div><ix:continuation id="f-677-1"><ix:continuation id="f-678-1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"/><td style="width:57.515%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.207%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accrued operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-679">51,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-680">65,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="insm:AccruedClinicalTrialExpenses" format="ixt:num-dot-decimal" scale="3" id="f-681">22,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="insm:AccruedClinicalTrialExpenses" format="ixt:num-dot-decimal" scale="3" id="f-682">23,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-683">16,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-684">13,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued technical operation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="insm:AccruedTechnicalOperationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-685">11,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="insm:AccruedTechnicalOperationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-686">9,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-687">42,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-688">48,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty and milestones payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-689">7,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-690">5,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-691">2,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-692">2,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interest Payments payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="insm:RevenueInterestPaymentsPayable" format="ixt:num-dot-decimal" scale="3" id="f-693">3,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="insm:RevenueInterestPaymentsPayable" format="ixt:num-dot-decimal" scale="3" id="f-694">3,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales allowances and related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="insm:AccruedSalesAllowancesAndRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-695">14,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="insm:AccruedSalesAllowancesAndRelatedCosts" format="ixt:num-dot-decimal" scale="3" id="f-696">10,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued France ATU reimbursement payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-697">17,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerRefundLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-698">14,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred and contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="insm:BusinessCombinationDeferredPaymentsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-699">81,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="insm:BusinessCombinationDeferredPaymentsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-700">6,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued milestone payment to AstraZeneca</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="insm:AccruedMilestonePaymentCurrent" format="ixt:num-dot-decimal" scale="3" id="f-701">12,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="insm:AccruedMilestonePaymentCurrent" format="ixt:fixed-zero" scale="3" id="f-702">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-703">8,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-704">10,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-705">290,844</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-706">214,987</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> milestone commitment became payable to AstraZeneca upon the Company's release of an official public statement that it intends to file a new drug application (NDA) for brensocatib.</span></div></ix:continuation><div id="ib049349da60d4a3c9beace0bfd291454_55"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeFinanceLeasesTextBlock" id="f-708" continuedAt="f-708-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-707" continuedAt="f-707-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9.      Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than <ix:nonNumeric contextRef="c-179" name="insm:LeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="f-709">one year</ix:nonNumeric> to <ix:nonNumeric contextRef="c-180" name="insm:LeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="f-710">ten years, ten months</ix:nonNumeric>. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:VariableLeaseCost" scale="6" id="f-711">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:VariableLeaseCost" scale="6" id="f-712">4.1</ix:nonFraction> million for the three months ended June&#160;30, 2024 and 2023, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:VariableLeaseCost" scale="6" id="f-713">8.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:VariableLeaseCost" scale="6" id="f-714">4.2</ix:nonFraction> million for the six months ended June&#160;30, 2024 and 2023, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-715" continuedAt="f-715-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):</span></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9.      Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Continued)</span></div></div><ix:continuation id="f-708-1"><ix:continuation id="f-707-1"><ix:continuation id="f-715-1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:33.469%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.483%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-716">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-717">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-718">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-720">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-721">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-722">5,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-723">1,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" scale="6" id="f-724">54.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" scale="6" id="f-725">49.1</ix:nonFraction> million incurred by the Company under these additional agreements have been classified within</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other assets in the Company's </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated balance sheet as of June&#160;30, 2024 and December&#160;31, 2023, respectively. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.</span></div></ix:continuation></ix:continuation><div id="ib049349da60d4a3c9beace0bfd291454_58"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-726" continuedAt="f-726-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10.      Debt</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-727" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of long-term debt and debt, long-term consists of the following commitments as of June&#160;30, 2024 and December&#160;31, 2023 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.608%"><tr><td style="width:1.0%"/><td style="width:46.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.090%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-728">790,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-729">788,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-730">380,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-731">366,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-732">224,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-733">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-734">946,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-735">1,155,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Convertible Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company completed an underwritten public offering of $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-736">575.0</ix:nonFraction> million aggregate principal amount of the 2028 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="insm:DebtInstrumentOptionToPurchaseAdditionalDebt" scale="6" id="f-737">75.0</ix:nonFraction> million in aggregate principal amount of 2028 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="f-738">15.7</ix:nonFraction>&#160;million, were approximately $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="f-739">559.3</ix:nonFraction> million. The 2028 Convertible Notes bear interest payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2021. The 2028 Convertible Notes mature on June 1, 2028, unless earlier converted, redeemed, or repurchased. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company completed an underwritten public offering of $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-740">450.0</ix:nonFraction> million aggregate principal amount of the 2025 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="insm:DebtInstrumentOptionToPurchaseAdditionalDebt" scale="6" id="f-741">50.0</ix:nonFraction> million in aggregate principal amount of 2025 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="f-742">14.2</ix:nonFraction> million, were approximately $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="f-743">435.8</ix:nonFraction> million. The 2025 Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The 2025 Convertible Notes would have matured on January 15, 2025 but, on June 27, 2024, the Company called the outstanding 2025 Convertible Notes for redemption, with a redemption date of August 9, 2024. See </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redemption of the 2025 Convertible Notes </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below for further details.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the net proceeds from the 2028 Convertible Notes was used to repurchase $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="6" id="f-744">225.0</ix:nonFraction> million of the Company's outstanding 2025 Convertible Notes. The Company recorded a loss on early extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-745">17.7</ix:nonFraction> million, primarily related to the premium paid on extinguishment of a portion the 2025 Convertible Notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after March 1, 2028, until the close of business on the second scheduled trading day immediately preceding June 1, 2028, holders may convert their 2028 Convertible Notes at any time. The initial conversion rate for the 2028 Convertible Notes is 30.7692 shares of common stock per $1,000 principal amount of 2028 Convertible Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-746">32.50</ix:nonFraction> per share of common stock). Upon conversion of either the 2025 Convertible Notes or the 2028 Convertible Notes, holders may receive cash, shares of the Company's common stock or a combination of cash and </span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10.      Debt (Continued)</span></div></div><ix:continuation id="f-726-1" continuedAt="f-726-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of the Company's common stock, at the Company's option. The conversion rates will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2028 Convertible Notes prior to March 1, 2028, only under the following circumstances, subject to the conditions set forth in the indenture: (i) during the <ix:nonFraction unitRef="day" contextRef="c-191" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="f-747"><ix:nonFraction unitRef="day" contextRef="c-192" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" format="ixt-sec:numwordsen" scale="0" id="f-748">five</ix:nonFraction></ix:nonFraction> business day period immediately after any <ix:nonFraction unitRef="day" contextRef="c-191" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="f-749"><ix:nonFraction unitRef="day" contextRef="c-192" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" format="ixt-sec:numwordsen" scale="0" id="f-750">five</ix:nonFraction></ix:nonFraction> consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of the 2028 Convertible Notes, as determined following a request by a holder of such notes, for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="c-192" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-751"><ix:nonFraction unitRef="number" contextRef="c-191" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-752">98</ix:nonFraction></ix:nonFraction>% of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than <ix:nonFraction unitRef="day" contextRef="c-193" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-753"><ix:nonFraction unitRef="day" contextRef="c-194" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-754">45</ix:nonFraction></ix:nonFraction> days from the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the <ix:nonFraction unitRef="day" contextRef="c-193" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-755"><ix:nonFraction unitRef="day" contextRef="c-194" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-756">10</ix:nonFraction></ix:nonFraction> consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company's assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding <ix:nonFraction unitRef="number" contextRef="c-193" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-757"><ix:nonFraction unitRef="number" contextRef="c-194" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-758">10</ix:nonFraction></ix:nonFraction>% of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the 2028 Convertible Notes may be surrendered by a holder for conversion at any time from or after the date that is <ix:nonFraction unitRef="day" contextRef="c-195" decimals="INF" name="insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" scale="0" id="f-759"><ix:nonFraction unitRef="day" contextRef="c-196" decimals="INF" name="insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" scale="0" id="f-760">30</ix:nonFraction></ix:nonFraction> scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on June 30, 2021 (and only during such calendar quarter), the last reported sale price of the common stock for at least <ix:nonFraction unitRef="day" contextRef="c-197" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-761"><ix:nonFraction unitRef="day" contextRef="c-198" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-762">20</ix:nonFraction></ix:nonFraction> trading days (whether or not consecutive) during the period of <ix:nonFraction unitRef="day" contextRef="c-198" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-763"><ix:nonFraction unitRef="day" contextRef="c-197" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-764">30</ix:nonFraction></ix:nonFraction> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to <ix:nonFraction unitRef="number" contextRef="c-197" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-765"><ix:nonFraction unitRef="number" contextRef="c-198" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-766">130</ix:nonFraction></ix:nonFraction>% of the conversion price on each applicable trading day (each, a Stock Price Convertibility Trigger), or (v) if the Company sends a notice of redemption, a holder may surrender all or any portion of its 2028 Convertible Notes to which the notice of redemption relates for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a)&#160;the second business day immediately preceding the related redemption date or (b)&#160;if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid. As of June&#160;30, 2024, there have not been any holder-initiated conversion requests for either series of convertible notes. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each series of convertible notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in both series of convertible notes are not required to be separately accounted for as a derivative. However, since the convertible notes are within the scope of the accounting guidance for cash convertible instruments, the Company is required to separate each series of convertible notes into liability and equity components. The carrying amount of the liability component of each series of convertible notes as of the date of issuance was calculated by measuring the fair value of a similar liability that did not have an associated equity component. The fair value was based on data from readily available pricing sources which utilize market observable inputs and other characteristics for similar types of instruments. The carrying amount of the equity component representing the embedded conversion option for each series of convertible notes was determined by deducting the fair value of the liability component from the gross proceeds of the applicable convertible notes. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in the accounting guidance for contracts in an entity&#8217;s own equity. The fair value of the liability component of the 2025 Convertible Notes on the date of issuance was estimated at $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="6" id="f-767">309.1</ix:nonFraction>&#160;million using an effective interest rate of <ix:nonFraction unitRef="number" contextRef="c-187" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-768">7.6</ix:nonFraction>% and, accordingly, the residual equity component on the date of issuance was $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" format="ixt:num-dot-decimal" scale="6" id="f-769">140.9</ix:nonFraction>&#160;million. The fair value of the liability component of the 2028 Convertible Notes on the date of issuance was estimated at $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="6" id="f-770">371.6</ix:nonFraction>&#160;million using an effective interest rate of <ix:nonFraction unitRef="number" contextRef="c-185" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-771">7.1</ix:nonFraction>% and, accordingly, the residual equity component on the date of issuance was $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" format="ixt:num-dot-decimal" scale="6" id="f-772">203.4</ix:nonFraction>&#160;million. The respective discounts were amortized to interest expense over the term of the applicable series of convertible notes through December&#160;31, 2022, prior to the adoption of ASU 2020-06. The 2028 Convertible Notes have a remaining term of approximately <ix:nonNumeric contextRef="c-199" name="insm:ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" format="ixt-sec:duryear" id="f-773">3.92</ix:nonNumeric> years. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="f-774">566.1</ix:nonFraction> million carrying value of the 2028 Convertible Notes as of June&#160;30, 2024 is net of $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="f-775">8.9</ix:nonFraction> million of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10.      Debt (Continued)</span></div></div><ix:continuation id="f-726-2" continuedAt="f-726-3"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unamortized debt issuance costs. The $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="f-776">224.4</ix:nonFraction> million carrying value of the 2025 Convertible Notes as of June&#160;30, 2024 is net of $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="f-777">0.6</ix:nonFraction> million of unamortized debt issuance costs. The 2028 Convertible Notes and 2025 Convertible Notes are long-term and current liabilities, respectively, as of June&#160;30, 2024. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtTableTextBlock" id="f-778" continuedAt="f-778-1" escape="true">The following table presents the carrying value of the Company's convertible notes balance (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-778-1" continuedAt="f-778-2"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"/><td style="width:55.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.755%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of outstanding convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="f-779">800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:SecuredDebt" format="ixt:num-dot-decimal" scale="3" id="f-780">800,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-781">9,447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-782">11,091</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-783">224,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-784">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term convertible notes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-785">566,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-786">788,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redemption of the 2025 Convertible Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 27, 2024, the Company issued a redemption notice for its 2025 Convertible Notes with a redemption date of August 9, 2024 (the Redemption Date). All then outstanding 2025 Convertible Notes will be redeemed at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="c-204" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="f-787">100</ix:nonFraction>% of the principal amount of the 2025 Convertible Notes, plus accrued and unpaid interest on the 2025 Convertible Notes to, but excluding, the Redemption Date (the Redemption Price). For each $1,000 principal amount of 2025 Convertible Notes, the Redemption Price will be equal to approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-204" decimals="INF" name="insm:DebtInstrumentRedemptionPricePerShare" format="ixt:num-dot-decimal" scale="0" id="f-788">1,001.17</ix:nonFraction>. The Company has elected to settle any conversions of the 2025 Convertible Notes that occur on or before the business day prior to the Redemption Date in shares of common stock. As of June&#160;30, 2024, none of the 2025 Convertible Notes converted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Secured Senior Term Loan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, the Company entered into a $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-789">350</ix:nonFraction>&#160;million senior secured term loan agreement with Pharmakon Advisors LP (Pharmakon), manager of the BioPharma Credit funds (the Term Loan). The Term Loan matures on October 19, 2027 and bears interest at a rate based upon the secured overnight financing rate (SOFR), subject to a SOFR floor of <ix:nonFraction unitRef="number" contextRef="c-206" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-790">2.5</ix:nonFraction>%, in addition to a margin of <ix:nonFraction unitRef="number" contextRef="c-207" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-791">7.75</ix:nonFraction>% per annum. Up to <ix:nonFraction unitRef="number" contextRef="c-207" decimals="2" name="insm:DebtInstrumentPercentOfInterestPayable" scale="-2" id="f-792">50</ix:nonFraction>% of the interest payable during the first <ix:nonNumeric contextRef="c-207" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durmonth" id="f-793">24</ix:nonNumeric> months from the closing of the Term Loan may be paid-in-kind at the Company's election. If elected, paid-in-kind interest will be capitalized and added to the principal amount of the Term Loan. The Term Loan, including the paid-in-kind interest, will be repaid in eight equal quarterly payments starting in the 13th quarter following the closing of the Term Loan (i.e., the quarter ending March 31, 2026), except that the repayment start date may be extended at the Company's option for an additional four quarters, so that repayments start in the 17th quarter following the closing of the Term Loan, subject to the achievement of specified ARIKAYCE data thresholds and certain other conditions. Net proceeds from the Term Loan, after deducting the lenders' fees and deal expenses of $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="f-794">15.2</ix:nonFraction> million, were $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:ProceedsFromLoans" format="ixt:num-dot-decimal" scale="6" id="f-795">334.8</ix:nonFraction>&#160;million. During the six months ended June 30, 2024, paid-in-kind interest capitalized was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaidInKindInterest" format="ixt:num-dot-decimal" scale="6" id="f-796">12.6</ix:nonFraction>&#160;million. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="f-797" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the carrying value of the Company&#8217;s Term Loan balance as of June&#160;30, 2024 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.169%"><tr><td style="width:1.0%"/><td style="width:45.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.103%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.276%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.103%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.277%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original Term Loan balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-798">350,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-799">350,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid-in-kind interest capitalized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:AccumulatedCapitalizedInterestCosts" format="ixt:num-dot-decimal" scale="3" id="f-800">40,108</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:AccumulatedCapitalizedInterestCosts" format="ixt:num-dot-decimal" scale="3" id="f-801">27,537</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan issuance costs, unamortized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="f-802">9,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="f-803">11,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-804">380,720</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-805">366,404</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10.      Debt (Continued)</span></div></div><ix:continuation id="f-726-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-806" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, future principal repayments of debt for each of the years through maturity were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.543%"><tr><td style="width:1.0%"/><td style="width:64.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.265%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-807">225,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="f-808">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-809">195,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-810">195,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="f-811">575,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="insm:LongTermDebtMaturityAfterYearFourAndThereafter" format="ixt:fixed-zero" scale="3" id="f-812">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-813">1,190,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redemption notice the Company issued for its 2025 Convertible Notes, the principal balance of the 2025 Convertible Notes was reclassified to due within the current year.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="f-814" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to debt and finance leases for the three and six months ended June&#160;30, 2024 and 2023 is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.056%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.797%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-815">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-816">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-817">4,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-818">4,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan contractual interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-819">12,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-820">11,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-821">25,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-822">22,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Financing Agreement interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-823">4,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-824">4,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-825">9,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-826">9,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-827">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-828">2,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-829">3,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-830">3,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swap interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestIncomeOther" scale="3" id="f-831">710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestIncomeOther" scale="3" id="f-832">354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeOther" format="ixt:num-dot-decimal" scale="3" id="f-833">1,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestIncomeOther" scale="3" id="f-834">427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total debt interest expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="insm:InterestExpenseExcludingFinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-835">20,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="insm:InterestExpenseExcludingFinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-836">20,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="insm:InterestExpenseExcludingFinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-837">41,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="insm:InterestExpenseExcludingFinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-838">39,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-839">564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="f-840">612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-841">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-842">1,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-843">21,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-844">20,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-845">42,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-846">40,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib049349da60d4a3c9beace0bfd291454_64"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock" id="f-850" continuedAt="f-850-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11.      Royalty Financing Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2022, the Company entered into the Royalty Financing Agreement with OrbiMed. Under the Royalty Financing Agreement, OrbiMed paid the Company $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-6" name="insm:ProceedsFromRoyaltyFinancing" format="ixt:num-dot-decimal" scale="6" id="f-851">150</ix:nonFraction>&#160;million in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to <ix:nonFraction unitRef="number" contextRef="c-127" decimals="2" name="insm:DebtInstrumentRoyaltyStatedPercentage" scale="-2" id="f-852">4</ix:nonFraction>% of ARIKAYCE global net sales prior to September 1, 2025 and <ix:nonFraction unitRef="number" contextRef="c-128" decimals="3" name="insm:DebtInstrumentRoyaltyStatedPercentage" scale="-2" id="f-853">4.5</ix:nonFraction>% of ARIKAYCE global net sales on or after September 1, 2025, as well as <ix:nonFraction unitRef="number" contextRef="c-129" decimals="4" name="insm:DebtInstrumentRoyaltyStatedPercentage" format="ixt:num-dot-decimal" scale="0" id="f-854">0.75</ix:nonFraction>% of brensocatib global net sales, if approved. In the event that OrbiMed has not received aggregate Revenue Interest Payments of at least $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-6" name="insm:ProceedsFromRoyaltyFinancing" format="ixt:num-dot-decimal" scale="6" id="f-855">150</ix:nonFraction>&#160;million on or prior to March 31, 2028, the Company must make a one-time payment to OrbiMed for the difference between the $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-856">150</ix:nonFraction>&#160;million and the aggregated Revenue Interest Payments that have been paid. In addition, the royalty rate for ARIKAYCE will be increased beginning March 31, 2028 to the rate which would have resulted in aggregate Revenue Interest Payments as of March 31, 2028 equaling $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-6" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="6" id="f-857">150</ix:nonFraction>&#160;million. The total Revenue Interest Payments payable by the Company to OrbiMed are capped at <ix:nonFraction unitRef="number" contextRef="c-225" decimals="INF" name="insm:DebtInstrumentRoyaltyPayableMaximum" scale="0" id="f-858">1.8</ix:nonFraction>x of the purchase price or up to a maximum of <ix:nonFraction unitRef="number" contextRef="c-226" decimals="INF" name="insm:DebtInstrumentRoyaltyPayableMaximum" scale="0" id="f-859">1.9</ix:nonFraction>x of the purchase price under certain conditions. Net proceeds from the Royalty Financing Agreement, after deducting the lenders' fees and deal expenses of $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:DebtInstrumentFeeAmount" format="ixt:num-dot-decimal" scale="6" id="f-860">3.8</ix:nonFraction>&#160;million were, $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="insm:ProceedsFromRoyaltyFinancingAgreementNet" format="ixt:num-dot-decimal" scale="6" id="f-861">146.2</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company&#8217;s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective interest method over the life of the arrangement, in accordance ASC 470, Debt and ASC 835, Interest. The initial annual effective interest rate was determined to be&#160;<ix:nonFraction unitRef="number" contextRef="c-130" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-862">12.4</ix:nonFraction>%. The Company is utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and updates the effective interest rate on a quarterly basis.&#160;</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11.      Royalty Financing Agreement (Continued)</span></div></div><ix:continuation id="f-850-1"><ix:continuation id="f-778-2"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account for the six-month period ended June&#160;30, 2024 and year ended December&#160;31, 2023 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"/><td style="width:48.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended <br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing agreement liability - beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-863">158,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-864">151,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interest Payments paid and payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-865">6,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-866">12,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-867">9,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-868">18,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing agreement liability - ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-869">161,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-870">158,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing issuance costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty issuance costs, unamortized - beginning balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="f-871">3,128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="f-872">3,523</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-873">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-874">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="insm:DebtIssuanceCostsOther" format="ixt:fixed-zero" scale="3" id="f-875">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="insm:DebtIssuanceCostsOther" scale="3" id="f-876">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred issuance costs, unamortized - ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="f-877">2,866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="f-878">3,128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Royalty Financing Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-879">158,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-880">155,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revenue Interest Payments payable in connection with the royalty financing agreement were $<ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="f-881">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="f-882">3.3</ix:nonFraction> million as of June&#160;30, 2024 and December&#160;31, 2023, respectively, which were recorded within accounts payable and accrued expenses on the consolidated balance sheet. Non-cash interest expense is recorded within interest expense in the consolidated statements of comprehensive loss.</span></div></ix:continuation><div id="ib049349da60d4a3c9beace0bfd291454_67"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-883" continuedAt="f-883-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">12.      Shareholders' Equity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;As of June&#160;30, 2024, the Company had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-884">500,000,000</ix:nonFraction> shares of common stock authorized with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-885">0.01</ix:nonFraction> per share and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-886"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-887">166,666,599</ix:nonFraction></ix:nonFraction> shares of common stock issued and outstanding. In addition, as of June&#160;30, 2024, the Company had reserved <ix:nonFraction unitRef="shares" contextRef="c-236" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-888">23,430,187</ix:nonFraction> shares of common stock for issuance upon the exercise of outstanding stock options, <ix:nonFraction unitRef="shares" contextRef="c-237" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-889">3,425,045</ix:nonFraction> shares of common stock for issuance upon the vesting of RSUs and <ix:nonFraction unitRef="shares" contextRef="c-238" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-890">664,724</ix:nonFraction> shares for issuance upon the vesting of PSUs. The Company has also reserved <ix:nonFraction unitRef="shares" contextRef="c-202" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-891">23,438,430</ix:nonFraction> shares of common stock in the aggregate for issuance upon conversion of the 2025 Convertible Notes and 2028 Convertible Notes, subject to adjustment in accordance with the applicable indentures. In connection with the Business Acquisition, the Company reserved <ix:nonFraction unitRef="shares" contextRef="c-239" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-892">9,406,112</ix:nonFraction> shares of the Company&#8217;s common stock, subject to certain closing-related reductions. The shares of the Company&#8217;s common stock reserved in connection with the Motus acquisition were partly issued as acquisition consideration at closing and on the first and second anniversaries of the closing date of the acquisition, and will also be issued upon the third anniversary of the closing date of the acquisition and upon the achievement of certain development and regulatory milestone events, subject to certain reductions. The shares of the Company&#8217;s common stock reserved in connection with the AlgaeneX acquisition will be issued upon the achievement of a development milestone event, subject to certain reductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Of the <ix:nonFraction unitRef="shares" contextRef="c-240" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-893">9,406,112</ix:nonFraction> shares reserved, subject to certain closing-related reductions, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-241" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-894">2,889,367</ix:nonFraction> shares of the Company's common stock in connection with the Business Acquisition (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 16 - Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) in the third quarter of 2021, after certain closing-related deductions. In the third quarter of 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-242" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-895">171,427</ix:nonFraction> shares of the Company's common stock to fulfill the payment required to Motus equityholders on the first anniversary of the Business Acquisition. In the third quarter of 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-243" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-896">177,203</ix:nonFraction> shares of the Company's common stock to fulfill the payment required to Motus equityholders on the second anniversary of the Business Acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the second quarter of 2023, in connection with the Company's acquisition of Adrestia Therapeutics Ltd. (Adrestia), the Company issued <ix:nonFraction unitRef="shares" contextRef="c-244" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-897">3,430,867</ix:nonFraction> shares of the Company's common stock as consideration at closing. See </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 16 - Acquisitions</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Company&#8217;s acquisition of Vertuis Bio, Inc. (Vertuis), the Company reserved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="shares" contextRef="c-245" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-898">550,000</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> shares of the Company&#8217;s common stock, subject to future adjustment. An aggregate of <ix:nonFraction unitRef="shares" contextRef="c-246" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-899">500,000</ix:nonFraction> of the reserved shares were issued as acquisition consideration at closing. See </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 16 - Acquisitions</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 17 - Subsequent Events</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for further details. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, the Company completed an underwritten offering of <ix:nonFraction unitRef="shares" contextRef="c-247" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-900">13,750,000</ix:nonFraction> shares of the Company's common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-248" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-901">20.00</ix:nonFraction> per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expense of $<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-902">16.2</ix:nonFraction>&#160;million, were $<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-903">258.8</ix:nonFraction>&#160;million.</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">12.      Shareholders' Equity (Continued)</span></div></div><ix:continuation id="f-883-1"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2021, the Company entered into a sales agreement with SVB Leerink LLC (now known as Leerink Partners LLC) (Leerink), to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-5" name="insm:CommonStockAuthorizedAggregateGrossSalesProceeds" format="ixt:num-dot-decimal" scale="6" id="f-904">250.0</ix:nonFraction>&#160;million, from time to time, through an &#8220;at the market&#8221; equity offering program (the ATM program), under which Leerink acted as sales agent. In</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> 2023, the Company issued and sold an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="shares" contextRef="c-251" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-905">6,503,041</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> shares of common stock through the ATM program at a weighted-average public offering price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-252" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-906">24.12</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> per share and received net proceeds of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-907">152.2</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2024, the Company entered into a new sales agreement with Leerink to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-5" name="insm:CommonStockAuthorizedAggregateGrossSalesProceeds" scale="6" id="f-908">500.0</ix:nonFraction> million, from time to time, through a new &#8220;at the market&#8221; equity offering program (the new ATM program), under which Leerink acts as sales agent. In connection with entering into the new ATM program, the Company terminated the ATM program. The Company has <ix:nonFraction unitRef="shares" contextRef="c-254" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-909">not</ix:nonFraction> issued any shares under the new ATM program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2024, the Company completed an underwritten offering of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="shares" contextRef="c-255" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-910">14,514,562</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> shares of the Company's common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-256" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-911">51.50</ix:nonFraction> per share. <ix:nonFraction unitRef="shares" contextRef="c-257" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-912">1,893,203</ix:nonFraction> of the shares of common stock were issued pursuant to the exercise in full of the underwriters' option to purchase additional shares. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and estimated offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-913">34.3</ix:nonFraction>&#160;million, were $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-914">713.2</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;As of June&#160;30, 2024, the Company had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-915">200,000,000</ix:nonFraction> shares of preferred stock authorized with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-916">0.01</ix:nonFraction> per share and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-917"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-918">no</ix:nonFraction></ix:nonFraction> shares of preferred stock were issued and outstanding.</span></div></ix:continuation><div id="ib049349da60d4a3c9beace0bfd291454_70"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-919" continuedAt="f-919-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">13.      Stock-Based Compensation</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's current equity compensation plan, the Insmed Incorporated Amended and Restated 2019 Incentive Plan (the 2019 Incentive Plan), was approved by shareholders at the Company's Annual Meeting of Shareholders on May&#160;13, 2024.&#160;The 2019 Incentive Plan replaced the Insmed Incorporated 2019 Incentive Plan. The 2019 Incentive Plan is administered by the Compensation Committee of the Board of Directors of the Company.&#160;Under the terms of the 2019 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards to eligible employees and non-employee directors.&#160;At the May 2024 Annual Meeting of Shareholders, the Company's shareholders approved Amendment No. 1 to the 2019 Incentive Plan, which provides for the issuance of an additional <ix:nonFraction unitRef="shares" contextRef="c-259" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-920">3,000,000</ix:nonFraction> shares under the plan. As of June&#160;30, 2024, <ix:nonFraction unitRef="shares" contextRef="c-260" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-921">4,780,711</ix:nonFraction> shares remain available for future issuance under the 2019 Incentive Plan. The 2019 Incentive Plan will terminate on April 3, 2029 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options to new hires, which awards are made pursuant to the Nasdaq's inducement grant exception to the shareholder approval requirement for grants of equity compensation. During the six months ended June&#160;30, 2024, the Company granted inducement stock options covering <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-922">899,330</ix:nonFraction> shares of the Company's common stock to new employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2018, the 2018 Employee Stock Purchase Plan (ESPP) was approved by shareholders at the Company's 2018 Annual Meeting of Shareholders. The Company has reserved the following for issuance under the ESPP: (i) <ix:nonFraction unitRef="shares" contextRef="c-261" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-923">1,000,000</ix:nonFraction> shares of common stock,&#160;plus&#160;(ii)&#160;commencing on January&#160;1, 2019 and ending on December&#160;31, 2023, an additional number of shares to be added on the first day of each calendar year equal to the lesser of (A) <ix:nonFraction unitRef="shares" contextRef="c-262" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-924">1,200,000</ix:nonFraction> shares of common stock, (B) <ix:nonFraction unitRef="number" contextRef="c-262" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-925">2</ix:nonFraction>% of the number of outstanding shares of common stock on such date and (C)&#160;an amount determined by the administrator.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;As of June&#160;30, 2024, there was $<ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-926">168.6</ix:nonFraction>&#160;million of unrecognized compensation expense related to unvested stock options. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company had performance-conditioned options totaling <ix:nonFraction unitRef="shares" contextRef="c-236" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-927">114,780</ix:nonFraction> shares outstanding which had not yet met the recognition criteria. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;As of June&#160;30, 2024, there was $<ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-928">72.8</ix:nonFraction>&#160;million of unrecognized compensation expense related to unvested RSU awards.</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Performance Stock Units</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;As of June&#160;30, 2024, there were <ix:nonFraction unitRef="shares" contextRef="c-238" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-929">265,887</ix:nonFraction> unvested PSUs outstanding with an unrecognized compensation expense of $<ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-930">10.4</ix:nonFraction> million. The PSUs are subject to two performance conditions based on brensocatib milestones. As of June 30, 2024, the Company achieved the first performance condition by issuing a press release announcing certain topline results from the ASPEN trial by June 30, 2024. The potential payout of the awards ranges from <ix:nonFraction unitRef="number" contextRef="c-263" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-931">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-264" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-932">250</ix:nonFraction>% of the target, dependent on a market condition that is based on the Company's total shareholder return compared to the NASDAQ Biotechnology Index, subject to certain adjustments (the Peer Group). During the second quarter of 2024, the Company's total shareholder return was compared to the Company's Peer Group and the potential payout of the awards was determined to be <ix:nonFraction unitRef="number" contextRef="c-71" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-933">250</ix:nonFraction>% of the target, pending the achievement of the second performance condition, the acceptance of an NDA by the FDA for brensocatib, and satisfaction of the remaining service condition to such awards.</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">13.      Stock-Based Compensation (Continued)</span></div></div><ix:continuation id="f-919-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-934" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options, RSUs and the ESPP during the three and six months ended June&#160;30, 2024 and 2023 (in thousands):&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:30.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-935">11,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-936">8,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-937">21,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-938">16,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-939">11,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-940">9,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-941">23,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-942">18,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-943">23,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-944">18,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-945">44,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-946">34,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="c-74" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-947"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-948">no</ix:nonFraction></ix:nonFraction> stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to PSUs during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended June&#160;30, 2024 or June&#160;30, 2023, as the second performance condition associated with the PSU awards was not probable as of either date.</span></div></ix:continuation><div id="ib049349da60d4a3c9beace0bfd291454_73"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-949" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">14.      Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a provision for income taxes of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-950">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-951">0.5</ix:nonFraction> million for the three months ended June 30, 2024 and 2023, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-952">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-953">1.0</ix:nonFraction> million for the six months ended June 30, 2024 and 2023, respectively. The provisions recorded for the three and six months ended June&#160;30, 2024 and 2023 are primarily a result of certain of the Company's international subsidiaries, which had taxable income during the periods. Additionally, the Company is impacted by certain state taxes which effectively impose income tax on modified gross revenues. In jurisdictions where the Company has net losses, there was a full valuation allowance recorded against the Company's deferred tax assets and therefore <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-954">no</ix:nonFraction> tax benefit was recorded.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to US federal, state and international income taxes and the statute of limitations for tax audit is open for the Company&#8217;s federal tax returns for the years ended 2020 and later, generally open for certain states for the years 2019 and later, and generally open for international jurisdictions for the years 2018 and later. The Company has incurred net operating losses since inception, except for the year ended December&#160;31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin. As of June&#160;30, 2024 and December&#160;31, 2023, the Company had recorded reserves for unrecognized income tax benefits against certain deferred tax assets in the US.&#160;However, given the Company&#8217;s valuation allowance position, these reserves do not have an impact on the balance sheet as of June&#160;30, 2024 and December&#160;31, 2023 or the consolidated statements of comprehensive loss for the three and six months ended June&#160;30, 2024 and 2023.&#160;The Company has <ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-955">no</ix:nonFraction>t recorded any accrued interest or penalties related to uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next twelve months.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Organisation for Economic Co-operation and Development (OECD) recently published a framework to implement a global corporate minimum income tax rate of 15% on income arising in low-tax jurisdictions (Pillar Two). The Pillar Two proposed legislation is applicable to multinational corporations with global revenue exceeding &#8364;750 million for at least two years of the preceding four years. Over 140 countries have agreed in principle to implement Pillar Two and many have, or are in the process of, enacting related legislation. The Pillar Two legislation is not anticipated to be effective for the Company until the Company&#8217;s annual global revenues have exceeded the &#8364;750 million threshold. The Company is still evaluating the potential consequences of Pillar Two on its longer-term financial position.</span></div></ix:nonNumeric><div id="ib049349da60d4a3c9beace0bfd291454_76"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-956" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">15.      Commitments and Contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense charged to operations was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-957">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-958">2.1</ix:nonFraction> million for the three months ended June 30, 2024 and 2023, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-959">5.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-960">4.3</ix:nonFraction> million for the six months ended June 30, 2024 and 2023, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="ib049349da60d4a3c9beace0bfd291454_79"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-961" continuedAt="f-961-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">16.      Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adrestia Therapeutics Ltd.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the Company acquired all of the issued and outstanding share capital of Adrestia, a privately held, preclinical stage company. At the closing of the transaction, the Company issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-277" decimals="INF" name="insm:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" format="ixt:num-dot-decimal" scale="0" id="f-962">3,430,867</ix:nonFraction> shares of the Company&#8217;s common stock to Adrestia&#8217;s former shareholders (collectively, the Adrestia shareholders). The closing share price on the date of the transaction was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-963">21.10</ix:nonFraction>, resulting in a purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="6" id="f-964">72.4</ix:nonFraction> million. The Adrestia shareholders may also become entitled to receive contingent payments up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" scale="6" id="f-965">326.5</ix:nonFraction> million in cash upon the achievement of certain development, regulatory and commercial milestone events, as well as royalty payments based upon a low single-digit percentage of net sales of certain products, both subject to the terms and conditions of the agreement.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the Company&#8217;s common stock issued to the Adrestia shareholders were issued pursuant to Section 4(a)(2) of the Securities Act of 1933 (and, with respect to certain Adrestia shareholders, in reliance on Regulation S promulgated under the Securities Act of 1933). The Company did not receive any net proceeds from the issuance of common stock to the Adrestia shareholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the acquisition under ASC 805 and ASU 2017-01 and concluded that substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets and accounted for the transaction as an asset acquisition. The Company determined that the IPR&amp;D acquired did not have any future alternative use and, in accordance with ASC 730, Research and Development, expensed the assets within research and development in the consolidated statement of comprehensive loss as of the date of the acquisition. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="f-966">76.5</ix:nonFraction> million as IPR&amp;D expense, after adjusting for working capital assumed in connection with the asset acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vertuis Bio, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company acquired Vertuis, a privately held, preclinical stage company. At the closing of the transaction, the Company issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-278" decimals="INF" name="insm:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" format="ixt:num-dot-decimal" scale="0" id="f-967">500,000</ix:nonFraction> shares of the Company&#8217;s common stock to Vertuis&#8217; former stockholders and an individual who are entitled to receive a portion of the acquisition consideration (collectively, the Vertuis equityholders). The closing share price on the date of the transaction was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-279" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-968">18.50</ix:nonFraction>. The Company is obligated to pay the Vertuis equityholders up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="f-969">23.0</ix:nonFraction>&#160;million in cash upon the achievement of certain development and regulatory milestone events, and up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="f-970">63.8</ix:nonFraction>&#160;million in cash upon the achievement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of certain net sales-based milestone events, in each case, subject to certain reductions. See </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17 - Subsequent Events</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the Company&#8217;s common stock issued to the Vertuis equityholders were issued pursuant to Section 4(a)(2) of the Securities Act of 1933.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:AssetAcquisitionTableTextBlock" id="f-971" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the purchase price (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.543%"><tr><td style="width:1.0%"/><td style="width:72.276%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.146%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.278%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of Insmed common stock issued on closing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-4" name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" scale="6" id="f-972">9.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of Insmed common stock issued in July 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-4" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" scale="6" id="f-973">1.00</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-4" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="6" id="f-974">10.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the acquisition under ASC 805 and ASU 2017-01 and concluded that substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets and accounted for the transaction as an asset acquisition. The Company determined that the assets acquired did not have any future alternative use and, in accordance with ASC 730, Research and Development, expensed the assets within research and development in the consolidated statement of comprehensive loss as of the date of the acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combination</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2021, the Company acquired all of the equity interests of Motus and AlgaeneX, each a privately held, preclinical stage company. In connection with the closing of the Company&#8217;s acquisition of Motus, the Company issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-282" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-975">2,889,367</ix:nonFraction> shares of the Company&#8217;s common stock, following certain closing-related reductions, to Motus&#8217;s former stockholders and option holders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, Motus equityholders), subject to certain adjustments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company is obligated to issue to Motus equityholders an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-976"><ix:nonFraction unitRef="shares" contextRef="c-92" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-977"><ix:nonFraction unitRef="shares" contextRef="c-93" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-978">184,433</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s common stock on each of the first, second and third anniversaries of the closing date and up to <ix:nonFraction unitRef="shares" contextRef="c-98" decimals="INF" name="insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-979">5,348,572</ix:nonFraction> shares in the aggregate upon the achievement of certain development and regulatory milestone </span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">16.      Acquisitions (Continued)</span></div></div><ix:continuation id="f-961-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">events, and to pay to the Motus equityholders an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-980">35</ix:nonFraction>&#160;million upon the achievement of certain net sales-based milestones and a portion of the value of a priority review voucher (to the extent issued to the Company), in each case, subject to certain reductions. During August 2022 and August 2023, the Company fulfilled the payments due on the first and second anniversaries of the closing date by issuing <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-981">171,427</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="c-95" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-982">177,203</ix:nonFraction> shares of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's common stock, respectively, after certain reductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing of the Company&#8217;s acquisition of AlgaeneX, the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-983">1.5</ix:nonFraction>&#160;million in cash to AlgaeneX&#8217;s former stockholders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, the AlgaeneX equityholders). The Company is obligated to issue to the AlgaeneX equityholders an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-984">368,867</ix:nonFraction> shares of the Company&#8217;s common stock upon the achievement of a development milestone event and pay to the AlgaeneX equityholders a mid-single digits licensing fee on certain future payments received by the Company in licensing transactions for AlgaeneX&#8217;s manufacturing technology, in each case, subject to certain reductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the Company&#8217;s common stock issued to the Motus equityholders and the AlgaeneX equityholders were issued, and the shares issuable in the future will be issued, pursuant to Section 4(a)(2) of the Securities Act of 1933, and the numbers of such issued and issuable shares was calculated based on a per share value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-285" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="f-985"><ix:nonFraction unitRef="usdPerShare" contextRef="c-286" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="f-986">27.11</ix:nonFraction></ix:nonFraction>, which was the weighted average price per share of the Company's common stock preceding the closing of the Business Acquisition for the <ix:nonFraction unitRef="days" contextRef="c-287" decimals="INF" name="insm:BusinessAcquisitionConsecutiveTradingDayPeriod" scale="0" id="f-987">45</ix:nonFraction> consecutive trading day period beginning on May 24, 2021. The Company will not receive any proceeds from the issuance of common stock to the Motus equityholders or the AlgaeneX equityholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Business Acquisition under ASC 805 and ASU 2017-01. The Company concluded that substantially all of the fair value of the gross assets acquired is not concentrated in a single identifiable asset or a group of similar identifiable assets. The transaction does not pass the screen test and thus management performed a full assessment to determine if the acquired entities met the definition of a business. For the full assessment, management considered whether it has acquired (a) inputs, (b) substantive processes, and (c) outputs. Under ASC 805, to be considered a business, a set of activities and assets is required to have only the first two of the three elements, which together are or will be used in the future to create outputs. Management determined that the acquired entities met the definition of a business since the Company acquired inputs and substantive processes capable of producing outputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, the transaction has been accounted for under the acquisition method of accounting. Under the acquisition method, the total purchase price of the acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on the fair values as of the date of the acquisition. The fair value of the consideration totaled approximately $<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-988">165.5</ix:nonFraction>&#160;million. The results of Motus's and AlgaeneX's operations have been included in the Company's consolidated statements of comprehensive loss beginning on the acquisition date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D was capitalized as of the acquisition date and accounted for as indefinite-lived intangible assets until completion or disposition of the assets or abandonment of the associated research and development efforts. Upon successful completion of the development efforts, the useful lives of the IPR&amp;D assets will be determined based on the anticipated period of regulatory exclusivity and will be amortized within operating expenses. Until that time, the IPR&amp;D assets will be subject to impairment testing and will not be amortized. The goodwill recorded related to the acquisition is the excess of the fair value of the consideration transferred by the acquirer over the fair value of the net identifiable assets acquired and liabilities assumed at the date of acquisition. The goodwill recorded is not deductible for tax purposes.</span></div></ix:continuation><div id="ib049349da60d4a3c9beace0bfd291454_979"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-989" continuedAt="f-989-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">17.      Subsequent Events</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conversions of 2025 Convertible Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of August 7, 2024, holders of $<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="f-990">224.7</ix:nonFraction>&#160;million aggregate principal amount of the outstanding 2025 Convertible Notes elected to convert their notes into shares of the Company's</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> common stock at a conversion rate of 25.5384 shares of common stock per $1,000 principal amount of 2025 Convertible Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-290" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-991">39.16</ix:nonFraction> per share of common stock). These conversions will result in the issuance of an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-289" decimals="INF" name="us-gaap:ConversionOfStockSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-992">5,739,433</ix:nonFraction> shares of the Company&#8217;s common stock. Unless earlier converted, on the Redemption Date, the remaining $<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-5" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:num-dot-decimal" scale="6" id="f-993">0.3</ix:nonFraction>&#160;million aggregate principal amount of 2025 Convertible Notes outstanding will be redeemed by the Company at the Redemption Price. See</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 10 - Debt</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Conversions of 2028 Convertible Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2024, the 2028 Convertible Notes became convertible by the holders of such notes due to the satisfaction of the Stock Price Convertibility Trigger applicable to such notes. The current conversion rate for the 2028 Convertible Notes is </span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">17.      Subsequent Events (Continued)</span></div></div><ix:continuation id="f-989-1"><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.7692 shares of common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-291" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-994">32.50</ix:nonFraction> per share of comm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on stock). The Company has elected to settle any conversions of the 2028 Convertible Notes in shares of common stock.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of August 2, 20</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24, holders of <ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt-sec:numwordsen" scale="3" id="f-995">nine</ix:nonFraction> thousand dollars of aggregate principal amount of 2028 Convertible Notes elected to convert their notes, resulting in an issuance of an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-292" decimals="INF" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="f-996">276</ix:nonFraction> shares of the Company&#8217;s common stock. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The 2028 Convertible Notes will only be convertible during the third quarter of 2024 unless another triggering event occurs. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Note 10 - Debt </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vertuis Deferred Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, the Company issued the Vertuis equityholders an additional $<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="f-997">1.0</ix:nonFraction>&#160;million of shares of the Company's common stock, or <ix:nonFraction unitRef="shares" contextRef="c-293" decimals="INF" name="insm:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" format="ixt:num-dot-decimal" scale="0" id="f-998">14,773</ix:nonFraction> shares of common stock, based on the closing share price on June 28, 2024. See Note 16 &#8211; Acquisitions for further details.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="ib049349da60d4a3c9beace0bfd291454_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form&#160;10-Q contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) identify forward-looking statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements are based on our current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timing discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">failure to continue to successfully commercialize ARIKAYCE, our only approved product, in the US, Europe or Japan (amikacin liposome inhalation suspension, Liposomal 590 mg Nebuliser Dispersion, and amikacin sulfate inhalation drug product, respectively), or to maintain US, European or Japanese approval for ARIKAYCE;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to obtain full approval of ARIKAYCE from the FDA, including the risk that we will not successfully or in a timely manner complete the confirmatory post-marketing clinical trial required for full approval of ARIKAYCE, or our failure to obtain regulatory approval to expand ARIKAYCE&#8217;s indication to a broader patient population; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">failure to obtain, or delays in obtaining, regulatory approvals for brensocatib, TPIP or our other product candidates in the US, Europe or Japan or for ARIKAYCE outside the US, Europe or Japan, including separate regulatory approval for Lamira in each market and for each usage; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully commercialize brensocatib, TPIP or our other product candidates, if approved by applicable regulatory authorities, or to maintain applicable regulatory approvals for brensocatib, TPIP or our other product candidates, if approved; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties or changes in the degree of market acceptance of ARIKAYCE or, if approved, brensocatib or TPIP by physicians, patients, third-party payors and others in the healthcare community; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to obtain and maintain adequate reimbursement from government or third-party payors for ARIKAYCE or, if approved, brensocatib or TPIP, or acceptable prices for ARIKAYCE or, if approved, brensocatib or TPIP;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">inaccuracies in our estimates of the size of the potential markets for ARIKAYCE, brensocatib, TPIP or our other product candidates or in data we have used to identify physicians, expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">failure of third parties on which the Company is dependent to manufacture sufficient quantities of ARIKAYCE, brensocatib, or TPIP for commercial or clinical needs, to conduct the Company's clinical trials, or to comply with the Company's agreements or laws and regulations that impact the Company's business; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risks and uncertainties associated with, and the perceived benefits of, our secured senior loan with certain funds managed by Pharmakon and our royalty financing with OrbiMed, including our ability to maintain compliance with the covenants in the agreements for the senior secured loan and royalty financing and the impact of the restrictions on our operations under these agreements;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to create or maintain an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE or any of our product candidates that are approved in the future;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully conduct future clinical trials for ARIKAYCE, brensocatib, TPIP and our other product candidates and our potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval of our product candidates or to permit the use of ARIKAYCE in the broader population of patients with MAC lung disease, among other things;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">development of unexpected safety or efficacy concerns related to ARIKAYCE, brensocatib, TPIP or our other product candidates; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risks that our clinical studies will be delayed, that serious side effects will be identified during drug development, or that any protocol amendments submitted will be rejected;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or may be interpreted differently if additional data are disclosed, or that blinded data will not be predictive of unblinded data;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risk that our competitors may obtain orphan drug exclusivity for a product that is essentially the same as a product we are developing for a particular indication; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to attract and retain key personnel or to effectively manage our growth;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to successfully integrate our recent acquisitions and appropriately manage the amount of management&#8217;s time and attention devoted to integration activities;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risks that our acquired technologies, products and product candidates are not commercially successful;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">inability to adapt to our highly competitive and changing environment;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">inability to access, upgrade or expand our technology systems or difficulties in updating our existing technology or developing or implementing new technology;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risk that we are unable to maintain our significant customers;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risk that government healthcare reform materially increases our costs and damages our financial condition;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risk that our current and potential future use of artificial intelligence (AI) and machine learning may not be successful;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">deterioration in general economic conditions in the US, Europe, Japan and globally, including the effect of prolonged periods of inflation, affecting us, our suppliers, third-party service providers and potential partners;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that we could become involved in costly intellectual property disputes, be unable to adequately protect our intellectual property rights or prevent disclosure of our trade secrets and other proprietary information, and incur costs associated with litigation or other proceedings related to such matters;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions or other obligations imposed on us by agreements related to ARIKAYCE, brensocatib or our other product candidates, including our license agreements with PARI and AstraZeneca AB (AstraZeneca), and failure to comply with our obligations under such agreements;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and potential reputational damage resulting from litigation to which we are or may become a party, including product liability claims;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risk that our operations are subject to a material disruption in the event of a cybersecurity attack or issue;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our limited experience operating internationally;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws and regulations applicable to our business, including any pricing reform and laws that impact our ability to utilize certain third parties in the research, development or manufacture of our product candidates, and failure to comply with such laws and regulations;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our history of operating losses, and the possibility that we never achieve or maintain profitability;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">goodwill impairment charges affecting our results of operations and financial condition;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">inability to repay our existing indebtedness and uncertainties with respect to our ability to access future capital; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">delays in the execution of plans to build out an additional third-party manufacturing facility approved by the appropriate regulatory authorities and unexpected expenses associated with those plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Any forward-looking statement is based on information current as of the date of this Quarterly Report on Form 10-Q and speaks only as of the date on which such statement is made. Actual events or results may differ materially from the results, plans, intentions or expectations anticipated in these forward-looking statements as a result of a variety of factors, many of which are beyond our control. More information on factors that could cause actual results to differ materially from those anticipated is included from time to time in our reports filed with the Securities and Exchange Commission (SEC), including, but not limited to, those described in the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this Quarterly Report on Form 10-Q and included in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000110450624000008/insm-20231231.htm">Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 202</a>3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on&#160;Form&#160;10-Q and the consolidated financial statements and related notes thereto in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000110450624000008/insm-20231231.htm">Annual Report on Form&#160;10-K for the year ended December&#160;31, 202</a>3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="ib049349da60d4a3c9beace0bfd291454_85"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;We are a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Our first commercial product, ARIKAYCE, is approved in the US as ARIKAYCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the EC approved ARIKAYCE for the treatment of NTM lung infections caused by MAC in adults with limited treatment options who do not have CF. In March 2021, Japan's MHLW approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. NTM lung disease caused by MAC (which we refer to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lun</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g damage and can be fatal.</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pipeline includes clinical-stage programs brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of DPP1, which we are developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including CRSsNP and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HS</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. TPIP is an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for PH-ILD and PAH. Our early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information below summarizes our updates and anticipated near-term milestones for ARIKAYCE and our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARIKAYCE</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We announced positive topline results from the ARISE trial in the third quarter of 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2024, we met and aligned with the FDA on the primary endpoint for the ENCORE study. If the data are positive, ENCORE may support a label expansion to include all MAC lung patients as well as support full approval for the current refractory indication. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are targeting enrollment of 400 patients in the ENCORE study. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anticipate reporting topline data from ENCORE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the first quarter of 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Brensocatib</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We announced positive topline results from the ASPEN trial in May 2024. The study met its primary endpoint, with both dosage strengths of brensocatib demonstrating statistically significant reductions in the annualized rate of adjudicated pulmonary exacerbations (PEs) versus placebo. We plan to file an NDA with the FDA for brensocatib in patients with bronchiectasis in the fourth quarter of 2024, followed by filings with the European and Japanese regulatory authorities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are advancing commercial readiness activities in preparation for a launch of brensocatib for patients with bronchiectasis, if approved. If successful, we anticipate a launch in the US in mid-2025, followed by launches in Europe and Japan in the first half of 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are exploring the potential of brensocatib in additional neu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trophil-mediated diseases. The Phase 2b BiRCh trial of brensocatib in patients with CRSsNP is underway and we expect to initiate a Phase 2 study of brensocatib in patients with HS in the second half of 2024.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TPIP</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">In May 2024, we reported topline safety data and certain exploratory efficacy endpoints from the Phase 2 study of TPIP in patients with PH-ILD. Based on these Phase 2 results in PH-ILD, we are advancing toward discussions with global regulatory authorities on the design of a Phase 3 study in PH-ILD, which we anticipate initiating in 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enrollment in the Phase 2 study of TPIP in PAH remains ongoing. We anticipate topline results in 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Early-Stage Research</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We continue to progress our early-stage research programs across a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protein manufacturing, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA end-joining, and synthetic rescue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To complement our internal research and development, we also actively evaluate in-licensing and acquisition opportunities for products, product candidates and technologies, including those that address serious and rare diseases with significant unmet need.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to develop and commercialize first- and best-in-class therapies that serve patient communities where the need is greatest. Our first product, ARIKAYCE, is approved in the US as ARIKAYCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). We are not aware of any other approved inhaled therapies specifically indicated to treat MAC lung disease in North America, Europe or Japan. We believe that ARIKAYCE has the potential to prove beneficial in other patients with refractory MAC. Our product candidates are brensocatib, our Phase 3 product candidate that we are developing for patients with bronchiectasis and other neutrophil-mediated diseases, and TPIP, our Phase 2 product candidate that may offer a differentiated product profile for patients with PH-ILD and PAH. We announced positive topline results from our Phase 3 ASPEN trial in brensocatib in May 2024 and plan to file an NDA with the FDA for brensocatib in patients with bronchiectasis in the fourth quarter of 2024, followed by filings with the European and Japanese regulatory authorities. We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are also advancing our early-stage research programs encompassing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our key priorities are as follows:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continue to provide ARIKAYCE to appropriate patients and expand our reliable revenue stream;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Produce topline clinical data readouts in the near and long term;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advance commercial readiness activities to serve significantly more patients facing serious diseases; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Control spending, prudently deploying capital to support the best return-generating opportunities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARIKAYCE for Patients with MAC Lung Disease</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARIKAYCE is our first approved product. ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of refractory MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. In October 2020, ARIKAYCE received approval in Europe for the treatment of NTM lung infections caused by MAC in adults with limited treatment options who do not have CF. In March 2021, ARIKAYCE received approval in Japan for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Amikacin solution for parenteral administration is an established drug that has activity against a variety of NTM; however, its use is limited by the need to administer it intravenously and by toxicity to hearing, balance, and kidney function. Unlike amikacin solution for intravenous administration, our proprietary Pulmovance&#8482; technology uses charge-neutral liposomes to deliver amikacin directly to the lungs where liposomal amikacin is taken up by the lung macrophages where the MAC infection resides. This technology also prolongs the release of amikacin in the lungs, while minimizing systemic exposure, thereby offering the potential for decreased systemic toxicities. ARIKAYCE's ability to deliver high levels of amikacin directly to the lung and sites of MAC infection via the use of our Pulmovance technology distinguishes it from intravenous amikacin. ARIKAYCE is administered once-daily using Lamira, an inhalation device developed and manufactured by PARI. Lamira is a portable nebulizer that enables aerosolization of liquid medications via a vibrating, perforated membrane, and was designed specifically for ARIKAYCE delivery.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has designated ARIKAYCE as an orphan drug and a Qualified Infectious Disease Product (QIDP) for NTM lung disease. Orphan designated drugs are eligible for seven years of exclusivity for the orphan indication. QIDP designation provides an additional five years of exclusivity for the designated indication. The FDA granted a total of 12 years of exclusivity in the indication for which ARIKAYCE was approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARIKAYCE also has been included in the international treatment guidelines for NTM lung disease. The evidence-based guidelines, issued by the American Thoracic Society (ATS), European Respiratory Society (ERS), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and Infectious Diseases Society of America (IDSA), strongly recommend the use of ARIKAYCE for MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options who have failed to convert to a negative sputum culture after at least six months of treatment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FDA approved a supplemental new drug application for ARIKAYCE, adding important efficacy data regarding the durability and sustainability of culture conversion to the ARIKAYCE label. The data, which are from the Phase 3 CONVERT study of ARIKAYCE, demonstrate that the addition of ARIKAYCE to guideline-based therapy (GBT) was </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated with sustained culture conversion through the end of treatment as well as durable culture conversion three months post-treatment compared with GBT alone.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accelerated Approval</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we submitted an NDA for ARIKAYCE to the FDA to request accelerated approval. Accelerated approval allows drugs that (i) are being developed to treat a serious or life-threatening disease or condition and (ii) provide a meaningful therapeutic benefit over existing treatments to be approved substantially based on an intermediate endpoint or a surrogate endpoint that is reasonably likely to predict clinical benefit, rather than a clinical endpoint such as survival or irreversible morbidity. In September 2018, the FDA granted accelerated approval for ARIKAYCE under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) for the treatment of refractory MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. LPAD, which was enacted as part of the 21st Century Cures Act, serves to advance the development of new antibacterial drugs to treat serious or life-threatening infections in limited populations of patients with unmet needs. As required for drugs approved under the LPAD pathway, labeling for ARIKAYCE includes certain statements to convey that the drug has been shown to be safe and effective only for use in a limited population.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of accelerated approval, we must conduct a post-marketing confirmatory clinical trial. In December 2020, we commenced the post-marketing confirmatory clinical trial program for ARIKAYCE in patients with MAC lung disease consisting of the ARISE trial, an interventional study designed to validate cross-sectional and longitudinal characteristics of a PRO tool in MAC lung disease, and the ENCORE trial, designed to establish the clinical benefits and evaluate the safety of ARIKAYCE in patients with newly diagnosed or recurrent MAC lung infection who have not started antibiotics using the PRO tool validated in the ARISE trial. In September 2023, we announced positive topline results from the ARISE trial. The study met its primary objective of demonstrating that the QOL-B respiratory domain works effectively as a PRO tool in patients with MAC lung disease. Based on these results, we have proposed to the FDA that the change of the respiratory score derived from the QOL-B respiratory domain PRO be the primary endpoint for the ENCORE study. In June 2024, we met and aligned with the FDA on the primary endpoint for the ENCORE study. If the data are positive, ENCORE may support a label expansion to include all MAC lung patients as well as support full approval for the current refractory indication. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on feedback and in alignment with the FDA, we have determined that the primary endpoint for the ENCORE study will include 8 questions from the QOL-B respiratory domain PRO. We are targeting enrollment of 400 patients in the ENCORE study and expect to report topline data in the first quarter of 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Pathway Outside of the US</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the EC granted marketing authorization for ARIKAYCE for the treatment of NTM lung infections caused by MAC in adults with limited treatment options who do not have CF. ARIKAYCE can now be prescribed for patients across the European Union (EU) countries as well as in the UK. ARIKAYCE is reimbursed nationally in France, Belgium, the Netherlands, the UK and Ireland. We have worked with the German National Association of Statutory Health Insurance Funds (GKV-SV) towards an agreement on the price of ARIKAYCE that would allow us to better serve the needs of patients in Germany; however, since we have been unable to reach an agreement, patient supply of ARIKAYCE in Germany was enabled by import from other EU countries in September 2022. We are working to ensure an uninterrupted supply of ARIKAYCE for patients in Germany and to provide physicians and pharmacists the information they need to obtain ARIKAYCE for their patients through the importation pathway. In January 2023, we agreed upon reimbursement terms with the French authorities. To date, we have been unable to reach an acceptable agreement of a nationally reimbursed price with the Italian Medicines Agency (AIFA); however, ARIKAYCE remains commercially available for physicians to prescribe in Italy under Class C, where we set the price and funding is agreed locally.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Japan's MHLW approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. In July 2021, we launched ARIKAYCE in Japan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The CONVERT Study and 312 Study</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated approval of ARIKAYCE was supported by preliminary data from the CONVERT study, a global Phase 3 study evaluating the safety and efficacy of ARIKAYCE in adult patients with refractory MAC lung disease, using achievement of sputum culture conversion (defined as three consecutive negative monthly sputum cultures) by Month 6 as the primary endpoint. Patients who achieved sputum culture conversion by Month 6 continued in the CONVERT study for an additional 12 months of treatment following the first monthly negative sputum culture in order to assess the durability of culture conversion, as defined by patients that have completed treatment and continued in the CONVERT study off all therapy for three months. In May 2019, we presented at the American Thoracic Society meeting that 41/65 (63.1%) of patients on ARIKAYCE plus GBT who had achieved culture conversion by Month 6 had maintained durable culture conversion for three months off all therapy </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to 0/10 (0%) on GBT only (p&lt;0.0002). Safety data for these patients were consistent with safety data previously reported for patients by Month 6 of the CONVERT study.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who did not culture convert by Month 6 may have been eligible to enroll in the 312 study, an open-label extension study for these non-converting patients who completed six months of treatment in the CONVERT study. The primary objective of the 312 study was to evaluate the long-term safety and tolerability of ARIKAYCE in combination with a standard multi-drug regimen. The secondary objectives of the 312 study included evaluating the proportion of subjects achieving culture conversion (defined in the same way as the CONVERT study) by Month 6 and the proportion of subjects achieving culture conversion by Month 12, which was the end of treatment. We previously reported interim data as of December 2017 for patients in the 312 study, with 28.4% of patients who received GBT only in the CONVERT study (19/67) and 12.3% of patients who had received ARIKAYCE plus GBT in the CONVERT study (7/57) achieving culture conversion by Month 6 of the 312 study. The 312 study has concluded and final efficacy data regarding culture conversion were consistent with these interim data. We have analyzed the safety and efficacy data from the 312 study, and we did not observe any new safety signals.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The ARISE Study</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ARISE trial was a global, randomized, double-blind, placebo-controlled Phase 3b study in adult patients with newly diagnosed or recurrent MAC infections that aimed to generate evidence demonstrating the domain specification, reliability, validity, and responsiveness of PRO-based scores, including a respiratory symptom score. The ARISE study met its primary objective of demonstrating that the QOL-B respiratory domain works effectively as a PRO tool in patients with MAC lung disease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in ARISE (N=99) were randomized 1:1 to treatment with ARIKAYCE plus macrolide-based background regimen (ARIKAYCE arm) or placebo plus macrolide-based background regimen (comparator arm) once daily for six months, followed by one month off treatment. ARIKAYCE-treated patients performed better than those in the comparator arm as measured by the QOL-B instrument, with 43.8% of patients achieving an improvement in QOL-B respiratory score above the estimated meaningful within-subject score difference of 14.8, compared with 33.3% of patients in the comparator arm. While the study was not powered to show a statistically significant difference between treatment arms, a strong trend toward significance was observed for improvement from baseline at Month 7 (12.24 vs. 7.76, p=0.1073). Patients in the ARIKAYCE arm also achieved nominally statistically significantly higher culture conversion rates at Month 7 versus patients in the comparator arm (78.8% vs. 47.1%, p=0.0010), and culture conversion was faster and more likely to persist through Month 7 for the ARIKAYCE arm.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the results of ARISE, we plan to explore accelerating the filing for approval of ARIKAYCE in newly infected patients with MAC lung disease with the FDA. Consistent with our expectations, the PMDA in Japan confirmed that it would not consider a label expansion for ARIKAYCE based on data from the ARISE study alone.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ARISE Culture Conversion</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with prior clinical studies, a higher proportion of patients in the ARIKAYCE arm achieved culture conversion by Month 6 (defined as negative cultures at Months 5 and 6) compared to patients in the comparator arm (80.6% vs. 63.9%, p=0.0712). Among patients who achieved culture conversion by Month 6, more patients in the ARIKAYCE arm achieved the first of their two required monthly negative cultures for clinical conversion at Month 1 versus the comparator arm (74.3% vs. 46.7%). As reported above, at Month 7 (one month following the cessation of treatment), 78.8% of patients in the ARIKAYCE arm vs. 47.1% of patients in the comparator arm were culture-converted, suggesting that ARIKAYCE-treated patients are more likely to remain negative.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Correlation Between ARISE Culture Conversion and QOL-B Performance</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the ARIKAYCE arm who achieved culture conversion at both Month 6 and Month 7 had nominally statistically significantly greater improvements in QOL-B respiratory domain scores at Month 7 compared to patients in the ARIKAYCE arm who did not achieve culture conversion (15.74 vs. 3.53, p=0.0167 at Month 6 and 14.89 vs. 4.50, p=0.0416 at Month 7).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ARISE Safety and Tolerability</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discontinuation rate of ARIKAYCE or the placebo used in the comparator arm was 22.9% in the ARIKAYCE arm and 7.8% in the comparator arm. Study completion rates were 91.7% in the ARIKAYCE arm and 94.1% in the comparator arm. No new safety events were observed in the ARIKAYCE arm, and the safety profile in general was as expected in both treatment arms. Treatment-emergent adverse events (TEAEs) were reported by 91.7% of patients in the ARIKAYCE arm and 80.4% of patients in the comparator arm. The most common TEAEs were dysphonia (41.7% for the ARIKAYCE arm vs. 3.9% for the comparator arm), cough (27.1% vs. 7.8%), diarrhea (27.1% vs. 25.5%), and COVID-19 (12.5% vs. 9.8%). Of the treatment-emergent serious adverse events observed in the trial, none were determined to be related to ARIKAYCE by investigators.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Further Research and Lifecycle Management</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently exploring and supporting research and lifecycle management programs for ARIKAYCE beyond treatment of refractory MAC lung disease as part of a combination antibacterial regimen for adult patients who have limited or no treatment options. As noted above, we will continue to advance the post-marketing confirmatory MAC lung disease clinical trial program for ARIKAYCE, through the ARISE and ENCORE trials, which are intended to fulfill the FDA's post-marketing requirement to allow for the full approval of ARIKAYCE in the US, as well as to support the use of ARIKAYCE as a treatment for patients with MAC lung disease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The ENCORE trial is a randomized, double-blind, placebo-controlled Phase 3b study to evaluate the efficacy and safety of an ARIKAYCE-based regimen in patients with newly diagnosed or recurrent MAC infection who have not started antibiotics. Patients are randomized 1:1 to receive ARIKAYCE plus background regimen or placebo plus background regimen once daily for 12 months. Patients will then discontinue all study treatments and remain in the trial for three months for the assessment of durability of culture conversion. The primary endpoint is change from baseline to Month 13 in respiratory symptom score. The key secondary endpoint is the proportion of subjects achieving durable culture conversion at Month 15. In June 2024, we met and aligned with the FDA on the primary endpoint for the ENCORE study. If the data are positive, ENCORE may support a label expansion to include all MAC lung patients as well as support full approval for the current refractory indication. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on feedback and in alignment with the FDA, we have determined that the primary endpoint for the ENCORE study will include 8 questions from the QOL-B respiratory domain PRO. We are targeting enrollment of 400 patients in the ENCORE study and expect to report topline data in the first quarter of 2026.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subsequent lifecycle management studies could also potentially enable us to reach more patients. These initiatives may include new clinical studies sponsored by us and may also include investigator-initiated studies, which are independent clinical studies initiated and sponsored by physicians or research institutions, with funding from us.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Pipeline</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Brensocatib</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brensocatib is a small molecule, oral, reversible inhibitor of DPP1, which we licensed from AstraZeneca in October 2016. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs) in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. Neutrophils contain the NSPs (including neutrophil elastase, proteinase 3, and cathepsin G) that have been implicated in a variety of inflammatory diseases. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2020, AstraZeneca exercised its first option pursuant to our October 2016 license agreement under which AstraZeneca can advance clinical development of brensocatib in the indications of chronic obstructive pulmonary disease (COPD) or asthma. Under the terms of the agreement, upon exercise of this option, AstraZeneca is solely responsible for all aspects of the development of brensocatib up to and including Phase 2b clinical trials in COPD or asthma. In March 2024, AstraZeneca exercised its second and final option under the agreement, to further develop brensocatib beyond Phase 2b clinical trials and, if approved, commercialize brensocatib in the indications of COPD or asthma, upon reaching agreement after good faith negotiations resulting in terms, including financial terms, satisfactory to us and to AstraZeneca for such further development and commercialization. In June 2024, the negotiation period following such exercise of the final option expired. No agreement was reached between us and AstraZeneca to permit AstraZeneca to further develop and, if approved, commercialize brensocatib in the indications of COPD or asthma. We retain full worldwide development and commercialization rights for brensocatib in all indications other than COPD or asthma and AstraZeneca has no further development or commercialization rights for brensocatib in COPD, asthma or any other indication.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, the FDA granted breakthrough therapy designation for brensocatib for the treatment of adu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">lt patients with non-cystic fibrosis bronchiectasis (NCFBE) for reducing exacerbations. The FDA's breakthrough therapy designation is designed to expedite the development and review of therapies that are intended to treat serious or life-threatening diseases and for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy. The benefits of breakthrough therapy designation include more frequent communication and meetings with the FDA, eligibility for rolling and priority review, intensive guidance on an efficient drug development program, and organizational commitment from the FDA involving senior managers. In November 2020, brensocatib was granted access to the PRIME scheme from the European Medicines Agency (EMA) for patients with NCFBE.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the EMA&#8217;s Paediatric Committee approved the brensocatib Pediatric Investigational Plan for the treatment of patients with NCFBE. As a result, the ASPEN trial includes 41 adolescent patients between ages 12 to 17, which will fulfill the pediatric study requirements to support marketing applications in this patient population in the US, Europe and Japan.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The WILLOW Study</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The WILLOW study was a randomized, double-blind, placebo-controlled, parallel-group, multi-center, multi-national, Phase 2 study to assess the efficacy, safety and tolerability, and pharmacokinetics of brensocatib administered once daily for 24 weeks in patients with NCFBE. The WILLOW study was conducted at 116 sites and enrolled 256 adult patients diagnosed with NCFBE who had at least two documented pulmonary exacerbations in the 12 months prior to screening. Patients were randomized 1:1:1 to receive either 10 mg or 25 mg of brensocatib or matching placebo. The primary efficacy endpoint was the time to first pulmonary exacerbation over the 24-week treatment period in the brensocatib arms compared to the placebo arm.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WILLOW Efficacy Data</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We announced topline data for the WILLOW study in February 2020 and full data for the WILLOW study in June 2020. In September 2020, final results from the WILLOW study were published online in the New England Journal of Medicine. The data demonstrate that the WILLOW study met its primary endpoint of time to first pulmonary exacerbation over the 24-week treatment period for both the 10 mg and 25 mg dosage groups of brensocatib compared to placebo (p=0.027, p=0.044, respectively). The risk of exacerbation at any time during the trial was reduced by 42% for the 10 mg group versus placebo (HR 0.58, p=0.029) and by 38% for the 25 mg group versus placebo (HR 0.62, p=0.046). In addition, treatment with brensocatib 10 mg resulted in a significant reduction in the rate of pulmonary exacerbations, a key secondary endpoint, versus placebo. Specifically, patients treated with brensocatib experienced a 36% reduction in the 10 mg arm (p=0.041) and a 25% reduction in the 25 mg arm (p=0.167) versus placebo. Change in concentration of active neutrophil elastase in sputum versus placebo from baseline to the end of the treatment period was also statistically significant (p=0.034 for 10 mg, p=0.021 for 25 mg).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WILLOW Safety and Tolerability Data</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brensocatib was generally well-tolerated in the study. Rates of AEs leading to discontinuation in patients treated with placebo, brensocatib 10 mg, and brensocatib 25 mg were 10.6%, 7.4%, and 6.7%, respectively. The most common AEs in patients treated with brensocatib were cough, headache, sputum increase, dyspnea, fatigue, and upper respiratory tract infection. Rates of adverse events of special interest (AESIs) in patients treated with placebo, brensocatib 10 mg, and brensocatib 25 mg, respectively, were as follows: rates of skin events (including hyperkeratosis) were 11.8%, 14.8%, and 23.6%; rates of dental events were 3.5%, 16.0%, and 10.1%; and rates of infections that were considered AESIs were 17.6%, 13.6%, and 16.9%.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The ASPEN Study</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Base</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d on the positive results of the WILLOW study, in December 2020 we commenced the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in adult patients with b</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ronchiectasis. Patients with bronchiectasis due to CF were not enrolled in the study. The primary endpoint was the rate of adjudicated PEs over the 52-week treatment period. Secondary endpoints included the time to first adjudicated PE, the proportion of subjects free of adjudicated PE by 52 weeks, the absolute change from baseline in post-bronchodilator FEV1, the reduction in annualized rate of severe adjudicated PE, and the change from baseline in the Bronchiectasis QOL-B Respiratory Symptoms Domain Score.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the ASPEN study&#8217;s conduct, more than 460 trial sites were engaged in nearly 40 countries. After excluding sites that did not enroll any patients and all sites in Ukraine, due to the ongoing conflict, the total number of active sites in ASPEN was 391 sites in 35 countries. Adult patients (ages 18 to 85 years) were randomized 1:1:1 and adolescent patients (ages 12 to &lt;18 years) were randomized 2:2:1 for treatment with brensocatib 10 mg, brensocatib 25 mg, or placebo once daily for 52 weeks, followed by 4 weeks off treatment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASPEN Safety and Efficacy Data</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We announced positive topline results from the ASPEN trial in May 2024. The primary efficacy analysis included data from 1,680 adult patients and 41 adolescent patients.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brensocatib was well-tolerated in the study. In addition, the study met its primary endpoint, with both dosage strengths of brensocatib demonstrating statistically significant reductions in the annualized rate of adjudicated PEs versus placebo. The study also met several of its prespecified secondary endpoints with statistical significance. We plan to file an NDA with the FDA for brensocatib in patients with bronchiectasis in the fourth quarter of 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Topline efficacy results from the ASPEN study were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.638%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.530%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brensocatib 10 mg compared to placebo</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="6" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brensocatib 25 mg<br/>compared to placebo</span></td></tr><tr><td colspan="18" style="background-color:#ffffff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Primary Endpoint</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction in annualized rate of PEs</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">p=0.0019*</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">p=0.0046*</span></td></tr><tr><td colspan="18" style="background-color:#ffffff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Secondary Endpoints</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolongation of time to first PE</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7%</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">p=0.0100*</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5%</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">p=0.0182*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in odds of remaining exacerbation free over 52 weeks</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.2%</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">p=0.0059*</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0%</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">p=0.0074*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change from baseline in post-bronchodilator forced expiratory volume in 1 second (FEV1) at week 52</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 mL</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">p=0.3841</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 mL</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">p=0.0054*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction in annualized rate of severe PEs</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.8%</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">p=0.1277</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0%</span></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">p=0.1025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change from baseline in the Quality of Life &#8211; Bronchiectasis (QOL-B) Respiratory Score at week 52</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 points</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">p=0.0594</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8 points</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">p=0.0004&#x5E;</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* - Statistically significant</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#x5E; - Nominally significant p-value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Further Research and Development</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we received notice from the FDA that we were awarded a development grant of $1.8 million for specific work to be performed on a PRO tool. The grant funding is for the development of a novel PRO tool for use in clinical trials to measure symptoms in patients with NCFBE with and without NTM lung infection.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2023, we reported topline data from the Phase 2, multiple-dose, pharmacokinetic/pharmacodynamic study of brensocatib in patients with CF. This Phase 2 study included both patients who were on background CFTR modulator drugs and patients who were not on CFTR modulator drugs. The study duration was approximately one month and dosed CF patients to placebo, 10 mg, 25 mg, and 40 mg of brensocatib. A clear dose-dependent and exposure-dependent inhibition of blood NSPs was observed in patients treated with brensocatib across all doses in this study, consistent with the mechanism of action of brensocatib. Safety and tolerability were consistent with what was observed during the Phase 2 WILLOW study, with no significant drug-related findings. We concluded that an additional cohort evaluating a 65 mg dose of brensocatib is not needed in this patient population</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also plan to explore the potential of brensocatib in additional neutrophil-mediated diseases, including CRSsNP and HS. CRSsNP currently has one approved pharmacological therapy (corticosteriod nasal spray); however, many patients do not respond to corticosteroids or endoscopic sinus surgery. The Phase 2b BiRCh trial of brensocatib in patients with CRSsNP is underway and we expect to initiate a Phase 2 study of brensocatib in patients with HS in the second half of 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treprostinil Palmitil Inhalation Powder</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TPIP is an investigational inhaled formulation of a treprostinil prodrug that has the potential to address certain of the current limitations of existing prostanoid therapies. We believe that TPIP prolongs duration of effect and may provide patients with greater consistency in pulmonary arterial pressure reduction over time. Current inhaled prostanoid therapies must be dosed </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">four to nine times per day. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reducing dose frequency has the potential to ease treatment burden for patients and improve compliance. Additionally, we believe that TPIP may be associated with fewer side effects, including severity and/or frequency of cough, headache, throat irritation, nausea, flushing and dizziness that are associated with high initial drug levels and local upper airway exposure when using current inhaled prostanoid therapies. We believe TPIP may offer a differentiated product profile for PH-ILD and PAH.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we announced topline results from the Phase 1 study of TPIP in healthy volunteers. The objective of this first-in-human single ascending dose and multiple ascending dose study was to assess the pharmacokinetics and tolerability profile of TPIP. Data from the study demonstrated that TPIP was generally well tolerated, with a pharmacokinetic profile that supports continued development with once-daily dosing. The most common AEs across all cohorts in the study were cough, dizziness, headache, and nausea. Most AEs were mild in severity and consistent in nature with those typically seen with other inhaled prostanoid therapies. There were few moderate AEs and no severe or serious AEs. Subjects in the multiple dose panel that incorporated an up-titration approach beginning at 112.5 &#181;g once-daily and progressing to 225 &#181;g once-daily reported fewer AEs compared to the panel dosed with 225 &#181;g once-daily from the first dose.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall pharmacokinetic results demonstrated that treprostinil exposure (AUC and Cmax) was dose-proportional, with low to moderate inter-subject variability. Treprostinil was detected in the plasma at 24 hours at all doses and throughout the 48-hour sampling period for the two highest doses. Compared with currently available inhaled treprostinil therapy, TPIP showed </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantially lower Cmax and longer half-life. Data from this study were presented in an oral session at the European Society of Cardiology Congress in August 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2024, we reported topline safety data and certain exploratory efficacy endpoints from the Phase 2 study of TPIP in patients with PH-ILD. Based on these Phase 2 results in PH-ILD, we are advancing toward discussions with global regulatory authorities on the design of a Phase 3 study in PH-ILD, which we anticipate initiating in 2025. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have an ongoing Phase 2 study designed to investigate the effect of TPIP in patients with PAH. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Enrollment in the Phase 2 study of TPIP in PAH remains ongoing and we anticipate topline results in 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Early-Stage Research</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our early-stage research efforts are comprised of our preclinical programs, advanced through internal research and development and augmented through business development activities. In March 2021, we acquired a proprietary protein deimmunization platform, called Deimmunized by Design, focused on the reengineering of therapeutic proteins to evade immune recognition and reaction. In August 2021, we acquired Motus and AlgaeneX, preclinical stage companies engaged in the research, development and manufacturing of gene therapies for rare genetic disorders. In January 2023, we acquired Vertuis, a privately held, preclinical stage company engaged in the research and development of gene therapies for rare genetic disorders. In June 2023, we acquired Adrestia, a privately held, preclinical stage company using precision genetic models to search for therapeutic targets, precision diagnostics, novel drug compounds and new applications for existing drugs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to progress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> our early-stage research programs across a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Development</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue to develop, acquire, in-license or co-promote other products, product candidates and technologies, including those that address serious and rare diseases that currently have significant unmet needs. We are focused broadly on serious and rare disease therapeutics and prioritizing those areas that best align with our core competencies.</span></div><div id="ib049349da60d4a3c9beace0bfd291454_88"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KEY COMPONENTS OF OUR RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Revenues, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net, consist of net sales of ARIKAYCE. In October 2018, we began shipping ARIKAYCE to our customers in the US, which include specialty pharmacies and specialty distributors. In December 2020, we began commercial sales of ARIKAYCE in Europe. In July 2021, we began recognizing product revenue from commercial sales of ARIKAYCE in Japan. We recognize revenue for product received by our customers net of allowances for customer credits, including prompt pay discounts, service fees, estimated rebates, including government rebates, such as Medicaid rebates and Medicare Part D coverage gap reimbursements in the US, and chargebacks.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Product Revenues (Excluding Amortization of Intangible Assets)</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses. We began capitalizing ARIKAYCE related inventory upon FDA approval of ARIKAYCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in September 2018. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in our research and development functions, including medical affairs and program management. R&amp;D expenses also includes other internal operating expenses, the cost of manufacturing product candidates, including the medical devices for drug delivery, for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities. In addition, R&amp;D expenses include payments to third parties for the license rights to products in development (prior to marketing approval), such as brensocatib, and may include the cost of asset acquisitions. Our R&amp;D expenses related to manufacturing our product candidates and medical devices for clinical study are primarily related to activities at CMOs that manufacture brensocatib, TPIP and early-stage research activities. Our R&amp;D expenses related to clinical trials are primarily related to activities at contract research organizations (CROs) that conduct and manage clinical trials on our behalf. These contracts with CROs set forth the scope of work to be completed at a fixed fee or amount per patient enrolled. Payments under these contracts with CROs primarily depend on performance criteria such as the successful enrollment of patients or the completion of clinical trial milestones as well as time-based fees. Expenses are accrued based on contracted amounts applied to the level of patient enrollment and to activity according to the clinical trial protocol. Deposits for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are then recognized as an expense as the related goods are delivered or the services are performed. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative (SG&amp;A) Expenses</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses consist of salaries, benefits and other related costs, including stock-based compensation, for our non-employee directors and personnel serving in our executive, finance and accounting, legal and compliance, commercial and pre-commercial, corporate development, field sales, information technology and human resource functions. SG&amp;A expenses also include professional fees for legal services, consulting services, including commercial activities, insurance, board of director fees, tax and accounting services and certain milestones related to ARIKAYCE.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of ARIKAYCE, our intangible assets began to be amortized over their estimated useful lives. The fair values assigned to our intangible assets are based on estimates and assumptions we believe are reasonable based on available facts and circumstances. Unanticipated events or circumstances may occur that require us to review the assets for impairment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Fair Value of Deferred and Contingent Consideration Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Business Acquisition, we recorded deferred and contingent consideration liabilities related to potential future milestone payments. Adjustments to the fair value are due to changes in: our stock price; the probability of achieving milestones; or certain other estimated assumptions. The change in fair value of deferred and contingent consideration liabilities is calculated quarterly with gains and losses recorded in the consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment Income and Interest Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income consists of interest and dividend income earned on our cash and cash equivalents and marketable securities. Interest expense consists primarily of contractual interest costs, Royalty Financing Agreement non-cash interest expense and the amortization of debt issuance costs related to our debt. Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Our balance sheet reflects debt, net of the debt issuance costs paid to the lender, and other third-party costs. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Fair Value of Interest Rate Swap</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We record derivative and hedge transactions in accordance with GAAP. In the fourth quarter of 2022, we entered into an interest rate swap contract (the Swap Contract) with a notional value of $350 million to economically hedge our variable rate-based term debt for three years, effectively changing the variable rate under the term debt to a fixed interest rate. Our interest rate swap has not been designated as a hedging instrument for accounting purposes. Consequently, all changes in the fair value of the Swap Contract are reported as a component of net loss in the consolidated statements of comprehensive loss. </span></div><div id="ib049349da60d4a3c9beace0bfd291454_91"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Three Months Ended June 30, 2024 and 2023 </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview - Operating Results</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results for the three months ended June 30, 2024, included the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product revenues, net, increased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$13.1 million, or 17.0%,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as compared to the same period in the prior year as a result of the growth in ARIKAYCE sales;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost of product revenues (excluding amortization of intangible assets) increased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.4 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as compared to the same period in the prior year as a result of the increase in sales volumes of ARIKAYCE;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">R&amp;D expenses decreased $50.2 million as compared to the same period in the prior year primarily as a result of the non-cash cost of the Adrestia acquisition in the second quarter of 2023;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SG&amp;A expenses increased $22.1 million as compared to the same period in the prior year primarily as a result of increases i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n compensation and benefit-related expenses </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and stock-based compensation costs;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Amortization of intangible assets of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was consistent with the same period in the prior year; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Change in fair value of deferred and contingent consideration liabilities increased $90.2 million, primarily as a result of the change in our share price; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interest expense increased $0.6 million as compared to the same period in the prior year due to the Term Loan.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Revenues, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net, consists of net sales of ARIKAYCE. The following table summarizes revenue by geography for the three months ended June&#160;30, 2024 and 2023 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:28.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.970%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.4%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe and rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.9%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total product revenues, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,340&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,229&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,111&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net, for the three months ended June 30, 2024 increased to $90.3 million as compared to $77.2 million in the same period in 2023, an increase of 17.0%, as a result of growth in ARIKAYCE sales in the US, Japan and Europe and the rest of the world. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Product Revenues (excluding amortization of intangible assets)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) for the three months ended June 30, 2024 and 2023 were comprised of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"/><td style="width:37.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.685%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.685%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.685%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.690%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenues (excluding amortization of intangible assets)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cost of product revenues, as % of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) increased by $4.4 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or 26.3%,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to $21.0 million for the three months ended June 30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$16.6 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the same period in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase in cost of product revenues (excluding amortization of intangibles) for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended June 30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was primarily attributable to the increase in product revenues discussed above.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">R&amp;D Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses for the three months ended June 30, 2024 and 2023 were comprised of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:41.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase&#160;(decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">External Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical development&#160;and research</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone payable to AstraZeneca</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NA</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,774)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory, quality assurance, and medical affairs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adrestia non-cash asset acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal&#8212;external expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,897&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,505)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Internal Expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefit-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other internal operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,725)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal&#8212;internal expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,356&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,072&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,284&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total R&amp;D expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,748&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196,969&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,221)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses decreased to $146.7 million during the three months ended June 30, 2024 from $197.0 million in the same period in 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The $50.2 million decrease in R&amp;D expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was primarily due to the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$76.5 million non-cash asset acquisition cost of Adrestia in the second quarter of 2023, partially offset by an increase of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$14.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in compensation and benefit-related expenses and stock-based compensation costs due to an increase in headcount and a $12.5&#160;million milestone payment due to AstraZeneca u</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pon our release of an official public statement that we intend to file an NDA for brensocatib</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">External R&amp;D expenses by product for the three months ended June&#160;30, 2024 and 2023 were comprised of the following (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:34.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.637%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARIKAYCE external R&amp;D expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(477)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brensocatib external R&amp;D expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TPIP external R&amp;D expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash asset acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external R&amp;D expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total external R&amp;D expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,392&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,897&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,505)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SG&amp;A Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses for the three months ended June 30, 2024 and 2023 were comprised of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:39.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.753%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefit-related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and other external expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility related and other internal expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total SG&amp;A expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,569&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,431&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses increased to $106.6 million during the three months ended June 30, 2024 from $84.4 million in the same period in 2023. The $22.1 million increase resulted primarily from an $9.7 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase in compensation and benefit-related expenses and stock-based compensation costs due to an increase in headcount and an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8.8 million increase in professional fees and other external expenses driven by commercial readiness activities fo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r brensocatib.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets for both the three months ended June&#160;30, 2024 and 2023 was $1.3 million. Amortization of intangible assets is comprised of amortization of acquired ARIKAYCE R&amp;D and amortization of the milestones paid to PARI for the FDA and EC approvals of ARIKAYCE.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Fair Value of Deferred and Contingent Consideration Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of deferred and contingent consideration for the three months ended June 30, 2024 was $103.7&#160;million. The change is related to the fair value of the potential future consideration to be paid to former equityholders of the businesses we acquired. The change in fair value of deferred and contingent consideration for the three months ended June 30, 2024 was primarily due to the increase in our share price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment Income</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income decreased to $10.3 million for the three months ended June&#160;30, 2024 as compared to $11.2 million in the same period in 2023 primarily due to a decrease in our average cash and cash equivalents and marketable securities balances in 2024 relative to 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased to $21.3 million for the three months ended June&#160;30, 2024 as compared to $20.6 million in the same period in 2023 primarily due to interest related to the Term Loan. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10 - Debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11 - Royalty Financing Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in this Quarterly Report on Form 10-Q for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Fair Value of Interest Rate Swap</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of interest rate swap for the three months ended June 30, 2024 was $0.4 million. Adjustments to the fair value are due to changes in interest rates as of June&#160;30, 2024 relative to the fair value of interest rate swap as of December&#160;31, 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Six Months Ended June 30, 2024 and 2023 </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview - Operating Results</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results for the six months ended June 30, 2024, included the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product revenues, net, increased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$23.4 million, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.4%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as compared to the same period in the prior year as a result of the growth in ARIKAYCE sales;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost of product revenues (excluding amortization of intangible assets) increased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as compared to the same period in the prior year as a result of the increase in sales volumes of ARIKAYCE;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">R&amp;D expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$57.0 million as compared to the same period in the prior year primarily as a result of the non-cash costs of the Adrestia and Vertuis acquisitions in 2023;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SG&amp;A expenses increased $35.3 million as compared to the same period in the prior year primarily as a result of increases i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n compensation and benefit-related expenses </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and stock-based compensation costs;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Amortization of intangible assets of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.5 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was consistent with the same period in the prior year; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Change in fair value of deferred and contingent consideration liabilities increased $87.8 million, primarily as a result of the change in our share price; an</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interest expense increased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.7 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as compared to the same period in the prior year due to the Term Loan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Revenues, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net, consists of net sales of ARIKAYCE. The following table summarizes revenue by geography for the six months ended June&#160;30, 2024 and 2023 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:28.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.970%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe and rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total product revenues, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,840&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,443&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,397&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net, for the six months ended June 30, 2024 increased to $165.8 million as compared to $142.4 million in the same period in 2023, an increase of 16.4%, as a result of growth in ARIKAYCE sales in the US, Japan and Europe and the rest of the world. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Product Revenues (excluding amortization of intangible assets)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) for the six months ended June 30, 2024 and 2023 were comprised of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.959%"><tr><td style="width:1.0%"/><td style="width:37.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.685%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.685%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.685%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.690%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenues (excluding amortization of intangible assets)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,424&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cost of product revenues, as % of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) increased by $8.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.3%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to $38.4 million for the six months ended June 30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as compared to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$30.4 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the same period in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase in cost of product revenues (excluding amortization of intangibles) for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was primarily attributable to the increase in product revenues discussed above.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">R&amp;D Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses for the six months ended June 30, 2024 and 2023 were comprised of the following (in thousands):</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:41.392%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.569%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase&#160;(decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">External Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical development&#160;and research</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone payment to AstraZeneca</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NA</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory, quality assurance, and medical affairs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,013)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash asset acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,747)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal&#8212;external expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,334)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Internal Expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefit-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other internal operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal&#8212;internal expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,607&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,331&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total R&amp;D expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,831&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324,834&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,003)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses decreased to $267.8 million during the six months ended June 30, 2024 from $324.8 million in the same period in 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$57.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decrease in R&amp;D expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was primarily due to the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$86.7 million non-cash asset acquisition cost of Adrestia and Vertuis in the first half of 2023, partially offset by an increase of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$24.7 million in compensation and benefit-related expenses and stock-based compensation costs due to an increase in headcount and a $12.5 million milestone payment due to AstraZeneca u</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pon our release of an official public statement that we intend to file an NDA for brensocatib</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">External R&amp;D expenses by product for the six months ended June 30, 2024 and 2023 were comprised of the following (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:34.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARIKAYCE external R&amp;D expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,800)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brensocatib external R&amp;D expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TPIP external R&amp;D expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash asset acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86,747)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external R&amp;D expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total external R&amp;D expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,893&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,227&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,334)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SG&amp;A Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses for the six months ended June 30, 2024 and 2023 were comprised of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:39.843%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.055%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.753%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefit-related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and other external expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility related and other internal expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total SG&amp;A expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,671&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,345&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,326&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses increased to $199.7 million during the six months ended June 30, 2024 from $164.3 million in the same period in 2023. The $35.3 million increase resulted primarily from an $16.5 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase in compensation and benefit-related expenses and stock-based compensation costs due to an increase in headcount and a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$13.5 million increase in professional fees and other external expenses driven by commercial readiness activities fo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r brensocatib.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets for both the six months ended June 30, 2024 and 2023 was $2.5 million. Amortization of intangible assets is comprised of amortization of acquired ARIKAYCE R&amp;D and amortization of the milestones paid to PARI for the FDA and EC approvals of ARIKAYCE.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Fair Value of Deferred and Contingent Consideration Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of deferred and contingent consideration for the six months ended June 30, 2024 was $91.8 million. The change is related to the fair value of the potential future consideration to be paid to former equityholders of the businesses we acquired. The change in fair value of deferred and contingent consideration for the six months ended June 30, 2024 was primarily due to the increase in our share price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment Income</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income decreased to $19.1 million for the six months ended June 30, 2024 as compared to $21.7 million in the same period in 2023 primarily due to a decrease in our average cash and cash equivalents and marketable securities balances in 2024 relative to 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased to $42.3 million for the six months ended June 30, 2024 as compared to $40.6 million in the same period in 2023 primarily due to interest related to the Term Loan. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10 - Debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11 - Royalty Financing Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in this Quarterly Report on Form 10-Q for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change in Fair Value of Interest Rate Swap</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of interest rate swap for the six months ended June 30, 2024 was $2.7 million. Adjustments to the fair value are due to changes in interest rates as of June&#160;30, 2024 relative to the fair value of interest rate swap as of December&#160;31, 2023.</span></div><div id="ib049349da60d4a3c9beace0bfd291454_94"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;There is considerable time and cost associated with developing potential pharmaceutical products to the point of regulatory approval and commercialization. We commenced commercial shipments of ARIKAYCE in October 2018. We expect to continue to incur consolidated operating losses, including losses at our US and certain international entities, as we plan to fund R&amp;D for ARIKAYCE, brensocatib, TPIP and our other pipeline programs, continue commercialization and regulatory activities for ARIKAYCE, fund pre-commercialization activities for brensocatib, and engage in other general and administrative activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2024, we completed an underwritten offering of 14,514,562 shares of our common stock at a public offering price of $51.50 per share. 1,893,203 of the shares of common stock were issued pursuant to the exercise in full of the underwriters'</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">option to purchase additional shares. Our net proceeds from the sale of the shares, after deducting underwriting discounts and estimated offering expenses of $34.3 million, were $713.2 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2024, the Company entered into a new sales agreement with Leerink to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $500.0 million, from time to time, through the new ATM program, under which Leerink acts as sales agent. No shares were sold through the new ATM program during the six months ended June&#160;30, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, we entered into the $350&#160;million Term Loan with Pharmakon that matures on October 19, 2027. The Term Loan bears interest at a rate based upon the SOFR, subject to a SOFR floor of 2.5% in addition to a margin of 7.75% per annum. Up to 50% of the interest payable during the first 24 months from the closing of the Term Loan may be paid-in-kind at our election. If elected, paid-in-kind interest will be capitalized and added to the principal amount of the Term Loan. The Term Loan, including the paid-in-kind interest, will be repaid in eight equal quarterly payments starting in the 13th quarter following the closing of the Term Loan (i.e., the quarter ending March 31, 2026), except that the repayment start date may be extended at our option for an additional four quarters, so that repayments start in the 17th quarter following the closing of the Term Loan, subject to the achievement of specified ARIKAYCE data thresholds and certain other conditions. Net proceeds from the Term Loan, after deducting the lenders' fees and deal expenses of $15.2 million, were $334.8&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, we entered into the Royalty Financing Agreement with OrbiMed, whereby OrbiMed paid us $150&#160;million in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% of ARIKAYCE global net sales on or after September 1, 2025, as well as 0.75% of brensocatib global net sales, if approved. In the event that OrbiMed has not received aggregate Revenue Interest Payments equal to or greater than $150&#160;million on or prior to March 31, 2028, the royalty rate for ARIKAYCE will be increased for all subsequent fiscal quarters to a rate which, if applied retroactively, would have resulted in aggregate Revenue </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Interest Payments to OrbiMed for all fiscal quarters ended on or prior to March 31, 2028 equal to $150&#160;million. In addition, we must make a one-time payment to OrbiMed in an amount that, when added to the aggregate amount of Revenue Interest Payments received by OrbiMed as of March 31, 2028, would equal $150&#160;million. The total Revenue Interest Payments payable by us to OrbiMed are capped at 1.8x of the purchase price or up to a maximum of 1.9x of the purchase price under certain conditions. Net proceeds from the Royalty Financing Agreement, after deducting the lenders' fees and deal expenses of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$3.8&#160;million, were $146.2&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, we also completed an underwritten offering of 13,750,000 shares of our common stock at a public offering price of $20.00 per share. Our net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expense of $16.2&#160;million, were $258.8&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may need to raise additional capital to fund our operations, the continued commercialization of ARIKAYCE, launch readiness activities for the potential launch of brensocatib for th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e treatment of p</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">atients with bronchiectasis, if approved, clinical trials for brensocatib, TPIP, and our future product candidates, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. While we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> believe we currently have sufficient funds to meet our financial needs for at least the next 12 months, we may opportunistically raise additional capital and may do so through equity or debt financing(s), strategic transactions or otherwise. Our cash requirements for the next 12 months will be impacted by a number of factors, the most significant of which we expect to be the ASPEN trial, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">expenses related to our commercialization efforts and our ARISE and ENCORE clinical trials for ARIKAYCE, and other development activities for brensocatib, and to a lesser extent, expenses related to the clinical development of TPIP and our early-research programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, we had cash and cash equivalents of $1,246.8 million, as compared with $482.4 million as of December&#160;31, 2023. In addition, as of December&#160;31, 2023, we had marketable securities of $298.1 million. The $764.4 million increase in cash and cash equivalents was primarily due to our underwritten offering of common stock in May 2024 and the maturity of marketable securities, partially offset by our cash used in operating activities. Our working capital was $894.0 million as of June&#160;30, 2024, as compared with $703.4 million as of December&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $307.0 million and $269.1 million for the six months ended June&#160;30, 2024 and 2023, respectively. The net cash used in operating activities during the six months ended June&#160;30, 2024 and 2023 was primarily for the commercial, clinical and manufacturing activities related to ARIKAYCE, as well as other SG&amp;A expenses and clinical trial expenses related to brensocatib and TPIP. The increase in cash used in operating activities for the six months ended June 30, 2024 compared to the corresponding period in 2023 was primarily due to the increase in net loss, excluding the adjustments to reconcile net loss to net cash used in operating activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) investing activities was $288.5 million and $(232.6) million for the six months ended June&#160;30, 2024 and 2023, respectively. The increase in 2024 is due to the maturity of marketable securities in the six months ended June 30, 2024 and purchase of marketable securities in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $784.5 million and $43.9 million for the six months ended June&#160;30, 2024 and 2023, respectively. The increase in 2024 is due to net proceeds received from the issuance of common stock in our underwritten offering in May 2024 and proceeds from exercise of stock options and our ESPP in the six months ended June&#160;30, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes outside of the ordinary course of business in our contractual obligations during the six months ended June 30, 2024 from those disclosed in Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources&#8212;Contractual Obligations&#8221; in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000110450624000008/insm-20231231.htm">Annual Report on Form&#160;10-K for the year ended December&#160;31, 202</a>3.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. We do not have any interest in special purpose entities, structured finance entities or other variable interest entities.</span></div><div id="ib049349da60d4a3c9beace0bfd291454_97"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our critical accounting policies and estimates as disclosed in our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000110450624000008/insm-20231231.htm">Annual Report on Form&#160;10-K for the year ended December&#160;31, 202</a>3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the required interim disclosure updates related to our accounting policies and estimates, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2 -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in this Quarterly Report on Form&#160;10-Q.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="ib049349da60d4a3c9beace0bfd291454_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, our cash and cash equivalents were in cash accounts and money market funds. Our investments in money market funds are not insured by the federal government. As of June&#160;30, 2024, we had no marketable securities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, we had $800.0 million of convertible notes outstanding. Our 2025 Convertible Notes and our 2028 Convertible Notes bear interest at a coupon rate of 1.75% and 0.75%, respectively. In addition, as of June&#160;30, 2024, we had a $350 million Term Loan and a $150.0 million Royalty Financing Agreement outstanding. The Term Loan accrues interest quarterly at the SOFR subject to a floor of 2.5%, plus a margin of 7.75% per annum. We entered into the Swap Contract as a hedge to the Term Loan variable interest rate. The Royalty Financing Agreement requires a Revenue Interest Payment of 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% thereafter as well as 0.75% of brensocatib global net sales, if approved. If a 10% change in interest rates had occurred on June&#160;30, 2024, it would not have had a material effect on the fair value of our debt as of that date, nor would it have a material effect on our future earnings or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our business is conducted in US dollars. However, we do conduct certain transactions in other currencies, including Euros, British Pounds, and Japanese Yen. Historically, fluctuations in foreign currency exchange rates have not materially affected our results of operations and during the six months ended June&#160;30, 2024 and 2023, our results of operations were not materially affected by fluctuations in foreign currency exchange rates.</span></div><div id="ib049349da60d4a3c9beace0bfd291454_103"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June&#160;30, 2024.&#160;The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities and Exchange Act of 1934, as amended (the Exchange Act), means controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit with the SEC is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules&#160;and forms, and to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.&#160;Based on that evaluation as of June&#160;30, 2024, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June&#160;30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div id="ib049349da60d4a3c9beace0bfd291454_106"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II. OTHER INFORMATION</span></div><div id="ib049349da60d4a3c9beace0bfd291454_109"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of our business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on our consolidated financial position, results of operations or cash flows.</span></div><div id="ib049349da60d4a3c9beace0bfd291454_112"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to substantial risks and uncertainties. You should carefully consider the information contained in this Quarterly Report on Form 10-Q, the risks and uncertainties described below, and the risk factors and other information contained in our other public filings in evaluating our business, including our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000110450624000008/insm-20231231.htm">Annual Report on Form&#160;10-K for the year ended December&#160;31, 202</a>3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was filed with the SEC on February 22, 2024. Any of the risks and uncertainties described herein and in our other filings with the SEC, either alone or taken together, could materially and adversely affect our business, financial condition, results of operations, prospects for growth, and the value of an investment in our common stock. In addition, these risks and uncertainties could cause actual results to differ materially from those expressed or implied by forward-looking statements contained in this Form 10-Q (please read "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cautionary Note Regarding Forward-Looking Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">" in this Quarterly Report on Form 10-Q).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We rely on third parties including collaborators, CROs, clinical and analytical laboratories, CMOs and other providers for many services that are critical to our business. If we are unable to form and sustain these relationships, or if any third-party arrangements that we may enter into are unsuccessful, including due to non-compliance by such third parties with our agreements or applicable law, our ability to develop and commercialize our products may be materially adversely affected. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely, and expect to continue to rely, on third parties for significant research, analytical services, preclinical development, clinical development and manufacturing of our product candidates and commercial scale manufacturing of ARIKAYCE and Lamira. For example, we do not own facilities for clinical-scale or commercial manufacturing of our product candidates, and we expect that our future supply requirements for brensocatib and TPIP will be manufactured by CMOs. We currently rely on Resilience Biotechnologies Inc. to provide our clinical and commercial supply of ARIKAYCE, and intend to also rely on Patheon in the future. We currently primarily rely on Esteve Pharmaceuticals, S.A. and Thermo Fisher to provide our clinical supply for brensocatib. Additionally, almost all of our clinical trial work is done by CROs, such as PPD Development, L.P., our CRO for the ARISE, ENCORE, ASPEN, BiRCh, and TPIP trials, and clinical laboratories. In addition, we rely on third parties to manufacture clinical materials for our early-stage research programs. Reliance on these third parties poses a number of risks, including the following: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The diversion of management time and cost of third-party advisers associated with the negotiation, documentation and implementation of agreements with third parties in the pharmaceutical industry;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The inability to control whether third parties devote sufficient resources to our programs or products, including with respect to meeting contractual deadlines; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The inability to control the regulatory and contractual compliance of third parties, including their quality systems, processes and procedures, systems utilized to collect and analyze data, and equipment used to test drug product and/or clinical supplies; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The inability to establish and implement collaborations or other alternative arrangements on favorable terms; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disputes with third parties, including CROs, leading to loss of intellectual property rights, delay or termination of research, development, or commercialization of product candidates or litigation or arbitration;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contracts with our collaborators fail to provide sufficient protection of our intellectual property; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulty enforcing our contractual rights if one of these third parties fails to perform. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on third parties to select and enter into agreements with clinical investigators to conduct clinical trials to support approval of our product candidates, and the failure of these third parties to appropriately carry out such evaluation and selection can adversely affect the quality of the data from these studies and, potentially, the approval of our products. In particular, as part of future drug approval submissions to the FDA, we must disclose certain financial interests of investigators who participated in any of the clinical studies being submitted in support of approval, or must certify to the absence of such financial interests. The FDA evaluates the information contained in such disclosures to determine whether disclosed interests may have an impact on the reliability of a study. If the FDA determines that financial interests of any clinical investigator raise serious questions of data integrity, the FDA can institute a data audit, request that we submit further data analyses, conduct additional independent studies to confirm the results of the questioned study, or refuse to use the data from the questioned study as a basis for approval. A finding by the FDA that a financial relationship of an investigator raises serious questions of data integrity could delay or otherwise adversely affect approval of our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2024, the US House of Representatives introduced the BIOSECURE Act (H.R. 7085) and the Senate advanced a substantially similar bill (S.3558), which legislation, if passed and enacted into law, would potentially restrict our ability to purchase services or products from, or otherwise collaborate with, any "biotechnology company of concern,&#8221; which includes certain Chinese biotechnology companies, without losing the ability to contract with, or otherwise receive funding from, the US government. We do business with companies in China and it is possible some of our contractual counterparties could be impacted by this legislation. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks could materially harm our business, financial condition, results of operations and prospects and the value of our common stock. </span></div><div id="ib049349da60d4a3c9beace0bfd291454_115"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None.</span></div><div id="ib049349da60d4a3c9beace0bfd291454_118"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule 10b5-1 Trading Plans</span></div><ix:nonNumeric contextRef="c-1" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-1001" continuedAt="f-1001-1" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policy governing transactions in our securities by our directors, officers and employees permits our directors, officers and employees to enter into trading plans complying with Rule 10b5-1 under the Exchange Act. The following table describes the written plans for the sale of our securities <ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1002">adopted</ix:nonNumeric>, modified or <ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1003">terminated</ix:nonNumeric> by our executive officers and directors during the second quarter of 2024, each of which was entered into during an open trading window and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (each, a Trading Plan).</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><ix:continuation id="f-1001-1"><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.850%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.433%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.440%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Adoption of Trading Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scheduled Start Date of Trading Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scheduled Expiration Date of Trading Plan (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maximum Shares Subject to Trading Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date Plan Terminated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-295" name="ecd:TrdArrIndName" id="f-1004">S. Nicole Schaeffer</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-295" name="ecd:TrdArrIndTitle" id="f-1005">Chief People Strategy Officer</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-295" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1006"><ix:nonNumeric contextRef="c-295" name="ecd:TrdArrAdoptionDate" id="f-1007">2/27/2024</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/03/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/21/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-296" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1008">63,734</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-295" name="ecd:TrdArrTerminationDate" id="f-1009"><ix:nonNumeric contextRef="c-295" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true" id="f-1010">06/07/2024</ix:nonNumeric></ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-297" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1011"><ix:nonNumeric contextRef="c-297" name="ecd:TrdArrAdoptionDate" id="f-1012">6/11/2024</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/10/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-297" name="ecd:TrdArrExpirationDate" id="f-1013">04/01/2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-298" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1014">46,309</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-299" name="ecd:TrdArrIndName" id="f-1015">Martina Flammer</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-299" name="ecd:TrdArrIndTitle" id="f-1016">Chief Medical Officer</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-299" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1017"><ix:nonNumeric contextRef="c-299" name="ecd:TrdArrAdoptionDate" id="f-1018">6/07/2024</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/06/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-299" name="ecd:TrdArrExpirationDate" id="f-1019">08/29/2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-300" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1020">370,536</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-301" name="ecd:TrdArrIndName" id="f-1021">Michael Smith</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-301" name="ecd:TrdArrIndTitle" id="f-1022">Chief Legal Officer</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-301" name="ecd:TrdArrAdoptionDate" id="f-1023"><ix:nonNumeric contextRef="c-301" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1024">6/13/2024</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/13/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-301" name="ecd:TrdArrExpirationDate" id="f-1025">05/21/2025</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-302" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1026">27,871</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan&#8217;s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="ib049349da60d4a3c9beace0bfd291454_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit Index</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:6.817%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:90.250%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1104506/000114036113012797/ex3_1.htm">3.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Articles of Incorporation of Insmed Incorporated, as amended through June&#160;14, 2012 (incorporated by reference from Exhibit&#160;3.1 to Insmed Incorporated&#8217;s Annual Report on Form&#160;10-K filed on March&#160;18, 2013).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1104506/000114036123024132/brhc20052827_ex3-1.htm">3.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Bylaws of Insmed Incorporated (effective as of May 11, 2023) (incorporated by reference from Exhibit&#160;3.1 to Insmed Incorporated&#8217;s Current Report on Form&#160;8-K filed on May&#160;11, 2023).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1104506/000114036124016917/ny20015223x1_def14a.htm">10.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 1 to Insmed Incorporated Amended and Restated 2019 Incentive Plan (incorporated by reference from Appendix A to Insmed Incorporated&#8217;s Proxy Statement on Schedule 14A, filed on April 1, 2024).</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm-20240630ex1011.htm">10.1.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Award Agreement for Non-Qualified Stock Options pursuant to the Insmed Incorporated Amended and Restated 2019 Incentive Plan.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm-20240630ex1012.htm">10.1.2</a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Award Agreement for Non-Qualified Stock Options to non-U.S. employees pursuant to the Insmed Incorporated Amended and Restated 2019 Incentive Plan.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm-20240630ex1013.htm">10.1.3</a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Award Agreement for Restricted Stock Units pursuant to the Insmed Incorporated Amended and Restated 2019 Incentive Plan.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm-20240630ex1014.htm">10.1.4</a></span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Award Agreement for Restricted Stock Units to non-U.S. employees pursuant to the Insmed Incorporated Amended and Restated 2019 Incentive Plan.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm-20240630ex102.htm">10.2**</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omnibus Amendment to Insmed Incorporated Incentive Awards and Inducement Awards, dated May 8, 2024.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm-20240630ex103.htm">10.3**</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Non-Qualified Stock Option Inducement Award Agreement.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm-20240630ex104.htm">10.4**</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Non-Qualified Stock Option Inducement Award Agreement for non-U.S. employees.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm-20240630ex105.htm">10.5*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercialization Agreement, dated July 8, 2014, between Insmed Incorporated and PARI Pharma GmbH.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm029240630ex1051.htm">10.5.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 1 to the Commercialization Agreement between Insmed Incorporated and PARI Pharma GmbH, effective as of July 21, 2017.</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm-20240630ex311.htm">31.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of William H. Lewis, Chair and Chief Executive Officer (Principal Executive Officer) of Insmed Incorporated, pursuant to Rules&#160;13a-14(a)&#160;and 15d-14(a)&#160;promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes Oxley Act of 2002.</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm-20240630ex312.htm">31.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Sara Bonstein, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) of Insmed Incorporated, pursuant to Rules&#160;13a-14(a)&#160;and 15d-14(a)&#160;promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes Oxley Act of 2002.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm-20240630ex321.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of William H. Lewis, Chair and Chief Executive Officer (Principal Executive Officer) of Insmed Incorporated, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes Oxley Act of 2002.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm-20240630ex322.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Sara Bonstein, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) of Insmed Incorporated, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes Oxley Act of 2002.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Insmed Incorporated&#8217;s quarterly report on Form&#160;10-Q for the quarter ended June 30, 2024 formatted in iXBRL (Inline eXtensible Business Reporting Language): (i)&#160;Consolidated Balance Sheets as of June 30, 2024 and December&#160;31, 2023, (ii)&#160;Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2024 and 2023, (iii)&#160;Consolidated Statements of Shareholders' Deficit for the three and six months ended June 30, 2024 and 2023, (iv) Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023, (v)&#160;Notes to the Unaudited Consolidated Financial Statements, and (vi) Cover Page.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cover page from the Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, formatted in iXBRL and contained in Exhibit 101.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Certain portions of this exhibit have been redacted.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** Management contract or compensatory plan or arrangement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="ib049349da60d4a3c9beace0bfd291454_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib049349da60d4a3c9beace0bfd291454_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.269%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INSMED INCORPORATED</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 8, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Sara Bonstein</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sara Bonstein</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1 1
<SEQUENCE>2
<FILENAME>insm-20240630ex1011.htm
<DESCRIPTION>EX-10.1 1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i5949469d70864a27a9afdaf4a870cb6f_1"></div><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NON-QUALIFIED STOCK OPTION AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FOR U.S. PARTICIPANTS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">No. of shares subject to Option&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#47;$AwardsGranted$&#47;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this &#8220;Agreement&#8221;) dated this &#47;$GrantDate$&#47;, between INSMED INCORPORATED, a Virginia corporation (the &#34;Company&#34;), and &#47;$ParticipantName$&#47; (&#34;Participant&#34;), is made pursuant and subject to the provisions of the Insmed Incorporated Amended and Restated 2019 Incentive Plan, as amended (the &#34;Plan&#34;), a copy of which has been made available to Participant.&#160;&#160;All terms used herein that are defined in the Plan have the same meaning given them in the Plan.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions and provisions of any employment, consulting or similar services agreement between Participant and the Company (or any of its Affiliates, as applicable) as may be in effect (the &#8220;Service Agreement&#8221;), the Service Agreement shall control, and this Agreement shall be deemed to be modified accordingly so long as such modification is not expressly prohibited by the Plan.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;Pursuant to the Plan, the Company, on &#47;$GrantDate$&#47; (the &#34;Date of Grant&#34;), granted to Participant, subject to the terms and conditions of the Plan and subject further to the terms and conditions herein set forth, the right and Option to purchase from the Company all or any part of an aggregate of &#47;$AwardsGranted$&#47; shares of Common Stock at the Option price of &#47;$GrantPrice$&#47; per share, being not less than the Fair Market Value of such shares on the Date of Grant.&#160;&#160;This Option is intended to be a nonqualified stock option and not an &#34;incentive stock option&#34; within the meaning of Section 422 of the Code.&#160;&#160;This Option is exercisable as hereinafter provided.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Terms and Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;This Option is subject to the following terms and conditions&#58;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.68pt">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;This Option shall expire ten years from the Date of Grant (the &#34;Expiration Date&#34;).</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160; Except as provided in paragraphs 3, 4 and 5, this Option shall be exercisable with respect to twenty-five percent (25%) of the shares of Common Stock subject to this Option on the first annual anniversary of the first day of the month immediately following the Date of Grant (the &#8220;First Vesting Date&#8221;) and with respect to an additional twelve and a half percent (12.5%) of the shares of Common Stock subject to this Option on the six-month anniversary of the First Vesting Date and each six-month anniversary date thereafter through the fourth annual anniversary of the first day of the month immediately following the Date of Grant. If the foregoing schedule would produce fractional shares, the number of shares for which the Option becomes exercisable shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">rounded down to the nearest whole share. Once this Option has become exercisable in accordance with this subparagraph 2(b) it shall continue to be exercisable until the termination of Participant's rights hereunder pursuant to paragraph 3, 4 or 5 or until the Option has expired pursuant to subparagraph 2(a).&#160; A partial exercise of this Option shall not affect Participant's right to exercise this Option with respect to the remaining shares, subject to the conditions of the Plan and this Agreement.</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.68pt">Method of Exercising Option and Payment for Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;This Option shall be exercised by written notice delivered to the attention of the Company's Chief Financial Officer at the Company's principal office in New Jersey.&#160;&#160;The exercise date shall be (i) in the case of notice by mail, the date of postmark, or (ii) if delivered in person, the date of delivery.&#160;&#160;Such notice shall be accompanied by payment of the Option price in full, in cash or cash equivalent acceptable to the Committee, or such other method as determined by the Committee, including an irrevocable commitment by a broker to pay over such amount from a sale of the shares of Common Stock issuable under the Option, the delivery of previously owned shares of Common Stock or withholding of shares of Common Stock deliverable upon exercise which, together with any cash or cash equivalent paid, is not less than the Option price for the number of shares for which this Option is being exercised.</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Agreement with Terms.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Execution of this Agreement by Participant or receipt of any benefits under this Agreement by Participant shall constitute Participant&#8217;s acknowledgement of and agreement with all of the provisions of this Agreement and of the Plan that are applicable to this Option, and the Company shall administer this Agreement accordingly.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.68pt">Termination of Employment or Service&#59; Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as provided in this subparagraph 2(e), in the event of Participant&#8217;s termination of employment or service, any vested portion of this Option that is not exercised during the period specified in paragraph 3, paragraph 4 or paragraph 5 of this Agreement, as applicable, shall be forfeited upon the expiration of such period, and any portion of this Option that is unvested as of the date of Participant&#8217;s termination of employment or service shall be forfeited on such date. Notwithstanding the preceding sentence, if Participant&#8217;s employment or service terminates prior to the Expiration Date on account of Participant&#8217;s death or Participant becoming permanently and totally disabled within the meaning of Section 22(e)(3) of the Code (&#8220;Permanently and Totally Disabled&#8221;), then any unvested portion of this Option shall immediately become vested and exercisable on Participant&#8217;s termination date.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:29.01pt">Change in Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A change in the status (whether as employee, member of the Board or other non-employee advisor or service provider) in which Participant renders service to the Company and its Affiliates or a change in the entity for which Participant renders such service shall not constitute a termination of Participant&#8217;s employment or service for purposes of this Agreement, so long as there is no interruption or termination of Participant&#8217;s services to the Company and its Affiliates&#59; provided, however, that if the entity employing or engaging Participant ceases to be an Affiliate of the Company, as determined by the Administrator, Participant&#8217;s employment or service shall be considered to have terminated on the date such entity ceased to be an Affiliate.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Exercise in the Event of Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;In the event Participant dies before the expiration of this Option pursuant to subparagraph 2(a), this Option shall be exercisable with respect to all or part of the shares of Common Stock that Participant was entitled to purchase under subparagraph 2(b) and subparagraph 2(e) on the date of Participant&#8217;s death.&#160;&#160;In that event, this Option may be exercised, to the extent exercisable, by Participant's estate or by the person or persons to whom his rights under this Option shall pass by will or the laws of descent and distribution.&#160;&#160;Participant's estate or such persons may exercise this Option within one (1) year after Participant's death or during the remainder of the period preceding the Expiration Date, whichever is shorter. </font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Exercise in the Event of Permanent and Total Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;In the event Participant becomes Permanently and Totally Disabled before the expiration of this Option pursuant to subparagraph 2(a), this Option shall be exercisable with respect to all or part of the shares of Common Stock that Participant was entitled to purchase under subparagraph 2(b) and subparagraph 2(e) on the date he ceases to be employed or engaged by the Company and its Affiliates as a result of his becoming Permanently and Totally Disabled.&#160;In that event, Participant may exercise this Option, to the extent exercisable, within one (1) year after the date he ceases to be employed or engaged by the Company and its Affiliates as a result of his becoming Permanently and Totally Disabled or during the period preceding the Expiration Date, whichever is shorter. </font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Exercise After Termination of Employment or Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Except as provided in paragraphs 3 and 4 hereof, if Participant ceases to be employed or engaged by the Company and its Affiliates prior to the Expiration Date, this Option shall be exercisable for all or part of the number of shares that Participant was entitled to purchase under subparagraph 2(b), as well as set forth under any Service Agreement, on the date of Participant&#8217;s termination of employment or service. In that event, Participant may exercise this Option, to the extent exercisable under subparagraph 2(b) and&#47;or under any Service Agreement, during the remainder of the period preceding the Expiration Date or until the date that is three (3) months (or such other period of time provided under any Service Agreement) after the date he ceases to be employed or engaged by the Company and its Affiliates, whichever is shorter. </font></div><div style="text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;Any notice or other communication given pursuant to this Agreement shall be in writing and shall be personally delivered or mailed by United States registered or certified mail, postage prepaid, return receipt requested, to the Company at its principal place of business or to Participant at the address on the payroll records of the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.&#160;&#160;Additionally, if such notice or communication is by the Company to Participant, the Company may provide such notice electronically (including via email).  Any such notice shall be deemed to have been given (a) on the date of postmark, in the case of notice by mail, or (b) on the date of delivery, if delivered in person or electronically.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Fractional Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;Fractional shares shall not be issuable hereunder, and when any provision hereof may entitle Participant to a fractional share such fraction shall be disregarded.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Tax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.68pt">Withholding. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participant shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, local or other taxes required by law to be withheld on account of such taxable event.  The Company shall have no obligation to deliver shares of Common Stock until such withholding requirements have been fully satisfied by Participant.  </font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Tax Obligations. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nothing in the Plan or in this Agreement shall be interpreted or construed to transfer any liability for any tax (including, without limitation, a tax or penalty due as a result of a failure to comply with Section 409A of the Code) due by Participant to the Company, any Subsidiary or Affiliate, or to any other individual or entity, and the Company shall have no liability to Participant, or any other party, thereto.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participant acknowledges that the Company and its Subsidiaries and Affiliates&#58; (a)&#160;make no representations or undertakings regarding the tax treatment in connection with any aspect of the Option&#59; and (b)&#160;do not commit to structure the terms of the grant or any other aspect of the Option to reduce or eliminate Participant&#8217;s tax liabilities.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">No Right to Continued Employment or Other Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing in the Plan or this Agreement shall interfere with or limit in any way the right of the Company, its Subsidiaries and&#47;or its Affiliates to terminate Participant&#8217;s employment at any time or for any reason in accordance with the Company&#8217;s Bylaws, governing law and any applicable Service Agreement, nor shall any terms of the Plan or this Agreement confer upon Participant any right to continue his or her employment for any specified period of time.  Neither this Agreement nor any benefits arising under the Plan or this Agreement shall constitute an employment contract or service contract with the Company, any Subsidiary and&#47;or its Affiliates.  If Participant is not an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">employee, nothing in the Plan or this Agreement shall interfere with or limit in any way the right of the Company, its Subsidiaries and&#47;or its Affiliates to terminate Participant&#8217;s service, (i) if a member of the Board, on the Board at any time or for any reason in accordance with the Company&#8217;s Bylaws and governing law, or (ii) if a non-employee consultant or advisor, in accordance with the terms of the contract with such consultant or advisor.  In no event shall any of the terms of the Plan or this Agreement itself confer upon Participant any right to continue his or her service for any specified period of time.  </font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Adjustments Upon Certain Unusual or Nonrecurring Events or Other Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon certain unusual or nonrecurring events, or other events, the terms of this Option shall be adjusted by the Administrator pursuant to Section 14 of the Plan.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;This Agreement shall be governed by the laws of the Commonwealth of Virginia.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;In the event of any conflict between the provisions of the Plan as in effect on the date hereof and the provisions of this Agreement, the provisions of the Plan shall govern.&#160;&#160;All references herein to the Plan shall mean the Plan as in effect on the date hereof.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Award and Participant Bound by Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;Notwithstanding anything herein to the contrary, this Option and this Agreement shall be subject to and governed by all the terms and conditions of the Plan.  Participant hereby acknowledges receipt of a copy of the Plan and agrees to be bound by all the terms and provisions thereof.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;Subject to the limitations stated above and in the Plan, this Agreement shall be binding upon and inure to the benefit of the legatees, distributees, and personal representatives of Participant and the successors of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Company has caused this Agreement to be signed by a duly authorized officer, and Participant has affixed his signature hereto.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160; </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#160;&#160;&#160;&#160;&#47;s&#47; Sara Bonstein</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PARTICIPANT</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;&#47;s&#47; &#47;$ParticipantName$&#47;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1 2
<SEQUENCE>3
<FILENAME>insm-20240630ex1012.htm
<DESCRIPTION>EX-10.1 2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ie940194e1bf54a94a6f1c935357a4403_1"></div><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NON-QUALIFIED STOCK OPTION AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FOR NON-U.S. PARTICIPANTS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">No. of shares subject to Option&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$AwardsGranted$&#47;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this &#8220;Agreement&#8221;) dated this </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$GrantDate$&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, between INSMED INCORPORATED, a Virginia corporation (the &#34;Company&#34;), and </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$ParticipantName$&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (&#34;Participant&#34;), is made pursuant and subject to the provisions of the Insmed Incorporated Amended and Restated 2019 Incentive Plan, as amended (the &#34;Plan&#34;), a copy of which has been made available to Participant.&#160;&#160;All terms used herein that are defined in the Plan have the same meaning given them in the Plan.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions and provisions of any employment, consulting or similar services agreement between Participant and the Company (or any of its Affiliates, as applicable) as may be in effect (the &#8220;Service Agreement&#8221;), the Service Agreement shall control, and this Agreement shall be deemed to be modified accordingly so long as such modification is not expressly prohibited by the Plan.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;Pursuant to the Plan, the Company, on </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$GrantDate$&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#34;Date of Grant&#34;), granted to Participant, subject to the terms and conditions of the Plan and subject further to the terms and conditions herein set forth, the right and Option to purchase from the Company all or any part of an aggregate of </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$AwardsGranted$&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shares of Common Stock at the Option price of </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$GrantPrice$&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> per share, being not less than the Fair Market Value of such shares on the Date of Grant.&#160;&#160;This Option is intended to be a nonqualified stock option and not an &#34;incentive stock option&#34; within the meaning of Section 422 of the Code.&#160;&#160;This Option is exercisable as hereinafter provided.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Terms and Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;This Option is subject to the following terms and conditions&#58;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.68pt">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;This Option shall expire ten years from the Date of Grant (the &#34;Expiration Date&#34;).</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160; Except as provided in paragraphs 3, 4 and 5, this Option shall be exercisable with respect to twenty-five percent (25%) of the shares of Common Stock subject to this Option on the first annual anniversary of the first day of the month immediately following the Date of Grant (the &#8220;First Vesting Date&#8221;) and with respect to an additional twelve and a half percent (12.5%) of the shares of Common Stock subject to this Option on the six-month anniversary of the First Vesting Date and each six-month anniversary date thereafter through the fourth annual anniversary of the first day of the month immediately following the Date of Grant. If the foregoing schedule would produce fractional shares, the number of shares for which the Option becomes exercisable shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">rounded down to the nearest whole share. Once this Option has become exercisable in accordance with this subparagraph 2(b) it shall continue to be exercisable until the termination of Participant's rights hereunder pursuant to paragraph 3, 4 or 5 or until the Option has expired pursuant to subparagraph 2(a).&#160; A partial exercise of this Option shall not affect Participant's right to exercise this Option with respect to the remaining shares, subject to the conditions of the Plan and this Agreement.</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.68pt">Method of Exercising Option and Payment for Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;This Option shall be exercised by written notice delivered to the attention of the Company's Chief Financial Officer at the Company's principal office in New Jersey.&#160;&#160;The exercise date shall be (i) in the case of notice by mail, the date of postmark, or (ii) if delivered in person, the date of delivery.&#160;&#160;Such notice shall be accompanied by payment of the Option price in full, in cash or cash equivalent acceptable to the Committee, or such other method as determined by the Committee, including an irrevocable commitment by a broker to pay over such amount from a sale of the shares of Common Stock issuable under the Option, the delivery of previously owned shares of Common Stock or withholding of shares of Common Stock deliverable upon exercise which, together with any cash or cash equivalent paid, is not less than the Option price for the number of shares for which this Option is being exercised.</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Agreement with Terms.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Execution of this Agreement by Participant or receipt of any benefits under this Agreement by Participant shall constitute Participant&#8217;s acknowledgement of and agreement with all of the provisions of this Agreement and of the Plan that are applicable to this Option, and the Company shall administer this Agreement accordingly.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.68pt">Termination of Employment or Service&#59; Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as provided in this subparagraph 2(e), in the event of Participant&#8217;s termination of employment or service, any vested portion of this Option that is not exercised during the period specified in paragraph 3, paragraph 4 or paragraph 5 of this Agreement, as applicable, shall be forfeited upon the expiration of such period, and any portion of this Option that is unvested as of the date of Participant&#8217;s termination of employment or service shall be forfeited on such date. Notwithstanding the preceding sentence, if Participant&#8217;s employment or service terminates prior to the Expiration Date on account of Participant&#8217;s death or Participant becoming permanently and totally disabled within the meaning of Section 22(e)(3) of the Code (&#8220;Permanently and Totally Disabled&#8221;), then any unvested portion of this Option shall immediately become vested and exercisable on Participant&#8217;s termination date.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt">2</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:29.01pt">Change in Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. A change in the status (whether as employee, member of the Board or other non-employee advisor or service provider) in which Participant renders service to the Company and its Affiliates or a change in the entity for which Participant renders such service shall not constitute a termination of Participant&#8217;s employment or service for purposes of this Agreement, so long as there is no interruption or termination of Participant&#8217;s services to the Company and its Affiliates&#59; provided, however, that if the entity employing or engaging Participant ceases to be an Affiliate of the Company, as determined by the Administrator, Participant&#8217;s employment or service shall be considered to have terminated on the date such entity ceased to be an Affiliate.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Exercise in the Event of Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;In the event Participant dies before the expiration of this Option pursuant to subparagraph 2(a), this Option shall be exercisable with respect to all or part of the shares of Common Stock that Participant was entitled to purchase under subparagraph 2(b) and subparagraph 2(e) on the date of Participant&#8217;s death.&#160;&#160;In that event, this Option may be exercised, to the extent exercisable, by Participant's estate or by the person or persons to whom his rights under this Option shall pass by will or the laws of descent and distribution.&#160;&#160;Participant's estate or such persons may exercise this Option within one (1) year after Participant's death or during the remainder of the period preceding the Expiration Date, whichever is shorter.  </font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Exercise in the Event of Permanent and Total Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;In the event Participant becomes Permanently and Totally Disabled before the expiration of this Option pursuant to subparagraph 2(a), this Option shall be exercisable with respect to all or part of the shares of Common Stock that Participant was entitled to purchase under subparagraph 2(b) and subparagraph 2(e) on the date he ceases to be employed or engaged by the Company and its Affiliates as a result of his becoming Permanently and Totally Disabled. In that event, Participant may exercise this Option, to the extent exercisable, within one (1) year after the date he ceases to be employed or engaged by the Company and its Affiliates as a result of his becoming Permanently and Totally Disabled or during the period preceding the Expiration Date, whichever is shorter.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Exercise After Termination of Employment or Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;Except as provided in paragraphs 3 and 4 hereof, if Participant ceases to be employed or engaged by the Company and its Affiliates prior to the Expiration Date, this Option shall be exercisable for all or part of the number of shares that Participant was entitled to purchase under subparagraph 2(b), as well as set forth under any Service Agreement, on the date of Participant&#8217;s termination of employment or service. In that event, Participant may exercise this Option, to the extent exercisable under subparagraph 2(b) and&#47;or under any Service Agreement, during the remainder of the period preceding the Expiration Date or until the date that is three (3) months (or such other period of time provided under any Service Agreement) after the date he ceases to be employed or engaged by the Company and its Affiliates, whichever is shorter. </font></div><div style="text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt">3</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;Any notice or other communication given pursuant to this Agreement shall be in writing and shall be personally delivered or mailed by United States registered or certified mail, postage prepaid, return receipt requested, to the Company at its principal place of business or to Participant at the address on the payroll records of the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.&#160;&#160;Additionally, if such notice or communication is by the Company to Participant, the Company may provide such notice electronically (including via email).  Any such notice shall be deemed to have been given (a) on the date of postmark, in the case of notice by mail, or (b) on the date of delivery, if delivered in person or electronically.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Fractional Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;Fractional shares shall not be issuable hereunder, and when any provision hereof may entitle Participant to a fractional share such fraction shall be disregarded.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Tax Responsibility and Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160; Participant hereby authorizes withholding from payroll and any other amounts payable to Participant, and otherwise agrees to make adequate provision for any sums required to satisfy the federal, state, local and foreign tax (including, without limitation, social insurance contributions or National Insurance Contributions) withholding obligations of the Company and its Affiliates, if any, which arise in connection with the Option including, without limitation, the grant, vesting or exercise of the Option and the subsequent sale of shares of Common Stock (the &#8220;Tax Obligations&#8221;).  The Company shall have no obligation to deliver shares of Common Stock until the Tax Obligations have been fully satisfied by Participant.  Participant acknowledges that the ultimate liability for all Tax Obligations legally due by Participant is and remains Participant&#8217;s responsibility and that the Company and its Subsidiaries and Affiliates&#58; (a)&#160;make no representations or undertakings regarding the Tax Obligations or tax treatment in connection with any aspect of the Option&#59; and (b)&#160;do not commit to structure the terms of the grant or any other aspect of the Option to reduce or eliminate Participant&#8217;s Tax Obligations or any other tax liabilities. Further, if Participant is subject to Tax Obligations in more than one jurisdiction, Participant acknowledges that the Company and&#47;or the applicable Affiliate may be required to withhold or account for Tax Obligations in more than one jurisdiction. The Company shall have the right, but not the obligation, to require Participant to satisfy all or any portion of the Tax Obligations by deducting from the shares of Common Stock otherwise issuable to Participant upon such exercise a number of whole shares having a fair market value, as determined by the Company as of the date of exercise, not in excess of the amount of such Tax Obligations determined by the applicable minimum statutory withholding rates.  The Company may require Participant to direct a broker, upon the exercise of the Option, to sell a portion of the shares subject to the Option determined by the Company in its discretion to be sufficient to cover the Tax Obligations of the Company or its Affiliates or subsidiaries and to remit an amount equal to such Tax Obligations to the Company in cash. Depending on the withholding method, the Company or the applicable Affiliate may withhold or account for Tax Obligations by considering applicable statutory withholding amounts or other applicable withholding rates, including maximum applicable rates, in which case Participant will receive a refund of any over-withheld amount in cash and will have no entitlement to the Common Stock equivalent. If the obligation for Tax Obligations is satisfied by withholding shares, for tax purposes, Participant is deemed to have been issued the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt">4</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">full number of shares subject to the exercised Option, notwithstanding that a number of the shares are held back solely for the purpose of paying the Tax Obligations. Finally, Participant agrees to pay to the Company and&#47;or the applicable Affiliate any amount of Tax Obligations that the Company and&#47;or the applicable Affiliate may be required to withhold or account for as a result of the Option that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the shares or the proceeds of the sale of shares if Participant fails to comply with Participant&#8217;s obligations in connection with the Tax Obligations. Participant authorizes the Company to disclose all information on Participant and his participation in this Agreement that is or may be relevant for the calculation of the Tax Obligations, to the competent local tax authorities and the Company&#8217;s Affiliates, including but not limited to the exercise notice, the day such notice was received, the number of shares for which the Option is exercised, the exercise price and the fair market value of the shares at the time of the exercise of the Option. Nothing in the Plan or in this Agreement shall be interpreted or construed to transfer any liability for any tax due by Participant to the Company, any Subsidiary or Affiliate, or to any other individual or entity, and the Company shall have no liability to Participant, or any other party, thereto.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">No Right to Continued Employment and Other Service Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As a condition to accepting the Option, Participant acknowledges and agrees as follows&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Nothing in the Plan or this Agreement shall interfere with or limit in any way the right of the Company, its Subsidiaries and&#47;or its Affiliates to terminate Participant&#8217;s employment at any time or for any reason in accordance with the Company&#8217;s Bylaws, governing law and any applicable Service Agreement&#59;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">No terms of the Plan or this Agreement shall confer upon Participant any right to continue his or her employment for any specified period of time.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">Neither this Agreement nor any benefits arising under the Plan or this Agreement shall constitute an employment contract or service contract with the Company, any Subsidiary and&#47;or its Affiliates.  </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">If Participant is not an employee, nothing in the Plan or this Agreement shall interfere with or limit in any way the right of the Company, its Subsidiaries and&#47;or its Affiliates to terminate Participant&#8217;s service, (i) if a member of the Board, on the Board at any time or for any reason in accordance with the Company&#8217;s Bylaws and governing law, or (ii) if a non-employee consultant or advisor, in accordance with the terms of the contract with such consultant or advisor.  </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">In no event shall any of the terms of the Plan or this Agreement itself confer upon Participant any right to continue his or her service for any specified period of time.  </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt">5</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.01pt">Any notice period mandated under applicable law shall not be treated as service for the purpose of determining the vesting of the Option&#59; and Participant&#8217;s right to vesting of shares in settlement of the Option after termination of service, if any, will be measured by the date of termination of Participant&#8217;s active service and will not be extended by any notice period mandated under applicable law.  Subject to the foregoing and the provisions of this Agreement, the Company, in its sole discretion, shall determine whether Participant&#8217;s service has terminated and the effective date of such termination. </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The grant of the Option is voluntary and occasional and does not create any contractual or other right to receive future grants of Options, or benefits in lieu of Options, even if Options have been granted repeatedly in the past.  All decisions with respect to future Option grants, if any, will be at the sole discretion of the Company. </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Participant is voluntarily participating in the grant of the Option. </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.67pt">The Option is an extraordinary item that does not constitute compensation of any kind for service of any kind rendered to the Company or its affiliates or subsidiaries, and which is outside the scope of Participant&#8217;s employment or service contract, if any.  The Option is not part of normal or expected compensation or salary for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, end-of-service payments, bonuses, long-service awards, pension or retirement benefits or similar payments. </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.67pt">The future value of the underlying shares of Common Stock is unknown and cannot be predicted with certainty.  The value of the shares may increase or decrease, even below the exercise price. If the underlying shares of Common Stock do not increase in value, the Option will have no value.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">No claim or entitlement to compensation or damages arises from termination of the Option or diminution in value of the Option or shares and Participant irrevocably releases the Company and its affiliates and subsidiaries from any such claim that may arise.  If, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen then, by signing this Agreement, Participant shall be deemed irrevocably to have waived Participant&#8217;s entitlement to pursue such a claim. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.67pt">The Option and the benefits evidenced by the Agreement do not create any entitlement not otherwise specifically provided for in the Agreement or provided by the Company in its discretion, to have the Option or any such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt">6</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">benefits transferred to, or assumed by, another company, nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Common Stock.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.67pt">Neither the Company nor any of its Affiliates shall be liable for any foreign exchange rate fluctuation between Participant&#8217;s local currency and the U.S. dollar that may affect the value of the Option or any amounts due to Participant pursuant to the exercise of the Option or the subsequent sale of any shares acquired upon exercise of the Option. To the extent the Company determines that a currency exchange or conversion is necessary in connection with the exercise of the Option or any other matter, such exchange shall be calculated and determined by the Company in its sole discretion, and the Company&#8217;s determination shall be final and binding.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Data Privacy.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Participant understands that the Company may collect, use and transfer, in electronic or other form, Participant&#8217;s personal data as described in this Agreement for the exclusive purpose of implementing, administering and managing Participant&#8217;s Option.  Participant understands that the Company holds certain personal information about Participant, including, but not limited to, Participant&#8217;s name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares or directorships held in the Company, details of all Options or any other entitlement to shares awarded, canceled, exercised, vested, unvested or outstanding in Participant&#8217;s favor, for the purpose of implementing, administering and managing Participant&#8217;s Option (&#8220;Data&#8221;).  Participant understands that Data may be transferred to any third parties assisting in the implementation, administration and management of the Option, that these recipients may be located in Participant&#8217;s country or elsewhere, and that the recipient&#8217;s country may have different data privacy laws and protections than Participant&#8217;s country.  Participant understands that he or she may request a list with the names and addresses of any potential recipients of the Data by contacting Participant&#8217;s local human resources representative.  Participant understands that recipients may receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing Participant&#8217;s Option, including any requisite transfer of such Data as may be required to a broker or other third party with whom Participant may elect to deposit any shares acquired pursuant to the Option.  Participant understands that Data will be held only as long as is necessary to implement, administer and manage Participant&#8217;s Option.  Participant understands that he or she may, at any time, view Data, request additional information about the storage and processing of Data or require any necessary amendments to Data, by contacting in writing Participant&#8217;s local human resources representative.  For more information on the processing of Data for the purposes set out above, Participant understands that he or she may contact Participant&#8217;s local human resources representative. For Participants located within the European Union or the United Kingdom, Participant understands that Data will always be processed in accordance with the Insmed EU Employee Personal Data Processing Notice or the Insmed UK Employee Personal Data Processing Notice, respectively, a copy of which has been appended to the Agreement, if applicable, and is also available from Participant&#8217;s local human resources representative.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt">7</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Not a Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The grant of the Option is not intended to be a public offering of securities in Participant&#8217;s country of employment or service (or country of residence, if different). The Company has not submitted any registration statement, prospectus, or other filings with the local securities authorities (unless otherwise required under local law), and the grant of the Option is not subject to the supervision of the local securities authorities.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">No Advice Regarding Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Investment in shares of the Company&#8217;s Common Stock involves a degree of risk. Before deciding to acquire shares by exercising the Option, Participant should carefully consider all risk factors relevant to the acquisition of shares of Common Stock and carefully review all of the materials related to the Option. The Company is not providing any tax, legal, or financial advice, nor is the Company making any recommendations regarding Participant&#8217;s participation in the Plan, or Participant&#8217;s acquisition or sale of the shares underlying the Option. Participant is hereby advised to consult with Participant&#8217;s own personal tax, legal, and financial advisors regarding Participant&#8217;s participation in the Plan before taking any action related to the Option.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If the Plan, the Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control to the maximum extent permitted by applicable law.</font></div><div style="text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Imposition of Additional Requirements&#59; Repatriation&#59; Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The grant of the Option and the issuance and delivery of shares under the Option are subject to all applicable laws, rules, and regulations and to such approvals by any governmental agencies or securities exchange as may be required. Notwithstanding any provision of the Agreement, the Company has no liability to deliver any shares under the Option or make any payment unless such delivery or payment would comply with all laws and the applicable requirements of any governmental agency, securities exchange, or similar entity, and unless and until Participant has taken all actions required by the Company in connection with the Option. The Company reserves the right to impose other requirements on the Option and on the shares acquired upon the exercise of the Option to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. Participant agrees to repatriate all payments attributable to the shares and&#47;or cash acquired under the Option in accordance with applicable foreign exchange rules and regulations in Participant&#8217;s country of employment or service (and country of residence, if different). In addition, Participant agrees to take any and all actions, and consents to any and all actions taken by the Company and any of its Affiliates, as may be required to allow the Company and any of its Affiliates to comply with local laws, rules, and&#47;or regulations in Participant&#8217;s country of employment or service (and country of residence, if different). Finally, Participant agrees to take any and all actions as may be required to comply with Participant&#8217;s personal obligations under local laws, rules, and&#47;or regulations in Participant&#8217;s country of employment or service (and country of residence, if different). Neither the Company nor any of its Affiliates shall be liable for any costs, fines, or penalties resulting from Participant&#8217;s failure to comply with such personal obligations.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt">8</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Foreign Asset and Account Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant&#8217;s country of employment or service (and country of residence, if different) may have certain exchange control and&#47;or foreign asset&#47;account reporting requirements which may affect Participant&#8217;s ability to acquire or hold shares under the Option or cash received in connection with the Option (including from any dividends received or sale proceeds resulting from the sale of shares) in a brokerage or bank account outside of Participant&#8217;s country. Participant may be required to report such accounts, assets, or transactions to the tax or other authorities in Participant&#8217;s country. Participant acknowledges that it is Participant&#8217;s responsibility to comply with any applicable regulations, and that Participant should speak to Participant&#8217;s personal advisor on this matter.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Annex of Country-Specific Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any provisions in this Agreement, this Option may be subject to special terms and conditions set forth in the Annex to this Agreement for Participant&#8217;s country of employment or service (and country of residence, if different).  Moreover, if Participant relocates to one of the countries included in the Annex, the special terms and conditions for such country will apply to Participant, to the extent the Company determines at its discretion that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Annex constitutes part of this Agreement.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Adjustments Upon Certain Unusual or Nonrecurring Events or Other Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon certain unusual or nonrecurring events, or other events, the terms of this Option shall be adjusted by the Administrator pursuant to Section 14 of the Plan.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;This Agreement shall be governed by the laws of the Commonwealth of Virginia.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;In the event of any conflict between the provisions of the Plan as in effect on the date hereof and the provisions of this Agreement, the provisions of the Plan shall govern.&#160;&#160;All references herein to the Plan shall mean the Plan as in effect on the date hereof.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Award and Participant Bound by Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;Notwithstanding anything herein to the contrary, this Option and this Agreement shall be subject to and governed by all the terms and conditions of the Plan.  Participant hereby acknowledges receipt of a copy of the Plan and agrees to be bound by all the terms and provisions thereof.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;Subject to the limitations stated above and in the Plan, this Agreement shall be binding upon and inure to the benefit of the legatees, distributees, and personal representatives of Participant and the successors of the Company.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Company has caused this Agreement to be signed by a duly authorized officer, and Participant has affixed his signature hereto.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt">9</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#160;&#160;&#160;&#160;&#47;s&#47; Sara Bonstein</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PARTICIPANT</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;&#47;s&#47; </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$ParticipantName$&#47;</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt">10</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ANNEX</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TO</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NON-QUALIFIED STOCK OPTION AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ADDITIONAL NOTICES, TERMS AND CONDITIONS FOR NON-US PARTICIPANTS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Further Terms and Conditions of the Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  It is understood and agreed that the Option evidenced by the Non-Qualified Stock Option Agreement (&#8220;Agreement&#8221;) to which this is annexed is subject to the following additional terms and conditions&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participant understands that this Annex includes special terms and conditions applicable to Participant if Participant resides and&#47;or works in one of the countries below.  These terms and conditions are in addition to those set forth in the Agreement and the Plan.  Any capitalized term used in this Annex without definition shall have the meaning ascribed to it in the Agreement or the Plan, as applicable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participant further understands that this Annex also includes information relating to laws and regulatory requirements of which Participant should be aware with respect to his or her participation in the Plan.  The information is based on the laws in effect in the respective countries as of May 2023.  Such laws are often complex and change frequently.  As a result, Participant understands that the Company strongly recommends that Participant not rely on the information herein as the only source of information relating to the consequences of participation in the Plan because the information may be out of date at the time that Participant&#8217;s Option are settled or Participant sells shares of Stock acquired under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Finally, Participant understands that if&#58; (a) Participant is a citizen or resident of a country other than the one in which Participant is currently working, (b) transfers employment after grant of the Option, or (c) is considered a resident of another country for local law purposes, the information contained herein may not apply to Participant, and the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall apply.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company may, from time to time, add or impose additional terms and conditions in respect of Participant&#8217;s Option in order to ensure compliance with any local laws and regulations. </font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AUSTRALIA</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The offer of the Option is intended to comply with the provisions of the Corporations Act 2001. If Participant acquires shares under the Option and subsequently offers such shares for sale to a person or entity resident in Australia, the offer may be subject to disclosure requirements under Australian law. Participant should obtain legal advice on disclosure obligations prior to making any such offer.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt">11</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Breach of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary in the Agreement, Participant will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Agreement if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Tax Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Option is an award to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) applies (subject to the conditions in such Act).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BELGIUM</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Tax Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant agrees and acknowledges that the Company will only accept a countersigned Agreement after the 60th day following Participant&#8217;s receipt of the Agreement. By formally accepting in writing the Agreement through signature and by returning it to the Company within 60 days from receipt of the Agreement, Participant would normally become subject to income tax on a lump-sum benefit in kind on the 60th day following receipt of the Agreement (being the &#8220;grant date&#8221; for Belgian tax purposes).  In that case, no taxation should be triggered upon vesting or exercise.  However, if written acceptance and return of the Agreement would take place after the 60th day following receipt of the Agreement, as required by the Company, taxation will normally be delayed to the date of exercise of this Option.  In that case, grant or vesting should not trigger taxation.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CANADA</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This paragraph supplements the provisions of Section 10 (Data Privacy) of the Agreement. Participant hereby authorizes the Company and the Company&#8217;s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Agreement and the Option. Participant further authorizes the Company and any of its Affiliates and the Administrator to disclose and discuss the Agreement and the Option with their advisors. Participant further authorizes the Company and any of its Affiliates to record such information and to keep such information in Participant&#8217;s employee file.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">English Language Consent - Quebec</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The parties acknowledge that it is their express wish that the Agreement, as well as all documents, notices, and legal proceedings entered into, given, or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Les parties reconnaissent avoir expressement souhait&#233; que la convention (le &#171;&#160;Agreement&#160;&#187;), ainsi que tous les documents, avis et proc&#233;dures judiciaries, &#233;xecut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;, directement ou indirectement &#224; la pr&#233;sente convention, soient r&#233;dig&#233;s en langue anglaise.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DENMARK</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt">12</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FRANCE</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Non-Qualification of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Option is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> intended to be tax qualified under French tax laws including, without limitation, under Articles L.225-177-1 and seq. of the French Commercial Code.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In accepting the grant of the Option and this Agreement which provides for the terms and conditions of the Option, Participant confirms that he or she has read and understood the documents relating to the Option (this Agreement), which were provided in the English language.  Participant accepts the terms of these documents accordingly.</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Consentement Relatif &#224; la Langue Utilis&#233;e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">En acceptant cette attribution gratuite d&#8217;actions et ce contrat qui contient les termes et conditions de cette attribution gratuite d&#8217;actions, l&#8217;employ&#233; confirme ainsi avoir lu et compris les documents relatifs &#224; cette attribution (le Contrat d&#8217;Attribution) qui lui ont &#233;t&#233; communiqu&#233;s en langue anglaise. L&#8217;employ&#233; en accepte les termes en connaissance de cause.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GERMANY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IRELAND</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITALY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JAPAN</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NETHERLANDS</font></div><div style="margin-bottom:12pt;text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:103px;margin-bottom:5pt;vertical-align:text-bottom;width:464px"></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Waiver of Termination Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant hereby waives any and all rights to compensation or damages as a result of Participant&#8217;s termination of employment or service with the Company and its Affiliates for any reason whatsoever, insofar as those rights result or may result from (i) the loss or diminution in value of such rights or entitlements under the Option, or (ii) Participant&#8217;s ceasing to have rights under the Option as a result of such termination.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt">13</font></div><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PORTUGAL</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SWITZERLAND</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Neither this Agreement nor any other materials relating to the Option (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;FinSA&#8221;), (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than Participant, or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority (&#8220;FINMA&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED KINGDOM</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">National Insurance Contributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company may require, as a condition of the exercise of the Option, that Participant shall, to the extent applicable&#58; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">agree to reimburse the Company in whole or in part for any employer&#8217;s secondary national insurance contributions arising on the exercise of the Option&#59; or </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">enter into an election with the Company to assume in whole or part the liability for any secondary Class 1 national insurance contributions, payable on the exercise of the Option, including an election under paragraph 3B of Schedule 1 to the Social Security Contributions and Benefits Act 1992&#59; or </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#2e74b5;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">agree to pay the employer&#8217;s national insurance contributions, social security contributions, and other levies and taxes arising on the exercise of the Option to the extent permitted by law, in any other jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Section 431 Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;Participant agrees that, if requested to do so by the Company, Participant shall immediately upon the exercise of the Option enter into an irrevocable joint election with the Company pursuant to section 431 of the U.K. Income Tax (Earnings and Pensions) Act 2003 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ITEPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in a form specified by the Company that, for the relevant tax purposes, the market value of the share acquired is to be calculated as if the share were not restricted securities (as defined in section 423 of ITEPA) and sections 425 to 430 of ITEPA shall not apply to such shares.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Outstanding Amounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;If Participant fails to make payment to the Company to satisfy Participant&#8217;s Tax Obligations in accordance with this Agreement immediately upon request, Participant shall be liable to make good any amount outstanding on demand.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt">14</font></div><div><font><br></font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1 3
<SEQUENCE>4
<FILENAME>insm-20240630ex1013.htm
<DESCRIPTION>EX-10.1 3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="if17f6cc209b44393ab215fab6ef3a505_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1.3</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RESTRICTED STOCK UNIT AWARD AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FOR U.S. GRANTEES</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grantee Name&#58; </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$ParticipantName$&#47;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Number of RSUs&#58; </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$AwardsGranted$&#47;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$GrantDate$&#47;</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the Insmed Incorporated Amended and Restated 2019 Incentive Plan (the &#8220;Plan&#8221;) as amended through the date hereof and this Restricted Stock Unit Award Agreement (this &#8220;Agreement&#8221;), Insmed Incorporated (the &#8220;Company&#8221;) hereby grants an award of </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$AwardsGranted$&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">restricted stock units (the &#8220;Restricted Stock Units&#8221; or the &#8220;RSU Award&#8221;) to the individual named above (the &#8220;Grantee&#8221;). Subject to the restrictions and conditions set forth herein and in the Plan, Grantee shall receive the number of Restricted Stock Units specified above. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions and provisions of any employment, consulting or similar services agreement between Grantee and the Company (or any of its Affiliates, as applicable) as may be in effect (the &#8220;Service Agreement&#8221;), the Service Agreement shall control, and this Agreement shall be deemed to be modified accordingly so long as such modification is not expressly prohibited by the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company acknowledges the receipt from Grantee of consideration with respect to the par value of the shares of Common Stock subject to the RSU Award in the form of cash, past or future services rendered to the Company by Grantee or such other form of consideration as is acceptable to the Administrator and permitted under the Plan and applicable law.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Agreement with Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Execution of this Agreement by Grantee or receipt of any benefits under this Agreement by Grantee shall constitute Grantee&#8217;s acknowledgement of and agreement with all of the provisions of this Agreement and of the Plan that are applicable to this RSU Award, and the Company shall administer this Agreement accordingly.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Restrictions and Conditions on Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Restricted Stock Units granted herein shall be subject to all the terms, conditions and restrictions set forth herein and in the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Timing and Form of Payout of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As soon as practicable (but in no event later than 30 days) following the applicable Vesting Date (as defined below) or, if earlier, the date the RSU Award vests in accordance with Section 5 or Section 6 of this Agreement, the vested Restricted Stock Units shall be settled in shares of Common Stock (except as provided in Section 5 of this Agreement). </font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Vesting of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Except as set forth in Section 4(b), Section 4(c) or Section 5 of this Agreement, the restrictions and conditions in Section 2 of this Agreement shall lapse with respect to 25% of the RSU Award on each anniversary of the first day of the month immediately following the Grant Date (each a &#8220;Vesting Date&#8221;) through the fourth anniversary thereof, so long as Grantee remains an employee or other service provider of the Company or its Affiliates on the applicable Vesting Date. </font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">If the Grantee&#8217;s employment or service with the Company and its Affiliates terminates on account of the Grantee&#8217;s death or the Grantee becoming permanently and totally disabled within the meaning of Section 22(e)(3) of the Code, then any unvested portion of the RSU Award shall immediately become vested on the Grantee&#8217;s termination date, which shall be treated as the Vesting Date for purposes of this Agreement.</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Notwithstanding anything to the contrary herein or in the Plan, the Administrator may at any time accelerate the vesting schedule specified in this Section 4.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event of a Change in Control, vesting of the RSU Award may be accelerated in accordance with the provisions of the Plan and&#47;or Service Agreement. If, in connection with a Change in Control, the RSU Award is not assumed and no award is substituted for the RSU Award, then the vested Restricted Stock Units shall be settled in cash in an amount equal to the Fair Market Value of the shares of Common Stock underlying such vested Restricted Stock Units determined as of the date of the Change in Control. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Termination of Employment or Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as otherwise provided in this Agreement or the Plan and&#47;or Service Agreement, any unvested portion of the RSU Award shall be forfeited without payment of consideration upon the termination of Grantee&#8217;s employment or service with the Company or its Affiliates for any reason. A change in the status (whether as employee, member of the Board or other non-employee advisor or service provider) in which Grantee renders service to the Company and its Affiliates or a change in the entity for which Grantee renders such service shall not constitute a termination of Grantee&#8217;s employment or service for purposes of this Agreement, so long as there is no interruption or termination of Grantee&#8217;s services to the Company and its Affiliates&#59; provided, however, that if the entity employing or engaging Grantee ceases to be an Affiliate of the Company, as determined by the Administrator, Grantee&#8217;s employment or service shall be considered to have terminated on the date such entity ceased to be an Affiliate.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Voting Rights and Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Until such time as Restricted Stock Units are paid out in shares of Common Stock (if at all), Grantee shall not have any voting, dividend or other shareholder rights with respect to any shares of Common Stock underlying this RSU Award (&#8220;Underlying Shares&#8221;). No dividend equivalents shall accrue or be paid to Grantee with respect to the Underlying Shares. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Adjustments Upon Certain Unusual or Nonrecurring Events or Other Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon certain unusual or nonrecurring events, or other events, the terms of these Restricted Stock Units shall be adjusted by the Administrator pursuant to Section 14 of the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Incorporation of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding anything herein to the contrary, this RSU Award and this Agreement shall be subject to and governed by all the terms and conditions of the Plan. To the extent any provision hereof is inconsistent with a provision of the Plan, the provisions of the Plan will govern. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Taxes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By accepting this Agreement, Grantee hereby elects to either (A) sell Underlying Shares in an amount and at such time as is determined in accordance with this Section 10, and to allow the Agent (as defined below) to remit the cash proceeds of such sales to the Company as more specifically set forth below (the &#8220;Sell to Cover&#8221;) to permit Grantee to satisfy any Federal, state, local or other taxes required by law to be withheld in respect of the vesting of the RSU Award (&#8220;Withholding Obligations&#8221;) that arise on future Vesting Dates or (B) make arrangements to the Administrator&#8217;s satisfaction under his or her existing 10b5-1 trading plan (&#8220;Existing 10b5-1 Plan&#8221;) to provide for the satisfaction of any Withholding Obligations that arise on future Vesting Dates. If Grantee does not make arrangements satisfying any Withholding Obligations to the Administrator&#8217;s satisfaction under their Existing 10b5-1 Plan by the time of the next Vesting Date, then any such Withholding Obligations for the newly vested Underlying Shares will be satisfied through a Sell to Cover as outlined in Section 10(b) of this Agreement. </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In the event of a Sell to Cover under this Agreement, Grantee acknowledges and agrees as follows&#58;</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:2.67pt">Grantee irrevocably appoints Merrill Lynch, Pierce, Fenner &#38; Smith Inc., or such other registered broker-dealer that is a member of the Financial Industry Regulatory Authority, Inc. as the Administrator may select, as his or her agent (the &#8220;Agent&#8221;), and authorizes and directs the Agent to&#58;</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Sell on the open market at the then prevailing market price(s), on Grantee&#8217;s behalf, as soon as reasonably practicable on or after each Vesting Date, the number (rounded up to the next whole number) of Underlying Shares that is sufficient to generate proceeds to cover (A) the Withholding Obligations arising from the vesting of the applicable portion of the RSU Award and the related issuance of Underlying Shares to Grantee and (B) all applicable fees and commissions due to, or required to be collected by, the Agent with respect thereto&#59;</font></div><div style="padding-left:126pt;text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Remit directly to the Company the proceeds necessary to satisfy the Withholding Obligations&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:126pt;text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Retain the amount required to cover all applicable fees and commissions due to, or required to be collected by, the Agent, relating directly to the sale of the Underlying Shares referred to in clause (1) above&#59; and</font></div><div style="padding-left:126pt;text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Remit to Grantee any remaining funds from the sale of Underlying Shares referred to in clause (1).</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.34pt">Grantee acknowledges that its agreement to Sell to Cover and the corresponding authorization and instruction to the Agent set forth in this Section 10 are intended to constitute a &#8220;non-Rule 10b5-1 trading arrangement&#8221; within the meaning of Item 408(c) of Regulation S-K under the Act, and will be interpreted to comply with the requirements of such Item 408(c) (the Grantee&#8217;s agreement to Sell to Cover and the provisions of this Section 10, collectively, the &#8220;Trading Plan&#8221;). In furtherance thereof, Grantee acknowledges and agrees as follows&#58;</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">This Trading Plan is being entered into in good faith and not as part of a plan or scheme to evade the requirements of Item 408(c). </font></div><div style="padding-left:126pt;text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Grantee is not, as of the date of adoption of this Trading Plan, aware of any material nonpublic information about the Common Stock or the Company.</font></div><div style="padding-left:126pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.01pt">Grantee acknowledges that by accepting this RSU Award, he or she is adopting the Trading Plan to permit Grantee to satisfy Withholding Obligations. Grantee hereby authorizes the Company and the Agent to cooperate and communicate with one another to determine the number of Underlying Shares that must be sold to satisfy the Withholding Obligations.</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.67pt">Grantee acknowledges that the Agent is under no obligation to arrange for the sale of Underlying Shares at any particular price under this Trading Plan and that the Agent may effect sales as provided in this Trading Plan in one or more sales and that the average price for executions resulting from bunched orders may be assigned to their account. Grantee further acknowledges that he or she will be responsible for all brokerage fees and other costs of sale associated with this Trading Plan, and agrees to indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale. In addition, Grantee acknowledges that it may not be possible to sell Underlying Shares as provided for in this Trading Plan due to (A) a legal or contractual restriction applicable to Grantee or the Agent, (B) a market disruption, (C) a sale effected pursuant to this Trading Plan that would not comply (or in the reasonable opinion of the Agent&#8217;s counsel is likely not to comply) with the Act, (D) the Company&#8217;s determination that sales may not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">be effected under this Trading Plan or (E) rules governing order execution priority on the national exchange where the Common Stock may be traded. If the Agent is not able to sell the Underlying Shares, then Grantee shall continue to be responsible for the timely payment to the Company of all Withholding Obligations.</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">v.Grantee acknowledges that regardless of any other term or condition of this Trading Plan, the Agent will not be liable to Grantee for (A) special, indirect, punitive, exemplary, or consequential damages, or incidental losses or damages of any kind, or (B) any failure to perform or for any delay in performance that results from a cause or circumstance that is beyond the Agent&#8217;s reasonable control.</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">vi.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.67pt">Grantee agrees to execute and deliver to the Agent any other agreements or documents as the Agent reasonably deems necessary or appropriate to carry out the purposes and intent of this Trading Plan. The Agent is a third-party beneficiary of this Section 10 and the terms of this Trading Plan.</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">vii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.34pt">Grantee&#8217;s agreement to Sell to Cover and to enter into this Trading Plan is irrevocable. Upon acceptance of the RSU Award, Grantee shall have agreed to Sell to Cover and to enter into this Trading Plan, and Grantee acknowledges that they may not change this decision at any time in the future with respect to the RSU Award. This Trading Plan shall terminate on the earlier of&#58; </font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the date on which the Withholding Obligations arising from the last vesting event in respect of the RSU Award and the related issuance of the Underlying Shares having been satisfied&#59;</font></div><div style="padding-left:126pt;text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Grantee&#8217;s, Administrator&#8217;s or Agent&#8217;s reasonable determination that Grantee has not complied with the Trading Plan or applicable securities laws&#59;</font></div><div style="padding-left:126pt;text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">receipt by the Agent of a written notice from the Company, Administrator or Grantee regarding&#58; (a) a public announcement having been made of a tender or exchange offer involving the Company&#8217;s securities&#59; (b) a definitive agreement having been announced relating to a merger, reorganization, consolidation or similar transaction in which the Underlying Shares covered by this Trading Plan would be subject to a lock-up provision or would be exchanged or converted into cash, securities or other property&#59; (c) a sale having been made of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, or a transaction affecting the Company occurring in which the owners of the Company&#8217;s outstanding voting power prior to the transaction do not own at least a majority of the outstanding voting power of the successor entity </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">immediately upon completion of the transaction&#59; (d) a dissolution or liquidation of the Company having taken place or being in process, or the commencement or impending commencement of any proceedings in respect of or triggered by the Company&#8217;s bankruptcy or insolvency&#59; or (e) this Trading Plan or its attendant transactions possibly causing the breach of a contract or agreement to which the Company is a party or by which the Company is bound&#59;</font></div><div style="padding-left:126pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">receipt by the Agent of written notice of Grantee&#8217;s death or legal incapacity from the Administrator or the Company&#59; or</font></div><div style="padding-left:126pt;text-align:justify"><font><br></font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">receipt by the Agent of written notice of termination from Grantee that is signed by the Administrator or the Company.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Company shall have no obligation to deliver Underlying Shares until all applicable Withholding Obligations have been fully satisfied by Grantee. The Company makes no representation or undertaking regarding the tax treatment of the grant, vesting, or settlement of this RSU Award or the subsequent sale of any of the Underlying Shares. The Company does not commit and is under no obligation to structure this RSU Award to reduce or eliminate Grantee&#8217;s tax liability.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Section 409A of the Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This RSU Award is intended to comply with the requirements of Section 409A of the Code or an exemption thereto, and this Agreement shall be interpreted in a manner consistent with this intent in order to avoid the imposition of any additional tax, interest or penalties under Section 409A of the Code. Notwithstanding anything to the contrary in this Agreement, in no event shall any delivery of shares of Common Stock or other payment pursuant to this RSU Award occur after the short-term deferral period described in Treas. Reg. &#167; 1.409A-1(b)(4). In no event shall the Company be liable for any additional tax, interest or penalties that may be imposed on Grantee pursuant to Section 409A of the Code or any damages for failing to comply with Section 409A of the Code or an exemption thereto.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">No Right to Continued Employment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Nothing in the Plan or this Agreement shall interfere with or limit in any way the right of the Company, its Subsidiaries and&#47;or its Affiliates to terminate Grantee&#8217;s employment at any time or for any reason in accordance with the Company&#8217;s Bylaws, governing law and any applicable Service Agreement, nor shall any terms of the Plan or this Agreement confer upon Grantee any right to continue his or her employment for any specified period of time. Neither this Agreement nor any benefits arising under the Plan or this Agreement shall constitute an employment contract with the Company, any Subsidiary and&#47;or its Affiliates. If Grantee is not an employee, nothing in the Plan or this Agreement shall interfere with or limit in any way the right of the Company, its Subsidiaries and&#47;or its Affiliates to terminate Grantee&#8217;s service, (i) if a member of the Board, on the Board at any time or for any reason in accordance with the Company&#8217;s Bylaws and governing law, or (ii) if a non-employee consultant or advisor, in accordance with the terms of the contract with such consultant or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">advisor. In no event shall any of the terms of the Plan or this Agreement itself confer upon Grantee any right to continue his or her service for any specified period of time. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notice or other communication given pursuant to this Agreement shall be in writing and shall be personally delivered or mailed by United States registered or certified mail, postage prepaid, return receipt requested, to the Company at its principal place of business or to Grantee at the address on the Company&#8217;s records or, in either case, at such other address as one party may subsequently furnish to the other party in writing. Additionally, if such notice or communication is by the Company to Grantee, the Company may provide such notice electronically (including via email). Any such notice shall be deemed to have been given (a) on the date of postmark, in the case of notice by mail, or (b) on the date of delivery, if delivered in person or electronically.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="if17f6cc209b44393ab215fab6ef3a505_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:36pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Sara Bonstein</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$ParticipantName$&#47;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature Page to Restricted Stock Unit Award Agreement&#93;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1 4
<SEQUENCE>5
<FILENAME>insm-20240630ex1014.htm
<DESCRIPTION>EX-10.1 4
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i435fa89767044a5e96302bcf00ce9cc2_1"></div><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1.4</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RESTRICTED STOCK UNIT AWARD AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN<br>FOR NON-U.S. GRANTEES</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grantee Name&#58; </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$ParticipantName$&#47;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Number of RSUs&#58; </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$AwardsGranted$&#47;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant Date&#58; </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$GrantDate$&#47;</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the Insmed Incorporated Amended and Restated 2019 Incentive Plan (the &#8220;Plan&#8221;) as amended through the date hereof and this Restricted Stock Unit Award Agreement (this &#8220;Agreement&#8221;), Insmed Incorporated (the &#8220;Company&#8221;) hereby grants an award of </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$AwardsGranted$&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">restricted stock units (the &#8220;Restricted Stock Units&#8221; or the &#8220;RSU Award&#8221;) to the individual named above (the &#8220;Grantee&#8221;). Subject to the restrictions and conditions set forth herein and in the Plan, Grantee shall receive the number of Restricted Stock Units specified above. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions and provisions of any employment, consulting or similar services agreement between Grantee and the Company (or any of its Affiliates, as applicable) as may be in effect (the &#8220;Service Agreement&#8221;), the Service Agreement shall control, and this Agreement shall be deemed to be modified accordingly so long as such modification is not expressly prohibited by the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company acknowledges the receipt from Grantee of consideration with respect to the par value of the shares of Common Stock subject to the RSU Award in the form of cash, past or future services rendered to the Company by Grantee or such other form of consideration as is acceptable to the Administrator and permitted under the Plan and applicable law.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Agreement with Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Execution of this Agreement by Grantee or receipt of any benefits under this Agreement by Grantee shall constitute Grantee&#8217;s acknowledgement of and agreement with all of the provisions of this Agreement and of the Plan that are applicable to this RSU Award, and the Company shall administer this Agreement accordingly.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Restrictions and Conditions on Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Restricted Stock Units granted herein shall be subject to all the terms, conditions and restrictions set forth herein and in the Plan.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Timing and Form of Payout of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As soon as practicable (but in no event later than 30 days) following the applicable Vesting Date (as defined below) or, if earlier, the date the RSU Award vests in accordance with Section 5 or Section 6 of this Agreement, the vested Restricted Stock Units shall be settled in shares of Common Stock (except as provided in Section 5 of this Agreement).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Vesting of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.153%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Except as set forth in Section 4(b), Section 4(c) or Section 5 of this Agreement, the restrictions and conditions in Section 2 of this Agreement shall lapse with respect to 25% of the RSU Award on each anniversary of the first day of the month immediately following the Grant Date (each a &#8220;Vesting Date&#8221;) through the fourth anniversary thereof, so long as Grantee remains an employee or other service provider of the Company or its Affiliates on the applicable Vesting Date.</font></div><div style="padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">If the Grantee&#8217;s employment or service with the Company and its Affiliates terminates on account of the Grantee&#8217;s death or the Grantee becoming permanently and totally disabled within the meaning of Section 22(e)(3) of the Code, then any unvested portion of the RSU Award shall immediately become vested on the Grantee&#8217;s termination date, which shall be treated as the Vesting Date for purposes of this Agreement.</font></div><div style="padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Notwithstanding anything to the contrary herein or in the Plan, the Administrator may at any time accelerate the vesting schedule specified in this Section 4.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event of a Change in Control, vesting of the RSU Award may be accelerated in accordance with the provisions of the Plan and&#47;or Service Agreement. If, in connection with a Change in Control, the RSU Award is not assumed and no award is substituted for the RSU Award, then the vested Restricted Stock Units shall be settled in cash in an amount equal to the Fair Market Value of the shares of Common Stock underlying such vested Restricted Stock Units determined as of the date of the Change in Control.   </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Termination of Employment or Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise provided in this Agreement or the Plan and&#47;or Service Agreement, any unvested portion of the RSU Award shall be forfeited without payment of consideration upon the termination of Grantee&#8217;s employment or service with the Company or its Affiliates for any reason. A change in the status (whether as employee, member of the Board or other non-employee advisor or service provider) in which Grantee renders service to the Company and its Affiliates or a change in the entity for which Grantee renders such service shall not constitute a termination of Grantee&#8217;s employment or service for purposes of this Agreement, so long as there is no interruption or termination of Grantee&#8217;s services to the Company and its Affiliates&#59; provided, however, that if the entity employing or engaging Grantee ceases to be an Affiliate of the Company, as determined by the Administrator, Grantee&#8217;s employment or service shall be considered to have terminated on the date such entity ceased to be an Affiliate.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Voting Rights and Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Until such time as Restricted Stock Units are paid out in shares of Common Stock (if at all), Grantee shall not have any voting, dividend or other shareholder rights with respect to any shares of Common Stock underlying this RSU Award (&#8220;Underlying Shares&#8221;). No dividend equivalents shall accrue or be paid to Grantee with respect to the Underlying Shares. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div style="text-align:center"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Adjustments Upon Certain Unusual or Nonrecurring Events or Other Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon certain unusual or nonrecurring events, or other events, the terms of these Restricted Stock Units shall be adjusted by the Administrator pursuant to Section 14 of the Plan.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Incorporation of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything herein to the contrary, this RSU Award and this Agreement shall be subject to and governed by all the terms and conditions of the Plan.  To the extent any provision hereof is inconsistent with a provision of the Plan, the provisions of the Plan will govern.  Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">By accepting this Agreement, Grantee hereby elects to either (A) sell Underlying Shares in an amount and at such time as is determined in accordance with this Section 10, and to allow the Agent (as defined below) to remit the cash proceeds of such sales to the Company as more specifically set forth below (the &#8220;Sell to Cover&#8221;) to permit Grantee to satisfy any Federal, state, local, foreign or other taxes required by law to be withheld (including without limitation social insurance contributions or national insurance contributions) in respect of the vesting of the RSU Award (&#8220;Withholding Obligations&#8221;) that arise on future Vesting Dates or (B) make arrangements to the Administrator&#8217;s satisfaction under his or her existing 10b5-1 trading plan (&#8220;Existing 10b5-1 Plan&#8221;) to provide for the satisfaction of any Withholding Obligations that arise on future Vesting Dates. If Grantee does not make arrangements satisfying any Withholding Obligations to the Administrator&#8217;s satisfaction under their Existing 10b5-1 Plan by the time of the next Vesting Date, then any such Withholding Obligations for the newly vested Underlying Shares will be satisfied through a Sell to Cover as outlined in Section 10(b) of this Agreement.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">In the event of a Sell to Cover under this Agreement, Grantee acknowledges and agrees as follows&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.67pt">Grantee irrevocably appoints Merrill Lynch, Pierce, Fenner &#38; Smith Inc., or such other registered broker-dealer that is a member of the Financial Industry Regulatory Authority, Inc. as the Administrator may select, as his or her agent (the &#8220;Agent&#8221;), and authorizes and directs the Agent to&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.Sell on the open market at the then prevailing market price(s), on Grantee&#8217;s behalf, as soon as reasonably practicable on or after each Vesting Date, the number (rounded up to the next whole number) of Underlying Shares that is sufficient to generate proceeds to cover (A) the Withholding Obligations arising from the vesting of the applicable portion of the RSU Award and the related issuance of Underlying Shares to Grantee and (B) all applicable fees and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div style="text-align:center"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">commissions due to, or required to be collected by, the Agent with respect thereto&#59;</font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.Remit directly to the Company the proceeds necessary to satisfy the Withholding Obligations&#59;</font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.Retain the amount required to cover all applicable fees and commissions due to, or required to be collected by, the Agent, relating directly to the sale of the Underlying Shares referred to in clause (1) above&#59; and</font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.Remit to Grantee any remaining funds from the sale of Underlying Shares referred to in clause (1).</font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:8.34pt">Grantee acknowledges that its agreement to Sell to Cover and the corresponding authorization and instruction to the Agent set forth in this Section 10 are intended to constitute a &#8220;non-Rule 10b5-1 trading arrangement&#8221; within the meaning of Item 408(c) of Regulation S-K under the Act, and will be interpreted to comply with the requirements of such Item 408(c) (the Grantee&#8217;s agreement to Sell to Cover and the provisions of this Section 10, collectively, the &#8220;Trading Plan&#8221;). In furtherance thereof, Grantee acknowledges and agrees as follows&#58;</font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">This Trading Plan is being entered into in good faith and not as part of a plan or scheme to evade the requirements of Item 408(c). </font></div><div style="padding-left:180pt;text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Grantee is not, as of the date of adoption of this Trading Plan, aware of any material nonpublic information about the Common Stock or the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:5.01pt">Grantee acknowledges that by accepting this RSU Award, he or she is adopting the Trading Plan to permit Grantee to satisfy Withholding Obligations. Grantee hereby authorizes the Company and the Agent to cooperate and communicate with one another to determine the number of Underlying Shares that must be sold to satisfy the Withholding Obligations.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:5.67pt">Grantee acknowledges that the Agent is under no obligation to arrange for the sale of Underlying Shares at any particular price under this Trading Plan and that the Agent may effect sales as provided in this Trading Plan in one or more sales and that the average price for executions resulting from bunched orders may be assigned to their account. Grantee further acknowledges that he or she will be responsible for all brokerage fees and other costs of sale associated with this Trading Plan, and agrees to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div style="text-align:center"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">indemnify and hold the Company harmless from any losses, costs, damages, or expenses relating to any such sale. In addition, Grantee acknowledges that it may not be possible to sell Underlying Shares as provided for in this Trading Plan due to (A) a legal or contractual restriction applicable to Grantee or the Agent, (B) a market disruption, (C) a sale effected pursuant to this Trading Plan that would not comply (or in the reasonable opinion of the Agent&#8217;s counsel is likely not to comply) with the Act, (D) the Company&#8217;s determination that sales may not be effected under this Trading Plan or (E) rules governing order execution priority on the national exchange where the Common Stock may be traded. If the Agent is not able to sell the Underlying Shares, then Grantee shall continue to be responsible for the timely payment to the Company of all Withholding Obligations.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">v.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Grantee acknowledges that regardless of any other term or condition of this Trading Plan, the Agent will not be liable to Grantee for (A) special, indirect, punitive, exemplary, or consequential damages, or incidental losses or damages of any kind, or (B) any failure to perform or for any delay in performance that results from a cause or circumstance that is beyond the Agent&#8217;s reasonable control.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">vi.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:5.67pt">Grantee agrees to execute and deliver to the Agent any other agreements or documents as the Agent reasonably deems necessary or appropriate to carry out the purposes and intent of this Trading Plan. The Agent is a third-party beneficiary of this Section 10 and the terms of this Trading Plan.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">vii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:2.34pt">Grantee&#8217;s agreement to Sell to Cover and to enter into this Trading Plan is irrevocable. Upon acceptance of the RSU Award, Grantee shall have agreed to Sell to Cover and to enter into this Trading Plan, and Grantee acknowledges that they may not change this decision at any time in the future with respect to the RSU Award. This Trading Plan shall terminate on the earlier of&#58;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.the date on which the Withholding Obligations arising from the last vesting event in respect of the RSU Award and the related issuance of the Underlying Shares having been satisfied&#59;</font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.Grantee&#8217;s, Administrator&#8217;s or Agent&#8217;s reasonable determination that Grantee has not complied with the Trading Plan or applicable securities laws&#59;</font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.receipt by the Agent of a written notice from the Company, Administrator or Grantee regarding&#58; (a) a public announcement having been made of a tender or exchange offer involving the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div><div style="text-align:center"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company&#8217;s securities&#59; (b) a definitive agreement having been announced relating to a merger, reorganization, consolidation or similar transaction in which the Underlying Shares covered by this Trading Plan would be subject to a lock-up provision or would be exchanged or converted into cash, securities or other property&#59; (c) a sale having been made of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, or a transaction affecting the Company occurring in which the owners of the Company&#8217;s outstanding voting power prior to the transaction do not own at least a majority of the outstanding voting power of the successor entity immediately upon completion of the transaction&#59; (d) a dissolution or liquidation of the Company having taken place or being in process, or the commencement or impending commencement of any proceedings in respect of or triggered by the Company&#8217;s bankruptcy or insolvency&#59; or (e) this Trading Plan or its attendant transactions possibly causing the breach of a contract or agreement to which the Company is a party or by which the Company is bound&#59;</font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.receipt by the Agent of written notice of Grantee&#8217;s death or legal incapacity from the Administrator or the Company&#59; or</font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div style="padding-left:144pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.receipt by the Agent of written notice of termination from Grantee that is signed by the Administrator or the Company.</font></div><div style="padding-left:144pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">The Company shall have no obligation to deliver Underlying Shares until all applicable Withholding Obligations have been fully satisfied by Grantee. The Company makes no representation or undertaking regarding the tax treatment of the grant, vesting, or settlement of this RSU Award or the subsequent sale of any of the Underlying Shares. The Company does not commit and is under no obligation to structure this RSU Award to reduce or eliminate Grantee&#8217;s tax liability. Grantee authorizes the Company to disclose all information on Grantee and his or her participation in this Agreement that is or may be relevant for the calculation of applicable tax obligations to the competent local tax authorities and the Company&#8217;s Affiliates.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Section 409A of the Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This RSU Award is intended to comply with the requirements of Section 409A of the Code or an exemption thereto, and this Agreement shall be interpreted in a manner consistent with this intent in order to avoid the imposition of any additional tax, interest or penalties under Section 409A of the Code. Notwithstanding anything to the contrary in this Agreement, in no event shall any delivery of shares of Common Stock or other payment pursuant to this RSU Award occur after the short-term deferral period described in Treas. Reg. &#167; 1.409A-1(b)(4). In no event shall the Company be liable for any additional tax, interest or penalties that may be imposed on Grantee pursuant to Section 409A of the Code or any damages for failing to comply with Section 409A of the Code or an exemption thereto.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div><div style="text-align:center"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice or other communication given pursuant to this Agreement shall be in writing and shall be personally delivered or mailed by United States registered or certified mail, postage prepaid, return receipt requested, to the Company at its principal place of business or to Grantee at the address on the Company&#8217;s records or, in either case, at such other address as one party may subsequently furnish to the other party in writing.&#160;&#160;Additionally, if such notice or communication is by the Company to Grantee, the Company may provide such notice electronically (including via email).  Any such notice shall be deemed to have been given (a) on the date of postmark, in the case of notice by mail, or (b) on the date of delivery, if delivered in person or electronically.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">No Right to Continued Employment and Other Service Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As a condition to accepting this RSU Award, Grantee acknowledges and agrees as follows&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Nothing in the Plan or this Agreement shall interfere with or limit in any way the right of the Company, its Subsidiaries and&#47;or its Affiliates to terminate Grantee&#8217;s employment at any time or for any reason in accordance with the Company&#8217;s Bylaws, governing law and any applicable employment agreement&#59;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">No terms of the Plan or this Agreement shall confer upon Grantee any right to continue his or her employment for any specified period of time.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Neither this Agreement nor any benefits arising under the Plan or this Agreement shall constitute an employment contract with the Company, any Subsidiary and&#47;or its Affiliates.  </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">If Grantee is not an employee, nothing in the Plan or this Agreement shall interfere with or limit in any way the right of the Company, its Subsidiaries and&#47;or its Affiliates to terminate Grantee&#8217;s service, (i) if a member of the Board, on the Board at any time or for any reason in accordance with the Company&#8217;s Bylaws and governing law, or (ii) if a non-employee consultant or advisor, in accordance with the terms of the contract with such consultant or advisor.  </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">In no event shall any of the terms of the Plan or this Agreement itself confer upon Grantee any right to continue his or her service for any specified period of time.  </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.01pt">Any notice period mandated under applicable law shall not be treated as service for the purpose of determining the vesting of this RSU Award&#59; and Grantee&#8217;s right to vesting of this RSU Award after termination of service, if any, will be measured by the date of termination of Grantee&#8217;s active service and will not be extended by any notice period mandated under applicable law.  Subject to the foregoing and the provisions of this Agreement, the Company, in its sole discretion, shall determine whether Grantee&#8217;s service has terminated and the effective date of such termination. </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div><div style="text-align:center"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The grant of this RSU Award is voluntary and occasional and does not create any contractual or other right to receive future grants of RSU Awards, or benefits in lieu of RSU Awards, even if RSU Awards have been granted repeatedly in the past.  All decisions with respect to future RSU Award grants, if any, will be at the sole discretion of the Company. </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Grantee is voluntarily participating in the grant of this RSU Award. </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.67pt">This RSU Award is an extraordinary item that does not constitute compensation of any kind for service of any kind rendered to the Company or its Affiliates or Subsidiaries, and which is outside the scope of Grantee&#8217;s employment contract, if any.  This RSU Award is not part of normal or expected compensation or salary for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, end-of-service payments, bonuses, long-service awards, pension or retirement benefits or similar payments. </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.67pt">The future value of the underlying shares of Common Stock is unknown and cannot be predicted with certainty.  The value of the shares may increase or decrease. </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">No claim or entitlement to compensation or damages arises from termination of this RSU Award or diminution in value of this RSU Award or shares of Common Stock subject thereto, and Grantee irrevocably releases the Company and its Affiliates and Subsidiaries from any such claim that may arise.  If, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen then, by signing this Agreement, Grantee shall be deemed irrevocably to have waived Grantee&#8217;s entitlement to pursue such a claim. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.67pt">The RSU Award and the benefits evidenced by the Agreement do not create any entitlement not otherwise specifically provided for in the Agreement or provided by the Company in its discretion, to have the RSU Award or any such benefits transferred to, or assumed by, another company, nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Common Stock.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.67pt">Neither the Company nor any of its Affiliates shall be liable for any foreign exchange rate fluctuation between Grantee&#8217;s local currency and the U.S. dollar that may affect the value of the RSU Award or any amounts due to Grantee in connection with the RSU Award or the subsequent sale of any shares acquired upon settlement of the RSU Award. To the extent the Company determines that a currency exchange or conversion is necessary in connection with the settlement of the RSU Award or any other matter, such exchange shall be calculated and determined by the Company in its sole discretion, and the Company&#8217;s determination shall be final and binding.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div><div style="text-align:center"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Grantee understands that the Company may collect, use and transfer, in electronic or other form, Grantee&#8217;s personal data as described in this Agreement for the exclusive purpose of implementing, administering and managing Grantee&#8217;s RSU Award.  Grantee understands that the Company holds certain personal information about Grantee, including, but not limited to, Grantee&#8217;s name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares or directorships held in the Company, details of all RSU Awards or any other entitlement to shares awarded, canceled, exercised, vested, unvested or outstanding in Grantee&#8217;s favor, for the purpose of implementing, administering and managing Grantee&#8217;s RSU Award (&#8220;Data&#8221;).  Grantee understands that Data may be transferred to any third parties assisting in the implementation, administration and management of this RSU Award, that these recipients may be located in Grantee&#8217;s country or elsewhere, and that the recipient&#8217;s country may have different data privacy laws and protections than Grantee&#8217;s country.  Grantee understands that he or she may request a list with the names and addresses of any potential recipients of the Data by contacting Grantee&#8217;s local human resources representative.  Grantee understands that recipients may receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing Grantee&#8217;s RSU Award, including any requisite transfer of such Data as may be required to a broker or other third party with whom Grantee may elect to deposit any shares acquired pursuant to this RSU Award.  Grantee understands that Data will be held only as long as is necessary to implement, administer and manage Grantee&#8217;s RSU Award.  Grantee understands that he or she may, at any time, view Data, request additional information about the storage and processing of Data or require any necessary amendments to Data, by contacting in writing Grantee&#8217;s local human resources representative.  For more information on the processing of Data for the purposes set out above, Grantee understands that he or she may contact Grantee&#8217;s local human resources representative. For Grantees located within the European Union or the United Kingdom, Grantee understands that Data will always be processed in accordance with the Insmed EU Employee Personal Data Processing Notice or the Insmed UK Employee Personal Data Processing Notice, respectively, a copy of which has been appended to the Agreement, if applicable, and is also available from Grantee&#8217;s local human resources representative.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Not a Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The grant of the RSU Award is not intended to be a public offering of securities in Grantee&#8217;s country of employment or service (or country of residence, if different). The Company has not submitted any registration statement, prospectus, or other filings with the local securities authorities (unless otherwise required under local law), and the grant of the RSU Award is not subject to the supervision of the local securities authorities.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">No Advice Regarding Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Investment in shares of the Company&#8217;s Common Stock involves a degree of risk. Before deciding to accept the Award, Grantee should carefully consider all risk factors relevant to the acquisition of shares of Common Stock and carefully review all of the materials related to the RSU Award. The Company is not providing any tax, legal, or financial advice, nor is the Company making any recommendations regarding Grantee&#8217;s participation in the Plan, or Grantee&#8217;s acquisition or sale of the shares underlying the RSU Award. Grantee is hereby advised to consult with Grantee&#8217;s own personal tax, legal, and financial advisors regarding Grantee&#8217;s participation in the Plan before taking any action related to the RSU Award.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div><div style="text-align:center"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">31.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Language.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If the Plan, this Agreement or any other document related to the Plan is translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control to the maximum extent permitted by applicable law.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">32.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.5pt;text-decoration:underline">Imposition of Additional Requirements&#59; Repatriation&#59; Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The grant of the RSU Award and the issuance and delivery of shares under the RSU Award are subject to all applicable laws, rules, and regulations and to such approvals by any governmental agencies or securities exchange as may be required. Notwithstanding any provision of the Agreement, the Company has no liability to deliver any shares under the RSU Award or make any payment unless such delivery or payment would comply with all laws and the applicable requirements of any governmental agency, securities exchange, or similar entity, and unless and until Grantee has taken all actions required by the Company in connection with the RSU Award. The Company reserves the right to impose other requirements on the RSU Award and on any shares acquired upon the settlement of the RSU Award to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Grantee to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. Grantee agrees to repatriate all payments attributable to the shares and&#47;or cash acquired under the RSU Award in accordance with applicable foreign exchange rules and regulations in Grantee&#8217;s country of employment or service (and country of residence, if different). In addition, Grantee agrees to take any and all actions, and consents to any and all actions taken by the Company and any of its Affiliates, as may be required to allow the Company and any of its Affiliates to comply with local laws, rules, and&#47;or regulations in Grantee&#8217;s country of employment or service (and country of residence, if different). Finally, Grantee agrees to take any and all actions as may be required to comply with Grantee&#8217;s personal obligations under local laws, rules, and&#47;or regulations in Grantee&#8217;s country of employment or service (and country of residence, if different). Neither the Company nor any of its Affiliates shall be liable for any costs, fines, or penalties resulting from Grantee&#8217;s failure to comply with such personal obligations.</font></div><div style="padding-left:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">33.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">34.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Foreign Asset and Account Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Grantee&#8217;s country of employment or service (and country of residence, if different) may have certain exchange control and&#47;or foreign asset&#47;account reporting requirements which may affect Grantee&#8217;s ability to acquire or hold shares under the RSU Award or cash received in connection with the RSU Award (including from any dividends received or sale proceeds resulting from the sale of shares) in a brokerage or bank account outside of Grantee&#8217;s country. Grantee may be required to report such accounts, assets, or transactions to the tax or other authorities in Grantee&#8217;s country. Grantee acknowledges that it is Grantee&#8217;s responsibility to comply with any applicable regulations, and that Grantee should speak to Grantee&#8217;s personal advisor on this matter.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">35.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">36.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Annex of Country-Specific Terms.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Notwithstanding any provisions in this Agreement, this RSU Award may be subject to special terms and conditions set forth in the Annex to this Agreement for Grantee&#8217;s country of employment or service (and country of residence, if different).  Moreover, if Grantee relocates to one of the countries included in the Annex, the special terms and conditions for such country will apply to Grantee, to the extent the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div><div style="text-align:center"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company determines at its discretion that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Annex constitutes part of this Agreement.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">37.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">38.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:36pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INSMED INCORPORATED</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;&#47;s&#47; Sara Bonstein</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font><br></font></div><div style="margin-bottom:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$ParticipantName$&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;      </font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div><div style="text-align:center"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ANNEX </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TO</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RESTRICTED STOCK UNIT AWARD AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN<br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ADDITIONAL NOTICES, TERMS AND CONDITIONS FOR NON-U.S. GRANTEES</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Further Terms and Conditions of the RSU Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  It is understood and agreed that the RSU Award evidenced by the Restricted Stock Unit Award Agreement (&#8220;Agreement&#8221;) to which this is annexed is subject to the following additional terms and conditions&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grantee understands that this Annex includes special terms and conditions applicable to Grantee if Grantee resides and&#47;or works in one of the countries below.  These terms and conditions are in addition to those set forth in the Agreement and the Plan.  Any capitalized term used in this Annex without definition shall have the meaning ascribed to it in the Agreement or the Plan, as applicable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grantee further understands that this Annex also includes information relating to laws and regulatory requirements of which Grantee should be aware with respect to his or her participation in the Plan.  The information is based on the laws in effect in the respective countries as of May 2023.  Such laws are often complex and change frequently.  As a result, Grantee understands that the Company strongly recommends that Grantee not rely on the information herein as the only source of information relating to the consequences of participation in the Plan because the information may be out of date at the time that Grantee&#8217;s RSU Award is settled or Grantee sells shares of Common Stock acquired under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Finally, Grantee understands that if&#58; (a) Grantee is a citizen or resident of a country other than the one in which Grantee is currently working, (b) transfers employment after grant of the RSU Award, or (c) is considered a resident of another country for local law purposes, the information contained herein may not apply to Grantee, and the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall apply.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company may,  from time to time, add or impose additional terms and conditions in respect of Grantee&#8217;s RSU Award in order to ensure compliance with any local laws and regulations. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AUSTRALIA</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The offer of the RSU Award is intended to comply with the provisions of the Corporations Act 2001. If Grantee acquires shares under the RSU Award and subsequently offers such shares for sale to a person or entity resident in Australia, the offer may be subject to disclosure requirements under Australian law. Grantee should obtain legal advice on disclosure obligations prior to making any such offer.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div><div style="text-align:center"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Breach of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary in the Agreement, Grantee will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Agreement if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Tax Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The RSU Award is an award to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) applies (subject to the conditions in such Act).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BELGIUM</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CANADA</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This paragraph supplements the provisions of Section 14 (Data Privacy) of the Agreement. Grantee hereby authorizes the Company and the Company&#8217;s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Agreement and the RSU Award. Grantee further authorizes the Company and any of its Affiliates and the Administrator to disclose and discuss the Agreement and the RSU Award with their advisors. Grantee further authorizes the Company and any of its Affiliates to record such information and to keep such information in Grantee&#8217;s employee file.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">English Language Consent - Quebec</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The parties acknowledge that it is their express wish that the Agreement, as well as all documents, notices, and legal proceedings entered into, given, or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Les parties reconnaissent avoir expressement souhait&#233; que la convention (le &#171;&#160;Agreement&#160;&#187;), ainsi que tous les documents, avis et proc&#233;dures judiciaries, &#233;xecut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;, directement ou indirectement &#224; la pr&#233;sente convention, soient r&#233;dig&#233;s en langue anglaise.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DENMARK</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FRANCE</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Non-Qualification of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The RSU Award is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> intended to be tax qualified under French tax laws including, without limitation, under Articles L. 225-197-1 and seq. of the French Commercial Code.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In accepting the grant of the RSU Award and this Agreement which provides for the terms and conditions of the RSU Award, Grantee confirms that he or she has </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div><div style="text-align:center"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">read and understood the documents relating to the RSU Award (this Agreement), which were provided in the English language.  Grantee accepts the terms of these documents accordingly.</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Consentement Relatif &#224; la Langue Utilis&#233;e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">En acceptant cette attribution gratuite d&#8217;actions et ce contrat qui contient les termes et conditions de cette attribution gratuite d&#8217;actions, l&#8217;employ&#233; confirme ainsi avoir lu et compris les documents relatifs &#224; cette attribution (le Contrat d&#8217;Attribution) qui lui ont &#233;t&#233; communiqu&#233;s en langue anglaise. L&#8217;employ&#233; en accepte les termes en connaissance de cause.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GERMANY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IRELAND</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITALY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JAPAN</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NETHERLANDS</font></div><div style="margin-bottom:12pt;text-align:center"><img alt="image_01a.jpg" src="image_01a.jpg" style="height:103px;margin-bottom:5pt;vertical-align:text-bottom;width:464px"></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Waiver of Termination Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Grantee hereby waives any and all rights to compensation or damages as a result of Grantee&#8217;s termination of employment or service with the Company and its Affiliates for any reason whatsoever, insofar as those rights result or may result from (i) the loss or diminution in value of such rights or entitlements under the RSU Award, or (ii) Grantee&#8217;s ceasing to have rights under the RSU Award as a result of such termination.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PORTUGAL</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SWITZERLAND</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div><div style="text-align:center"><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Neither this Agreement nor any other materials relating to the RSU Award (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;FinSA&#8221;), (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than Grantee, or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority (&#8220;FINMA&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED KINGDOM</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">National Insurance Contributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company may require, as a condition of the settlement of the RSU Award, that Grantee shall, to the extent applicable&#58; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">agree to reimburse the Company in whole or in part for any employer&#8217;s secondary national insurance contributions arising in connection with the RSU Award&#59; or </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">enter into an election with the Company to assume in whole or part the liability for any secondary Class 1 national insurance contributions, payable in connection with the RSU Award, including an election under paragraph 3B of Schedule 1 to the Social Security Contributions and Benefits Act 1992&#59; or </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#365f91;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">agree to pay the employer&#8217;s national insurance contributions, social security contributions, and other levies and taxes arising in connection with the RSU Award to the extent permitted by law, in any other jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Section 431 Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;Grantee agrees that, if requested to do so by the Company, Grantee shall immediately upon the settlement of the RSU Award enter into an irrevocable joint election with the Company pursuant to section 431 of the U.K. Income Tax (Earnings and Pensions) Act 2003 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ITEPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in a form specified by the Company that, for the relevant tax purposes, the market value of the share acquired is to be calculated as if the share were not restricted securities (as defined in section 423 of ITEPA) and sections 425 to 430 of ITEPA shall not apply to such shares.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Outstanding Amounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;If Grantee fails to make payment to the Company to satisfy Grantee&#8217;s Tax Obligations in accordance with this Agreement immediately upon request, Grantee shall be liable to make good any amount outstanding on demand.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div><div style="text-align:center"><font><br></font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>6
<FILENAME>insm-20240630ex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0454e301a80247ffb091d57ee88a4fc1_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OMNIBUS AMENDMENT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TO INSMED INCORPORATED INCENTIVE AWARDS </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AND INDUCEMENT AWARDS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">May 8, 2024</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Insmed Incorporated (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) sponsors and maintains the Insmed Incorporated 2013 Incentive Plan, the Insmed Incorporated 2015 Incentive Plan, the Insmed Incorporated 2017 Incentive Plan and the Insmed Incorporated Amended and Restated 2019 Incentive Plan (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#894; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Company has granted certain stock option awards as an inducement material to a participant&#8217;s entry into employment with the Company or a subsidiary of the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Inducement Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Company desires to provide for the accelerated vesting of outstanding restricted stock units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">RSU Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and outstanding non-qualified stock options (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) granted under the Plans as well as outstanding Inducement Awards in the event of a termination of employment or service with the Company and its affiliates due to death or a qualifying disability&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, each Plan authorizes the Compensation Committee of the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to amend any agreement or other document evidencing an award made under a Plan in accordance with the terms and conditions of such Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, the award agreements for Options, RSU Awards, and Inducement Awards are hereby amended as follows, effective as of the date hereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Each award agreement evidencing the grant of an Option to an optionholder under a Plan and each Inducement Award shall be amended such that&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">If the optionholder&#8217;s employment or service with the Company and its affiliates terminates on or after the Amendment Effective Date and prior to the expiration of the Option or Inducement Award (as applicable) on account of the optionholder&#8217;s death or the optionholder becoming permanently and totally disabled within the meaning of Section 22(e)(3) of the Internal Revenue Code then any unvested portion of such Option or Inducement Award shall immediately become vested and exercisable on the optionholder&#8217;s termination date&#59; and</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Any Options and Inducement Awards that become vested and exercisable pursuant to the foregoing paragraph 1.a. may be exercised by the optionholder (or, in the case of the optionholder&#8217;s death, the optionholder&#8217;s estate or the person(s) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to whom the optionholder&#8217;s rights under the Option or Inducement Award shall pass by will or the laws of descent and distribution) during the post-termination exercise period following a termination due to death or disability (as applicable) set forth in such award agreement.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Each award agreement evidencing the grant of an RSU Award to a grantee under a Plan shall be amended such that&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">If the grantee&#8217;s employment or service with the Company and its affiliates terminates on or after the Amendment Effective Date on account of the grantee&#8217;s death or the grantee becoming permanently and totally disabled within the meaning of Section 22(e)(3) of the Internal Revenue Code, then any unvested portion of such RSU Award shall immediately become vested on the grantee&#8217;s termination date&#59; and</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Any restricted stock units that become vested pursuant to the foregoing paragraph 2.a. shall be settled as soon as practicable (but in no event later than 30 days) following the grantee&#8217;s termination date. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">This Omnibus Amendment shall be and is hereby incorporated in, and forms a part of, each award agreement evidencing the grant of an Option, RSU Award, or Inducement Award. All other terms and provisions of the Options, RSU Awards, and Inducement Awards shall remain unchanged except as specifically modified by this Omnibus Amendment. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature page follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the undersigned officer hereby certifies that the foregoing Omnibus Amendment was duly adopted by the Committee.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INSMED INCORPORATED</font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Michael A. Smith</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Michael A. Smith</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Chief Legal Officer</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>7
<FILENAME>insm-20240630ex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ib1f5da9dde07492898975f26be5995a8_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">INSMED INCORPORATED </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">No. of shares subject to Option&#58; </font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:135%">&#47;$AwardsGranted$&#47;</font></div><div><font style="color:#333333;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:135%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">THIS AGREEMENT dated this </font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:135%">&#47;$GrantDate$&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;), between INSMED INCORPORATED, a Virginia corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;), and </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#47;$ParticipantName$&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;), is an inducement material to Participant&#8217;s entry into employment with the Company or a subsidiary of the Company within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Inducement Award Rule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;). If and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions and provisions of Participant&#8217;s offer letter or employment agreement with the Company or the applicable subsidiary thereof, dated as of </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:135%">&#47;$HireDate$&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> (the &#8220;Employment Agreement&#8221;), the Employment Agreement shall control, and this Agreement shall be deemed to be modified accordingly so long as such modification is consistent with the Inducement Award Rule and applicable law.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">. The Company, on &#47;$GrantDate$&#47; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Date of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;), granted to Participant, subject to the terms and conditions herein set forth, the right and option to purchase from the Company all or any part of an aggregate of &#47;$AwardsGranted$&#47; shares of common stock of the Company, par value US $0.01 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;) at the option price of &#47;$GrantPrice$&#47; per share, being not less than the closing price of a share of the Company&#8217;s Common Stock on the NASDAQ on the Date of Grant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;). The Option is intended to be a nonqualified stock option and not an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;). The Option is exercisable as hereinafter provided.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">2. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">Terms and Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">. The Option is subject to the following terms and conditions&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">a. </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">. The Option shall expire ten years from the Date of Grant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">b.</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">. Except as provided in paragraphs 3, 4 and 5, the Option shall be exercisable with respect to twenty-five percent (25%) of the shares of Common Stock subject to the Option on the first annual anniversary of the Date of Grant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">First Anniversary Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;) and with respect to twelve and a half percent (12.5%) of the shares of Common Stock subject to the Option on the six-month anniversary of the First Anniversary Date and each six-month anniversary date thereafter through the fourth annual anniversary of the Date of Grant, subject to Participant&#8217;s continued employment through each applicable date. If the foregoing schedule would produce fractional shares, the number of shares for which the Option </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">becomes exercisable shall be rounded down to the nearest whole share. Once the Option has become exercisable in accordance with this subparagraph 2(b) it shall continue to be exercisable until the termination of Participant&#8217;s rights hereunder pursuant to paragraph 3, 4 or 5 or until the Option has expired pursuant to subparagraph 2(a). A partial exercise of the Option shall not affect Participant&#8217;s right to exercise the Option with respect to the remaining shares, subject to the conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">c.</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Method of Exercising Option and Payment for Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">. The Option shall be exercised by written notice in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Attachment A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> &#8212; &#8220;Notice of Option Exercise&#8221; or such other form as may be approved by the Company, delivered to the attention of the Company&#8217;s Chief Financial Officer at the Company&#8217;s principal place of business. The exercise date shall be (i) in the case of notice by mail, the date of postmark, or (ii) if delivered in person, the date of delivery. Such notice shall be accompanied by payment of the Option price in full, in cash or cash equivalent acceptable to the Compensation Committee of the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221; and the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;), or such other method as determined by the Compensation Committee, including an irrevocable commitment by a broker to pay over such amount from a sale of the shares of Common Stock issuable under the Option, the delivery of previously owned shares of Common Stock or withholding of shares of Common Stock deliverable upon exercise which, together with any cash or cash equivalent paid, is not less than the Option price for the number of shares for which the Option is being exercised.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">d. </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Agreement with Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">. Execution of this Agreement by Participant or receipt of any benefits under this Agreement by Participant shall constitute Participant&#8217;s acknowledgement of, and agreement with, all of the provisions of this Agreement, and the Company shall administer this Agreement accordingly.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">e. </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Shareholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">. Participant shall not have any rights as a shareholder with respect to shares subject to the Option until Participant exercises such Option and becomes the holder of record of such shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">f. </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Termination of Employment or Service&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">. Except as provided in this subparagraph 2(f), in the event of Participant&#8217;s termination of employment, any vested portion of the Option that is not exercised during the period specified in paragraph 3, paragraph 4 or paragraph 5, as applicable, shall be forfeited upon the expiration of such period, and any portion of the Option that is unvested as of the date of Participant&#8217;s termination of employment shall be forfeited on such date. Notwithstanding the preceding sentence, if Participant&#8217;s employment or service terminates prior to the Expiration Date on account of Participant&#8217;s death or Participant becoming permanently and totally disabled within the meaning of Section 22(e)(3) of the Code (&#8220;Permanently and Totally Disabled&#8221;), then any unvested portion of this Option shall immediately become vested and exercisable on Participant&#8217;s termination date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">Exercise in the Event of Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">. In the event Participant dies before the expiration of the Option pursuant to subparagraph 2(a), the Option shall be exercisable with respect to all or part of the shares of Common Stock that Participant was entitled to purchase under subparagraph 2(b) and subparagraph 2(f) on the date of Participant&#8217;s death. In that event, the Option may be exercised, to the extent exercisable, by Participant&#8217;s estate or by the other person or persons to whom Participant&#8217;s rights under the Option shall pass by will or the laws of descent and distribution. Participant&#8217;s estate or such persons may exercise the Option within one year after Participant&#8217;s death or during the remainder of the period preceding the Expiration Date, whichever is shorter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">Exercise in the Event of Permanent and Total Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">. In the event Participant becomes Permanently and Totally Disabled before the expiration of the Option pursuant to subparagraph 2(a), the Option shall be exercisable with respect to all or part of the shares of Common Stock that Participant was entitled to purchase under subparagraph 2(b) and subparagraph 2(f) on the date Participant ceases to be employed by the Company or, as determined by the Compensation Committee from time to time, any entity in which the Company has a substantial direct or indirect equity interest (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;), as a result of Participant&#8217;s becoming Permanently and Totally Disabled. In that event, Participant may exercise the Option, to the extent exercisable, within one year after the date Participant ceases to be employed by the Company and its Affiliates as a result of Participant&#8217;s becoming Permanently and Totally Disabled or during the period preceding the Expiration Date, whichever is shorter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">5.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">Exercise After Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">. Except as provided in paragraphs 3 and 4 hereof, if Participant ceases to be employed by the Company and its Affiliates prior to the Expiration Date, the Option shall be exercisable for all or part of the number of shares that Participant was entitled to purchase under subparagraph 2(b) and, if applicable, any additional number of shares specified under the Employment Agreement on the date of Participant&#8217;s termination of employment. In that event, Participant may exercise the Option, to the extent exercisable under subparagraph 2(b) and&#47;or under the Employment Agreement, during the remainder of the period preceding the Expiration Date or until the date that is three months (or such other period of time provided under the Employment Agreement, if any) after the date Participant ceases to be employed by the Company and its Affiliates, whichever is shorter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">6.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">. Any notice or other communication given pursuant to this Agreement shall be in writing and shall be personally delivered or mailed by United States registered or certified mail, postage prepaid, return receipt requested, to the Company at its principal place of business or to Participant at the address on the payroll records of the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. Additionally, if such notice or communication is by the Company to Participant, the Company may provide such notice electronically (including via email). Any such notice shall be deemed to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">have been given (a) on the date of postmark, in the case of notice by mail, or (b) on the date of delivery, if delivered in person or electronically.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">7.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">Fractional Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">. Fractional shares shall not be issuable hereunder, and when any provision hereof may entitle Participant to a fractional share such fraction shall be disregarded.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">8.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">No Right to Continued Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">. Nothing in this Agreement shall interfere with or limit in any way the right of the Company, its subsidiaries and&#47;or its Affiliates to terminate Participant&#8217;s employment at any time or for any reason in accordance with the Company&#8217;s Bylaws, governing law and the Employment Agreement, nor shall any terms of this Agreement confer upon Participant any right to continue Participant&#8217;s employment for any specified period of time. Neither this Agreement nor any benefits arising under this Agreement shall constitute an employment contract with the Company or any of its subsidiaries or Affiliates. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">9.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">Change in Capital Structure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> The terms of the Option (including the number or kind of shares subject hereto and the option price) shall be equitably adjusted as the Compensation Committee determines is equitably required to reflect any reorganization, reclassification, combination of shares, stock split, reverse stock split, spin-off, dividend or distribution of securities, property or cash (other than regular, quarterly cash dividends), or any other event or transaction that affects the number or kind of shares of Common Stock outstanding. No fractional shares of Common Stock shall be issued pursuant to such an adjustment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">10.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">. The Compensation Committee shall have the discretion to determine the treatment of the Option upon the occurrence of a Change in Control (as defined below). Unless otherwise expressly provided in the Employment Agreement or under the terms of a transaction constituting a Change in Control, the following shall occur upon a Participant&#8217;s involuntary termination of employment within twenty-four (24) months following a Change in Control, provided that such termination does not result from the Participant&#8217;s termination for disability, cause or gross misconduct&#58; the Option shall immediately become exercisable and shall remain exercisable for three (3) years following such termination (or until the Expiration Date, if earlier).  For purposes of this paragraph 10, the following definitions apply, subject to applicable laws to the extent mandatory&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> a.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221; means the occurrence of any one of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">i. </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">any Person becomes the beneficial owner (as such term is defined in Rule 13d-3 under the U.S. Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;)) of at least 50% of either (A) the value of the then outstanding shares of common stock of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Outstanding Company Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;) or (B) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Outstanding Company Voting Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;) (the foregoing beneficial ownership hereinafter being referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Controlling Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;)&#59; provided, however, that for purposes of this definition, the following acquisitions shall not constitute or result in a Change in Control&#58; (v) any acquisition directly from the Company&#59; (w) any acquisition by the Company&#59; (x) any acquisition by any person that as of the Date of Grant has beneficial ownership of a Controlling Interest&#59; (y) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Affiliate&#59; or (z) any acquisition by any corporation pursuant to a transaction which complies with subparagraphs 10(b)(iii)(A), (B) and (C) below&#59; or</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">ii.</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">during any period of two consecutive years (not including any period prior to the Date of Grant) individuals who constitute the Board on the Date of Grant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Incumbent Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;) cease for any reason to constitute at least a majority of the Board&#59; provided, however, that any individual becoming a director subsequent to the Date of Grant whose election, or nomination for election by the Company&#8217;s shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board&#59; or</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">iii.</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">consummation of a reorganization, merger, statutory share exchange or consolidation or similar corporate transaction involving the Company or any of its subsidiaries, a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition of assets or stock of another entity by the Company or any of its subsidiaries (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Business Combination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;), in each case, unless, following such Business Combination, (A) all or substantially all of the Persons who were </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">the beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company&#8217;s assets either directly or through one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Acquiring Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;) in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (B) no Person (excluding the Acquiring Corporation or any employee benefit plan (or related trust) of the Company or such Acquiring Corporation) beneficially owns, directly or indirectly, more than 50% of the then outstanding shares of common stock of the corporation resulting from such Business Combination or the combined voting power of the then outstanding voting securities of such corporation except to the extent that such ownership existed prior to the Business Combination, and (C) at least a majority of the members of the board of the corporation resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business Combination&#59; or</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">iv.</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">the complete liquidation or dissolution of the Company.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">Notwithstanding the foregoing, to the extent required to avoid the imposition of additional taxes and&#47;or penalties pursuant to Section 409A of the Code, no event or transaction will constitute a Change in Control hereunder unless it also constitutes a &#8220;change in control event&#8221; under Section 409A of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> b.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221; has the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (i) the Company or any of its Affiliates, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its Subsidiaries, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities or (iv) a corporation owned, directly </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of stock of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">11.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">. To the extent required by applicable federal, state, local or foreign law, the Company may and&#47;or Participant shall make arrangements satisfactory to the Company for the satisfaction of any withholding tax obligations that arise with respect to the Option, or the issuance or sale of any shares of Common Stock. The Company shall not be required to recognize any Participant rights under the Option, to issue shares of Common Stock or to recognize the disposition of such shares of Common Stock until such obligations are satisfied. To the extent permitted or required by the Company, these obligations may or shall be satisfied by the Company withholding cash from any compensation otherwise payable to or for the benefit of Participant in accordance with applicable law, the Company withholding a portion of the shares of Common Stock that otherwise would be issued to a Participant under the Option or any other award held by Participant or by Participant tendering to the Company cash or, if allowed by the Company, shares of Common Stock. Nothing in this Agreement shall be interpreted or construed to transfer any liability for any tax (including, without limitation, a tax or penalty due as a result of a failure to comply with Section 409A of the Code) due by Participant to the Company, any subsidiary thereof or any Affiliate, or to any other individual or entity, and the Company shall have no liability to Participant, or any other party, with respect thereto. Participant acknowledges that the Company and its subsidiaries and Affiliates&#58; (a) make no representations or undertakings regarding the tax treatment in connection with any aspect of the Option and (b) do not commit to structure the terms of the grant or any other aspect of the Option to reduce or eliminate Participant&#8217;s tax liabilities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">12.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> Any question concerning the interpretation of this Agreement or the Option, any adjustments required to be made to the Option hereunder, and any controversy that may arise with respect to the Option will be determined by the Compensation Committee in its sole and absolute discretion. All decisions by the Compensation Committee shall be final and binding on Participant and Participant&#8217;s beneficiaries, heirs and assigns.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">13.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">Compliance with Laws and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">  Participant hereby acknowledges, represents and warrants to the Company that, unless a registration statement under the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;), with respect to the shares of Common Stock to be received upon the exercise of the Option is effective and current at the time of exercise of the Option, (i) the shares of Common Stock to be issued upon the exercise of the Option will be unregistered and acquired by Participant for Participant&#8217;s own account, for investment only and not with a view to the resale or distribution thereof and (ii) the shares of Common Stock to be issued upon the exercise of the Option may not be sold or transferred unless a registration statement under the Securities Act with respect to the resale of such shares is effective and current or such registration is determined by the Company to be unnecessary. Nothing herein shall be construed as requiring the Company to register the shares subject to the Option for sale </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">or resale under the Securities Act. Notwithstanding anything herein to the contrary, if at any time the Company shall determine, in its sole discretion, that the listing or qualification of the shares of Common Stock subject to the Option on any securities exchange or under any applicable law, or the consent or approval of any governmental agency or regulatory body, is necessary or desirable as a condition to, or in connection with, the issuance of shares of Common Stock hereunder, the Option may not be exercised in whole or in part unless such listing, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">14.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">This Agreement shall be governed by the laws of the Commonwealth of Virginia, without regard to any rule or principle of conflicts of laws that otherwise would result in the application of the substantive laws of another jurisdiction. Any reference in this Agreement to a provision of law or to a rule or regulation shall be deemed to include any successor law, rule or regulation of similar effect or applicability.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">15.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> It is intended that the provisions of this Agreement comply with Section 409A of the Code (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#8221;), and all provisions of the Option shall be construed and interpreted in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">16.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">Nontransferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">.  This Option may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated by Participant except by will or by the laws of descent and distribution.  During Participant&#8217;s lifetime, this Option may be exercised only by Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">17.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">. Participant acknowledges and agrees that Participant has no right to receive any equity compensation following the Date of Grant other than as set forth in this Agreement or otherwise approved by the Board or Compensation Committee on or before the Date of Grant, and that the Option is granted in full satisfaction of Participant&#8217;s right, if any, to an equity award under any offer letter, transition letter, or similar letter, agreement, or communication from the Company or any Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">18.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> Subject to the limitations stated above, this Agreement shall be binding upon and inure to the benefit of the legatees, distributees, and personal representatives of Participant and the successors of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">IN WITNESS WHEREOF, the Company has caused this Agreement to be signed by a duly authorized officer, and Participant has affixed Participant&#8217;s signature hereto.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">INSMED INCORPORATED</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">By&#58; &#47;s&#47; Sara Bonstein</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">Chief Financial Officer</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">PARTICIPANT</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#47;s&#47; </font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:135%">&#47;$ParticipantName$&#47;</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Attachment A</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">Insmed Incorporated</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">700 US Highway 202&#47;206</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">Bridgewater, NJ 08807</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">Notice Of Option Exercise</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">This letter is notice of my decision to exercise the Option that was granted to me on ______________.  Terms used but not defined in this notice have the meanings given to them in the Nonqualified Stock Option Inducement Award Agreement between the Company and myself on _______________.  The exercise will be effective on _____________. I am exercising the Option for ______________ shares of Common Stock. I have chosen the following form of payment to cover the aggregate Option price for the number of shares for which I am exercising the Option (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:135%">check one</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">)&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#91;    &#93;</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">1. </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">Cash</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#91;    &#93;</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">2.</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">Certified or bank check payable to Insmed Incorporated</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#91;    &#93;</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">3.</font><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:135%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">Other (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:135%">please describe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">)&#58; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">______________________________________________________</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">Sincerely,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">                                                                                   </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">Name&#58;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">Address&#58;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:18.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.029%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.030%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:134%">Accepted by&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:134%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:134%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:134%">&#160;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:134%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:134%">Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:134%">&#160;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.3</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;text-decoration:underline">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">&#58; The date of exercise cannot be earlier than the date of delivery of this notice or the postmark, if the notice is mailed.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>8
<FILENAME>insm-20240630ex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i953139f1192d4ad8b3581b07dd1ceae3_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.4</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT FOR NON-US EMPLOYEES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">No. of shares subject to Option&#58; </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$AwardsGranted$&#47;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THIS AGREEMENT dated this </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$GrantDate$&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), between INSMED INCORPORATED, a Virginia corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and &#91;NAME&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), is an inducement material to Participant&#8217;s entry into employment with the Company or a subsidiary of the Company within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Inducement Award Rule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). If and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions and provisions of Participant&#8217;s offer letter or employment agreement with the Company or the applicable subsidiary thereof, dated as of &#91;DATE&#93; (the &#8220;Employment Agreement&#8221;), the Employment Agreement shall control, and this Agreement shall be deemed to be modified accordingly so long as such modification is consistent with the Inducement Award Rule and applicable law.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company, on &#47;$GrantDate$&#47; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Date of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), granted to Participant, subject to the terms and conditions herein set forth, the right and option to purchase from the Company all or any part of an aggregate of &#47;$AwardsGranted$&#47; shares of common stock of the Company, par value US $0.01 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) at the option price of &#47;$GrantPrice$&#47; per share, being not less than the closing price of a share of the Company&#8217;s Common Stock on the NASDAQ on the Date of Grant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Option is intended to be a nonqualified stock option and not an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Option is exercisable as hereinafter provided.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Terms and Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Option is subject to the following terms and conditions&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Option shall expire ten years from the Date of Grant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as provided in paragraphs 3, 4 and 5, the Option shall be exercisable with respect to twenty-five percent (25%) of the shares of Common Stock subject to the Option on the first annual anniversary of the Date of Grant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">First Anniversary Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and with respect to twelve and a half percent (12.5%) of the shares of Common Stock subject to the Option on the six-month anniversary of the First Anniversary Date and each six-month anniversary date thereafter through the fourth annual anniversary of the Date of Grant, subject to Participant&#8217;s continued employment through each applicable date. If the foregoing schedule would produce fractional shares, the number of shares for which the Option becomes exercisable shall be rounded down to the nearest whole share. Once the Option has become exercisable in accordance with this subparagraph 2(b) it shall continue to be exercisable until the termination of Participant&#8217;s rights hereunder pursuant to paragraph 3, 4 or 5 or until the Option has expired pursuant to subparagraph 2(a). A partial exercise of the Option shall not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.153%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">affect Participant&#8217;s right to exercise the Option with respect to the remaining shares, subject to the conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Method of Exercising Option and Payment for Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Option shall be exercised by written notice in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Attachment A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8212; &#8220;Notice of Option Exercise&#8221; or such other form as may be approved by the Company, delivered to the attention of the Company&#8217;s Chief Financial Officer at the Company&#8217;s principal place of business. The exercise date shall be (i) in the case of notice by mail, the date of postmark, or (ii) if delivered in person, the date of delivery. Such notice shall be accompanied by payment of the Option price in full, in cash or cash equivalent acceptable to the Compensation Committee of the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), or such other method as determined by the Compensation Committee, including an irrevocable commitment by a broker to pay over such amount from a sale of the shares of Common Stock issuable under the Option, the delivery of previously owned shares of Common Stock or withholding of shares of Common Stock deliverable upon exercise which, together with any cash or cash equivalent paid, is not less than the Option price for the number of shares for which the Option is being exercised.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement with Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Execution of this Agreement by Participant or receipt of any benefits under this Agreement by Participant shall constitute Participant&#8217;s acknowledgement of, and agreement with, all of the provisions of this Agreement, and the Company shall administer this Agreement accordingly.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Shareholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant shall not have any rights as a shareholder with respect to shares subject to the Option until Participant exercises such Option and becomes the holder of record of such shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination of Employment or Service&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as provided in this subparagraph 2(f), in the event of Participant&#8217;s termination of employment, any vested portion of the Option that is not exercised during the period specified in paragraph 3, paragraph 4 or paragraph 5, as applicable, shall be forfeited upon the expiration of such period, and any portion of the Option that is unvested as of the date of Participant&#8217;s termination of employment shall be forfeited on such date. Notwithstanding the preceding sentence, if Participant&#8217;s employment or service terminates prior to the Expiration Date on account of Participant&#8217;s death or Participant becoming permanently and totally disabled within the meaning of Section 22(e)(3) of the Code (&#8220;Permanently and Totally Disabled&#8221;), then any unvested portion of this Option shall immediately become vested and exercisable on Participant&#8217;s termination date</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exercise in the Event of Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Participant dies before the expiration of the Option pursuant to subparagraph 2(a), the Option shall be exercisable with respect to all or part of the shares of Common Stock that Participant was entitled to purchase under subparagraph 2(b) and subparagraph 2(f) on the date of Participant&#8217;s death. In that event, the Option may be exercised, to the extent exercisable, by Participant&#8217;s estate or by the other person or persons to whom Participant&#8217;s rights under the Option shall pass by will or the laws of descent and distribution. Participant&#8217;s estate or such persons may exercise the Option within one year after Participant&#8217;s death or during the remainder of the period preceding the Expiration Date, whichever is shorter.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exercise in the Event of Permanent and Total Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Participant becomes Permanently and Totally Disabled before the expiration of the Option pursuant to subparagraph 2(a), the Option shall be exercisable with respect to all or part of the shares of Common Stock that Participant was entitled to purchase under subparagraph 2(b) and subparagraph 2(f) on the date Participant ceases to be employed by the Company or, as determined by the Compensation Committee from time to time, any entity in which the Company has a substantial direct or indirect equity interest (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as a result of Participant&#8217;s becoming Permanently and Totally Disabled. In that event, Participant may exercise the Option, to the extent exercisable, within one year after the date Participant ceases to be employed by the Company and its Affiliates as a result of Participant&#8217;s becoming Permanently and Totally Disabled or during the period preceding the Expiration Date, whichever is shorter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exercise After Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as provided in paragraphs 3 and 4 hereof, if Participant ceases to be employed by the Company and its Affiliates prior to the Expiration Date, the Option shall be exercisable for all or part of the number of shares that Participant was entitled to purchase under subparagraph 2(b) and, if applicable, any additional number of shares specified under the Employment Agreement on the date of Participant&#8217;s termination of employment. In that event, Participant may exercise the Option, to the extent exercisable under subparagraph 2(b) and&#47;or under the Employment Agreement, during the remainder of the period preceding the Expiration Date or until the date that is three months (or such other period of time provided under the Employment Agreement, if any) after the date Participant ceases to be employed by the Company and its Affiliates, whichever is shorter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notice or other communication given pursuant to this Agreement shall be in writing and shall be personally delivered or mailed by United States registered or certified mail, postage prepaid, return receipt requested, to the Company at its principal place of business or to Participant at the address on the payroll records of the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. Additionally, if such notice or communication is by the Company to Participant, the Company may provide such notice electronically (including via email). Any such notice shall be deemed to have been given (a) on the date of postmark, in the case of notice by mail, or (b) on the date of delivery, if delivered in person or electronically.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Fractional Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Fractional shares shall not be issuable hereunder, and when any provision hereof may entitle Participant to a fractional share such fraction shall be disregarded.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">No Right to Continued Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Nothing in this Agreement shall interfere with or limit in any way the right of the Company, its subsidiaries and&#47;or its Affiliates to terminate Participant&#8217;s employment at any time or for any reason in accordance with the Company&#8217;s Bylaws, governing law and the Employment Agreement, nor shall any terms of this Agreement confer upon Participant any right to continue Participant&#8217;s employment for any specified period of time. Neither this Agreement nor any benefits arising under this Agreement shall constitute an employment contract with the Company or any of its subsidiaries or Affiliates. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Change in Capital Structure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The terms of the Option (including the number or kind of shares subject hereto and the option price) shall be equitably adjusted as the Compensation Committee determines is equitably required to reflect any reorganization, reclassification, combination of shares, stock split, reverse stock split, spin-off, dividend or distribution of securities, property or cash (other than regular, quarterly cash dividends), or any other event or transaction that affects the number or kind of shares of Common Stock outstanding. No fractional shares of Common Stock shall be issued pursuant to such an adjustment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Compensation Committee shall have the discretion to determine the treatment of the Option upon the occurrence of a Change in Control (as defined below). Unless otherwise expressly provided in the Employment Agreement or under the terms of a transaction constituting a Change in Control, the following shall occur upon a Participant&#8217;s involuntary termination of employment within twenty-four (24) months following a Change in Control, provided that such termination does not result from the Participant&#8217;s termination for disability, cause or gross misconduct&#58; the Option shall immediately become exercisable and shall remain exercisable for three (3) years following such termination (or until the Expiration Date, if earlier).  For purposes of this paragraph 10, the following definitions apply, subject to applicable laws to the extent mandatory&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> a.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the occurrence of any one of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.&#160;&#160;&#160;&#160;any Person becomes the beneficial owner (as such term is defined in Rule 13d-3 under the U.S. Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)) of at least 50% of either (A) the value of the then outstanding shares of common stock of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Outstanding Company Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) or (B) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Outstanding Company Voting Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (the foregoing beneficial ownership hereinafter being referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Controlling Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, however, that for purposes of this definition, the following acquisitions shall not constitute or result in a Change in Control&#58; (v) any acquisition directly from the Company&#59; (w) any acquisition by the Company&#59; (x) any acquisition by any person that as of the Date of Grant has beneficial ownership of a Controlling Interest&#59; (y) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Affiliate&#59; or (z) any acquisition by any corporation pursuant to a transaction which complies with subparagraphs 10(b)(iii)(A), (B) and (C) below&#59; or</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.&#160;&#160;&#160;&#160;during any period of two consecutive years (not including any period prior to the Date of Grant) individuals who constitute the Board on the Date of Grant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Incumbent Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) cease for any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">reason to constitute at least a majority of the Board&#59; provided, however, that any individual becoming a director subsequent to the Date of Grant whose election, or nomination for election by the Company&#8217;s shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board&#59; or</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.&#160;&#160;&#160;&#160;consummation of a reorganization, merger, statutory share exchange or consolidation or similar corporate transaction involving the Company or any of its subsidiaries, a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition of assets or stock of another entity by the Company or any of its subsidiaries (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Business Combination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in each case, unless, following such Business Combination, (A) all or substantially all of the Persons who were the beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company&#8217;s assets either directly or through one or more subsidiaries) (such resulting or acquiring corporation is referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Acquiring Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (B) no Person (excluding the Acquiring Corporation or any employee benefit plan (or related trust) of the Company or such Acquiring Corporation) beneficially owns, directly or indirectly, more than 50% of the then outstanding shares of common stock of the corporation resulting from such Business Combination or the combined voting power of the then outstanding voting securities of such corporation except to the extent that such ownership existed prior to the Business Combination, and (C) at least a majority of the members of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">board of the corporation resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business Combination&#59; or</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv.&#160;&#160;&#160;&#160;the complete liquidation or dissolution of the Company.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, to the extent required to avoid the imposition of additional taxes and&#47;or penalties pursuant to Section 409A of the Code, no event or transaction will constitute a Change in Control hereunder unless it also constitutes a &#8220;change in control event&#8221; under Section 409A of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> b.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (i) the Company or any of its Affiliates, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its Subsidiaries, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities or (iv) a corporation owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as their ownership of stock of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. To the extent required by applicable federal, state, local or foreign law, the Company may and&#47;or Participant shall make arrangements satisfactory to the Company for the satisfaction of any withholding tax obligations that arise with respect to the Option, or the issuance or sale of any shares of Common Stock. The Company shall not be required to recognize any Participant rights under the Option, to issue shares of Common Stock or to recognize the disposition of such shares of Common Stock until such obligations are satisfied. To the extent permitted or required by the Company, these obligations may or shall be satisfied by the Company withholding cash from any compensation otherwise payable to or for the benefit of Participant in accordance with applicable law, the Company withholding a portion of the shares of Common Stock that otherwise would be issued to a Participant under the Option or any other award held by Participant or by Participant tendering to the Company cash or, if allowed by the Company, shares of Common Stock. Nothing in this Agreement shall be interpreted or construed to transfer any liability for any tax (including, without limitation, a tax or penalty due as a result of a failure to comply with Section 409A of the Code) due by Participant to the Company, any subsidiary thereof or any Affiliate, or to any other individual or entity, and the Company shall have no liability to Participant, or any other party, with respect thereto. Participant acknowledges that the Company and its subsidiaries and Affiliates&#58; (a) make no representations or undertakings regarding the tax treatment in connection with any aspect of the Option and (b) do not commit to structure the terms of the grant or any other aspect of the Option to reduce or eliminate Participant&#8217;s tax liabilities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Any question concerning the interpretation of this Agreement or the Option, any adjustments required to be made to the Option hereunder, and any controversy that may arise with respect to the Option will be determined by the Compensation Committee in its sole and absolute discretion. All decisions by the Compensation Committee shall be final and binding on Participant and Participant&#8217;s beneficiaries, heirs and assigns.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Compliance with Laws and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Participant hereby acknowledges, represents and warrants to the Company that, unless a registration statement under the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), with respect to the shares of Common Stock to be received upon the exercise of the Option is effective and current at the time of exercise of the Option, (i) the shares of Common Stock to be issued upon the exercise of the Option will be unregistered and acquired by Participant for Participant&#8217;s own account, for investment only and not with a view to the resale or distribution thereof and (ii) the shares of Common Stock to be issued upon the exercise of the Option may not be sold or transferred unless a registration statement under the Securities Act with respect to the resale of such shares is effective and current or such registration is determined by the Company to be unnecessary. Nothing herein shall be construed as requiring the Company to register the shares subject to the Option for sale or resale under the Securities Act. Notwithstanding anything herein to the contrary, if at any time the Company shall determine, in its sole discretion, that the listing or qualification of the shares of Common Stock subject to the Option on any securities exchange or under any applicable law, or the consent or approval of any governmental agency or regulatory body, is necessary or desirable as a condition to, or in connection with, the issuance of shares of Common Stock hereunder, the Option may not be exercised in whole or in part unless such listing, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement shall be governed by the laws of the Commonwealth of Virginia, without regard to any rule or principle of conflicts of laws that otherwise would result in the application of the substantive laws of another jurisdiction. Any reference in this Agreement to a provision of law or to a rule or regulation shall be deemed to include any successor law, rule or regulation of similar effect or applicability.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> It is intended that the provisions of this Agreement comply with Section 409A of the Code (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and all provisions of the Option shall be construed and interpreted in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Nontransferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;&#160;This Option may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated by Participant except by will or by the laws of descent and distribution.&#160;&#160;During Participant&#8217;s lifetime, this Option may be exercised only by Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant acknowledges and agrees that Participant has no right to receive any equity compensation following the Date of Grant other than as set forth in this Agreement or otherwise approved by the Board or Compensation Committee on or before the Date of Grant, and that the Option is granted in full satisfaction of Participant&#8217;s right, if any, to an equity award under any offer letter, transition letter, or similar letter, agreement or communication from the Company or any Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Subject to the limitations stated above, this Agreement shall be binding upon and inure to the benefit of the legatees, distributees, and personal representatives of Participant and the successors of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Non-U.S. Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding the provisions in this Agreement, if Participant resides and&#47;or works outside the United States, the Option shall be subject to the special terms and conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Attachment B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Moreover, if Participant relocates to one of the jurisdictions included in Attachment B, the special terms and conditions for such jurisdiction will apply to Participant, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Company has caused this Agreement to be signed by a duly authorized officer, and Participant has affixed Participant&#8217;s signature hereto.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INSMED INCORPORATED</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Sara Bonstein</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PARTICIPANT</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; </font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;$ParticipantName$&#47;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Attachment A</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insmed Incorporated</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">700 US Highway 202&#47;206</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Bridgewater, NJ 08807</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notice Of Option Exercise</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This letter is notice of my decision to exercise the Option that was granted to me on ______________.  Terms used but not defined in this notice have the meanings given to them in the Nonqualified Stock Option Inducement Award Agreement between the Company and myself on _______________.  The exercise will be effective on _____________. I am exercising the Option for ______________ shares of Common Stock. I have chosen the following form of payment to cover the aggregate Option price for the number of shares for which I am exercising the Option (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">check one</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;    &#93;&#160;&#160;&#160;&#160;1. &#160;&#160;&#160;&#160;Cash<br>&#160;&#160;&#160;&#160;&#91;    &#93;&#160;&#160;&#160;&#160;2.&#160;&#160;&#160;&#160;Certified or bank check payable to Insmed Incorporated&#160;&#160;&#160;&#160;<br>&#160;&#160;&#160;&#160;&#91;    &#93;&#160;&#160;&#160;&#160;3.&#160;&#160;&#160;&#160;Other (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">please describe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)&#58; </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;______________________________________________________</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sincerely,</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Address&#58;</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.423%"><tr><td style="width:1.0%"></td><td style="width:17.179%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.761%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Accepted by&#58;</font></td><td colspan="3" style="padding:0 1pt 0 3.77pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Date&#58;</font></td><td colspan="3" style="padding:0 1pt 0 3.77pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; The date of exercise cannot be earlier than the date of delivery of this notice or the postmark, if the notice is mailed.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Attachment B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SPECIAL TERMS AND CONDITIONS FOR NON-U.S. PARTICIPANTS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Attachment B includes special terms and conditions that supplement the terms and conditions in the Agreement for any Participant who resides and&#47;or works outside of the United States. Capitalized terms used but not defined herein shall have the meanings assigned to them in the Agreement (of which this Attachment B is a part). The information is general in nature and may not apply to Participant&#8217;s particular situation, and the Company is not in a position to assure Participant of any particular result. Accordingly, Participant should seek appropriate professional advice as to how the relevant laws in Participant&#8217;s country apply to Participant&#8217;s specific situation.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ALL COUNTRIES OUTSIDE THE UNITED STATES</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As a condition to the exercise of the Option, Participant agrees to make adequate provision for all income tax, social insurance, social contribution, payroll tax, fringe benefits tax, payment on account, or other tax-related items related to the Option and legally applicable to Participant (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Participant acknowledges that, regardless of any action taken by the Company or, if different, any Affiliate of the Company to whom Participant is rendering services (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Service Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the ultimate liability for all Tax-Related Items is and remains Participant&#8217;s responsibility and may exceed the amount actually withheld by the Company or the Service Recipient. Participant further acknowledges that the Company and&#47;or the Service Recipient (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Option, including, but not limited to, the grant, vesting, or exercise of the Option&#59; the subsequent sale of shares acquired pursuant to such exercise&#59; and the receipt of any dividends&#59; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Option to reduce or eliminate Participant&#8217;s liability for Tax-Related Items or achieve any particular tax result. Further, if Participant is subject to Tax-Related Items in more than one jurisdiction, Participant acknowledges that the Company and&#47;or the Service Recipient (or former service recipient, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction. Prior to the relevant taxable or tax withholding event, as applicable, Participant agrees to make adequate arrangements satisfactory to the Company and&#47;or the Service Recipient to satisfy all Tax-Related Items. In this regard, Participant authorizes the Company and&#47;or the Service Recipient, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by (to the maximum extent permitted by applicable law)&#58; (i) requiring a cash payment paid by Participant&#59; (ii)&#160;withholding from Participant&#8217;s wages or other cash compensation paid to Participant by the Company and&#47;or any Affiliate of the Company&#59; (iii)&#160;withholding from proceeds of the sale of shares acquired at exercise of the Option either through a broker-assisted cashless exercise (provided that a public market for the Common Stock exists) or other voluntary sale, mandatory sale, or other cashless exercise method arranged by the Company (in each case on Participant&#8217;s behalf pursuant to this authorization and without further consent)&#59; and&#47;or (iv)&#160;withholding from the shares to be issued upon exercise. Depending on the withholding method, the Company may withhold or account for Tax-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Related Items by considering applicable statutory withholding amounts or other applicable withholding rates, including maximum applicable rates, in which case Participant will receive a refund of any over-withheld amount in cash and will have no entitlement to the Common Stock equivalent. If the obligation for Tax-Related Items is satisfied by withholding shares, for tax purposes, Participant is deemed to have been issued the full number of shares subject to the exercised Option, notwithstanding that a number of the shares are held back solely for the purpose of paying the Tax-Related Items. Finally, Participant agrees to pay to the Company and&#47;or the Service Recipient any amount of Tax-Related Items that the Company and&#47;or the Service Recipient may be required to withhold or account for as a result of the Option that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the shares or the proceeds of the sale of shares if Participant fails to comply with Participant&#8217;s obligations in connection with the Tax-Related Items.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Not a Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The grant of the Option is not intended to be a public offering of securities in Participant&#8217;s country of employment (or country of residence, if different). The Company has not submitted any registration statement, prospectus, or other filings with the local securities authorities (unless otherwise required under local law), and the grant of the Option is not subject to the supervision of the local securities authorities. </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">No Advice Regarding Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Investment in shares of the Company&#8217;s Common Stock involves a degree of risk. Before deciding to acquire shares by exercising the Option, Participant should carefully consider all risk factors relevant to the acquisition of shares of the Company&#8217;s Common Stock and carefully review all of the materials related to the Option. The Company is not providing any tax, legal, or financial advice, nor is the Company making any recommendations regarding Participant&#8217;s participation in the Agreement, or Participant&#8217;s acquisition or sale of the shares underlying the Option. Participant is hereby advised to consult with Participant&#8217;s own personal tax, legal, and financial advisors regarding Participant&#8217;s participation in the Agreement before taking any action related to the Option. </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If Participant has received this Agreement, or any other document related to this Option, translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of the Option, Participant&#8217;s service will be considered terminated as of the earlier of (i) the date Participant receives notice of termination from the Company or Service Recipient or (ii) the date Participant is no longer actively providing services to the Company or one of its Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is engaged or the terms of the Employment Agreement) and, unless otherwise expressly provided in the Agreement or determined by the Company, Participant&#8217;s right to vest in the Option under the Agreement, if any, will terminate as of such date and will not be extended by any notice period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Participant&#8217;s period of service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under employment laws or other laws in the jurisdiction where Participant is engaged). The Company shall have the exclusive discretion to determine when Participant is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">no longer actively providing services for purposes of the Option (including whether Participant may still be considered to be providing services while on an approved leave of absence). Notwithstanding the foregoing, if applicable local law explicitly requires continued vesting during a statutory notice period, Participant&#8217;s right to vest in the Option under the Agreement, if any, will terminate effective as of the last day of Participant&#8217;s minimum statutory notice period.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Imposition of Additional Requirements&#59; Repatriation&#59; Compliance with Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The grant of the Option and the issuance and delivery of shares under the Option are subject to all applicable laws, rules, and regulations and to such approvals by any governmental agencies or securities exchange as may be required. Notwithstanding any provision of the Agreement, the Company has no liability to deliver any shares under the Option or make any payment unless such delivery or payment would comply with all laws and the applicable requirements of any governmental agency, securities exchange, or similar entity, and unless and until Participant has taken all actions required by the Company in connection with the Option. The Company reserves the right to impose other requirements on the Option and on the shares acquired upon the exercise of the Option to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. Participant agrees to repatriate all payments attributable to the shares and&#47;or cash acquired under the Option in accordance with applicable foreign exchange rules and regulations in Participant&#8217;s country of employment (and country of residence, if different). In addition, Participant agrees to take any and all actions, and consents to any and all actions taken by the Company and any of its affiliates, as may be required to allow the Company and any of its Affiliates to comply with local laws, rules, and&#47;or regulations in Participant&#8217;s country of employment (and country of residence, if different). Finally, Participant agrees to take any and all actions as may be required to comply with Participant&#8217;s personal obligations under local laws, rules, and&#47;or regulations in Participant&#8217;s country of employment (and country of residence, if different). Neither the Company nor any of its Affiliates shall be liable for any costs, fines, or penalties resulting from Participant&#8217;s failure to comply with such personal obligations.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Foreign Asset and Account Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant&#8217;s country of employment (and country of residence, if different) may have certain exchange control and&#47;or foreign asset&#47;account reporting requirements which may affect Participant&#8217;s ability to acquire or hold shares under the Option or cash received in connection with the Option (including from any dividends received or sale proceeds resulting from the sale of shares) in a brokerage or bank account outside of Participant&#8217;s country. Participant may be required to report such accounts, assets, or transactions to the tax or other authorities in Participant&#8217;s country. Participant acknowledges that it is Participant&#8217;s responsibility to comply with any applicable regulations, and that Participant should speak to Participant&#8217;s personal advisor on this matter.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Acknowledgements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In accepting the Option, Participant acknowledges and agrees that&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">the grant of the Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of stock options, or benefits in lieu of stock options, even if stock options or other awards have been granted in the past&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">all decisions with respect to future awards, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Participant&#8217;s participation in the Agreement is voluntary&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the Option and Participant&#8217;s participation in the Agreement shall not create a right to employment or service or be interpreted as forming an employment contract with the Company or any of its Affiliates and shall not interfere with the ability of the Company or any of its Affiliates to terminate Participant&#8217;s employment relationship (as otherwise may be permitted under local law)&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">the Option and any shares acquired under the Option and the income and value of the same are not part of normal or expected compensation or remuneration for any purpose&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.01pt">the future value of the shares underlying the Option is unknown, indeterminable, and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">if the shares underlying the Option do not increase in value, the Option will have no value&#59; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">if Participant exercises the Option and acquires the underlying shares, the value of such shares may increase or decrease in value, even below the exercise price&#59; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.67pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the Option resulting from termination of Participant&#8217;s employment (for any reason whatsoever and whether or not in breach of applicable laws or later found invalid) and, in consideration of the Option, Participant agrees not to institute any claim against the Company or any of its Affiliates&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.67pt">the Option and the benefits evidenced by the Agreement do not create any entitlement not otherwise specifically provided for in the Agreement or provided by the Company in its discretion, to have the Option or any such benefits transferred to, or assumed by, another company, nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Common Stock&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">neither the Company nor any of its Affiliates shall be liable for any foreign exchange rate fluctuation between Participant&#8217;s local currency and the U.S. dollar that may affect the value of the Option or any amounts due to Participant pursuant to the exercise of the Option or the subsequent sale of any shares acquired upon exercise of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Option. To the extent the Company determines that a currency exchange or conversion is necessary in connection with the exercise of the Option or any other matter, such exchange shall be calculated and determined by the Company in its sole discretion, and the Company&#8217;s determination shall be final and binding.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ALL COUNTRIES IN THE EUROPEAN UNION</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participant understands and acknowledges that the Company shall collect, use, and transfer Participant&#8217;s personal information for the purpose of implementing the Agreement and administering Participant&#8217;s participation in the Option in accordance with the Insmed EU Employee Personal Data Processing Notice, a copy of which has been appended to the Agreement, if applicable to Participant.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AUSTRALIA</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The offer of the Option is intended to comply with the provisions of the Corporations Act 2001. If Participant acquires shares under the Option and subsequently offers such shares for sale to a person or entity resident in Australia, the offer may be subject to disclosure requirements under Australian law. Participant should obtain legal advice on disclosure obligations prior to making any such offer.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Breach of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary in the Agreement, Participant will not be entitled to, and shall not claim any benefit (including without limitation a legal right) under the Agreement if the provision of such benefit would give rise to a breach of Part 2D.2 of the Corporations Act 2001 (Cth), any other provision of that Act, or any other applicable statute, rule or regulation which limits or restricts the giving of such benefits.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Tax Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Option is an award to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) applies (subject to the conditions in such Act).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BELGIUM</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.75pt;text-decoration:underline">Tax Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Participant agrees and acknowledges that the Company will only accept a countersigned Agreement after the 60th day following the Participant&#8217;s receipt of the Agreement. By formally accepting in writing the Agreement through signature and by returning it to the Company within 60 days from receipt of the Agreement, the Participant would normally become subject to income tax on a lump-sum benefit in kind on the 60th day following receipt of the Agreement (being the &#8220;grant date&#8221; for Belgian tax purposes).  In that case, no taxation should be triggered upon vesting or exercise.  However, if written acceptance and return of the Agreement would take place after the 60th day following receipt of the Agreement, as required by the Company, taxation will normally be delayed to the date of exercise of this Option.  In that case, grant or vesting should not trigger taxation.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CANADA</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant hereby authorizes the Company and the Company&#8217;s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Agreement and the Option. Participant further authorizes the Company and any of its Affiliates and the Compensation Committee to disclose and discuss the Agreement and the Option with their advisors. Participant further authorizes the Company and any of its Affiliates to record such information and to keep such information in Participant&#8217;s employee file.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">English Language Consent - Quebec</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The parties acknowledge that it is their express wish that the Agreement, as well as all documents, notices, and legal proceedings entered into, given, or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Les parties reconnaissent avoir expressement souhait&#233; que la convention (le &#171;&#160;Agreement&#160;&#187;), ainsi que tous les documents, avis et proc&#233;dures judiciaries, &#233;xecut&#233;s, donn&#233;s ou intent&#233;s en vertu de, ou li&#233;, directement ou indirectement &#224; la pr&#233;sente convention, soient r&#233;dig&#233;s en langue anglaise.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DENMARK</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FRANCE</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Non-Qualification of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Option is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> intended to be tax qualified under French tax laws including, without limitation, under Articles L. 225-177-1 and seq. of the French Commercial Code.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Language Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In accepting the grant of the Option and this Agreement which provides for the terms and conditions of the Option, the Participant confirms that he or she has read and understood the documents relating to the Option (this Agreement), which were provided in the English language.  The Participant accepts the terms of these documents accordingly.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Consentement Relatif &#224; la Langue Utilis&#233;e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">En acceptant cette attribution gratuite d&#8217;actions et ce contrat qui contient les termes et conditions de cette attribution gratuite d&#8217;actions, l&#8217;employ&#233; confirme ainsi avoir lu et compris les documents relatifs &#224; cette attribution (le Contrat d&#8217;Attribution) qui lui ont &#233;t&#233; communiqu&#233;s en langue anglaise. L&#8217;employ&#233; en accepte les termes en connaissance de cause.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">GERMANY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IRELAND</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITALY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JAPAN</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NETHERLANDS</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><img alt="image_0b.jpg" src="image_0b.jpg" style="height:139px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Waiver of Termination Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant hereby waives any and all rights to compensation or damages as a result of Participant&#8217;s termination of employment with the Company and its Affiliates for any reason whatsoever, insofar as those rights result or may result from (i) the loss or diminution in value of such rights or entitlements under the Option, or (ii) Participant&#8217;s ceasing to have rights under the Option as a result of such termination.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PORTUGAL</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No specific provisions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SWITZERLAND</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Neither this Agreement nor any other materials relating to the Option (i) constitutes a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (&#8220;FinSA&#8221;), (ii) may be publicly distributed or otherwise made publicly available in Switzerland to any person other than the Participant, or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 of FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority (&#8220;FINMA&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED KINGDOM</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Participant understands and acknowledges that the Company shall collect, use, and transfer Participant&#8217;s personal information for the purpose of implementing the Agreement and administering Participant&#8217;s participation in the Option in accordance with the Insmed UK Employee Personal Data Processing Notice, a copy of which has been appended to the Agreement, if applicable to Participant.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">National Insurance Contributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company may require, as a condition of the exercise of the Option, that Participant shall, to the extent applicable&#58; </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">agree to reimburse the Company in whole or in part for any employer&#8217;s secondary national insurance contributions arising on the exercise of the Option&#59; or </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">enter into an election with the Company to assume in whole or part the liability for any secondary Class 1 national insurance contributions, payable on the exercise of the Option, including an election under paragraph 3B of Schedule 1 to the Social Security Contributions and Benefits Act 1992&#59; or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">agree to pay the employer&#8217;s national insurance contributions, social security contributions, and other levies and taxes arising on the exercise of the Option to the extent permitted by law, in any other jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Section 431 Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;Participant agrees that, if requested to do so by the Company, Participant shall immediately upon the exercise of the Option enter into an irrevocable joint election with the Company pursuant to section 431 of the U.K. Income Tax (Earnings and Pensions) Act 2003 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">ITEPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in a form specified by the Company that, for the relevant tax purposes, the market value of the share acquired is to be calculated as if the share were not restricted securities (as defined in section 423 of ITEPA) and sections 425 to 430 of ITEPA shall not apply to such shares.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Outstanding Amounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#160;If Participant fails to make payment to the Company in accordance with the &#8220;Tax Withholding&#8221; paragraph under the &#8220;All Countries Outside the United States&#8221; section of this Attachment B immediately upon request, Participant shall be liable to make good any amount outstanding on demand.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%;text-decoration:underline">PERSONAL DATA PROCESSING- EMPLOYEE NOTICE (UNITED KINGDOM ONLY)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> <br></font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">As your employer, Insmed Ltd, with registered office in London (the &#8220;Company&#8221;) collects, uses and discloses personal information relating to you. The Company is committed to ensure that your personal information will be handled in accordance with all applicable data protection laws.</font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The information that the Company holds on you, collected in both paper and electronic format, is limited to what is necessary in the context of your employment. </font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Such information includes&#58;</font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">personal details (name, contact details, date and place of birth, nationality, gender, marital status, family members, bank account information, social security number)&#59;</font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">employment information (also embedded in the employment contract&#58; employment date, job description, function&#47;title, reporting)&#59;</font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">compensation (salary, bonus, equity, benefits, holidays)&#59;</font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:-12.15pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">recruitment process (application documents, CV, compensation history, employment agreement)&#59;</font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">business expense reports&#59;</font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">performance appraisals&#47;ratings&#59;</font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">holidays and sickness leave, and any other personal data strictly required by applicable laws and regulations.</font></div><div style="margin-bottom:10.35pt;margin-top:0.5pt;padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company collects and holds personal information relating to you for the purposes of&#58; </font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">the justification, implementation and termination of the employment agreement, both during and after your employment with the Company, including salary and benefits administration&#59;  </font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">compliance with laws and regulations, including labour, social security and health laws&#59; and&#59; </font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">the Company&#8217;s legitimate interests, including employee management and administration generally (both during and after your employment), evaluating performances, administrating and monitoring compliance with internal policies, conducting disciplinary investigations and proceedings, and maintaining and monitoring usage of internal networks and IT systems.</font></div><div style="margin-bottom:10.35pt;padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:5.75pt;padding-right:5.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You should be aware that in certain instances the Company may need to transfer or disclose your personal information to third parties, including third party service providers. Common examples of third party service providers are payroll processors, IT companies, and companies that provide technical or administrative support. Other third parties may include other Insmed entities, regulatory authorities (including tax authorities) and government agencies, banks and insurance companies, and, potentially, third parties with whom the Company may merge or which may be acquired by the Company. These third parties and Insmed entities may be located in countries, such as the United States (for instance Insmed Incorporated), whose data protection laws may not be equivalent to those </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5.75pt;padding-right:5.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">applicable in your own country. The Company, however, put in place contractual guarantees to ensure an appropriate level of protection.  For more information and a copy, please contact&#58;  </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">privacy&#64;insmed.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10.35pt;padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subject to limitation in the law, you have certain rights in respect of your personal information, such as a right of access, correction, restriction, opposition and deletion. Your personal information will be retained as long as required, in compliance with company policy and retention obligations imposed by law. Should you have any questions or concerns in connection with the Company&#8217;s handling of your personal information, please consult with </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Johannes Diependaal, Senior Director EU Operations </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Christel R&#246;ssig, Senior Director Corporate Counsel &#38; Compliance EU</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  If you still have concerns, you have a right to lodge a complaint with the Supervisory Authority for data protection in your country. </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%;text-decoration:underline">PERSONAL DATA PROCESSING- EMPLOYEE NOTICE (IRELAND ONLY)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> <br></font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">As your employer, Insmed Ireland Ltd, with registered office in Dublin (the &#8220;Company&#8221;) collects, uses and discloses personal information relating to you. The Company is committed to ensure that your personal information will be handled in accordance with all applicable data protection laws.</font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The information that the Company holds on you, collected in both paper and electronic format, is limited to what is necessary in the context of your employment. </font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Such information includes&#58;</font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">personal details (name, contact details, date and place of birth, nationality, gender, marital status, family members, bank account information, social security number)&#59;</font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">employment information (also embedded in the employment contract&#58; employment date, job description, function&#47;title, reporting)&#59;</font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">compensation (salary, bonus, equity, benefits, holidays)&#59;</font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:-12.15pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">recruitment process (application documents, CV, compensation history, employment agreement)&#59;</font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">business expense reports&#59;</font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">performance appraisals&#47;ratings&#59;</font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">holidays and sickness leave, and any other personal data strictly required by applicable laws and regulations.</font></div><div style="margin-bottom:10.35pt;margin-top:0.5pt;padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company collects and holds personal information relating to you for the purposes of&#58; </font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">the justification, implementation and termination of the employment agreement, both during and after your employment with the Company, including salary and benefits administration&#59;  </font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">compliance with laws and regulations, including labour, social security and health laws&#59; and&#59; </font></div><div style="margin-bottom:10.35pt;padding-left:23.95pt;padding-right:5.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:129%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:129%;padding-left:14.15pt">the Company&#8217;s legitimate interests, including employee management and administration generally (both during and after your employment), evaluating performances, administrating and monitoring compliance with internal policies, conducting disciplinary investigations and proceedings, and maintaining and monitoring usage of internal networks and IT systems.</font></div><div style="margin-bottom:10.35pt;padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:5.75pt;padding-right:5.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You should be aware that in certain instances the Company may need to transfer or disclose your personal information to third parties, including third party service providers. Common examples of third party service providers are payroll processors, IT companies, and companies that provide technical or administrative support. Other third parties may include other Insmed entities, regulatory authorities (including tax authorities) and government agencies, banks and insurance companies, and, potentially, third parties with whom the Company may merge or which may be acquired by the Company. These third parties and Insmed entities may be located in countries, such as the United States (for instance Insmed Incorporated), whose data protection laws may not be equivalent to those </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5.75pt;padding-right:5.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">applicable in your own country. The Company, however, put in place contractual guarantees to ensure an appropriate level of protection.  For more information and a copy, please contact&#58;  </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">privacy&#64;insmed.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10.35pt;padding-left:0.5pt;text-indent:-0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subject to limitation in the law, you have certain rights in respect of your personal information, such as a right of access, correction, restriction, opposition and deletion. Your personal information will be retained as long as required, in compliance with company policy and retention obligations imposed by law. </font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Should you have any questions or concerns in connection with the Company&#8217;s handling of your personal information, </font><font style="background-color:#ffff00;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">your first point of contact is</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Mariela Pochon, Director Human resources EMEA </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Hortense de Lummen, Legal Counsel EMEA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Legal is your first point of contact regarding data privacy topics. </font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="background-color:#ffff00;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Also, at Insmed, an external Data Protection Officer (DPO) is appointed. This means that if our first point of contact (as indicated above) is not suitable in your case, you can directly contact our DPO&#58; </font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="background-color:#ffff00;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Oliver Meyer-van Raay </font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="background-color:#ffff00;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tel.&#58; +49 721 &#47; 17029034</font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="background-color:#ffff00;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">E-Mail&#58; om&#64;v-formation.gmbh</font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="background-color:#ffff00;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DPO&#8217;s address details are&#58; </font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="background-color:#ffff00;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">V-Formation GmbH</font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="background-color:#ffff00;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stephanienstrasse 18</font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="background-color:#ffff00;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">76133 Karlsruhe, Germany</font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="background-color:#ffff00;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Requests concerning the handling of your employee data will be treated by DPO on a confidential basis if so requested.</font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If you still have concerns, you have a right to lodge a complaint with the Supervisory Authority for data protection in your country. </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>9
<FILENAME>insm-20240630ex105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i6322a47f8f104c34abb99d4dc273576f_1"></div><div style="min-height:96.48pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by &#91;***&#93;) has been omitted from Exhibit 10.1 because it (i) is not material and (ii) is the type of information the Company both customarily and actually treats as private or confidential.</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COMMERCIALIZATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COMMERCIALIZATION AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), dated as of July 8, 2014 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), is made between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PARI PHARMA GMBH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a German corporation, with a principal place of business at Moosstrasse 3, D-82319 Starnberg, Germany (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PARI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Delaware corporation, with a place of business at 10 Finderne Avenue, Building 10, Suite F, Bridgewater, NJ&#160; 08807-3365 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  PARI and INSMED are sometimes referred to herein individually as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> PARI is in the business of developing, manufacturing and commercializing, among other things, drug inhalation devices and optimized formulations used in the treatment of respiratory tract disorders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> INSMED is in the business of developing and commercializing drugs for various diseases and conditions, including without limitation the treatment of respiratory tract disorders and infectious diseases.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> PARI and INSMED are parties to a certain license agreement effective as of 25 April 25, 2008, as amended by Amendment No. 1 the 24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> day of June 2009, Assignment and Amendment No. 2 the 22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> day of December 2010, Amendment No. 3 the 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> day of March 2012, and Amendment No. 4 the 21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> day of May 2012 (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">W</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> pursuant to Section 8.9 of the License Agreement, the Parties desire to enter into this Agreement for PARI to manufacture and supply the Device (as defined below) and Device Accessories (as defined below) for use with the INSMED Product (as defined below).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in consideration of the premises and direct and indirect benefits to the Parties hereto and other consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.7pt"><br>DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.34pt">&#8220;Affiliate&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of a Party means any person or entity that directly or indirectly owns or controls, is owned or controlled by or is under common control with such Party, in each case, only for so long as such control exists.  As used in this definition only, &#34;control&#34; of an entity means beneficial ownership, directly or indirectly, of fifty percent (50%) or more of the outstanding voting shares or securities or the ability otherwise to elect or appoint a majority of the board of directors or other managing authority of such entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.34pt">&#8220;Applicable Laws and Standards&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means (a) all applicable laws, ordinances, rules, orders, directives and regulations of any and all supra-national, federal, state, provincial and local authorities and agencies, including without limitation all laws and regulations of such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">territories applicable to the maintenance of the manufacturing equipment and facilities and the manufacturing, transportation, storage, use, handling and disposal of medical devices, components and of any hazardous materials, (b) applicable regulations and guidelines of the FDA and other Regulatory Authorities and the ICH guidelines&#59; (c) as applicable to the particular activities performed, Good Manufacturing Practices, Good Laboratory Practices and Good Clinical Practices promulgated by the FDA and other Regulatory Authorities or the ICH&#59; and (d) all applicable industry and trade standards, including the applicable standards of the International Organization for Standardization (ISO).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.34pt">&#8220;Business Day&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means a day other than a Saturday or Sunday on which banking institutions in Berlin, Germany and New York, United States of America, are open for business</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.34pt">&#8220;Confidential Information&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of a Party, means the confidential or proprietary scientific, regulatory, clinical, technical or business information, materials and technologies disclosed or learned under this Agreement, whether in written, oral, electronic, photographic, magnetic or other form.  For clarity, the Intellectual Property owned by a Party shall be deemed the Confidential Information of such Party.  Confidential Information shall exclude any information to the extent that the receiving Party can demonstrate it&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">is known by the receiving Party without restriction at the time of receipt and not through a prior disclosure by the disclosing Party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">is at the time of disclosure or thereafter becomes published or otherwise part of the public domain through no breach of this Agreement by the receiving Party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">is subsequently disclosed to the receiving Party without restriction by a third party having the right to make such a disclosure&#59; or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">is developed by the receiving Party independent of and without access to Confidential Information received by it from the disclosing Party hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.34pt">&#8220;Control&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means, with respect to an item of information or intellectual property rights, possession by such Party of the power and authority, whether arising by ownership, license, or other authorization, to disclose such item as required by this Agreement, and&#47;or to grant and authorize licenses or sublicenses under such items that are within the scope granted to the other Party under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.34pt">&#8220;Cure Period&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the &#91;***&#93; Business Day period following the date of issuance of a Notice of Failure Event.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.34pt">&#8220;Current Good Manufacturing Practices,&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;cGMP&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means all good manufacturing practices as promulgated by the Regulatory Authority of the country where the Device is being sold, in the form of laws or regulations or guidance documents, for the manufacturing of medical devices, including 21 CFR &#167; 820 &#8211; Quality System Regulation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">2</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.34pt">&#8220;cGMP Manufacturing&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means all processes and activities typically engaged in by a person or entity in the pharmaceutical or medical device industry for the cGMP manufacture of a product or component thereof, including procuring raw materials, manufacturing, quality control and assurance testing, cGMP record keeping, packaging and labeling. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all data, data sets, test data, pre-clinical and clinical trial data, technical and non-technical data, price data (but excluding cost information and&#47;or data), marketing data, sales data, analyses, reports, regulatory filings and approvals and the information therein or associated therewith (including drug master files and device master files, supporting data, regulatory correspondence and meeting minutes) and rights to reference the same. Each Party&#8217;s Data shall be deemed its Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Device&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the eFlow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">nebulizer system intended to be branded as the &#91;***&#93;&#8482; Nebulizer System that has been optimized for the INSMED Product as more specifically described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and any Territory-Specific Appendix. For clarity, the Parties agree that the Device will not include the &#91;***&#93;&#8482; functionality, i.e. a &#91;***&#93; which &#91;***&#93; of the &#91;***&#93; to the &#91;***&#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Device Accessories&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means those types of accessories sold by PARI as of the Effective Date or during the Term for use with Devices, which are not specific to the drug substance being delivered by such Devices, including </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> power adapters, carrying cases, face masks, and any replacement parts associated with the foregoing. For the avoidance of doubt, Device Accessories do not include an &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Device Specifications&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the characteristics, processing, labeling, and packaging requirements and standards for the Device and Device Accessories, as set forth in the applicable Territory Specific Appendix.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Durable Components&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the &#91;***&#93;, the AC power supply and the &#91;***&#93; of each Device.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;eFlow&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the nebulizer proprietary to PARI or its Affiliates that is based on &#91;***&#93; technology and includes the &#91;***&#93; and &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;EU&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the members states of the European Union, as it may be constituted from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;FDA&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the United States Food and Drug Administration, or any successor thereto having the administrative authority to regulate the marketing of medical devices and drugs in the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;First Commercial Sale&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the first commercial sale of the INSMED Product subject to royalties under Article 6 of the License Agreement, by or under authority of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">3</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INSMED, its Affiliates and&#47;or their Sublicensees (as such term is defined in the License Agreement) in a country in the INSMED Territory, after Marketing Approval in such country has been obtained. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Forecast&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning set forth in Section 6.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Initial Purchase Order&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning set forth in Section 6.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;INSMED Field&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means (a) the pulmonary administration of INSMED Product for the treatment or prophylaxis in cystic fibrosis (CF), bronchiectasis and&#47;or Non-tuberculosis Mycobacteria infections, and (b) any Secondary Indication (as defined in the License Agreement) that is added to the Transave Field (as defined in the License Agreement) in accordance with the provisions of Section 2.6 of the License Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;INSMED Product&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means INSMED&#8217;s proprietary amikacin antibiotic based on INSMED&#8217;s proprietary sustained release liposomal technology that is formulated for delivery via pulmonary administration exclusively for use with the Device in the INSMED Field.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;INSMED Territory&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the entire world.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Intellectual Property&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means (a) any of the following, whether existing now or in the future anywhere in the world&#58;  patents, inventor's certificates, registrations and applications therefor, including any provisionals, additions, divisionals, continuations, substitutions, continuations-in-part, together with re-examinations, reissues, renewals or extensions thereof and all foreign counterparts of any of the foregoing (collectively, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#34;Patent Rights&#34;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and (b) all Data, ideas, pharmaceutical, chemical and  biological materials, products and compositions, tests, assays, techniques, methods, procedures, and other information relating to any of the foregoing, drawings, plans, designs, diagrams, sketches, specifications or other documents containing such information or materials, and  business processes, price information, marketing information, sales information, marketing plans and market research (collectively, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#34;Know-How&#34;).    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">It </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">is understood, however, that Know-How does not include information that falls within exceptions of the definition of &#34;Confidential Information&#34; set forth in Section 11.1 of the License Agreement. Intellectual Property includes all enforcement rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Joint Steering Committee&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning set forth in Section 2.1(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;MAA&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means a fully completed marketing authorization application, including a New Drug Application, (filed with the FDA, if in the United States or to the counterpart of the FDA if outside the United States), including all supporting documentation and Data required for such application to be accepted for substantive review, filed with a Regulatory Authority to seek Marketing Approval for a particular indication in a particular country.  It is understood that MAA does not include applications for pricing or reimbursement approval.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:16.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacture&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means all activities related to the production, manufacture, processing, finishing, packaging, labelling, shipping and holding of the PARI Products, including </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">4</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture of the PARI Products, process improvements and optimization, product characterization, quality assurance, quality control and release.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Marketing Approval&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means all approvals, registrations or authorizations of any governmental entity that are necessary for the sale of products in a regulatory jurisdiction excluding reimbursement approvals. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Nebulizer Handset&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the eFlow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">nebulizer handset intended to be branded as the &#91;***&#93; Nebulizer Handset that has been optimized for the INSMED Product as set forth in more detail in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;New Drug Application&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means a New Drug Application filed pursuant to the requirements of the FDA, or the equivalent application or filing in a country other than the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;PARI Competitor&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;PARI Intellectual Property&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean PARI Patents and PARI Know-How.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;PARI Know-How&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean all Know-How Controlled by PARI or Affiliates as of the Effective Date or at any time during the Term that relates to any of the PARI Product(s) or any component thereof and&#47;or the Manufacture or use of the PARI Products or any component thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;PARI Patents&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean the patents and patent applications set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, which include all patents and patent applications owned and Controlled by PARI or its Affiliates as of the Effective Date or at any time during the Term, which claim or relate to any of the PARI Product(s) or any component thereof and&#47;or the Manufacture or use of the PARI Products or any component thereof&#59; and any divisionals, continuations, substitutions, continuations-in-part, extensions, renewals or reissues of any of the foregoing.  Upon request by INSMED, PARI shall provide update(s), if any, to the list of patents and patent applications set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;PARI Products&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means, collectively, Devices, &#91;***&#93;, Nebulizer Handsets and Device Accessories.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Prices&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning set forth in Section 4.1.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Quality Agreements&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning set forth in Section 6.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Recall&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means a recall, withdrawal, or field correction of any product for any reason, or a dissemination of information regarding such product due to a change in the labeling of such product.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">5</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Regulatory Approval&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means approval by the applicable Regulatory Authority of (x) the manufacture, use, importation, packaging, labeling, marketing, pricing and sale of the PARI Product or (y) a MAA, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Regulatory Authority&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means any regional, state, national (e.g., the FDA), international, supra-national (e.g., the European Commission, the Council of the European Union, or the EMA), or other governmental entity involved in regulation of or the granting of Marketing Approval for the INSMED Product or PARI Products, as applicable, or the development, manufacture, use or commercialization thereof with jurisdiction over either Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Regulatory Requirements&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means all applicable requirements of the Regulatory Authorities relating to the sale, manufacture and supply of any PARI Product or the INSMED Product, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;ROW&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means all the countries in the INSMED Territory excluding the United States and Canada.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Term&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall have the meaning set forth in Section 12.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Territory-Specific Appendix&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means each sub-appendix attached to this Agreement under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> summarizing the applicable Device Specifications and the specific commercial terms for the Manufacture and supply of PARI Products in one or more particular country(ies) in the INSMED Territory.  From time to time, the Parties may agree to add the INSMED Territory-Specific Appendices, or modify the INSMED Territory-Specific Appendices applicable to one or more particular country(ies) to this Agreement.  Such Territory-Specific Appendices may contain provisions, terms and conditions that are exceptions to or different from this Agreement to address country specific conditions, provided, both Parties have agreed thereto in writing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Third Party&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means any person or entity that is not PARI, INSMED or any Affiliate of either PARI or INSMED.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;Third Party License Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means that agreement entered into between the &#91;***&#93; and PARI dated &#91;***&#93;, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:16.34pt">&#8220;United States&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the United States of America and all of its territories and possessions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:5.04pt"><br>GOVERNANCE&#59; JOINT STEERING COMMITTEE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">II.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:17.68pt">Joint Steering Committee.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Membership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties hereby agree to utilize the JSC (as defined in the License Agreement and established pursuant to Section 2.3.1 of the License Agreement), to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">6</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">perform the additional responsibilities set forth below.  As set forth in the License Agreement, the JSC shall consist of three (3) representatives from each Party.  The representatives of the JSC as of the Effective Date are set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> attached hereto.  Each Party shall designate one (1) of its representatives as the co-chairperson of the JSC.  Each Party may replace its appointed JSC representatives or co-chairperson at any time upon reasonable written notice to the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The responsibilities of the JSC under this Agreement shall be&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">to discuss INSMED&#8217;s worldwide strategy for the commercialization of the INSMED Product&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">to discuss the strategy for the sublicensing and commercialization of the PARI Products with INSMED&#8217;s strategy set forth in subsection (i) above&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">to facilitate the exchange of information between the Parties with respect to the activities hereunder&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">to establish procedures for the efficient sharing of information necessary for the supply of the PARI Products&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">to share and discuss PARI&#8217;s performance under this Agreement, including without limitation the quality of the PARI Products supplied hereunder&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">to share, discuss and coordinate between the Parties to ensure that the overall market demand of PARI Products for use with INSMED Product is met&#59;  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.36pt">to create subcommittees as the JSC may find necessary or desirable from time to time to coordinate specific activities within the scope of the JSC&#8217;s responsibilities&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">to review, discuss and decide the process for establishing a call center for support and processing complaints regarding the INSMED Product and PARI Products in the EU&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">to review, discuss and implement appropriate policies regarding social media related to the Parties activities contemplated by this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">to oversee the activities of subcommittees created under this Agreement&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(xi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">to perform such other functions as appropriate to further the purposes of this Agreement as allocated to it in writing by the Parties.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">7</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Guiding Principles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The JSC shall perform its responsibilities based on the principles of good faith, diligence, prudence and good scientific and business judgment.  The JSC shall have only the powers assigned expressly to it under this Article 2 and elsewhere in this Agreement, and the JSC shall not have any power to amend, modify or waive compliance under this Agreement. The Parties acknowledge and agree that if there is any inconsistency between the JSC&#8217;s role and responsibilities under the License Agreement and the role and responsibilities of the JSC under this Agreement, in each case with respect to the manufacture and supply of PARI Products, this Agreement shall control. In addition, the scope of the JSC&#8217;s role and responsibilities under this Agreement or the License Agreement shall not in any way limit a Party&#8217;s rights under this Agreement, including any decisions allocated to it hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">JSC Meetings.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">JSC meetings shall be held as often as the Parties mutually agree are necessary but at least twice every year (alternating each in-person meeting between a location selected by PARI and a location selected by INSMED), or on another schedule agreed to by the Parties. In person meetings may be waived and conference calls substituted as agreed to by the JSC. With the consent of the representatives of each Party serving on the JSC, other representatives of each Party may attend meetings as non-voting observers (provided such non-voting observers have confidentiality obligations to such Party that are at least as stringent as those set forth in this Agreement).  Meetings of the JSC shall be effective only if at least one (1) representative of each Party is present or participating.  Each Party shall be responsible for all of its own expenses of participating in the JSC meetings. The JSC will be chaired by a representative of INSMED.  The role of the chairperson shall be to convene and preside at meetings of the JSC, but the chairperson shall have no additional powers or rights beyond those held by the other Committee representatives. Within &#91;***&#93; Business Days following each JSC meeting, the chairperson shall prepare and deliver to the members of the JSC the minutes of such meeting for review and approval by both Parties.  The minutes shall reflect, without limitation, all material decisions made at such meetings.  Such minutes will be deemed approved unless one or more members of the JSC object to the accuracy of such minutes within &#91;***&#93; Business Days of receipt thereof. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Void Decisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in this Agreement, no decision by either Party would be effective if such decision requires the other Party to breach any obligation or agreement with a Third Party, or to perform any activities that are different or greater in scope than those provided for specifically under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">II.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:17.68pt">Subcommittees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Membership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The JSC may establish subcommittees to coordinate specific activities within the scope of the JSC&#8217;s responsibilities.  Each such subcommittee shall consist of two (2) representatives from each Party.  Each Party may replace its appointed subcommittee representatives at any time upon reasonable written notice to the other Party.  Each </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">8</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Party shall designate one (1) of its representatives as the co-chairpersons of each subcommittee. The Parties will agree on the responsibilities of a subcommittee before it will be established.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">No Decision Making</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No subcommittee shall have the authority to make any decisions on behalf of the Parties. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Subcommittee Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Other representatives of each Party may attend meetings as nonvoting observers (provided such nonvoting observers have confidentiality obligations to such Party that are at least as stringent as those set forth in this Agreement).  Meetings of the subcommittees shall be effective only if at least one (1) representative of each Party is present or participating.  Each Party shall be responsible for all of its own expenses of participating in the subcommittee meetings.  Within &#91;***&#93; Business Days following each subcommittee meeting, INSMED shall prepare and deliver to the members of the subcommittee the minutes of such meeting for review and approval by both Parties.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:0.38pt"><br>COMMERCIALIZATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">III.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.02pt">Overview</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  PARI shall be responsible for Manufacturing and supplying PARI Products to INSMED, its Affiliates and permitted Sublicensees (as such term is defined in the License Agreement) in the INSMED Territory in compliance with the terms of this Agreement, including all Applicable Laws and Standards, and for training the appropriate key INSMED commercial team members who train general INSMED commercial team members. Unless expressly provided otherwise and agreed to by the Parties in the Territory-Specific Appendix, INSMED shall have the sole right to, in its sole discretion, promote, advertise, and distribute INSMED Products, provided that INSMED shall do so in compliance with all Applicable Laws and Standards.  The Parties shall cooperate in good faith to fulfill their respective obligations under this Agreement. Notwithstanding the foregoing, PARI must approve all PARI Products related sections of promotional and&#47;or advertising materials generated for the INSMED Products prior to any use or dissemination of such materials&#59; provided that such approval shall not be unreasonably withheld or delayed, and PARI&#8217;s failure to respond to a request for approval within &#91;***&#93; Business Days will be deemed approval.  PARI shall not use or disseminate any promotional and&#47;or advertising materials for the Device, except that PARI shall be permitted to do so as to Device Accessories and the &#91;***&#93; (as a stand alone item), or, to the extent not exclusively related to the INSMED Products, any other PARI Products without INSMED&#8217;s prior written approval&#59; provided that such approval shall not be unreasonably withheld or delayed, and INSMED&#8217;s failure to respond to a request for approval within &#91;***&#93; Business Days will be deemed approval.  PARI agrees to comply with the following INSMED policies and instructions to the extent applicable&#58; (i) tracking expenditures in sufficient detail, and providing such information in a timely manner and a form and format required by INSMED so as to enable INSMED to comply with Applicable Laws, including any state or federal &#8220;sunshine&#8221; reporting requirements applicable to the INSMED Product&#59; (ii) any policies regarding social media (which might include, for example, disabling &#8220;comment&#8221; features) implemented by the JSC&#59; (iii) refrain from editing any promotional content (for the avoidance of doubt promotional content shall not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">9</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">include any labelling or packaging of PARI Products) relating to the INSMED Product other than as may be specifically requested by INSMED and approved through INSMED&#8217;s promotional review process&#59; and (iv) submission of any proposed promotional content or scripts relating to the INSMED Product sufficiently in advance of proposed use to permit INSMED time to approve&#47;reject&#47;modify such data.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">III.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.02pt">Commercialization of PARI Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  PARI shall sell the PARI Products to INSMED or any Third Party designated by INSMED (other than a PARI Competitor) as its representative in accordance with the terms of this Agreement to be further distributed to end users for use with the INSMED Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">III.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.02pt">Territory-Specific Appendixes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Promptly after INSMED submits a MAA for an INSMED Product in a particular country(ies), but in any event no later than &#91;***&#93; days prior to the earliest anticipated approval date by the appropriate Regulatory Authority in a particular country(ies), the Parties shall agree on a Territory-Specific Appendix setting forth the commercial terms governing such country(ies), which shall contain the applicable Price for each territory in the ROW (other than EU), the T-S Branding Strategy and any other material terms and conditions that are specifically necessary to commence commercial sales of the PARI Products and INSMED Product in such country(ies).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Such Territory-Specific Appendixes shall then be attached to this Agreement and incorporated in this Agreement.  Thereafter, the Parties may modify or supplement such Territory-Specific Appendixes from time to time by written agreement&#59; provided, that PARI shall not withhold consent to any modification or supplement to a Territory-Specific Appendix to the extent such modification or supplement is required by the appropriate Regulatory Authority in the applicable country. If the Parties are unable to agree on the terms of any Territory-Specific Appendix (including any T-S Branding Strategy included therein) within &#91;***&#93; days after either Party begins negotiations for such Territory-Specific Appendix, then the provisions of Section 13.8 of this Agreement shall apply. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">III.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.02pt">Branding Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to applicable Regulatory Requirements, the packaging, labeling and promotional materials for both the PARI Products and the INSMED Products will be consistent with a branding strategy to be agreed upon by the Parties and included as part of each Territory-Specific Appendix (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;T-S Branding Strategy(ies)&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).  Unless the Parties agree otherwise under the applicable T-S Branding Strategy, each T-S Branding Strategy shall contain the following elements&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">PARI Product Branding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  PARI shall be responsible for, and shall work together with INSMED in good faith in selecting trademarks for use on or in connection with any PARI Product that is aligned with PARI&#8217;s branding strategy for eFlow products.  PARI will label the packaging for the Device and the packaging for the Nebulizer Handset of the Device.  As determined by PARI (and reasonably acceptable to INSMED), packaging for the Device will include the PARI word mark and&#47;or logo and&#47;or the PARI Pharma logo, the eFlow&#174; technology word mark and logo, a dedicated, unique brand name for the Device, and the Drug Reference (as defined below).  The Nebulizer Handset component of the Device will include the dedicated, unique brand name for the Device and the Drug Reference.  The aerosol head component of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">10</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Device will include only the dedicated, unique brand name for the Device.  Each of the above Device components will have a distinct item number, and all such item numbers will be identified on the packaging for the Device and the packaging for the Nebulizer Handset.  For purposes of this Section 3.4, unless specified otherwise by Regulatory Authorities, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Drug Reference&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means either (i) the generic drug name associated with the INSMED Product, and&#47;or (ii) INSMED&#8217;s trademark for such INSMED Product, depending upon the status of INSMED&#8217;s branding for the INSMED Product at the time of commercialization by the Parties as contemplated herein.  Notwithstanding the foregoing, the Parties shall discuss the precise forms of co-branding to accompany the Device and Nebulizer Handset and the INSMED Products, including support or other promotional materials therefor, to promote the use of the Device and Nebulizer Handset exclusively with the INSMED Product and use of the INSMED Product in the INSMED Field exclusively with the Device and Nebulizer Handset.  INSMED shall not modify PARI&#8217;s labeling in any way (including by over-labeling).  Except as expressly set forth in this Agreement (including, but not limited to Section 3.1), INSMED shall not use any videos, photographs or graphic depictions of the PARI Products without PARI&#8217;s prior written approval&#59; provided that such approval shall not be unreasonably withheld or delayed, and PARI&#8217;s failure to respond to a request for approval within &#91;***&#93; Business Days will be deemed approval. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">INSMED Product Branding&#47;PARI Product Recognition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  INSMED shall be responsible for, and shall have sole discretion, in selecting trademarks for the use on or in connection with any INSMED Product and determining the packaging, labeling and branding of any INSMED Product&#59; provided, however, that, where it determines are appropriate, INSMED shall provide recognition of the PARI Product approved by the applicable Regulatory Authority for use with the INSMED Product.  In addition, subject to Regulatory Requirements, INSMED agrees to include in the product labeling for the INSMED Product the precise Device brand name and the Device item number(s) approved to administer the INSMED Product. Except as expressly set forth in this Agreement, PARI shall not use any videos, photographs or graphic depictions of the INSMED Products without INSMED&#8217;s prior written approval&#59; provided that such approval shall not be unreasonably withheld or delayed, and INSMED&#8217;s failure to respond to a request for approval within &#91;***&#93; Business Days will be deemed approval.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">PARI Supply Restriction. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> PARI shall not supply any Devices or any other product that is branded for use with any INSMED Product to any Third Party for use with any product other than an INSMED Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">III.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.02pt">Product Support</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  PARI shall, at its own expense, and in accordance with Applicable Law and Standards establish and maintain product support capabilities for PARI Products consistent with the terms to be set forth in any Territory-Specific Appendix, including without limitation a call center or call centers and hotlines for patient support and warranty claims for PARI Products to all patients using PARI Products in the United States and Germany with toll-free access in the United States. Unless the Territory-Specific Appendix for the United States expressly states otherwise, INSMED will establish a call center for support in the United States and there will be a warm transfer of telephone calls received by the INSMED call center to PARI of all problems and complaints regarding the PARI Products. The process for establishing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">11</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a call center for support and processing complaints regarding the INSMED Product and PARI Products in the EU will be reviewed, discussed and decided by the JSC. PARI shall establish such patient support capabilities for PARI Products prior to the first commercial sale of any INSMED Product in the United States and Germany, pursuant to the specific requirements in the applicable Territory-Specific Appendix and in compliance with any requirements set forth in the Safety Data Exchange Agreement. For all other countries PARI will establish an English speaking service support to communicate with local distributors which will be available during normal business hours in Germany.  Each Territory-Specific Appendix may set forth any additional product support capabilities for PARI Products and for INSMED Products. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:1.04pt"><br>PAYMENTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IV.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.68pt">Pricing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Prices. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PARI shall Manufacture and sell the PARI Products at the prices (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Prices&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each Party acknowledges that the Prices were determined pursuant to an arms-length transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Distributors. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in this Agreement or the License Agreement, the Parties acknowledge that PARI has established a network of distributors. If requested by INSMED, INSMED and PARI will discuss in good faith the possibility of utilizing that existing network on terms to be mutually agreed and as set forth in this Agreement&#59; provided that the foregoing shall not limit INSMED&#8217;s right or ability to utilize distributors of its own choice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">&#91;***&#93;. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in this Agreement, during the Term, PARI agrees to sell the Device to INSMED in any country at the &#91;***&#93; at which any &#91;***&#93; is sold by &#91;***&#93; or its &#91;***&#93;, as applicable, to a Third Party in the respective &#91;***&#93;, taking into account &#91;***&#93; for the Device in transactions with &#91;***&#93;, and in each case based on &#91;***&#93; and &#91;***&#93;.  For purposes of the foregoing, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;&#91;***&#93;&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means any &#91;***&#93; with a &#91;***&#93; and &#91;***&#93; used for the same &#91;***&#93;, or, if no &#91;***&#93; is used for the same &#91;***&#93;, for &#91;***&#93; and &#91;***&#93; and with a &#91;***&#93; (based on &#91;***&#93;) and &#91;***&#93; (as described in more detail in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IV.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.68pt">Invoicing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise set forth in Article VI of this Agreement, PARI shall invoice INSMED when PARI &#91;***&#93; the PARI Products pursuant to the Initial Purchase Order or the Purchase Orders.  Subject to the terms and conditions of this Agreement, INSMED shall pay all undisputed invoices for the PARI Products delivered and accepted in accordance with Section 7.4 within &#91;***&#93; calendar days after the acceptance of shipment and receipt of the invoice.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">12</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IV.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.68pt">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Currency.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All references to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Dollars&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the legal currency of the United States.  All references to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Euros&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;&#8364;&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the legal currency of the Eurozone.  In the event any PARI Product is ordered for delivery outside the United States or Canada, the currency for payment shall be Euros.  With respect to the Prices for the United States and Canada set forth in Section 4.1 above, if the exchange rate of Euros to Dollars, based on the conversion rate reported by Reuters, Ltd. for the last Business Day immediately preceding the applicable invoice date (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Invoice Date Exchange Rate&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), is higher or lower than the mean exchange rate of the &#91;***&#93; prior to  the Effective Date (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Effective Date Exchange Rate&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,  by &#91;***&#93;% or more,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">then the Price shall be adjusted as follows&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">if the exchange rate has increased by more than &#91;***&#93;%&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Price shall be equal to the sum of (X) the Price set forth in Section 4.1(a)(i), (ii) or (iii), as applicable, plus (Y) the product of (A) the Price set forth in Section 4.1(a)(i), (ii) or (iii), as applicable, multiplied by (B) the amount equal to (x) the quotient of (a) the Invoice Date Exchange Rate divided by (b) the Effective Date Exchange Rate, minus (y) &#91;***&#93;.  By means of example, if the Effective Date Exchange Rate is &#91;***&#93;, the Price is $&#91;***&#93; and the Invoice Date Exchange Rate is &#91;***&#93;, then the new Price will be computed as follows&#58; $&#91;***&#93; + ($&#91;***&#93; x ((&#91;***&#93;&#47;&#91;***&#93;) &#8211; &#91;***&#93;))) &#61; $&#91;***&#93;.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">if the exchange rate has decreased by more than &#91;***&#93;%&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Price shall be an amount equal to the difference between (X) the Price set forth in Section 4.1(a)(i), (ii) or (iii), as applicable, and (Y) the product of (A) the Price set forth in Section 4.1(a)(i), (ii) or (iii), as applicable, multiplied by (B) the amount equal to (x) &#91;***&#93; minus (y) the amount equal to the quotient of (a) the Invoice Date Exchange Rate divided by (b) the Effective Date Exchange Rate.  By means of example, if the Effective Date Exchange Rate is &#91;***&#93;, the Price is $&#91;***&#93; and the Invoice Date Exchange Rate is &#91;***&#93;, then the new Price will be computed as follows&#58; $&#91;***&#93; - ($&#91;***&#93; x (&#91;***&#93; - (&#91;***&#93;&#47;&#91;***&#93;))) &#61; $&#91;***&#93;.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Payment Type</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All payments pursuant to this Agreement for the PARI Products shall be paid to the address listed on the applicable invoice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Withholding of Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  INSMED may withhold from payments due to PARI amounts for payment of any withholding tax that is required by law to be paid to any taxing authority with respect to such payments.  INSMED shall provide to PARI all necessary documents and correspondence and written evidence to demonstrate the payment of such tax, and shall also provide to PARI any other cooperation or assistance on a reasonable basis as may be necessary to enable PARI to claim exemption from such withholding taxes and to receive a full refund of such withholding tax or claim a tax credit. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">13</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any payments or portions thereof due hereunder which are not paid when due (unless disputed by INSMED in good faith) shall bear interest equal to the prime rate as reported by the Chase Manhattan Bank, New York, New York, on the date such payment is due, plus an additional &#91;***&#93; percent (&#91;***&#93;%) per year calculated on the number of days such payment is delinquent or the maximum amount allowed by Applicable Laws and Standards, whichever is lower.  This Section 4.3(d) shall not limit other remedies available to PARI.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IV.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.68pt">Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  INSMED shall pay PARI royalties pursuant to Article 6 of the License Agreement in accordance with the terms of the License Agreement, as amended pursuant to Section 12.1 of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:5.7pt"><br>REGULATORY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">V.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18.34pt">Regulatory Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The Parties shall cooperate in good faith to obtain any Regulatory Approvals for the use of PARI Products with INSMED Products&#59; provided, however, that as to ROW PARI shall be provided with sufficient lead time and prior to requesting any such cooperation from PARI, INSMED shall be committed to use commercially reasonable efforts to launch the INSMED Products in the applicable country(ies).  PARI shall provide regulatory and technical information relating to the Manufacture and supply of PARI Products and&#47;or components thereof as reasonably requested by INSMED to the extent required by a Regulatory Authority or that the Parties mutually agree will be helpful for a filing with a Regulatory Authority.  Alternatively, if PARI determines it is reasonably necessary to protect PARI Know-How related to eFlow or the Manufacture of PARI Products and if permitted by the applicable Regulatory Authority, PARI shall notify INSMED and make such information available to Regulatory Authorities directly (e.g. via a master file for devices or equivalent documents). INSMED shall provide regulatory and technical information and Data relating to the INSMED Products as reasonably requested by PARI to the extent required by a Regulatory Authority or that the Parties mutually agree will be helpful for a filing with a Regulatory Authority or in order for PARI to create its technical file of the CE documentation or similar documents.  PARI shall cooperate with any inspection of its facilities (including facilities of its Affiliates) by any Regulatory Authority relating to the PARI Products.  INSMED shall cooperate with any inspection of its facilities (including facilities of its Affiliates) by any Regulatory Authority relating to the INSMED Products.  Each Party shall notify the other Party, as soon as reasonably practicable but in any event within &#91;***&#93; Business Days via telephone, followed by a notice in writing in the event any action is taken or threatened by a Regulatory Authority relating to the PARI Products and the INSMED Products, as applicable. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">It is currently anticipated by the Parties that, with respect to the United States, the Device regulatory path shall not include a separate 510(k) submission to CDRH for clearance of the Device.  Instead, the Parties currently anticipate proceeding with a single </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">14</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">marketing application for the combination product (Device and INSMED Product) in the form of a New Drug Application for the INSMED Product, which single marketing application will contain a Device module similar in format and content to a 510(k) application.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">V.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18.34pt">Reimbursement Assistance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties shall cooperate in good faith to obtain any reimbursement approval for the use of the Device with the INSMED Product (subject to the provisio set forth in the first sentence of Section 5.1(a) above).  Each Party shall provide to the other reasonable and accurate regulatory and technical information relating to the PARI Products and&#47;or components thereof or the INSMED Products and&#47;or components thereof, as applicable, as reasonably requested by a payor source (without compromising confidentiality and in compliance with all applicable laws). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">V.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18.34pt">Safety Data Exchange Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Within &#91;***&#93; days after submission to a Regulatory Authority for Marketing Approval in any given country of the INSMED Product, the Parties shall enter, with respect to such country, into a safety data exchange agreement governing the safety data exchange, adverse event reporting, patient support and management of patient compliance relating to the Device, Device Accessories and INSMED Product (each a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> &#8220;Safety Data Exchange Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">V.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18.34pt">Recall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">PARI Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">Each Party shall promptly notify the other Party in writing (which notice shall be provided within &#91;***&#93; hours) if any Regulatory Authority or other governmental agency having jurisdiction requests or orders it to conduct a Recall of any PARI Product, or with respect to PARI, if PARI determines to undertake a Recall of any PARI Product voluntarily.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Prior to the beginning of any such Recall, the Parties agree to discuss the Recall process if practicable.  Promptly after being notified of such Recall, but in no event later than may be required to permit such Party conducting such Recall to meet applicable Regulatory Requirements, the other Party shall provide the Party conducting such Recall with reasonable assistance in connection with such Recall as requested by the Party conducting such Recall.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">If PARI is required or determines to effect any such Recall of the PARI Product, then PARI shall solely manage such Recall and be responsible for (i) the cost of notifying end users&#59; (ii) costs associated with the collection and shipment from end users of the PARI Product(s) subject to such Recall&#59; and (iii) costs of replacing such PARI Product(s), including the cost of shipping the replacement PARI Product(s) to the affected end users. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">In the event that the INSMED Product is Recalled and such Recall does not result from a PARI Product or from PARI&#8217;s breach of its obligations hereunder or the gross negligence or willful misconduct of PARI or any of its Affiliates in its or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">15</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">their performance under this Agreement or the Quality Agreement and as a consequence the FDA or other Regulatory Authority also requires the Device be retrieved or recalled for any reason, then INSMED will bear the costs (x) of notifying end users&#59; (y) costs associated with the collection and shipment from end users of the PARI Product(s) subject to such Recall&#59; and (z) costs of replacing such PARI Product(s), including the cost of shipping the replacement PARI Product(s) to the affected end users.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">INSMED Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  INSMED shall promptly notify PARI in writing if any Regulatory Authority or other governmental agency having jurisdiction requests or orders it to conduct a Recall of any INSMED Product, or if it determines to undertake a Recall of any INSMED Product voluntarily.  Prior to the beginning of any such Recall, the Parties agree to discuss the Recall process if practicable.  INSMED shall solely manage such Recall and be responsible for (i) the cost of notifying end users&#59; (ii) costs associated with the collection and shipment from end users of the INSMED Product subject to such Recall&#59; and (iii) costs of replacing such INSMED Product, including the cost of shipping the replacement INSMED Product(s) to the affected end users.  Notwithstanding anything to the contrary in this Section 5.4(b), to the extent INSMED is required to effect any Recall of an INSMED Product and such Recall results from a PARI Product or from PARI&#8217;s breach of its obligations hereunder or the gross negligence or willful misconduct of PARI or any of its Affiliates in its or their performance under this Agreement or the Quality Agreement, PARI shall, to the extent resulting from the PARI Product or from PARI&#8217;s or its Affiliates&#8217; (as applicable) breach of its obligations hereunder, or gross negligence or willful misconduct in its or their performance under this Agreement or the Quality Agreement, bear the expense of repackaging any INSMED Product that is still in INSMED&#8217;s or its Affiliates&#8217; or their distributor&#8217;s possession or control and replacing the PARI Products packaged with such INSMED Products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">V.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18.34pt">Deficiency Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. INSMED shall have the right at its own cost to inspect and audit, or cause to be inspected and audited, the facilities, books and records of PARI which directly relate to (i) a Regulatory Authority-identified deficiency, provided that such deficiency is related to information or materials that PARI provided to INSMED&#59; and&#47;or (ii) a material breach in PARI&#8217;s performance under this Agreement (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Deficiency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). INSMED shall have the right at its own cost to inspect or audit, or caused to be inspected or audited, any document, process, system, procedure, product or material that has resulted in a Deficiency (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Deficiency Audit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:1.04pt"><br>MANUFACTURE AND SUPPLY OF PARI PRODUCTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VI.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.68pt">Manufacture of PARI Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  PARI shall Manufacture all PARI Product(s) in accordance with this Agreement, the Quality Agreements, the applicable Device Specifications and Applicable Laws and Standards.  Within &#91;***&#93; days from the Effective Date, the Parties will enter into two substantially equivalent agreements (one to cover the US&#47;Canada and the other for the ROW) governing the change control processes, cGMP, quality system regulations, other standards and procedures for manufacturing and supplying the Device and the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">16</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Device Accessories as required by Applicable Laws and Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and Regulatory Requirements customary for similar agreements (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Quality Agreements&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">). Upon their execution, the Quality Agreements will be attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any modification(s) to the Device Specifications that could&#58; (i) affect the Regulatory Approval of the Device or Device Accessories, as applicable, or (ii) have a material adverse effect on the development of the PARI Products and the manufacture thereof, including the quality, reliability, robustness or user interface of the Device or which would otherwise have an adverse effect on the INSMED Product when used with the Device or Device Accessories, as applicable, shall be subject to the Parties&#8217; written agreement prior to their implementation provided, however, that if INSMED has not responded to PARI in writing within &#91;***&#93; Business Days of receipt of PARI&#8217;s notice regarding such modifications, then INSMED shall be deemed to have approved such modifications. PARI shall promptly inform the JSC of any other PARI Product modification(s) that could give rise to questions on the part of end-users or others involved in Device distribution. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VI.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.68pt">Forecasts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to Section 6.3 with respect to the Initial Forecast, after submission to a Regulatory Authority for Marketing Approval of the INSMED Product in any given country but no less than &#91;***&#93; months prior to the anticipated First Commercial Sale in such country and thereafter on a quarterly basis during the Term, at least &#91;***&#93; days before the end of each calendar quarter, INSMED shall provide PARI with its good faith, reasonable written projections (broken down by Devices, &#91;***&#93; and Nebulizer Handsets) of the anticipated total market requirements of PARI Products for each country in the INSMED Territory (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Forecast&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), on a &#91;***&#93; basis during the &#91;***&#93; period immediately following the calendar quarter in which such projection is issued. The forecasted quantities of PARI Products set forth in each Forecast are non-binding, good faith estimates provided solely to assist PARI in its production planning.   All Forecasts shall be deemed INSMED Confidential Information. PARI shall use commercially reasonable efforts to commence scale-up activities to transition from clinical supply to commercial supply based on INSMED&#8217;s Forecasts which shall be reasonably explained by INSMED to PARI.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VI.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.68pt">Initial Purchase Orders for PARI Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No later than &#91;***&#93; days prior to the earliest anticipated approval date by the Regulatory Authority of a MAA in any given country of the INSMED Product, INSMED shall provide PARI with a PARI Product purchase order for a quantity of PARI Products by item number (each an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Initial Purchase Order&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).  PARI shall produce sub-components for Devices and Nebulizer Handsets as specified in the Initial Purchase Order. Such sub-components shall not be labeled with a trademark or according to the branding strategy until INSMED and PARI will have mutually agreed and confirmed in writing the labeling of the Devices and Nebulizer Handsets. The shipment date of the Devices and Nebulizer Handsets covered by such Initial Purchase Order shall allow PARI a lead time of &#91;***&#93; days from the date of written agreement on the labeling of the Device and Nebulizer Handset for completing the finished components.  Notwithstanding the above, if requested in writing by INSMED as an amendment to the Initial Purchase Order, PARI shall complete production and ship &#91;***&#93; as requested in the amendment of the PARI Products ordered in the Initial Purchase Order within &#91;***&#93; days of the receipt of such amendment.  The amendment </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">17</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall include the requested labeling of the Device including the Nebulizer Handset, packaging, and instruction for use. The remaining balance of the Initial Purchase Order shall be shipped within &#91;***&#93; days from the date of written confirmation by INSMED on the labeling of the Device and Nebulizer Handset.  For the avoidance of doubt, if INSMED requests the production and shipment of &#91;***&#93; of the PARI Products ordered in the Initial Purchase Order before the date of written agreement on the labeling of the Device and Nebulizer Handset, INSMED shall pay for such portion of the Initial Purchase Order as set forth below regardless of whether the labeling of the Device and Nebulizer Handset changes for any reason. Notwithstanding the foregoing, if PARI needs to change the labeling upon request by INSMED or any relevant Regulatory Authority, then INSMED shall promptly reimburse PARI for the additional cost incurred by PARI and any resulting delay in shipment shall not be deemed a breach of this Agreement and such late shipment shall not be included to determine a Failure Event.  PARI shall store such PARI Products until such time as PARI delivers such PARI Products on the dates and to the locations to be provided by INSMED, to the extent allowed by applicable law, in written instructions to PARI prior to the First Commercial Sale in the U.S. or in the European Union, as applicable.  Notwithstanding Section 4.2 above, PARI shall provide INSMED with an invoice for the PARI Products manufactured by PARI pursuant to such Initial Purchase Order upon receipt and confirmation of the Initial Purchase Order, and INSMED shall pay the invoice submitted by PARI for the Initial Purchase Order within &#91;***&#93; calendar days after the date of invoice. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VI.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.68pt">Subsequent Purchase Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">PARI shall supply PARI Products to INSMED in accordance with the terms and conditions of this Agreement, and in accordance with the purchase orders submitted to PARI by INSMED (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Purchase Orders&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).  Each Purchase Order shall include item numbers and quantity, delivery location(s), contact information and shipment date(s).  PARI shall ship the quantity of PARI Products specified in each Purchase Order no less than &#91;***&#93; days after the date and confirmation of such Purchase Order by PARI, unless otherwise agreed to by PARI and INSMED&#59; provided, however, that no such Purchase Order shall have a shipment date prior to the &#91;***&#93; day following the date of receipt by PARI of the Initial Purchase Order.  PARI shall accept all Purchase Orders for quantities of PARI Products that are set forth in the most recent Forecast for the applicable time period, and PARI shall use commercially reasonable efforts to accept and fill Purchase Orders placed by INSMED that are &#91;***&#93; of the forecasted quantities for such time period.  PARI shall notify INSMED within &#91;***&#93; Business Days if it cannot meet the requested shipment date for the &#91;***&#93;&#59; provided, however that failure by PARI to fulfill such &#91;***&#93; shall not be deemed a breach under this Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">PARI&#8217;s sale of PARI Products hereunder shall be subject to the terms and conditions of this Agreement and not to any terms and conditions stated on any Purchase Order, PARI&#8217;s written acceptance of a Purchase Order or other document not effectively amending this Agreement, except insofar as such Purchase Order or other document establishes the quantity, delivery date, specific shipping requirements and destination of shipment of PARI Products </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">18</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ordered.  Any additional, inconsistent or different terms and conditions contained in such other documents are hereby expressly rejected.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Rush orders for PARI Products requesting a delivery date sooner than &#91;***&#93; days after the date of such Purchase Order (other than the Initial Purchase Order) may incur additional charges.  Such additional charges shall be equal to the actual cost incurred by PARI (over and above non-rush order costs) due to such rush order.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VI.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.68pt">Continuity of Supply.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Parties recognize that continuity in the manufacture and supply of the PARI Products is critical for patient care and for the commercial success of the PARI Products and the INSMED Product(s).  The Parties have agreed on the following terms and conditions in this Section 6.5 to minimize the risk of discontinuity in such manufacture and&#47;or supply.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Contingency Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  On or about &#91;***&#93; days prior to the earliest anticipated First Commercial Sale of the INSMED Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> PARI will provide to INSMED its draft contingency plan for ensuring the continuity of manufacture and supply of PARI Products in the event of a Supply Interruption or other Failure Event (each as defined in Section 6.5(c)) (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Contingency Plan&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).  INSMED shall have the opportunity to review and comment on such draft Contingency Plan and the Parties shall finalize such Contingency Plan by mutual written agreement (not to be unreasonably withheld).  As part of such Contingency Plan, the Parties may discuss in the future the possibility for PARI to use commercially reasonable efforts to negotiate in good faith and implement a reasonably acceptable &#91;***&#93; for the PARI Products, which may include a &#91;***&#93; for such PARI Products by PARI or its Affiliates, and any such discussions shall also include the &#91;***&#93; of &#91;***&#93; and &#91;***&#93; related to the implementation of such a &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Safety Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For the purpose of guarding against unexpected changes in market demand or unforeseen manufacturing failures, delays and shortfalls, PARI agrees to maintain, at its own cost and expense, safety stock of the Devices, &#91;***&#93; and Nebulizer Handsets (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Safety Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), equal to &#91;***&#93; months supply as set forth in the most current Forecast.  PARI shall have the Safety Stock in place beginning &#91;***&#93; days after the first Marketing Approval of the INSMED Product. PARI shall have the right to freshen the Safety Stock from time to time by rotating such Safety Stock provided that the minimum quantity of Safety Stock is not reduced through such process.  In addition, an additional &#91;***&#93; months of safety stock may be maintained by INSMED at its expense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Back-up Manufacturer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">Notice of Supply Interruption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of any interruption of PARI&#8217;s ability to supply Devices in accordance with this Agreement for any reason, (a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Supply Interruption&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), PARI shall promptly notify INSMED.  Upon the occurrence of any Supply Interruption, the Parties will meet immediately and discuss in good faith all appropriate actions to remedy and cure the Supply Interruption.  PARI will use &#91;***&#93; to cure the Supply Interruption as soon as possible.  Upon the occurrence of a Supply </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">19</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Interruption, PARI shall be permitted to use the Safety Stock to cure such Supply Interruption.  Promptly following the event of a Supply Interruption, PARI shall prepare a plan to address any deficiencies or cause(s) of such interruption, provide a draft of the plan to INSMED (including a plan for filling up the Safety Stock if PARI used the Safety Stock to cure the Supply Interruption or an otherwise potentially incomplete Purchase Order) for review and agreement, and will implement all reasonable comments from INSMED as soon as possible.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt;text-decoration:underline">Failure Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties acknowledge the possibility that one or more of the following events (each, a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Failure Event&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) may occur&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">PARI undergoes a voluntary or involuntary dissolution&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">PARI ceases to conduct business in the normal course, becomes insolvent, files for bankruptcy, is subject to a bankruptcy proceeding or otherwise becomes bankrupt, makes a general assignment for the benefit of creditors, admits in writing its inability to pay its debts as they are due, permits the appointment of a receiver for its business or assets, avails itself of or becomes subject to any proceeding under any statute of any governing authority relating to insolvency or the protection of rights of creditors&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">PARI&#8217;s failure to supply at least &#91;***&#93; percent (&#91;***&#93;%) of all quantities of Devices, Nebulizer Handsets and &#91;***&#93; (which, for purposes of calculating a Failure Event under this subsection (3), shall be calculated &#91;***&#93;) set forth in all accumulated Purchase Orders (but only to the extent each such Purchase Order is within the applicable forecasted amount) in any &#91;***&#93; consecutive &#91;***&#93;&#59; provided that in order for a shortage in supply to qualify under this subsection (3), the delivery date in the applicable Purchase Order corresponding to such supply shortage must be at least &#91;***&#93; days from the delivery date in any other Purchase Order for which a shortage in supply occurred and is being applied towards a Failure Event under this subsection (3)&#59; and provided further that PARI shall be permitted to use Safety Stock to avoid an incomplete Purchase Order, in which case such Purchase Order shall be deemed complete and not be counted towards the occurrence of a Failure Event.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Notification of Failure Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  PARI shall promptly notify INSMED in writing upon the occurrence of any Failure Event set forth in subsection (1) or (2) in clause (ii) above. INSMED may notify PARI in writing upon the occurrence of an event set forth in subsection (3) of clause (ii) above (each such notice provided pursuant to this Section 6.4(c)(iii), a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Notice of Failure Event&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">20</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt;text-decoration:underline">Cure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If a Failure Event set forth in Section 6.5(c)(ii)(3) occurs, PARI shall provide INSMED a written proposal which includes&#58; (1) a statement of the exact amount of Safety Stock and other PARI Products available pro rata to INSMED, as applicable, remaining in PARI&#8217;s inventory&#59; (2) the current and expected (based on the Forecast) shipments for PARI Products&#59; and (3) PARI&#8217;s plans for remedying such Failure Event within the Cure Period.  Such remedies may include, but are not limited to, PARI&#8217;s implementation of the Contingency Plan, establishment of a new manufacturing line at an alternate PARI facility or PARI establishing an agreement with a Third Party to begin manufacturing.  INSMED will have &#91;***&#93; days to review and give good faith consideration to PARI&#8217;s written proposal and, provide comments to PARI&#8217;s proposal for cure.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Alternative Supplie</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">r.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If a Failure Event set forth in Section 6.5(c)(ii)(1) or Section 6.5(c)(ii)(2) occurs or if PARI fails to cure any Failure Event set forth in Section 6.5(c)(ii)(3) within the Cure Period, then INSMED shall have the right to obtain PARI Products from an alternate supplier of its choice other than a PARI Competitor (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Alternative Supplier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and the further provisions of this Section 6.5(c)(v) shall apply.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">PARI shall grant INSMED a limited, non-exclusive right and license, with the right to grant sublicenses of INSMED&#8217;s rights under the PARI Intellectual Property (in accordance with the terms and conditions of this Agreement and the License Agreement, excluding the payment terms for PARI Products under this Agreement), to make or have made the PARI Products solely for use with the INSMED Product(s) in the INSMED Field in the INSMED Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Back-Up License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Back-Up License shall survive any termination of this Agreement by INSMED solely pursuant to Section 12.2(c) or 12.2(d) of this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">In the event INSMED requests that PARI initiate the transfer of its Data to an Alternative Supplier to support the Manufacture of PARI Products in accordance herewith, such Alternative Supplier shall first enter into a reasonable non-disclosure&#47;confidentiality rights agreement with PARI to protect PARI&#8217;s Data, Confidential Information and PARI Intellectual Property associated with such transfer and such transfer shall be in accordance with the terms and conditions of this Agreement and the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Upon written notice from INSMED, PARI shall promptly initiate and complete the transfer of the Data set forth below to support the Manufacture of PARI Products pursuant to the Back-Up License at PARI&#8217;s sole cost and expense to INSMED or INSMED&#8217;s Alternative Supplier in accordance herewith, and provide related reasonable technical assistance (including the availability of personnel) reasonably useful or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">21</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">necessary for such Manufacture, including the right to review all records related to such Manufacture upon reasonable advance written notice in accordance with Article X of this Agreement&#58; </font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a) the complete Manufacture standard operating procedures (&#8220;SOPs&#8221;), including a complete description of all PARI Intellectual Property, to the extent related to the Manufacture of PARI Products&#59;</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b) all technical reports and materials related to the Manufacture process activities for the PARI Products, including all reports, documentation and other materials generated, to the extent not previously delivered to INSMED (if any), which at the time of such transfer are relevant to and would be required or useful to Manufacture the PARI Products as set forth herein using the processes as performed by PARI at such time&#59; </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c) all regulatory filings relating to the Manufacture of the PARI Products, including the materials comprising the PARI Products&#59; and</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(d) all necessary Chemistry, Manufacturing and Controls (&#8220;CMC&#8221;) section documentation relating to the Manufacture of the PARI Products and required for regulatory filings.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">Notwithstanding anything set forth in this Agreement or the License Agreement, in acknowledgment of PARI&#8217;s reasonable concern over the protection of PARI Intellectual Property, INSMED shall not (directly or indirectly) undertake, or cause to be undertaken by the Alternative Supplier, the proprietary aspects of Manufacture of the PARI Products (including without limitation the Device&#8217;s or Nebulizer Handset&#8217;s aerosol heads) in the countries listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto, except to the extent such country currently listed no longer is listed on the TRIPS Priority Watch list.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:15.36pt">If PARI regains the ability to manufacture and supply PARI Products and INSMED reasonably determines in good faith that PARI does have the ability to manufacture and supply PARI Products, then INSMED will use its &#91;***&#93; to transition back to PARI the Manufacture of the PARI Products within a reasonable timeframe determined by INSMED in good faith after consultation with PARI, such timeframe not to exceed &#91;***&#93; days, provided that  such maximum timeframe shall be reasonably extended to the extent necessary to comply with any necessary regulatory requirements or for INSMED to perform any ongoing clinical development activities.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">22</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(viii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.03pt">For clarity, INSMED shall remain responsible for its royalty obligations in accordance with the terms of the License Agreement, as amended pursuant to Section 12.1 of this Agreement. Notwithstanding anything to the contrary contained herein, the Back-Up License and related rights set forth in this Section 6.5(c) shall terminate concurrently with any termination of the License Agreement by PARI under Section 15.2 of the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ix)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">If INSMED and&#47;or its Alternative Supplier (directly or indirectly) modifies or improves any PARI Intellectual Property, all such improvements and modifications, and all Intellectual Property rights thereto, are and will be exclusively owned by PARI (and included within the scope of the Back-Up License) and INSMED does hereby and will promptly (and shall secure and cause its Alternative Supplier to promptly) transfer and assign any and all such rights in such improvements and modifications to PARI without further consideration at INSMED&#8217;s sole cost and expense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VI.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.68pt">Relationship to the License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The provisions of this Agreement shall replace and supersede Section 8.9 and Exhibit 8.9 of the License Agreement in their entirety.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:32.38pt"><br>DELIVERY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VII.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.02pt">Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  PARI shall deliver to INSMED all PARI Products in conformance with each applicable Purchase Order.  PARI recognizes that time is of the essence under this Agreement.  PARI shall report to INSMED the occurrence of any event within or beyond its control which is likely to affect delivery under this Agreement. All PARI Product so delivered shall be accompanied by the following documentation, as applicable&#58; (a) the serial numbers of the delivered Devices or aerosol heads&#59; (b) any documentation required under this Agreement or the Quality Agreements, and (c) any documentation that PARI customarily includes in shipments of such Device and&#47;or Device Accessories.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VII.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.02pt">Shipping&#59; Risk of Loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All shipments for PARI Products will be made (x) &#91;***&#93; in &#91;***&#93; (INCOTERMS 2010) by a common carrier selected by PARI&#59; and (y) in case of the United States and Canada, &#91;***&#93; in &#91;***&#93; (INCOTERMS 2010) by a common carrier selected by INSMED, such selection to be reasonably acceptable to PARI acting in good faith. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VII.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.02pt">Testing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  PARI shall test the orders of PARI Product to be supplied to INSMED in accordance with the terms and conditions set forth in the Quality Agreements.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VII.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.02pt">Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  INSMED shall have a period of &#91;***&#93; Business Days from the date of receipt of any shipment of the PARI Products to test for quality and visually inspect each shipment for shortage in quantity or visible damages.  INSMED shall have the right to reject all or a portion of a shipment for any visible damage, or request for the shipment of additional units </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">23</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">to the extent there is a shortage in quantity.  If INSMED rejects a shipment, it shall notify PARI in writing within such &#91;***&#93; Business Days, indicating the order number, date of delivery and the nature of the Device defect. Upon PARI&#8217;s receipt of a rejection from INSMED and PARI&#8217;s acceptance in good faith of such a rejection, PARI shall, at the option of INSMED, replace the Device and&#47;or Device Accessory or replace the defective part or component, in each case at PARI&#8217;s sole expense.  Time shall be of the essence in PARI&#8217;s replacement of such defective part or component.  In the event INSMED does not so notify PARI of visible damage, a shortage of PARI Products or a quality issue within &#91;***&#93; Business Days after its receipt of any shipment thereof, INSMED shall be deemed to have accepted such shipment and shall be obligated to make payment therefor as provided in this Agreement.  Thereafter, INSMED may return any PARI Product only pursuant to Section 8.3 below.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.72pt"><br>REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VIII.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.36pt">Mutual Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party hereby represents and warrants to the other Party as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Due Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Such Party has taken all necessary action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Enforcement of Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   This Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against such Party in accordance with its terms.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">No Conflict</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The execution and delivery of this Agreement and the performance of such Party&#8217;s obligations hereunder do not conflict with, or constitute a default or require any consent under, any contractual obligation of such Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Each Party represents and warrants and covenants that all relationships or arrangement between such Party and any federal, state or local government (or an agency thereof)) or any elected or appointed public official shall comply with all Applicable Laws and Standards, including without limitation lobbying restrictions, conflicts of interest requirements, and the Foreign Corrupt Practices Act.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VIII.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.36pt">Representations and Warranties of PARI. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> PARI represents, warrants, and covenants to INSMED  as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">PARI is not debarred pursuant to the Federal Food, Drug and Cosmetic Act, excluded from a federal health care program, or debarred from federal contracting, and PARI shall not use any employee or consultant, in the United States, who has ever been so debarred or excluded or is, to PARI&#8217;s knowledge (after reasonable inquiry), the subject of such debarment or exclusion proceedings, or who has been convicted of or pled nolo contendere to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">24</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any felony, or to any federal or state legal violation (including misdemeanors) relating to prescription drug or device products or fraud, or convicted of  any other crime for which an entity or person could be so debarred or excluded (including by the FDA under 21 U.S.C. &#167; 335a (or subject to a similar sanction of any other Regulatory Authority in the United States)).  PARI agrees that, if, during the Term, all or part of the above statement ceases to be accurate,  PARI shall immediately notify INSMED of such circumstance, and at INSMED&#8217;s option, acting reasonably, this Agreement shall terminate automatically as of the first date of such noncompliance)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">PARI has not and shall not enter into any agreement or arrangement with any other entity that could reasonably be expected to prevent, in any material respect, or in any other negative way materially interfere with, PARI&#8217;s ability to perform its obligations pursuant to this Agreement, or that would prevent INSMED  from exercising its rights under this Agreement or the License Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">PARI is a ISO-certified manufacturer following ISO 13485, and PARI agrees to inform INSMED  immediately regarding any change in this status&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">PARI agrees to inform INSMED immediately regarding any change in its registration or status with the FDA or any other Regulatory Authority&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">PARI owns or otherwise Controls all necessary rights to make, use, import, export, offer for sale and sell and commercialize all Devices, &#91;***&#93; and Nebulizer Handsets as contemplated under this Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">PARI has not received any written notice that any Regulatory Authority has commenced, or threatened to initiate, any action to withdraw approval, place marketing or sale restrictions, or request the recall of the PARI Products, or commenced, or threatened to initiate, any action to enjoin or place restrictions on the production, sale, or marketing of the PARI Products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VIII.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.36pt">Device Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  PARI represents, warrants and guarantees that each unit of PARI Products supplied by PARI under this Agreement&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">as of the time of first use, complies with the terms of this Agreement and the applicable Device Specifications set forth in the applicable Territory-Specific Appendix&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">has been manufactured in compliance with Applicable Laws and Standards&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">has been manufactured in compliance with the terms and conditions of the Quality Agreements&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">25</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">with respect to the Durable Components of each Device, will have no material defect in workmanship for a period of at least &#91;***&#93; months from the date of receipt by an end user&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">with respect to each Nebulizer Handset and Device Accessory, will have no material defect in workmanship when the Nebulizer Handset and Device Accessory is used by such end user for the first time, provided such Nebulizer Handset and Device Accessory has been properly used and maintained in accordance with any product user manual or the &#8220;Instructions for Use&#8221; for the applicable Nebulizer Handset and Device Accessory&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">is, upon shipment to INSMED, free and clear of all security interests, liens and other encumbrances of any kind or character&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">to the knowledge of PARI, is not a product, the manufacture, use or sale of which infringes any patent rights or other intellectual property rights of any Third Party in the INSMED Field and subject to the license and cross-license agreements mentioned in Exhibit C.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The foregoing warranties shall survive any inspection, delivery, acceptance, or payment by INSMED, any subsequent sublicense or distribution to third parties by INSMED, its Affiliates or its authorized agents, and shall be enforceable by INSMED as well as its successors and permitted assigns for itself or the benefit of any third party Sublicensee or distributor of the INSMED Product.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VIII.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.36pt">Warranty Replacement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Warranty to End Users</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The period and requirement of the warranty set forth under Section 8.3(c) shall be included with the Device.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">PARI&#8217;s Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  PARI shall be solely responsible, at its cost, for any warranty claim that it accepts which alleges that any PARI Product does not conform with any of the warranties described under Sections 8.3, by replacing the non-conforming units.  INSMED shall not be obligated to bear any costs, including transportation costs, in connection with the replacement of such non-conforming units unless otherwise defined in the Territory-Specific Appendix.  The Parties shall establish appropriate timelines and procedures for responding to warranty calls in the different countries within the INSMED Territory.  PARI shall have the right to inspect defective Devices and&#47;or Device Accessories to determine the validity of warranty claims under this Section 8.4 or to comply with applicable Regulatory Requirements. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VIII.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.36pt">Warranty Limitations or Disclaimers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  THE WARRANTIES, LIMITATIONS AND DISCLAIMERS DESCRIBED IN THIS ARTICLE 8 ARE EXCLUSIVE AND SUPERSEDE ANY OTHER WARRANTY LIMITATIONS AND DISCLAIMERS GIVEN BY PARI OR INSMED, WHETHER WRITTEN OR ORAL.  EXCEPT FOR THE EXPRESS WARRANTIES IN SECTION 8.3, PARI MAKES NO WARRANTIES OF ANY KIND WITH RESPECT TO ANY PARI PRODUCT, WHETHER EXPRESS OR IMPLIED, INCLUDING, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">26</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OF FITNESS FOR A PARTICULAR PURPOSE, FOR ANY IMPLIED WARRANTIES ARISING FROM COURSE OF PERFORMANCE, COURSE OF DEALING, OR USAGE OF TRADE.  INSMED AND ITS DESIGNEES SHALL NOT MAKE ANY REPRESENTATION OR WARRANTY ON BEHALF OF PARI THAT EXCEEDS THE EXPRESS WARRANTIES IN SECTION 8.3.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VIII.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.36pt">Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party certifies that it shall not violate any Applicable Law, including but not limited to, the federal anti-kickback statute, set forth at 42 U.S.C. sec. 1320a-7b(b), the Public Contracts Anti-Kickback Act, 41 U.S.C. sec 50 et seq., any state anti-kickback law, the Health Insurance Portability and Accountability Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HIPAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), set forth at 42 U.S.C. sec. 1320d-2, and the Foreign Corrupt Practices Act, set forth at 15 U.S.C. sec. 78dd-1, et seq. Each Party certifies that it shall cooperate with the other Party as required to comply with Applicable Laws, including providing assistance with any disclosures required by Applicable Laws</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:1.04pt"><br>INTELLECTUAL PROPERTY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IX.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.68pt">Trademark.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">License and Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">Subject to the terms and conditions set forth in this Agreement, PARI hereby grants to INSMED and its designees, a non-exclusive, non-transferable right and license to use PARI&#8217;s trademark(s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> attached hereto, in the INSMED Territory in connection with (w) the PARI Products, (x) the INSMED Products offered by INSMED and its designees, and (y) any advertising or promotional materials associated therewith, in the manner mutually agreed to by the Parties pursuant to Section 3.4 of this Agreement, and (z) packaging and prescribing information.  The license set forth herein shall immediately terminate with respect to (w), (x), and (y), upon expiration or sooner termination of this Agreement and with respect to (z), upon expiration or sooner termination of the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">Subject to the terms and conditions set forth in this Agreement, INSMED hereby grants to PARI a non-exclusive, non-transferable right and license to use INSMED&#8217;s trademark(s) set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> attached hereto, in the INSMED Territory in connection with (x) the PARI Products and (y) any advertising or promotional materials associated therewith, in the manner mutually agreed to by the Parties pursuant to Section 3.4 of this Agreement, and (z) packaging and prescribing information.  The license set forth herein shall immediately terminate with respect to (x), and (y), upon expiration or sooner termination of this Agreement and with respect to (z), upon expiration or sooner termination of the License Agreement.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">27</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each of PARI and INSMED agree to use commercially reasonable efforts to mark all materials, including packaging, advertising and promotional materials, that incorporate the trademarks of the other Party hereto that are licensed above in Section 9.1(a) with the symbol &#8482; or &#174;, as applicable, and the following attribution notice&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;&#91;Insert applicable trademark from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is a trademark of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;insert applicable Party that owns the relevant trademark&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;.  In addition, each Party shall comply with any additional requirements established by the other Party with respect to the use of its trademarks.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party represents and warrants that it owns all right, title and interest in and to its trademarks set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Neither Party shall challenge, cause others to challenge or assist in any challenge to the validity of the other Party&#8217;s trademarks, any registrations thereof or the ownership thereof.  Each of INSMED and PARI shall be solely responsible for taking such actions as it deems appropriate to obtain trademark, service mark or copyright registration for its trademarks.  All uses of or references to each Party&#8217;s trademarks shall inure to the benefit thereof, and all rights with respect to such Party trademarks not specifically granted in this Agreement shall be and are hereby reserved to such Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If either Party learns of any activity by a Third Party which might constitute an infringement of the other Party&#8217;s rights in any of its trademarks, or if any Third Party asserts that a Party&#8217;s use of the other Party&#8217;s trademarks constitutes unauthorized use or infringement, such Party shall so notify the other Party. The notifying Party shall make all reasonable efforts to assist the other Party, at the other Party&#8217;s expense and request, with any litigation concerning such trademarks, including providing such evidence and&#47;or expert assistance as the notifying Party may have within its control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Quality Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Party hereto acknowledges and agrees that the other Party shall be entitled to monitor the use of its respective trademarks pursuant to this Agreement.  If a Party determines that any of its trademarks is not being used properly, it shall so notify the other Party in writing or through the Joint Steering Committee and such other Party shall take steps to&#58; (i) reassure the notifying Party that the trademark usage is proper or (ii) comply with any changes necessary to address the notifying Party&#8217;s concerns.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:5.7pt"><br>CONFIDENTIALITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">X.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18.34pt">Confidentiality and Non-Use Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Article 11 of the License Agreement is hereby incorporated herein by reference and shall govern all Confidential Information exchanged between the Parties under this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">X.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18.34pt">Injunctive Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties expressly acknowledge and agree that any breach or threatened breach of Article 9 or Article 10 may cause immediate and irreparable harm which may not be adequately compensated by damages.  Each Party therefore agrees that in the event of such breach or threatened breach and in addition to any remedies available at law, the non-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">28</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">breaching Party shall have the right to secure equitable and injunctive relief, without bond, in connection with such a breach or threatened breach.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE XI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:1.04pt"><br>INDEMNIFICATION </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.34pt">Indemnification of INSMED.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PARI shall at all times be responsible for, and shall defend, indemnify and hold INSMED, its Affiliates, and their respective directors, officers, employees, agents and representatives (collectively, &#8220;INSMED Indemnitees&#8221;), harmless from and against any and all losses, expenses, recoveries and damages, including reasonable legal expenses, costs and attorneys&#8217; fees (collectively &#8220;Losses&#8221;), arising out of Third Party claims, lawsuits, judgments, or proceedings of any kind or nature (collectively, &#8220;Claims&#8221;) to the extent arising from&#58; (i) any product liability claim or lawsuit directly arising from the authorized use, design, manufacture or function of a Devices, &#91;***&#93; and&#47;or Nebulizer Handsets&#59; (ii) any claim of infringement of any patent rights, trade secrets rights or other intellectual property rights of a Third Party arising from the authorized use, design or function of a Devices, &#91;***&#93; and&#47;or Nebulizer Handsets or manufacture by PARI thereof&#59; (iii) PARI&#8217;s failure to manufacture the  PARI Products in accordance with the applicable Device Specifications, Applicable Laws and Standards or the terms of the Quality Agreement&#59; (iv) PARI's material breach of any representation or warranty or covenant given in this Agreement by PARI&#59; or (v) any negligent conduct or willful misconduct by PARI in  performance under this Agreement&#59; except, in each case to the extent that any Claim arises out of or results from any negligent conduct or willful misconduct by INSMED or INSMED&#8217;s material breach of any representation or warranty or covenant given in this Agreement by INSMED. INSMED, at its expense, may participate in the defense of any such claim or lawsuit.  The Parties acknowledge and agree that INSMED&#8217;s indemnifications rights and PARI&#8217;s indemnification obligations under this Section 11.1 shall control over Section 13.1 of the License Agreement with respect to any Claims arising from activities performed under this Agreement and nothing in this Section 11.1 shall permit a duplicative recovery by INSMED or its Affiliates for any Losses for which indemnity is obtained hereunder and the indemnification obligations of PARI under Section 13.1 of the License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.34pt">Indemnification of PARI.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INSMED shall at all times be responsible for, and shall defend, indemnify and hold PARI, its Affiliates, and their respective directors, officers, employees, agents and representatives (collectively, &#8220;PARI Indemnitees&#8221;), harmless from and against any and all Losses arising out of Third Party Claims to the extent arising from&#58; (i) any product liability claim or lawsuit directly arising from the INSMED Product&#59; (ii) any claim of infringement of any patent rights, trade secrets rights or other intellectual property rights of a Third Party arising from the INSMED Product or the manufacture thereof&#59; (iii) INSMED&#8217;s material breach of any representation, warranty or covenant given in this Agreement by INSMED&#59; and (iv) any negligent conduct or willful misconduct by INSMED in performance under this Agreement&#59; except, in each case to the extent that any Claim arises out of or results from any negligent conduct or willful misconduct by PARI or PARI&#8217;s material breach of any representation or warranty or covenant given in this Agreement by PARI.  PARI, at its expense, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">29</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">may participate in the defense of any such claim or lawsuit. The Parties acknowledge and agree that PARI&#8217;s indemnifications rights and INSMED&#8217;s indemnification obligations under this Section 11.2 shall control over Section 13.2 of the License Agreement with respect to any Claims arising from activities performed under this Agreement and nothing in this Section 11.2 shall permit a duplicative recovery by PARI or its Affiliates for any Losses for which indemnity is obtained hereunder and the indemnification obligations of INSMED under Section 13.2 of the License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.34pt">Indemnification Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of any claim that may be subject to indemnification under this Article 11, the indemnified Party shall (a)&#160;promptly notify the indemnifying Party of such claim&#59; (b)&#160;at indemnifying Party expense, reasonably cooperate with the indemnifying Party in the defense of such claim&#59; and (c)&#160;not settle any such claim without the indemnifying Party&#8217;s written consent, which shall not be unreasonably withheld, conditioned or delayed.  The indemnifying Party shall keep the indemnified Party informed at all times as to the status of its efforts.  The indemnifying Party shall not settle any such claim without the prior written consent of the indemnified Party, which shall not be unreasonably withheld, conditioned or delayed, unless (x) such settlement includes an unconditional release of the indemnified Party from all liability arising out of such claim, (y) does not contain any admission or statement suggesting any wrongdoing or liability on behalf of the indemnified Party and (z) does not contain any equitable order, judgment or term that in any manner affects, restrains or interferes with the business of the indemnified Party.  The indemnified Party may participate in proceedings relating to any indemnified claim with counsel of its own choosing at its own expense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.34pt">Insurance. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> During the Term and for a reasonable period of time thereafter, each Party or its Affiliates shall maintain appropriate product liability insurance with respect to any clinical trials, Manufacture, development, sales, marketing, distribution and promotion activities performed by such Party hereunder.  Each Party shall furnish the other Party, upon the other Party&#8217;s request, with a certificate of insurance evidencing coverage under the foregoing policies of insurance, along with any amendments and revisions thereto.  PARI shall be (i) named as an additional insured on any such policies maintained hereunder by INSMED, and (ii) also added by endorsement on such policies.  With respect to the United States, INSMED shall be (i) named as an additional insured on any such policy maintained hereunder by PARI&#8217;s Affiliate, PRE Holding, Inc., and (ii) also added by endorsement on such policies of PRE Holding, Inc.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XI.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:13.68pt">Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY UNDER ANY CIRCUMSTANCES OR ANY LEGAL OR EQUITABLE THEORY, WHETHER IN CONTRACT, STRICT LIABILITY OR OTHERWISE, FOR ANY INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR DAMAGES FOR LOST PROFITS ARISING OUT OF OR RELATED TO THIS AGREEMENT, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.  THESE LIMITATIONS SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OR ANY LIMITED REMEDY. THE LIMITATION OF THIS SECTION 11.5 SHALL NOT APPLY, HOWEVER, TO A PARTY&#8217;S INDEMNIFICATION OBLIGATIONS FOR THIRD PARTY CLAIMS </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">30</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 11.1 OF THIS AGREEMENT, OR TO A PARTY&#8217;S MATERIAL BREACH OF ITS OBLIGATIONS UNDER ARTICLE 10.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE XII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:32.38pt"><br>TERM</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XII.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.02pt">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall become effective upon the Effective Date and unless earlier terminated pursuant to Section 12.2 below shall remain in full force and effect until fifteen (15) years from First Commercial Sale, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided that INSMED may extend the Term of the Agreement for an additional five (5) years by providing written notice thereof to PARI at least one (1) year prior to the expiration of the Initial Term (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Renewal Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and the Initial Term plus any Renewal Term, collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Parties acknowledge and agree that if INSMED elects to extend the Term of the Agreement for the Renewal Term, then INSMED shall be responsible for paying PARI royalties on Net Sales of the Drug Product (as such terms are defined in the License Agreement) in accordance with Article 6 of the License Agreement until expiration of the Renewal Term (unless terminated earlier pursuant to Section 12.2 below).  In addition, notwithstanding anything to the contrary in the License Agreement or this Agreement, (x) the Royalty Term (as defined in the License Agreement) shall automatically be extended for the entire duration of the Term of this Agreement, and (y) the provisions of Article 6 of the License Agreement shall survive the termination or expiration of the License Agreement if this Agreement remains in effect after the expiration or termination of the License Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XII.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.02pt">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">For Convenience.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  This Agreement may be terminated by INSMED at any time upon prior written notice to PARI if INSMED terminates the License Agreement in accordance with the provisions of Section 15.3 of the License Agreement&#59; provided, that INSMED shall provide PARI with written notice of its intent to terminate this Agreement if PARI does not cure its default under the License Agreement concurrent with the written notice of default provided to PARI pursuant to Section 15.3 of the License Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">By Mutual Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be terminated at any time upon the mutual written agreement of the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">For Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be terminated by either Party in the event the other Party files an application for commencement of bankruptcy, civil rehabilitation, corporate reorganization, corporate liquidation or special liquidation procedures, or any mailing of order or notice of attachment or provisional attachment on any assets of such other Party, or any other insolvency.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">For Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If a Party is in material breach of this Agreement, then the non-breaching Party may deliver notice of such material breach to the other Party.  For all material breaches other than a failure to make a payment set forth in this Agreement, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">31</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">breaching Party shall have &#91;***&#93; days to cure such material breach from the receipt of the notice or to dispute.  With respect to any failure to make a payment set forth in this Agreement, the breaching Party shall have &#91;***&#93; days from the receipt of the notice to dispute or cure such non-payment.  If the Party receiving notice of material breach or failure to make a payment fails to cure, or fails to dispute, that material breach or failure to make a payment within the applicable period set forth above, then the non-breaching Party may terminate this Agreement immediately on written notice of termination.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XII.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.02pt">No Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The termination or expiration of this Agreement, as the case may be, shall not act as a waiver of any breach of this Agreement and shall not act as a release of either Party from any liability or obligation incurred under this Agreement through the date of such termination or expiration, including payments due PARI pursuant to this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XII.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.02pt">Consequences of Expiration and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Supply Following Expiration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  At INSMED&#8217;s request, prior to the expiration of this Agreement under Section 12.1 above, the parties shall meet and discuss in good faith a new agreement, containing commercially reasonable, arms-length terms, pursuant to which PARI and its Affiliates may make, have made, import and export PARI Products to INSMED following the expiration of this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Reimbursement of Safety Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If INSMED terminates this Agreement pursuant to Section 12.2(a), then INSMED shall reimburse PARI no later than &#91;***&#93; Business Days after the effective date of termination of this Agreement for all reasonable costs related to the remaining Safety Stock, other PARI Products manufactured and raw material &#47; unfinished goods specific for the Device by PARI pursuant to Purchase Orders submitted by INSMED in accordance with this Agreement that, in each case, cannot be reallocated or reused by PARI through PARI&#8217;s use of commercially reasonable efforts to do so. Any PARI Products that INSMED reimburses PARI for pursuant to this Section 12.4(b) shall be promptly delivered to INSMED in accordance with the provisions of Section 7.2. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Rights in Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All rights and licenses granted under this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code, licenses of a right to &#8220;intellectual property&#8221; as defined under Section 101(60) of the United States Bankruptcy Code.  Each Party, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the United States Bankruptcy Code in the event of the commencement of a bankruptcy proceeding by or against the licensor Party under the United States Bankruptcy Code, including without limitation the right to treat this Agreement or any agreement supplementary to this Agreement as terminated or to retain its rights under this Agreement or any agreement supplementary to this Agreement.  In the event that the licensee Party elects to retain its rights under this Agreement or any agreement supplementary to this Agreement, the licensor Party shall provide to the licensee Party, within &#91;***&#93; calendar days after written notice by the licensee Party to the licensor Party in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">32</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">accordance with Section 13.1 of this Agreement, all intellectual property and all embodiments of such intellectual property within the possession or Control of the licensor Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Sections 4.2, 4.3, 6.5(c)(v), 8.2, 8.3, 8.4, and 12.4, and Articles 1, 10, 11 (with respect to any Claim that is attributable to any cause that occurs under this Agreement prior to its expiration or termination, as applicable) and 13 of this Agreement shall survive expiration or termination of this Agreement for any reason.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ARTICLE XIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.72pt"><br>MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XIII.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.36pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All notices and other communications given hereunder shall be in writing and shall be deemed to have been delivered and received (a) when personally delivered, (b) on the &#91;***&#93; Business Day after which sent by registered or certified mail, postage prepaid, return receipt requested, (c) on the date on which transmitted by facsimile or other electronic means generating a receipt evidencing a successful transmission (provided that, on that same date, a copy of such notice is sent by registered or certified mail, postage prepaid, return receipt requested), or (d) on the &#91;***&#93; Business Day after the Business Day on which deposited with a regulated public carrier (e.g., Federal Express) for overnight delivery (receipt verified), freight prepaid, addressed to the Party for whom intended at the mailing address or facsimile number set forth below, or such other mailing address or facsimile number, notice of which is given in a manner permitted by this Section 13.1&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.75pt">If to PARI to&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PARI Pharma GmbH</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Moosstrasse 3 </font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">D-82319 Starnberg, Germany</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; &#91;***&#93;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; President</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Telefax No.&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with a copy to&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">McGuireWoods LLP</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">One James Center</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">901 East Cary Street</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Richmond, Virginia 23219</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; &#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Telefax No.&#58; &#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">33</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If to INSMED to&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insmed Incorporated</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10 Finderne Avenue, Building 10 </font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Bridgewater, NJ&#160; 08807-3365 </font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Chief Commercial Officer</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Telefax No.&#58; &#91;***&#93;</font><font style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with a copy to&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insmed Incorporated</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10 Finderne Avenue, Building 10 </font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Bridgewater, NJ&#160; 08807-3365 </font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58;  General Counsel</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Telefax No.&#58; &#91;***&#93;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any Party may by such notice change the address to which notice or other communications to it are to be delivered or mailed.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XIII.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.36pt">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No failure or omission by either Party in the performance of any obligation under this Agreement shall be deemed a breach of this Agreement or create any liability if the same shall arise from any cause or causes beyond the control of such Party including, but not limited to, the following which, for the purposes of this Agreement, shall be regarded as beyond the control of the Party in question&#58; (a) any act or omission of any government&#59; (b) any future rule, regulation or order issued by any governmental authority or by any officer, department, agency, or instrumentality thereof which makes such performance impossible or commercially unreasonable&#59; or (c) any Act of God, fire, storm, flood, earthquake, accident, war, terrorism, rebellion, insurrection, riot, invasion, strike, and lockout.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XIII.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.36pt">Relationship of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In making and performing this Agreement, the Parties are acting, and intend to be treated, as independent entities and nothing contained in this Agreement shall be construed or implied to create an agency, partnership, joint venture, or employer and employee relationship between or among any of the Parties.  Except as otherwise provided herein, no Party may make any representation, warranty or commitment, whether express or implied, on behalf of or incur any charges or expenses for or in the name of any other Party.  No Party shall be liable for the act of any other party unless such act is expressly authorized in writing by such Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XIII.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.36pt">Choice of Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement, originally written in the English language, shall be governed by the English language.  In the event any dispute arises with respect to this Agreement, the meanings of all terms and provisions of this Agreement shall be interpreted in their original English form.  The governing language of all correspondence related to reporting, negotiation, disputes, arbitration and notice requirements shall be the English </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">34</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">language.  The Parties shall bear their own expenses for having text or other communications translated into the English language.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XIII.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.36pt">Waivers and Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be amended or modified, and the terms and conditions hereof may be waived, only by a written instrument signed by the Parties hereto or, in the case of a waiver, by the Party waiving compliance.  No delay on the part of any Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any waiver on the part of any Party of any right, power or privilege hereunder, nor any total or partial exercise of any other right, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, power or privilege hereunder.  The rights and remedies herein provided are cumulative and are not exclusive of other rights or remedies which any Party may otherwise have.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XIII.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.36pt">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement shall not be assignable by either Party without the prior written consent of the other Party, which consent shall not be unreasonably withheld, delayed or conditioned, except that without consent either Party may assign or transfer the rights and obligations of this Agreement to any Affiliate or to any successor in interest in connection with any merger, consolidation, or sale of all or substantially all of the assets to which this Agreement relates&#59; provided, however, that (a) such assignment or transfer by INSMED to a PARI Competitor shall require the prior written consent of PARI&#59; and (b) in the event of any such assignment or transfer by INSMED to &#91;***&#93; or any of its subsidiaries (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (i) notwithstanding the provisions of Section 6.5(c)(v), in the event &#91;***&#93; is entitled to obtain supply of PARI Products from an Alternative Supplier in accordance with Section 6.5(c)(v), PARI shall grant the Back-Up License in accordance therewith (including in accordance with the terms and conditions of this Agreement and the License Agreement) and perform the technology transfer of the Data for Manufacture  in accordance with 6.5(c)(v) to a Third Party reasonably acceptable to &#91;***&#93; and shall not be obligated to grant such Back-Up License or provide such Data directly to &#91;***&#93;.  This Agreement shall inure to the benefit of and be binding upon the Parties hereto and their respective successors and permitted assigns.  Any assignment in contravention of the foregoing shall be null and void.  The Parties acknowledge and agree that, notwithstanding anything to the contrary in the License Agreement, INSMED may also assign the License Agreement to &#91;***&#93; if this Agreement is assigned to &#91;***&#93; in any instance permitted under this Section 13.6.</font></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%">XIII.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:135%;padding-left:4.36pt">Choice of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:135%">. This Agreement is construed in accordance with, and its performance is governed by, the laws of State of New York, excluding its or any other jurisdiction&#8217;s choice of law principles.  In the event of any conflict between US and foreign laws, regulations and rules, US laws, regulations and rules shall govern.  The UN Convention on contracts for the International Sale of Goods shall not apply to this Agreement. Any dispute arising hereunder shall be brought exclusively in the state or federal courts located in the State of New York in the division of Manhattan. The Parties hereby consent to the exclusive jurisdiction and venue of such courts and waive any objections to the jurisdiction and venue thereof. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">35</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XIII.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.36pt">Disputes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> PARI and INSMED shall endeavor to resolve any claim or controversy arising out of the threatened breach, breach, enforcement, interpretation, termination or validity of this Agreement informally by good faith negotiation between the senior executives, officers or management of PARI and INSMED. Either Party may give the other Party written notice of any claim or controversy not resolved in the normal course of business (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#34;Disputing Party Notice&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">). Within &#91;***&#93; calendar days after the delivery of the Disputing Party Notice, the receiving Party shall submit to the other Patty a written response (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#34;Response&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">). The Disputing Party Notice and Response shall include a statement of each Party's position and a summary of the arguments supporting that position. Within &#91;***&#93; days after the Disputing Party Notice, such designated senior executives, officers or management of PARI and INSMED shall meet at a mutually acceptable time and place and thereafter as often as they reasonably deem necessary to attempt to resolve the claim or controversy. All negotiations pursuant to this Section 13.8 are confidential and without prejudice and shall be treated as compromise and settlement negotiations for purposes of applicable rules of evidence. Any claim or controversy unresolved after application of this Section 13.8 shall be subject to Section 13.7 of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XIII.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:4.36pt">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement and the License Agreement contain the entire understanding of the Parties hereto with respect to the subject matter contained herein and supersede and cancel all prior agreements, negotiations, correspondence, undertakings and communications among the Parties, oral or written, with respect to such subject matter.  The License Agreement shall remain in full force and effect except for those provisions that are inconsistent with the terms and conditions under this Agreement, in which event the terms and conditions under this Agreement shall control.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XIII.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:34.36pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Both Parties hereby expressly state that it is the intention of neither Party to violate any law.  If any of the provisions of this Agreement are held to be void or unenforceable, then such void or unenforceable provisions shall be replaced by valid and enforceable provisions which will achieve as far as possible the economic business intentions of the Parties. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XIII.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:34.36pt">Section Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The section headings contained in this Agreement are for the purpose of convenience and are not intended to define or limit the contents of such sections.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XIII.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:34.36pt">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon the reasonable request of either Party, the other Party shall execute any additional certificates or other documents that may be reasonably necessary to fully implement this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XIII.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:34.36pt">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be signed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  This Agreement may be executed in one or more counterparts, each of which shall be an original, but taken together constituting one and the same instrument.  Execution of a facsimile copy or in Adobe&#8482; Portable Document Format (PDF) sent by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">36</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">electronic mail shall have the same force and effect as execution of an original, and a facsimile or PDF signature shall be deemed an original and valid signature.</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;SIGNATURES APPEAR ON THE NEXT PAGE&#93;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">37</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:96.48pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, each Party hereto has executed or caused this Agreement to be executed on its behalf as of the Effective Date.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">PARI PHARMA GMBH</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Dr. Martin Knoch&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;Dr. Martin Knoch</font></div><div style="padding-left:216pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;President</font></div><div style="padding-left:216pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED</font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; William H. Lewis&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;William H. Lewis</font></div><div style="padding-left:216pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;CEO &#38; President</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">38</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><div id="i6322a47f8f104c34abb99d4dc273576f_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">EXHIBIT A</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">Device</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The &#8220;Device&#8221; comprises of the following components&#58; </font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">Specifications of the Device&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;padding-left:14.01pt">&#91;***&#93; (&#91;***&#93;)&#58; &#91;***&#93; to &#91;***&#93;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;padding-left:14.01pt">&#91;***&#93; (&#91;***&#93;)&#58;  &#91;***&#93;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%;padding-left:14.01pt">&#91;***&#93;&#58; &#91;***&#93; (&#91;***&#93;) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">For clarity, Device does not mean&#58; the &#91;***&#93;, the &#91;***&#93;, the &#91;***&#93; or the &#91;***&#93;.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Nebulizer Handset</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">The &#8220;Nebulizer Handset&#8221; comprises of the following components&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">EXHIBIT B</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">PARI Competitors</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event of a merger, consolidation, sale of all or substantially all of the assets or business or other change of control involving the above entities (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Original Competitors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), such Original Competitor listed above shall be replaced with the successor thereof that is continuing to engage in the business of developing and&#47;or commercializing nebulizers.  However, if the merger or acquisition partner had separate lines of business, divisions or operations prior to such change of control, whether or not relating to nebulizers, the merger or acquisition partner shall be deemed a PARI Competitor only to the extent it is continuing the business of the Original Competitor, and not with respect to any such separate lines of business, divisions or operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, PARI Competitors shall include any subsidiary that is formed by the Original Competitors, but shall not include any subsidiaries acquired by the Original Competitors if such subsidiaries had separate lines of business, divisions or operations prior to such acquisition, whether or not relating to nebulizers.  However, PARI Competitors shall include such subsidiaries to the extent such subsidiaries continue the lines of business, divisions or operations of the Original Competitors relating to nebulizers.</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div><div id="i6322a47f8f104c34abb99d4dc273576f_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">EXHIBIT C</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">Patents</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">PARI Patents and Patent Applications</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">&#91;***&#93;</font></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Application number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filing date</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issue date</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#91;***&#93;</font></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Application number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filing date</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issue date</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#91;***&#93;</font></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Application number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filing date</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issue date</font></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">&#91;***&#93;</font></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Application number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filing date</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issue date</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#91;***&#93;</font></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Application number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filing date</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issue date</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#91;***&#93;</font></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Application number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filing date</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issue date</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#91;***&#93;</font></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Application number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filing date</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issue date</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.045%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.516%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Application number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filing date</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issue date</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#91;***&#93;</font></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.118%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Application number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filing date</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issue date</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#91;***&#93;</font></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Application number</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication number</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filing date</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent number</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issue date</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.294%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.041%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.202%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Application number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filing date</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issue date</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.294%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.041%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.202%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Application number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filing date</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issue date</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:2pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Additional Patents and Patent Applications from Insmed (with PARI Know How)&#58;</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">&#91;***&#93;</font></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.202%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Application number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filing date</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issue date</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#91;***&#93;</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Patents licensed from &#91;***&#93;&#58;</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">&#91;***&#93;</font></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Application number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filing date</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issue date</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#91;***&#93;</font></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Application number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filing date</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issue date</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#91;***&#93;</font></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Application number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filing date</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issue date</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#91;***&#93;</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Patents licensed from &#91;***&#93;&#58;</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">&#91;***&#93;</font></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#91;***&#93;</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Patents licensed from &#91;***&#93; (non-exclusive)&#58;</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">&#91;***&#93;</font></div><div style="padding-left:5.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Application number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Publication number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Filing date</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Patent number</font></td><td colspan="3" style="border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Issue date</font></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT D</font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Representatives of the JSC</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Joint Steering Committee</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PARI&#58; &#91;***&#93; and &#91;***&#93;</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INSMED&#58;  &#91;***&#93; and &#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div><div id="i6322a47f8f104c34abb99d4dc273576f_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT E</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">Effective Date Exchange Rate</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">&#91;***&#93; EUR &#61; &#91;***&#93; USD</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div><div id="i6322a47f8f104c34abb99d4dc273576f_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">EXHIBIT F</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">Quality Agreements</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;To be agreed to by the Parties in writing and attached hereto after the Effective Date as set forth in Section 6.1.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div><div id="i6322a47f8f104c34abb99d4dc273576f_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT G</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRIPS Priority Watch List</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div><div id="i6322a47f8f104c34abb99d4dc273576f_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT H</font></div><div style="margin-bottom:36pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Trademarks</font></div><div style="margin-bottom:30pt;padding-left:31.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">PARI Marks&#58;</font></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">1.  &#91;***&#93;</font></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div><div id="i6322a47f8f104c34abb99d4dc273576f_22"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">INSMED Marks&#58; </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:2pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:3.35pt;padding-right:3.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:232%">MARK</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:3.35pt;padding-right:3.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:232%">Owner</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">COUNTRY</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:2pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:3.35pt;padding-right:3.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:232%">APPLICATION&#47;</font></div><div style="padding-left:3.35pt;padding-right:3.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:232%">REGISTRATION</font></div><div style="margin-bottom:6pt;padding-left:3.35pt;padding-right:3.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:232%">NO.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GOODS</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:2pt double #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">STATUS</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:2pt double #000000;border-left:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:2pt double #000000;border-left:0.5pt solid #000000;border-right:2pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div><div id="i6322a47f8f104c34abb99d4dc273576f_25"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:11.25pt;padding-right:11.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">EXHIBIT I</font></div><div style="margin-bottom:6pt;padding-left:11.25pt;padding-right:11.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">Price </font></div><div style="margin-bottom:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">1. Price</font></div><div style="padding-left:35.05pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:44.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prices for &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prices for &#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prices for &#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for each unit of &#91;***&#93; </font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">*</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for each unit of &#91;***&#93; </font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91;***&#93;* </font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Euro &#160;&#160;&#91;***&#93;* </font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Euro &#160;&#160;&#91;***&#93;*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for each unit of &#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91;***&#93; </font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Euro &#91;***&#93; </font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">*</font></div></td></tr></table></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">* Price includes &#91;***&#93;</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">2. &#91;***&#93;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#91;***&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">58272594_1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:232%">EAST&#92;84442498.1</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5 1
<SEQUENCE>10
<FILENAME>insm029240630ex1051.htm
<DESCRIPTION>EX-10.5 1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ib2b33127c562401b9d9e08aab85ac402_1"></div><div style="min-height:110.88pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by &#91;***&#93;) has been omitted from Exhibit 10.5.1 because it (i) is not material and (ii) is the type of information the Company both customarily and actually treats as private or confidential.</font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.5.1</font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDMENT NO. 1<br>TO COMMERCIALIZATION AGREEMENT BETWEEN<br>INSMED INCORPORATED AND PARI PHARMA GMBH</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This first amendment (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment No. 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) effective 21 July 2017 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment No. 1 Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the Commercialization Agreement dated and effective the 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of July 2014 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) between PARI Pharma GmbH, a German corporation with a principal place of business at Moosstrasse 3, D-82319 Starnberg, Germany (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PARI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Insmed Incorporated, a Virginia corporation with a principal place of business at 10 Finderne Avenue, Building 10, Bridgewater, NJ&#160; 08807-3365 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Insmed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), is entered into between PARI and Insmed.  PARI and Insmed shall be referred to collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;. </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Parties now desire to amend the terms and conditions of the Agreement to reflect certain business discussions between the Parties.</font></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the recitals set forth above, the mutual covenants, terms and conditions set forth below, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows&#58; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Definitions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Capitalized terms used but not defined in this Amendment No. 1 shall have the meanings ascribed to them in the Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Section 1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall be deleted and replaced as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.14 &#8220;&#91;***&#93;&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean a unit of Device which comprises of &#91;***&#93;.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Section 4.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Section 4.3(c) of the Agreement is hereby amended by adding the following at the end of such subsection&#58; &#8220;If there are material changes in the applicable tax laws during the Term, the parties shall negotiate in good faith to determine whether any amendments are required to the terms of this Agreement&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Section 6.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Section 6.1 of the Agreement is hereby amended by deleting &#8220;Within &#91;***&#93; days from the Effective Date&#8221; and replacing it with &#8220;Prior to the first MAA submission&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Section 6.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Section 6.2 of the Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forecasts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to Section 6.3 with respect to the Initial Purchase Order, no less than &#91;***&#93; months (for the United States) or &#91;***&#93; months (for any major market such as the EU or Japan other than the United States) prior to the earliest anticipated delivery date of the Initial Purchase Order and thereafter on a quarterly basis during the Term, at least &#91;***&#93; days before the end of each calendar quarter, INSMED shall provide PARI with its good faith, reasonable written projections (broken down by Devices, &#91;***&#93; and &#91;***&#93;) of the anticipated total market requirements of PARI Products for each major market (such as the United States, the EU </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:110.88pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.5.1</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">or Japan) in the INSMED Territory (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forecast</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), on a &#91;***&#93; basis during the &#91;***&#93; month period immediately following (i) the calendar quarter in which such projection is issued or (ii) in case of the first Forecast for the First Commercial Sale in each major market (such as the EU or Japan). The forecasted quantities of PARI Products set forth in each Forecast for (i) the first &#91;***&#93; month period in such Forecast are binding and (ii)&#160;&#91;***&#93; in such Forecast are non-binding, good faith estimates provided solely to assist PARI in its production planning.   All Forecasts shall be deemed INSMED Confidential Information. PARI shall use commercially reasonable efforts to commence scale-up activities to transition from clinical supply to commercial supply based on INSMED&#8217;s Forecasts which shall be reasonably explained by INSMED to PARI.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Section 6.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The first sentence of Section 6.3 is hereby deleted and replaced as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:28.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No later than &#91;***&#93; months (for the United States) or &#91;***&#93; months (for each major market such as the EU or Japan other than the United States) prior to the earliest anticipated delivery date of the Initial Purchase Order, INSMED shall provide PARI with a purchase order for a quantity by item number of PARI Products needed for initial supply of INSMED Product and PARI Products in the respective major market (such as the United States, the EU or Japan) (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Initial Purchase Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  For the Initial Purchase Order for the United States, PARI shall deliver (i) at least &#91;***&#93; of the quantity ordered in the Initial Purchase Order within &#91;***&#93; months of the Initial Purchase Order, (ii) at least &#91;***&#93; of the quantity ordered in the Initial Purchase Order within &#91;***&#93; months, of the Initial Purchase Order and (iii) the remaining &#91;***&#93; shall be delivered within &#91;***&#93; months of the Initial Purchase Order. The Parties agree that the above-mentioned lead times for the Initial Purchase Order are based on an assumed demand of aerosol heads in the Initial Purchase Order for the United States which does not exceed &#91;***&#93; aerosol heads in aggregate. In case the actual amount of aerosol heads in the Initial Purchase Order for the United States exceeds &#91;***&#93; aerosol heads in aggregate the Parties will discuss in good faith an adapted delivery.&#8221;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:28.5pt">7.&#160;&#160;&#160;&#160;Section 6.4. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.4 (a) is hereby amended by deleting in the third sentence &#8220;that no such Purchase Order shall have a shipment date prior to the &#91;***&#93; day following the date of receipt by PARI of the Initial Purchase Order&#8221; and replacing it by &#8220;that no such Purchase Order shall have a shipment date prior to the earliest anticipated delivery date of the Initial Purchase Order and further provided that the quantities of PARI Products stipulated in an Purchase Order for delivery in the first &#91;***&#93; months after the First Commercial Sale in a major market (such as the EU or Japan) do not exceed the quantities of PARI Products stipulated in the first Forecast which is provided to PARI at least &#91;***&#93; months for the United States and &#91;***&#93; months for other major markets (such as the EU or Japan) prior to the earliest anticipated delivery date of the Initial Purchase Order&#8221; so that such third sentence of Section 6.4 (a) reads&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:32.46pt">&#8220;PARI shall ship the quantity of PARI Products specified in each Purchase Order no less than &#91;***&#93; days after the date and confirmation of such Purchase Order by PARI, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:110.88pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.5.1</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">unless otherwise agreed to by PARI and INSMED&#59; provided, however, that no such Purchase Order shall have a shipment date prior to the earliest anticipated delivery date of the Initial Purchase Order and further provided that the quantities of PARI Products stipulated in a Purchase Order for delivery in the first &#91;***&#93; months after the First Commercial Sale in a major market (such as the EU or Japan) do not exceed the quantities of PARI Products stipulated in the first Forecast which is provided to PARI at least &#91;***&#93; months for the United States and &#91;***&#93; months for other major markets (such as the EU or Japan) prior to the earliest anticipated delivery date of the Initial Purchase Order.&#8221; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Exhibit D. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Exhibit D to the Agreement is hereby amended by deleting it in its entirety and replacing it with Exhibit D attached hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Exhibit E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Exhibit E to the Agreement is hereby amended by deleting &#8220;&#91;***&#93;&#8221; and replacing it with &#8220;&#91;***&#93;&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Exhibit I.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit I to the Agreement is hereby amended by deleting it in its entirety and replacing it with Exhibit I attached hereto. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Miscellaneous.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Upon execution, this Amendment No. 1 shall be made part of the Agreement and shall be incorporated therein by reference.  Except as provided herein, all other terms and conditions of the Agreement shall remain in full force and effect.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties have executed this Amendment No. 1 as of the Amendment No. 1 Effective Date indicated above. </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Insmed Incorporated&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;PARI Pharma GmbH</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">  &#47;s&#47; William H. Lewis&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">  &#47;s&#47; Martin Knoch&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; William H. Lewis&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; Dr. Martin Knoch&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; CEO &#38; President&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58; President</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; 25-Jul-2017&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date&#58; 28&#47;07&#47;2017</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:110.88pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.5.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT D</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Representatives of the JSC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Joint Steering Committee</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PARI&#58;  &#91;***&#93;, &#91;***&#93; and &#91;***&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INSMED&#58; &#91;***&#93;, &#91;***&#93; and &#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:110.88pt;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.5.1</font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT I</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Price</font></div><div style="margin-bottom:12pt;padding-left:22.5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1. United States&#47;Canada Price</font></div><div style="padding-left:35.05pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.660%"><tr><td style="width:1.0%"></td><td style="width:69.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Description</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prices for United</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> States and Canada</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for each unit &#91;***&#93;*</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">See table below</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for each unit of &#91;***&#93; </font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The price for each &#91;***&#93; shall be determined as follows&#58;</font></div><div style="padding-left:38.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:73.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.250%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Number of &#91;***&#93; Purchased in a Calendar Year</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Price&#47;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#91;***&#93;*</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;-&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;-&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93; and over</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">* &#91;***&#93;.</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:36pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.  EU&#47;ROW Price.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Prices for EU and ROW markets shall be negotiated in good faith and set forth in the applicable Territory-Specific Appendix. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:10.00pt"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>11
<FILENAME>insm-20240630ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3b96095785a24e1caa0ac2df1a70837c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 Certification</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, William H. Lewis, Chief Executive Officer of Insmed Incorporated, certify that&#58;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) I have reviewed this quarterly report on Form 10-Q of Insmed Incorporated&#59;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Date&#58;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">August&#160;8, 2024</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                                                                                                            &#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; William H. Lewis</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William H. Lewis</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>12
<FILENAME>insm-20240630ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ia934cf5565864eeeb3e8826a17bde0c4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 Certification</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sara Bonstein, Chief Financial Officer of Insmed Incorporated, certify that&#58;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) I have reviewed this quarterly report on Form 10-Q of Insmed Incorporated&#59;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;August&#160;8, 2024</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                  </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sara Bonstein</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sara Bonstein</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>13
<FILENAME>insm-20240630ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i1bc4b1ccb39245148b9498b34f125cf4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2003</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this Quarterly Report on Form 10-Q of Insmed Incorporated (the &#34;Company&#34;) for the period ended June&#160;30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), I, William H. Lewis, Chief Executive Officer of the Company, certify, pursuant to 18 USC. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2003, that&#58;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                                                                                                    </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                                                                                                      &#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; William H. Lewis</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William H. Lewis</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August&#160;8, 2024</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Insmed Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>14
<FILENAME>insm-20240630ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id64da06899d242efaee1920e6f2cb12d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;32.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2003</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this Quarterly Report on Form 10-Q of Insmed Incorporated (the &#34;Company&#34;) for the period ended June&#160;30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), I, Sara Bonstein, Chief Financial Officer of the Company, certify, pursuant to 18 USC. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2003, that&#58;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)  the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)  the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                                                                                                      &#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sara Bonstein</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sara Bonstein</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August&#160;8, 2024</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Insmed Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>insm-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c55c6bb2-e1ff-4fc1-8df4-decd904b3b6b,g:5264b7b4-c672-47ab-b9d7-1b1bb5962c46-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:insm="http://www.insmed.com/20240630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.insmed.com/20240630">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.insmed.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossunaudited" roleURI="http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited">
        <link:definition>9952153 - Statement - Consolidated Statements of Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquityDeficitunaudited" roleURI="http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited">
        <link:definition>9952154 - Statement - Consolidated Statements of Shareholders' Equity (Deficit) (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsunaudited" roleURI="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited">
        <link:definition>9952155 - Statement - Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompanyandBasisofPresentation" roleURI="http://www.insmed.com/role/TheCompanyandBasisofPresentation">
        <link:definition>9952156 - Disclosure - The Company and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.insmed.com/role/FairValueMeasurements">
        <link:definition>9952158 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenuesNet" roleURI="http://www.insmed.com/role/ProductRevenuesNet">
        <link:definition>9952159 - Disclosure - Product Revenues, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.insmed.com/role/Inventory">
        <link:definition>9952160 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesNetandGoodwill" roleURI="http://www.insmed.com/role/IntangiblesNetandGoodwill">
        <link:definition>9952161 - Disclosure - Intangibles, Net and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsNet" roleURI="http://www.insmed.com/role/FixedAssetsNet">
        <link:definition>9952162 - Disclosure - Fixed Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilities" roleURI="http://www.insmed.com/role/AccountsPayableandAccruedLiabilities">
        <link:definition>9952163 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.insmed.com/role/Leases">
        <link:definition>9952164 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.insmed.com/role/Debt">
        <link:definition>9952165 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyFinancingAgreement" roleURI="http://www.insmed.com/role/RoyaltyFinancingAgreement">
        <link:definition>9952166 - Disclosure - Royalty Financing Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.insmed.com/role/ShareholdersEquity">
        <link:definition>9952167 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.insmed.com/role/StockBasedCompensation">
        <link:definition>9952168 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.insmed.com/role/IncomeTaxes">
        <link:definition>9952169 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.insmed.com/role/CommitmentsandContingencies">
        <link:definition>9952170 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.insmed.com/role/Acquisitions">
        <link:definition>9952171 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.insmed.com/role/SubsequentEvents">
        <link:definition>9952172 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.insmed.com/role/FairValueMeasurementsTables">
        <link:definition>9954473 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenuesNetTables" roleURI="http://www.insmed.com/role/ProductRevenuesNetTables">
        <link:definition>9954474 - Disclosure - Product Revenues, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.insmed.com/role/InventoryTables">
        <link:definition>9954475 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesNetandGoodwillTables" roleURI="http://www.insmed.com/role/IntangiblesNetandGoodwillTables">
        <link:definition>9954476 - Disclosure - Intangibles, Net and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsNetTables" roleURI="http://www.insmed.com/role/FixedAssetsNetTables">
        <link:definition>9954477 - Disclosure - Fixed Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesTables" roleURI="http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesTables">
        <link:definition>9954478 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.insmed.com/role/LeasesTables">
        <link:definition>9954479 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.insmed.com/role/DebtTables">
        <link:definition>9954480 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyFinancingAgreementTables" roleURI="http://www.insmed.com/role/RoyaltyFinancingAgreementTables">
        <link:definition>9954481 - Disclosure - Royalty Financing Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.insmed.com/role/StockBasedCompensationTables">
        <link:definition>9954482 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.insmed.com/role/AcquisitionsTables">
        <link:definition>9954483 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompanyandBasisofPresentationDetails" roleURI="http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails">
        <link:definition>9954484 - Disclosure - The Company and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails">
        <link:definition>9954485 - Disclosure - Summary of Significant Accounting Policies - Schedule of Percentage of Gross Product Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9954486 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails">
        <link:definition>9954487 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of the Weighted Average Number of Common Shares Used to Compute Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails">
        <link:definition>9954488 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails" roleURI="http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails">
        <link:definition>9954489 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis and Carrying Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>9954490 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails" roleURI="http://www.insmed.com/role/FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails">
        <link:definition>9954491 - Disclosure - Fair Value Measurements - Schedule of Observable Inputs in Valuation of Deferred Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails" roleURI="http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails">
        <link:definition>9954492 - Disclosure - Fair Value Measurements - Schedule of Valuation of Development and Regulatory Milestones and Priority Review Voucher Milestone (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails" roleURI="http://www.insmed.com/role/FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails">
        <link:definition>9954493 - Disclosure - Fair Value Measurements - Schedule of Changes in Fair Value of Valuations for Deferred and Contingent Consideration Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenuesNetDetails" roleURI="http://www.insmed.com/role/ProductRevenuesNetDetails">
        <link:definition>9954494 - Disclosure - Product Revenues, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.insmed.com/role/InventoryDetails">
        <link:definition>9954495 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesNetandGoodwillNarrativeDetails" roleURI="http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails">
        <link:definition>9954496 - Disclosure - Intangibles, Net and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails" roleURI="http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails">
        <link:definition>9954497 - Disclosure - Intangibles, Net and Goodwill - Schedule of Rollforward of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsNetDetails" roleURI="http://www.insmed.com/role/FixedAssetsNetDetails">
        <link:definition>9954498 - Disclosure - Fixed Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesDetails" roleURI="http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails">
        <link:definition>9954499 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.insmed.com/role/LeasesNarrativeDetails">
        <link:definition>9954500 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofSupplementalNoncashDisclosuresDetails" roleURI="http://www.insmed.com/role/LeasesScheduleofSupplementalNoncashDisclosuresDetails">
        <link:definition>9954501 - Disclosure - Leases - Schedule of Supplemental Non-cash Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails" roleURI="http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails">
        <link:definition>9954502 - Disclosure - Debt - Schedule of Current Portion of Long-Term Debt and Debt, Long-Term (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.insmed.com/role/DebtNarrativeDetails">
        <link:definition>9954503 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails" roleURI="http://www.insmed.com/role/DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails">
        <link:definition>9954504 - Disclosure - Debt - Schedule of Carrying Value of Convertible Notes Balance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofCarryingValueofTermLoanBalanceDetails" roleURI="http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails">
        <link:definition>9954505 - Disclosure - Debt - Schedule of Carrying Value of Term Loan Balance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofFuturePrincipalRepaymentsofDebtDetails" roleURI="http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails">
        <link:definition>9954506 - Disclosure - Debt - Schedule of Future Principal Repayments of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails" roleURI="http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails">
        <link:definition>9954507 - Disclosure - Debt - Schedule of Interest Expense related to Debt and Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyFinancingAgreementNarrativeDetails" roleURI="http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails">
        <link:definition>9954508 - Disclosure - Royalty Financing Agreement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails" roleURI="http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails">
        <link:definition>9954509 - Disclosure - Royalty Financing Agreement - Schedule of Carrying Value of Royalty Financing Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDetails" roleURI="http://www.insmed.com/role/ShareholdersEquityDetails">
        <link:definition>9954510 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>9954511 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails" roleURI="http://www.insmed.com/role/StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails">
        <link:definition>9954512 - Disclosure - Stock-Based Compensation - Schedule of Aggregate Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.insmed.com/role/IncomeTaxesDetails">
        <link:definition>9954513 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.insmed.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9954514 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.insmed.com/role/AcquisitionsNarrativeDetails">
        <link:definition>9954515 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsScheduleofPurchasePriceDetails" roleURI="http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails">
        <link:definition>9954516 - Disclosure - Acquisitions - Schedule of Purchase Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.insmed.com/role/SubsequentEventsDetails">
        <link:definition>9954517 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="insm_VertuisBioIncMember" abstract="true" name="VertuisBioIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_AdrestiaTherapeuticsLtdMember" abstract="true" name="AdrestiaTherapeuticsLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_AccretionOfDebtDiscountMarketableSecurities" abstract="false" name="AccretionOfDebtDiscountMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_NoncashOperatingLeaseExpense" abstract="false" name="NoncashOperatingLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_NoncashAcquisitionRelatedExpense" abstract="false" name="NoncashAcquisitionRelatedExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_ProceedsFromCashAcquiredInAssetAcquisition" abstract="false" name="ProceedsFromCashAcquiredInAssetAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock" abstract="false" name="BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock" abstract="false" name="InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="insm_CustomerAMember" abstract="true" name="CustomerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_CustomerBMember" abstract="true" name="CustomerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_CustomerCMember" abstract="true" name="CustomerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_ScheduleofEarningsPerShareBasicandDilutedTable" abstract="true" name="ScheduleofEarningsPerShareBasicandDilutedTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" abstract="true" name="ScheduleofEarningsPerShareBasicandDilutedLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="insm_BusinessCombinationDeferredLiability" abstract="false" name="BusinessCombinationDeferredLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_MotusBiosciencesIncMember" abstract="true" name="MotusBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_AlgaeneXIncMember" abstract="true" name="AlgaeneXIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_MeasurementInputProbabilityOfSuccessMember" abstract="true" name="MeasurementInputProbabilityOfSuccessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member" abstract="true" name="ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" abstract="true" name="OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_DevelopmentAndRegulatoryMilestonesMember" abstract="true" name="DevelopmentAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_ARIKAYCEGlobalNetSalesMember" abstract="true" name="ARIKAYCEGlobalNetSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_BrensocatibGlobalNetSalesMember" abstract="true" name="BrensocatibGlobalNetSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" abstract="false" name="BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage" abstract="false" name="ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage" abstract="false" name="AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders" abstract="false" name="NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="insm_ProceedsFromRoyaltyFinancing" abstract="false" name="ProceedsFromRoyaltyFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_DebtInstrumentRoyaltyStatedPercentage" abstract="false" name="DebtInstrumentRoyaltyStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput" abstract="false" name="BusinessCombinationDeferredConsiderationLiabilityMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="insm_PriorityReviewVoucherMilestoneMember" abstract="true" name="PriorityReviewVoucherMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_EuropeAndTheRestOfTheWorldMember" abstract="true" name="EuropeAndTheRestOfTheWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_AcquiredResearchAndDevelopmentMember" abstract="true" name="AcquiredResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_ComputerHardwareAndSoftwareMember" abstract="true" name="ComputerHardwareAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_ManufacturingEquipmentMember" abstract="true" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_AccruedClinicalTrialExpenses" abstract="false" name="AccruedClinicalTrialExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_AccruedTechnicalOperationExpenses" abstract="false" name="AccruedTechnicalOperationExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_RevenueInterestPaymentsPayable" abstract="false" name="RevenueInterestPaymentsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_AccruedSalesAllowancesAndRelatedCosts" abstract="false" name="AccruedSalesAllowancesAndRelatedCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_BusinessCombinationDeferredPaymentsCurrent" abstract="false" name="BusinessCombinationDeferredPaymentsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_AccruedMilestonePaymentCurrent" abstract="false" name="AccruedMilestonePaymentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_LeaseRemainingLeaseTerm" abstract="false" name="LeaseRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="insm_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_RedemptionOfThe2025ConvertibleNotesMember" abstract="true" name="RedemptionOfThe2025ConvertibleNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_DebtInstrumentConversionTermAxis" abstract="true" name="DebtInstrumentConversionTermAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="insm_DebtInstrumentConversionTermDomain" abstract="true" name="DebtInstrumentConversionTermDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_DebtInstrumentConversionTermOneMember" abstract="true" name="DebtInstrumentConversionTermOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_DebtInstrumentConversionTermTwoMember" abstract="true" name="DebtInstrumentConversionTermTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_DebtInstrumentConversionTermThreeMember" abstract="true" name="DebtInstrumentConversionTermThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_DebtInstrumentConversionTermFourMember" abstract="true" name="DebtInstrumentConversionTermFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_DebtInstrumentOptionToPurchaseAdditionalDebt" abstract="false" name="DebtInstrumentOptionToPurchaseAdditionalDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" abstract="false" name="DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" abstract="false" name="ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="insm_DebtInstrumentRedemptionPricePerShare" abstract="false" name="DebtInstrumentRedemptionPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="insm_DebtInstrumentPercentOfInterestPayable" abstract="false" name="DebtInstrumentPercentOfInterestPayable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="insm_LongTermDebtMaturityAfterYearFourAndThereafter" abstract="false" name="LongTermDebtMaturityAfterYearFourAndThereafter" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_InterestExpenseExcludingFinanceLeaseInterestExpense" abstract="false" name="InterestExpenseExcludingFinanceLeaseInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_DebtInstrumentRoyaltyPayableMaximum" abstract="false" name="DebtInstrumentRoyaltyPayableMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="insm_ProceedsFromRoyaltyFinancingAgreementNet" abstract="false" name="ProceedsFromRoyaltyFinancingAgreementNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_RoyaltyFinancingAgreementRollForward" abstract="true" name="RoyaltyFinancingAgreementRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="insm_DebtIssuanceCostsOther" abstract="false" name="DebtIssuanceCostsOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_AtTheMarketAgreementMember" abstract="true" name="AtTheMarketAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_CommonStockAuthorizedAggregateGrossSalesProceeds" abstract="false" name="CommonStockAuthorizedAggregateGrossSalesProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_A2019IncentivePlanMember" abstract="true" name="A2019IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_A2019IncentivePlanThirdAmendmentMember" abstract="true" name="A2019IncentivePlanThirdAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_EmployeeStockPurchasePlan2018Member" abstract="true" name="EmployeeStockPurchasePlan2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="insm_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_TriggeringEventAxis" abstract="true" name="TriggeringEventAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="insm_TriggeringEventDomain" abstract="true" name="TriggeringEventDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_MilestoneEvent1Member" abstract="true" name="MilestoneEvent1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_MilestoneEvent2Member" abstract="true" name="MilestoneEvent2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_MotusBiosciencesIncAndAlgaeneXIncMember" abstract="true" name="MotusBiosciencesIncAndAlgaeneXIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" abstract="false" name="AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="insm_BusinessAcquisitionConsecutiveTradingDayPeriod" abstract="false" name="BusinessAcquisitionConsecutiveTradingDayPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="insm_A2025ConvertibleNotesMember" abstract="true" name="A2025ConvertibleNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_A2028ConvertibleNotesMember" abstract="true" name="A2028ConvertibleNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_S.NicoleSchaefferMember" abstract="true" name="S.NicoleSchaefferMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_S.NicoleSchaeffer2Member" abstract="true" name="S.NicoleSchaeffer2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_MartinaFlammerMember" abstract="true" name="MartinaFlammerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="insm_MichaelSmithMember" abstract="true" name="MichaelSmithMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>insm-20240630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c55c6bb2-e1ff-4fc1-8df4-decd904b3b6b,g:5264b7b4-c672-47ab-b9d7-1b1bb5962c46-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="insm-20240630.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_eea7c646-e087-4c69-9acb-cc0696ed7471" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fa74ac06-7339-4548-a7ef-636bb9bae1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_eea7c646-e087-4c69-9acb-cc0696ed7471" xlink:to="loc_us-gaap_Liabilities_fa74ac06-7339-4548-a7ef-636bb9bae1a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e58ad3ab-ae1f-48ce-8af6-48b97faa1f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_eea7c646-e087-4c69-9acb-cc0696ed7471" xlink:to="loc_us-gaap_StockholdersEquity_e58ad3ab-ae1f-48ce-8af6-48b97faa1f5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6909451f-29da-43ad-9275-3e0c20143b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1dc0f5e6-142e-497f-96fc-402b8c18e973" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6909451f-29da-43ad-9275-3e0c20143b2d" xlink:to="loc_us-gaap_LiabilitiesCurrent_1dc0f5e6-142e-497f-96fc-402b8c18e973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_da38d7c3-9acf-40d4-85fe-8b3ad4b78200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6909451f-29da-43ad-9275-3e0c20143b2d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_da38d7c3-9acf-40d4-85fe-8b3ad4b78200" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_550b1230-bc2d-4e88-a553-2ef429c99e24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6909451f-29da-43ad-9275-3e0c20143b2d" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_550b1230-bc2d-4e88-a553-2ef429c99e24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_14dd2d8a-d53b-4aa8-a8b2-70fbaafde6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6909451f-29da-43ad-9275-3e0c20143b2d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_14dd2d8a-d53b-4aa8-a8b2-70fbaafde6a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0538350b-33bc-4bea-aae8-6b5aaf2b4ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6909451f-29da-43ad-9275-3e0c20143b2d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0538350b-33bc-4bea-aae8-6b5aaf2b4ec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2c2dccd4-be37-4082-80ad-36cdfb9a36e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6909451f-29da-43ad-9275-3e0c20143b2d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2c2dccd4-be37-4082-80ad-36cdfb9a36e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_554402b6-dd34-4585-9575-b2def50d0bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6909451f-29da-43ad-9275-3e0c20143b2d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_554402b6-dd34-4585-9575-b2def50d0bd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_de6db912-254f-4c86-a3ec-6450ce55fa57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7a5e2888-e58e-4716-8b71-54b11f0c3611" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_de6db912-254f-4c86-a3ec-6450ce55fa57" xlink:to="loc_us-gaap_CommonStockValue_7a5e2888-e58e-4716-8b71-54b11f0c3611" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_760d7bcb-b2f5-4b51-8dc5-0b89e1591909" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_de6db912-254f-4c86-a3ec-6450ce55fa57" xlink:to="loc_us-gaap_AdditionalPaidInCapital_760d7bcb-b2f5-4b51-8dc5-0b89e1591909" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c3321c9a-69b3-4564-a764-4d8e0b2da495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_de6db912-254f-4c86-a3ec-6450ce55fa57" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c3321c9a-69b3-4564-a764-4d8e0b2da495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a69f9bcb-2339-4c5f-9a6e-e99db135cdde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_de6db912-254f-4c86-a3ec-6450ce55fa57" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a69f9bcb-2339-4c5f-9a6e-e99db135cdde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f795b923-85f2-4be8-8ebf-2eb935925862" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6085bf4a-52e7-4ee3-8bcf-d9e404c45a22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f795b923-85f2-4be8-8ebf-2eb935925862" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6085bf4a-52e7-4ee3-8bcf-d9e404c45a22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_6f785e65-a458-4d17-a2af-051123e42951" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f795b923-85f2-4be8-8ebf-2eb935925862" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_6f785e65-a458-4d17-a2af-051123e42951" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_90e9a8bc-beb6-47e6-80aa-f75388b275cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f795b923-85f2-4be8-8ebf-2eb935925862" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_90e9a8bc-beb6-47e6-80aa-f75388b275cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f0e12d50-7226-4006-a4d0-0a5908752176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f795b923-85f2-4be8-8ebf-2eb935925862" xlink:to="loc_us-gaap_InventoryNet_f0e12d50-7226-4006-a4d0-0a5908752176" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7802082-0148-45d5-8ff3-5a96d6cdfa10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f795b923-85f2-4be8-8ebf-2eb935925862" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7802082-0148-45d5-8ff3-5a96d6cdfa10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_799ca442-083e-45e6-9d91-788444827501" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_94899321-0dc1-4ff8-ba0b-34b6e0a08091" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_799ca442-083e-45e6-9d91-788444827501" xlink:to="loc_us-gaap_AssetsCurrent_94899321-0dc1-4ff8-ba0b-34b6e0a08091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fcd4515f-6c44-4aee-ac2d-ea4549d6dfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_799ca442-083e-45e6-9d91-788444827501" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fcd4515f-6c44-4aee-ac2d-ea4549d6dfc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_f3d38d4c-3d91-49c1-8c70-e3e80ed7ac21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_799ca442-083e-45e6-9d91-788444827501" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_f3d38d4c-3d91-49c1-8c70-e3e80ed7ac21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5133e41f-ff33-4459-a66f-2ac1c2f54533" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_799ca442-083e-45e6-9d91-788444827501" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5133e41f-ff33-4459-a66f-2ac1c2f54533" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4f617ffa-7a60-4fed-97de-d668d71a9952" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_799ca442-083e-45e6-9d91-788444827501" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4f617ffa-7a60-4fed-97de-d668d71a9952" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_324f2661-8dd8-4700-a68b-6d7aae51ec98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_799ca442-083e-45e6-9d91-788444827501" xlink:to="loc_us-gaap_Goodwill_324f2661-8dd8-4700-a68b-6d7aae51ec98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_47c0e35b-2a37-4c07-b51f-dbce27fd4747" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_799ca442-083e-45e6-9d91-788444827501" xlink:to="loc_us-gaap_OtherAssets_47c0e35b-2a37-4c07-b51f-dbce27fd4747" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b22313a1-93fa-4368-b88c-be5817db0eea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_28e24d70-418e-46fa-ba84-4a6f98a312a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b22313a1-93fa-4368-b88c-be5817db0eea" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_28e24d70-418e-46fa-ba84-4a6f98a312a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_146d522c-8c19-4d9a-b4ee-553c2fe4b3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b22313a1-93fa-4368-b88c-be5817db0eea" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_146d522c-8c19-4d9a-b4ee-553c2fe4b3d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_560d8c38-2e1d-4242-bdb3-4fc75b4e6ead" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b22313a1-93fa-4368-b88c-be5817db0eea" xlink:to="loc_us-gaap_LongTermDebtCurrent_560d8c38-2e1d-4242-bdb3-4fc75b4e6ead" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9d512cbb-3585-4a49-9ab7-9416467e72e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b22313a1-93fa-4368-b88c-be5817db0eea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9d512cbb-3585-4a49-9ab7-9416467e72e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="simple" xlink:href="insm-20240630.xsd#ConsolidatedStatementsofComprehensiveLossunaudited"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_db4ab4db-e609-4ed9-abd8-9a4457290a06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6abe0f4c-6552-4f1b-be90-47b14c7991be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_db4ab4db-e609-4ed9-abd8-9a4457290a06" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6abe0f4c-6552-4f1b-be90-47b14c7991be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1889e7be-d9a9-43a3-b5d5-5294695774e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_db4ab4db-e609-4ed9-abd8-9a4457290a06" xlink:to="loc_us-gaap_CostsAndExpenses_1889e7be-d9a9-43a3-b5d5-5294695774e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_44c16968-e299-48dc-8147-471cc68dab1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9850eb37-e2c6-4eda-b22c-fd7864bd1730" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_44c16968-e299-48dc-8147-471cc68dab1c" xlink:to="loc_us-gaap_OperatingIncomeLoss_9850eb37-e2c6-4eda-b22c-fd7864bd1730" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_10822603-0278-49d6-a671-9d945ffcc47c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_44c16968-e299-48dc-8147-471cc68dab1c" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_10822603-0278-49d6-a671-9d945ffcc47c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_1211623e-dc03-40ce-b9f6-184932440eae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_44c16968-e299-48dc-8147-471cc68dab1c" xlink:to="loc_us-gaap_InterestExpenseNonoperating_1211623e-dc03-40ce-b9f6-184932440eae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_3e08c809-bc66-468d-9053-39b065544f05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_44c16968-e299-48dc-8147-471cc68dab1c" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_3e08c809-bc66-468d-9053-39b065544f05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_52da5898-5ce0-46e9-92f7-238ea0517cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_44c16968-e299-48dc-8147-471cc68dab1c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_52da5898-5ce0-46e9-92f7-238ea0517cc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f495ab0a-97ec-4723-b5c4-48511cde862a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_fd8d5fc3-24f2-4687-9289-a498ad64352d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f495ab0a-97ec-4723-b5c4-48511cde862a" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_fd8d5fc3-24f2-4687-9289-a498ad64352d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6c85170f-bbd4-4e09-884c-23958493387b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f495ab0a-97ec-4723-b5c4-48511cde862a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6c85170f-bbd4-4e09-884c-23958493387b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1e145dc4-dbc5-48e2-acce-5ef5c840eed0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f495ab0a-97ec-4723-b5c4-48511cde862a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1e145dc4-dbc5-48e2-acce-5ef5c840eed0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_17dd5344-548b-43e6-87e0-7d8821ff246e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_cb1fe318-0611-4bef-be46-80b1d562006d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_17dd5344-548b-43e6-87e0-7d8821ff246e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_cb1fe318-0611-4bef-be46-80b1d562006d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_22474439-3277-4f83-9d26-b2b2a4f0d730" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_17dd5344-548b-43e6-87e0-7d8821ff246e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_22474439-3277-4f83-9d26-b2b2a4f0d730" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_bf252017-d0c9-40f2-9b12-3f232529c3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_17dd5344-548b-43e6-87e0-7d8821ff246e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_bf252017-d0c9-40f2-9b12-3f232529c3c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1f42c954-bdce-47a4-99bb-afdf2b3a6f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_17dd5344-548b-43e6-87e0-7d8821ff246e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1f42c954-bdce-47a4-99bb-afdf2b3a6f4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7ef1c4cb-c107-4e67-b1ab-f97247b9c081" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_17dd5344-548b-43e6-87e0-7d8821ff246e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7ef1c4cb-c107-4e67-b1ab-f97247b9c081" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a7adb9b4-3eb5-477e-8adb-de210b595612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_240e92ad-21d7-43ae-ae84-e96d5918fff2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a7adb9b4-3eb5-477e-8adb-de210b595612" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_240e92ad-21d7-43ae-ae84-e96d5918fff2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_20da050e-009f-431d-a0d9-c6ed93411c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a7adb9b4-3eb5-477e-8adb-de210b595612" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_20da050e-009f-431d-a0d9-c6ed93411c9e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="insm-20240630.xsd#ConsolidatedStatementsofCashFlowsunaudited"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0daa065b-6496-4c33-9434-23655a2cf57e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_us-gaap_NetIncomeLoss_0daa065b-6496-4c33-9434-23655a2cf57e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d4be89ba-d1c7-4426-8473-dbb2b7338d95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_us-gaap_Depreciation_d4be89ba-d1c7-4426-8473-dbb2b7338d95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_35611d5e-b20f-48b9-a8d1-7e92d6a8a10b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_35611d5e-b20f-48b9-a8d1-7e92d6a8a10b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7bab014b-b949-486b-9306-00162190a8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_us-gaap_ShareBasedCompensation_7bab014b-b949-486b-9306-00162190a8e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_79e5c349-9507-4664-8503-25b61de0e0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_79e5c349-9507-4664-8503-25b61de0e0fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_c2df0689-f8b9-4b3b-85e2-365214fa2962" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_us-gaap_PaidInKindInterest_c2df0689-f8b9-4b3b-85e2-365214fa2962" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_e6054175-7005-4f7f-a271-acbd3422abfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_us-gaap_OtherNoncashExpense_e6054175-7005-4f7f-a271-acbd3422abfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_98ae4fae-2128-4cc6-a47d-d8b77e420142" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_98ae4fae-2128-4cc6-a47d-d8b77e420142" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_86d70a5f-4c1d-45ec-83c6-31a3fd052efd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_86d70a5f-4c1d-45ec-83c6-31a3fd052efd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_f351450e-9d42-45be-9c70-913f42ad33c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_f351450e-9d42-45be-9c70-913f42ad33c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NoncashAcquisitionRelatedExpense_d0232c29-c095-45e5-9950-f802b8e18bf9" xlink:href="insm-20240630.xsd#insm_NoncashAcquisitionRelatedExpense"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_insm_NoncashAcquisitionRelatedExpense_d0232c29-c095-45e5-9950-f802b8e18bf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NoncashOperatingLeaseExpense_d9c000f7-c305-4b7f-b858-9f046f60a590" xlink:href="insm-20240630.xsd#insm_NoncashOperatingLeaseExpense"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_insm_NoncashOperatingLeaseExpense_d9c000f7-c305-4b7f-b858-9f046f60a590" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c652c610-6114-4895-9b49-512246f7089e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c652c610-6114-4895-9b49-512246f7089e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_06310554-bf87-4021-8c51-3d47c1718c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_06310554-bf87-4021-8c51-3d47c1718c9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_42a6b5e8-90a2-41ed-89c4-11a00af207bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_42a6b5e8-90a2-41ed-89c4-11a00af207bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1151639a-18a6-499f-be93-8d0077c9b954" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_1151639a-18a6-499f-be93-8d0077c9b954" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9cc3c588-a781-4abb-bb84-78d5b8a38a34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9cc3c588-a781-4abb-bb84-78d5b8a38a34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f43c77e6-12d5-4541-9ce8-2393843d6374" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f43c77e6-12d5-4541-9ce8-2393843d6374" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccretionOfDebtDiscountMarketableSecurities_2028e7f1-1b0e-4705-9b6f-ad061996e922" xlink:href="insm-20240630.xsd#insm_AccretionOfDebtDiscountMarketableSecurities"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e0df8ba-744d-4d51-9e52-8689adeda8ff" xlink:to="loc_insm_AccretionOfDebtDiscountMarketableSecurities_2028e7f1-1b0e-4705-9b6f-ad061996e922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_de27606c-93fc-4e74-99e1-00bb3f3f194a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_7a195a9a-1b5b-4ec7-80b2-2cbc25de18e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_de27606c-93fc-4e74-99e1-00bb3f3f194a" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_7a195a9a-1b5b-4ec7-80b2-2cbc25de18e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d204f9e8-ab12-4a2a-9fb8-9ee588d4a2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_de27606c-93fc-4e74-99e1-00bb3f3f194a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d204f9e8-ab12-4a2a-9fb8-9ee588d4a2e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_229a1135-5803-4b9d-821b-15426d7fcb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_de27606c-93fc-4e74-99e1-00bb3f3f194a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_229a1135-5803-4b9d-821b-15426d7fcb8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_1725360d-60d5-4e90-8598-42e616dd656d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_de27606c-93fc-4e74-99e1-00bb3f3f194a" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_1725360d-60d5-4e90-8598-42e616dd656d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8acea2b6-4c71-4291-9a2b-06753b601248" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cafc436-5d58-4719-933c-ab913be3f117" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8acea2b6-4c71-4291-9a2b-06753b601248" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cafc436-5d58-4719-933c-ab913be3f117" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c35938f3-b84f-4f36-92be-7fd9bc412374" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8acea2b6-4c71-4291-9a2b-06753b601248" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c35938f3-b84f-4f36-92be-7fd9bc412374" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3558ecd2-8101-4c2c-bb5f-4e78a5b19711" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8acea2b6-4c71-4291-9a2b-06753b601248" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3558ecd2-8101-4c2c-bb5f-4e78a5b19711" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c35ff737-e265-43ca-91e0-8ebe007e497b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8acea2b6-4c71-4291-9a2b-06753b601248" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c35ff737-e265-43ca-91e0-8ebe007e497b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f83990ad-3813-4c98-8bac-0964b6e9f83d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_e2217f67-49cd-4fb6-b253-497aba108852" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f83990ad-3813-4c98-8bac-0964b6e9f83d" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_e2217f67-49cd-4fb6-b253-497aba108852" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3fca7d97-5e82-4699-a635-8e30ae0b4b12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f83990ad-3813-4c98-8bac-0964b6e9f83d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3fca7d97-5e82-4699-a635-8e30ae0b4b12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_756cee91-fa97-4998-a89a-ae6e244205ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f83990ad-3813-4c98-8bac-0964b6e9f83d" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_756cee91-fa97-4998-a89a-ae6e244205ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ProceedsFromCashAcquiredInAssetAcquisition_89464e0d-9deb-488b-b95a-73e36972dd1d" xlink:href="insm-20240630.xsd#insm_ProceedsFromCashAcquiredInAssetAcquisition"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f83990ad-3813-4c98-8bac-0964b6e9f83d" xlink:to="loc_insm_ProceedsFromCashAcquiredInAssetAcquisition_89464e0d-9deb-488b-b95a-73e36972dd1d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a741eac5-2559-446c-8c95-0249f1a6f324" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dfc8e1ee-10dc-4f82-8924-de2c2d771553" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a741eac5-2559-446c-8c95-0249f1a6f324" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dfc8e1ee-10dc-4f82-8924-de2c2d771553" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_210af849-e974-46dc-9368-1a92d72a3d59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a741eac5-2559-446c-8c95-0249f1a6f324" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_210af849-e974-46dc-9368-1a92d72a3d59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_5d87eafa-f083-474d-8b2f-c2944f3f6b80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a741eac5-2559-446c-8c95-0249f1a6f324" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_5d87eafa-f083-474d-8b2f-c2944f3f6b80" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/InventoryDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0bb26b56-2a1c-4227-8e5d-b80c6b6e4094" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d6e7dd56-632c-4fd7-82c7-a9396acf7385" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0bb26b56-2a1c-4227-8e5d-b80c6b6e4094" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d6e7dd56-632c-4fd7-82c7-a9396acf7385" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_332ca6a7-635e-4510-becd-1a35e0c58d02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0bb26b56-2a1c-4227-8e5d-b80c6b6e4094" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_332ca6a7-635e-4510-becd-1a35e0c58d02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_79ee8ea4-7b29-4de8-92bf-a2b18a9c39bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0bb26b56-2a1c-4227-8e5d-b80c6b6e4094" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_79ee8ea4-7b29-4de8-92bf-a2b18a9c39bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNetDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#FixedAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/FixedAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_24e0a46b-6f4d-49cd-9243-f0087d916276" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_055ca961-3ed5-487b-a9ff-e04266850ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_24e0a46b-6f4d-49cd-9243-f0087d916276" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_055ca961-3ed5-487b-a9ff-e04266850ca4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0006f18f-0972-4ca9-9b63-be19202a02d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_24e0a46b-6f4d-49cd-9243-f0087d916276" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0006f18f-0972-4ca9-9b63-be19202a02d2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#AccountsPayableandAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8b5f35e5-2627-468d-95b9-1632c9e985e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedSalesAllowancesAndRelatedCosts_9623cb07-afa1-48fd-9784-c4b9f531ad82" xlink:href="insm-20240630.xsd#insm_AccruedSalesAllowancesAndRelatedCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8b5f35e5-2627-468d-95b9-1632c9e985e6" xlink:to="loc_insm_AccruedSalesAllowancesAndRelatedCosts_9623cb07-afa1-48fd-9784-c4b9f531ad82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_3bd8d226-b795-48a9-9b74-07c1eb5af68f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8b5f35e5-2627-468d-95b9-1632c9e985e6" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_3bd8d226-b795-48a9-9b74-07c1eb5af68f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_c404382e-4881-48e7-b772-93178b031e28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8b5f35e5-2627-468d-95b9-1632c9e985e6" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_c404382e-4881-48e7-b772-93178b031e28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_a809d761-eae9-4000-a52e-f5ccc58336e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8b5f35e5-2627-468d-95b9-1632c9e985e6" xlink:to="loc_us-gaap_InterestPayableCurrent_a809d761-eae9-4000-a52e-f5ccc58336e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_dff14782-2576-4c22-a31d-7918e83c8159" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8b5f35e5-2627-468d-95b9-1632c9e985e6" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_dff14782-2576-4c22-a31d-7918e83c8159" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedTechnicalOperationExpenses_6f16d1d3-cec2-4ffd-8bd3-e54620362d4c" xlink:href="insm-20240630.xsd#insm_AccruedTechnicalOperationExpenses"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8b5f35e5-2627-468d-95b9-1632c9e985e6" xlink:to="loc_insm_AccruedTechnicalOperationExpenses_6f16d1d3-cec2-4ffd-8bd3-e54620362d4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_d8a847a0-e5b0-434b-abaa-bdcdfa1ec54b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8b5f35e5-2627-468d-95b9-1632c9e985e6" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_d8a847a0-e5b0-434b-abaa-bdcdfa1ec54b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedClinicalTrialExpenses_cb10da69-fb6b-477e-bc96-80e6f9900e52" xlink:href="insm-20240630.xsd#insm_AccruedClinicalTrialExpenses"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8b5f35e5-2627-468d-95b9-1632c9e985e6" xlink:to="loc_insm_AccruedClinicalTrialExpenses_cb10da69-fb6b-477e-bc96-80e6f9900e52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ea21d660-7497-4c8c-b5c5-5eec6570636c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8b5f35e5-2627-468d-95b9-1632c9e985e6" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ea21d660-7497-4c8c-b5c5-5eec6570636c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_RevenueInterestPaymentsPayable_678c5cbf-ecda-410b-8a36-8d816ddeb435" xlink:href="insm-20240630.xsd#insm_RevenueInterestPaymentsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8b5f35e5-2627-468d-95b9-1632c9e985e6" xlink:to="loc_insm_RevenueInterestPaymentsPayable_678c5cbf-ecda-410b-8a36-8d816ddeb435" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredPaymentsCurrent_b64a1581-5ec5-45dc-877d-8e8079b39af3" xlink:href="insm-20240630.xsd#insm_BusinessCombinationDeferredPaymentsCurrent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8b5f35e5-2627-468d-95b9-1632c9e985e6" xlink:to="loc_insm_BusinessCombinationDeferredPaymentsCurrent_b64a1581-5ec5-45dc-877d-8e8079b39af3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a73a5e9f-df32-4db4-9967-ceabe11b3501" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8b5f35e5-2627-468d-95b9-1632c9e985e6" xlink:to="loc_us-gaap_AccountsPayableCurrent_a73a5e9f-df32-4db4-9967-ceabe11b3501" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedMilestonePaymentCurrent_cfbe03dc-9806-431c-b7a9-2833b00328a3" xlink:href="insm-20240630.xsd#insm_AccruedMilestonePaymentCurrent"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8b5f35e5-2627-468d-95b9-1632c9e985e6" xlink:to="loc_insm_AccruedMilestonePaymentCurrent_cfbe03dc-9806-431c-b7a9-2833b00328a3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_54e710ff-7567-4232-afd4-66a2d2778cac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7e41c9d2-2b17-4fea-9f82-d105d8a5043e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_54e710ff-7567-4232-afd4-66a2d2778cac" xlink:to="loc_us-gaap_LongTermDebtCurrent_7e41c9d2-2b17-4fea-9f82-d105d8a5043e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_68ca0151-2eed-4d4d-a7ee-95915b48b584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_54e710ff-7567-4232-afd4-66a2d2778cac" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_68ca0151-2eed-4d4d-a7ee-95915b48b584" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#DebtScheduleofFuturePrincipalRepaymentsofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_af4cf0e9-6256-4550-aa43-a5ceec341107" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3ede6a95-e8c5-4c03-b0ef-ea2b1675fc19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_af4cf0e9-6256-4550-aa43-a5ceec341107" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3ede6a95-e8c5-4c03-b0ef-ea2b1675fc19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e6bfbf47-7f5d-4d79-9553-11a41877c135" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_af4cf0e9-6256-4550-aa43-a5ceec341107" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e6bfbf47-7f5d-4d79-9553-11a41877c135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d5319840-1cb4-4527-9ced-39fd7e4335d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_af4cf0e9-6256-4550-aa43-a5ceec341107" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d5319840-1cb4-4527-9ced-39fd7e4335d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_b3d31553-0eeb-4e00-b69c-b284a478c495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_af4cf0e9-6256-4550-aa43-a5ceec341107" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_b3d31553-0eeb-4e00-b69c-b284a478c495" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_0ff803bb-2ad8-4c60-8fbf-70b72080ed71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_af4cf0e9-6256-4550-aa43-a5ceec341107" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_0ff803bb-2ad8-4c60-8fbf-70b72080ed71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LongTermDebtMaturityAfterYearFourAndThereafter_d2a5e37d-8659-40a6-91ba-50e16103889e" xlink:href="insm-20240630.xsd#insm_LongTermDebtMaturityAfterYearFourAndThereafter"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_af4cf0e9-6256-4550-aa43-a5ceec341107" xlink:to="loc_insm_LongTermDebtMaturityAfterYearFourAndThereafter_d2a5e37d-8659-40a6-91ba-50e16103889e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_10c9cf60-26ee-4816-b195-c19a74bc9117" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InterestExpenseExcludingFinanceLeaseInterestExpense_7e42aa79-1c60-4407-891b-118774e46e40" xlink:href="insm-20240630.xsd#insm_InterestExpenseExcludingFinanceLeaseInterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_10c9cf60-26ee-4816-b195-c19a74bc9117" xlink:to="loc_insm_InterestExpenseExcludingFinanceLeaseInterestExpense_7e42aa79-1c60-4407-891b-118774e46e40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_c64a631a-7264-4ae4-bbef-1882df89f12d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_10c9cf60-26ee-4816-b195-c19a74bc9117" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_c64a631a-7264-4ae4-bbef-1882df89f12d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InterestExpenseExcludingFinanceLeaseInterestExpense_73fefedc-2a5a-4744-adea-b8adea03918d" xlink:href="insm-20240630.xsd#insm_InterestExpenseExcludingFinanceLeaseInterestExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_bf3afd1d-557e-4f85-9960-3586f98655df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_insm_InterestExpenseExcludingFinanceLeaseInterestExpense_73fefedc-2a5a-4744-adea-b8adea03918d" xlink:to="loc_us-gaap_InterestExpenseDebt_bf3afd1d-557e-4f85-9960-3586f98655df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_07da382c-ad05-4e70-9fff-0a803cd83e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_insm_InterestExpenseExcludingFinanceLeaseInterestExpense_73fefedc-2a5a-4744-adea-b8adea03918d" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_07da382c-ad05-4e70-9fff-0a803cd83e5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_1b951520-0d9c-4aef-90b0-c3d759fabe05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_insm_InterestExpenseExcludingFinanceLeaseInterestExpense_73fefedc-2a5a-4744-adea-b8adea03918d" xlink:to="loc_us-gaap_InterestIncomeOther_1b951520-0d9c-4aef-90b0-c3d759fabe05" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#AcquisitionsScheduleofPurchasePriceDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_53495127-27bf-4b64-8a8b-cac7ab2f67a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_173c6aa5-830e-44fe-bb53-54d61cc4f52c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred_53495127-27bf-4b64-8a8b-cac7ab2f67a3" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_173c6aa5-830e-44fe-bb53-54d61cc4f52c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_ab7811ce-1d78-4453-a8b3-56e32f937596" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred_53495127-27bf-4b64-8a8b-cac7ab2f67a3" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_ab7811ce-1d78-4453-a8b3-56e32f937596" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>insm-20240630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c55c6bb2-e1ff-4fc1-8df4-decd904b3b6b,g:5264b7b4-c672-47ab-b9d7-1b1bb5962c46-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited" xlink:type="simple" xlink:href="insm-20240630.xsd#ConsolidatedStatementsofShareholdersEquityDeficitunaudited"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_15ebfb90-f103-4c80-9216-5c150acfec10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c0d7ec80-8608-4f41-823d-871d79ad761a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_15ebfb90-f103-4c80-9216-5c150acfec10" xlink:to="loc_us-gaap_StatementTable_c0d7ec80-8608-4f41-823d-871d79ad761a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_90289a37-ebc6-4f15-8cdc-c24d4d5402ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c0d7ec80-8608-4f41-823d-871d79ad761a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_90289a37-ebc6-4f15-8cdc-c24d4d5402ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_90289a37-ebc6-4f15-8cdc-c24d4d5402ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_90289a37-ebc6-4f15-8cdc-c24d4d5402ad" xlink:to="loc_us-gaap_EquityComponentDomain_90289a37-ebc6-4f15-8cdc-c24d4d5402ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c95c2263-75ed-43e9-b05c-fb1e1f0a6c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_90289a37-ebc6-4f15-8cdc-c24d4d5402ad" xlink:to="loc_us-gaap_EquityComponentDomain_c95c2263-75ed-43e9-b05c-fb1e1f0a6c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e40cdc68-688e-48fd-8add-1a9556d3a43f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c95c2263-75ed-43e9-b05c-fb1e1f0a6c1f" xlink:to="loc_us-gaap_CommonStockMember_e40cdc68-688e-48fd-8add-1a9556d3a43f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b7f48334-f019-4fc2-92d8-db2fe2c9de54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c95c2263-75ed-43e9-b05c-fb1e1f0a6c1f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b7f48334-f019-4fc2-92d8-db2fe2c9de54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0b74e793-54e7-445d-84f0-fc66c0a977d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c95c2263-75ed-43e9-b05c-fb1e1f0a6c1f" xlink:to="loc_us-gaap_RetainedEarningsMember_0b74e793-54e7-445d-84f0-fc66c0a977d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8860f3c9-9d33-4d9a-bc4d-811522bc1669" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c95c2263-75ed-43e9-b05c-fb1e1f0a6c1f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8860f3c9-9d33-4d9a-bc4d-811522bc1669" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15ebfb90-f103-4c80-9216-5c150acfec10" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_bb8ca7b9-6f81-4f69-a0b4-c6020c3fd06b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_SharesOutstanding_bb8ca7b9-6f81-4f69-a0b4-c6020c3fd06b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_03e68736-a84b-4809-977d-99b2f9dea7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockholdersEquity_03e68736-a84b-4809-977d-99b2f9dea7f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fc7633cf-e7a3-4126-b12a-42bcf74ebfba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fc7633cf-e7a3-4126-b12a-42bcf74ebfba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cfc9dfc9-984d-4ad3-99d4-78ad454ba2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fc7633cf-e7a3-4126-b12a-42bcf74ebfba" xlink:to="loc_us-gaap_NetIncomeLoss_cfc9dfc9-984d-4ad3-99d4-78ad454ba2d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_db264c5f-8a4d-4406-9419-1900dde574ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fc7633cf-e7a3-4126-b12a-42bcf74ebfba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_db264c5f-8a4d-4406-9419-1900dde574ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b762db70-faf5-4164-9fe8-5c0afb7782b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b762db70-faf5-4164-9fe8-5c0afb7782b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_df9d70fb-ad60-4c64-8026-c4b60ecd234d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_df9d70fb-ad60-4c64-8026-c4b60ecd234d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_90d10aaa-4f95-4443-b161-a942c1f1afc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_90d10aaa-4f95-4443-b161-a942c1f1afc4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0865f241-f933-483b-b0cf-77b9ddf9ca5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0865f241-f933-483b-b0cf-77b9ddf9ca5c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_dcf96bac-e188-4c47-b010-59d454f04bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_dcf96bac-e188-4c47-b010-59d454f04bfb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_9effd862-7459-45e3-b565-6263cd7fc025" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_9effd862-7459-45e3-b565-6263cd7fc025" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_4b400d1e-18a9-4dda-8dd9-b57d4cd9fc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_4b400d1e-18a9-4dda-8dd9-b57d4cd9fc7e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_d2390657-da57-46ec-8c3b-2e1b8ef0a6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_d2390657-da57-46ec-8c3b-2e1b8ef0a6e5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0489b0d7-d159-4677-bd99-f5973aa3324e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0489b0d7-d159-4677-bd99-f5973aa3324e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_35b5d423-50e8-442a-8c02-1fb59677df27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a69286f0-bb66-4a3b-b764-d7c82b0a0954" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="insm-20240630.xsd#ConsolidatedStatementsofCashFlowsunaudited"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_eebcf1c3-97aa-4908-8a66-4a197ef4a7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:to="loc_us-gaap_StatementTable_eebcf1c3-97aa-4908-8a66-4a197ef4a7c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_fda471ae-3cec-4911-9fb0-65bb15c63bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_eebcf1c3-97aa-4908-8a66-4a197ef4a7c2" xlink:to="loc_us-gaap_AssetAcquisitionAxis_fda471ae-3cec-4911-9fb0-65bb15c63bc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_fda471ae-3cec-4911-9fb0-65bb15c63bc2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_fda471ae-3cec-4911-9fb0-65bb15c63bc2" xlink:to="loc_us-gaap_AssetAcquisitionDomain_fda471ae-3cec-4911-9fb0-65bb15c63bc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b8f8c5bb-18be-4def-806b-689b76d3f477" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_fda471ae-3cec-4911-9fb0-65bb15c63bc2" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b8f8c5bb-18be-4def-806b-689b76d3f477" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_VertuisBioIncMember_fa2d6fc8-2fe1-4d9e-97ea-941c7b95cf11" xlink:href="insm-20240630.xsd#insm_VertuisBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b8f8c5bb-18be-4def-806b-689b76d3f477" xlink:to="loc_insm_VertuisBioIncMember_fa2d6fc8-2fe1-4d9e-97ea-941c7b95cf11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AdrestiaTherapeuticsLtdMember_bc71c9d5-2dbd-4d04-bc52-629de61ec6c2" xlink:href="insm-20240630.xsd#insm_AdrestiaTherapeuticsLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b8f8c5bb-18be-4def-806b-689b76d3f477" xlink:to="loc_insm_AdrestiaTherapeuticsLtdMember_bc71c9d5-2dbd-4d04-bc52-629de61ec6c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8260b595-0b33-43fe-8ee2-afbc1edeaae8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8260b595-0b33-43fe-8ee2-afbc1edeaae8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d2d3037e-4e16-45af-bf1e-eb03aebada99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8260b595-0b33-43fe-8ee2-afbc1edeaae8" xlink:to="loc_us-gaap_NetIncomeLoss_d2d3037e-4e16-45af-bf1e-eb03aebada99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8260b595-0b33-43fe-8ee2-afbc1edeaae8" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_fe4f34ff-7f05-4230-8d8e-749e2e956aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_Depreciation_fe4f34ff-7f05-4230-8d8e-749e2e956aa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9ca44ee2-591e-40d1-ac42-9c5fdc5c539f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9ca44ee2-591e-40d1-ac42-9c5fdc5c539f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_052dd307-c40d-45b9-87e4-0d94083ed1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_ShareBasedCompensation_052dd307-c40d-45b9-87e4-0d94083ed1ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bbd32f62-5940-411b-ba6a-e311f0743274" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bbd32f62-5940-411b-ba6a-e311f0743274" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_195260cb-fb36-4796-ac03-95422735e951" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_PaidInKindInterest_195260cb-fb36-4796-ac03-95422735e951" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_dd5c81e8-7369-417d-ace0-ea0770697df2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_OtherNoncashExpense_dd5c81e8-7369-417d-ace0-ea0770697df2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccretionOfDebtDiscountMarketableSecurities_b2fb49cc-7b9d-4a1f-8653-faa4fba9fdc5" xlink:href="insm-20240630.xsd#insm_AccretionOfDebtDiscountMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_insm_AccretionOfDebtDiscountMarketableSecurities_b2fb49cc-7b9d-4a1f-8653-faa4fba9fdc5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_fe133c66-70f3-44b7-a95e-602c4510796e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_fe133c66-70f3-44b7-a95e-602c4510796e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NoncashOperatingLeaseExpense_fe7fcb88-62ce-4cfc-8c0e-4e0152dff2fd" xlink:href="insm-20240630.xsd#insm_NoncashOperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_insm_NoncashOperatingLeaseExpense_fe7fcb88-62ce-4cfc-8c0e-4e0152dff2fd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_d0aa6b63-3d2f-419e-96a2-09e058fed970" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_d0aa6b63-3d2f-419e-96a2-09e058fed970" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_3c7b27c3-0ef7-484e-81cb-2c576c4b5cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_3c7b27c3-0ef7-484e-81cb-2c576c4b5cdc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NoncashAcquisitionRelatedExpense_492e33c5-d268-488f-a848-5d54e6c97944" xlink:href="insm-20240630.xsd#insm_NoncashAcquisitionRelatedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_insm_NoncashAcquisitionRelatedExpense_492e33c5-d268-488f-a848-5d54e6c97944" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NoncashAcquisitionRelatedExpense_fbcc2ef6-c465-401f-959e-17d232725fb8" xlink:href="insm-20240630.xsd#insm_NoncashAcquisitionRelatedExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_65c37e39-282b-44bb-a148-449bb191a86d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_65c37e39-282b-44bb-a148-449bb191a86d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1286798d-df04-47cf-ba17-cc68476bd07b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_65c37e39-282b-44bb-a148-449bb191a86d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1286798d-df04-47cf-ba17-cc68476bd07b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_62cc016f-6441-41d2-8925-8a7bc036bcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_65c37e39-282b-44bb-a148-449bb191a86d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_62cc016f-6441-41d2-8925-8a7bc036bcbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e6a837a5-81a6-4ffb-836e-effdee8f0877" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_65c37e39-282b-44bb-a148-449bb191a86d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e6a837a5-81a6-4ffb-836e-effdee8f0877" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_4818a026-a0fb-412d-a242-976e7fdadffa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_65c37e39-282b-44bb-a148-449bb191a86d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_4818a026-a0fb-412d-a242-976e7fdadffa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1bb90f53-e72f-4ef3-8995-a6e7eba734df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_65c37e39-282b-44bb-a148-449bb191a86d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1bb90f53-e72f-4ef3-8995-a6e7eba734df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7df5723d-464a-4ccf-99c3-44d43216507e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_65c37e39-282b-44bb-a148-449bb191a86d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7df5723d-464a-4ccf-99c3-44d43216507e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59c9ef22-b7e9-4098-9f5d-106c9927d7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59c9ef22-b7e9-4098-9f5d-106c9927d7f0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_07ac2ab3-1ad1-49fe-bb23-d7a6dedb5b03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_07ac2ab3-1ad1-49fe-bb23-d7a6dedb5b03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_86d34c0f-142a-42c4-ae39-04d9331c3d35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_07ac2ab3-1ad1-49fe-bb23-d7a6dedb5b03" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_86d34c0f-142a-42c4-ae39-04d9331c3d35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_984b792d-ea27-4903-b0f9-df4897869180" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_07ac2ab3-1ad1-49fe-bb23-d7a6dedb5b03" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_984b792d-ea27-4903-b0f9-df4897869180" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ProceedsFromCashAcquiredInAssetAcquisition_1afa77a2-232f-4c45-a944-fd16b524b2af" xlink:href="insm-20240630.xsd#insm_ProceedsFromCashAcquiredInAssetAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_07ac2ab3-1ad1-49fe-bb23-d7a6dedb5b03" xlink:to="loc_insm_ProceedsFromCashAcquiredInAssetAcquisition_1afa77a2-232f-4c45-a944-fd16b524b2af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7d7c0301-2860-401d-a764-8cb7024d257c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_07ac2ab3-1ad1-49fe-bb23-d7a6dedb5b03" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7d7c0301-2860-401d-a764-8cb7024d257c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b774bd38-c37c-4b45-a2a6-43bae0b68b66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_07ac2ab3-1ad1-49fe-bb23-d7a6dedb5b03" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b774bd38-c37c-4b45-a2a6-43bae0b68b66" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c91e612d-8692-4323-ba1b-e8d65d17f387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c91e612d-8692-4323-ba1b-e8d65d17f387" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_53c05baa-1f25-4b01-b6fa-544c4798b61b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c91e612d-8692-4323-ba1b-e8d65d17f387" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_53c05baa-1f25-4b01-b6fa-544c4798b61b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_378aa82b-d78e-45bf-9a16-45f582091189" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c91e612d-8692-4323-ba1b-e8d65d17f387" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_378aa82b-d78e-45bf-9a16-45f582091189" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_bc1263e1-a8ee-4eb1-9af4-7c469ab3ec16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c91e612d-8692-4323-ba1b-e8d65d17f387" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_bc1263e1-a8ee-4eb1-9af4-7c469ab3ec16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e0c6d1e1-a59f-4552-9fd0-3013e42528a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c91e612d-8692-4323-ba1b-e8d65d17f387" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e0c6d1e1-a59f-4552-9fd0-3013e42528a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa4f356b-8355-40f2-b517-51fae556bf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c91e612d-8692-4323-ba1b-e8d65d17f387" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa4f356b-8355-40f2-b517-51fae556bf6c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_69618a9a-5972-4fff-8b3e-04aa965cc009" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_69618a9a-5972-4fff-8b3e-04aa965cc009" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4adf5a0d-2144-4c61-8f26-c9f8dc1fe29b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4adf5a0d-2144-4c61-8f26-c9f8dc1fe29b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ccfe67ae-8842-4aa4-a8e9-65b452a968cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ccfe67ae-8842-4aa4-a8e9-65b452a968cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_412c764e-b215-4192-953d-fe560d09eab3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_89a51b24-2572-4d46-a790-daba83e71531" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_89a51b24-2572-4d46-a790-daba83e71531" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_37c38ef6-e83c-4e3e-bd4b-1a2d9fff9f81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_89a51b24-2572-4d46-a790-daba83e71531" xlink:to="loc_us-gaap_InterestPaidNet_37c38ef6-e83c-4e3e-bd4b-1a2d9fff9f81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_80857bf5-195b-495e-91ed-ef7d695f70c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_89a51b24-2572-4d46-a790-daba83e71531" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_80857bf5-195b-495e-91ed-ef7d695f70c4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_ec1140e4-91b2-420f-b598-c4873ec8fb10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_77566cb4-2070-41b0-97e4-0f9a7775e888" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ec1140e4-91b2-420f-b598-c4873ec8fb10" xlink:to="loc_us-gaap_ConcentrationRiskTable_77566cb4-2070-41b0-97e4-0f9a7775e888" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d95552fe-2022-4774-be52-987ce8bbea55" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_77566cb4-2070-41b0-97e4-0f9a7775e888" xlink:to="loc_srt_MajorCustomersAxis_d95552fe-2022-4774-be52-987ce8bbea55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d95552fe-2022-4774-be52-987ce8bbea55_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_d95552fe-2022-4774-be52-987ce8bbea55" xlink:to="loc_srt_NameOfMajorCustomerDomain_d95552fe-2022-4774-be52-987ce8bbea55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0e0f33c1-a77e-4268-bd9c-3c21d6943d67" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_d95552fe-2022-4774-be52-987ce8bbea55" xlink:to="loc_srt_NameOfMajorCustomerDomain_0e0f33c1-a77e-4268-bd9c-3c21d6943d67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerAMember_c3ad3d7b-2529-4403-a371-52364391304c" xlink:href="insm-20240630.xsd#insm_CustomerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0e0f33c1-a77e-4268-bd9c-3c21d6943d67" xlink:to="loc_insm_CustomerAMember_c3ad3d7b-2529-4403-a371-52364391304c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerBMember_ea18e5bd-1b78-4629-8c34-0d628adce7a9" xlink:href="insm-20240630.xsd#insm_CustomerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0e0f33c1-a77e-4268-bd9c-3c21d6943d67" xlink:to="loc_insm_CustomerBMember_ea18e5bd-1b78-4629-8c34-0d628adce7a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerCMember_0c03a822-941e-4c35-9d30-c46b87533f08" xlink:href="insm-20240630.xsd#insm_CustomerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0e0f33c1-a77e-4268-bd9c-3c21d6943d67" xlink:to="loc_insm_CustomerCMember_0c03a822-941e-4c35-9d30-c46b87533f08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5e36d8ae-9c52-4f64-9b6c-c3bb1788802f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_77566cb4-2070-41b0-97e4-0f9a7775e888" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5e36d8ae-9c52-4f64-9b6c-c3bb1788802f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5e36d8ae-9c52-4f64-9b6c-c3bb1788802f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5e36d8ae-9c52-4f64-9b6c-c3bb1788802f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5e36d8ae-9c52-4f64-9b6c-c3bb1788802f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_289289d8-3a21-419a-9684-95e77b074303" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5e36d8ae-9c52-4f64-9b6c-c3bb1788802f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_289289d8-3a21-419a-9684-95e77b074303" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_29c655d9-f753-4ee2-8aa7-25548f8a9165" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_289289d8-3a21-419a-9684-95e77b074303" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_29c655d9-f753-4ee2-8aa7-25548f8a9165" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f928d05e-85ce-45b2-b9b7-874ae6960909" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_77566cb4-2070-41b0-97e4-0f9a7775e888" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f928d05e-85ce-45b2-b9b7-874ae6960909" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f928d05e-85ce-45b2-b9b7-874ae6960909_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f928d05e-85ce-45b2-b9b7-874ae6960909" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f928d05e-85ce-45b2-b9b7-874ae6960909_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_02c1470f-51cb-41e7-a0dc-d115be795903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f928d05e-85ce-45b2-b9b7-874ae6960909" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_02c1470f-51cb-41e7-a0dc-d115be795903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_29d4c3a5-6cbf-497d-8adb-3402cb0325f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_02c1470f-51cb-41e7-a0dc-d115be795903" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_29d4c3a5-6cbf-497d-8adb-3402cb0325f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_787a2da0-ec13-4bc1-8879-65e0861f04bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ec1140e4-91b2-420f-b598-c4873ec8fb10" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_787a2da0-ec13-4bc1-8879-65e0861f04bd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_8f04bfea-68aa-479b-9ac6-7f5ce49476d7" xlink:href="insm-20240630.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_30a00766-1d00-4d51-8c31-dad74c91fef8" xlink:href="insm-20240630.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_8f04bfea-68aa-479b-9ac6-7f5ce49476d7" xlink:to="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_30a00766-1d00-4d51-8c31-dad74c91fef8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_aa5c4fe4-23f8-489a-b1b9-9ae69ea7640b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_30a00766-1d00-4d51-8c31-dad74c91fef8" xlink:to="loc_us-gaap_AwardTypeAxis_aa5c4fe4-23f8-489a-b1b9-9ae69ea7640b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa5c4fe4-23f8-489a-b1b9-9ae69ea7640b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_aa5c4fe4-23f8-489a-b1b9-9ae69ea7640b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa5c4fe4-23f8-489a-b1b9-9ae69ea7640b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78dbcad0-bbc4-40d5-9be3-6b60b2959926" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_aa5c4fe4-23f8-489a-b1b9-9ae69ea7640b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78dbcad0-bbc4-40d5-9be3-6b60b2959926" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1ee31c02-aed9-46ef-9414-d9afdc35aeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78dbcad0-bbc4-40d5-9be3-6b60b2959926" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1ee31c02-aed9-46ef-9414-d9afdc35aeeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1906d38f-6b23-4e10-860b-930e3db35ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78dbcad0-bbc4-40d5-9be3-6b60b2959926" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1906d38f-6b23-4e10-860b-930e3db35ff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_b95a34c3-bdf5-456b-86fe-d6e98b7ce9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78dbcad0-bbc4-40d5-9be3-6b60b2959926" xlink:to="loc_us-gaap_PerformanceSharesMember_b95a34c3-bdf5-456b-86fe-d6e98b7ce9cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_6538e2d9-acb8-4c3b-8db1-17b0d54f8902" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_8f04bfea-68aa-479b-9ac6-7f5ce49476d7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_6538e2d9-acb8-4c3b-8db1-17b0d54f8902" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9817b5ab-b2fe-4cb8-9568-7a1bb8915664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_6538e2d9-acb8-4c3b-8db1-17b0d54f8902" xlink:to="loc_us-gaap_NetIncomeLoss_9817b5ab-b2fe-4cb8-9568-7a1bb8915664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_180ab6e8-cae0-44d2-baf1-922ad868345a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_8f04bfea-68aa-479b-9ac6-7f5ce49476d7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_180ab6e8-cae0-44d2-baf1-922ad868345a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0e3bef61-4407-4be6-bbf5-b66d4ef85a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_180ab6e8-cae0-44d2-baf1-922ad868345a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0e3bef61-4407-4be6-bbf5-b66d4ef85a0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_f388a90e-1dc0-485f-b0ac-b3ae877c658b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_180ab6e8-cae0-44d2-baf1-922ad868345a" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_f388a90e-1dc0-485f-b0ac-b3ae877c658b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1465c251-b8b5-4a0c-ad3c-a8f8534f019b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_f388a90e-1dc0-485f-b0ac-b3ae877c658b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1465c251-b8b5-4a0c-ad3c-a8f8534f019b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_1b662f82-e680-4785-94fb-57a425792504" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_f388a90e-1dc0-485f-b0ac-b3ae877c658b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_1b662f82-e680-4785-94fb-57a425792504" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ec8d4b53-3be6-486a-8d53-4f5cf9f93b69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_180ab6e8-cae0-44d2-baf1-922ad868345a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ec8d4b53-3be6-486a-8d53-4f5cf9f93b69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f4cc8f03-47e4-4a34-9d73-f00a57fab752" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_8f04bfea-68aa-479b-9ac6-7f5ce49476d7" xlink:to="loc_us-gaap_EarningsPerShareAbstract_f4cc8f03-47e4-4a34-9d73-f00a57fab752" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e82013d4-ef9d-4dd0-88df-e9b7c415c92b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f4cc8f03-47e4-4a34-9d73-f00a57fab752" xlink:to="loc_us-gaap_EarningsPerShareBasic_e82013d4-ef9d-4dd0-88df-e9b7c415c92b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ed83a969-d97f-4661-b3ab-2995f14da808" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f4cc8f03-47e4-4a34-9d73-f00a57fab752" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ed83a969-d97f-4661-b3ab-2995f14da808" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8d0f8632-7e51-40e5-b79c-8bc9a694c764" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8f2d60ae-f242-4a9f-8be3-d43e4fa5cf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8d0f8632-7e51-40e5-b79c-8bc9a694c764" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8f2d60ae-f242-4a9f-8be3-d43e4fa5cf8a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_031feff1-26ec-4847-a1d0-a60a17e83027" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8f2d60ae-f242-4a9f-8be3-d43e4fa5cf8a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_031feff1-26ec-4847-a1d0-a60a17e83027" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_031feff1-26ec-4847-a1d0-a60a17e83027_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_031feff1-26ec-4847-a1d0-a60a17e83027" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_031feff1-26ec-4847-a1d0-a60a17e83027_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fef9ec12-8069-44e9-a3ec-7e532c5989ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_031feff1-26ec-4847-a1d0-a60a17e83027" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fef9ec12-8069-44e9-a3ec-7e532c5989ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e0e9e150-0a63-4112-b782-d8ff76d039d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fef9ec12-8069-44e9-a3ec-7e532c5989ab" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e0e9e150-0a63-4112-b782-d8ff76d039d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dc6ee1a0-08b5-4017-a452-512f965d36a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fef9ec12-8069-44e9-a3ec-7e532c5989ab" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dc6ee1a0-08b5-4017-a452-512f965d36a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_c080fa95-970a-4d3f-9543-3003c49c8f58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fef9ec12-8069-44e9-a3ec-7e532c5989ab" xlink:to="loc_us-gaap_PerformanceSharesMember_c080fa95-970a-4d3f-9543-3003c49c8f58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_0340b246-e4b2-432a-a1ad-c06f0e0047fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fef9ec12-8069-44e9-a3ec-7e532c5989ab" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_0340b246-e4b2-432a-a1ad-c06f0e0047fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4381b86f-60d2-43f0-9014-cc5580001e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8d0f8632-7e51-40e5-b79c-8bc9a694c764" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4381b86f-60d2-43f0-9014-cc5580001e9b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_879327c2-a189-4db9-8b3c-f21f967c84fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_307d69f9-e428-4ce4-b262-ee8739ab004b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_879327c2-a189-4db9-8b3c-f21f967c84fa" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_307d69f9-e428-4ce4-b262-ee8739ab004b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_67a3de3a-ae56-4240-9028-b489c629107f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_307d69f9-e428-4ce4-b262-ee8739ab004b" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_67a3de3a-ae56-4240-9028-b489c629107f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_67a3de3a-ae56-4240-9028-b489c629107f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_67a3de3a-ae56-4240-9028-b489c629107f" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_67a3de3a-ae56-4240-9028-b489c629107f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0c954a94-e0c6-4234-b09b-99be8db9c0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_67a3de3a-ae56-4240-9028-b489c629107f" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0c954a94-e0c6-4234-b09b-99be8db9c0f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fa569eaa-f793-442a-8d73-1d7b68bc0dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0c954a94-e0c6-4234-b09b-99be8db9c0f4" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fa569eaa-f793-442a-8d73-1d7b68bc0dc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9686c8ca-a8b6-4de1-819a-aa1fcc0610ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fa569eaa-f793-442a-8d73-1d7b68bc0dc3" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9686c8ca-a8b6-4de1-819a-aa1fcc0610ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d52fe563-93a7-4bc3-bcaa-3bc3571c5b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fa569eaa-f793-442a-8d73-1d7b68bc0dc3" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d52fe563-93a7-4bc3-bcaa-3bc3571c5b4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2dd87bf9-2478-4a13-bb5a-463aa276431e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_307d69f9-e428-4ce4-b262-ee8739ab004b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2dd87bf9-2478-4a13-bb5a-463aa276431e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2dd87bf9-2478-4a13-bb5a-463aa276431e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2dd87bf9-2478-4a13-bb5a-463aa276431e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2dd87bf9-2478-4a13-bb5a-463aa276431e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_500da50f-31ee-49d7-b3ad-380ac3a9c506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2dd87bf9-2478-4a13-bb5a-463aa276431e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_500da50f-31ee-49d7-b3ad-380ac3a9c506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_48632362-ac73-4754-b232-d2fa5561141c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_500da50f-31ee-49d7-b3ad-380ac3a9c506" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_48632362-ac73-4754-b232-d2fa5561141c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e799260f-e6e1-4ddd-b8bf-8863ef356165" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_307d69f9-e428-4ce4-b262-ee8739ab004b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e799260f-e6e1-4ddd-b8bf-8863ef356165" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e799260f-e6e1-4ddd-b8bf-8863ef356165_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e799260f-e6e1-4ddd-b8bf-8863ef356165" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e799260f-e6e1-4ddd-b8bf-8863ef356165_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99a447f1-d252-4301-a9af-62f0d4f4daa8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e799260f-e6e1-4ddd-b8bf-8863ef356165" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99a447f1-d252-4301-a9af-62f0d4f4daa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_528687f0-cbf1-4d4a-bdee-ed9de462f02d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99a447f1-d252-4301-a9af-62f0d4f4daa8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_528687f0-cbf1-4d4a-bdee-ed9de462f02d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e5ecac43-b7f7-499b-a98d-5f79b5c5a83a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99a447f1-d252-4301-a9af-62f0d4f4daa8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e5ecac43-b7f7-499b-a98d-5f79b5c5a83a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ba3e7798-d2a5-48bf-afe7-24b4ebcac67e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99a447f1-d252-4301-a9af-62f0d4f4daa8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ba3e7798-d2a5-48bf-afe7-24b4ebcac67e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_489918a0-5e96-44eb-bbcc-487e7ca4cce1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_879327c2-a189-4db9-8b3c-f21f967c84fa" xlink:to="loc_us-gaap_AssetsAbstract_489918a0-5e96-44eb-bbcc-487e7ca4cce1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_903133ea-ab96-4362-93bd-beb7c87b8f73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_489918a0-5e96-44eb-bbcc-487e7ca4cce1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_903133ea-ab96-4362-93bd-beb7c87b8f73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_70b4dde7-e717-4736-8050-26523f004feb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_489918a0-5e96-44eb-bbcc-487e7ca4cce1" xlink:to="loc_us-gaap_MarketableSecurities_70b4dde7-e717-4736-8050-26523f004feb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_423b2731-99f3-4f10-b9e9-850735aa12e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_489918a0-5e96-44eb-bbcc-487e7ca4cce1" xlink:to="loc_us-gaap_DerivativeAssets_423b2731-99f3-4f10-b9e9-850735aa12e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_ec815746-982c-4a6a-8d35-60bc1c57740b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_879327c2-a189-4db9-8b3c-f21f967c84fa" xlink:to="loc_us-gaap_LiabilitiesAbstract_ec815746-982c-4a6a-8d35-60bc1c57740b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_c5a8cc0c-8187-4cf5-b006-e4ec0cb16e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_ec815746-982c-4a6a-8d35-60bc1c57740b" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_c5a8cc0c-8187-4cf5-b006-e4ec0cb16e9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_9552e6c4-6e92-4572-8267-1673a5a9d0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_ec815746-982c-4a6a-8d35-60bc1c57740b" xlink:to="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_9552e6c4-6e92-4572-8267-1673a5a9d0eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredLiability_320452c3-ad67-482f-868a-b269da38aa33" xlink:href="insm-20240630.xsd#insm_BusinessCombinationDeferredLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_ec815746-982c-4a6a-8d35-60bc1c57740b" xlink:to="loc_insm_BusinessCombinationDeferredLiability_320452c3-ad67-482f-868a-b269da38aa33" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_df696498-cefd-47c5-a3e8-b846ce1ca57f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_ec815746-982c-4a6a-8d35-60bc1c57740b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_df696498-cefd-47c5-a3e8-b846ce1ca57f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_89d63032-f90e-4762-80ab-43e28b845a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_89d63032-f90e-4762-80ab-43e28b845a0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_89d63032-f90e-4762-80ab-43e28b845a0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_89d63032-f90e-4762-80ab-43e28b845a0b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_89d63032-f90e-4762-80ab-43e28b845a0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_77986022-6e1e-411c-8a54-aa4351293e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_89d63032-f90e-4762-80ab-43e28b845a0b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_77986022-6e1e-411c-8a54-aa4351293e4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncMember_bd0d4b91-27c8-41ca-84e5-37bcfe624d9e" xlink:href="insm-20240630.xsd#insm_MotusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_77986022-6e1e-411c-8a54-aa4351293e4d" xlink:to="loc_insm_MotusBiosciencesIncMember_bd0d4b91-27c8-41ca-84e5-37bcfe624d9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AlgaeneXIncMember_4835daa4-cd4e-4363-bd64-14fdb33e63ca" xlink:href="insm-20240630.xsd#insm_AlgaeneXIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_77986022-6e1e-411c-8a54-aa4351293e4d" xlink:to="loc_insm_AlgaeneXIncMember_4835daa4-cd4e-4363-bd64-14fdb33e63ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_af59a03d-114a-49af-bc36-bdea51a46a14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_af59a03d-114a-49af-bc36-bdea51a46a14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_af59a03d-114a-49af-bc36-bdea51a46a14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_af59a03d-114a-49af-bc36-bdea51a46a14" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_af59a03d-114a-49af-bc36-bdea51a46a14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_139dec0d-5f3e-4b54-97fe-8b5a72f21698" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_af59a03d-114a-49af-bc36-bdea51a46a14" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_139dec0d-5f3e-4b54-97fe-8b5a72f21698" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6b76794f-b789-4274-a991-16f7ad53988e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_139dec0d-5f3e-4b54-97fe-8b5a72f21698" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6b76794f-b789-4274-a991-16f7ad53988e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a1dce35-5273-4657-a2ef-5df1f5298d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a1dce35-5273-4657-a2ef-5df1f5298d6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a1dce35-5273-4657-a2ef-5df1f5298d6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a1dce35-5273-4657-a2ef-5df1f5298d6e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a1dce35-5273-4657-a2ef-5df1f5298d6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f138b75-43b6-4e90-adcc-0405f87493f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a1dce35-5273-4657-a2ef-5df1f5298d6e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f138b75-43b6-4e90-adcc-0405f87493f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_34922534-0b85-4987-92bf-be09bab7401b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f138b75-43b6-4e90-adcc-0405f87493f5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_34922534-0b85-4987-92bf-be09bab7401b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5ddfc2c7-35c4-47fd-bb4b-ed6e8fc6cdb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f138b75-43b6-4e90-adcc-0405f87493f5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5ddfc2c7-35c4-47fd-bb4b-ed6e8fc6cdb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_41226a57-fd4a-4cbb-8b01-520e48e63496" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_41226a57-fd4a-4cbb-8b01-520e48e63496" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_41226a57-fd4a-4cbb-8b01-520e48e63496_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_41226a57-fd4a-4cbb-8b01-520e48e63496" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_41226a57-fd4a-4cbb-8b01-520e48e63496_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cb7d7336-c637-4b76-86d2-f1fa519eac2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_41226a57-fd4a-4cbb-8b01-520e48e63496" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cb7d7336-c637-4b76-86d2-f1fa519eac2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MeasurementInputProbabilityOfSuccessMember_15ba94ca-1307-4e5d-9de0-7893e72e12a7" xlink:href="insm-20240630.xsd#insm_MeasurementInputProbabilityOfSuccessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cb7d7336-c637-4b76-86d2-f1fa519eac2a" xlink:to="loc_insm_MeasurementInputProbabilityOfSuccessMember_15ba94ca-1307-4e5d-9de0-7893e72e12a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_df2ec437-cab6-41c3-b608-923ddc30ad81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_DebtInstrumentAxis_df2ec437-cab6-41c3-b608-923ddc30ad81" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_df2ec437-cab6-41c3-b608-923ddc30ad81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_df2ec437-cab6-41c3-b608-923ddc30ad81" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_df2ec437-cab6-41c3-b608-923ddc30ad81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c0d091b9-e9ef-440d-a483-8c474a362c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_df2ec437-cab6-41c3-b608-923ddc30ad81" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c0d091b9-e9ef-440d-a483-8c474a362c7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_6244f4e9-df04-4a95-a4f9-87f5b2ab6ccb" xlink:href="insm-20240630.xsd#insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c0d091b9-e9ef-440d-a483-8c474a362c7c" xlink:to="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_6244f4e9-df04-4a95-a4f9-87f5b2ab6ccb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2a0bda31-fa46-419d-be84-aa618f2800ab" xlink:href="insm-20240630.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c0d091b9-e9ef-440d-a483-8c474a362c7c" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2a0bda31-fa46-419d-be84-aa618f2800ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember_7229645b-908a-4895-9348-1c56431f6e14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c0d091b9-e9ef-440d-a483-8c474a362c7c" xlink:to="loc_us-gaap_RoyaltyAgreementsMember_7229645b-908a-4895-9348-1c56431f6e14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_526de43b-acb9-4a66-b724-54e4550c38f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_526de43b-acb9-4a66-b724-54e4550c38f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_526de43b-acb9-4a66-b724-54e4550c38f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_526de43b-acb9-4a66-b724-54e4550c38f1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_526de43b-acb9-4a66-b724-54e4550c38f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c9093dc3-b970-4899-ae55-39bde3c29abb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_526de43b-acb9-4a66-b724-54e4550c38f1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c9093dc3-b970-4899-ae55-39bde3c29abb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_f3fb9108-3244-41a5-bf77-b45eaa224bca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c9093dc3-b970-4899-ae55-39bde3c29abb" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_f3fb9108-3244-41a5-bf77-b45eaa224bca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_9ac7c333-c6d2-4768-a840-a81ba7c2629e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_9ac7c333-c6d2-4768-a840-a81ba7c2629e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_9ac7c333-c6d2-4768-a840-a81ba7c2629e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_9ac7c333-c6d2-4768-a840-a81ba7c2629e" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_9ac7c333-c6d2-4768-a840-a81ba7c2629e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_42add4f5-57cb-4877-870f-8e8449696f66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_9ac7c333-c6d2-4768-a840-a81ba7c2629e" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_42add4f5-57cb-4877-870f-8e8449696f66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_93002711-6043-4639-a13f-ed594f26cea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_42add4f5-57cb-4877-870f-8e8449696f66" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_93002711-6043-4639-a13f-ed594f26cea0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ff573801-d88e-4a8c-8ad9-75074fb7ec6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_93002711-6043-4639-a13f-ed594f26cea0" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ff573801-d88e-4a8c-8ad9-75074fb7ec6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_6b50c1cd-15fd-4a07-b8ab-b3bc1a91467e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_VestingAxis_6b50c1cd-15fd-4a07-b8ab-b3bc1a91467e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_6b50c1cd-15fd-4a07-b8ab-b3bc1a91467e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_6b50c1cd-15fd-4a07-b8ab-b3bc1a91467e" xlink:to="loc_us-gaap_VestingDomain_6b50c1cd-15fd-4a07-b8ab-b3bc1a91467e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_e6037862-9090-4204-824e-e4c764e9e10d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_6b50c1cd-15fd-4a07-b8ab-b3bc1a91467e" xlink:to="loc_us-gaap_VestingDomain_e6037862-9090-4204-824e-e4c764e9e10d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f7eea63b-cffd-449c-b3d6-5e6ef185225c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_e6037862-9090-4204-824e-e4c764e9e10d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f7eea63b-cffd-449c-b3d6-5e6ef185225c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_92dbdf70-14c3-4e57-8050-592b3da03ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_e6037862-9090-4204-824e-e4c764e9e10d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_92dbdf70-14c3-4e57-8050-592b3da03ab1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_a21ebb40-aaa0-475e-9da5-c3ace950cfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_e6037862-9090-4204-824e-e4c764e9e10d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_a21ebb40-aaa0-475e-9da5-c3ace950cfc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_31385fed-b82f-4fb0-91d8-845f8e823a86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_31385fed-b82f-4fb0-91d8-845f8e823a86" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_31385fed-b82f-4fb0-91d8-845f8e823a86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_31385fed-b82f-4fb0-91d8-845f8e823a86" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_31385fed-b82f-4fb0-91d8-845f8e823a86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f120e9ba-9995-4777-85e1-233bd9d7872a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_31385fed-b82f-4fb0-91d8-845f8e823a86" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f120e9ba-9995-4777-85e1-233bd9d7872a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DevelopmentAndRegulatoryMilestonesMember_e2be4c0c-7210-4ce6-9f41-bcc1c32cabfe" xlink:href="insm-20240630.xsd#insm_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f120e9ba-9995-4777-85e1-233bd9d7872a" xlink:to="loc_insm_DevelopmentAndRegulatoryMilestonesMember_e2be4c0c-7210-4ce6-9f41-bcc1c32cabfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_afc1636a-a539-4234-94e9-9a4a261ef71a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_CreditFacilityAxis_afc1636a-a539-4234-94e9-9a4a261ef71a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_afc1636a-a539-4234-94e9-9a4a261ef71a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_afc1636a-a539-4234-94e9-9a4a261ef71a" xlink:to="loc_us-gaap_CreditFacilityDomain_afc1636a-a539-4234-94e9-9a4a261ef71a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_fc91e2d9-103a-48ff-ba5c-0834c3415dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_afc1636a-a539-4234-94e9-9a4a261ef71a" xlink:to="loc_us-gaap_CreditFacilityDomain_fc91e2d9-103a-48ff-ba5c-0834c3415dc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_5f452d91-9f93-4096-9b4b-217dd304da45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_fc91e2d9-103a-48ff-ba5c-0834c3415dc0" xlink:to="loc_us-gaap_SecuredDebtMember_5f452d91-9f93-4096-9b4b-217dd304da45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c76b732b-30e9-4117-af96-b6f634168652" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_srt_StatementScenarioAxis_c76b732b-30e9-4117-af96-b6f634168652" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c76b732b-30e9-4117-af96-b6f634168652_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_c76b732b-30e9-4117-af96-b6f634168652" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c76b732b-30e9-4117-af96-b6f634168652_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_13e1611a-3190-4554-802e-c9f028469b39" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_c76b732b-30e9-4117-af96-b6f634168652" xlink:to="loc_srt_ScenarioUnspecifiedDomain_13e1611a-3190-4554-802e-c9f028469b39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_2a1b6c7f-889d-4e4f-ad78-961184b23306" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_13e1611a-3190-4554-802e-c9f028469b39" xlink:to="loc_srt_ScenarioForecastMember_2a1b6c7f-889d-4e4f-ad78-961184b23306" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5531b80b-3e7d-4a46-83da-80d0d76de7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5531b80b-3e7d-4a46-83da-80d0d76de7d8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5531b80b-3e7d-4a46-83da-80d0d76de7d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5531b80b-3e7d-4a46-83da-80d0d76de7d8" xlink:to="loc_us-gaap_SegmentDomain_5531b80b-3e7d-4a46-83da-80d0d76de7d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_31aa383f-02ea-45eb-bfa9-19ee0fee2aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5531b80b-3e7d-4a46-83da-80d0d76de7d8" xlink:to="loc_us-gaap_SegmentDomain_31aa383f-02ea-45eb-bfa9-19ee0fee2aa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ARIKAYCEGlobalNetSalesMember_2c7a37f9-abb6-424c-9cea-a2c20cab29cd" xlink:href="insm-20240630.xsd#insm_ARIKAYCEGlobalNetSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_31aa383f-02ea-45eb-bfa9-19ee0fee2aa2" xlink:to="loc_insm_ARIKAYCEGlobalNetSalesMember_2c7a37f9-abb6-424c-9cea-a2c20cab29cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BrensocatibGlobalNetSalesMember_60428210-0e54-49dd-a7e6-6d0d6a68b98b" xlink:href="insm-20240630.xsd#insm_BrensocatibGlobalNetSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_31aa383f-02ea-45eb-bfa9-19ee0fee2aa2" xlink:to="loc_insm_BrensocatibGlobalNetSalesMember_60428210-0e54-49dd-a7e6-6d0d6a68b98b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_76426794-a6f8-4e69-865a-d086d9e9fa78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_76426794-a6f8-4e69-865a-d086d9e9fa78" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_76426794-a6f8-4e69-865a-d086d9e9fa78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_76426794-a6f8-4e69-865a-d086d9e9fa78" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_76426794-a6f8-4e69-865a-d086d9e9fa78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ce0977c0-8bee-4e4d-ab4e-7a45925f9cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_76426794-a6f8-4e69-865a-d086d9e9fa78" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ce0977c0-8bee-4e4d-ab4e-7a45925f9cfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_9818cba9-26a1-4b15-855d-e86c1dbdd6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ce0977c0-8bee-4e4d-ab4e-7a45925f9cfb" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_9818cba9-26a1-4b15-855d-e86c1dbdd6d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c803c925-f2bf-46df-94f0-ac8714d57aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c803c925-f2bf-46df-94f0-ac8714d57aaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_7e523c8e-5963-4157-aab4-d8e858d37c41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_MarketableSecurities_7e523c8e-5963-4157-aab4-d8e858d37c41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_dd6efdf0-cde1-42b4-a42b-362e57419158" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_dd6efdf0-cde1-42b4-a42b-362e57419158" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredLiability_c335199c-00f3-46aa-92ff-36cb1023b9ce" xlink:href="insm-20240630.xsd#insm_BusinessCombinationDeferredLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_insm_BusinessCombinationDeferredLiability_c335199c-00f3-46aa-92ff-36cb1023b9ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_0307f063-029d-44f7-bedd-0f30d00e91c1" xlink:href="insm-20240630.xsd#insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_0307f063-029d-44f7-bedd-0f30d00e91c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_79bb681a-2296-4b2f-ba96-a3e5961a55fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_79bb681a-2296-4b2f-ba96-a3e5961a55fe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage_96a4ccd5-7f10-43dc-a4cb-666710160436" xlink:href="insm-20240630.xsd#insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage_96a4ccd5-7f10-43dc-a4cb-666710160436" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage_71528941-bf51-458b-8341-f29d6cfe9caa" xlink:href="insm-20240630.xsd#insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage_71528941-bf51-458b-8341-f29d6cfe9caa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders_5a94dbce-2de5-4d2a-8e21-c5a6833cb1c5" xlink:href="insm-20240630.xsd#insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders_5a94dbce-2de5-4d2a-8e21-c5a6833cb1c5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f7e0fee5-5986-40f2-bd50-33c6d1909b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f7e0fee5-5986-40f2-bd50-33c6d1909b0d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_82e2188a-9251-417f-9050-8c8340d25d10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_82e2188a-9251-417f-9050-8c8340d25d10" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_316942dd-6a55-4eac-9069-8b120f2a68c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_316942dd-6a55-4eac-9069-8b120f2a68c2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_83c41659-6edc-4c70-b3b5-9c64898746f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_83c41659-6edc-4c70-b3b5-9c64898746f1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ProceedsFromRoyaltyFinancing_e4a19ae2-f534-453c-bd60-85aa2830a55a" xlink:href="insm-20240630.xsd#insm_ProceedsFromRoyaltyFinancing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_insm_ProceedsFromRoyaltyFinancing_e4a19ae2-f534-453c-bd60-85aa2830a55a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentRoyaltyStatedPercentage_946c5f56-0e30-4df7-bf51-4f424da2e760" xlink:href="insm-20240630.xsd#insm_DebtInstrumentRoyaltyStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_insm_DebtInstrumentRoyaltyStatedPercentage_946c5f56-0e30-4df7-bf51-4f424da2e760" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c857cb07-ae3f-45d0-bc78-b9ef72a4cfb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c857cb07-ae3f-45d0-bc78-b9ef72a4cfb3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_c5800ebf-6d38-44ad-a267-7320541d5731" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_c5800ebf-6d38-44ad-a267-7320541d5731" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd6e07b-94b0-4829-a0ba-6d7931728a80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4e0760c-2c1b-4739-aaad-e50354dd31f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd6e07b-94b0-4829-a0ba-6d7931728a80" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4e0760c-2c1b-4739-aaad-e50354dd31f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_38952255-8611-4629-94cf-e2eec38302ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4e0760c-2c1b-4739-aaad-e50354dd31f1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_38952255-8611-4629-94cf-e2eec38302ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_38952255-8611-4629-94cf-e2eec38302ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_38952255-8611-4629-94cf-e2eec38302ec" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_38952255-8611-4629-94cf-e2eec38302ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_39a134a9-2542-4dea-9c2f-235fc03e56f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_38952255-8611-4629-94cf-e2eec38302ec" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_39a134a9-2542-4dea-9c2f-235fc03e56f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1ee39822-9cca-4b13-8d4c-92a7e1944e12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_39a134a9-2542-4dea-9c2f-235fc03e56f7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1ee39822-9cca-4b13-8d4c-92a7e1944e12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1862d922-45b4-44b0-be64-b874a91b970f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4e0760c-2c1b-4739-aaad-e50354dd31f1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1862d922-45b4-44b0-be64-b874a91b970f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1862d922-45b4-44b0-be64-b874a91b970f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1862d922-45b4-44b0-be64-b874a91b970f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1862d922-45b4-44b0-be64-b874a91b970f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_ce29fa9d-8329-4158-9ef1-74d2410fb2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1862d922-45b4-44b0-be64-b874a91b970f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_ce29fa9d-8329-4158-9ef1-74d2410fb2a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_257e7a29-a657-472f-a720-d4d7f65e90e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ce29fa9d-8329-4158-9ef1-74d2410fb2a2" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_257e7a29-a657-472f-a720-d4d7f65e90e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredLiability_d40d203c-931c-4d92-9de8-9409afdc8d57" xlink:href="insm-20240630.xsd#insm_BusinessCombinationDeferredLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd6e07b-94b0-4829-a0ba-6d7931728a80" xlink:to="loc_insm_BusinessCombinationDeferredLiability_d40d203c-931c-4d92-9de8-9409afdc8d57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput_ae9f8081-4476-4d4c-bd0d-cf2b264702d7" xlink:href="insm-20240630.xsd#insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd6e07b-94b0-4829-a0ba-6d7931728a80" xlink:to="loc_insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput_ae9f8081-4476-4d4c-bd0d-cf2b264702d7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d505c3c4-661c-4eba-8fb9-0dce76e0d0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4ae80ce-2fdc-4054-ad93-a6e5df6e82ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d505c3c4-661c-4eba-8fb9-0dce76e0d0b6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4ae80ce-2fdc-4054-ad93-a6e5df6e82ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_502aba8b-55a2-4e60-a84e-4679b32a0503" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4ae80ce-2fdc-4054-ad93-a6e5df6e82ad" xlink:to="loc_srt_RangeAxis_502aba8b-55a2-4e60-a84e-4679b32a0503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_502aba8b-55a2-4e60-a84e-4679b32a0503_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_502aba8b-55a2-4e60-a84e-4679b32a0503" xlink:to="loc_srt_RangeMember_502aba8b-55a2-4e60-a84e-4679b32a0503_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cd83efd0-b2bf-4dbb-9280-f0d51e7234d1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_502aba8b-55a2-4e60-a84e-4679b32a0503" xlink:to="loc_srt_RangeMember_cd83efd0-b2bf-4dbb-9280-f0d51e7234d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_64eb1bcc-d4b4-4535-8281-d3e4e041d5f3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cd83efd0-b2bf-4dbb-9280-f0d51e7234d1" xlink:to="loc_srt_MinimumMember_64eb1bcc-d4b4-4535-8281-d3e4e041d5f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f6b98816-83af-45cf-b92b-dca782f343a4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cd83efd0-b2bf-4dbb-9280-f0d51e7234d1" xlink:to="loc_srt_MaximumMember_f6b98816-83af-45cf-b92b-dca782f343a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_cf570fcb-08ed-49b8-89c7-e2ffddec99eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4ae80ce-2fdc-4054-ad93-a6e5df6e82ad" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_cf570fcb-08ed-49b8-89c7-e2ffddec99eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cf570fcb-08ed-49b8-89c7-e2ffddec99eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_cf570fcb-08ed-49b8-89c7-e2ffddec99eb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_cf570fcb-08ed-49b8-89c7-e2ffddec99eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_692d6a61-131c-4a59-9686-ba990ceb86a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_cf570fcb-08ed-49b8-89c7-e2ffddec99eb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_692d6a61-131c-4a59-9686-ba990ceb86a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DevelopmentAndRegulatoryMilestonesMember_b641536c-a4a5-4dc4-abe0-5ff368f01886" xlink:href="insm-20240630.xsd#insm_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_692d6a61-131c-4a59-9686-ba990ceb86a0" xlink:to="loc_insm_DevelopmentAndRegulatoryMilestonesMember_b641536c-a4a5-4dc4-abe0-5ff368f01886" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PriorityReviewVoucherMilestoneMember_ec68fb7d-f68d-43b6-8cac-b1d1324e7b88" xlink:href="insm-20240630.xsd#insm_PriorityReviewVoucherMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_692d6a61-131c-4a59-9686-ba990ceb86a0" xlink:to="loc_insm_PriorityReviewVoucherMilestoneMember_ec68fb7d-f68d-43b6-8cac-b1d1324e7b88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_5da35d38-fa73-4ae4-b5c9-0fc8916ca9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4ae80ce-2fdc-4054-ad93-a6e5df6e82ad" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_5da35d38-fa73-4ae4-b5c9-0fc8916ca9e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_5da35d38-fa73-4ae4-b5c9-0fc8916ca9e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_5da35d38-fa73-4ae4-b5c9-0fc8916ca9e8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_5da35d38-fa73-4ae4-b5c9-0fc8916ca9e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_caebf7cd-ba1b-41f2-9f7c-9b24ebffb49f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_5da35d38-fa73-4ae4-b5c9-0fc8916ca9e8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_caebf7cd-ba1b-41f2-9f7c-9b24ebffb49f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MeasurementInputProbabilityOfSuccessMember_e02db5c2-e9c1-4aa8-92f5-e7446cfe4756" xlink:href="insm-20240630.xsd#insm_MeasurementInputProbabilityOfSuccessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_caebf7cd-ba1b-41f2-9f7c-9b24ebffb49f" xlink:to="loc_insm_MeasurementInputProbabilityOfSuccessMember_e02db5c2-e9c1-4aa8-92f5-e7446cfe4756" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_cff3ccf3-7f8f-43d2-99dd-078f8e5a54c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_caebf7cd-ba1b-41f2-9f7c-9b24ebffb49f" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_cff3ccf3-7f8f-43d2-99dd-078f8e5a54c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ffb81562-0937-4cc0-8974-52fbc56d6d26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4ae80ce-2fdc-4054-ad93-a6e5df6e82ad" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ffb81562-0937-4cc0-8974-52fbc56d6d26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ffb81562-0937-4cc0-8974-52fbc56d6d26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ffb81562-0937-4cc0-8974-52fbc56d6d26" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ffb81562-0937-4cc0-8974-52fbc56d6d26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_937c70cb-9fef-4299-ae34-9beed9ea64e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ffb81562-0937-4cc0-8974-52fbc56d6d26" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_937c70cb-9fef-4299-ae34-9beed9ea64e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2c722c84-8c3b-4ade-9025-fc7144e3001f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_937c70cb-9fef-4299-ae34-9beed9ea64e9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2c722c84-8c3b-4ade-9025-fc7144e3001f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_59743015-c345-4844-b098-277c54060b37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d505c3c4-661c-4eba-8fb9-0dce76e0d0b6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_59743015-c345-4844-b098-277c54060b37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_298be289-ea98-499c-8502-5fb39cfbbdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d505c3c4-661c-4eba-8fb9-0dce76e0d0b6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_298be289-ea98-499c-8502-5fb39cfbbdc9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76923a91-6143-438e-8bd8-a5357900d53e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ea104c7-cac9-4c02-8f6f-c6fe6a6ecae3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76923a91-6143-438e-8bd8-a5357900d53e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ea104c7-cac9-4c02-8f6f-c6fe6a6ecae3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c94efaa1-dab5-4c18-a8cc-8669b65de468" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ea104c7-cac9-4c02-8f6f-c6fe6a6ecae3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c94efaa1-dab5-4c18-a8cc-8669b65de468" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c94efaa1-dab5-4c18-a8cc-8669b65de468_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c94efaa1-dab5-4c18-a8cc-8669b65de468" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c94efaa1-dab5-4c18-a8cc-8669b65de468_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7061e831-726b-4716-acb1-b14203dc4e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c94efaa1-dab5-4c18-a8cc-8669b65de468" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7061e831-726b-4716-acb1-b14203dc4e3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d34745f7-ff08-40e3-877c-fd90693f24f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7061e831-726b-4716-acb1-b14203dc4e3a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d34745f7-ff08-40e3-877c-fd90693f24f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_689858ed-804e-4082-b9a0-8eefa0bbf8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7061e831-726b-4716-acb1-b14203dc4e3a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_689858ed-804e-4082-b9a0-8eefa0bbf8dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a3e6c0b8-1ccf-4fab-9711-c6ff8c4ae059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76923a91-6143-438e-8bd8-a5357900d53e" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a3e6c0b8-1ccf-4fab-9711-c6ff8c4ae059" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ab789819-bc29-41e4-80e2-5c27fe560163" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a3e6c0b8-1ccf-4fab-9711-c6ff8c4ae059" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ab789819-bc29-41e4-80e2-5c27fe560163" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_c9accd54-fa1d-4137-bf98-744febccd5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a3e6c0b8-1ccf-4fab-9711-c6ff8c4ae059" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_c9accd54-fa1d-4137-bf98-744febccd5f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions_3b673f8f-63e9-44be-998d-fa723913588c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a3e6c0b8-1ccf-4fab-9711-c6ff8c4ae059" xlink:to="loc_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions_3b673f8f-63e9-44be-998d-fa723913588c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments_f8d4d28a-1f18-4236-9fdb-efad01d84d64" xlink:href="insm-20240630.xsd#insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a3e6c0b8-1ccf-4fab-9711-c6ff8c4ae059" xlink:to="loc_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments_f8d4d28a-1f18-4236-9fdb-efad01d84d64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f886ef13-15ba-4c1b-8d9a-99eef236a753" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ProductRevenuesNetDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#ProductRevenuesNetDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/ProductRevenuesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4e9b97a4-64e8-4284-8364-595d9a9e4a47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3d8379f4-ef51-4ad1-abf4-1990874b96ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4e9b97a4-64e8-4284-8364-595d9a9e4a47" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3d8379f4-ef51-4ad1-abf4-1990874b96ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_81a1fc9b-d0d3-4447-b9fd-17d825cbdfd9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3d8379f4-ef51-4ad1-abf4-1990874b96ec" xlink:to="loc_srt_StatementGeographicalAxis_81a1fc9b-d0d3-4447-b9fd-17d825cbdfd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_81a1fc9b-d0d3-4447-b9fd-17d825cbdfd9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_81a1fc9b-d0d3-4447-b9fd-17d825cbdfd9" xlink:to="loc_srt_SegmentGeographicalDomain_81a1fc9b-d0d3-4447-b9fd-17d825cbdfd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0ff3d0ae-23dd-4fdc-82a4-233131169d68" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_81a1fc9b-d0d3-4447-b9fd-17d825cbdfd9" xlink:to="loc_srt_SegmentGeographicalDomain_0ff3d0ae-23dd-4fdc-82a4-233131169d68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_48c9b982-233e-4a18-a6a1-6c1c03dc03ec" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0ff3d0ae-23dd-4fdc-82a4-233131169d68" xlink:to="loc_country_US_48c9b982-233e-4a18-a6a1-6c1c03dc03ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_522e4cce-6204-4aae-be5f-d2a2bdfff7b0" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0ff3d0ae-23dd-4fdc-82a4-233131169d68" xlink:to="loc_country_JP_522e4cce-6204-4aae-be5f-d2a2bdfff7b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EuropeAndTheRestOfTheWorldMember_18eef343-74b3-4faf-87f9-fa0d63e40f75" xlink:href="insm-20240630.xsd#insm_EuropeAndTheRestOfTheWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_0ff3d0ae-23dd-4fdc-82a4-233131169d68" xlink:to="loc_insm_EuropeAndTheRestOfTheWorldMember_18eef343-74b3-4faf-87f9-fa0d63e40f75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_454b8bdc-cba2-4510-8a2f-9d13f2943653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4e9b97a4-64e8-4284-8364-595d9a9e4a47" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_454b8bdc-cba2-4510-8a2f-9d13f2943653" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62207347-5395-4fc3-8eff-41333819a7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e937e6f7-0d0d-45a1-b206-c22def8c644f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62207347-5395-4fc3-8eff-41333819a7f9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e937e6f7-0d0d-45a1-b206-c22def8c644f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d1578341-6b74-4be0-92b0-1ad9d7b6c153" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e937e6f7-0d0d-45a1-b206-c22def8c644f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d1578341-6b74-4be0-92b0-1ad9d7b6c153" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d1578341-6b74-4be0-92b0-1ad9d7b6c153_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d1578341-6b74-4be0-92b0-1ad9d7b6c153" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d1578341-6b74-4be0-92b0-1ad9d7b6c153_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ccabc2e3-18bd-4ffd-8099-c377d727f6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d1578341-6b74-4be0-92b0-1ad9d7b6c153" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ccabc2e3-18bd-4ffd-8099-c377d727f6a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AcquiredResearchAndDevelopmentMember_180c1226-1ebb-4c45-ad69-b56375e82fbd" xlink:href="insm-20240630.xsd#insm_AcquiredResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ccabc2e3-18bd-4ffd-8099-c377d727f6a1" xlink:to="loc_insm_AcquiredResearchAndDevelopmentMember_180c1226-1ebb-4c45-ad69-b56375e82fbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_b133da90-6239-44c1-8259-8d8e9b2c4021" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ccabc2e3-18bd-4ffd-8099-c377d727f6a1" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_b133da90-6239-44c1-8259-8d8e9b2c4021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_4de753bc-c19b-4362-ae7c-cfe6603c8f89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ccabc2e3-18bd-4ffd-8099-c377d727f6a1" xlink:to="loc_us-gaap_LicensingAgreementsMember_4de753bc-c19b-4362-ae7c-cfe6603c8f89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_b2ce5786-74ab-47b0-8589-fa794cd0c30c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62207347-5395-4fc3-8eff-41333819a7f9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_b2ce5786-74ab-47b0-8589-fa794cd0c30c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b4216da7-b111-4420-8245-8262d6700a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_b2ce5786-74ab-47b0-8589-fa794cd0c30c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b4216da7-b111-4420-8245-8262d6700a3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_a8f66d5b-417f-4b89-a5c5-7bdae4edffbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_b2ce5786-74ab-47b0-8589-fa794cd0c30c" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_a8f66d5b-417f-4b89-a5c5-7bdae4edffbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_bc12cb97-1334-4261-9398-536178b3d78b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_b2ce5786-74ab-47b0-8589-fa794cd0c30c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_bc12cb97-1334-4261-9398-536178b3d78b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2531528e-e2dd-4f58-8589-3e59e2f8d797" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_b2ce5786-74ab-47b0-8589-fa794cd0c30c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2531528e-e2dd-4f58-8589-3e59e2f8d797" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNetDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#FixedAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/FixedAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b494c5f-da52-4a60-a6cd-6f880f7a7ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5c2ea809-7f0e-406f-b7c3-1a6189b40f22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b494c5f-da52-4a60-a6cd-6f880f7a7ee6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5c2ea809-7f0e-406f-b7c3-1a6189b40f22" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5afcd7ff-7cfc-4a43-a836-44590b313ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5c2ea809-7f0e-406f-b7c3-1a6189b40f22" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5afcd7ff-7cfc-4a43-a836-44590b313ef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5afcd7ff-7cfc-4a43-a836-44590b313ef6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5afcd7ff-7cfc-4a43-a836-44590b313ef6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5afcd7ff-7cfc-4a43-a836-44590b313ef6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b32b7915-b687-4171-82e5-40b43b154f95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5afcd7ff-7cfc-4a43-a836-44590b313ef6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b32b7915-b687-4171-82e5-40b43b154f95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c03c91e8-c8e6-4614-b0eb-00c3e9b411c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b32b7915-b687-4171-82e5-40b43b154f95" xlink:to="loc_us-gaap_EquipmentMember_c03c91e8-c8e6-4614-b0eb-00c3e9b411c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0540fec4-3e15-4e3c-a898-6b9ed93fe459" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b32b7915-b687-4171-82e5-40b43b154f95" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0540fec4-3e15-4e3c-a898-6b9ed93fe459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ComputerHardwareAndSoftwareMember_40b91c0c-a6ad-4c24-b92d-b99ac52b8e12" xlink:href="insm-20240630.xsd#insm_ComputerHardwareAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b32b7915-b687-4171-82e5-40b43b154f95" xlink:to="loc_insm_ComputerHardwareAndSoftwareMember_40b91c0c-a6ad-4c24-b92d-b99ac52b8e12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_9c99b0aa-e8f6-46bf-8223-69953f5b58a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b32b7915-b687-4171-82e5-40b43b154f95" xlink:to="loc_us-gaap_OfficeEquipmentMember_9c99b0aa-e8f6-46bf-8223-69953f5b58a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ManufacturingEquipmentMember_140a2380-6dfb-48fb-b5d0-44aebf8ad04c" xlink:href="insm-20240630.xsd#insm_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b32b7915-b687-4171-82e5-40b43b154f95" xlink:to="loc_insm_ManufacturingEquipmentMember_140a2380-6dfb-48fb-b5d0-44aebf8ad04c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_6b681226-9f3c-4a82-acee-cc9b73c5570e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b32b7915-b687-4171-82e5-40b43b154f95" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_6b681226-9f3c-4a82-acee-cc9b73c5570e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_ad226d80-4543-4906-b2ff-946b2ebe77a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b32b7915-b687-4171-82e5-40b43b154f95" xlink:to="loc_us-gaap_ConstructionInProgressMember_ad226d80-4543-4906-b2ff-946b2ebe77a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2ea108cc-ab83-4ad7-be54-708637edee4a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5c2ea809-7f0e-406f-b7c3-1a6189b40f22" xlink:to="loc_srt_RangeAxis_2ea108cc-ab83-4ad7-be54-708637edee4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2ea108cc-ab83-4ad7-be54-708637edee4a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2ea108cc-ab83-4ad7-be54-708637edee4a" xlink:to="loc_srt_RangeMember_2ea108cc-ab83-4ad7-be54-708637edee4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_34123b93-461c-4650-9145-a8a1f5d10ac6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2ea108cc-ab83-4ad7-be54-708637edee4a" xlink:to="loc_srt_RangeMember_34123b93-461c-4650-9145-a8a1f5d10ac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_92cecd93-95cc-40c0-8f4f-7f0cf9188a08" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_34123b93-461c-4650-9145-a8a1f5d10ac6" xlink:to="loc_srt_MinimumMember_92cecd93-95cc-40c0-8f4f-7f0cf9188a08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c8092597-6750-4c9d-9015-7c90092c739b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_34123b93-461c-4650-9145-a8a1f5d10ac6" xlink:to="loc_srt_MaximumMember_c8092597-6750-4c9d-9015-7c90092c739b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_25b121dd-002e-4258-8f70-78ce39098358" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b494c5f-da52-4a60-a6cd-6f880f7a7ee6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_25b121dd-002e-4258-8f70-78ce39098358" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a029f69d-2926-44c5-af4a-e3e547fe4a26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b494c5f-da52-4a60-a6cd-6f880f7a7ee6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a029f69d-2926-44c5-af4a-e3e547fe4a26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4e22a782-bd2a-406b-8abe-2438a0b04d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b494c5f-da52-4a60-a6cd-6f880f7a7ee6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4e22a782-bd2a-406b-8abe-2438a0b04d0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2db203f0-dc8e-4a7b-a0fa-2432c52a4bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b494c5f-da52-4a60-a6cd-6f880f7a7ee6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2db203f0-dc8e-4a7b-a0fa-2432c52a4bf1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_386dd8d5-e488-4413-8e72-c6edff981b92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_8631ac57-84b6-49f0-8121-bc640b1ae3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_386dd8d5-e488-4413-8e72-c6edff981b92" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_8631ac57-84b6-49f0-8121-bc640b1ae3f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_acfaeb1b-3792-47d4-9c13-63ddfd1eafbe" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8631ac57-84b6-49f0-8121-bc640b1ae3f4" xlink:to="loc_srt_RangeAxis_acfaeb1b-3792-47d4-9c13-63ddfd1eafbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_acfaeb1b-3792-47d4-9c13-63ddfd1eafbe_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_acfaeb1b-3792-47d4-9c13-63ddfd1eafbe" xlink:to="loc_srt_RangeMember_acfaeb1b-3792-47d4-9c13-63ddfd1eafbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9c918e91-fa5f-4f97-b133-afe21538b5f4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_acfaeb1b-3792-47d4-9c13-63ddfd1eafbe" xlink:to="loc_srt_RangeMember_9c918e91-fa5f-4f97-b133-afe21538b5f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2fcd97eb-fc1e-4879-9d29-f6f9f6bfd059" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9c918e91-fa5f-4f97-b133-afe21538b5f4" xlink:to="loc_srt_MinimumMember_2fcd97eb-fc1e-4879-9d29-f6f9f6bfd059" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_89d44d0f-338b-48e8-b245-ea5676047a0c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9c918e91-fa5f-4f97-b133-afe21538b5f4" xlink:to="loc_srt_MaximumMember_89d44d0f-338b-48e8-b245-ea5676047a0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LeaseRemainingLeaseTerm_8098aa42-2ca7-464c-b811-a4e3180f5dc9" xlink:href="insm-20240630.xsd#insm_LeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_386dd8d5-e488-4413-8e72-c6edff981b92" xlink:to="loc_insm_LeaseRemainingLeaseTerm_8098aa42-2ca7-464c-b811-a4e3180f5dc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_f6059b93-241f-44f6-bfe0-c4b2520cfb22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_386dd8d5-e488-4413-8e72-c6edff981b92" xlink:to="loc_us-gaap_VariableLeaseCost_f6059b93-241f-44f6-bfe0-c4b2520cfb22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_2a603f20-7715-4c7b-af40-a8dae1d22a78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_386dd8d5-e488-4413-8e72-c6edff981b92" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_2a603f20-7715-4c7b-af40-a8dae1d22a78" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_aae694a3-03e3-4e44-9677-e80945f5fce0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7ff6851d-c96e-4e02-b890-7fd98441712a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aae694a3-03e3-4e44-9677-e80945f5fce0" xlink:to="loc_us-gaap_DebtInstrumentTable_7ff6851d-c96e-4e02-b890-7fd98441712a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_79894c7a-df6a-4e91-88c7-bc5577495c64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7ff6851d-c96e-4e02-b890-7fd98441712a" xlink:to="loc_us-gaap_DebtInstrumentAxis_79894c7a-df6a-4e91-88c7-bc5577495c64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_79894c7a-df6a-4e91-88c7-bc5577495c64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_79894c7a-df6a-4e91-88c7-bc5577495c64" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_79894c7a-df6a-4e91-88c7-bc5577495c64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_405b01cf-f018-413c-baa9-ca24d3bec93d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_79894c7a-df6a-4e91-88c7-bc5577495c64" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_405b01cf-f018-413c-baa9-ca24d3bec93d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_85311f46-0cef-4d83-a853-c13835c355b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_405b01cf-f018-413c-baa9-ca24d3bec93d" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_85311f46-0cef-4d83-a853-c13835c355b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_TermLoanMember_7bec8927-61f0-4233-9f42-31efa35210ee" xlink:href="insm-20240630.xsd#insm_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_405b01cf-f018-413c-baa9-ca24d3bec93d" xlink:to="loc_insm_TermLoanMember_7bec8927-61f0-4233-9f42-31efa35210ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e4d23395-056a-416d-ae23-0f7ae30ebc65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aae694a3-03e3-4e44-9677-e80945f5fce0" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e4d23395-056a-416d-ae23-0f7ae30ebc65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ee21548a-a508-42a6-b7e9-b352b6a76023" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aae694a3-03e3-4e44-9677-e80945f5fce0" xlink:to="loc_us-gaap_LongTermDebtCurrent_ee21548a-a508-42a6-b7e9-b352b6a76023" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_397b42e7-8e11-42e7-b105-e5c21c276043" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aae694a3-03e3-4e44-9677-e80945f5fce0" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_397b42e7-8e11-42e7-b105-e5c21c276043" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5023e02e-874c-4efe-8bcb-be040316e89f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5023e02e-874c-4efe-8bcb-be040316e89f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5023e02e-874c-4efe-8bcb-be040316e89f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5023e02e-874c-4efe-8bcb-be040316e89f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5023e02e-874c-4efe-8bcb-be040316e89f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a5fd39be-02bd-4ce2-a09c-6e0b77b6b9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5023e02e-874c-4efe-8bcb-be040316e89f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a5fd39be-02bd-4ce2-a09c-6e0b77b6b9ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_e59c90e4-0551-4c8d-bc01-c07e7f31f5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a5fd39be-02bd-4ce2-a09c-6e0b77b6b9ab" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_e59c90e4-0551-4c8d-bc01-c07e7f31f5e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4e27202f-7807-4740-a832-16e3e9b17749" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_us-gaap_DebtInstrumentAxis_4e27202f-7807-4740-a832-16e3e9b17749" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4e27202f-7807-4740-a832-16e3e9b17749_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4e27202f-7807-4740-a832-16e3e9b17749" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4e27202f-7807-4740-a832-16e3e9b17749_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8958c383-342f-4eff-bf9f-f1ba02449ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4e27202f-7807-4740-a832-16e3e9b17749" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8958c383-342f-4eff-bf9f-f1ba02449ae0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_cc4941d4-118d-443a-a8ea-8df4b60a8052" xlink:href="insm-20240630.xsd#insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8958c383-342f-4eff-bf9f-f1ba02449ae0" xlink:to="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_cc4941d4-118d-443a-a8ea-8df4b60a8052" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_0e90f566-9626-4fa0-8683-502dabd9f8cb" xlink:href="insm-20240630.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8958c383-342f-4eff-bf9f-f1ba02449ae0" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_0e90f566-9626-4fa0-8683-502dabd9f8cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_RedemptionOfThe2025ConvertibleNotesMember_e31c8ef3-8245-44b7-a323-a8dd028a3686" xlink:href="insm-20240630.xsd#insm_RedemptionOfThe2025ConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8958c383-342f-4eff-bf9f-f1ba02449ae0" xlink:to="loc_insm_RedemptionOfThe2025ConvertibleNotesMember_e31c8ef3-8245-44b7-a323-a8dd028a3686" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_TermLoanMember_b73aead9-14d0-4f17-bd5b-7edcf7a7b3fd" xlink:href="insm-20240630.xsd#insm_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8958c383-342f-4eff-bf9f-f1ba02449ae0" xlink:to="loc_insm_TermLoanMember_b73aead9-14d0-4f17-bd5b-7edcf7a7b3fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermAxis_a40144b6-f4d7-4085-9749-c35a48c07f98" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_insm_DebtInstrumentConversionTermAxis_a40144b6-f4d7-4085-9749-c35a48c07f98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermDomain_a40144b6-f4d7-4085-9749-c35a48c07f98_default" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_insm_DebtInstrumentConversionTermAxis_a40144b6-f4d7-4085-9749-c35a48c07f98" xlink:to="loc_insm_DebtInstrumentConversionTermDomain_a40144b6-f4d7-4085-9749-c35a48c07f98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermDomain_ccae5843-0fa3-4131-89a5-6fa76d0665de" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_insm_DebtInstrumentConversionTermAxis_a40144b6-f4d7-4085-9749-c35a48c07f98" xlink:to="loc_insm_DebtInstrumentConversionTermDomain_ccae5843-0fa3-4131-89a5-6fa76d0665de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermOneMember_03351cbd-652a-43b1-a0e7-1fbc313b3b9d" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_ccae5843-0fa3-4131-89a5-6fa76d0665de" xlink:to="loc_insm_DebtInstrumentConversionTermOneMember_03351cbd-652a-43b1-a0e7-1fbc313b3b9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermTwoMember_e032a8b4-a10c-4708-9f73-77f014219c7f" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_ccae5843-0fa3-4131-89a5-6fa76d0665de" xlink:to="loc_insm_DebtInstrumentConversionTermTwoMember_e032a8b4-a10c-4708-9f73-77f014219c7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermThreeMember_793591f1-67a7-4a41-a3a6-82f29657b242" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_ccae5843-0fa3-4131-89a5-6fa76d0665de" xlink:to="loc_insm_DebtInstrumentConversionTermThreeMember_793591f1-67a7-4a41-a3a6-82f29657b242" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermFourMember_112e8b83-b837-40fe-9152-09bbdb771070" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_ccae5843-0fa3-4131-89a5-6fa76d0665de" xlink:to="loc_insm_DebtInstrumentConversionTermFourMember_112e8b83-b837-40fe-9152-09bbdb771070" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_92e92df1-155a-4824-ae18-30712245013c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_us-gaap_CreditFacilityAxis_92e92df1-155a-4824-ae18-30712245013c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_92e92df1-155a-4824-ae18-30712245013c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_92e92df1-155a-4824-ae18-30712245013c" xlink:to="loc_us-gaap_CreditFacilityDomain_92e92df1-155a-4824-ae18-30712245013c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_495f8daa-769e-42c2-8341-389b8665d178" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_92e92df1-155a-4824-ae18-30712245013c" xlink:to="loc_us-gaap_CreditFacilityDomain_495f8daa-769e-42c2-8341-389b8665d178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_64eca65b-66a1-4e8e-ba4d-b2e533e2bd80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_495f8daa-769e-42c2-8341-389b8665d178" xlink:to="loc_us-gaap_SecuredDebtMember_64eca65b-66a1-4e8e-ba4d-b2e533e2bd80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83d18cb7-c2a3-4534-aa05-427f1a2f170d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83d18cb7-c2a3-4534-aa05-427f1a2f170d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_83d18cb7-c2a3-4534-aa05-427f1a2f170d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83d18cb7-c2a3-4534-aa05-427f1a2f170d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_83d18cb7-c2a3-4534-aa05-427f1a2f170d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4b5feab2-c7dc-449a-8639-69098596ac8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83d18cb7-c2a3-4534-aa05-427f1a2f170d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4b5feab2-c7dc-449a-8639-69098596ac8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_72bcc919-e674-4428-9281-8caa80db7a78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4b5feab2-c7dc-449a-8639-69098596ac8c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_72bcc919-e674-4428-9281-8caa80db7a78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_da09a517-7d3f-42d7-aef3-b92177263141" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_da09a517-7d3f-42d7-aef3-b92177263141" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_da09a517-7d3f-42d7-aef3-b92177263141_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_da09a517-7d3f-42d7-aef3-b92177263141" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_da09a517-7d3f-42d7-aef3-b92177263141_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2c625107-e5d2-4b8f-b5a3-bdc84897ffdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_da09a517-7d3f-42d7-aef3-b92177263141" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2c625107-e5d2-4b8f-b5a3-bdc84897ffdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c6ad58ca-a636-41f0-9881-6f6ba51ee3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2c625107-e5d2-4b8f-b5a3-bdc84897ffdd" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c6ad58ca-a636-41f0-9881-6f6ba51ee3b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b3a9abc8-3149-483d-a290-37cedf5967df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c6ad58ca-a636-41f0-9881-6f6ba51ee3b2" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b3a9abc8-3149-483d-a290-37cedf5967df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eb0ed8a4-da2f-490f-9347-eb1c6652fa4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eb0ed8a4-da2f-490f-9347-eb1c6652fa4e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb0ed8a4-da2f-490f-9347-eb1c6652fa4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eb0ed8a4-da2f-490f-9347-eb1c6652fa4e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb0ed8a4-da2f-490f-9347-eb1c6652fa4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_768c367a-b603-4c91-a125-1ada02f0d115" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eb0ed8a4-da2f-490f-9347-eb1c6652fa4e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_768c367a-b603-4c91-a125-1ada02f0d115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2ba9f40e-c8dc-4801-9cf2-19fedb89f428" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_768c367a-b603-4c91-a125-1ada02f0d115" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2ba9f40e-c8dc-4801-9cf2-19fedb89f428" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2a378992-b2fe-4981-b9df-8b0490a12c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2a378992-b2fe-4981-b9df-8b0490a12c2c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2a378992-b2fe-4981-b9df-8b0490a12c2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2a378992-b2fe-4981-b9df-8b0490a12c2c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2a378992-b2fe-4981-b9df-8b0490a12c2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_db222ba0-1ced-46d4-a153-b4a3aea5f5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2a378992-b2fe-4981-b9df-8b0490a12c2c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_db222ba0-1ced-46d4-a153-b4a3aea5f5c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_26c4903c-2b52-4ae2-a7a9-2ad857d7406f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_db222ba0-1ced-46d4-a153-b4a3aea5f5c4" xlink:to="loc_us-gaap_SubsequentEventMember_26c4903c-2b52-4ae2-a7a9-2ad857d7406f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_c5c1db20-321f-4bcb-b130-7823f25c11e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_us-gaap_VariableRateAxis_c5c1db20-321f-4bcb-b130-7823f25c11e2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c5c1db20-321f-4bcb-b130-7823f25c11e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_c5c1db20-321f-4bcb-b130-7823f25c11e2" xlink:to="loc_us-gaap_VariableRateDomain_c5c1db20-321f-4bcb-b130-7823f25c11e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4977d046-383d-4431-93c6-50dff815de99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_c5c1db20-321f-4bcb-b130-7823f25c11e2" xlink:to="loc_us-gaap_VariableRateDomain_4977d046-383d-4431-93c6-50dff815de99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_2c51a10f-5568-42ae-876b-d2f7c74d54e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_4977d046-383d-4431-93c6-50dff815de99" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_2c51a10f-5568-42ae-876b-d2f7c74d54e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0f7ec4cd-0033-450d-affa-4b903a964df7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0f7ec4cd-0033-450d-affa-4b903a964df7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_2c9efa58-dbbb-4f52-9f68-5861c9ed2e8b" xlink:href="insm-20240630.xsd#insm_DebtInstrumentOptionToPurchaseAdditionalDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_2c9efa58-dbbb-4f52-9f68-5861c9ed2e8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_16df2cd5-2bc5-4919-9dbb-2742ff84586a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_16df2cd5-2bc5-4919-9dbb-2742ff84586a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_ff5ff064-ad19-46e5-8086-ed25817184dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_ff5ff064-ad19-46e5-8086-ed25817184dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_ea4c7c83-dad8-4cbf-9024-e3de69825446" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_ea4c7c83-dad8-4cbf-9024-e3de69825446" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3f1cf216-5851-4465-b9b0-a3bab89d2447" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3f1cf216-5851-4465-b9b0-a3bab89d2447" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_a7aafbf7-28f7-4996-b0bc-d9a92dc4cadc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_a7aafbf7-28f7-4996-b0bc-d9a92dc4cadc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_09dd1190-2ee3-4920-9c7a-0dab13999b50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_09dd1190-2ee3-4920-9c7a-0dab13999b50" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_7e6a975c-53c1-4330-828d-85469f521ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_7e6a975c-53c1-4330-828d-85469f521ecb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c5156973-2c4f-407f-8225-fba3dd41da31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c5156973-2c4f-407f-8225-fba3dd41da31" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f36ee58f-18b8-46d5-94bf-70458e1f12d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f36ee58f-18b8-46d5-94bf-70458e1f12d2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_3a7ba367-57b7-4791-967c-1c3bb0d8239a" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_3a7ba367-57b7-4791-967c-1c3bb0d8239a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_6ae2558e-7f0f-44c6-94ed-745213eff3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_6ae2558e-7f0f-44c6-94ed-745213eff3a8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_f3b5b265-3d1b-4471-9e40-915303d33f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_f3b5b265-3d1b-4471-9e40-915303d33f6d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_47566403-9951-4a13-9ef5-b31e9081643f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_47566403-9951-4a13-9ef5-b31e9081643f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining_1454ca1b-6f5c-4761-bc47-2133a31bce01" xlink:href="insm-20240630.xsd#insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining_1454ca1b-6f5c-4761-bc47-2133a31bce01" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_90b2d62b-9a48-4c5c-a652-fc1f3750a09f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_90b2d62b-9a48-4c5c-a652-fc1f3750a09f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentRedemptionPricePerShare_dcb90902-7f14-4d1f-a069-22a778c90ce8" xlink:href="insm-20240630.xsd#insm_DebtInstrumentRedemptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_insm_DebtInstrumentRedemptionPricePerShare_dcb90902-7f14-4d1f-a069-22a778c90ce8" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_90afc105-95a8-469e-8d47-e1fa8be0bca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_90afc105-95a8-469e-8d47-e1fa8be0bca0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentPercentOfInterestPayable_fdab0d2e-934c-4655-88db-28a8848875c6" xlink:href="insm-20240630.xsd#insm_DebtInstrumentPercentOfInterestPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_insm_DebtInstrumentPercentOfInterestPayable_fdab0d2e-934c-4655-88db-28a8848875c6" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_cccde346-6d37-4667-8340-dd551c94434a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentTerm_cccde346-6d37-4667-8340-dd551c94434a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLoans_51103bb3-7487-471c-a293-231453a986b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLoans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_ProceedsFromLoans_51103bb3-7487-471c-a293-231453a986b3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_cb098e5a-3c21-4c5c-892f-eb7aa0917147" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_PaidInKindInterest_cb098e5a-3c21-4c5c-892f-eb7aa0917147" xlink:type="arc" order="22"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4a1581a4-0b04-4dff-bf97-f8a43d8a0a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ca474614-4f15-4e1c-b075-c9fad4685477" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a1581a4-0b04-4dff-bf97-f8a43d8a0a7b" xlink:to="loc_us-gaap_DebtInstrumentTable_ca474614-4f15-4e1c-b075-c9fad4685477" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b347d0da-374b-4e64-b2bc-e20481da0b97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ca474614-4f15-4e1c-b075-c9fad4685477" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b347d0da-374b-4e64-b2bc-e20481da0b97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b347d0da-374b-4e64-b2bc-e20481da0b97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b347d0da-374b-4e64-b2bc-e20481da0b97" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b347d0da-374b-4e64-b2bc-e20481da0b97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d42e00de-6b33-4962-aca8-d43e022c5713" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b347d0da-374b-4e64-b2bc-e20481da0b97" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d42e00de-6b33-4962-aca8-d43e022c5713" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_eadc6185-fec9-4cea-a668-98ba16e2c5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d42e00de-6b33-4962-aca8-d43e022c5713" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_eadc6185-fec9-4cea-a668-98ba16e2c5e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_fd817c96-05be-4fcc-acd1-4f82ae79b1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a1581a4-0b04-4dff-bf97-f8a43d8a0a7b" xlink:to="loc_us-gaap_SecuredDebt_fd817c96-05be-4fcc-acd1-4f82ae79b1c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_e3b57915-e06e-41d9-9d69-633b8f41813c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a1581a4-0b04-4dff-bf97-f8a43d8a0a7b" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_e3b57915-e06e-41d9-9d69-633b8f41813c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_754fbc00-2ba1-4773-b7ae-b01d8aba948a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a1581a4-0b04-4dff-bf97-f8a43d8a0a7b" xlink:to="loc_us-gaap_LongTermDebtCurrent_754fbc00-2ba1-4773-b7ae-b01d8aba948a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_dc5b8d61-3b36-4777-8daf-137c4f134bda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a1581a4-0b04-4dff-bf97-f8a43d8a0a7b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_dc5b8d61-3b36-4777-8daf-137c4f134bda" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#DebtScheduleofCarryingValueofTermLoanBalanceDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_820f2bd6-c26c-45b3-b764-0e221b0fee0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a111a798-e91e-4ca6-aa52-afb08eb08ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820f2bd6-c26c-45b3-b764-0e221b0fee0a" xlink:to="loc_us-gaap_DebtInstrumentTable_a111a798-e91e-4ca6-aa52-afb08eb08ac2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_784dd5b3-5dcb-47d9-8a4c-b5d2c4a1b6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a111a798-e91e-4ca6-aa52-afb08eb08ac2" xlink:to="loc_us-gaap_CreditFacilityAxis_784dd5b3-5dcb-47d9-8a4c-b5d2c4a1b6d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_784dd5b3-5dcb-47d9-8a4c-b5d2c4a1b6d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_784dd5b3-5dcb-47d9-8a4c-b5d2c4a1b6d6" xlink:to="loc_us-gaap_CreditFacilityDomain_784dd5b3-5dcb-47d9-8a4c-b5d2c4a1b6d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9d33ee6f-9896-4be6-a6ae-b591653f9640" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_784dd5b3-5dcb-47d9-8a4c-b5d2c4a1b6d6" xlink:to="loc_us-gaap_CreditFacilityDomain_9d33ee6f-9896-4be6-a6ae-b591653f9640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_e9449c15-d1eb-4ee9-b082-613da344a8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_9d33ee6f-9896-4be6-a6ae-b591653f9640" xlink:to="loc_us-gaap_SecuredDebtMember_e9449c15-d1eb-4ee9-b082-613da344a8ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e3905fbb-13a7-4963-b330-bb4eb1881c48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a111a798-e91e-4ca6-aa52-afb08eb08ac2" xlink:to="loc_us-gaap_DebtInstrumentAxis_e3905fbb-13a7-4963-b330-bb4eb1881c48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e3905fbb-13a7-4963-b330-bb4eb1881c48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e3905fbb-13a7-4963-b330-bb4eb1881c48" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e3905fbb-13a7-4963-b330-bb4eb1881c48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d609d5dc-cc05-4301-a9d3-ea40cc4ed628" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e3905fbb-13a7-4963-b330-bb4eb1881c48" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d609d5dc-cc05-4301-a9d3-ea40cc4ed628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_TermLoanMember_3c06ed09-05a7-4edf-bcde-4f36fa0d7a43" xlink:href="insm-20240630.xsd#insm_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d609d5dc-cc05-4301-a9d3-ea40cc4ed628" xlink:to="loc_insm_TermLoanMember_3c06ed09-05a7-4edf-bcde-4f36fa0d7a43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4fec98da-294f-4e99-a46c-930ddc6a404b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820f2bd6-c26c-45b3-b764-0e221b0fee0a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4fec98da-294f-4e99-a46c-930ddc6a404b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedCapitalizedInterestCosts_cfb0e858-7620-46f6-a391-7c8629ace071" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedCapitalizedInterestCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820f2bd6-c26c-45b3-b764-0e221b0fee0a" xlink:to="loc_us-gaap_AccumulatedCapitalizedInterestCosts_cfb0e858-7620-46f6-a391-7c8629ace071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_c1df24a4-3ef7-4873-923f-ef36551f1391" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820f2bd6-c26c-45b3-b764-0e221b0fee0a" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_c1df24a4-3ef7-4873-923f-ef36551f1391" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_14c1ef3e-5692-4e8f-b28f-aec0650dda26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820f2bd6-c26c-45b3-b764-0e221b0fee0a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_14c1ef3e-5692-4e8f-b28f-aec0650dda26" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fda6b47c-994a-4110-849c-455c01334264" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8a0cd99b-7758-4923-a851-4826d120f3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fda6b47c-994a-4110-849c-455c01334264" xlink:to="loc_us-gaap_DebtInstrumentTable_8a0cd99b-7758-4923-a851-4826d120f3d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_22a6de24-b341-4ec1-a66c-b1d8bef8eeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8a0cd99b-7758-4923-a851-4826d120f3d0" xlink:to="loc_us-gaap_DebtInstrumentAxis_22a6de24-b341-4ec1-a66c-b1d8bef8eeb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_22a6de24-b341-4ec1-a66c-b1d8bef8eeb1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_22a6de24-b341-4ec1-a66c-b1d8bef8eeb1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_22a6de24-b341-4ec1-a66c-b1d8bef8eeb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_48c57815-cff3-4c95-ae05-e4bdc9b6be81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_22a6de24-b341-4ec1-a66c-b1d8bef8eeb1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_48c57815-cff3-4c95-ae05-e4bdc9b6be81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_5936ab56-91e5-40d0-aaf6-44232808053d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_48c57815-cff3-4c95-ae05-e4bdc9b6be81" xlink:to="loc_us-gaap_ConvertibleDebtMember_5936ab56-91e5-40d0-aaf6-44232808053d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_TermLoanMember_b2bb66ca-cf61-480a-9542-3f0365529e7f" xlink:href="insm-20240630.xsd#insm_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_48c57815-cff3-4c95-ae05-e4bdc9b6be81" xlink:to="loc_insm_TermLoanMember_b2bb66ca-cf61-480a-9542-3f0365529e7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember_99bc963e-b66a-44b3-a68f-143121ab8891" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_48c57815-cff3-4c95-ae05-e4bdc9b6be81" xlink:to="loc_us-gaap_RoyaltyAgreementsMember_99bc963e-b66a-44b3-a68f-143121ab8891" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_1a351226-2a4e-40fd-9682-ce0688f8d6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fda6b47c-994a-4110-849c-455c01334264" xlink:to="loc_us-gaap_InterestExpenseDebt_1a351226-2a4e-40fd-9682-ce0688f8d6d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_1a8f1675-80f1-454a-9d38-1ebcc2224b92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fda6b47c-994a-4110-849c-455c01334264" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_1a8f1675-80f1-454a-9d38-1ebcc2224b92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_312896e4-581c-4d37-a978-ad99caae8544" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fda6b47c-994a-4110-849c-455c01334264" xlink:to="loc_us-gaap_InterestIncomeOther_312896e4-581c-4d37-a978-ad99caae8544" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InterestExpenseExcludingFinanceLeaseInterestExpense_88e01f8c-a0c7-4fa8-afce-419dc76575a0" xlink:href="insm-20240630.xsd#insm_InterestExpenseExcludingFinanceLeaseInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fda6b47c-994a-4110-849c-455c01334264" xlink:to="loc_insm_InterestExpenseExcludingFinanceLeaseInterestExpense_88e01f8c-a0c7-4fa8-afce-419dc76575a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_f87063ac-cfdb-4e27-a084-e520d5b6a051" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fda6b47c-994a-4110-849c-455c01334264" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_f87063ac-cfdb-4e27-a084-e520d5b6a051" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0f6867d3-2019-40a2-9899-ee012322ddae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fda6b47c-994a-4110-849c-455c01334264" xlink:to="loc_us-gaap_InterestExpense_0f6867d3-2019-40a2-9899-ee012322ddae" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#RoyaltyFinancingAgreementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ad5cc248-428b-46a2-9200-e011d9c03e46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_us-gaap_DebtInstrumentTable_ad5cc248-428b-46a2-9200-e011d9c03e46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f3ea2b51-d68f-4a76-bd87-c8f219f7647f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ad5cc248-428b-46a2-9200-e011d9c03e46" xlink:to="loc_us-gaap_CreditFacilityAxis_f3ea2b51-d68f-4a76-bd87-c8f219f7647f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f3ea2b51-d68f-4a76-bd87-c8f219f7647f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_f3ea2b51-d68f-4a76-bd87-c8f219f7647f" xlink:to="loc_us-gaap_CreditFacilityDomain_f3ea2b51-d68f-4a76-bd87-c8f219f7647f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5c3d926f-82e3-4b3f-b580-33f2a2f218c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_f3ea2b51-d68f-4a76-bd87-c8f219f7647f" xlink:to="loc_us-gaap_CreditFacilityDomain_5c3d926f-82e3-4b3f-b580-33f2a2f218c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_39d53bb4-eaf6-4561-9dbc-068ed2d04279" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5c3d926f-82e3-4b3f-b580-33f2a2f218c4" xlink:to="loc_us-gaap_SecuredDebtMember_39d53bb4-eaf6-4561-9dbc-068ed2d04279" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_07c584bf-17eb-4faf-928e-c589df9557bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ad5cc248-428b-46a2-9200-e011d9c03e46" xlink:to="loc_us-gaap_DebtInstrumentAxis_07c584bf-17eb-4faf-928e-c589df9557bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_07c584bf-17eb-4faf-928e-c589df9557bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_07c584bf-17eb-4faf-928e-c589df9557bb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_07c584bf-17eb-4faf-928e-c589df9557bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6649960b-0d85-4d13-a173-b2ddfdc1b811" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_07c584bf-17eb-4faf-928e-c589df9557bb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6649960b-0d85-4d13-a173-b2ddfdc1b811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember_912439c3-3157-4e47-9302-73ee627c0a75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6649960b-0d85-4d13-a173-b2ddfdc1b811" xlink:to="loc_us-gaap_RoyaltyAgreementsMember_912439c3-3157-4e47-9302-73ee627c0a75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6ee47b25-168b-411c-8660-b78d2d1d09c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ad5cc248-428b-46a2-9200-e011d9c03e46" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6ee47b25-168b-411c-8660-b78d2d1d09c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6ee47b25-168b-411c-8660-b78d2d1d09c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6ee47b25-168b-411c-8660-b78d2d1d09c8" xlink:to="loc_us-gaap_SegmentDomain_6ee47b25-168b-411c-8660-b78d2d1d09c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d0f1b273-5f41-4d68-b0de-54173df62ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6ee47b25-168b-411c-8660-b78d2d1d09c8" xlink:to="loc_us-gaap_SegmentDomain_d0f1b273-5f41-4d68-b0de-54173df62ba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ARIKAYCEGlobalNetSalesMember_b8589829-02fd-4ea9-b252-2b425ba6c37f" xlink:href="insm-20240630.xsd#insm_ARIKAYCEGlobalNetSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d0f1b273-5f41-4d68-b0de-54173df62ba0" xlink:to="loc_insm_ARIKAYCEGlobalNetSalesMember_b8589829-02fd-4ea9-b252-2b425ba6c37f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BrensocatibGlobalNetSalesMember_2a02e53f-ca2c-4888-93f3-3ad85930f3e4" xlink:href="insm-20240630.xsd#insm_BrensocatibGlobalNetSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d0f1b273-5f41-4d68-b0de-54173df62ba0" xlink:to="loc_insm_BrensocatibGlobalNetSalesMember_2a02e53f-ca2c-4888-93f3-3ad85930f3e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f8b43ca5-cacb-481d-bd92-a3d801f105b9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ad5cc248-428b-46a2-9200-e011d9c03e46" xlink:to="loc_srt_RangeAxis_f8b43ca5-cacb-481d-bd92-a3d801f105b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f8b43ca5-cacb-481d-bd92-a3d801f105b9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f8b43ca5-cacb-481d-bd92-a3d801f105b9" xlink:to="loc_srt_RangeMember_f8b43ca5-cacb-481d-bd92-a3d801f105b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a07f18b-23d3-4d7a-9914-696bff912766" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f8b43ca5-cacb-481d-bd92-a3d801f105b9" xlink:to="loc_srt_RangeMember_5a07f18b-23d3-4d7a-9914-696bff912766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8b6fd4ec-5a34-4f3e-8c6b-ccdb2117bb75" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5a07f18b-23d3-4d7a-9914-696bff912766" xlink:to="loc_srt_MinimumMember_8b6fd4ec-5a34-4f3e-8c6b-ccdb2117bb75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4f137271-7c5f-4dce-aa03-4cf6b8c906a3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5a07f18b-23d3-4d7a-9914-696bff912766" xlink:to="loc_srt_MaximumMember_4f137271-7c5f-4dce-aa03-4cf6b8c906a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_110a2bcd-88b8-4b9c-9375-5f903f5230e9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ad5cc248-428b-46a2-9200-e011d9c03e46" xlink:to="loc_srt_StatementScenarioAxis_110a2bcd-88b8-4b9c-9375-5f903f5230e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_110a2bcd-88b8-4b9c-9375-5f903f5230e9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_110a2bcd-88b8-4b9c-9375-5f903f5230e9" xlink:to="loc_srt_ScenarioUnspecifiedDomain_110a2bcd-88b8-4b9c-9375-5f903f5230e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bb1c64e7-46c8-404e-8404-f63f01f2dec2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_110a2bcd-88b8-4b9c-9375-5f903f5230e9" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bb1c64e7-46c8-404e-8404-f63f01f2dec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a79fa5fc-c850-43f2-8b96-90d4dcc7b1ec" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_bb1c64e7-46c8-404e-8404-f63f01f2dec2" xlink:to="loc_srt_ScenarioForecastMember_a79fa5fc-c850-43f2-8b96-90d4dcc7b1ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ProceedsFromRoyaltyFinancing_abcd8085-62d4-4b80-8324-3fafdf725347" xlink:href="insm-20240630.xsd#insm_ProceedsFromRoyaltyFinancing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_insm_ProceedsFromRoyaltyFinancing_abcd8085-62d4-4b80-8324-3fafdf725347" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentRoyaltyStatedPercentage_a2a0ab1c-ca6d-4267-86da-015c2533b046" xlink:href="insm-20240630.xsd#insm_DebtInstrumentRoyaltyStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_insm_DebtInstrumentRoyaltyStatedPercentage_a2a0ab1c-ca6d-4267-86da-015c2533b046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_95eab147-d60e-48ab-946c-34ec5611169f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_95eab147-d60e-48ab-946c-34ec5611169f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_0cfbf8a6-beaf-447e-b12c-678455782897" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_0cfbf8a6-beaf-447e-b12c-678455782897" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentRoyaltyPayableMaximum_ba7063ba-7a4d-4361-8205-5db959dfa920" xlink:href="insm-20240630.xsd#insm_DebtInstrumentRoyaltyPayableMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_insm_DebtInstrumentRoyaltyPayableMaximum_ba7063ba-7a4d-4361-8205-5db959dfa920" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_c0e93287-f1e0-4fe4-8e41-f2cd194d83ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_c0e93287-f1e0-4fe4-8e41-f2cd194d83ed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ProceedsFromRoyaltyFinancingAgreementNet_9a9b4a07-d399-41e7-abfe-d799bc4a0efc" xlink:href="insm-20240630.xsd#insm_ProceedsFromRoyaltyFinancingAgreementNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_insm_ProceedsFromRoyaltyFinancingAgreementNet_9a9b4a07-d399-41e7-abfe-d799bc4a0efc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6b10293f-bba9-46e6-8f70-d7ab294a105e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6b10293f-bba9-46e6-8f70-d7ab294a105e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_356e1e35-5e18-4802-ab2b-19e18035cd44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_356e1e35-5e18-4802-ab2b-19e18035cd44" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a4218046-add1-49cf-9f31-f5fb23f44623" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b8f212f0-faa8-4f01-901d-a6036cfac9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a4218046-add1-49cf-9f31-f5fb23f44623" xlink:to="loc_us-gaap_DebtInstrumentTable_b8f212f0-faa8-4f01-901d-a6036cfac9f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c57e17b3-8fbc-419a-8eac-1143a05ec316" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b8f212f0-faa8-4f01-901d-a6036cfac9f1" xlink:to="loc_us-gaap_CreditFacilityAxis_c57e17b3-8fbc-419a-8eac-1143a05ec316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c57e17b3-8fbc-419a-8eac-1143a05ec316_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_c57e17b3-8fbc-419a-8eac-1143a05ec316" xlink:to="loc_us-gaap_CreditFacilityDomain_c57e17b3-8fbc-419a-8eac-1143a05ec316_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ffa231d4-d919-4200-82f1-6b92b9bf797d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_c57e17b3-8fbc-419a-8eac-1143a05ec316" xlink:to="loc_us-gaap_CreditFacilityDomain_ffa231d4-d919-4200-82f1-6b92b9bf797d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_3963b636-488e-45b6-ae03-71cb075c0f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_ffa231d4-d919-4200-82f1-6b92b9bf797d" xlink:to="loc_us-gaap_SecuredDebtMember_3963b636-488e-45b6-ae03-71cb075c0f8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3938653c-c21a-4b51-9629-c4afabcf8f51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b8f212f0-faa8-4f01-901d-a6036cfac9f1" xlink:to="loc_us-gaap_DebtInstrumentAxis_3938653c-c21a-4b51-9629-c4afabcf8f51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3938653c-c21a-4b51-9629-c4afabcf8f51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3938653c-c21a-4b51-9629-c4afabcf8f51" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3938653c-c21a-4b51-9629-c4afabcf8f51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_09f8c5b9-933a-4a3b-95f5-72d7bff01e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3938653c-c21a-4b51-9629-c4afabcf8f51" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_09f8c5b9-933a-4a3b-95f5-72d7bff01e6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember_48a935cd-970a-41c6-9aa1-4fc09f875d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_09f8c5b9-933a-4a3b-95f5-72d7bff01e6b" xlink:to="loc_us-gaap_RoyaltyAgreementsMember_48a935cd-970a-41c6-9aa1-4fc09f875d4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:href="insm-20240630.xsd#insm_RoyaltyFinancingAgreementRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a4218046-add1-49cf-9f31-f5fb23f44623" xlink:to="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_58a33f47-2825-4914-8be7-4080560ab50b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_58a33f47-2825-4914-8be7-4080560ab50b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_34ebfb06-5253-4af2-9a5a-c828ce166c60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:to="loc_us-gaap_PaymentsForRoyalties_34ebfb06-5253-4af2-9a5a-c828ce166c60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_7939a87e-7fee-4c91-abce-18b86f9cb0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:to="loc_us-gaap_InterestExpenseDebt_7939a87e-7fee-4c91-abce-18b86f9cb0a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_7c889cd4-5c71-452e-9425-b62f1c8f620b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_22a4b6fa-edbd-4c9b-b679-457759bd3a96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_22a4b6fa-edbd-4c9b-b679-457759bd3a96" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_be6c1565-0238-4fc7-b815-265385737136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_be6c1565-0238-4fc7-b815-265385737136" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtIssuanceCostsOther_a6a1432f-e308-4055-abe4-706e874df87d" xlink:href="insm-20240630.xsd#insm_DebtIssuanceCostsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:to="loc_insm_DebtIssuanceCostsOther_a6a1432f-e308-4055-abe4-706e874df87d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_5f9b1587-2909-4955-b763-e4c00a02362a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_1689d570-9bb2-4d8a-a553-884bab0bb57b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#ShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_51d9b9d6-27c0-4620-862f-d4321f33d4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_51d9b9d6-27c0-4620-862f-d4321f33d4d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bd78e5f4-e7f0-4c09-82d6-c6f16ad50a77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51d9b9d6-27c0-4620-862f-d4321f33d4d8" xlink:to="loc_us-gaap_AwardTypeAxis_bd78e5f4-e7f0-4c09-82d6-c6f16ad50a77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd78e5f4-e7f0-4c09-82d6-c6f16ad50a77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bd78e5f4-e7f0-4c09-82d6-c6f16ad50a77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd78e5f4-e7f0-4c09-82d6-c6f16ad50a77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe207717-6b6d-4186-a502-b5b887f03794" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bd78e5f4-e7f0-4c09-82d6-c6f16ad50a77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe207717-6b6d-4186-a502-b5b887f03794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6ea4d208-a659-452a-9fb7-1d7cae2ca8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe207717-6b6d-4186-a502-b5b887f03794" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6ea4d208-a659-452a-9fb7-1d7cae2ca8a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e5583a98-fcee-41cf-991e-076c55cfceed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe207717-6b6d-4186-a502-b5b887f03794" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e5583a98-fcee-41cf-991e-076c55cfceed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_8916051c-a019-4b38-8a17-82d1df635fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe207717-6b6d-4186-a502-b5b887f03794" xlink:to="loc_us-gaap_PerformanceSharesMember_8916051c-a019-4b38-8a17-82d1df635fbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fa5fb8f8-6d34-4f9d-8c02-5b234fdce21a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51d9b9d6-27c0-4620-862f-d4321f33d4d8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fa5fb8f8-6d34-4f9d-8c02-5b234fdce21a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fa5fb8f8-6d34-4f9d-8c02-5b234fdce21a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fa5fb8f8-6d34-4f9d-8c02-5b234fdce21a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fa5fb8f8-6d34-4f9d-8c02-5b234fdce21a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fa592b94-e245-45ea-b2ef-5983186069f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fa5fb8f8-6d34-4f9d-8c02-5b234fdce21a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fa592b94-e245-45ea-b2ef-5983186069f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_845987eb-0b41-42ec-ab13-3a491ca14ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fa592b94-e245-45ea-b2ef-5983186069f7" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_845987eb-0b41-42ec-ab13-3a491ca14ff3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4f259020-92fc-456a-9411-15abf61ee9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51d9b9d6-27c0-4620-862f-d4321f33d4d8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4f259020-92fc-456a-9411-15abf61ee9a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f259020-92fc-456a-9411-15abf61ee9a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4f259020-92fc-456a-9411-15abf61ee9a2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f259020-92fc-456a-9411-15abf61ee9a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b00945cd-40df-4c79-b21b-6af6db06c9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4f259020-92fc-456a-9411-15abf61ee9a2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b00945cd-40df-4c79-b21b-6af6db06c9d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncMember_7c754e6f-ad3b-427a-b97d-41c8c0649be1" xlink:href="insm-20240630.xsd#insm_MotusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b00945cd-40df-4c79-b21b-6af6db06c9d5" xlink:to="loc_insm_MotusBiosciencesIncMember_7c754e6f-ad3b-427a-b97d-41c8c0649be1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AdrestiaTherapeuticsLtdMember_4ee687a5-7f57-4652-8d14-0b1755d637f4" xlink:href="insm-20240630.xsd#insm_AdrestiaTherapeuticsLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b00945cd-40df-4c79-b21b-6af6db06c9d5" xlink:to="loc_insm_AdrestiaTherapeuticsLtdMember_4ee687a5-7f57-4652-8d14-0b1755d637f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_VertuisBioIncMember_a0f096c2-387b-4edf-b94e-3057964e9bf1" xlink:href="insm-20240630.xsd#insm_VertuisBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b00945cd-40df-4c79-b21b-6af6db06c9d5" xlink:to="loc_insm_VertuisBioIncMember_a0f096c2-387b-4edf-b94e-3057964e9bf1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_913b10a9-c7de-4c89-899d-40c94d5699a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51d9b9d6-27c0-4620-862f-d4321f33d4d8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_913b10a9-c7de-4c89-899d-40c94d5699a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_913b10a9-c7de-4c89-899d-40c94d5699a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_913b10a9-c7de-4c89-899d-40c94d5699a2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_913b10a9-c7de-4c89-899d-40c94d5699a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3ee36f30-88da-4ec3-9d93-3704432e3966" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_913b10a9-c7de-4c89-899d-40c94d5699a2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3ee36f30-88da-4ec3-9d93-3704432e3966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PublicStockOfferingMember_e9b461e9-ece0-470a-888c-1a5ec6db3172" xlink:href="insm-20240630.xsd#insm_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3ee36f30-88da-4ec3-9d93-3704432e3966" xlink:to="loc_insm_PublicStockOfferingMember_e9b461e9-ece0-470a-888c-1a5ec6db3172" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AtTheMarketAgreementMember_abb48e92-77f5-4a17-9208-84b7e514f9bc" xlink:href="insm-20240630.xsd#insm_AtTheMarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3ee36f30-88da-4ec3-9d93-3704432e3966" xlink:to="loc_insm_AtTheMarketAgreementMember_abb48e92-77f5-4a17-9208-84b7e514f9bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_a36b827a-9044-4944-b328-7958c3e6389b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3ee36f30-88da-4ec3-9d93-3704432e3966" xlink:to="loc_us-gaap_OverAllotmentOptionMember_a36b827a-9044-4944-b328-7958c3e6389b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8e01c7d4-1a9d-4128-87b6-e78de9a7ab58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8e01c7d4-1a9d-4128-87b6-e78de9a7ab58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f66b9667-158f-48b3-a2bf-327fac98eed4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f66b9667-158f-48b3-a2bf-327fac98eed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5a413689-8ba0-4c6c-a79c-84bba097c5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_CommonStockSharesIssued_5a413689-8ba0-4c6c-a79c-84bba097c5bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1157ef2c-e74b-4ccc-ae8b-14033d752501" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1157ef2c-e74b-4ccc-ae8b-14033d752501" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e3fe8eb2-efbb-4b69-b9ab-eab5b52d1668" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e3fe8eb2-efbb-4b69-b9ab-eab5b52d1668" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_21ec87f7-48a2-452a-a94a-97dd6e4c1718" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_21ec87f7-48a2-452a-a94a-97dd6e4c1718" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_16f7980e-de74-4c3e-8752-da4937ad184a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_16f7980e-de74-4c3e-8752-da4937ad184a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7cfeb04b-10d4-40ce-8a3b-a4b767757260" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7cfeb04b-10d4-40ce-8a3b-a4b767757260" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_6f59240e-a889-42b2-af27-9f1db4355223" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_6f59240e-a889-42b2-af27-9f1db4355223" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_8e89049b-cb97-4d68-841f-bd85a5385c18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_8e89049b-cb97-4d68-841f-bd85a5385c18" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_86d11532-ec91-4d70-ad2d-4edf0099889d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_86d11532-ec91-4d70-ad2d-4edf0099889d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CommonStockAuthorizedAggregateGrossSalesProceeds_cf70bd9f-1f98-4b6b-b7ce-b1163a3e29c1" xlink:href="insm-20240630.xsd#insm_CommonStockAuthorizedAggregateGrossSalesProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_insm_CommonStockAuthorizedAggregateGrossSalesProceeds_cf70bd9f-1f98-4b6b-b7ce-b1163a3e29c1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6beeca01-a658-4092-9861-bc25bcbc8dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6beeca01-a658-4092-9861-bc25bcbc8dc9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_20cd7803-c865-4823-9a54-9b4efe44c222" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_20cd7803-c865-4823-9a54-9b4efe44c222" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f60e0b2c-226a-4c99-b888-20e021e41777" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f60e0b2c-226a-4c99-b888-20e021e41777" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3ea47697-b3c1-40bd-bd72-5ba0321c58de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3ea47697-b3c1-40bd-bd72-5ba0321c58de" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c58010b9-44a6-4a0d-9bc8-442123223d64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c58010b9-44a6-4a0d-9bc8-442123223d64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d95cbb9d-1e60-4298-8770-cdf684d936e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c58010b9-44a6-4a0d-9bc8-442123223d64" xlink:to="loc_us-gaap_PlanNameAxis_d95cbb9d-1e60-4298-8770-cdf684d936e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d95cbb9d-1e60-4298-8770-cdf684d936e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d95cbb9d-1e60-4298-8770-cdf684d936e2" xlink:to="loc_us-gaap_PlanNameDomain_d95cbb9d-1e60-4298-8770-cdf684d936e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cc60804e-7edd-4e57-82d5-2776a0aaf5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d95cbb9d-1e60-4298-8770-cdf684d936e2" xlink:to="loc_us-gaap_PlanNameDomain_cc60804e-7edd-4e57-82d5-2776a0aaf5f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2019IncentivePlanMember_3f03c446-0f24-435c-9259-269ebeb6119c" xlink:href="insm-20240630.xsd#insm_A2019IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cc60804e-7edd-4e57-82d5-2776a0aaf5f4" xlink:to="loc_insm_A2019IncentivePlanMember_3f03c446-0f24-435c-9259-269ebeb6119c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2019IncentivePlanThirdAmendmentMember_3d7e5c00-e172-423a-af8d-f6d6386e8e04" xlink:href="insm-20240630.xsd#insm_A2019IncentivePlanThirdAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cc60804e-7edd-4e57-82d5-2776a0aaf5f4" xlink:to="loc_insm_A2019IncentivePlanThirdAmendmentMember_3d7e5c00-e172-423a-af8d-f6d6386e8e04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EmployeeStockPurchasePlan2018Member_93fc3ea7-a030-4b66-b9eb-9b7fbf0bfd3e" xlink:href="insm-20240630.xsd#insm_EmployeeStockPurchasePlan2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cc60804e-7edd-4e57-82d5-2776a0aaf5f4" xlink:to="loc_insm_EmployeeStockPurchasePlan2018Member_93fc3ea7-a030-4b66-b9eb-9b7fbf0bfd3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_80486006-08a2-4bb5-8f70-a102e4bc620b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c58010b9-44a6-4a0d-9bc8-442123223d64" xlink:to="loc_us-gaap_AwardTypeAxis_80486006-08a2-4bb5-8f70-a102e4bc620b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80486006-08a2-4bb5-8f70-a102e4bc620b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_80486006-08a2-4bb5-8f70-a102e4bc620b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80486006-08a2-4bb5-8f70-a102e4bc620b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9fd59c1-fc59-4b7e-a5dc-f7f31fbeb021" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_80486006-08a2-4bb5-8f70-a102e4bc620b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9fd59c1-fc59-4b7e-a5dc-f7f31fbeb021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_252677e4-8989-47a6-ab91-99308d5a15ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9fd59c1-fc59-4b7e-a5dc-f7f31fbeb021" xlink:to="loc_us-gaap_EmployeeStockOptionMember_252677e4-8989-47a6-ab91-99308d5a15ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_57618cb4-fe80-4b79-9dbf-a6e6612e11f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9fd59c1-fc59-4b7e-a5dc-f7f31fbeb021" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_57618cb4-fe80-4b79-9dbf-a6e6612e11f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_01e0c350-9c96-4a0f-b612-c07302f9c7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9fd59c1-fc59-4b7e-a5dc-f7f31fbeb021" xlink:to="loc_us-gaap_PerformanceSharesMember_01e0c350-9c96-4a0f-b612-c07302f9c7bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b50ec1ad-46fc-4fa9-8072-525c247aebb6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c58010b9-44a6-4a0d-9bc8-442123223d64" xlink:to="loc_srt_RangeAxis_b50ec1ad-46fc-4fa9-8072-525c247aebb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b50ec1ad-46fc-4fa9-8072-525c247aebb6_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b50ec1ad-46fc-4fa9-8072-525c247aebb6" xlink:to="loc_srt_RangeMember_b50ec1ad-46fc-4fa9-8072-525c247aebb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_845763f2-e994-4dc6-866d-1fac67b3b64d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b50ec1ad-46fc-4fa9-8072-525c247aebb6" xlink:to="loc_srt_RangeMember_845763f2-e994-4dc6-866d-1fac67b3b64d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_44d6ddb7-de66-4d7c-b4ad-569201466fa3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_845763f2-e994-4dc6-866d-1fac67b3b64d" xlink:to="loc_srt_MinimumMember_44d6ddb7-de66-4d7c-b4ad-569201466fa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7fb59bb5-380a-42d5-bdee-6d2058703ea4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_845763f2-e994-4dc6-866d-1fac67b3b64d" xlink:to="loc_srt_MaximumMember_7fb59bb5-380a-42d5-bdee-6d2058703ea4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_13ce6276-6e0b-4795-b5d3-70560909be73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_13ce6276-6e0b-4795-b5d3-70560909be73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ea261d53-1cd2-4040-9897-a5fed38fe029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ea261d53-1cd2-4040-9897-a5fed38fe029" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_3623a9fe-8fe7-4fff-98e0-b1eea7d5a100" xlink:href="insm-20240630.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_3623a9fe-8fe7-4fff-98e0-b1eea7d5a100" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b6febf69-93c4-4d17-9ca6-397c37acd2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b6febf69-93c4-4d17-9ca6-397c37acd2f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_d75a34a0-3a0b-469b-9190-027da29c7ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_d75a34a0-3a0b-469b-9190-027da29c7ce4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_eadd4aef-e46d-4aef-b214-78aaeef92792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_eadd4aef-e46d-4aef-b214-78aaeef92792" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_db4057b1-b2cb-426c-9406-936ec4ad35dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_db4057b1-b2cb-426c-9406-936ec4ad35dc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b8dff16f-0d49-4f1e-b574-bbe5edb7a2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b8dff16f-0d49-4f1e-b574-bbe5edb7a2e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2460ba75-406e-4ae3-8cb0-e9cc8f3e1f75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2460ba75-406e-4ae3-8cb0-e9cc8f3e1f75" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d3b2e46f-7f23-46bb-b393-5f5c9ff0a1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d3b2e46f-7f23-46bb-b393-5f5c9ff0a1d7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2ad620f9-38a9-4ce1-9510-4483cd2ac4da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2ad620f9-38a9-4ce1-9510-4483cd2ac4da" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_03292309-e192-4b62-9b55-2696eceb6789" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_03292309-e192-4b62-9b55-2696eceb6789" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd04c11b-a23f-4fba-ae39-05fa29ca75f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec1aeff2-a0fb-4a09-a3a5-46f410fcc515" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd04c11b-a23f-4fba-ae39-05fa29ca75f2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec1aeff2-a0fb-4a09-a3a5-46f410fcc515" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d241290c-4e13-4fbc-80a1-7ede79e5aa69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec1aeff2-a0fb-4a09-a3a5-46f410fcc515" xlink:to="loc_us-gaap_AwardTypeAxis_d241290c-4e13-4fbc-80a1-7ede79e5aa69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d241290c-4e13-4fbc-80a1-7ede79e5aa69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d241290c-4e13-4fbc-80a1-7ede79e5aa69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d241290c-4e13-4fbc-80a1-7ede79e5aa69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fa06787-0cff-4866-afc2-984de89376df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d241290c-4e13-4fbc-80a1-7ede79e5aa69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fa06787-0cff-4866-afc2-984de89376df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_StockOptionsAndRestrictedStockUnitsMember_901db12b-6628-4621-805f-e0a2c4128582" xlink:href="insm-20240630.xsd#insm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fa06787-0cff-4866-afc2-984de89376df" xlink:to="loc_insm_StockOptionsAndRestrictedStockUnitsMember_901db12b-6628-4621-805f-e0a2c4128582" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bee6ad8a-9a3e-4d42-b985-d34d41fac990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec1aeff2-a0fb-4a09-a3a5-46f410fcc515" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bee6ad8a-9a3e-4d42-b985-d34d41fac990" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bee6ad8a-9a3e-4d42-b985-d34d41fac990_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bee6ad8a-9a3e-4d42-b985-d34d41fac990" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bee6ad8a-9a3e-4d42-b985-d34d41fac990_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8a3b544f-5f8a-44c5-87f1-4c6344b3ebce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bee6ad8a-9a3e-4d42-b985-d34d41fac990" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8a3b544f-5f8a-44c5-87f1-4c6344b3ebce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1ea1af6b-0573-4b31-a5cf-120125a569b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8a3b544f-5f8a-44c5-87f1-4c6344b3ebce" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1ea1af6b-0573-4b31-a5cf-120125a569b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e65f35fa-b300-4014-a02e-f05d9c5f43c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8a3b544f-5f8a-44c5-87f1-4c6344b3ebce" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e65f35fa-b300-4014-a02e-f05d9c5f43c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_cdbbc3f4-c9b5-452e-bf5d-293184b1b938" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd04c11b-a23f-4fba-ae39-05fa29ca75f2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_cdbbc3f4-c9b5-452e-bf5d-293184b1b938" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7def9dc-1637-41e1-98eb-d28f8020aed4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7def9dc-1637-41e1-98eb-d28f8020aed4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_5759e2e0-fd92-4613-aa74-384d29c2d8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7def9dc-1637-41e1-98eb-d28f8020aed4" xlink:to="loc_us-gaap_AssetAcquisitionAxis_5759e2e0-fd92-4613-aa74-384d29c2d8b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_5759e2e0-fd92-4613-aa74-384d29c2d8b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_5759e2e0-fd92-4613-aa74-384d29c2d8b7" xlink:to="loc_us-gaap_AssetAcquisitionDomain_5759e2e0-fd92-4613-aa74-384d29c2d8b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_76317e2c-0959-482b-a6d4-13dbf1c557c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_5759e2e0-fd92-4613-aa74-384d29c2d8b7" xlink:to="loc_us-gaap_AssetAcquisitionDomain_76317e2c-0959-482b-a6d4-13dbf1c557c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AdrestiaTherapeuticsLtdMember_af26597f-bdb1-4505-9482-8a57b1d4b27b" xlink:href="insm-20240630.xsd#insm_AdrestiaTherapeuticsLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_76317e2c-0959-482b-a6d4-13dbf1c557c2" xlink:to="loc_insm_AdrestiaTherapeuticsLtdMember_af26597f-bdb1-4505-9482-8a57b1d4b27b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_VertuisBioIncMember_bc9a8841-e6f0-46f0-a156-8ff2f73ce795" xlink:href="insm-20240630.xsd#insm_VertuisBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_76317e2c-0959-482b-a6d4-13dbf1c557c2" xlink:to="loc_insm_VertuisBioIncMember_bc9a8841-e6f0-46f0-a156-8ff2f73ce795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_TriggeringEventAxis_d193ef08-6078-45d9-b29d-e74d98a99608" xlink:href="insm-20240630.xsd#insm_TriggeringEventAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7def9dc-1637-41e1-98eb-d28f8020aed4" xlink:to="loc_insm_TriggeringEventAxis_d193ef08-6078-45d9-b29d-e74d98a99608" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_TriggeringEventDomain_d193ef08-6078-45d9-b29d-e74d98a99608_default" xlink:href="insm-20240630.xsd#insm_TriggeringEventDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_insm_TriggeringEventAxis_d193ef08-6078-45d9-b29d-e74d98a99608" xlink:to="loc_insm_TriggeringEventDomain_d193ef08-6078-45d9-b29d-e74d98a99608_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_TriggeringEventDomain_94871098-1c9c-41e0-8c31-6a6a36589ac4" xlink:href="insm-20240630.xsd#insm_TriggeringEventDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_insm_TriggeringEventAxis_d193ef08-6078-45d9-b29d-e74d98a99608" xlink:to="loc_insm_TriggeringEventDomain_94871098-1c9c-41e0-8c31-6a6a36589ac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestoneEvent1Member_b0456ce1-2e3b-4871-858c-2eeb987759ec" xlink:href="insm-20240630.xsd#insm_MilestoneEvent1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_TriggeringEventDomain_94871098-1c9c-41e0-8c31-6a6a36589ac4" xlink:to="loc_insm_MilestoneEvent1Member_b0456ce1-2e3b-4871-858c-2eeb987759ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestoneEvent2Member_753429d4-41fe-494e-998f-d2a071f8bd1d" xlink:href="insm-20240630.xsd#insm_MilestoneEvent2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_TriggeringEventDomain_94871098-1c9c-41e0-8c31-6a6a36589ac4" xlink:to="loc_insm_MilestoneEvent2Member_753429d4-41fe-494e-998f-d2a071f8bd1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_caf79f89-700a-4966-8fc6-8aaf1beedf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7def9dc-1637-41e1-98eb-d28f8020aed4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_caf79f89-700a-4966-8fc6-8aaf1beedf8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_caf79f89-700a-4966-8fc6-8aaf1beedf8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_caf79f89-700a-4966-8fc6-8aaf1beedf8a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_caf79f89-700a-4966-8fc6-8aaf1beedf8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3dde47e8-3fc9-4bb1-95bc-57f6a13d71f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_caf79f89-700a-4966-8fc6-8aaf1beedf8a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3dde47e8-3fc9-4bb1-95bc-57f6a13d71f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember_7871e191-eaad-4cde-a6a1-c3ac49f64d0b" xlink:href="insm-20240630.xsd#insm_MotusBiosciencesIncAndAlgaeneXIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3dde47e8-3fc9-4bb1-95bc-57f6a13d71f6" xlink:to="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember_7871e191-eaad-4cde-a6a1-c3ac49f64d0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncMember_4b54cfb9-0767-473b-9f0c-a1c291f8587f" xlink:href="insm-20240630.xsd#insm_MotusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember_7871e191-eaad-4cde-a6a1-c3ac49f64d0b" xlink:to="loc_insm_MotusBiosciencesIncMember_4b54cfb9-0767-473b-9f0c-a1c291f8587f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AlgaeneXIncMember_da7ce1e2-e1e9-416c-834e-f1e8cf152671" xlink:href="insm-20240630.xsd#insm_AlgaeneXIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember_7871e191-eaad-4cde-a6a1-c3ac49f64d0b" xlink:to="loc_insm_AlgaeneXIncMember_da7ce1e2-e1e9-416c-834e-f1e8cf152671" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_102f6e11-a598-4b80-a1a9-063bcd30b5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7def9dc-1637-41e1-98eb-d28f8020aed4" xlink:to="loc_us-gaap_VestingAxis_102f6e11-a598-4b80-a1a9-063bcd30b5e1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_102f6e11-a598-4b80-a1a9-063bcd30b5e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_102f6e11-a598-4b80-a1a9-063bcd30b5e1" xlink:to="loc_us-gaap_VestingDomain_102f6e11-a598-4b80-a1a9-063bcd30b5e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_74998a61-78d2-418b-9468-d298208a89ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_102f6e11-a598-4b80-a1a9-063bcd30b5e1" xlink:to="loc_us-gaap_VestingDomain_74998a61-78d2-418b-9468-d298208a89ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3530f994-50ba-4b05-979d-443f35ffda3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_74998a61-78d2-418b-9468-d298208a89ab" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3530f994-50ba-4b05-979d-443f35ffda3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_57c8a12a-974d-49c8-b6d1-ee2831afbf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_74998a61-78d2-418b-9468-d298208a89ab" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_57c8a12a-974d-49c8-b6d1-ee2831afbf0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_5103be6a-8e94-4517-baf3-24023acba6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_74998a61-78d2-418b-9468-d298208a89ab" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_5103be6a-8e94-4517-baf3-24023acba6c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_dc8e5d08-142c-4224-a7b7-fefffddb07ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7def9dc-1637-41e1-98eb-d28f8020aed4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_dc8e5d08-142c-4224-a7b7-fefffddb07ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_dc8e5d08-142c-4224-a7b7-fefffddb07ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_dc8e5d08-142c-4224-a7b7-fefffddb07ab" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_dc8e5d08-142c-4224-a7b7-fefffddb07ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_13c409a7-4ed3-40dc-aef3-825952a97840" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_dc8e5d08-142c-4224-a7b7-fefffddb07ab" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_13c409a7-4ed3-40dc-aef3-825952a97840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_903edcda-149e-4b45-9a2e-cce67894c110" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_13c409a7-4ed3-40dc-aef3-825952a97840" xlink:to="loc_us-gaap_SubsequentEventMember_903edcda-149e-4b45-9a2e-cce67894c110" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1878cf4f-59ab-4c30-807d-940ad0cfae5f" xlink:href="insm-20240630.xsd#insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1878cf4f-59ab-4c30-807d-940ad0cfae5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_70b7778f-cb68-486a-acc5-ed26a617fd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_SharePrice_70b7778f-cb68-486a-acc5-ed26a617fd5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_ec360ae3-9c57-43cd-993c-2dce59ae86d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_ec360ae3-9c57-43cd-993c-2dce59ae86d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_c088874d-7d84-4d19-8e77-61b618fc0f29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_c088874d-7d84-4d19-8e77-61b618fc0f29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_835e698f-1b7e-4221-8997-5675c6552a33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_835e698f-1b7e-4221-8997-5675c6552a33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_056e4bb6-5eef-47e5-a45d-ed2d33e9138c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_056e4bb6-5eef-47e5-a45d-ed2d33e9138c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_76bbf84e-e2d9-451b-b19b-932bd47ba079" xlink:href="insm-20240630.xsd#insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_76bbf84e-e2d9-451b-b19b-932bd47ba079" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_edb82742-890a-4638-a2f4-f09bbfed488d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_edb82742-890a-4638-a2f4-f09bbfed488d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_54d326ff-9b38-4fa5-9486-a273506f9372" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_54d326ff-9b38-4fa5-9486-a273506f9372" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_f19c738b-a502-414e-b0a3-559c89f1bc04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_f19c738b-a502-414e-b0a3-559c89f1bc04" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessAcquisitionConsecutiveTradingDayPeriod_f7e4c8dc-3b16-4ed8-aba9-2dc17a7980d5" xlink:href="insm-20240630.xsd#insm_BusinessAcquisitionConsecutiveTradingDayPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_insm_BusinessAcquisitionConsecutiveTradingDayPeriod_f7e4c8dc-3b16-4ed8-aba9-2dc17a7980d5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_93a88dce-9a47-4b62-a7a5-ab1b830ea00b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_93a88dce-9a47-4b62-a7a5-ab1b830ea00b" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#AcquisitionsScheduleofPurchasePriceDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_17280f25-870d-4f81-88b9-1c000a58ca24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6bdf1e06-6693-40d6-9927-1aabfc64462f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17280f25-870d-4f81-88b9-1c000a58ca24" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6bdf1e06-6693-40d6-9927-1aabfc64462f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_e357906c-2f7e-40a8-bedc-ed3c0b38ecdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6bdf1e06-6693-40d6-9927-1aabfc64462f" xlink:to="loc_us-gaap_AssetAcquisitionAxis_e357906c-2f7e-40a8-bedc-ed3c0b38ecdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_e357906c-2f7e-40a8-bedc-ed3c0b38ecdd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_e357906c-2f7e-40a8-bedc-ed3c0b38ecdd" xlink:to="loc_us-gaap_AssetAcquisitionDomain_e357906c-2f7e-40a8-bedc-ed3c0b38ecdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_602599f6-94c4-4efd-9bcd-3b4eaf3766f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_e357906c-2f7e-40a8-bedc-ed3c0b38ecdd" xlink:to="loc_us-gaap_AssetAcquisitionDomain_602599f6-94c4-4efd-9bcd-3b4eaf3766f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_VertuisBioIncMember_03fa4271-6a91-4edf-ae62-dcde77fe4fc3" xlink:href="insm-20240630.xsd#insm_VertuisBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_602599f6-94c4-4efd-9bcd-3b4eaf3766f1" xlink:to="loc_insm_VertuisBioIncMember_03fa4271-6a91-4edf-ae62-dcde77fe4fc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_599a7ee4-c920-4e2c-87b6-cfcbe6298118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17280f25-870d-4f81-88b9-1c000a58ca24" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_599a7ee4-c920-4e2c-87b6-cfcbe6298118" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_9522340f-5e95-41cd-8f89-558fb28e3c65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17280f25-870d-4f81-88b9-1c000a58ca24" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_9522340f-5e95-41cd-8f89-558fb28e3c65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_bb580c39-26a5-481c-be6d-b462ecb24108" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17280f25-870d-4f81-88b9-1c000a58ca24" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_bb580c39-26a5-481c-be6d-b462ecb24108" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_7e240d89-449f-4321-88e7-82367f382ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_0fa8926c-762f-4527-b87e-78bfb854bbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_7e240d89-449f-4321-88e7-82367f382ae3" xlink:to="loc_us-gaap_SubsequentEventTable_0fa8926c-762f-4527-b87e-78bfb854bbd3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_25a50b2c-83e0-4bd0-8e3a-1f8208fe358a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0fa8926c-762f-4527-b87e-78bfb854bbd3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_25a50b2c-83e0-4bd0-8e3a-1f8208fe358a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_25a50b2c-83e0-4bd0-8e3a-1f8208fe358a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_25a50b2c-83e0-4bd0-8e3a-1f8208fe358a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_25a50b2c-83e0-4bd0-8e3a-1f8208fe358a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_66c4d3a6-e3d0-4158-823f-c2a7a8a9d196" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_25a50b2c-83e0-4bd0-8e3a-1f8208fe358a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_66c4d3a6-e3d0-4158-823f-c2a7a8a9d196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_79086a50-19aa-49c0-80c8-28e9ffffb54d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_66c4d3a6-e3d0-4158-823f-c2a7a8a9d196" xlink:to="loc_us-gaap_SubsequentEventMember_79086a50-19aa-49c0-80c8-28e9ffffb54d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d23ea7b3-0f4a-4988-be83-b755d61555b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0fa8926c-762f-4527-b87e-78bfb854bbd3" xlink:to="loc_us-gaap_DebtInstrumentAxis_d23ea7b3-0f4a-4988-be83-b755d61555b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d23ea7b3-0f4a-4988-be83-b755d61555b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d23ea7b3-0f4a-4988-be83-b755d61555b9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d23ea7b3-0f4a-4988-be83-b755d61555b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3444f060-33d3-47ed-99d2-6caf98444387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d23ea7b3-0f4a-4988-be83-b755d61555b9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3444f060-33d3-47ed-99d2-6caf98444387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2025ConvertibleNotesMember_d656ca9b-1d94-40b8-859f-55cda201b328" xlink:href="insm-20240630.xsd#insm_A2025ConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3444f060-33d3-47ed-99d2-6caf98444387" xlink:to="loc_insm_A2025ConvertibleNotesMember_d656ca9b-1d94-40b8-859f-55cda201b328" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2028ConvertibleNotesMember_4c01e62e-8bde-40ae-8a33-2a63abb615c0" xlink:href="insm-20240630.xsd#insm_A2028ConvertibleNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3444f060-33d3-47ed-99d2-6caf98444387" xlink:to="loc_insm_A2028ConvertibleNotesMember_4c01e62e-8bde-40ae-8a33-2a63abb615c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a13af623-d005-4d25-b8c6-4730082f620f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0fa8926c-762f-4527-b87e-78bfb854bbd3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a13af623-d005-4d25-b8c6-4730082f620f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a13af623-d005-4d25-b8c6-4730082f620f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a13af623-d005-4d25-b8c6-4730082f620f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a13af623-d005-4d25-b8c6-4730082f620f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_819f9c19-9176-4625-bae2-08efe7d9fe90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a13af623-d005-4d25-b8c6-4730082f620f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_819f9c19-9176-4625-bae2-08efe7d9fe90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_461f068f-4fc6-4cd8-9e61-5b79b10432c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_819f9c19-9176-4625-bae2-08efe7d9fe90" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_461f068f-4fc6-4cd8-9e61-5b79b10432c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_6800dae0-d08c-47df-a46b-c7974e9478f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0fa8926c-762f-4527-b87e-78bfb854bbd3" xlink:to="loc_us-gaap_AssetAcquisitionAxis_6800dae0-d08c-47df-a46b-c7974e9478f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_6800dae0-d08c-47df-a46b-c7974e9478f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_6800dae0-d08c-47df-a46b-c7974e9478f0" xlink:to="loc_us-gaap_AssetAcquisitionDomain_6800dae0-d08c-47df-a46b-c7974e9478f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_0162a48b-14cf-4855-89b9-3510622ef37c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_6800dae0-d08c-47df-a46b-c7974e9478f0" xlink:to="loc_us-gaap_AssetAcquisitionDomain_0162a48b-14cf-4855-89b9-3510622ef37c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_VertuisBioIncMember_59c7e37c-1c9e-4f27-b9c5-7171a6ed5e19" xlink:href="insm-20240630.xsd#insm_VertuisBioIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_0162a48b-14cf-4855-89b9-3510622ef37c" xlink:to="loc_insm_VertuisBioIncMember_59c7e37c-1c9e-4f27-b9c5-7171a6ed5e19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_9f6ecd65-4965-4f0f-84c2-877fb67e94ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7e240d89-449f-4321-88e7-82367f382ae3" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_9f6ecd65-4965-4f0f-84c2-877fb67e94ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_c5508656-1fce-436d-9b37-ecedd9fce21d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7e240d89-449f-4321-88e7-82367f382ae3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_c5508656-1fce-436d-9b37-ecedd9fce21d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d41563b8-e7e8-4a4a-ad66-72717a1ce3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7e240d89-449f-4321-88e7-82367f382ae3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d41563b8-e7e8-4a4a-ad66-72717a1ce3ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_e6c9fc4d-2570-4685-a9c6-472433ed987e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7e240d89-449f-4321-88e7-82367f382ae3" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_e6c9fc4d-2570-4685-a9c6-472433ed987e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_a77c69af-cbff-45ca-a186-6984efaaf497" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7e240d89-449f-4321-88e7-82367f382ae3" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_a77c69af-cbff-45ca-a186-6984efaaf497" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_3c1acab0-b4e4-41eb-a3e3-d977c74a8e93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7e240d89-449f-4321-88e7-82367f382ae3" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_3c1acab0-b4e4-41eb-a3e3-d977c74a8e93" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_a29fc3d0-3475-42ed-b522-107f4b95f9bd" xlink:href="insm-20240630.xsd#insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_7e240d89-449f-4321-88e7-82367f382ae3" xlink:to="loc_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_a29fc3d0-3475-42ed-b522-107f4b95f9bd" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_StockOptionsAndRestrictedStockUnitsMember_45a6472e-1a03-494f-b34f-26d76d53306e" xlink:href="insm-20240630.xsd#insm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_insm_StockOptionsAndRestrictedStockUnitsMember_45a6472e-1a03-494f-b34f-26d76d53306e" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_S.NicoleSchaefferMember_d40530c0-d0d9-4fda-9385-a0d70404fa82" xlink:href="insm-20240630.xsd#insm_S.NicoleSchaefferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_insm_S.NicoleSchaefferMember_d40530c0-d0d9-4fda-9385-a0d70404fa82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_S.NicoleSchaeffer2Member_887f91bd-2d83-4409-8a2b-97c7280d8282" xlink:href="insm-20240630.xsd#insm_S.NicoleSchaeffer2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_insm_S.NicoleSchaeffer2Member_887f91bd-2d83-4409-8a2b-97c7280d8282" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MartinaFlammerMember_d2c2ad8e-4237-43e7-99c2-4827fa1969e5" xlink:href="insm-20240630.xsd#insm_MartinaFlammerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_insm_MartinaFlammerMember_d2c2ad8e-4237-43e7-99c2-4827fa1969e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MichaelSmithMember_cf91813e-c656-4a5c-8b93-2b9fb19d10ad" xlink:href="insm-20240630.xsd#insm_MichaelSmithMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_insm_MichaelSmithMember_cf91813e-c656-4a5c-8b93-2b9fb19d10ad" xlink:type="arc" order="5"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>insm-20240630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c55c6bb2-e1ff-4fc1-8df4-decd904b3b6b,g:5264b7b4-c672-47ab-b9d7-1b1bb5962c46-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_insm_NoncashOperatingLeaseExpense_0c48d394-7720-42b2-99b6-67998b1ac07d_terseLabel_en-US" xlink:label="lab_insm_NoncashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_insm_NoncashOperatingLeaseExpense_label_en-US" xlink:label="lab_insm_NoncashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Operating Lease Expense</link:label>
    <link:label id="lab_insm_NoncashOperatingLeaseExpense_documentation_en-US" xlink:label="lab_insm_NoncashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Operating Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NoncashOperatingLeaseExpense" xlink:href="insm-20240630.xsd#insm_NoncashOperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_NoncashOperatingLeaseExpense" xlink:to="lab_insm_NoncashOperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_79b8b7b4-f755-4228-b647-eb1efc0ca901_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8b8fc15d-8eec-4a9a-9286-a4954e29d5bc_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_153cd5b2-9334-4382-aa70-550e2c46e8e8_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Supplemental Non-cash Disclosures</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions_a45ea588-e903-4443-ac9c-3f6d47508bcb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value</link:label>
    <link:label id="lab_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions_label_en-US" xlink:label="lab_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" xlink:to="lab_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CustomerAMember_2e7c54d4-c9e3-4a2b-b1d5-9db9b110c536_terseLabel_en-US" xlink:label="lab_insm_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_insm_CustomerAMember_label_en-US" xlink:label="lab_insm_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_insm_CustomerAMember_documentation_en-US" xlink:label="lab_insm_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerAMember" xlink:href="insm-20240630.xsd#insm_CustomerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CustomerAMember" xlink:to="lab_insm_CustomerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f8b12b0a-071b-4d92-8fc7-8e8feab5fe84_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_164bceb1-eca1-4bb3-9559-ba88c8aa5564_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentConversionTermAxis_653aefa6-0a5f-4533-b59c-90300f89edd7_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Term [Axis]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermAxis_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Term [Axis]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermAxis_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermAxis" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermAxis" xlink:to="lab_insm_DebtInstrumentConversionTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_EuropeAndTheRestOfTheWorldMember_09efe0c4-f4a0-489f-9eb5-754ffa43cf1f_terseLabel_en-US" xlink:label="lab_insm_EuropeAndTheRestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe and rest of world</link:label>
    <link:label id="lab_insm_EuropeAndTheRestOfTheWorldMember_label_en-US" xlink:label="lab_insm_EuropeAndTheRestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe And The Rest Of The World [Member]</link:label>
    <link:label id="lab_insm_EuropeAndTheRestOfTheWorldMember_documentation_en-US" xlink:label="lab_insm_EuropeAndTheRestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Europe And The Rest Of The World</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EuropeAndTheRestOfTheWorldMember" xlink:href="insm-20240630.xsd#insm_EuropeAndTheRestOfTheWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_EuropeAndTheRestOfTheWorldMember" xlink:to="lab_insm_EuropeAndTheRestOfTheWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_cef1f359-ae43-49bc-adf3-a8a75fe5d559_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_15462d3b-fcf9-402b-92eb-ea989f7233e7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_RedemptionOfThe2025ConvertibleNotesMember_42b60237-f539-4b49-ab9b-ac8a1506185d_terseLabel_en-US" xlink:label="lab_insm_RedemptionOfThe2025ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption of the 2025 Convertible Notes</link:label>
    <link:label id="lab_insm_RedemptionOfThe2025ConvertibleNotesMember_label_en-US" xlink:label="lab_insm_RedemptionOfThe2025ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redemption Of The 2025 Convertible Notes [Member]</link:label>
    <link:label id="lab_insm_RedemptionOfThe2025ConvertibleNotesMember_documentation_en-US" xlink:label="lab_insm_RedemptionOfThe2025ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Redemption Of The 2025 Convertible Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_RedemptionOfThe2025ConvertibleNotesMember" xlink:href="insm-20240630.xsd#insm_RedemptionOfThe2025ConvertibleNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_RedemptionOfThe2025ConvertibleNotesMember" xlink:to="lab_insm_RedemptionOfThe2025ConvertibleNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_f8a429a7-51af-4978-8867-3694a4bf41ea_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_f6151a55-86b3-4a5a-8a11-321bf6312b2a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_918f136a-9d4f-452c-83bb-a59abcd751af_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial conversion rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentConversionTermDomain_45b79f5b-8fa6-4b7f-8e4f-be896e5b7790_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Term [Domain]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermDomain_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Term [Domain]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermDomain_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Debt Instrument Conversion Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermDomain" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermDomain" xlink:to="lab_insm_DebtInstrumentConversionTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_2f992cf2-ad6f-4ec5-addf-2e7cbc1042cc_terseLabel_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_label_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_documentation_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:href="insm-20240630.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:to="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_66fac9e0-ae49-468b-a42b-41047963f089_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_9c7e83b1-28cd-4c2c-8dfb-7cb0ef0f3025_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d311cd42-0f15-41d0-b3d8-0ea16bd9402d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Company and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_570916b4-b0c9-4077-94d1-30846708199c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for vesting of RSUs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8c6a354c-ab00-4e3d-9b67-d164b9ddb7ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_c9950c34-dde9-48fb-bfb3-d8e7e25c0b01_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options and ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_MeasurementInputProbabilityOfSuccessMember_46e290d4-9b23-4920-bfdc-1200f8b47a99_terseLabel_en-US" xlink:label="lab_insm_MeasurementInputProbabilityOfSuccessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probabilities of success</link:label>
    <link:label id="lab_insm_MeasurementInputProbabilityOfSuccessMember_label_en-US" xlink:label="lab_insm_MeasurementInputProbabilityOfSuccessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability Of Success [Member]</link:label>
    <link:label id="lab_insm_MeasurementInputProbabilityOfSuccessMember_documentation_en-US" xlink:label="lab_insm_MeasurementInputProbabilityOfSuccessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability Of Success</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MeasurementInputProbabilityOfSuccessMember" xlink:href="insm-20240630.xsd#insm_MeasurementInputProbabilityOfSuccessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MeasurementInputProbabilityOfSuccessMember" xlink:to="lab_insm_MeasurementInputProbabilityOfSuccessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1bc0b87a-a007-4851-8423-a9148855da2e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets, 2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_c4efb70f-570e-4881-ae60-285b7272b8cd_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_0d0bb90a-3424-46d4-b540-675e93ef6332_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8d1af381-c2c2-41b3-a5ef-6d10156d85b0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, outstanding shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_7cc86e42-0969-4d8b-8716-95d110fc789f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense charged to operations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_d36f7d42-de4a-4c8e-ae62-f5066e4fbd9c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c61dfe7d-5eec-43e5-a5d4-ff725ad720b1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_96604b0e-6940-4879-b0fe-dd8a21724ee6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1bddf1d7-1f99-4d8e-bdcd-ab426a8dfc98_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_RevenueInterestPaymentsPayable_fdc22c3d-a0d8-47a5-88f2-6fcd68d01b1d_terseLabel_en-US" xlink:label="lab_insm_RevenueInterestPaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Interest Payments payable</link:label>
    <link:label id="lab_insm_RevenueInterestPaymentsPayable_label_en-US" xlink:label="lab_insm_RevenueInterestPaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Interest Payments Payable</link:label>
    <link:label id="lab_insm_RevenueInterestPaymentsPayable_documentation_en-US" xlink:label="lab_insm_RevenueInterestPaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Interest Payments Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_RevenueInterestPaymentsPayable" xlink:href="insm-20240630.xsd#insm_RevenueInterestPaymentsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_RevenueInterestPaymentsPayable" xlink:to="lab_insm_RevenueInterestPaymentsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_b20982b4-9389-49ee-88fd-5085b07bfd30_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease interest expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AccruedMilestonePaymentCurrent_83dd9628-f88a-4709-8884-40305e6623c1_terseLabel_en-US" xlink:label="lab_insm_AccruedMilestonePaymentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued milestone payment to AstraZeneca</link:label>
    <link:label id="lab_insm_AccruedMilestonePaymentCurrent_label_en-US" xlink:label="lab_insm_AccruedMilestonePaymentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Milestone Payment, Current</link:label>
    <link:label id="lab_insm_AccruedMilestonePaymentCurrent_documentation_en-US" xlink:label="lab_insm_AccruedMilestonePaymentCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Milestone Payment, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedMilestonePaymentCurrent" xlink:href="insm-20240630.xsd#insm_AccruedMilestonePaymentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedMilestonePaymentCurrent" xlink:to="lab_insm_AccruedMilestonePaymentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_92b54037-5b6d-4529-abab-b78e0c9b5371_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_ff4e2bb7-a901-4576-b675-59d46d712da1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_eded537d-13f9-4dc5-a1cc-e258861eb2d7_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_59bcb376-054b-4d1c-9076-22e7446fd540_verboseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_c1b4f9a0-6e26-4cb6-a83b-490cd0222f8c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_92016088-11a5-419b-bb43-53ffc6ddb638_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_5d525a52-8532-4134-b9cb-7f9b9af2afcd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Current Portion of Long-Term Debt and Debt, Long-Term</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebt_2605e43f-b517-4a4f-acd6-0156a16ed614_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Face value of outstanding convertible notes</link:label>
    <link:label id="lab_us-gaap_SecuredDebt_label_en-US" xlink:label="lab_us-gaap_SecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebt" xlink:to="lab_us-gaap_SecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_450368a8-187d-4e50-94f2-08d107468945_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_BusinessCombinationDeferredPaymentsCurrent_f09bc2a7-9ef1-4b87-a253-e6e2582ef482_terseLabel_en-US" xlink:label="lab_insm_BusinessCombinationDeferredPaymentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred and contingent consideration</link:label>
    <link:label id="lab_insm_BusinessCombinationDeferredPaymentsCurrent_label_en-US" xlink:label="lab_insm_BusinessCombinationDeferredPaymentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Deferred Payments, Current</link:label>
    <link:label id="lab_insm_BusinessCombinationDeferredPaymentsCurrent_documentation_en-US" xlink:label="lab_insm_BusinessCombinationDeferredPaymentsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Deferred Payments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredPaymentsCurrent" xlink:href="insm-20240630.xsd#insm_BusinessCombinationDeferredPaymentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_BusinessCombinationDeferredPaymentsCurrent" xlink:to="lab_insm_BusinessCombinationDeferredPaymentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_81d38bba-7f7b-491b-8de7-e4721b7a2659_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue_c36c93f0-be8e-4c05-b899-f588a801705c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Derivative Assets, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:to="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a9de4336-8d89-43bf-a8ed-bec1fa5924b2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b085a350-a4b0-40f1-867e-2060a2beef0a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate net proceeds from stock offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a4538f69-cde9-4fc4-8c5e-3003dac3051e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_MartinaFlammerMember_label_en-US" xlink:label="lab_insm_MartinaFlammerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Martina Flammer [Member]</link:label>
    <link:label id="lab_insm_MartinaFlammerMember_documentation_en-US" xlink:label="lab_insm_MartinaFlammerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Martina Flammer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MartinaFlammerMember" xlink:href="insm-20240630.xsd#insm_MartinaFlammerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MartinaFlammerMember" xlink:to="lab_insm_MartinaFlammerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_b1f63d2b-9262-408d-9f28-9762b514fad2_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_TermLoanMember_1506b5c3-381f-4032-8094-13c2a2910199_terseLabel_en-US" xlink:label="lab_insm_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_insm_TermLoanMember_label_en-US" xlink:label="lab_insm_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_insm_TermLoanMember_documentation_en-US" xlink:label="lab_insm_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_TermLoanMember" xlink:href="insm-20240630.xsd#insm_TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_TermLoanMember" xlink:to="lab_insm_TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f0412bd3-aadb-4dbb-89bf-02ae779465fb_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_e25a1a64-a235-48c0-87ae-8e45256865ee_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_407af9a2-274d-435b-b28c-0bd3e81a5850_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_a0e50aa4-befd-4fdb-857f-45586f7ed456_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5afc835e-d9fa-4daf-85c1-b1ca96608715_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_223555e2-29e8-48a5-b29a-9b8b5cf66fc8_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Revenue, Product Line</link:label>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueProductLineMember" xlink:to="lab_us-gaap_SalesRevenueProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_a0b2946b-6232-42f4-9f09-30684aaee988_terseLabel_en-US" xlink:label="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducement stock options granted to new employees (in shares)</link:label>
    <link:label id="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Inducement Options Grants In Period Gross</link:label>
    <link:label id="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_documentation_en-US" xlink:label="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross number of inducement share options (or share units) granted during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:href="insm-20240630.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:to="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_6d9cbfaa-fe4d-49e4-bb74-a6d8db0d3403_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_b137914d-37fb-433c-94af-412256e0c130_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_BusinessAcquisitionConsecutiveTradingDayPeriod_60b53f17-120a-4773-8a09-d4683d0f09bd_terseLabel_en-US" xlink:label="lab_insm_BusinessAcquisitionConsecutiveTradingDayPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consecutive trading day period</link:label>
    <link:label id="lab_insm_BusinessAcquisitionConsecutiveTradingDayPeriod_label_en-US" xlink:label="lab_insm_BusinessAcquisitionConsecutiveTradingDayPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Consecutive Trading Day Period</link:label>
    <link:label id="lab_insm_BusinessAcquisitionConsecutiveTradingDayPeriod_documentation_en-US" xlink:label="lab_insm_BusinessAcquisitionConsecutiveTradingDayPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition, Consecutive Trading Day Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessAcquisitionConsecutiveTradingDayPeriod" xlink:href="insm-20240630.xsd#insm_BusinessAcquisitionConsecutiveTradingDayPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_BusinessAcquisitionConsecutiveTradingDayPeriod" xlink:to="lab_insm_BusinessAcquisitionConsecutiveTradingDayPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_eaa864a2-e31c-4e7b-aa99-07fb8dc88a63_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_2adefe4f-ea1f-49f4-8f29-0dd14989b904_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued France ATU reimbursement payable</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_83aff478-d5ba-4aff-8e73-8051197f60c3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_4f96e28c-6466-4535-aa51-3baa6371460e_verboseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_5b02e113-5fbe-4ce3-b91e-33ecc285a048_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_c37b8cad-c217-4d93-ab3b-f18c79543dec_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_4142331b-7472-43f4-b135-67a84561d528_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_c3bef9f2-2bfe-49e6-8477-a057b6e503f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_d376e127-fca8-4010-9c90-6d7edf50cb13_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration (Level 3 Liabilities)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75b9564b-88b9-4f6b-99e6-ba201a8d33ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_a02ee858-9308-415f-9cf0-a750629a8a65_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_f90725de-9298-4f9b-8c45-9b7f8836c378_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of interest rate swap</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_654b6e7b-488c-4377-b9c4-c8ae8621e5a6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of interest rate swap</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_06aa7645-9c92-4fc1-afc8-010d8647c146_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_17b1de80-7e97-4147-bfd6-96f63816c1ef_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_31d5fe15-f049-4460-8709-3bab69278c73_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_30763a16-1e34-4135-925e-7053406eab87_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Anniversary of Closing Date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_36919397-e96f-458d-b980-cd10c3a46957_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_230319c3-0cb5-45b4-90c5-ceab2178c70b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent payment, value</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_53a6cfb9-8742-4203-93eb-fdf3846d6cb7_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares of Insmed common stock issued in July 2024</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_6d79ad15-2c44-4e57-9f79-fdabf3d1229d_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7c6528f4-a53e-4971-8c70-250c34ed04d4_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bd711281-e4bf-4009-aeb3-1d0a6cfac1a8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_RoyaltyFinancingAgreementRollForward_2202ee37-f7c3-41da-b3bc-31e1ec84cd3c_terseLabel_en-US" xlink:label="lab_insm_RoyaltyFinancingAgreementRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Financing Agreement [Roll Forward]</link:label>
    <link:label id="lab_insm_RoyaltyFinancingAgreementRollForward_label_en-US" xlink:label="lab_insm_RoyaltyFinancingAgreementRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Financing Agreement [Roll Forward]</link:label>
    <link:label id="lab_insm_RoyaltyFinancingAgreementRollForward_documentation_en-US" xlink:label="lab_insm_RoyaltyFinancingAgreementRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Financing Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_RoyaltyFinancingAgreementRollForward" xlink:href="insm-20240630.xsd#insm_RoyaltyFinancingAgreementRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_RoyaltyFinancingAgreementRollForward" xlink:to="lab_insm_RoyaltyFinancingAgreementRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentRoyaltyPayableMaximum_69cd741b-6bb8-477c-a170-9ace4d5141c1_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentRoyaltyPayableMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty maximum</link:label>
    <link:label id="lab_insm_DebtInstrumentRoyaltyPayableMaximum_label_en-US" xlink:label="lab_insm_DebtInstrumentRoyaltyPayableMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Royalty Payable, Maximum</link:label>
    <link:label id="lab_insm_DebtInstrumentRoyaltyPayableMaximum_documentation_en-US" xlink:label="lab_insm_DebtInstrumentRoyaltyPayableMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Royalty Payable, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentRoyaltyPayableMaximum" xlink:href="insm-20240630.xsd#insm_DebtInstrumentRoyaltyPayableMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentRoyaltyPayableMaximum" xlink:to="lab_insm_DebtInstrumentRoyaltyPayableMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0b1c8d86-4cdd-4e1b-8769-2fc5a5182af0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_bcd86722-9dce-4164-886a-5866d8777cb4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_S.NicoleSchaeffer2Member_label_en-US" xlink:label="lab_insm_S.NicoleSchaeffer2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">S. Nicole Schaeffer2 [Member]</link:label>
    <link:label id="lab_insm_S.NicoleSchaeffer2Member_documentation_en-US" xlink:label="lab_insm_S.NicoleSchaeffer2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">S. Nicole Schaeffer2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_S.NicoleSchaeffer2Member" xlink:href="insm-20240630.xsd#insm_S.NicoleSchaeffer2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_S.NicoleSchaeffer2Member" xlink:to="lab_insm_S.NicoleSchaeffer2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_2bb2533d-661d-466c-a1fe-da9ba5f2630f_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_d84d4e03-7614-40c7-a38f-58175587298b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_504e32a3-abba-48a2-a495-23a8cd2a3483_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_A2019IncentivePlanMember_919d7613-256f-43d7-bcbd-20a04824451d_terseLabel_en-US" xlink:label="lab_insm_A2019IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Incentive Plan</link:label>
    <link:label id="lab_insm_A2019IncentivePlanMember_label_en-US" xlink:label="lab_insm_A2019IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2019 Incentive Plan [Member]</link:label>
    <link:label id="lab_insm_A2019IncentivePlanMember_documentation_en-US" xlink:label="lab_insm_A2019IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2019 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2019IncentivePlanMember" xlink:href="insm-20240630.xsd#insm_A2019IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_A2019IncentivePlanMember" xlink:to="lab_insm_A2019IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3c779770-cc90-4bd7-afd3-37df7b57e88b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_e66bbc94-170d-462b-a6d2-16b57575ea58_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_768a3d22-af40-48d9-8886-8f98a8c7ecfc_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentConversionTermFourMember_e68e0246-91d6-4fe4-9f99-862def96d332_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion Term (iv)</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermFourMember_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Term Four [Member]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermFourMember_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Term Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermFourMember" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermFourMember" xlink:to="lab_insm_DebtInstrumentConversionTermFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7d80a4fc-725b-4d56-b801-19b0ab7ab6a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_09939f06-9fe3-4f5f-8e3a-77201731e053_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_3dde3f74-afc7-4eb1-adc4-00b04a68a820_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock_6e5b961c-6431-42d8-aa78-d0e6e5ecede8_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Financing Agreement</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Agreements, Resale Agreements, Securities Borrowed, and Securities Loaned Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock" xlink:to="lab_us-gaap_RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_67e0f0f0-52cd-44ae-9455-f60106c0b4ae_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b72408c3-aec6-4eb0-81b4-5ce0193de4c6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_a8c505ef-08d3-47eb-8f80-5f086926f296_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Paid-in-kind interest capitalized</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_defd9376-6558-434a-b1f4-44120def595d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_EmployeeStockPurchasePlan2018Member_80276be9-d75e-482e-b6c2-ec610d1d5582_terseLabel_en-US" xlink:label="lab_insm_EmployeeStockPurchasePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 ESPP</link:label>
    <link:label id="lab_insm_EmployeeStockPurchasePlan2018Member_label_en-US" xlink:label="lab_insm_EmployeeStockPurchasePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan 2018 [Member]</link:label>
    <link:label id="lab_insm_EmployeeStockPurchasePlan2018Member_documentation_en-US" xlink:label="lab_insm_EmployeeStockPurchasePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EmployeeStockPurchasePlan2018Member" xlink:href="insm-20240630.xsd#insm_EmployeeStockPurchasePlan2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_EmployeeStockPurchasePlan2018Member" xlink:to="lab_insm_EmployeeStockPurchasePlan2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_StockOptionsAndRestrictedStockUnitsMember_131d2f51-776a-46bf-b996-98d65b476ebc_terseLabel_en-US" xlink:label="lab_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options and RSUs</link:label>
    <link:label id="lab_insm_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_insm_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time. It also includes stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:href="insm-20240630.xsd#insm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_c613a5c9-ac6b-4afa-a953-7009dd671ed2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8789c7cc-5339-4c27-91e4-bc0915674972_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8f1e70bf-2739-46bc-8fd4-476f554d4361_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_MilestoneEvent2Member_a1d7d74b-f788-4990-b585-8b8dab3044f6_terseLabel_en-US" xlink:label="lab_insm_MilestoneEvent2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Event 2</link:label>
    <link:label id="lab_insm_MilestoneEvent2Member_label_en-US" xlink:label="lab_insm_MilestoneEvent2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Event 2 [Member]</link:label>
    <link:label id="lab_insm_MilestoneEvent2Member_documentation_en-US" xlink:label="lab_insm_MilestoneEvent2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Event 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestoneEvent2Member" xlink:href="insm-20240630.xsd#insm_MilestoneEvent2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MilestoneEvent2Member" xlink:to="lab_insm_MilestoneEvent2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_bf2e30e7-4ff5-4186-b005-ffcc840373c2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_114676e9-cb9f-4f29-8ff3-d87617b8f8cc_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_483b0a43-21c7-4553-8a02-4d374b4403e8_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_e011e545-da9c-4cc6-83a8-d3b0d62ba703_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_69dfad36-8abb-4aae-ba36-ac4bd5c0421b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_eedce926-bac4-4caa-81f3-db6ee5b6e22e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_729e98a2-caf7-4f4b-8e72-2e66a7af7c80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_a74a12b4-c3e5-409e-9239-b27d81769b2a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_LongTermDebtMaturityAfterYearFourAndThereafter_0dd7b73c-56af-436c-8095-088010269a9a_terseLabel_en-US" xlink:label="lab_insm_LongTermDebtMaturityAfterYearFourAndThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029 and thereafter</link:label>
    <link:label id="lab_insm_LongTermDebtMaturityAfterYearFourAndThereafter_label_en-US" xlink:label="lab_insm_LongTermDebtMaturityAfterYearFourAndThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four And Thereafter</link:label>
    <link:label id="lab_insm_LongTermDebtMaturityAfterYearFourAndThereafter_documentation_en-US" xlink:label="lab_insm_LongTermDebtMaturityAfterYearFourAndThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four And Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LongTermDebtMaturityAfterYearFourAndThereafter" xlink:href="insm-20240630.xsd#insm_LongTermDebtMaturityAfterYearFourAndThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_LongTermDebtMaturityAfterYearFourAndThereafter" xlink:to="lab_insm_LongTermDebtMaturityAfterYearFourAndThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput_1391ba74-c4c4-47af-96bc-c20535515dde_terseLabel_en-US" xlink:label="lab_insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insmed share price (in usd per share)</link:label>
    <link:label id="lab_insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Deferred Consideration Liability, Measurement Input</link:label>
    <link:label id="lab_insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput_documentation_en-US" xlink:label="lab_insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Deferred Consideration Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput" xlink:href="insm-20240630.xsd#insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput" xlink:to="lab_insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_5e6f5b5f-19fe-456a-b74c-7906ea6b6da7_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_338efe0d-42cb-422a-8c79-1b92b24f1c43_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d0784add-336b-4e24-9bd9-315f9193ec9f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b461c06b-c70e-457b-b314-ede2a15a985d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, issued shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_409b1824-c2ac-43e2-86c3-31a153bc281b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_cc54a99c-3a4d-4832-8878-6c907810c2ad_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_452ce4d2-5a85-47fa-bb1f-d7c5b489d640_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_7aac16bc-3740-4b24-bed4-3829e6a76925_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a19d4147-71dd-4c55-b5b5-251de502e186_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_ddfbac1b-0c6c-4c21-b535-4dc94eed3e1a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_1c1d70f9-dc0d-4ad8-a078-8af414e75a4e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d42465c0-3ee6-4157-b866-cbc5cb2992b1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options and ESPP shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_11993271-d014-4f9a-83c6-fadae3afe70d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_393fff44-5e4f-4ddb-9bf5-2c216a270836_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_f2e41c43-9349-4c21-9c6f-e037cef19f9f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_428da58e-fd07-481b-8093-8bb159c59f8d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, authorized shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_33ce0e27-1310-4616-99ce-5598966bd54b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average diluted common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5e07e028-c863-4d2a-8a3a-11590a630d92_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2f8646cb-3ef3-46bf-af7e-dd356054b001_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_93513f66-5ffb-4ef6-9456-9fc8cbaca404_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets, remainder of 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining_5914be93-aba8-450f-bee4-9492938d5ed8_terseLabel_en-US" xlink:label="lab_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining discount amortization period (in years)</link:label>
    <link:label id="lab_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining_label_en-US" xlink:label="lab_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Instrument, Discount Amortization Period, Remaining</link:label>
    <link:label id="lab_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining_documentation_en-US" xlink:label="lab_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Debt Instrument, Discount Amortization Period, Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" xlink:href="insm-20240630.xsd#insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" xlink:to="lab_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ManufacturingEquipmentMember_e62227d0-766c-477f-aef1-a330978c3f5f_terseLabel_en-US" xlink:label="lab_insm_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_insm_ManufacturingEquipmentMember_label_en-US" xlink:label="lab_insm_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_insm_ManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_insm_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ManufacturingEquipmentMember" xlink:href="insm-20240630.xsd#insm_ManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ManufacturingEquipmentMember" xlink:to="lab_insm_ManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_49caa670-c35c-48af-977c-112d49fc2723_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_4e7d8314-11bc-472d-8179-1c12c46e1f40_terseLabel_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Line Items]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_label_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Line Items]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_documentation_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:href="insm-20240630.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:to="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_792778cf-1383-49c4-a635-49c35f9c62ad_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_73e960fe-d749-4a43-90a6-4e246a52ee39_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_36df83b6-f66c-47a6-bb47-9045b33e16c5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_629b680c-9d90-4deb-b68f-57e537d89098_terseLabel_en-US" xlink:label="lab_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">0.75% Convertible Senior Notes Due 2028</link:label>
    <link:label id="lab_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_label_en-US" xlink:label="lab_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zero Point Seven Five Percent Convertible Senior Note Due 2028 [Member]</link:label>
    <link:label id="lab_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_documentation_en-US" xlink:label="lab_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zero Point Seven Five Percent Convertible Senior Note Due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member" xlink:href="insm-20240630.xsd#insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member" xlink:to="lab_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_083f62a5-ea59-4c38-b497-aafc72f6ac59_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_4515463b-724c-476e-9817-ecfb1fb01565_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_5b8cda00-d02d-4e62-8764-d20f1c0b1208_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f37de2d6-bff9-422a-a1bc-86c294651344_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Assets, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_94bef465-76a9-4afc-bde7-31d8bf14f30d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLoans_b977af95-6147-4a4e-b8ab-e932c3cc03eb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLoans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from loans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLoans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLoans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLoans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLoans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLoans" xlink:to="lab_us-gaap_ProceedsFromLoans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f58a8292-940f-45e9-b0f0-0019ae571054_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_a7ab0024-3802-4e90-9614-aa70ba534386_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9c509e03-3522-41b3-9df8-84e7a9814cdc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_6df9074d-0258-4db9-ba1b-f07b983353d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4f398172-58bd-4ab5-96f7-95bf7d78927d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock, maximum authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_270fcd48-b8ac-48ce-a57e-31868bd3bdbb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8fba0bf1-b503-49c0-a919-645f1df8dd9a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e457a09e-dcfe-4ba4-bfe0-59747584d711_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_ce8872a2-c9a9-4457-996b-a01a7052a93c_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2b1acec4-b7f8-44a3-b344-a38e2679319b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8f7fcbee-27a7-4345-8717-ebc589fd1c55_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_c1c801ce-bc87-4b36-910e-bdec6d24d149_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_77dd6a9f-36b2-4af8-ad03-cb30826697a0_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_e1cd380f-e328-4e34-b649-5a61dc4b3699_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_23b101b8-ef3b-4e83-8998-97df06b6d1ff_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price used to calculate issuable shares (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_73f0d04e-3424-4e8d-9c29-6170ebc0fbf1_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt securities</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_43d184db-5bab-4a75-b2bd-6ad530b9dd20_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets, 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_d9d6f539-606c-48a6-bef0-82f23ddc9e56_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CustomerCMember_183ce633-1b1d-4978-b0b6-8be607bb196d_terseLabel_en-US" xlink:label="lab_insm_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer C</link:label>
    <link:label id="lab_insm_CustomerCMember_label_en-US" xlink:label="lab_insm_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label id="lab_insm_CustomerCMember_documentation_en-US" xlink:label="lab_insm_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerCMember" xlink:href="insm-20240630.xsd#insm_CustomerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CustomerCMember" xlink:to="lab_insm_CustomerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d8d7b667-8419-4931-b97d-9a9c45b046b4_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_999ce66c-1336-47aa-89e3-89ad6149ff32_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AccruedTechnicalOperationExpenses_769fc76a-f712-48cd-bb7b-5d705bf7e035_terseLabel_en-US" xlink:label="lab_insm_AccruedTechnicalOperationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued technical operation expenses</link:label>
    <link:label id="lab_insm_AccruedTechnicalOperationExpenses_label_en-US" xlink:label="lab_insm_AccruedTechnicalOperationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Technical Operation Expenses</link:label>
    <link:label id="lab_insm_AccruedTechnicalOperationExpenses_documentation_en-US" xlink:label="lab_insm_AccruedTechnicalOperationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedTechnicalOperationExpenses" xlink:href="insm-20240630.xsd#insm_AccruedTechnicalOperationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedTechnicalOperationExpenses" xlink:to="lab_insm_AccruedTechnicalOperationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_6a205d22-9004-4e91-a58c-c557430d57e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedCapitalizedInterestCosts_4f28bf77-a656-46c2-bcf2-b04a93303894_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedCapitalizedInterestCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Paid-in-kind interest capitalized</link:label>
    <link:label id="lab_us-gaap_AccumulatedCapitalizedInterestCosts_label_en-US" xlink:label="lab_us-gaap_AccumulatedCapitalizedInterestCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Capitalized Interest Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedCapitalizedInterestCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedCapitalizedInterestCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedCapitalizedInterestCosts" xlink:to="lab_us-gaap_AccumulatedCapitalizedInterestCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage_f833bf8e-f9c7-4954-b619-b5da1f4ee932_terseLabel_en-US" xlink:label="lab_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds of sale of priority review voucher obligated to pay to equity holders, percentage</link:label>
    <link:label id="lab_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage_label_en-US" xlink:label="lab_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds Of Sale Of Priority Review Voucher Obligated To Pay To Equity Holders, Percentage</link:label>
    <link:label id="lab_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage_documentation_en-US" xlink:label="lab_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds Of Sale Of Priority Review Voucher Obligated To Pay To Equity Holders, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage" xlink:href="insm-20240630.xsd#insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage" xlink:to="lab_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d09b0289-08e8-4baf-94b2-8c72dfa9a5cc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_a641da49-8072-477d-b48f-7b7332e31cb4_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_2ad1a555-af5a-432d-886c-1bd476c31aae_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_c8efb8df-f453-460e-aa9b-d4c04926f514_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_27642425-d2e9-47ef-a3f5-b44dca26831d_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_c3ca6610-c851-4744-8adf-203c0eb30168_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_6db5defd-1869-43c4-8c06-baf2f5c6c6e5_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_e3d9ead6-ef9d-460c-bd09-e705a15a9cd4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_de07d6cc-1ec0-4a30-96c2-2286e98d73db_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_d3a5fc28-ac3d-4815-acee-606fb7f15cfe_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other accrued operating expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6e5e8c38-2df1-4a96-ae24-63838526ff23_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_b9f2a1ce-f702-412d-a8f2-bc77edd1ba34_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_5b959975-963d-4838-b879-1678fac0a3d3_terseLabel_en-US" xlink:label="lab_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued upon milestone achievements (in shares)</link:label>
    <link:label id="lab_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_label_en-US" xlink:label="lab_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares</link:label>
    <link:label id="lab_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_documentation_en-US" xlink:label="lab_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" xlink:href="insm-20240630.xsd#insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" xlink:to="lab_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_7c334e18-e453-401d-9069-c4528146809f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_ff43b185-f315-44c5-b8cc-66ccc1bf1eee_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Residual equity component of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8ad47a03-d34f-4574-9f17-e8f4a9ddd597_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_f62afb69-e532-4a93-80a6-1d4bd0d5130f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_cb04c32d-6687-499b-af81-e6d7132c57a3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_97fd9695-6069-4efb-aeea-df5654252609_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ade50c4c-c690-4862-b14d-1ad2dd770308_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_3a4215be-932f-4406-a5da-727f49b4d7bd_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_eed4158f-fb65-4073-ab13-b226d085565c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_7a28fe94-db11-4e94-ab24-965316b10b86_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PARI milestones</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_a3f8f92c-57b6-4e2e-bfb5-589742ac326d_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_1554a950-a260-4699-b12e-f8b4d528f0a3_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease, cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_9e11b857-5cbe-4f12-8bcf-c9739b96419a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AlgaeneXIncMember_06aa1518-2f53-4fd9-a922-f92eca5e4eea_terseLabel_en-US" xlink:label="lab_insm_AlgaeneXIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AlgaeneX</link:label>
    <link:label id="lab_insm_AlgaeneXIncMember_label_en-US" xlink:label="lab_insm_AlgaeneXIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AlgaeneX, Inc. [Member]</link:label>
    <link:label id="lab_insm_AlgaeneXIncMember_documentation_en-US" xlink:label="lab_insm_AlgaeneXIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AlgaeneX, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AlgaeneXIncMember" xlink:href="insm-20240630.xsd#insm_AlgaeneXIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AlgaeneXIncMember" xlink:to="lab_insm_AlgaeneXIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f213111f-1bbd-4fca-8d01-f27e20078952_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets estimated useful life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_57366bc1-49ba-43b2-a189-2bf453e62204_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_8abc8d95-4113-4766-9fc6-82219618cdae_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease liabilities, long-term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_3dfad2f2-5137-4b0f-9a6a-223dbb2e604e_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Amount Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_dcd1705d-71b8-4761-acb7-1104a66f7d4e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_4004ac1e-e695-4bba-a3ab-af33a15bac1b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ProceedsFromRoyaltyFinancing_ea07ca15-a95c-4888-ae75-68061a526274_terseLabel_en-US" xlink:label="lab_insm_ProceedsFromRoyaltyFinancing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from royalty financing</link:label>
    <link:label id="lab_insm_ProceedsFromRoyaltyFinancing_label_en-US" xlink:label="lab_insm_ProceedsFromRoyaltyFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Royalty Financing</link:label>
    <link:label id="lab_insm_ProceedsFromRoyaltyFinancing_documentation_en-US" xlink:label="lab_insm_ProceedsFromRoyaltyFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Royalty Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ProceedsFromRoyaltyFinancing" xlink:href="insm-20240630.xsd#insm_ProceedsFromRoyaltyFinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ProceedsFromRoyaltyFinancing" xlink:to="lab_insm_ProceedsFromRoyaltyFinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_234be2f8-b4ae-4706-9ef8-d24f545ac2c6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements (Not Yet Adopted)</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ProceedsFromCashAcquiredInAssetAcquisition_93bdcc18-e926-4d47-a56d-ab5447186686_terseLabel_en-US" xlink:label="lab_insm_ProceedsFromCashAcquiredInAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash acquired in asset acquisition</link:label>
    <link:label id="lab_insm_ProceedsFromCashAcquiredInAssetAcquisition_label_en-US" xlink:label="lab_insm_ProceedsFromCashAcquiredInAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Cash Acquired In Asset Acquisition</link:label>
    <link:label id="lab_insm_ProceedsFromCashAcquiredInAssetAcquisition_documentation_en-US" xlink:label="lab_insm_ProceedsFromCashAcquiredInAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Cash Acquired In Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ProceedsFromCashAcquiredInAssetAcquisition" xlink:href="insm-20240630.xsd#insm_ProceedsFromCashAcquiredInAssetAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ProceedsFromCashAcquiredInAssetAcquisition" xlink:to="lab_insm_ProceedsFromCashAcquiredInAssetAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_38fb9572-3df3-40e4-9430-5196a3d8ac3e_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ae36e106-a3c5-4a06-a6e1-534204591685_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_319af9d2-aad1-427d-8055-c2bf716a953e_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7f5ec949-2d52-4c36-99d6-b60cd5ac5a7e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_8d325cc5-97e4-4ed6-bc46-3bea25ced9e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of the Weighted Average Number of Common Shares Used to Compute Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_9448dc49-5a76-4056-a158-1c7cb65c0f21_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AccretionOfDebtDiscountMarketableSecurities_de37b77a-785c-48c8-97a0-7431d4b3f9b7_negatedLabel_en-US" xlink:label="lab_insm_AccretionOfDebtDiscountMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion of discount on marketable securities, net</link:label>
    <link:label id="lab_insm_AccretionOfDebtDiscountMarketableSecurities_label_en-US" xlink:label="lab_insm_AccretionOfDebtDiscountMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion Of Debt Discount, Marketable Securities</link:label>
    <link:label id="lab_insm_AccretionOfDebtDiscountMarketableSecurities_documentation_en-US" xlink:label="lab_insm_AccretionOfDebtDiscountMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accretion Of Debt Discount, Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccretionOfDebtDiscountMarketableSecurities" xlink:href="insm-20240630.xsd#insm_AccretionOfDebtDiscountMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccretionOfDebtDiscountMarketableSecurities" xlink:to="lab_insm_AccretionOfDebtDiscountMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_2e0295db-2446-4c54-a165-11f1ab179322_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets and Impairment Assessment</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_01845edc-6de3-4a3f-929d-c68775dee996_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_3bdeb607-a4c1-431c-9944-52049148661d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption price percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CustomerBMember_91ca7069-f14c-4aab-abd8-7884d785f01f_terseLabel_en-US" xlink:label="lab_insm_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_insm_CustomerBMember_label_en-US" xlink:label="lab_insm_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_insm_CustomerBMember_documentation_en-US" xlink:label="lab_insm_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Customer B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerBMember" xlink:href="insm-20240630.xsd#insm_CustomerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CustomerBMember" xlink:to="lab_insm_CustomerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_56a0a098-8d8f-48b3-a08f-a83e496037ea_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8d7cc2b7-9ee7-4c68-a31e-5a8ebf7c621b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis and Carrying Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_A2025ConvertibleNotesMember_13154f0c-90be-4ca1-9301-7edcfaf75b2e_terseLabel_en-US" xlink:label="lab_insm_A2025ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of 2025 Notes</link:label>
    <link:label id="lab_insm_A2025ConvertibleNotesMember_label_en-US" xlink:label="lab_insm_A2025ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025 Convertible Notes [Member]</link:label>
    <link:label id="lab_insm_A2025ConvertibleNotesMember_documentation_en-US" xlink:label="lab_insm_A2025ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2025 Convertible Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2025ConvertibleNotesMember" xlink:href="insm-20240630.xsd#insm_A2025ConvertibleNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_A2025ConvertibleNotesMember" xlink:to="lab_insm_A2025ConvertibleNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_974e7f6c-b8a1-40d3-948c-cb72218dd7f7_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_c0517fbc-d9b4-4c69-b784-ab1095219890_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:to="lab_us-gaap_LiabilitiesFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_f0e9d96f-42d9-4804-b26f-021e2ed94a72_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average probability of success</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_cb949289-5153-4d80-ad7c-98e4507747b0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Values</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_81df63c0-f2c3-4876-8eb8-3c6f98444764_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CommonStockAuthorizedAggregateGrossSalesProceeds_3eb28f83-4ccf-409d-a5a8-d2d02f1282c6_terseLabel_en-US" xlink:label="lab_insm_CommonStockAuthorizedAggregateGrossSalesProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock authorized, aggregate gross sales proceeds (up to)</link:label>
    <link:label id="lab_insm_CommonStockAuthorizedAggregateGrossSalesProceeds_label_en-US" xlink:label="lab_insm_CommonStockAuthorizedAggregateGrossSalesProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Authorized, Aggregate Gross Sales Proceeds</link:label>
    <link:label id="lab_insm_CommonStockAuthorizedAggregateGrossSalesProceeds_documentation_en-US" xlink:label="lab_insm_CommonStockAuthorizedAggregateGrossSalesProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Authorized, Aggregate Gross Sales Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CommonStockAuthorizedAggregateGrossSalesProceeds" xlink:href="insm-20240630.xsd#insm_CommonStockAuthorizedAggregateGrossSalesProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CommonStockAuthorizedAggregateGrossSalesProceeds" xlink:to="lab_insm_CommonStockAuthorizedAggregateGrossSalesProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_5895c8a2-a8a6-40ab-954b-dd5cbb04a0f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Anniversary of Closing Date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2b79cd10-511b-4012-b919-6fed82ea0690_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0fccb30b-facb-45af-832b-8ecd23572676_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_4b67b4f7-fc78-4609-89e4-b29bf4be1ebc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collateral for interest rate swap</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_256b88c9-2d19-4482-abc8-74af174703e5_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_b7d20bc0-0b04-4b81-9471-4ea18586b583_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Derivative Liabilities, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:to="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ProceedsFromRoyaltyFinancingAgreementNet_b1e5f65b-3dd1-4ad3-acd4-18a802de4f04_terseLabel_en-US" xlink:label="lab_insm_ProceedsFromRoyaltyFinancingAgreementNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from royalty financing agreement, net</link:label>
    <link:label id="lab_insm_ProceedsFromRoyaltyFinancingAgreementNet_label_en-US" xlink:label="lab_insm_ProceedsFromRoyaltyFinancingAgreementNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Royalty Financing Agreement, Net</link:label>
    <link:label id="lab_insm_ProceedsFromRoyaltyFinancingAgreementNet_documentation_en-US" xlink:label="lab_insm_ProceedsFromRoyaltyFinancingAgreementNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Royalty Financing Agreement, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ProceedsFromRoyaltyFinancingAgreementNet" xlink:href="insm-20240630.xsd#insm_ProceedsFromRoyaltyFinancingAgreementNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ProceedsFromRoyaltyFinancingAgreementNet" xlink:to="lab_insm_ProceedsFromRoyaltyFinancingAgreementNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_313a3529-62cb-4168-8aaf-b9b56b95ac48_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss, diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_08989663-24d4-4475-8b53-133dcf1d237c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenues, net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_f67158c3-d458-4260-a531-cc452fd9a59f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_df3eda06-876a-4462-8e61-b2247331f14e_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option to purchase additional debt</link:label>
    <link:label id="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_label_en-US" xlink:label="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Option To Purchase Additional Debt</link:label>
    <link:label id="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_documentation_en-US" xlink:label="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Option To Purchase Additional Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:href="insm-20240630.xsd#insm_DebtInstrumentOptionToPurchaseAdditionalDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:to="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_bed4089f-cb53-4968-8a75-57836b94faba_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e57388bf-42d9-46e4-89ea-8c0dfb035f43_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_0c5e880f-26aa-40bb-bb03-aa9990413727_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_05d64b5e-e509-40b0-99ae-c7ab5ac7455a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_284ce128-0948-4c93-b6eb-31026fc5770a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_3da8987a-8827-4b77-a1bc-9ef1a45b5a53_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ad81a271-8789-4479-96d7-2e2149efff23_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_7398a2bb-4783-4d43-9d20-02bbb0cc132d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_9ac400c3-dc69-410b-b7dd-ca96dd49f0ff_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and employee related costs</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_87cdfa74-75ab-4742-9a06-f32a19694d9b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_BrensocatibGlobalNetSalesMember_37666d13-4065-40b1-8691-99f8ac927b15_terseLabel_en-US" xlink:label="lab_insm_BrensocatibGlobalNetSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Brensocatib Global Net Sales</link:label>
    <link:label id="lab_insm_BrensocatibGlobalNetSalesMember_label_en-US" xlink:label="lab_insm_BrensocatibGlobalNetSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Brensocatib Global Net Sales [Member]</link:label>
    <link:label id="lab_insm_BrensocatibGlobalNetSalesMember_documentation_en-US" xlink:label="lab_insm_BrensocatibGlobalNetSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Brensocatib Global Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BrensocatibGlobalNetSalesMember" xlink:href="insm-20240630.xsd#insm_BrensocatibGlobalNetSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_BrensocatibGlobalNetSalesMember" xlink:to="lab_insm_BrensocatibGlobalNetSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e8489489-9328-4a24-9435-1c3497951cbb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_e8235e60-6baa-4206-9461-cd986a6376f8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentConversionTermThreeMember_851bd197-9358-4aa5-a98d-e042947a1cfe_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion Term (iii)</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermThreeMember_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Term Three [Member]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermThreeMember_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Term Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermThreeMember" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermThreeMember" xlink:to="lab_insm_DebtInstrumentConversionTermThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f61ccffb-9eae-4c21-b240-0ec9c8ae3580_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_TriggeringEventAxis_d909593a-ea9c-478b-a3c0-cf520070b74e_terseLabel_en-US" xlink:label="lab_insm_TriggeringEventAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Triggering Event [Axis]</link:label>
    <link:label id="lab_insm_TriggeringEventAxis_label_en-US" xlink:label="lab_insm_TriggeringEventAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Triggering Event [Axis]</link:label>
    <link:label id="lab_insm_TriggeringEventAxis_documentation_en-US" xlink:label="lab_insm_TriggeringEventAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Triggering Event</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_TriggeringEventAxis" xlink:href="insm-20240630.xsd#insm_TriggeringEventAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_TriggeringEventAxis" xlink:to="lab_insm_TriggeringEventAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_440324cf-154d-4896-83f4-9562d11b175a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Principal Repayments of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_13ed8fea-756d-475c-9ddb-abc3ed265ab3_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_MotusBiosciencesIncAndAlgaeneXIncMember_d31b28ad-db61-435c-8991-e49049696241_terseLabel_en-US" xlink:label="lab_insm_MotusBiosciencesIncAndAlgaeneXIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Motus and AlgaeneX</link:label>
    <link:label id="lab_insm_MotusBiosciencesIncAndAlgaeneXIncMember_label_en-US" xlink:label="lab_insm_MotusBiosciencesIncAndAlgaeneXIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Motus Biosciences, Inc. And AlgaeneX, Inc. [Member]</link:label>
    <link:label id="lab_insm_MotusBiosciencesIncAndAlgaeneXIncMember_documentation_en-US" xlink:label="lab_insm_MotusBiosciencesIncAndAlgaeneXIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Motus Biosciences, Inc. And AlgaeneX, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember" xlink:href="insm-20240630.xsd#insm_MotusBiosciencesIncAndAlgaeneXIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember" xlink:to="lab_insm_MotusBiosciencesIncAndAlgaeneXIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_NoncashAcquisitionRelatedExpense_6059c697-04bc-440b-97ea-758065b71623_terseLabel_en-US" xlink:label="lab_insm_NoncashAcquisitionRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vertuis acquisition</link:label>
    <link:label id="lab_insm_NoncashAcquisitionRelatedExpense_ce4e5da2-09d3-48f9-8790-87d0f15caf1c_verboseLabel_en-US" xlink:label="lab_insm_NoncashAcquisitionRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adrestia acquisition</link:label>
    <link:label id="lab_insm_NoncashAcquisitionRelatedExpense_label_en-US" xlink:label="lab_insm_NoncashAcquisitionRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Acquisition Related Expense</link:label>
    <link:label id="lab_insm_NoncashAcquisitionRelatedExpense_documentation_en-US" xlink:label="lab_insm_NoncashAcquisitionRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Acquisition Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NoncashAcquisitionRelatedExpense" xlink:href="insm-20240630.xsd#insm_NoncashAcquisitionRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_NoncashAcquisitionRelatedExpense" xlink:to="lab_insm_NoncashAcquisitionRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_c4aa7741-943c-4d36-b8fd-d3f9f5743767_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_d2384c9a-bc3d-40b9-8974-27a67000460b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a9c0f8a3-aee4-4dbf-a41f-b52502a2fdc4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for vesting of RSUs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a5420f01-38de-419e-aa58-e0d8e8b8febf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_9227c058-e98a-4b2c-85ac-094917d0b5ce_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_28f1f97e-8562-41b7-890d-c2d3cf5b317c_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_45168b89-722e-4d03-b416-cd63a5054b35_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ade04972-9ca4-4999-99d0-55db0456533d_verboseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_38e6f7a4-6448-4b7e-b51e-0993e48249a9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_5fccc242-9fcf-4e75-aa0e-3e3df40acad2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_3ac63ff7-8239-4fcc-8f12-3998094ff14c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_c01478cf-4110-4265-b28d-2cb70425e326_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_8bff8d84-9328-4268-b017-ecf2b9c836e7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_3f01eee0-59d6-42c6-a12b-339258f7f4cf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_7809e6dc-38ae-4474-9604-339582fd84d1_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ddfd47a6-d96f-40b5-a3f1-15d4f4ae9865_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_MichaelSmithMember_label_en-US" xlink:label="lab_insm_MichaelSmithMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Michael Smith [Member]</link:label>
    <link:label id="lab_insm_MichaelSmithMember_documentation_en-US" xlink:label="lab_insm_MichaelSmithMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Michael Smith</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MichaelSmithMember" xlink:href="insm-20240630.xsd#insm_MichaelSmithMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MichaelSmithMember" xlink:to="lab_insm_MichaelSmithMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_36c5d6be-355d-403e-bf32-e1141cdbb94d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_fc91d178-c1c7-4b16-9cb7-d34fda4e82e2_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_13c2d0cb-542c-413c-9982-0a82502643ee_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_b6958c4f-2a2e-4f2c-910b-8a9aa0c0a86d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Term Loan issuance costs, unamortized</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_5694fd0d-b135-4f03-8f1e-6b90ed6607b1_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Royalty issuance costs, unamortized - beginning balance</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_ccf54cc8-a019-4ca6-9f76-c70fe89b2853_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Deferred issuance costs, unamortized - ending balance</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_7aac12d1-f0cf-4ba0-a594-e578b63a1690_terseLabel_en-US" xlink:label="lab_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in asset acquisition (in shares)</link:label>
    <link:label id="lab_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_label_en-US" xlink:label="lab_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Interest Issued And Issuable, Shares</link:label>
    <link:label id="lab_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_documentation_en-US" xlink:label="lab_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Interest Issued And Issuable, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:href="insm-20240630.xsd#insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:to="lab_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a5a22b89-46fd-465b-aca5-0b90b4bd7e5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_TriggeringEventDomain_8ead302b-88b9-4c5c-8a74-8fe4102e9265_terseLabel_en-US" xlink:label="lab_insm_TriggeringEventDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Triggering Event [Domain]</link:label>
    <link:label id="lab_insm_TriggeringEventDomain_label_en-US" xlink:label="lab_insm_TriggeringEventDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Triggering Event [Domain]</link:label>
    <link:label id="lab_insm_TriggeringEventDomain_documentation_en-US" xlink:label="lab_insm_TriggeringEventDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Triggering Event [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_TriggeringEventDomain" xlink:href="insm-20240630.xsd#insm_TriggeringEventDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_TriggeringEventDomain" xlink:to="lab_insm_TriggeringEventDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_84ee02cc-bbfe-4e6d-87dd-ca4d7ae56c2d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8beeb2fc-4319-42f0-9c92-60cf4d210b06_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_390f98c7-38cc-4f09-94fd-dbf81bbc559a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_a54e50ca-c629-4eb0-947c-a118b9d7c0b2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_557758cf-7610-4f04-961a-8181f87602be_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_67041320-d915-4223-bb56-289be028b3ec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage_260afc8d-5678-46e1-845d-a91c2b7bc2d5_terseLabel_en-US" xlink:label="lab_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average sales prices of publicly disclosed priority review voucher sales obligated to pay equity holders, percentage</link:label>
    <link:label id="lab_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage_label_en-US" xlink:label="lab_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Sales Prices Of Publicly Disclosed Priority Review Voucher Sales Obligated To Pay Equity Holders, Percentage</link:label>
    <link:label id="lab_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage_documentation_en-US" xlink:label="lab_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average Sales Prices Of Publicly Disclosed Priority Review Voucher Sales Obligated To Pay Equity Holders, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage" xlink:href="insm-20240630.xsd#insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage" xlink:to="lab_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_82910b9a-8e6f-4415-b3a9-cb419e75f419_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_41a44491-8554-4b7c-831d-7230e804f962_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_62a0e322-dbe5-413b-8e6a-8f79dd0eede4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options and ESPP shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_15ba338e-7bca-4fa4-92e3-ea85fab3d66e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_21dcd477-0442-4f36-9635-8e45b50bb2be_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_1f64380e-754a-4782-9ee5-7e73985eb2af_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt term (in months)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_67c58fa7-2631-4e03-8c72-4f38ed12d6ab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchased amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d5613b71-d8eb-47d4-a61f-018c50fff7f0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets, 2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_364f1675-8cba-4980-858e-98dd3b58f3ea_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e596416c-a1c1-498c-994f-1794943ba32c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_PublicStockOfferingMember_ea3e0b0c-0f4b-4108-bd65-66e472c1a7c6_terseLabel_en-US" xlink:label="lab_insm_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Stock Offering</link:label>
    <link:label id="lab_insm_PublicStockOfferingMember_label_en-US" xlink:label="lab_insm_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_insm_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_insm_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PublicStockOfferingMember" xlink:href="insm-20240630.xsd#insm_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_PublicStockOfferingMember" xlink:to="lab_insm_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fc783905-eefb-4680-8957-00a6c7a8e934_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d85264e1-d52f-487d-b901-d1750e882c74_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_90c110a6-2830-4bb9-84eb-d78d532d7b6e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense related to unvested RSU awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_06fb7bb6-69ad-4407-a115-2a5f4e87cbbd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_cce49e13-3de2-434b-a59c-48e812e5e80c_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Percentage of Gross Product Revenue</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AdrestiaTherapeuticsLtdMember_8220f4ff-db8f-4dcb-a279-b46a908d5e86_terseLabel_en-US" xlink:label="lab_insm_AdrestiaTherapeuticsLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adrestia Therapeutics Ltd</link:label>
    <link:label id="lab_insm_AdrestiaTherapeuticsLtdMember_label_en-US" xlink:label="lab_insm_AdrestiaTherapeuticsLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adrestia Therapeutics Ltd [Member]</link:label>
    <link:label id="lab_insm_AdrestiaTherapeuticsLtdMember_documentation_en-US" xlink:label="lab_insm_AdrestiaTherapeuticsLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adrestia Therapeutics Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AdrestiaTherapeuticsLtdMember" xlink:href="insm-20240630.xsd#insm_AdrestiaTherapeuticsLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AdrestiaTherapeuticsLtdMember" xlink:to="lab_insm_AdrestiaTherapeuticsLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_ffed7aec-a880-4d96-b0bb-f89148d94d32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Third Anniversary of Closing Date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_10222458-cb19-415c-85e9-21b7a92f0d48_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNonoperating" xlink:to="lab_us-gaap_InvestmentIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_d0fbbec7-865b-4312-897c-778f42707447_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_68bde800-b6c0-4714-bd5f-5c7f5762a3e8_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_608ca212-147d-4846-93a6-97daafc6488f_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_de47f236-0b14-4d99-a4fb-d2967518a35a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7778baeb-cc9f-4474-b1c4-a0881f3c2d9d_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_4355ccdf-7c31-4e8a-b261-21fa831354b2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_a27b4821-3f20-42ea-8240-7dd37abdf839_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentPercentOfInterestPayable_87b7a114-c929-4983-86b3-722091541eab_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentPercentOfInterestPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:label id="lab_insm_DebtInstrumentPercentOfInterestPayable_label_en-US" xlink:label="lab_insm_DebtInstrumentPercentOfInterestPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Percent Of Interest Payable</link:label>
    <link:label id="lab_insm_DebtInstrumentPercentOfInterestPayable_documentation_en-US" xlink:label="lab_insm_DebtInstrumentPercentOfInterestPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Percent Of Interest Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentPercentOfInterestPayable" xlink:href="insm-20240630.xsd#insm_DebtInstrumentPercentOfInterestPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentPercentOfInterestPayable" xlink:to="lab_insm_DebtInstrumentPercentOfInterestPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_539ec7cc-64a7-48ea-98a7-6592f7edf768_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_afdbe10f-19c3-4b89-9ead-1e0e6a8c139f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_91406d13-0471-4fc0-99ac-6fd4bdfb5f0d_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_fbcce531-6123-4e1e-89a6-e2ae7d7460ba_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential award payout</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_388f852e-7704-4aa2-90f8-ec7654cd0710_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of Insmed common stock issued on closing</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c6381f05-556b-4169-9072-f877361abbcf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_eac65fe5-b016-4edd-ad50-caeb02b05c11_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6ece8851-1230-4b86-9bc4-6d49e2fde7a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c01e3cdc-236d-48be-bca3-9a1a6cf47e8f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_01e19fb2-0841-48ea-b035-b6bbd0998482_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_292b7d2e-4820-4683-b1ed-9b4dcca2f8ff_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fee3100c-155b-4000-ba85-08c2cc972cb2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_ae9cb217-d170-400c-aa00-79d857ce063c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0c99f7dd-a342-4d5c-afe2-befc9060d224_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_f13557fa-e341-414e-a227-96090879a79b_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_fc9a4c7f-1197-426b-ade8-4261a3a5c768_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_bee74686-fe2d-4ad5-9b0d-5b3d9856efba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_50c17da2-c5c6-43ce-87d2-6e4a9ee95275_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_993107d3-ec85-4902-a923-d662f561e9b1_verboseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_e0871ed0-a9cd-45e5-9b92-9e57b16250f2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8d79a2d0-d0eb-4e7f-97f2-de5bc7a4639f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_80259fba-865d-41ba-b4d7-40458f1fa5e5_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_f738e8c5-c746-4af4-8dd3-fc020710fce6_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_429c20ce-8224-4e1f-8ee3-002f90187733_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_0ffa2ea0-9e0f-4435-8f73-a8977a882cc0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_0c19a4a9-9231-4912-b57e-921dfbbf1606_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, interest and penalties accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_4655c852-2d41-4de1-830c-c27013ebd5dc_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0c03397c-cecb-4e21-9968-33d752124f0d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_16ccb351-1e44-4901-97ad-1261d0cec2f9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_MilestoneEvent1Member_651ca888-636b-4579-a6db-542248441df9_terseLabel_en-US" xlink:label="lab_insm_MilestoneEvent1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Event 1</link:label>
    <link:label id="lab_insm_MilestoneEvent1Member_label_en-US" xlink:label="lab_insm_MilestoneEvent1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Event 1 [Member]</link:label>
    <link:label id="lab_insm_MilestoneEvent1Member_documentation_en-US" xlink:label="lab_insm_MilestoneEvent1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Event 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestoneEvent1Member" xlink:href="insm-20240630.xsd#insm_MilestoneEvent1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MilestoneEvent1Member" xlink:to="lab_insm_MilestoneEvent1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_c3260acf-c55c-43da-97db-d5c51f97f414_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e2f9a552-cbfc-4a69-b363-c87ece707b7b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock_92e23c99-79cb-444d-8db0-5fd4e5957fdb_terseLabel_en-US" xlink:label="lab_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory and Cost of Product Revenues (excluding amortization of intangible assets)</link:label>
    <link:label id="lab_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory And Cost Of Product Revenues (Excluding Amortization Of Intangible Assets) [Policy Text Block]</link:label>
    <link:label id="lab_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock_documentation_en-US" xlink:label="lab_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory And Cost Of Product Revenues (Excluding Amortization Of Intangible Assets)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock" xlink:href="insm-20240630.xsd#insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock" xlink:to="lab_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_b36ccb52-d2e6-4793-adf4-496808c73298_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty financing agreement</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_4c69e6f8-28b6-4b75-8b93-89c532b09eb7_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Royalty financing agreement liability - beginning balance</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_41b1a9b9-85f9-4592-bba9-7c173c986fec_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Royalty financing agreement liability - ending balance</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_dd6ced50-955b-4c32-8736-11a572e0cc49_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_b5c5b02c-fed0-4384-a03d-8a5740e3c5c6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: current portion of convertible notes</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_e28e7885-a222-4e71-a956-f7d75d6d4211_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_294f3000-1b64-4240-913d-f304f81a7576_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_34e21f98-8df4-4d0d-a491-ce49c84e2485_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_fab1f754-178c-4667-b5fd-4822edbf151f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of deferred and contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_52634c0d-b771-40c9-88f7-d1f1b126b604_verboseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_e80b1ecf-e405-43c7-b7af-3f0207cfb695_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_1d0e7a92-28d4-4ad1-9d64-190cd428721c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AtTheMarketAgreementMember_747f68dc-5e5c-4e10-a046-0b404f1d8d02_terseLabel_en-US" xlink:label="lab_insm_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM Program</link:label>
    <link:label id="lab_insm_AtTheMarketAgreementMember_label_en-US" xlink:label="lab_insm_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Agreement [Member]</link:label>
    <link:label id="lab_insm_AtTheMarketAgreementMember_documentation_en-US" xlink:label="lab_insm_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At The Market Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AtTheMarketAgreementMember" xlink:href="insm-20240630.xsd#insm_AtTheMarketAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AtTheMarketAgreementMember" xlink:to="lab_insm_AtTheMarketAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_f0cd3202-3b41-4523-ba7b-abba97405597_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_50ece586-cb93-4dc6-b7ff-47a690422b4f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_3c58d5d5-2b40-4614-857c-ddf5e1b90f08_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest expense recognized</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_d8140ff8-e65f-4182-be75-4c332847e183_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2266f7d8-3b7e-4fb5-b15e-80170e3a0ecd_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_ab5f95fc-57c1-4bd5-8988-84df1860cc0e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_90a4419c-c11a-424a-a163-5bd75c1589c8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock_d1c847ca-8f92-4640-be6d-7a40ead303bd_terseLabel_en-US" xlink:label="lab_insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combinations and Asset Acquisitions</link:label>
    <link:label id="lab_insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations And Asset Acquisitions, Policy [Policy Text Block]</link:label>
    <link:label id="lab_insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combinations And Asset Acquisitions, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock" xlink:href="insm-20240630.xsd#insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock" xlink:to="lab_insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0c3a5836-c819-4045-b2f3-9ef1e5215dbe_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_LeaseRemainingLeaseTerm_27d1002e-ad2f-4b48-ae6e-53ed9e968f0d_terseLabel_en-US" xlink:label="lab_insm_LeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining lease term</link:label>
    <link:label id="lab_insm_LeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_insm_LeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Remaining Lease Term</link:label>
    <link:label id="lab_insm_LeaseRemainingLeaseTerm_documentation_en-US" xlink:label="lab_insm_LeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LeaseRemainingLeaseTerm" xlink:href="insm-20240630.xsd#insm_LeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_LeaseRemainingLeaseTerm" xlink:to="lab_insm_LeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_604b380c-1f13-4377-88ef-bcb99d3ec5a8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9fb5e9fb-060c-4350-bab6-4981ef6dfd8b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_bb6cc868-e68d-44c2-b03c-311c5e43a5cf_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Consideration, beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_d8f7d49d-e9fb-4649-b0d4-ffe66ffa24bc_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Consideration, ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_d1a24c8d-f1ee-4c0d-aab4-3efb7031ba1c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_12cd6812-5692-47da-a63c-96f5dbad1fab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_8e48e77f-5a31-4ad8-b717-05963f2ed409_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashExpense_2ffbe594-c7eb-44d3-b5d3-33b7b27c3a13_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty financing non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_OtherNoncashExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashExpense" xlink:to="lab_us-gaap_OtherNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_58fe2d0d-1292-40d7-9e1d-9f394b333bc1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_ac5830c9-afeb-4078-a996-96d81c57a4a4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Interest Expense related to Debt and Finance Leases</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_b7619f4f-191e-4238-8d64-490dedb587bd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Converted outstanding amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_dd84cdc4-e131-49bc-a27a-2d9bc1afaea3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_851ddaaa-93b5-4bb8-b44b-bd3044b2692a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_bf3efe4f-843e-497c-80d0-e88c660908e1_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_33fd8304-08ed-4fb9-bd2d-008ab9dcca38_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt, long-term</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_a040afc5-0350-4de7-8d7c-11e2ffc1ef3e_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total long-term convertible notes</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_12a70964-9214-4829-8e79-10afe74a2fe9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Observable Inputs in Valuation of Deferred Consideration, Development and Regulatory Milestones and Priority Review Voucher Milestone and Changes in Fair Value of Valuations for Deferred and Contingent Consideration Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_ab26eac2-4b92-4693-9c6c-0bc5ddbcbbf6_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease cost, future right-of-use asset</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_395f201c-6f87-4f12-a7d6-39908cdeaeb7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DevelopmentAndRegulatoryMilestonesMember_ea7cb1fe-cde6-4599-b680-64feac600b98_terseLabel_en-US" xlink:label="lab_insm_DevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and regulatory milestones</link:label>
    <link:label id="lab_insm_DevelopmentAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_insm_DevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_insm_DevelopmentAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_insm_DevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Regulatory Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DevelopmentAndRegulatoryMilestonesMember" xlink:href="insm-20240630.xsd#insm_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DevelopmentAndRegulatoryMilestonesMember" xlink:to="lab_insm_DevelopmentAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_MotusBiosciencesIncMember_8acf1494-d149-4eb7-85dc-103174b73f1c_terseLabel_en-US" xlink:label="lab_insm_MotusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Motus</link:label>
    <link:label id="lab_insm_MotusBiosciencesIncMember_label_en-US" xlink:label="lab_insm_MotusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Motus Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_insm_MotusBiosciencesIncMember_documentation_en-US" xlink:label="lab_insm_MotusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Motus Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncMember" xlink:href="insm-20240630.xsd#insm_MotusBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MotusBiosciencesIncMember" xlink:to="lab_insm_MotusBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_9e4d1624-04ad-46bd-b81a-ae09a22fdfb6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_c4809abf-3384-4fd3-b7fb-1b93fc57a5d3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_7732fa60-19f6-47e4-b9b9-0259e712e233_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6de14050-a856-408b-8abc-ec58f29c0004_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_e9a076da-19de-48f5-be7a-125cc6d08328_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_d1fd9e90-19d1-491e-a4d6-936fa6b570f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Value of Convertible Notes Balance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_dcbfdd12-5e7d-4b9f-8f3f-144976525954_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Value of Royalty Financing Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_ca8ebdc6-e86f-4f08-9a0d-d6f33d08b8f9_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6c5eb0cb-11e7-411b-b852-634cbea34366_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTableTextBlock_250006ed-3fa1-4b55-9668-be094ed2f7ed_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Purchase Price</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTableTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_b5d2ea98-1a1d-42f3-8fee-4f518746aedd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_b78ff88d-9e00-4e06-a57b-cae36ba7c73f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lenders fees and deal expenses</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2142cde-02c6-4f16-8c0f-2e02ba982fbf_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AcquiredResearchAndDevelopmentMember_81bcb072-37a3-4734-bcad-f461e964b72f_terseLabel_en-US" xlink:label="lab_insm_AcquiredResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired ARIKAYCE R&amp;D</link:label>
    <link:label id="lab_insm_AcquiredResearchAndDevelopmentMember_label_en-US" xlink:label="lab_insm_AcquiredResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Research And Development [Member]</link:label>
    <link:label id="lab_insm_AcquiredResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_insm_AcquiredResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquired Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AcquiredResearchAndDevelopmentMember" xlink:href="insm-20240630.xsd#insm_AcquiredResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AcquiredResearchAndDevelopmentMember" xlink:to="lab_insm_AcquiredResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_af99326c-00fb-4cba-9ba9-f7b2685d8b6e_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_edbba941-e010-4c54-b6a5-482b63a83e37_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Performance Stock Units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_065f6623-3f9b-431d-9a5f-f53f42c6e8d8_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_33502da6-2783-4c52-a8a2-2439de5567eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Swap interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_da530bdb-727b-4f2b-b577-e54226f6c1ad_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_16369aa5-ebcb-43eb-b3b4-95e9b70daeb1_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e008ecd9-d374-4c46-98b8-e04d5f3c5a43_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_f1af645b-a215-4fbb-ac2a-474d34fbbe6d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid in acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments_04eb153a-faf1-45db-a22d-f7d44140764a_terseLabel_en-US" xlink:label="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments_label_en-US" xlink:label="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments</link:label>
    <link:label id="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments_documentation_en-US" xlink:label="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" xlink:href="insm-20240630.xsd#insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" xlink:to="lab_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_21fe56d7-521e-4402-9cb3-fd6db01ee385_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles, Net and Goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_28890dc2-8788-4f2a-8500-6e9dfcc77ce8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation losses</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_39f4d5bf-fd7b-4a6f-a98d-2c1bbe4a64f6_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_c14882fc-7bd8-4695-9f0c-446cfeaa6422_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease amortization expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_VertuisBioIncMember_4527690b-38dc-4233-8e6b-3463c546be2b_terseLabel_en-US" xlink:label="lab_insm_VertuisBioIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vertuis Bio, Inc.</link:label>
    <link:label id="lab_insm_VertuisBioIncMember_label_en-US" xlink:label="lab_insm_VertuisBioIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vertuis Bio, Inc. [Member]</link:label>
    <link:label id="lab_insm_VertuisBioIncMember_documentation_en-US" xlink:label="lab_insm_VertuisBioIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vertuis Bio, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_VertuisBioIncMember" xlink:href="insm-20240630.xsd#insm_VertuisBioIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_VertuisBioIncMember" xlink:to="lab_insm_VertuisBioIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_26618b2c-06d9-445f-b32e-232cf593c889_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible List]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1d0ef269-7b89-40b7-b086-f98906736ec4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares sold in offering (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_60a2f8e5-ad90-4439-bb09-14fc012efed7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs, net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_e33d6abf-820d-4d71-98d4-418cbb3a9813_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_064b5fa6-91fb-447c-9f28-a71678c7c077_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_1fbf4aca-7058-4498-bc97-d164a300c719_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred Consideration (Level 2 Liabilities)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_299cce87-9a6a-41cf-80da-390d9b7f1817_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d2783b45-1f09-4948-95ed-dded78739ed7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_073c7eab-6d4e-415c-89dd-88507b59f8a3_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_S.NicoleSchaefferMember_label_en-US" xlink:label="lab_insm_S.NicoleSchaefferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">S. Nicole Schaeffer [Member]</link:label>
    <link:label id="lab_insm_S.NicoleSchaefferMember_documentation_en-US" xlink:label="lab_insm_S.NicoleSchaefferMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">S. Nicole Schaeffer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_S.NicoleSchaefferMember" xlink:href="insm-20240630.xsd#insm_S.NicoleSchaefferMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_S.NicoleSchaefferMember" xlink:to="lab_insm_S.NicoleSchaefferMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_f0a2a8e9-8ff6-4697-89eb-85ec6821bd98_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Original Term Loan balance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_ad4f76a4-5123-4b28-a28e-40a42f75e96a_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_5077fbfa-6414-4d98-8aca-a5acdba0cffe_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_67194590-493c-4794-b4e2-3191fcfb7de4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_87cef594-3ead-4abf-9dbc-6e10820a5835_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Aggregate Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_778d9d06-6c1d-4161-aeb8-c21f484e3f1a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_180230c4-29af-4a52-a4e7-a71e2b483628_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_950cc918-7d13-4750-b2ce-8dc5bc787eef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value; 500,000,000 authorized shares, 166,666,599 and 147,977,960 issued and outstanding shares at June&#160;30, 2024 and December&#160;31, 2023,&#160;respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_ef02faa1-81ee-443a-a149-c09c42f572a3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for asset acquisitions</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5175429f-fb54-4ec3-8918-61064f4b217c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_a13b6f4b-7f09-4ac9-ae21-31258f123879_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for asset acquisitions (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_c5723e20-16ae-4bab-8078-59a53c6c52b0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for business acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtIssuanceCostsOther_a45c142f-6745-4bc4-b946-0f9993b86229_negatedTerseLabel_en-US" xlink:label="lab_insm_DebtIssuanceCostsOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_insm_DebtIssuanceCostsOther_label_en-US" xlink:label="lab_insm_DebtIssuanceCostsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Other</link:label>
    <link:label id="lab_insm_DebtIssuanceCostsOther_documentation_en-US" xlink:label="lab_insm_DebtIssuanceCostsOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtIssuanceCostsOther" xlink:href="insm-20240630.xsd#insm_DebtIssuanceCostsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtIssuanceCostsOther" xlink:to="lab_insm_DebtIssuanceCostsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_f7996afa-9884-4f72-8161-b67cb8e64a01_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_c05a48aa-41cd-44e4-82d3-0103e05fcdaf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_6a88b8b2-7920-4e46-9e82-347d49e544fe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e0e068fd-df2c-4ec7-bd0a-76485703cddd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_692d88e9-25f0-4d7e-991a-9358b78bac52_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_5fd2582d-b284-46c1-b4f4-730a0927ae68_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_9d3d9e36-8aaa-436f-9f52-fe4a43c7bfd3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Life (years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_bba46916-6e80-4c52-8bbb-c61bad0952fb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year Ending December&#160;31:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AccruedClinicalTrialExpenses_23bd6c8a-858f-4613-9602-7add5fabdf57_terseLabel_en-US" xlink:label="lab_insm_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_insm_AccruedClinicalTrialExpenses_label_en-US" xlink:label="lab_insm_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expenses</link:label>
    <link:label id="lab_insm_AccruedClinicalTrialExpenses_documentation_en-US" xlink:label="lab_insm_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedClinicalTrialExpenses" xlink:href="insm-20240630.xsd#insm_AccruedClinicalTrialExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedClinicalTrialExpenses" xlink:to="lab_insm_AccruedClinicalTrialExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_91216537-584d-4d1e-9543-ae19f1ac2c04_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_eb310404-2b35-4bc6-b7a8-30650643c121_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_bae5309b-722d-4691-a921-f962d7888a49_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4b7e33a7-3caa-405e-a698-80005dcbddca_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_BusinessCombinationDeferredLiability_a9413e46-63ca-4739-a4b5-70c25d213e5b_terseLabel_en-US" xlink:label="lab_insm_BusinessCombinationDeferredLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred consideration</link:label>
    <link:label id="lab_insm_BusinessCombinationDeferredLiability_label_en-US" xlink:label="lab_insm_BusinessCombinationDeferredLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Deferred Liability</link:label>
    <link:label id="lab_insm_BusinessCombinationDeferredLiability_documentation_en-US" xlink:label="lab_insm_BusinessCombinationDeferredLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Deferred Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredLiability" xlink:href="insm-20240630.xsd#insm_BusinessCombinationDeferredLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_BusinessCombinationDeferredLiability" xlink:to="lab_insm_BusinessCombinationDeferredLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ComputerHardwareAndSoftwareMember_3da60dff-d610-4230-8b2d-cb2591918668_terseLabel_en-US" xlink:label="lab_insm_ComputerHardwareAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer hardware and software</link:label>
    <link:label id="lab_insm_ComputerHardwareAndSoftwareMember_label_en-US" xlink:label="lab_insm_ComputerHardwareAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Hardware And Software [Member]</link:label>
    <link:label id="lab_insm_ComputerHardwareAndSoftwareMember_documentation_en-US" xlink:label="lab_insm_ComputerHardwareAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer Hardware And Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ComputerHardwareAndSoftwareMember" xlink:href="insm-20240630.xsd#insm_ComputerHardwareAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ComputerHardwareAndSoftwareMember" xlink:to="lab_insm_ComputerHardwareAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_a16504c9-03b2-41e3-9a33-188d11440cb9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_00dea18c-20b9-4c1f-9764-9f780f23d7ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments of finance lease principal</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8419559a-8ed9-4a24-9dc3-6731f26c892b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss, basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_82cfd5ba-59e5-4a22-b862-07f0a56afa47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_40a58016-52ab-41d9-8de9-3d3914ad6cf5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_13ea67fb-d2ae-48ea-8cad-da52982e9d61_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_69019b5f-a8b6-4bfb-a7e7-ea6f4553dfb0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_2961ae38-848f-40b5-8aed-7b02d17bc0e0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_A2019IncentivePlanThirdAmendmentMember_6282ac60-1977-4b86-b302-9bf95f8475dc_terseLabel_en-US" xlink:label="lab_insm_A2019IncentivePlanThirdAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Incentive Plan</link:label>
    <link:label id="lab_insm_A2019IncentivePlanThirdAmendmentMember_label_en-US" xlink:label="lab_insm_A2019IncentivePlanThirdAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2019 Incentive Plan, Third Amendment [Member]</link:label>
    <link:label id="lab_insm_A2019IncentivePlanThirdAmendmentMember_documentation_en-US" xlink:label="lab_insm_A2019IncentivePlanThirdAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2019 Incentive Plan, Third Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2019IncentivePlanThirdAmendmentMember" xlink:href="insm-20240630.xsd#insm_A2019IncentivePlanThirdAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_A2019IncentivePlanThirdAmendmentMember" xlink:to="lab_insm_A2019IncentivePlanThirdAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_264106b7-257c-48bf-83f9-e28a7be7b8c4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets, 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_22aec57e-26ac-4251-976a-1e4980f96e58_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of product revenues (excluding amortization of intangible assets)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_dd3f28ee-d8a3-4342-a021-2556085e9a6a_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_90e10d71-8279-4775-a8b4-fa5f80603dc8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of fixed assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_b561c977-1396-4fdc-88e3-f4f183bf1547_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_InterestExpenseExcludingFinanceLeaseInterestExpense_9feeaccf-4eaa-4837-8e00-cf9760cad6c8_totalLabel_en-US" xlink:label="lab_insm_InterestExpenseExcludingFinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total debt interest expense</link:label>
    <link:label id="lab_insm_InterestExpenseExcludingFinanceLeaseInterestExpense_label_en-US" xlink:label="lab_insm_InterestExpenseExcludingFinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Excluding Finance Lease Interest Expense</link:label>
    <link:label id="lab_insm_InterestExpenseExcludingFinanceLeaseInterestExpense_documentation_en-US" xlink:label="lab_insm_InterestExpenseExcludingFinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Expense, Excluding Finance Lease Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InterestExpenseExcludingFinanceLeaseInterestExpense" xlink:href="insm-20240630.xsd#insm_InterestExpenseExcludingFinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_InterestExpenseExcludingFinanceLeaseInterestExpense" xlink:to="lab_insm_InterestExpenseExcludingFinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_bb777fc3-03c1-48fb-bcf0-276172b26a3d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of outstanding shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentRoyaltyStatedPercentage_beacc126-2dc6-4d8b-bed8-1ba12f758ffd_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentRoyaltyStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty percentage</link:label>
    <link:label id="lab_insm_DebtInstrumentRoyaltyStatedPercentage_label_en-US" xlink:label="lab_insm_DebtInstrumentRoyaltyStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Royalty, Stated Percentage</link:label>
    <link:label id="lab_insm_DebtInstrumentRoyaltyStatedPercentage_documentation_en-US" xlink:label="lab_insm_DebtInstrumentRoyaltyStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Royalty, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentRoyaltyStatedPercentage" xlink:href="insm-20240630.xsd#insm_DebtInstrumentRoyaltyStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentRoyaltyStatedPercentage" xlink:to="lab_insm_DebtInstrumentRoyaltyStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_b7fb222f-3581-45cb-b4cf-cc366afbfc21_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued royalty and milestones payable</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_5558c6b8-7b3f-43b0-a9d9-bd0f5cdc53d1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalty financing liability</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_de1deff7-b5ce-4647-8946-0f1b688f037b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_de4bc088-28b1-4449-945c-bd258cb4a14b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_5156725d-56ca-4b0b-b61f-87ccb7f88810_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold percent of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AccruedSalesAllowancesAndRelatedCosts_aef7e9a7-36c1-4a34-beb4-3298e9bcdcd3_terseLabel_en-US" xlink:label="lab_insm_AccruedSalesAllowancesAndRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued sales allowances and related costs</link:label>
    <link:label id="lab_insm_AccruedSalesAllowancesAndRelatedCosts_label_en-US" xlink:label="lab_insm_AccruedSalesAllowancesAndRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Sales Allowances And Related Costs</link:label>
    <link:label id="lab_insm_AccruedSalesAllowancesAndRelatedCosts_documentation_en-US" xlink:label="lab_insm_AccruedSalesAllowancesAndRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Sales Allowances And Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedSalesAllowancesAndRelatedCosts" xlink:href="insm-20240630.xsd#insm_AccruedSalesAllowancesAndRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedSalesAllowancesAndRelatedCosts" xlink:to="lab_insm_AccruedSalesAllowancesAndRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b5947f56-6813-4015-acf3-35188f6effa7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_37006900-111a-4238-a750-e3e3c864afc5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_df27678d-a8cb-4010-a729-53f6f586e64a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition, consideration transferred</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_7de4e57f-426b-4cf9-8df1-ea8c99558ad7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentRedemptionPricePerShare_cc65afb6-2f13-4347-907b-8d7a19189021_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption price per share (in dollars per share)</link:label>
    <link:label id="lab_insm_DebtInstrumentRedemptionPricePerShare_label_en-US" xlink:label="lab_insm_DebtInstrumentRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price Per Share</link:label>
    <link:label id="lab_insm_DebtInstrumentRedemptionPricePerShare_documentation_en-US" xlink:label="lab_insm_DebtInstrumentRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentRedemptionPricePerShare" xlink:href="insm-20240630.xsd#insm_DebtInstrumentRedemptionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentRedemptionPricePerShare" xlink:to="lab_insm_DebtInstrumentRedemptionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_123bb89a-4afa-489b-b705-56161f91bb94_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Geographic Summary of Product Revenues, Net</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_932123b0-c2c3-4c1c-aa61-7f3983c4a056_verboseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentConversionTermTwoMember_c9035e36-6e9f-42bf-9e73-438091351352_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion Term (ii)</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermTwoMember_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Term Two [Member]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermTwoMember_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Term Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermTwoMember" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermTwoMember" xlink:to="lab_insm_DebtInstrumentConversionTermTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_9d561118-fc14-4360-80b3-00351d733403_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_c4a6f67f-2950-44b2-b863-5db0aa417602_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_c577f121-d55c-414e-80da-20f8937799e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Value of Term Loan Balance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_2dfc168d-871e-44f3-88fd-95c97d2b6f8b_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_12b0a9ef-2ee6-4df9-8466-91368dddff42_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_690478d9-512d-4fd4-a2f1-dc1d01dd3015_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_745b02a7-bdde-49fd-9f45-885a54f3f3a4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_9624b805-dc38-4b8f-9961-609561d4d71b_terseLabel_en-US" xlink:label="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1.75% Convertible Senior Notes Due 2025</link:label>
    <link:label id="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_label_en-US" xlink:label="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]</link:label>
    <link:label id="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_documentation_en-US" xlink:label="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:href="insm-20240630.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:to="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_5088634c-7387-4057-af4b-ed974b9b8886_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1e81d0c5-73b5-499a-b55f-508c0787f616_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Rollforward of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentConversionTermOneMember_53e0750d-af1b-493e-88e9-10ce9bbeecf4_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion Term (i)</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermOneMember_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Term One [Member]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermOneMember_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Conversion Term One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermOneMember" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermOneMember" xlink:to="lab_insm_DebtInstrumentConversionTermOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders_d37f745f-2d89-46b3-a4f6-a374d5665861_terseLabel_en-US" xlink:label="lab_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of publicly disclosed sales used to determine average sales price owed to equity holders</link:label>
    <link:label id="lab_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders_label_en-US" xlink:label="lab_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Publicly Disclosed Sales Used To Determine Average Sales Price Owed To Equity Holders</link:label>
    <link:label id="lab_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders_documentation_en-US" xlink:label="lab_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Publicly Disclosed Sales Used To Determine Average Sales Price Owed To Equity Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders" xlink:href="insm-20240630.xsd#insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders" xlink:to="lab_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_54fd41c8-2756-4461-8dce-8078e8a06c0a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ARIKAYCEGlobalNetSalesMember_a2829c6a-0cb0-4625-b8df-2d9fef14b527_terseLabel_en-US" xlink:label="lab_insm_ARIKAYCEGlobalNetSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ARIKAYCE Global Net Sales</link:label>
    <link:label id="lab_insm_ARIKAYCEGlobalNetSalesMember_label_en-US" xlink:label="lab_insm_ARIKAYCEGlobalNetSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARIKAYCE Global Net Sales [Member]</link:label>
    <link:label id="lab_insm_ARIKAYCEGlobalNetSalesMember_documentation_en-US" xlink:label="lab_insm_ARIKAYCEGlobalNetSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ARIKAYCE Global Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ARIKAYCEGlobalNetSalesMember" xlink:href="insm-20240630.xsd#insm_ARIKAYCEGlobalNetSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ARIKAYCEGlobalNetSalesMember" xlink:to="lab_insm_ARIKAYCEGlobalNetSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_ac93108e-b3c3-463e-a1cd-dfec649bec24_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Revenues, Net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_9faa7128-179a-41b2-807d-f4e026f87a53_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b8df8313-0667-44b1-ae71-560543349ce5_verboseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_055705ea-b48e-49a7-860c-3be4c5f4dd8a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_6261b090-ed72-4abc-aa25-8b547f2570c0_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold trading days following fundamental change</link:label>
    <link:label id="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_label_en-US" xlink:label="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change</link:label>
    <link:label id="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:to="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_de74a0ab-82ec-4694-ac9f-d9f5dbb8d576_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c4916d26-1287-4d20-9865-2f47a7f9a521_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_a3cbdc79-d1c1-449f-83d9-5ca8042fdbcc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_62dc245c-22aa-4428-b905-a004a3b8093b_verboseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_be7231ee-4dc3-482d-91a1-31efb8f9c28e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyAgreementsMember_4f1cca63-c31a-4c3e-ae88-0d508a243723_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Agreements</link:label>
    <link:label id="lab_us-gaap_RoyaltyAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyAgreementsMember" xlink:to="lab_us-gaap_RoyaltyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_c78487ff-45a4-414f-b329-99e2528c383b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_f631cdae-9c80-4500-968b-2071d338ec42_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a072de4f-3aac-47a4-9d12-30f4577cb05c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, nonvested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_ffdfd95d-a4d1-4bee-8a32-28643c4e9d0d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Revenue Interest Payments paid and payable</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_A2028ConvertibleNotesMember_1d419f9a-3dc0-4f8e-9fd9-74acdb84222c_terseLabel_en-US" xlink:label="lab_insm_A2028ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of 2028 Notes</link:label>
    <link:label id="lab_insm_A2028ConvertibleNotesMember_label_en-US" xlink:label="lab_insm_A2028ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2028 Convertible Notes [Member]</link:label>
    <link:label id="lab_insm_A2028ConvertibleNotesMember_documentation_en-US" xlink:label="lab_insm_A2028ConvertibleNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2028 Convertible Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2028ConvertibleNotesMember" xlink:href="insm-20240630.xsd#insm_A2028ConvertibleNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_A2028ConvertibleNotesMember" xlink:to="lab_insm_A2028ConvertibleNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_994b8309-4ace-44f9-a288-c6b608ccdd45_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputSharePriceMember" xlink:to="lab_us-gaap_MeasurementInputSharePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_a807dad6-d63f-4b82-b364-9a268820286a_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList_5203d5a5-db5c-4b77-943b-72d155f0c234_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost, Product and Service [Extensible List]</link:label>
    <link:label id="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:to="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c56cf120-a639-4fe2-9439-e96a7ee01e39_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_00cc3f6e-73a8-45b3-8f46-c744993ee48d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_ceaf8432-2640-45fa-8abf-364faa69eda7_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b0da6fb4-ed5e-4803-ba23-50a23da52aaa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_efd0871f-0d5d-407b-96c3-dbad9a32aa71_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_79bdbb7b-33a3-4017-891e-be0a8d6c9d67_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_40ba13ab-3145-4829-b537-434639d0be44_verboseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f951692b-74ca-4012-875d-3adcbbb6a61e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_48e1d0ca-2faf-4fc1-a21d-81b3c75c5707_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_6927bf43-c44c-4958-8a58-7b87c7efec23_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_ebbcec6f-1ad9-4f4c-84ee-19d43910f1a3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_89a250e9-7bd5-408f-92cb-a8c42fadc4e1_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average basic common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_31de4b88-c1dc-4d5c-b0dc-271761f47261_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares used in calculation of basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_78a7825f-f043-47b6-9921-3ec6cab7288b_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RS and RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_389ed284-b761-4be4-8e12-5beff9c58cdd_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested RS and RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_22f63518-c04e-4311-99c1-15a74acbd341_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_PriorityReviewVoucherMilestoneMember_90d55f15-de3e-4bdb-bfda-e1149d95e3ba_terseLabel_en-US" xlink:label="lab_insm_PriorityReviewVoucherMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Priority review voucher milestone</link:label>
    <link:label id="lab_insm_PriorityReviewVoucherMilestoneMember_label_en-US" xlink:label="lab_insm_PriorityReviewVoucherMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Priority Review Voucher Milestone [Member]</link:label>
    <link:label id="lab_insm_PriorityReviewVoucherMilestoneMember_documentation_en-US" xlink:label="lab_insm_PriorityReviewVoucherMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Priority Review Voucher Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PriorityReviewVoucherMilestoneMember" xlink:href="insm-20240630.xsd#insm_PriorityReviewVoucherMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_PriorityReviewVoucherMilestoneMember" xlink:to="lab_insm_PriorityReviewVoucherMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9b3368ec-eaa2-4ae8-bbbd-e37c235b0e53_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_7cd8d757-953a-4744-a308-4bd322a28e32_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_abc32455-7cb3-465a-9ae0-5b840848ace4_verboseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_99fe4db5-e24a-4534-acd6-6268e3a05bda_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_921a4e5e-242e-4d91-a9a4-64ca20994510_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>insm-20240630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:c55c6bb2-e1ff-4fc1-8df4-decd904b3b6b,g:5264b7b4-c672-47ab-b9d7-1b1bb5962c46-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.insmed.com/role/CoverPage" xlink:type="simple" xlink:href="insm-20240630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_293780c2-222a-4f95-ac3d-f306ef8282d6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_DocumentType_293780c2-222a-4f95-ac3d-f306ef8282d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_2ed4523b-3dd3-4aea-81b6-dd596cd1ff2f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_DocumentQuarterlyReport_2ed4523b-3dd3-4aea-81b6-dd596cd1ff2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_94266e37-7022-4107-800b-7a6a89cc582a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_DocumentPeriodEndDate_94266e37-7022-4107-800b-7a6a89cc582a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ab6ef497-f04a-4bc0-8469-e7adadfe3aa5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_DocumentTransitionReport_ab6ef497-f04a-4bc0-8469-e7adadfe3aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f3ff05fd-f0b5-4bba-af9c-9f604b8b6e1d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_EntityFileNumber_f3ff05fd-f0b5-4bba-af9c-9f604b8b6e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_71d3f696-306d-4a44-9caf-885a17fcb772" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_EntityRegistrantName_71d3f696-306d-4a44-9caf-885a17fcb772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0c46d9b8-5499-46ef-9610-b8734801bd81" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0c46d9b8-5499-46ef-9610-b8734801bd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b8c9e363-1ab1-494a-9832-a91b7d1243c0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_EntityTaxIdentificationNumber_b8c9e363-1ab1-494a-9832-a91b7d1243c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_71d2dde3-c7be-42f2-bd97-0adb1bc3c01f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_EntityAddressAddressLine1_71d2dde3-c7be-42f2-bd97-0adb1bc3c01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7d48abc1-9c45-4fa1-89be-a94d6fcc3251" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_EntityAddressCityOrTown_7d48abc1-9c45-4fa1-89be-a94d6fcc3251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5fe7dfba-f7bb-48e8-9fdb-bc3a4492f700" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_EntityAddressStateOrProvince_5fe7dfba-f7bb-48e8-9fdb-bc3a4492f700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7016e19b-2f9b-402f-82e1-ded66bd293bd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_EntityAddressPostalZipCode_7016e19b-2f9b-402f-82e1-ded66bd293bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_940f1f6a-33e9-4ef4-944c-1808fde749ca" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_CityAreaCode_940f1f6a-33e9-4ef4-944c-1808fde749ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2dfb11af-2f15-406a-b074-63a410febd44" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_LocalPhoneNumber_2dfb11af-2f15-406a-b074-63a410febd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7cab748a-7974-4a47-a9d6-19f4749f1c38" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_Security12bTitle_7cab748a-7974-4a47-a9d6-19f4749f1c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0d7163b6-948a-40d3-9626-9dced6e6e6f1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_TradingSymbol_0d7163b6-948a-40d3-9626-9dced6e6e6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7f635e0a-14d4-4c8b-b2eb-5a8112a21ac7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_SecurityExchangeName_7f635e0a-14d4-4c8b-b2eb-5a8112a21ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_987d1f0e-78fd-4807-aa93-d6c13cae6281" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_EntityCurrentReportingStatus_987d1f0e-78fd-4807-aa93-d6c13cae6281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7922df9d-decb-4cf2-b7c8-526b828f2c5f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_EntityInteractiveDataCurrent_7922df9d-decb-4cf2-b7c8-526b828f2c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_087b25aa-b0e7-4167-849c-692a10dbb564" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_EntityFilerCategory_087b25aa-b0e7-4167-849c-692a10dbb564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ab08cd64-2901-4932-8d3a-249ff679196f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_EntitySmallBusiness_ab08cd64-2901-4932-8d3a-249ff679196f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7da30c63-d133-4465-bc7d-0addff236b79" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_EntityEmergingGrowthCompany_7da30c63-d133-4465-bc7d-0addff236b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4b687df7-dc2e-43e9-9707-42cfaccdae82" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_EntityShellCompany_4b687df7-dc2e-43e9-9707-42cfaccdae82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_dbab6e8f-50a2-4e63-bed3-3b701e5cc4b3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_dbab6e8f-50a2-4e63-bed3-3b701e5cc4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_cbea0bd9-3766-4a1c-9894-b5e8ea97bb03" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_EntityCentralIndexKey_cbea0bd9-3766-4a1c-9894-b5e8ea97bb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_08874412-4dae-44e9-8332-7b0329c61d9b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_AmendmentFlag_08874412-4dae-44e9-8332-7b0329c61d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9c6e9aab-4d2c-4144-87fd-22a2db27b21f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_CurrentFiscalYearEndDate_9c6e9aab-4d2c-4144-87fd-22a2db27b21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4e5cd68f-2073-4e1d-8d80-ac262c04a663" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_DocumentFiscalYearFocus_4e5cd68f-2073-4e1d-8d80-ac262c04a663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_651c80e6-c864-4de2-9d99-6ee0df1a5922" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57c4793a-68b3-42dd-a5aa-1cdfabf0659c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_651c80e6-c864-4de2-9d99-6ee0df1a5922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="insm-20240630.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_822812f9-5aaf-4ca8-aae2-0253d529f3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_afe08741-a1dd-404d-bf8b-2872dfb0fa6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_822812f9-5aaf-4ca8-aae2-0253d529f3ec" xlink:to="loc_us-gaap_AssetsAbstract_afe08741-a1dd-404d-bf8b-2872dfb0fa6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_baaf1724-ce4a-4076-b790-c27797224e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_afe08741-a1dd-404d-bf8b-2872dfb0fa6f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_baaf1724-ce4a-4076-b790-c27797224e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_48335d34-7353-4cb1-a3dd-5fc14a09610f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_baaf1724-ce4a-4076-b790-c27797224e8a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_48335d34-7353-4cb1-a3dd-5fc14a09610f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_540e927c-d056-48de-b84c-ed7b71d7996b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_baaf1724-ce4a-4076-b790-c27797224e8a" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_540e927c-d056-48de-b84c-ed7b71d7996b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4345807c-3983-4ddc-90d3-9dc61a995240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_baaf1724-ce4a-4076-b790-c27797224e8a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4345807c-3983-4ddc-90d3-9dc61a995240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_20e1a4bf-1097-4e8b-9195-613ef8a26fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_baaf1724-ce4a-4076-b790-c27797224e8a" xlink:to="loc_us-gaap_InventoryNet_20e1a4bf-1097-4e8b-9195-613ef8a26fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2328e458-9388-42eb-8b44-8376d6479176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_baaf1724-ce4a-4076-b790-c27797224e8a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2328e458-9388-42eb-8b44-8376d6479176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4486dfb7-4245-4a83-94ca-75649cb85230" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_baaf1724-ce4a-4076-b790-c27797224e8a" xlink:to="loc_us-gaap_AssetsCurrent_4486dfb7-4245-4a83-94ca-75649cb85230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2a842cbc-98f5-4556-8697-e7567f4bf40e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_afe08741-a1dd-404d-bf8b-2872dfb0fa6f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2a842cbc-98f5-4556-8697-e7567f4bf40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_d163df27-e9fd-4e35-9a4e-d7ac9513907c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_afe08741-a1dd-404d-bf8b-2872dfb0fa6f" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_d163df27-e9fd-4e35-9a4e-d7ac9513907c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_02868741-872f-48c2-9a6f-03547b4aecc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_afe08741-a1dd-404d-bf8b-2872dfb0fa6f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_02868741-872f-48c2-9a6f-03547b4aecc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ae3f5ed4-fd21-4964-8e84-a25888c14ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_afe08741-a1dd-404d-bf8b-2872dfb0fa6f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ae3f5ed4-fd21-4964-8e84-a25888c14ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2fdd5047-2477-42ec-a039-4604650b15fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_afe08741-a1dd-404d-bf8b-2872dfb0fa6f" xlink:to="loc_us-gaap_Goodwill_2fdd5047-2477-42ec-a039-4604650b15fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_8e829b53-ac81-4335-8e22-85ae340b3b48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_afe08741-a1dd-404d-bf8b-2872dfb0fa6f" xlink:to="loc_us-gaap_OtherAssets_8e829b53-ac81-4335-8e22-85ae340b3b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e18f641c-b74d-4d19-abea-11171d04ed28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_afe08741-a1dd-404d-bf8b-2872dfb0fa6f" xlink:to="loc_us-gaap_Assets_e18f641c-b74d-4d19-abea-11171d04ed28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7680cb7-daa0-4862-9c55-0c39e56ac963" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_822812f9-5aaf-4ca8-aae2-0253d529f3ec" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7680cb7-daa0-4862-9c55-0c39e56ac963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_06f0faa5-59b7-49ae-ae35-ad7761d23c54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7680cb7-daa0-4862-9c55-0c39e56ac963" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_06f0faa5-59b7-49ae-ae35-ad7761d23c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_f8e6fffd-b954-4369-80bc-6ed153b64dff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_06f0faa5-59b7-49ae-ae35-ad7761d23c54" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_f8e6fffd-b954-4369-80bc-6ed153b64dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_8af7fc74-512a-4035-9ef6-3537214d64ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_06f0faa5-59b7-49ae-ae35-ad7761d23c54" xlink:to="loc_us-gaap_LongTermDebtCurrent_8af7fc74-512a-4035-9ef6-3537214d64ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_aa31c6ab-c3e2-4da6-ad13-d7c62977c42a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_06f0faa5-59b7-49ae-ae35-ad7761d23c54" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_aa31c6ab-c3e2-4da6-ad13-d7c62977c42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d9dc5058-0b08-461a-90b2-0eae6d297a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_06f0faa5-59b7-49ae-ae35-ad7761d23c54" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d9dc5058-0b08-461a-90b2-0eae6d297a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d73a7c9e-e300-403b-a1a7-11faa38b3eff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_06f0faa5-59b7-49ae-ae35-ad7761d23c54" xlink:to="loc_us-gaap_LiabilitiesCurrent_d73a7c9e-e300-403b-a1a7-11faa38b3eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_20cbe8f6-9e0c-4d7f-bcd4-028dd35bd2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7680cb7-daa0-4862-9c55-0c39e56ac963" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_20cbe8f6-9e0c-4d7f-bcd4-028dd35bd2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_aecb9ce6-d955-4cbf-b2bf-efdf501592e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7680cb7-daa0-4862-9c55-0c39e56ac963" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_aecb9ce6-d955-4cbf-b2bf-efdf501592e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ff59fb37-24ce-42bb-934c-89f219335e00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7680cb7-daa0-4862-9c55-0c39e56ac963" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ff59fb37-24ce-42bb-934c-89f219335e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b00d6c8e-e5a3-437b-ba5a-68fd4176b937" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7680cb7-daa0-4862-9c55-0c39e56ac963" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b00d6c8e-e5a3-437b-ba5a-68fd4176b937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1bffb559-b0bd-4d2b-83d4-7a99f08a978f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7680cb7-daa0-4862-9c55-0c39e56ac963" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1bffb559-b0bd-4d2b-83d4-7a99f08a978f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_25b90755-01cc-4363-81bd-73b4dbbc96f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7680cb7-daa0-4862-9c55-0c39e56ac963" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_25b90755-01cc-4363-81bd-73b4dbbc96f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_daa2b470-ebbd-4315-a087-67d6077d57ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7680cb7-daa0-4862-9c55-0c39e56ac963" xlink:to="loc_us-gaap_Liabilities_daa2b470-ebbd-4315-a087-67d6077d57ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5dd0500f-6dbb-4611-92c0-b341f8e62522" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7680cb7-daa0-4862-9c55-0c39e56ac963" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5dd0500f-6dbb-4611-92c0-b341f8e62522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_69450a81-1e1a-4599-84b0-3ab3d837dc87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5dd0500f-6dbb-4611-92c0-b341f8e62522" xlink:to="loc_us-gaap_CommonStockValue_69450a81-1e1a-4599-84b0-3ab3d837dc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c88b162e-7a99-4836-9654-b36823ea228f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5dd0500f-6dbb-4611-92c0-b341f8e62522" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c88b162e-7a99-4836-9654-b36823ea228f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ccb7d5a0-2d18-4456-865b-19f634bd6a60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5dd0500f-6dbb-4611-92c0-b341f8e62522" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ccb7d5a0-2d18-4456-865b-19f634bd6a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ba1753ae-c926-4618-999d-f7cc14faf484" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5dd0500f-6dbb-4611-92c0-b341f8e62522" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ba1753ae-c926-4618-999d-f7cc14faf484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f58eeace-1d3c-437d-9a2d-7669c06a3c65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5dd0500f-6dbb-4611-92c0-b341f8e62522" xlink:to="loc_us-gaap_StockholdersEquity_f58eeace-1d3c-437d-9a2d-7669c06a3c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ed38132f-e713-4a95-b74c-ede192b5571e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f7680cb7-daa0-4862-9c55-0c39e56ac963" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ed38132f-e713-4a95-b74c-ede192b5571e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="insm-20240630.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2eb5ea60-5919-4cec-96a7-776ca124bfcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_032f8e0a-7832-419f-9658-1d5d8104c303" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2eb5ea60-5919-4cec-96a7-776ca124bfcb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_032f8e0a-7832-419f-9658-1d5d8104c303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6c099c30-d8e4-4be7-9d1a-9f7443c99788" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2eb5ea60-5919-4cec-96a7-776ca124bfcb" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6c099c30-d8e4-4be7-9d1a-9f7443c99788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_9ab34034-7a27-44c5-bcdc-0caf6845ed4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2eb5ea60-5919-4cec-96a7-776ca124bfcb" xlink:to="loc_us-gaap_CommonStockSharesIssued_9ab34034-7a27-44c5-bcdc-0caf6845ed4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_54503252-a86e-42c4-909b-28dee859b15a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2eb5ea60-5919-4cec-96a7-776ca124bfcb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_54503252-a86e-42c4-909b-28dee859b15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="simple" xlink:href="insm-20240630.xsd#ConsolidatedStatementsofComprehensiveLossunaudited"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_932b014b-7eb5-4850-b490-2574659a5adc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_932b014b-7eb5-4850-b490-2574659a5adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e56a21b2-2cfc-469d-93a0-a4c8ca3b3ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e56a21b2-2cfc-469d-93a0-a4c8ca3b3ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_60ace8b5-5252-46cf-8b99-e3719e922476" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_60ace8b5-5252-46cf-8b99-e3719e922476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_c57d2a71-ab11-4136-87b1-d31a49b3a80e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_60ace8b5-5252-46cf-8b99-e3719e922476" xlink:to="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_c57d2a71-ab11-4136-87b1-d31a49b3a80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e9e5a9a4-93ee-4ea1-9281-bac62aae4a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_60ace8b5-5252-46cf-8b99-e3719e922476" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e9e5a9a4-93ee-4ea1-9281-bac62aae4a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1e83d3d0-507c-4b47-b5e0-b698ce9ece4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_60ace8b5-5252-46cf-8b99-e3719e922476" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1e83d3d0-507c-4b47-b5e0-b698ce9ece4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f1356e35-8e73-4e4b-9649-069fd97e32ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_60ace8b5-5252-46cf-8b99-e3719e922476" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f1356e35-8e73-4e4b-9649-069fd97e32ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_aeac4287-5d6d-46d2-931c-c59137f7236b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_60ace8b5-5252-46cf-8b99-e3719e922476" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_aeac4287-5d6d-46d2-931c-c59137f7236b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_661c2031-2151-4f4e-b926-0704b4b1c382" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_60ace8b5-5252-46cf-8b99-e3719e922476" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_661c2031-2151-4f4e-b926-0704b4b1c382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_08440002-83d2-48d2-84ae-b49fa87e6ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_60ace8b5-5252-46cf-8b99-e3719e922476" xlink:to="loc_us-gaap_CostsAndExpenses_08440002-83d2-48d2-84ae-b49fa87e6ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f148e42c-79e3-4cd7-8928-94b720b80c16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_OperatingIncomeLoss_f148e42c-79e3-4cd7-8928-94b720b80c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_9bfbeb55-cf59-4fe4-96de-783a7316e352" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_9bfbeb55-cf59-4fe4-96de-783a7316e352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_9457220c-9b98-48f4-b0da-20919160cde6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_InterestExpenseNonoperating_9457220c-9b98-48f4-b0da-20919160cde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_1c439bcf-2a91-42a9-a510-c9c506d7b102" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_1c439bcf-2a91-42a9-a510-c9c506d7b102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_db14e892-806b-4452-8b41-34bf6317146f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_db14e892-806b-4452-8b41-34bf6317146f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1ec30185-6cf9-4442-ad98-76a2a1aa9c33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1ec30185-6cf9-4442-ad98-76a2a1aa9c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3e902476-ab57-4e71-917b-98c0ff9341b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3e902476-ab57-4e71-917b-98c0ff9341b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_71415169-a0f4-4d7a-8f77-e5672a32d56b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_NetIncomeLoss_71415169-a0f4-4d7a-8f77-e5672a32d56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_2df41c0d-c67e-4d98-bf09-09307e7472ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_EarningsPerShareBasic_2df41c0d-c67e-4d98-bf09-09307e7472ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_bf725f31-8e62-4f04-828e-9a475c609969" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_bf725f31-8e62-4f04-828e-9a475c609969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_805c3c91-8aa1-42ef-a3a8-ee7a5d7f6db3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_805c3c91-8aa1-42ef-a3a8-ee7a5d7f6db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_715499f7-168c-4e42-84be-ae995815ad73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_715499f7-168c-4e42-84be-ae995815ad73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6e152a5c-a6d0-4472-9eca-6b58db227e67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6e152a5c-a6d0-4472-9eca-6b58db227e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2033d207-5ca2-4f1a-b0b3-74dc714d9e34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2033d207-5ca2-4f1a-b0b3-74dc714d9e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_70ac143a-96e3-47ce-a68f-aa9a048bd713" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_70ac143a-96e3-47ce-a68f-aa9a048bd713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0ac487cc-cbca-48da-a344-ced459b9c827" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_70ac143a-96e3-47ce-a68f-aa9a048bd713" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0ac487cc-cbca-48da-a344-ced459b9c827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_850e5d2b-794a-4360-a61e-346a880444b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_70ac143a-96e3-47ce-a68f-aa9a048bd713" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_850e5d2b-794a-4360-a61e-346a880444b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b362b501-93d4-4c14-8fff-9b4b1489bb37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_86321782-4ed4-45e0-b9eb-b5bfd9a0ec2c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b362b501-93d4-4c14-8fff-9b4b1489bb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited" xlink:type="simple" xlink:href="insm-20240630.xsd#ConsolidatedStatementsofShareholdersEquityDeficitunaudited"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_dd8dff8e-e770-45f2-9fcb-4f822707793d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c0d7ec80-8608-4f41-823d-871d79ad761a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_dd8dff8e-e770-45f2-9fcb-4f822707793d" xlink:to="loc_us-gaap_StatementTable_c0d7ec80-8608-4f41-823d-871d79ad761a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_90289a37-ebc6-4f15-8cdc-c24d4d5402ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c0d7ec80-8608-4f41-823d-871d79ad761a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_90289a37-ebc6-4f15-8cdc-c24d4d5402ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c95c2263-75ed-43e9-b05c-fb1e1f0a6c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_90289a37-ebc6-4f15-8cdc-c24d4d5402ad" xlink:to="loc_us-gaap_EquityComponentDomain_c95c2263-75ed-43e9-b05c-fb1e1f0a6c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e40cdc68-688e-48fd-8add-1a9556d3a43f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c95c2263-75ed-43e9-b05c-fb1e1f0a6c1f" xlink:to="loc_us-gaap_CommonStockMember_e40cdc68-688e-48fd-8add-1a9556d3a43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b7f48334-f019-4fc2-92d8-db2fe2c9de54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c95c2263-75ed-43e9-b05c-fb1e1f0a6c1f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b7f48334-f019-4fc2-92d8-db2fe2c9de54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0b74e793-54e7-445d-84f0-fc66c0a977d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c95c2263-75ed-43e9-b05c-fb1e1f0a6c1f" xlink:to="loc_us-gaap_RetainedEarningsMember_0b74e793-54e7-445d-84f0-fc66c0a977d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8860f3c9-9d33-4d9a-bc4d-811522bc1669" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c95c2263-75ed-43e9-b05c-fb1e1f0a6c1f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8860f3c9-9d33-4d9a-bc4d-811522bc1669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_15ebfb90-f103-4c80-9216-5c150acfec10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c0d7ec80-8608-4f41-823d-871d79ad761a" xlink:to="loc_us-gaap_StatementLineItems_15ebfb90-f103-4c80-9216-5c150acfec10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15ebfb90-f103-4c80-9216-5c150acfec10" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_bb8ca7b9-6f81-4f69-a0b4-c6020c3fd06b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_SharesOutstanding_bb8ca7b9-6f81-4f69-a0b4-c6020c3fd06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_03e68736-a84b-4809-977d-99b2f9dea7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockholdersEquity_03e68736-a84b-4809-977d-99b2f9dea7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fc7633cf-e7a3-4126-b12a-42bcf74ebfba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fc7633cf-e7a3-4126-b12a-42bcf74ebfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cfc9dfc9-984d-4ad3-99d4-78ad454ba2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fc7633cf-e7a3-4126-b12a-42bcf74ebfba" xlink:to="loc_us-gaap_NetIncomeLoss_cfc9dfc9-984d-4ad3-99d4-78ad454ba2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_db264c5f-8a4d-4406-9419-1900dde574ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fc7633cf-e7a3-4126-b12a-42bcf74ebfba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_db264c5f-8a4d-4406-9419-1900dde574ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b762db70-faf5-4164-9fe8-5c0afb7782b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b762db70-faf5-4164-9fe8-5c0afb7782b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_df9d70fb-ad60-4c64-8026-c4b60ecd234d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_df9d70fb-ad60-4c64-8026-c4b60ecd234d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_90d10aaa-4f95-4443-b161-a942c1f1afc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_90d10aaa-4f95-4443-b161-a942c1f1afc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0865f241-f933-483b-b0cf-77b9ddf9ca5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0865f241-f933-483b-b0cf-77b9ddf9ca5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_dcf96bac-e188-4c47-b010-59d454f04bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_dcf96bac-e188-4c47-b010-59d454f04bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_9effd862-7459-45e3-b565-6263cd7fc025" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_9effd862-7459-45e3-b565-6263cd7fc025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_4b400d1e-18a9-4dda-8dd9-b57d4cd9fc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_4b400d1e-18a9-4dda-8dd9-b57d4cd9fc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_d2390657-da57-46ec-8c3b-2e1b8ef0a6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_d2390657-da57-46ec-8c3b-2e1b8ef0a6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0489b0d7-d159-4677-bd99-f5973aa3324e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0489b0d7-d159-4677-bd99-f5973aa3324e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_35b5d423-50e8-442a-8c02-1fb59677df27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_SharesOutstanding_35b5d423-50e8-442a-8c02-1fb59677df27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a69286f0-bb66-4a3b-b764-d7c82b0a0954" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93380d7b-ba00-4ccf-8d08-49f6fa9c08d7" xlink:to="loc_us-gaap_StockholdersEquity_a69286f0-bb66-4a3b-b764-d7c82b0a0954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="insm-20240630.xsd#ConsolidatedStatementsofCashFlowsunaudited"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c02e3e0f-10db-49e1-b0c6-aafa4dcb7189" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_eebcf1c3-97aa-4908-8a66-4a197ef4a7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c02e3e0f-10db-49e1-b0c6-aafa4dcb7189" xlink:to="loc_us-gaap_StatementTable_eebcf1c3-97aa-4908-8a66-4a197ef4a7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_fda471ae-3cec-4911-9fb0-65bb15c63bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_eebcf1c3-97aa-4908-8a66-4a197ef4a7c2" xlink:to="loc_us-gaap_AssetAcquisitionAxis_fda471ae-3cec-4911-9fb0-65bb15c63bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b8f8c5bb-18be-4def-806b-689b76d3f477" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_fda471ae-3cec-4911-9fb0-65bb15c63bc2" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b8f8c5bb-18be-4def-806b-689b76d3f477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_VertuisBioIncMember_fa2d6fc8-2fe1-4d9e-97ea-941c7b95cf11" xlink:href="insm-20240630.xsd#insm_VertuisBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b8f8c5bb-18be-4def-806b-689b76d3f477" xlink:to="loc_insm_VertuisBioIncMember_fa2d6fc8-2fe1-4d9e-97ea-941c7b95cf11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AdrestiaTherapeuticsLtdMember_bc71c9d5-2dbd-4d04-bc52-629de61ec6c2" xlink:href="insm-20240630.xsd#insm_AdrestiaTherapeuticsLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b8f8c5bb-18be-4def-806b-689b76d3f477" xlink:to="loc_insm_AdrestiaTherapeuticsLtdMember_bc71c9d5-2dbd-4d04-bc52-629de61ec6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_eebcf1c3-97aa-4908-8a66-4a197ef4a7c2" xlink:to="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8260b595-0b33-43fe-8ee2-afbc1edeaae8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8260b595-0b33-43fe-8ee2-afbc1edeaae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d2d3037e-4e16-45af-bf1e-eb03aebada99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8260b595-0b33-43fe-8ee2-afbc1edeaae8" xlink:to="loc_us-gaap_NetIncomeLoss_d2d3037e-4e16-45af-bf1e-eb03aebada99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8260b595-0b33-43fe-8ee2-afbc1edeaae8" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_fe4f34ff-7f05-4230-8d8e-749e2e956aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_Depreciation_fe4f34ff-7f05-4230-8d8e-749e2e956aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9ca44ee2-591e-40d1-ac42-9c5fdc5c539f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9ca44ee2-591e-40d1-ac42-9c5fdc5c539f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_052dd307-c40d-45b9-87e4-0d94083ed1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_ShareBasedCompensation_052dd307-c40d-45b9-87e4-0d94083ed1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bbd32f62-5940-411b-ba6a-e311f0743274" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_bbd32f62-5940-411b-ba6a-e311f0743274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_195260cb-fb36-4796-ac03-95422735e951" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_PaidInKindInterest_195260cb-fb36-4796-ac03-95422735e951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_dd5c81e8-7369-417d-ace0-ea0770697df2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_OtherNoncashExpense_dd5c81e8-7369-417d-ace0-ea0770697df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccretionOfDebtDiscountMarketableSecurities_b2fb49cc-7b9d-4a1f-8653-faa4fba9fdc5" xlink:href="insm-20240630.xsd#insm_AccretionOfDebtDiscountMarketableSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_insm_AccretionOfDebtDiscountMarketableSecurities_b2fb49cc-7b9d-4a1f-8653-faa4fba9fdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_fe133c66-70f3-44b7-a95e-602c4510796e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_fe133c66-70f3-44b7-a95e-602c4510796e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NoncashOperatingLeaseExpense_fe7fcb88-62ce-4cfc-8c0e-4e0152dff2fd" xlink:href="insm-20240630.xsd#insm_NoncashOperatingLeaseExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_insm_NoncashOperatingLeaseExpense_fe7fcb88-62ce-4cfc-8c0e-4e0152dff2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_d0aa6b63-3d2f-419e-96a2-09e058fed970" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_d0aa6b63-3d2f-419e-96a2-09e058fed970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_3c7b27c3-0ef7-484e-81cb-2c576c4b5cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_3c7b27c3-0ef7-484e-81cb-2c576c4b5cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NoncashAcquisitionRelatedExpense_492e33c5-d268-488f-a848-5d54e6c97944" xlink:href="insm-20240630.xsd#insm_NoncashAcquisitionRelatedExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_insm_NoncashAcquisitionRelatedExpense_492e33c5-d268-488f-a848-5d54e6c97944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NoncashAcquisitionRelatedExpense_fbcc2ef6-c465-401f-959e-17d232725fb8" xlink:href="insm-20240630.xsd#insm_NoncashAcquisitionRelatedExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_insm_NoncashAcquisitionRelatedExpense_fbcc2ef6-c465-401f-959e-17d232725fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_65c37e39-282b-44bb-a148-449bb191a86d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_65c37e39-282b-44bb-a148-449bb191a86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1286798d-df04-47cf-ba17-cc68476bd07b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_65c37e39-282b-44bb-a148-449bb191a86d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1286798d-df04-47cf-ba17-cc68476bd07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_62cc016f-6441-41d2-8925-8a7bc036bcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_65c37e39-282b-44bb-a148-449bb191a86d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_62cc016f-6441-41d2-8925-8a7bc036bcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e6a837a5-81a6-4ffb-836e-effdee8f0877" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_65c37e39-282b-44bb-a148-449bb191a86d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e6a837a5-81a6-4ffb-836e-effdee8f0877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_4818a026-a0fb-412d-a242-976e7fdadffa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_65c37e39-282b-44bb-a148-449bb191a86d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_4818a026-a0fb-412d-a242-976e7fdadffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1bb90f53-e72f-4ef3-8995-a6e7eba734df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_65c37e39-282b-44bb-a148-449bb191a86d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1bb90f53-e72f-4ef3-8995-a6e7eba734df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7df5723d-464a-4ccf-99c3-44d43216507e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_65c37e39-282b-44bb-a148-449bb191a86d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7df5723d-464a-4ccf-99c3-44d43216507e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59c9ef22-b7e9-4098-9f5d-106c9927d7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_896c0d50-99bf-4ddc-af67-6e1e0d5a9b3f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59c9ef22-b7e9-4098-9f5d-106c9927d7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_07ac2ab3-1ad1-49fe-bb23-d7a6dedb5b03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_07ac2ab3-1ad1-49fe-bb23-d7a6dedb5b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_86d34c0f-142a-42c4-ae39-04d9331c3d35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_07ac2ab3-1ad1-49fe-bb23-d7a6dedb5b03" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_86d34c0f-142a-42c4-ae39-04d9331c3d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_984b792d-ea27-4903-b0f9-df4897869180" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_07ac2ab3-1ad1-49fe-bb23-d7a6dedb5b03" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_984b792d-ea27-4903-b0f9-df4897869180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ProceedsFromCashAcquiredInAssetAcquisition_1afa77a2-232f-4c45-a944-fd16b524b2af" xlink:href="insm-20240630.xsd#insm_ProceedsFromCashAcquiredInAssetAcquisition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_07ac2ab3-1ad1-49fe-bb23-d7a6dedb5b03" xlink:to="loc_insm_ProceedsFromCashAcquiredInAssetAcquisition_1afa77a2-232f-4c45-a944-fd16b524b2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7d7c0301-2860-401d-a764-8cb7024d257c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_07ac2ab3-1ad1-49fe-bb23-d7a6dedb5b03" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7d7c0301-2860-401d-a764-8cb7024d257c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b774bd38-c37c-4b45-a2a6-43bae0b68b66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_07ac2ab3-1ad1-49fe-bb23-d7a6dedb5b03" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b774bd38-c37c-4b45-a2a6-43bae0b68b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c91e612d-8692-4323-ba1b-e8d65d17f387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c91e612d-8692-4323-ba1b-e8d65d17f387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_53c05baa-1f25-4b01-b6fa-544c4798b61b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c91e612d-8692-4323-ba1b-e8d65d17f387" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_53c05baa-1f25-4b01-b6fa-544c4798b61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_378aa82b-d78e-45bf-9a16-45f582091189" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c91e612d-8692-4323-ba1b-e8d65d17f387" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_378aa82b-d78e-45bf-9a16-45f582091189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_bc1263e1-a8ee-4eb1-9af4-7c469ab3ec16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c91e612d-8692-4323-ba1b-e8d65d17f387" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_bc1263e1-a8ee-4eb1-9af4-7c469ab3ec16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e0c6d1e1-a59f-4552-9fd0-3013e42528a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c91e612d-8692-4323-ba1b-e8d65d17f387" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e0c6d1e1-a59f-4552-9fd0-3013e42528a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa4f356b-8355-40f2-b517-51fae556bf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c91e612d-8692-4323-ba1b-e8d65d17f387" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa4f356b-8355-40f2-b517-51fae556bf6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_69618a9a-5972-4fff-8b3e-04aa965cc009" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_69618a9a-5972-4fff-8b3e-04aa965cc009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4adf5a0d-2144-4c61-8f26-c9f8dc1fe29b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4adf5a0d-2144-4c61-8f26-c9f8dc1fe29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ccfe67ae-8842-4aa4-a8e9-65b452a968cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ccfe67ae-8842-4aa4-a8e9-65b452a968cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_412c764e-b215-4192-953d-fe560d09eab3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_412c764e-b215-4192-953d-fe560d09eab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_89a51b24-2572-4d46-a790-daba83e71531" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_219c018b-acae-410c-9ed8-dd145f434a30" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_89a51b24-2572-4d46-a790-daba83e71531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_37c38ef6-e83c-4e3e-bd4b-1a2d9fff9f81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_89a51b24-2572-4d46-a790-daba83e71531" xlink:to="loc_us-gaap_InterestPaidNet_37c38ef6-e83c-4e3e-bd4b-1a2d9fff9f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_80857bf5-195b-495e-91ed-ef7d695f70c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_89a51b24-2572-4d46-a790-daba83e71531" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_80857bf5-195b-495e-91ed-ef7d695f70c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/TheCompanyandBasisofPresentation" xlink:type="simple" xlink:href="insm-20240630.xsd#TheCompanyandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/TheCompanyandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d85d1e32-215f-4e7e-a8bd-7723c3f178fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d29f4f0d-2fa8-41ea-b91a-427d037195de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d85d1e32-215f-4e7e-a8bd-7723c3f178fd" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d29f4f0d-2fa8-41ea-b91a-427d037195de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="insm-20240630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6fbad92b-124c-4340-818b-90950d2beb81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_df7b9d4b-1caa-45a7-9579-2abc6547577e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6fbad92b-124c-4340-818b-90950d2beb81" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_df7b9d4b-1caa-45a7-9579-2abc6547577e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="insm-20240630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cab39fe6-696f-4624-af84-d7d9146f679e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_805a1a56-a263-467f-ba00-82a5a6bfef56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cab39fe6-696f-4624-af84-d7d9146f679e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_805a1a56-a263-467f-ba00-82a5a6bfef56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ProductRevenuesNet" xlink:type="simple" xlink:href="insm-20240630.xsd#ProductRevenuesNet"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ProductRevenuesNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c3e87871-68d5-4bcf-895b-da1cb87b8fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5f0ae9dd-d253-42ab-a9e1-cc2206ad0729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c3e87871-68d5-4bcf-895b-da1cb87b8fa1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5f0ae9dd-d253-42ab-a9e1-cc2206ad0729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/Inventory" xlink:type="simple" xlink:href="insm-20240630.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_c3870188-f071-4f2d-a212-502fe7a20dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_ed656beb-fbb8-483b-bc6a-e0e5ba191484" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c3870188-f071-4f2d-a212-502fe7a20dcf" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_ed656beb-fbb8-483b-bc6a-e0e5ba191484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IntangiblesNetandGoodwill" xlink:type="simple" xlink:href="insm-20240630.xsd#IntangiblesNetandGoodwill"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IntangiblesNetandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85b75d43-743f-492c-89f8-0228379a1ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_05932ee4-c2d4-4749-ac9b-0cca1e916471" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85b75d43-743f-492c-89f8-0228379a1ae8" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_05932ee4-c2d4-4749-ac9b-0cca1e916471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNet" xlink:type="simple" xlink:href="insm-20240630.xsd#FixedAssetsNet"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FixedAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f98f77fe-8443-42c3-aac9-aa42f4c38c08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_027b018c-db0c-4469-96f6-826dfcb756e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f98f77fe-8443-42c3-aac9-aa42f4c38c08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_027b018c-db0c-4469-96f6-826dfcb756e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AccountsPayableandAccruedLiabilities" xlink:type="simple" xlink:href="insm-20240630.xsd#AccountsPayableandAccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/AccountsPayableandAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_61a37524-3bdf-4863-a35e-2f10b5af8eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_964cd275-4ab4-4e98-967b-d1b437cf6456" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_61a37524-3bdf-4863-a35e-2f10b5af8eb4" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_964cd275-4ab4-4e98-967b-d1b437cf6456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/Leases" xlink:type="simple" xlink:href="insm-20240630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e33439f7-be00-4487-8492-08ebb412568e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_fdc0c3c0-74e4-426d-a9b2-95c4bbb4687d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e33439f7-be00-4487-8492-08ebb412568e" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_fdc0c3c0-74e4-426d-a9b2-95c4bbb4687d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_1c5d69fb-2001-4283-8b10-f1b86c00d1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e33439f7-be00-4487-8492-08ebb412568e" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_1c5d69fb-2001-4283-8b10-f1b86c00d1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/Debt" xlink:type="simple" xlink:href="insm-20240630.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_07a84b00-b9b9-42de-b181-5dc066a8699d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_33a7dc20-3fba-4d8b-97ee-00ebc2ef1eed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_07a84b00-b9b9-42de-b181-5dc066a8699d" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_33a7dc20-3fba-4d8b-97ee-00ebc2ef1eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/RoyaltyFinancingAgreement" xlink:type="simple" xlink:href="insm-20240630.xsd#RoyaltyFinancingAgreement"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/RoyaltyFinancingAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2007d916-9af7-4c98-b4e9-d8c1e96c3171" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock_f810a06d-eca4-4300-8b4b-ebb41872d38e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2007d916-9af7-4c98-b4e9-d8c1e96c3171" xlink:to="loc_us-gaap_RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock_f810a06d-eca4-4300-8b4b-ebb41872d38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="insm-20240630.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d5b0a26b-e347-42d0-b76a-c740dfecbf09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ec6ab005-c9f5-4c52-8881-034760890104" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d5b0a26b-e347-42d0-b76a-c740dfecbf09" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ec6ab005-c9f5-4c52-8881-034760890104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="insm-20240630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_78d870bb-4332-48a8-b026-7dd7dca42954" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9bef64bf-c723-471e-addf-cbf154498cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_78d870bb-4332-48a8-b026-7dd7dca42954" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9bef64bf-c723-471e-addf-cbf154498cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxes" xlink:type="simple" xlink:href="insm-20240630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4fcad0fe-272d-4d7d-8aba-01a281e3e267" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3bca1c63-756f-48a2-b884-dabf00ceda7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4fcad0fe-272d-4d7d-8aba-01a281e3e267" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3bca1c63-756f-48a2-b884-dabf00ceda7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="insm-20240630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ac00e309-ed65-47e2-938a-e91b9a9e41a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_27e66cac-c721-4a24-90a6-4354001e88e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ac00e309-ed65-47e2-938a-e91b9a9e41a4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_27e66cac-c721-4a24-90a6-4354001e88e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/Acquisitions" xlink:type="simple" xlink:href="insm-20240630.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2569c554-6b82-4422-b019-3676f643b438" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_31fe7fc2-28a2-4926-99de-7bc0847f17c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2569c554-6b82-4422-b019-3676f643b438" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_31fe7fc2-28a2-4926-99de-7bc0847f17c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SubsequentEvents" xlink:type="simple" xlink:href="insm-20240630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_5eef26d2-8c73-4331-a040-179eb071496b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_c6408e62-c81b-4152-9f54-ee6cc7b07f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_5eef26d2-8c73-4331-a040-179eb071496b" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_c6408e62-c81b-4152-9f54-ee6cc7b07f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="insm-20240630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5e6882dc-2d44-4324-b2eb-01e2de7d65b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_17c60961-2010-4403-8b11-055be76cd40e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e6882dc-2d44-4324-b2eb-01e2de7d65b5" xlink:to="loc_us-gaap_UseOfEstimates_17c60961-2010-4403-8b11-055be76cd40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_0f6497f1-8e1e-4bce-901f-b9f4191194ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e6882dc-2d44-4324-b2eb-01e2de7d65b5" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_0f6497f1-8e1e-4bce-901f-b9f4191194ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_66001cc0-f6ea-42e8-92c9-77ca041e6bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e6882dc-2d44-4324-b2eb-01e2de7d65b5" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_66001cc0-f6ea-42e8-92c9-77ca041e6bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock_2b496c3f-7be3-4639-93f1-cef33847be66" xlink:href="insm-20240630.xsd#insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e6882dc-2d44-4324-b2eb-01e2de7d65b5" xlink:to="loc_insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock_2b496c3f-7be3-4639-93f1-cef33847be66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_3870d837-d9aa-48a7-b40f-355bf331679d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e6882dc-2d44-4324-b2eb-01e2de7d65b5" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_3870d837-d9aa-48a7-b40f-355bf331679d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_0d931fad-28ab-4fe4-8ea7-89219327df41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e6882dc-2d44-4324-b2eb-01e2de7d65b5" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_0d931fad-28ab-4fe4-8ea7-89219327df41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_807f06c5-8a73-4bcb-9848-9f113cc2f10a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e6882dc-2d44-4324-b2eb-01e2de7d65b5" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_807f06c5-8a73-4bcb-9848-9f113cc2f10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_62912229-59ab-4822-b469-a921946b2ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e6882dc-2d44-4324-b2eb-01e2de7d65b5" xlink:to="loc_us-gaap_DebtPolicyTextBlock_62912229-59ab-4822-b469-a921946b2ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_f96dc7be-4658-4cef-b96a-f94e37173448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e6882dc-2d44-4324-b2eb-01e2de7d65b5" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_f96dc7be-4658-4cef-b96a-f94e37173448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_c12705ea-e5c6-439d-ad97-21fadaacedcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e6882dc-2d44-4324-b2eb-01e2de7d65b5" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_c12705ea-e5c6-439d-ad97-21fadaacedcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock_3a9efc4e-7c95-4a3e-87d5-db77b7f130dc" xlink:href="insm-20240630.xsd#insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e6882dc-2d44-4324-b2eb-01e2de7d65b5" xlink:to="loc_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock_3a9efc4e-7c95-4a3e-87d5-db77b7f130dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_35101324-6b5f-4006-88b5-3a9c83369664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e6882dc-2d44-4324-b2eb-01e2de7d65b5" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_35101324-6b5f-4006-88b5-3a9c83369664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2a9df0a3-edc1-4ab0-bfec-b4e546379fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e6882dc-2d44-4324-b2eb-01e2de7d65b5" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2a9df0a3-edc1-4ab0-bfec-b4e546379fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_46017f96-7edb-43c2-9d66-b9bf0bc0bcf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5e6882dc-2d44-4324-b2eb-01e2de7d65b5" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_46017f96-7edb-43c2-9d66-b9bf0bc0bcf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="insm-20240630.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5b39f32e-6de3-4133-a905-33ddb7460f35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1bb5f4a8-d298-4712-a321-ec06531e6070" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b39f32e-6de3-4133-a905-33ddb7460f35" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1bb5f4a8-d298-4712-a321-ec06531e6070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_877695fc-53af-4b89-8383-e43f0fd155f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b39f32e-6de3-4133-a905-33ddb7460f35" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_877695fc-53af-4b89-8383-e43f0fd155f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_fc52d6a1-6d46-4e3f-9650-070c44816b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b39f32e-6de3-4133-a905-33ddb7460f35" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_fc52d6a1-6d46-4e3f-9650-070c44816b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="insm-20240630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e1c9568e-23c1-4587-9cfd-13db292d59c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_b0563b59-1533-4f76-91c6-dc67cb11995f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e1c9568e-23c1-4587-9cfd-13db292d59c7" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_b0563b59-1533-4f76-91c6-dc67cb11995f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_17151589-9ec2-49e8-8086-31b28df2e861" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e1c9568e-23c1-4587-9cfd-13db292d59c7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_17151589-9ec2-49e8-8086-31b28df2e861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ProductRevenuesNetTables" xlink:type="simple" xlink:href="insm-20240630.xsd#ProductRevenuesNetTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ProductRevenuesNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7fba43ee-3e82-4d54-a8ee-8fb0926c5434" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_076501e4-48ab-467c-9d6b-8348847d6109" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7fba43ee-3e82-4d54-a8ee-8fb0926c5434" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_076501e4-48ab-467c-9d6b-8348847d6109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/InventoryTables" xlink:type="simple" xlink:href="insm-20240630.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f4b5158c-159c-4541-99a5-23821233d371" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_335ed919-323c-40f3-ae71-ffc64adecffa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f4b5158c-159c-4541-99a5-23821233d371" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_335ed919-323c-40f3-ae71-ffc64adecffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IntangiblesNetandGoodwillTables" xlink:type="simple" xlink:href="insm-20240630.xsd#IntangiblesNetandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IntangiblesNetandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bc350a7b-24ef-4007-af0b-02cae8e7f175" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_17605896-40a9-4d1f-b426-fbe6764fddde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bc350a7b-24ef-4007-af0b-02cae8e7f175" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_17605896-40a9-4d1f-b426-fbe6764fddde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNetTables" xlink:type="simple" xlink:href="insm-20240630.xsd#FixedAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FixedAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cf5b6ff6-94bb-45a8-a5f8-2b1953fb35e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_632158f0-5b9c-4125-8f68-6e1bbaa580ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cf5b6ff6-94bb-45a8-a5f8-2b1953fb35e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_632158f0-5b9c-4125-8f68-6e1bbaa580ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="simple" xlink:href="insm-20240630.xsd#AccountsPayableandAccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_097cca21-c223-4e87-abf3-f86ae56e1705" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4f62c8e5-0a9e-47ff-b890-557d301094d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_097cca21-c223-4e87-abf3-f86ae56e1705" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4f62c8e5-0a9e-47ff-b890-557d301094d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesTables" xlink:type="simple" xlink:href="insm-20240630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_771937f9-dc58-43af-bfb4-3eee9a611bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_33125d82-5133-48f5-a06c-8fdb211a0a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_771937f9-dc58-43af-bfb4-3eee9a611bbf" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_33125d82-5133-48f5-a06c-8fdb211a0a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtTables" xlink:type="simple" xlink:href="insm-20240630.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c23c5fcf-390f-4b1a-b180-7ffa14127f50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_0650ccd2-fdfb-4104-8522-ace950b8b59d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c23c5fcf-390f-4b1a-b180-7ffa14127f50" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_0650ccd2-fdfb-4104-8522-ace950b8b59d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_5da39677-e9b1-4ced-9dbc-315a0577b907" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c23c5fcf-390f-4b1a-b180-7ffa14127f50" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_5da39677-e9b1-4ced-9dbc-315a0577b907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_a48f15c2-8fe2-4887-b79d-d57686d97d09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c23c5fcf-390f-4b1a-b180-7ffa14127f50" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_a48f15c2-8fe2-4887-b79d-d57686d97d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_c352d75a-8b10-461e-8d98-6abf191c9812" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c23c5fcf-390f-4b1a-b180-7ffa14127f50" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_c352d75a-8b10-461e-8d98-6abf191c9812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_50c963e5-091a-4f6f-96b9-b16bea93f39c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c23c5fcf-390f-4b1a-b180-7ffa14127f50" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_50c963e5-091a-4f6f-96b9-b16bea93f39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/RoyaltyFinancingAgreementTables" xlink:type="simple" xlink:href="insm-20240630.xsd#RoyaltyFinancingAgreementTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/RoyaltyFinancingAgreementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_85dc6add-138e-4d74-a13a-9a872acb4a43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_258979ee-49d4-46d5-ae9c-cf1cb93fb1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_85dc6add-138e-4d74-a13a-9a872acb4a43" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_258979ee-49d4-46d5-ae9c-cf1cb93fb1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="insm-20240630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4bcd932b-b6b1-4b21-94b4-b5e9e0ae58a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c626f44f-1130-4795-9b5c-718853fee2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4bcd932b-b6b1-4b21-94b4-b5e9e0ae58a5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c626f44f-1130-4795-9b5c-718853fee2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="insm-20240630.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_25bc397f-b0e2-4495-8a9b-581c6a690f12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTableTextBlock_496aa5e1-c71a-409f-8114-ee44d0beeeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_25bc397f-b0e2-4495-8a9b-581c6a690f12" xlink:to="loc_us-gaap_AssetAcquisitionTableTextBlock_496aa5e1-c71a-409f-8114-ee44d0beeeb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#TheCompanyandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f5e0de38-f48c-4037-a7c6-02d092e812aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_edaf46d3-e9b2-4d77-bd20-29b6c6610eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f5e0de38-f48c-4037-a7c6-02d092e812aa" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_edaf46d3-e9b2-4d77-bd20-29b6c6610eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_87f01741-9f21-4d16-a186-a58cf0e080c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f5e0de38-f48c-4037-a7c6-02d092e812aa" xlink:to="loc_us-gaap_NetIncomeLoss_87f01741-9f21-4d16-a186-a58cf0e080c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f6f463a0-516a-46fd-ba2b-ee588f8ad454" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_77566cb4-2070-41b0-97e4-0f9a7775e888" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6f463a0-516a-46fd-ba2b-ee588f8ad454" xlink:to="loc_us-gaap_ConcentrationRiskTable_77566cb4-2070-41b0-97e4-0f9a7775e888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d95552fe-2022-4774-be52-987ce8bbea55" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_77566cb4-2070-41b0-97e4-0f9a7775e888" xlink:to="loc_srt_MajorCustomersAxis_d95552fe-2022-4774-be52-987ce8bbea55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0e0f33c1-a77e-4268-bd9c-3c21d6943d67" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_d95552fe-2022-4774-be52-987ce8bbea55" xlink:to="loc_srt_NameOfMajorCustomerDomain_0e0f33c1-a77e-4268-bd9c-3c21d6943d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerAMember_c3ad3d7b-2529-4403-a371-52364391304c" xlink:href="insm-20240630.xsd#insm_CustomerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0e0f33c1-a77e-4268-bd9c-3c21d6943d67" xlink:to="loc_insm_CustomerAMember_c3ad3d7b-2529-4403-a371-52364391304c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerBMember_ea18e5bd-1b78-4629-8c34-0d628adce7a9" xlink:href="insm-20240630.xsd#insm_CustomerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0e0f33c1-a77e-4268-bd9c-3c21d6943d67" xlink:to="loc_insm_CustomerBMember_ea18e5bd-1b78-4629-8c34-0d628adce7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerCMember_0c03a822-941e-4c35-9d30-c46b87533f08" xlink:href="insm-20240630.xsd#insm_CustomerCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0e0f33c1-a77e-4268-bd9c-3c21d6943d67" xlink:to="loc_insm_CustomerCMember_0c03a822-941e-4c35-9d30-c46b87533f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5e36d8ae-9c52-4f64-9b6c-c3bb1788802f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_77566cb4-2070-41b0-97e4-0f9a7775e888" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5e36d8ae-9c52-4f64-9b6c-c3bb1788802f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_289289d8-3a21-419a-9684-95e77b074303" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_5e36d8ae-9c52-4f64-9b6c-c3bb1788802f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_289289d8-3a21-419a-9684-95e77b074303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_29c655d9-f753-4ee2-8aa7-25548f8a9165" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_289289d8-3a21-419a-9684-95e77b074303" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_29c655d9-f753-4ee2-8aa7-25548f8a9165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f928d05e-85ce-45b2-b9b7-874ae6960909" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_77566cb4-2070-41b0-97e4-0f9a7775e888" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f928d05e-85ce-45b2-b9b7-874ae6960909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_02c1470f-51cb-41e7-a0dc-d115be795903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f928d05e-85ce-45b2-b9b7-874ae6960909" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_02c1470f-51cb-41e7-a0dc-d115be795903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_29d4c3a5-6cbf-497d-8adb-3402cb0325f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_02c1470f-51cb-41e7-a0dc-d115be795903" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_29d4c3a5-6cbf-497d-8adb-3402cb0325f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_ec1140e4-91b2-420f-b598-c4873ec8fb10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_77566cb4-2070-41b0-97e4-0f9a7775e888" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_ec1140e4-91b2-420f-b598-c4873ec8fb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_787a2da0-ec13-4bc1-8879-65e0861f04bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_ec1140e4-91b2-420f-b598-c4873ec8fb10" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_787a2da0-ec13-4bc1-8879-65e0861f04bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_af7e4c31-2f86-4b83-8f82-e67d6da3889e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_dbc4e0ec-4ee2-443c-9728-284a1762dc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_af7e4c31-2f86-4b83-8f82-e67d6da3889e" xlink:to="loc_us-gaap_NumberOfReportingUnits_dbc4e0ec-4ee2-443c-9728-284a1762dc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_91a7524c-3dd7-4119-8d41-6c905cca5c86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_30a00766-1d00-4d51-8c31-dad74c91fef8" xlink:href="insm-20240630.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91a7524c-3dd7-4119-8d41-6c905cca5c86" xlink:to="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_30a00766-1d00-4d51-8c31-dad74c91fef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_aa5c4fe4-23f8-489a-b1b9-9ae69ea7640b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_30a00766-1d00-4d51-8c31-dad74c91fef8" xlink:to="loc_us-gaap_AwardTypeAxis_aa5c4fe4-23f8-489a-b1b9-9ae69ea7640b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78dbcad0-bbc4-40d5-9be3-6b60b2959926" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_aa5c4fe4-23f8-489a-b1b9-9ae69ea7640b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78dbcad0-bbc4-40d5-9be3-6b60b2959926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1ee31c02-aed9-46ef-9414-d9afdc35aeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78dbcad0-bbc4-40d5-9be3-6b60b2959926" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1ee31c02-aed9-46ef-9414-d9afdc35aeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1906d38f-6b23-4e10-860b-930e3db35ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78dbcad0-bbc4-40d5-9be3-6b60b2959926" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1906d38f-6b23-4e10-860b-930e3db35ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_b95a34c3-bdf5-456b-86fe-d6e98b7ce9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_78dbcad0-bbc4-40d5-9be3-6b60b2959926" xlink:to="loc_us-gaap_PerformanceSharesMember_b95a34c3-bdf5-456b-86fe-d6e98b7ce9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_8f04bfea-68aa-479b-9ac6-7f5ce49476d7" xlink:href="insm-20240630.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_30a00766-1d00-4d51-8c31-dad74c91fef8" xlink:to="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_8f04bfea-68aa-479b-9ac6-7f5ce49476d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_6538e2d9-acb8-4c3b-8db1-17b0d54f8902" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_8f04bfea-68aa-479b-9ac6-7f5ce49476d7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_6538e2d9-acb8-4c3b-8db1-17b0d54f8902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9817b5ab-b2fe-4cb8-9568-7a1bb8915664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_6538e2d9-acb8-4c3b-8db1-17b0d54f8902" xlink:to="loc_us-gaap_NetIncomeLoss_9817b5ab-b2fe-4cb8-9568-7a1bb8915664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_180ab6e8-cae0-44d2-baf1-922ad868345a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_8f04bfea-68aa-479b-9ac6-7f5ce49476d7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_180ab6e8-cae0-44d2-baf1-922ad868345a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0e3bef61-4407-4be6-bbf5-b66d4ef85a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_180ab6e8-cae0-44d2-baf1-922ad868345a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0e3bef61-4407-4be6-bbf5-b66d4ef85a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_f388a90e-1dc0-485f-b0ac-b3ae877c658b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_180ab6e8-cae0-44d2-baf1-922ad868345a" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_f388a90e-1dc0-485f-b0ac-b3ae877c658b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1465c251-b8b5-4a0c-ad3c-a8f8534f019b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_f388a90e-1dc0-485f-b0ac-b3ae877c658b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1465c251-b8b5-4a0c-ad3c-a8f8534f019b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_1b662f82-e680-4785-94fb-57a425792504" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_f388a90e-1dc0-485f-b0ac-b3ae877c658b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_1b662f82-e680-4785-94fb-57a425792504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ec8d4b53-3be6-486a-8d53-4f5cf9f93b69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_180ab6e8-cae0-44d2-baf1-922ad868345a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ec8d4b53-3be6-486a-8d53-4f5cf9f93b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f4cc8f03-47e4-4a34-9d73-f00a57fab752" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_8f04bfea-68aa-479b-9ac6-7f5ce49476d7" xlink:to="loc_us-gaap_EarningsPerShareAbstract_f4cc8f03-47e4-4a34-9d73-f00a57fab752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e82013d4-ef9d-4dd0-88df-e9b7c415c92b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f4cc8f03-47e4-4a34-9d73-f00a57fab752" xlink:to="loc_us-gaap_EarningsPerShareBasic_e82013d4-ef9d-4dd0-88df-e9b7c415c92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ed83a969-d97f-4661-b3ab-2995f14da808" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f4cc8f03-47e4-4a34-9d73-f00a57fab752" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ed83a969-d97f-4661-b3ab-2995f14da808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_38a504d5-010c-415e-9886-ee7b2dff9cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8f2d60ae-f242-4a9f-8be3-d43e4fa5cf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_38a504d5-010c-415e-9886-ee7b2dff9cc3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8f2d60ae-f242-4a9f-8be3-d43e4fa5cf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_031feff1-26ec-4847-a1d0-a60a17e83027" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8f2d60ae-f242-4a9f-8be3-d43e4fa5cf8a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_031feff1-26ec-4847-a1d0-a60a17e83027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fef9ec12-8069-44e9-a3ec-7e532c5989ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_031feff1-26ec-4847-a1d0-a60a17e83027" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fef9ec12-8069-44e9-a3ec-7e532c5989ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e0e9e150-0a63-4112-b782-d8ff76d039d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fef9ec12-8069-44e9-a3ec-7e532c5989ab" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e0e9e150-0a63-4112-b782-d8ff76d039d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dc6ee1a0-08b5-4017-a452-512f965d36a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fef9ec12-8069-44e9-a3ec-7e532c5989ab" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dc6ee1a0-08b5-4017-a452-512f965d36a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_c080fa95-970a-4d3f-9543-3003c49c8f58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fef9ec12-8069-44e9-a3ec-7e532c5989ab" xlink:to="loc_us-gaap_PerformanceSharesMember_c080fa95-970a-4d3f-9543-3003c49c8f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_0340b246-e4b2-432a-a1ad-c06f0e0047fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fef9ec12-8069-44e9-a3ec-7e532c5989ab" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_0340b246-e4b2-432a-a1ad-c06f0e0047fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8d0f8632-7e51-40e5-b79c-8bc9a694c764" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8f2d60ae-f242-4a9f-8be3-d43e4fa5cf8a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8d0f8632-7e51-40e5-b79c-8bc9a694c764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4381b86f-60d2-43f0-9014-cc5580001e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8d0f8632-7e51-40e5-b79c-8bc9a694c764" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4381b86f-60d2-43f0-9014-cc5580001e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c8feff5e-06cd-4a80-a8af-2e60d0abf242" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_307d69f9-e428-4ce4-b262-ee8739ab004b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c8feff5e-06cd-4a80-a8af-2e60d0abf242" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_307d69f9-e428-4ce4-b262-ee8739ab004b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_67a3de3a-ae56-4240-9028-b489c629107f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_307d69f9-e428-4ce4-b262-ee8739ab004b" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_67a3de3a-ae56-4240-9028-b489c629107f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0c954a94-e0c6-4234-b09b-99be8db9c0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_67a3de3a-ae56-4240-9028-b489c629107f" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0c954a94-e0c6-4234-b09b-99be8db9c0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fa569eaa-f793-442a-8d73-1d7b68bc0dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_0c954a94-e0c6-4234-b09b-99be8db9c0f4" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fa569eaa-f793-442a-8d73-1d7b68bc0dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9686c8ca-a8b6-4de1-819a-aa1fcc0610ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fa569eaa-f793-442a-8d73-1d7b68bc0dc3" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9686c8ca-a8b6-4de1-819a-aa1fcc0610ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d52fe563-93a7-4bc3-bcaa-3bc3571c5b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fa569eaa-f793-442a-8d73-1d7b68bc0dc3" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d52fe563-93a7-4bc3-bcaa-3bc3571c5b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2dd87bf9-2478-4a13-bb5a-463aa276431e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_307d69f9-e428-4ce4-b262-ee8739ab004b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2dd87bf9-2478-4a13-bb5a-463aa276431e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_500da50f-31ee-49d7-b3ad-380ac3a9c506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2dd87bf9-2478-4a13-bb5a-463aa276431e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_500da50f-31ee-49d7-b3ad-380ac3a9c506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_48632362-ac73-4754-b232-d2fa5561141c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_500da50f-31ee-49d7-b3ad-380ac3a9c506" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_48632362-ac73-4754-b232-d2fa5561141c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e799260f-e6e1-4ddd-b8bf-8863ef356165" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_307d69f9-e428-4ce4-b262-ee8739ab004b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e799260f-e6e1-4ddd-b8bf-8863ef356165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99a447f1-d252-4301-a9af-62f0d4f4daa8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e799260f-e6e1-4ddd-b8bf-8863ef356165" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99a447f1-d252-4301-a9af-62f0d4f4daa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_528687f0-cbf1-4d4a-bdee-ed9de462f02d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99a447f1-d252-4301-a9af-62f0d4f4daa8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_528687f0-cbf1-4d4a-bdee-ed9de462f02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e5ecac43-b7f7-499b-a98d-5f79b5c5a83a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99a447f1-d252-4301-a9af-62f0d4f4daa8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e5ecac43-b7f7-499b-a98d-5f79b5c5a83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ba3e7798-d2a5-48bf-afe7-24b4ebcac67e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99a447f1-d252-4301-a9af-62f0d4f4daa8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ba3e7798-d2a5-48bf-afe7-24b4ebcac67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_879327c2-a189-4db9-8b3c-f21f967c84fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_307d69f9-e428-4ce4-b262-ee8739ab004b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_879327c2-a189-4db9-8b3c-f21f967c84fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_489918a0-5e96-44eb-bbcc-487e7ca4cce1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_879327c2-a189-4db9-8b3c-f21f967c84fa" xlink:to="loc_us-gaap_AssetsAbstract_489918a0-5e96-44eb-bbcc-487e7ca4cce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_903133ea-ab96-4362-93bd-beb7c87b8f73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_489918a0-5e96-44eb-bbcc-487e7ca4cce1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_903133ea-ab96-4362-93bd-beb7c87b8f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_70b4dde7-e717-4736-8050-26523f004feb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_489918a0-5e96-44eb-bbcc-487e7ca4cce1" xlink:to="loc_us-gaap_MarketableSecurities_70b4dde7-e717-4736-8050-26523f004feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_423b2731-99f3-4f10-b9e9-850735aa12e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_489918a0-5e96-44eb-bbcc-487e7ca4cce1" xlink:to="loc_us-gaap_DerivativeAssets_423b2731-99f3-4f10-b9e9-850735aa12e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_ec815746-982c-4a6a-8d35-60bc1c57740b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_879327c2-a189-4db9-8b3c-f21f967c84fa" xlink:to="loc_us-gaap_LiabilitiesAbstract_ec815746-982c-4a6a-8d35-60bc1c57740b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_c5a8cc0c-8187-4cf5-b006-e4ec0cb16e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_ec815746-982c-4a6a-8d35-60bc1c57740b" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_c5a8cc0c-8187-4cf5-b006-e4ec0cb16e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_9552e6c4-6e92-4572-8267-1673a5a9d0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_ec815746-982c-4a6a-8d35-60bc1c57740b" xlink:to="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_9552e6c4-6e92-4572-8267-1673a5a9d0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredLiability_320452c3-ad67-482f-868a-b269da38aa33" xlink:href="insm-20240630.xsd#insm_BusinessCombinationDeferredLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_ec815746-982c-4a6a-8d35-60bc1c57740b" xlink:to="loc_insm_BusinessCombinationDeferredLiability_320452c3-ad67-482f-868a-b269da38aa33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_df696498-cefd-47c5-a3e8-b846ce1ca57f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_ec815746-982c-4a6a-8d35-60bc1c57740b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_df696498-cefd-47c5-a3e8-b846ce1ca57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d2f6fc24-015d-4a81-9d1a-65462191df3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d2f6fc24-015d-4a81-9d1a-65462191df3e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_89d63032-f90e-4762-80ab-43e28b845a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_89d63032-f90e-4762-80ab-43e28b845a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_77986022-6e1e-411c-8a54-aa4351293e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_89d63032-f90e-4762-80ab-43e28b845a0b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_77986022-6e1e-411c-8a54-aa4351293e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncMember_bd0d4b91-27c8-41ca-84e5-37bcfe624d9e" xlink:href="insm-20240630.xsd#insm_MotusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_77986022-6e1e-411c-8a54-aa4351293e4d" xlink:to="loc_insm_MotusBiosciencesIncMember_bd0d4b91-27c8-41ca-84e5-37bcfe624d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AlgaeneXIncMember_4835daa4-cd4e-4363-bd64-14fdb33e63ca" xlink:href="insm-20240630.xsd#insm_AlgaeneXIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_77986022-6e1e-411c-8a54-aa4351293e4d" xlink:to="loc_insm_AlgaeneXIncMember_4835daa4-cd4e-4363-bd64-14fdb33e63ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_af59a03d-114a-49af-bc36-bdea51a46a14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_af59a03d-114a-49af-bc36-bdea51a46a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_139dec0d-5f3e-4b54-97fe-8b5a72f21698" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_af59a03d-114a-49af-bc36-bdea51a46a14" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_139dec0d-5f3e-4b54-97fe-8b5a72f21698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6b76794f-b789-4274-a991-16f7ad53988e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_139dec0d-5f3e-4b54-97fe-8b5a72f21698" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6b76794f-b789-4274-a991-16f7ad53988e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a1dce35-5273-4657-a2ef-5df1f5298d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a1dce35-5273-4657-a2ef-5df1f5298d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f138b75-43b6-4e90-adcc-0405f87493f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7a1dce35-5273-4657-a2ef-5df1f5298d6e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f138b75-43b6-4e90-adcc-0405f87493f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_34922534-0b85-4987-92bf-be09bab7401b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f138b75-43b6-4e90-adcc-0405f87493f5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_34922534-0b85-4987-92bf-be09bab7401b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5ddfc2c7-35c4-47fd-bb4b-ed6e8fc6cdb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f138b75-43b6-4e90-adcc-0405f87493f5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5ddfc2c7-35c4-47fd-bb4b-ed6e8fc6cdb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_41226a57-fd4a-4cbb-8b01-520e48e63496" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_41226a57-fd4a-4cbb-8b01-520e48e63496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_cb7d7336-c637-4b76-86d2-f1fa519eac2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_41226a57-fd4a-4cbb-8b01-520e48e63496" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_cb7d7336-c637-4b76-86d2-f1fa519eac2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MeasurementInputProbabilityOfSuccessMember_15ba94ca-1307-4e5d-9de0-7893e72e12a7" xlink:href="insm-20240630.xsd#insm_MeasurementInputProbabilityOfSuccessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_cb7d7336-c637-4b76-86d2-f1fa519eac2a" xlink:to="loc_insm_MeasurementInputProbabilityOfSuccessMember_15ba94ca-1307-4e5d-9de0-7893e72e12a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_df2ec437-cab6-41c3-b608-923ddc30ad81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_DebtInstrumentAxis_df2ec437-cab6-41c3-b608-923ddc30ad81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c0d091b9-e9ef-440d-a483-8c474a362c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_df2ec437-cab6-41c3-b608-923ddc30ad81" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c0d091b9-e9ef-440d-a483-8c474a362c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_6244f4e9-df04-4a95-a4f9-87f5b2ab6ccb" xlink:href="insm-20240630.xsd#insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c0d091b9-e9ef-440d-a483-8c474a362c7c" xlink:to="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_6244f4e9-df04-4a95-a4f9-87f5b2ab6ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2a0bda31-fa46-419d-be84-aa618f2800ab" xlink:href="insm-20240630.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c0d091b9-e9ef-440d-a483-8c474a362c7c" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_2a0bda31-fa46-419d-be84-aa618f2800ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember_7229645b-908a-4895-9348-1c56431f6e14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c0d091b9-e9ef-440d-a483-8c474a362c7c" xlink:to="loc_us-gaap_RoyaltyAgreementsMember_7229645b-908a-4895-9348-1c56431f6e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_526de43b-acb9-4a66-b724-54e4550c38f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_526de43b-acb9-4a66-b724-54e4550c38f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c9093dc3-b970-4899-ae55-39bde3c29abb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_526de43b-acb9-4a66-b724-54e4550c38f1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c9093dc3-b970-4899-ae55-39bde3c29abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_f3fb9108-3244-41a5-bf77-b45eaa224bca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c9093dc3-b970-4899-ae55-39bde3c29abb" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_f3fb9108-3244-41a5-bf77-b45eaa224bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_9ac7c333-c6d2-4768-a840-a81ba7c2629e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_9ac7c333-c6d2-4768-a840-a81ba7c2629e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_42add4f5-57cb-4877-870f-8e8449696f66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_9ac7c333-c6d2-4768-a840-a81ba7c2629e" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_42add4f5-57cb-4877-870f-8e8449696f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_93002711-6043-4639-a13f-ed594f26cea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_42add4f5-57cb-4877-870f-8e8449696f66" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_93002711-6043-4639-a13f-ed594f26cea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ff573801-d88e-4a8c-8ad9-75074fb7ec6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_93002711-6043-4639-a13f-ed594f26cea0" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ff573801-d88e-4a8c-8ad9-75074fb7ec6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_6b50c1cd-15fd-4a07-b8ab-b3bc1a91467e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_VestingAxis_6b50c1cd-15fd-4a07-b8ab-b3bc1a91467e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_e6037862-9090-4204-824e-e4c764e9e10d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_6b50c1cd-15fd-4a07-b8ab-b3bc1a91467e" xlink:to="loc_us-gaap_VestingDomain_e6037862-9090-4204-824e-e4c764e9e10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f7eea63b-cffd-449c-b3d6-5e6ef185225c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_e6037862-9090-4204-824e-e4c764e9e10d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f7eea63b-cffd-449c-b3d6-5e6ef185225c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_92dbdf70-14c3-4e57-8050-592b3da03ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_e6037862-9090-4204-824e-e4c764e9e10d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_92dbdf70-14c3-4e57-8050-592b3da03ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_a21ebb40-aaa0-475e-9da5-c3ace950cfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_e6037862-9090-4204-824e-e4c764e9e10d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_a21ebb40-aaa0-475e-9da5-c3ace950cfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_31385fed-b82f-4fb0-91d8-845f8e823a86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_31385fed-b82f-4fb0-91d8-845f8e823a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f120e9ba-9995-4777-85e1-233bd9d7872a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_31385fed-b82f-4fb0-91d8-845f8e823a86" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f120e9ba-9995-4777-85e1-233bd9d7872a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DevelopmentAndRegulatoryMilestonesMember_e2be4c0c-7210-4ce6-9f41-bcc1c32cabfe" xlink:href="insm-20240630.xsd#insm_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_f120e9ba-9995-4777-85e1-233bd9d7872a" xlink:to="loc_insm_DevelopmentAndRegulatoryMilestonesMember_e2be4c0c-7210-4ce6-9f41-bcc1c32cabfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_afc1636a-a539-4234-94e9-9a4a261ef71a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_CreditFacilityAxis_afc1636a-a539-4234-94e9-9a4a261ef71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_fc91e2d9-103a-48ff-ba5c-0834c3415dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_afc1636a-a539-4234-94e9-9a4a261ef71a" xlink:to="loc_us-gaap_CreditFacilityDomain_fc91e2d9-103a-48ff-ba5c-0834c3415dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_5f452d91-9f93-4096-9b4b-217dd304da45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_fc91e2d9-103a-48ff-ba5c-0834c3415dc0" xlink:to="loc_us-gaap_SecuredDebtMember_5f452d91-9f93-4096-9b4b-217dd304da45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c76b732b-30e9-4117-af96-b6f634168652" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_srt_StatementScenarioAxis_c76b732b-30e9-4117-af96-b6f634168652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_13e1611a-3190-4554-802e-c9f028469b39" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_c76b732b-30e9-4117-af96-b6f634168652" xlink:to="loc_srt_ScenarioUnspecifiedDomain_13e1611a-3190-4554-802e-c9f028469b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_2a1b6c7f-889d-4e4f-ad78-961184b23306" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_13e1611a-3190-4554-802e-c9f028469b39" xlink:to="loc_srt_ScenarioForecastMember_2a1b6c7f-889d-4e4f-ad78-961184b23306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5531b80b-3e7d-4a46-83da-80d0d76de7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5531b80b-3e7d-4a46-83da-80d0d76de7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_31aa383f-02ea-45eb-bfa9-19ee0fee2aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5531b80b-3e7d-4a46-83da-80d0d76de7d8" xlink:to="loc_us-gaap_SegmentDomain_31aa383f-02ea-45eb-bfa9-19ee0fee2aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ARIKAYCEGlobalNetSalesMember_2c7a37f9-abb6-424c-9cea-a2c20cab29cd" xlink:href="insm-20240630.xsd#insm_ARIKAYCEGlobalNetSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_31aa383f-02ea-45eb-bfa9-19ee0fee2aa2" xlink:to="loc_insm_ARIKAYCEGlobalNetSalesMember_2c7a37f9-abb6-424c-9cea-a2c20cab29cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BrensocatibGlobalNetSalesMember_60428210-0e54-49dd-a7e6-6d0d6a68b98b" xlink:href="insm-20240630.xsd#insm_BrensocatibGlobalNetSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_31aa383f-02ea-45eb-bfa9-19ee0fee2aa2" xlink:to="loc_insm_BrensocatibGlobalNetSalesMember_60428210-0e54-49dd-a7e6-6d0d6a68b98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_76426794-a6f8-4e69-865a-d086d9e9fa78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_76426794-a6f8-4e69-865a-d086d9e9fa78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ce0977c0-8bee-4e4d-ab4e-7a45925f9cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_76426794-a6f8-4e69-865a-d086d9e9fa78" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ce0977c0-8bee-4e4d-ab4e-7a45925f9cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_9818cba9-26a1-4b15-855d-e86c1dbdd6d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ce0977c0-8bee-4e4d-ab4e-7a45925f9cfb" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_9818cba9-26a1-4b15-855d-e86c1dbdd6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_911e4833-1d26-44bd-a44e-1832bdb3dab5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c803c925-f2bf-46df-94f0-ac8714d57aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c803c925-f2bf-46df-94f0-ac8714d57aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_7e523c8e-5963-4157-aab4-d8e858d37c41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_MarketableSecurities_7e523c8e-5963-4157-aab4-d8e858d37c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_dd6efdf0-cde1-42b4-a42b-362e57419158" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_dd6efdf0-cde1-42b4-a42b-362e57419158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredLiability_c335199c-00f3-46aa-92ff-36cb1023b9ce" xlink:href="insm-20240630.xsd#insm_BusinessCombinationDeferredLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_insm_BusinessCombinationDeferredLiability_c335199c-00f3-46aa-92ff-36cb1023b9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_0307f063-029d-44f7-bedd-0f30d00e91c1" xlink:href="insm-20240630.xsd#insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_0307f063-029d-44f7-bedd-0f30d00e91c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_79bb681a-2296-4b2f-ba96-a3e5961a55fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_79bb681a-2296-4b2f-ba96-a3e5961a55fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage_96a4ccd5-7f10-43dc-a4cb-666710160436" xlink:href="insm-20240630.xsd#insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage_96a4ccd5-7f10-43dc-a4cb-666710160436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage_71528941-bf51-458b-8341-f29d6cfe9caa" xlink:href="insm-20240630.xsd#insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage_71528941-bf51-458b-8341-f29d6cfe9caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders_5a94dbce-2de5-4d2a-8e21-c5a6833cb1c5" xlink:href="insm-20240630.xsd#insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders_5a94dbce-2de5-4d2a-8e21-c5a6833cb1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f7e0fee5-5986-40f2-bd50-33c6d1909b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f7e0fee5-5986-40f2-bd50-33c6d1909b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_82e2188a-9251-417f-9050-8c8340d25d10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_82e2188a-9251-417f-9050-8c8340d25d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_316942dd-6a55-4eac-9069-8b120f2a68c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_316942dd-6a55-4eac-9069-8b120f2a68c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_83c41659-6edc-4c70-b3b5-9c64898746f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_83c41659-6edc-4c70-b3b5-9c64898746f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ProceedsFromRoyaltyFinancing_e4a19ae2-f534-453c-bd60-85aa2830a55a" xlink:href="insm-20240630.xsd#insm_ProceedsFromRoyaltyFinancing"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_insm_ProceedsFromRoyaltyFinancing_e4a19ae2-f534-453c-bd60-85aa2830a55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentRoyaltyStatedPercentage_946c5f56-0e30-4df7-bf51-4f424da2e760" xlink:href="insm-20240630.xsd#insm_DebtInstrumentRoyaltyStatedPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_insm_DebtInstrumentRoyaltyStatedPercentage_946c5f56-0e30-4df7-bf51-4f424da2e760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c857cb07-ae3f-45d0-bc78-b9ef72a4cfb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c857cb07-ae3f-45d0-bc78-b9ef72a4cfb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_c5800ebf-6d38-44ad-a267-7320541d5731" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f8d544f1-93cb-4c1c-a07b-4777faf9f472" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_c5800ebf-6d38-44ad-a267-7320541d5731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d8d04fce-8713-4ddf-8651-091ca48f4fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4e0760c-2c1b-4739-aaad-e50354dd31f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d8d04fce-8713-4ddf-8651-091ca48f4fe0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4e0760c-2c1b-4739-aaad-e50354dd31f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_38952255-8611-4629-94cf-e2eec38302ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4e0760c-2c1b-4739-aaad-e50354dd31f1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_38952255-8611-4629-94cf-e2eec38302ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_39a134a9-2542-4dea-9c2f-235fc03e56f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_38952255-8611-4629-94cf-e2eec38302ec" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_39a134a9-2542-4dea-9c2f-235fc03e56f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1ee39822-9cca-4b13-8d4c-92a7e1944e12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_39a134a9-2542-4dea-9c2f-235fc03e56f7" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1ee39822-9cca-4b13-8d4c-92a7e1944e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1862d922-45b4-44b0-be64-b874a91b970f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4e0760c-2c1b-4739-aaad-e50354dd31f1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1862d922-45b4-44b0-be64-b874a91b970f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_ce29fa9d-8329-4158-9ef1-74d2410fb2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1862d922-45b4-44b0-be64-b874a91b970f" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_ce29fa9d-8329-4158-9ef1-74d2410fb2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_257e7a29-a657-472f-a720-d4d7f65e90e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ce29fa9d-8329-4158-9ef1-74d2410fb2a2" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_257e7a29-a657-472f-a720-d4d7f65e90e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd6e07b-94b0-4829-a0ba-6d7931728a80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4e0760c-2c1b-4739-aaad-e50354dd31f1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd6e07b-94b0-4829-a0ba-6d7931728a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredLiability_d40d203c-931c-4d92-9de8-9409afdc8d57" xlink:href="insm-20240630.xsd#insm_BusinessCombinationDeferredLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd6e07b-94b0-4829-a0ba-6d7931728a80" xlink:to="loc_insm_BusinessCombinationDeferredLiability_d40d203c-931c-4d92-9de8-9409afdc8d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput_ae9f8081-4476-4d4c-bd0d-cf2b264702d7" xlink:href="insm-20240630.xsd#insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6fd6e07b-94b0-4829-a0ba-6d7931728a80" xlink:to="loc_insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput_ae9f8081-4476-4d4c-bd0d-cf2b264702d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f7aad77a-e29c-459b-8c61-5d8b4c2f9bce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4ae80ce-2fdc-4054-ad93-a6e5df6e82ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f7aad77a-e29c-459b-8c61-5d8b4c2f9bce" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4ae80ce-2fdc-4054-ad93-a6e5df6e82ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_502aba8b-55a2-4e60-a84e-4679b32a0503" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4ae80ce-2fdc-4054-ad93-a6e5df6e82ad" xlink:to="loc_srt_RangeAxis_502aba8b-55a2-4e60-a84e-4679b32a0503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cd83efd0-b2bf-4dbb-9280-f0d51e7234d1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_502aba8b-55a2-4e60-a84e-4679b32a0503" xlink:to="loc_srt_RangeMember_cd83efd0-b2bf-4dbb-9280-f0d51e7234d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_64eb1bcc-d4b4-4535-8281-d3e4e041d5f3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cd83efd0-b2bf-4dbb-9280-f0d51e7234d1" xlink:to="loc_srt_MinimumMember_64eb1bcc-d4b4-4535-8281-d3e4e041d5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f6b98816-83af-45cf-b92b-dca782f343a4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cd83efd0-b2bf-4dbb-9280-f0d51e7234d1" xlink:to="loc_srt_MaximumMember_f6b98816-83af-45cf-b92b-dca782f343a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_cf570fcb-08ed-49b8-89c7-e2ffddec99eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4ae80ce-2fdc-4054-ad93-a6e5df6e82ad" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_cf570fcb-08ed-49b8-89c7-e2ffddec99eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_692d6a61-131c-4a59-9686-ba990ceb86a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_cf570fcb-08ed-49b8-89c7-e2ffddec99eb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_692d6a61-131c-4a59-9686-ba990ceb86a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DevelopmentAndRegulatoryMilestonesMember_b641536c-a4a5-4dc4-abe0-5ff368f01886" xlink:href="insm-20240630.xsd#insm_DevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_692d6a61-131c-4a59-9686-ba990ceb86a0" xlink:to="loc_insm_DevelopmentAndRegulatoryMilestonesMember_b641536c-a4a5-4dc4-abe0-5ff368f01886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PriorityReviewVoucherMilestoneMember_ec68fb7d-f68d-43b6-8cac-b1d1324e7b88" xlink:href="insm-20240630.xsd#insm_PriorityReviewVoucherMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_692d6a61-131c-4a59-9686-ba990ceb86a0" xlink:to="loc_insm_PriorityReviewVoucherMilestoneMember_ec68fb7d-f68d-43b6-8cac-b1d1324e7b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_5da35d38-fa73-4ae4-b5c9-0fc8916ca9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4ae80ce-2fdc-4054-ad93-a6e5df6e82ad" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_5da35d38-fa73-4ae4-b5c9-0fc8916ca9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_caebf7cd-ba1b-41f2-9f7c-9b24ebffb49f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_5da35d38-fa73-4ae4-b5c9-0fc8916ca9e8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_caebf7cd-ba1b-41f2-9f7c-9b24ebffb49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MeasurementInputProbabilityOfSuccessMember_e02db5c2-e9c1-4aa8-92f5-e7446cfe4756" xlink:href="insm-20240630.xsd#insm_MeasurementInputProbabilityOfSuccessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_caebf7cd-ba1b-41f2-9f7c-9b24ebffb49f" xlink:to="loc_insm_MeasurementInputProbabilityOfSuccessMember_e02db5c2-e9c1-4aa8-92f5-e7446cfe4756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_cff3ccf3-7f8f-43d2-99dd-078f8e5a54c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_caebf7cd-ba1b-41f2-9f7c-9b24ebffb49f" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_cff3ccf3-7f8f-43d2-99dd-078f8e5a54c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ffb81562-0937-4cc0-8974-52fbc56d6d26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4ae80ce-2fdc-4054-ad93-a6e5df6e82ad" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ffb81562-0937-4cc0-8974-52fbc56d6d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_937c70cb-9fef-4299-ae34-9beed9ea64e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ffb81562-0937-4cc0-8974-52fbc56d6d26" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_937c70cb-9fef-4299-ae34-9beed9ea64e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2c722c84-8c3b-4ade-9025-fc7144e3001f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_937c70cb-9fef-4299-ae34-9beed9ea64e9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2c722c84-8c3b-4ade-9025-fc7144e3001f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d505c3c4-661c-4eba-8fb9-0dce76e0d0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4ae80ce-2fdc-4054-ad93-a6e5df6e82ad" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d505c3c4-661c-4eba-8fb9-0dce76e0d0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_59743015-c345-4844-b098-277c54060b37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d505c3c4-661c-4eba-8fb9-0dce76e0d0b6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_59743015-c345-4844-b098-277c54060b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_298be289-ea98-499c-8502-5fb39cfbbdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d505c3c4-661c-4eba-8fb9-0dce76e0d0b6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_298be289-ea98-499c-8502-5fb39cfbbdc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0afacd7e-d6eb-44e7-90e7-31897a5bce15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ea104c7-cac9-4c02-8f6f-c6fe6a6ecae3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0afacd7e-d6eb-44e7-90e7-31897a5bce15" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ea104c7-cac9-4c02-8f6f-c6fe6a6ecae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c94efaa1-dab5-4c18-a8cc-8669b65de468" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ea104c7-cac9-4c02-8f6f-c6fe6a6ecae3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c94efaa1-dab5-4c18-a8cc-8669b65de468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7061e831-726b-4716-acb1-b14203dc4e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c94efaa1-dab5-4c18-a8cc-8669b65de468" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7061e831-726b-4716-acb1-b14203dc4e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d34745f7-ff08-40e3-877c-fd90693f24f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7061e831-726b-4716-acb1-b14203dc4e3a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d34745f7-ff08-40e3-877c-fd90693f24f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_689858ed-804e-4082-b9a0-8eefa0bbf8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7061e831-726b-4716-acb1-b14203dc4e3a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_689858ed-804e-4082-b9a0-8eefa0bbf8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76923a91-6143-438e-8bd8-a5357900d53e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6ea104c7-cac9-4c02-8f6f-c6fe6a6ecae3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76923a91-6143-438e-8bd8-a5357900d53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a3e6c0b8-1ccf-4fab-9711-c6ff8c4ae059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_76923a91-6143-438e-8bd8-a5357900d53e" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a3e6c0b8-1ccf-4fab-9711-c6ff8c4ae059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ab789819-bc29-41e4-80e2-5c27fe560163" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a3e6c0b8-1ccf-4fab-9711-c6ff8c4ae059" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ab789819-bc29-41e4-80e2-5c27fe560163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_c9accd54-fa1d-4137-bf98-744febccd5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a3e6c0b8-1ccf-4fab-9711-c6ff8c4ae059" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_c9accd54-fa1d-4137-bf98-744febccd5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions_3b673f8f-63e9-44be-998d-fa723913588c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a3e6c0b8-1ccf-4fab-9711-c6ff8c4ae059" xlink:to="loc_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions_3b673f8f-63e9-44be-998d-fa723913588c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments_f8d4d28a-1f18-4236-9fdb-efad01d84d64" xlink:href="insm-20240630.xsd#insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a3e6c0b8-1ccf-4fab-9711-c6ff8c4ae059" xlink:to="loc_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments_f8d4d28a-1f18-4236-9fdb-efad01d84d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f886ef13-15ba-4c1b-8d9a-99eef236a753" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a3e6c0b8-1ccf-4fab-9711-c6ff8c4ae059" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f886ef13-15ba-4c1b-8d9a-99eef236a753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ProductRevenuesNetDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#ProductRevenuesNetDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ProductRevenuesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_82d5c3d5-594a-480b-9c9d-f77ca4e59fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3d8379f4-ef51-4ad1-abf4-1990874b96ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_82d5c3d5-594a-480b-9c9d-f77ca4e59fa9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3d8379f4-ef51-4ad1-abf4-1990874b96ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_81a1fc9b-d0d3-4447-b9fd-17d825cbdfd9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3d8379f4-ef51-4ad1-abf4-1990874b96ec" xlink:to="loc_srt_StatementGeographicalAxis_81a1fc9b-d0d3-4447-b9fd-17d825cbdfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0ff3d0ae-23dd-4fdc-82a4-233131169d68" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_81a1fc9b-d0d3-4447-b9fd-17d825cbdfd9" xlink:to="loc_srt_SegmentGeographicalDomain_0ff3d0ae-23dd-4fdc-82a4-233131169d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_48c9b982-233e-4a18-a6a1-6c1c03dc03ec" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0ff3d0ae-23dd-4fdc-82a4-233131169d68" xlink:to="loc_country_US_48c9b982-233e-4a18-a6a1-6c1c03dc03ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_522e4cce-6204-4aae-be5f-d2a2bdfff7b0" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_JP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0ff3d0ae-23dd-4fdc-82a4-233131169d68" xlink:to="loc_country_JP_522e4cce-6204-4aae-be5f-d2a2bdfff7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EuropeAndTheRestOfTheWorldMember_18eef343-74b3-4faf-87f9-fa0d63e40f75" xlink:href="insm-20240630.xsd#insm_EuropeAndTheRestOfTheWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_0ff3d0ae-23dd-4fdc-82a4-233131169d68" xlink:to="loc_insm_EuropeAndTheRestOfTheWorldMember_18eef343-74b3-4faf-87f9-fa0d63e40f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4e9b97a4-64e8-4284-8364-595d9a9e4a47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3d8379f4-ef51-4ad1-abf4-1990874b96ec" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_4e9b97a4-64e8-4284-8364-595d9a9e4a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_454b8bdc-cba2-4510-8a2f-9d13f2943653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4e9b97a4-64e8-4284-8364-595d9a9e4a47" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_454b8bdc-cba2-4510-8a2f-9d13f2943653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/InventoryDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_02660408-e57c-4042-9aad-fd9156525104" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_832549f3-b9a0-416c-8f58-326d44d00acf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_02660408-e57c-4042-9aad-fd9156525104" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_832549f3-b9a0-416c-8f58-326d44d00acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_b353e655-93a8-4bf4-ace6-c1e9ac7b441e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_02660408-e57c-4042-9aad-fd9156525104" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_b353e655-93a8-4bf4-ace6-c1e9ac7b441e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e82440c3-e3cb-4c9a-818d-19a15a32ba48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_02660408-e57c-4042-9aad-fd9156525104" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e82440c3-e3cb-4c9a-818d-19a15a32ba48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ec3ac055-0de8-40f4-8e46-65deedd9fa78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_02660408-e57c-4042-9aad-fd9156525104" xlink:to="loc_us-gaap_InventoryNet_ec3ac055-0de8-40f4-8e46-65deedd9fa78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#IntangiblesNetandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2dc350ec-9f7e-4348-87a4-1fbcb72f6a25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7b2469f3-3d66-4054-b774-a04efdcc3480" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2dc350ec-9f7e-4348-87a4-1fbcb72f6a25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7b2469f3-3d66-4054-b774-a04efdcc3480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6f646756-e7db-4077-af23-bf882345e56a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2dc350ec-9f7e-4348-87a4-1fbcb72f6a25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_6f646756-e7db-4077-af23-bf882345e56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c28a861f-47ff-4952-9d4c-eb9af164f961" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2dc350ec-9f7e-4348-87a4-1fbcb72f6a25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c28a861f-47ff-4952-9d4c-eb9af164f961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2466f957-b68d-4822-b9ff-0d8a52e59785" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2dc350ec-9f7e-4348-87a4-1fbcb72f6a25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2466f957-b68d-4822-b9ff-0d8a52e59785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6ca397fb-e338-404d-bede-358f9191522d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2dc350ec-9f7e-4348-87a4-1fbcb72f6a25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6ca397fb-e338-404d-bede-358f9191522d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d86f528e-1de3-4b8d-ac81-133f77bb0865" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2dc350ec-9f7e-4348-87a4-1fbcb72f6a25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d86f528e-1de3-4b8d-ac81-133f77bb0865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_002c09d1-e55e-4138-959f-e28be8d4d20b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2dc350ec-9f7e-4348-87a4-1fbcb72f6a25" xlink:to="loc_us-gaap_Goodwill_002c09d1-e55e-4138-959f-e28be8d4d20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_68b56f45-ece5-4fac-84d1-4293945d11e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e937e6f7-0d0d-45a1-b206-c22def8c644f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_68b56f45-ece5-4fac-84d1-4293945d11e0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e937e6f7-0d0d-45a1-b206-c22def8c644f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d1578341-6b74-4be0-92b0-1ad9d7b6c153" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e937e6f7-0d0d-45a1-b206-c22def8c644f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d1578341-6b74-4be0-92b0-1ad9d7b6c153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ccabc2e3-18bd-4ffd-8099-c377d727f6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d1578341-6b74-4be0-92b0-1ad9d7b6c153" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ccabc2e3-18bd-4ffd-8099-c377d727f6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AcquiredResearchAndDevelopmentMember_180c1226-1ebb-4c45-ad69-b56375e82fbd" xlink:href="insm-20240630.xsd#insm_AcquiredResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ccabc2e3-18bd-4ffd-8099-c377d727f6a1" xlink:to="loc_insm_AcquiredResearchAndDevelopmentMember_180c1226-1ebb-4c45-ad69-b56375e82fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_b133da90-6239-44c1-8259-8d8e9b2c4021" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ccabc2e3-18bd-4ffd-8099-c377d727f6a1" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_b133da90-6239-44c1-8259-8d8e9b2c4021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_4de753bc-c19b-4362-ae7c-cfe6603c8f89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ccabc2e3-18bd-4ffd-8099-c377d727f6a1" xlink:to="loc_us-gaap_LicensingAgreementsMember_4de753bc-c19b-4362-ae7c-cfe6603c8f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62207347-5395-4fc3-8eff-41333819a7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e937e6f7-0d0d-45a1-b206-c22def8c644f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62207347-5395-4fc3-8eff-41333819a7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_b2ce5786-74ab-47b0-8589-fa794cd0c30c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_62207347-5395-4fc3-8eff-41333819a7f9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_b2ce5786-74ab-47b0-8589-fa794cd0c30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b4216da7-b111-4420-8245-8262d6700a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_b2ce5786-74ab-47b0-8589-fa794cd0c30c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b4216da7-b111-4420-8245-8262d6700a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_a8f66d5b-417f-4b89-a5c5-7bdae4edffbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_b2ce5786-74ab-47b0-8589-fa794cd0c30c" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_a8f66d5b-417f-4b89-a5c5-7bdae4edffbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_bc12cb97-1334-4261-9398-536178b3d78b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_b2ce5786-74ab-47b0-8589-fa794cd0c30c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_bc12cb97-1334-4261-9398-536178b3d78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2531528e-e2dd-4f58-8589-3e59e2f8d797" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_b2ce5786-74ab-47b0-8589-fa794cd0c30c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2531528e-e2dd-4f58-8589-3e59e2f8d797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsNetDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#FixedAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FixedAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_86232995-be10-4fcc-b231-4f5585108295" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5c2ea809-7f0e-406f-b7c3-1a6189b40f22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_86232995-be10-4fcc-b231-4f5585108295" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5c2ea809-7f0e-406f-b7c3-1a6189b40f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5afcd7ff-7cfc-4a43-a836-44590b313ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5c2ea809-7f0e-406f-b7c3-1a6189b40f22" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5afcd7ff-7cfc-4a43-a836-44590b313ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b32b7915-b687-4171-82e5-40b43b154f95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5afcd7ff-7cfc-4a43-a836-44590b313ef6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b32b7915-b687-4171-82e5-40b43b154f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c03c91e8-c8e6-4614-b0eb-00c3e9b411c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b32b7915-b687-4171-82e5-40b43b154f95" xlink:to="loc_us-gaap_EquipmentMember_c03c91e8-c8e6-4614-b0eb-00c3e9b411c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0540fec4-3e15-4e3c-a898-6b9ed93fe459" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b32b7915-b687-4171-82e5-40b43b154f95" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0540fec4-3e15-4e3c-a898-6b9ed93fe459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ComputerHardwareAndSoftwareMember_40b91c0c-a6ad-4c24-b92d-b99ac52b8e12" xlink:href="insm-20240630.xsd#insm_ComputerHardwareAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b32b7915-b687-4171-82e5-40b43b154f95" xlink:to="loc_insm_ComputerHardwareAndSoftwareMember_40b91c0c-a6ad-4c24-b92d-b99ac52b8e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_9c99b0aa-e8f6-46bf-8223-69953f5b58a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b32b7915-b687-4171-82e5-40b43b154f95" xlink:to="loc_us-gaap_OfficeEquipmentMember_9c99b0aa-e8f6-46bf-8223-69953f5b58a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ManufacturingEquipmentMember_140a2380-6dfb-48fb-b5d0-44aebf8ad04c" xlink:href="insm-20240630.xsd#insm_ManufacturingEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b32b7915-b687-4171-82e5-40b43b154f95" xlink:to="loc_insm_ManufacturingEquipmentMember_140a2380-6dfb-48fb-b5d0-44aebf8ad04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_6b681226-9f3c-4a82-acee-cc9b73c5570e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b32b7915-b687-4171-82e5-40b43b154f95" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_6b681226-9f3c-4a82-acee-cc9b73c5570e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_ad226d80-4543-4906-b2ff-946b2ebe77a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b32b7915-b687-4171-82e5-40b43b154f95" xlink:to="loc_us-gaap_ConstructionInProgressMember_ad226d80-4543-4906-b2ff-946b2ebe77a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2ea108cc-ab83-4ad7-be54-708637edee4a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5c2ea809-7f0e-406f-b7c3-1a6189b40f22" xlink:to="loc_srt_RangeAxis_2ea108cc-ab83-4ad7-be54-708637edee4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_34123b93-461c-4650-9145-a8a1f5d10ac6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2ea108cc-ab83-4ad7-be54-708637edee4a" xlink:to="loc_srt_RangeMember_34123b93-461c-4650-9145-a8a1f5d10ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_92cecd93-95cc-40c0-8f4f-7f0cf9188a08" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_34123b93-461c-4650-9145-a8a1f5d10ac6" xlink:to="loc_srt_MinimumMember_92cecd93-95cc-40c0-8f4f-7f0cf9188a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c8092597-6750-4c9d-9015-7c90092c739b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_34123b93-461c-4650-9145-a8a1f5d10ac6" xlink:to="loc_srt_MaximumMember_c8092597-6750-4c9d-9015-7c90092c739b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b494c5f-da52-4a60-a6cd-6f880f7a7ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5c2ea809-7f0e-406f-b7c3-1a6189b40f22" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b494c5f-da52-4a60-a6cd-6f880f7a7ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_25b121dd-002e-4258-8f70-78ce39098358" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b494c5f-da52-4a60-a6cd-6f880f7a7ee6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_25b121dd-002e-4258-8f70-78ce39098358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a029f69d-2926-44c5-af4a-e3e547fe4a26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b494c5f-da52-4a60-a6cd-6f880f7a7ee6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a029f69d-2926-44c5-af4a-e3e547fe4a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4e22a782-bd2a-406b-8abe-2438a0b04d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b494c5f-da52-4a60-a6cd-6f880f7a7ee6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4e22a782-bd2a-406b-8abe-2438a0b04d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2db203f0-dc8e-4a7b-a0fa-2432c52a4bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6b494c5f-da52-4a60-a6cd-6f880f7a7ee6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2db203f0-dc8e-4a7b-a0fa-2432c52a4bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#AccountsPayableandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3fe61282-b865-4499-8058-b1b3d6be1da8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c85da602-2709-47ae-a1e7-a4ca9a59faeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3fe61282-b865-4499-8058-b1b3d6be1da8" xlink:to="loc_us-gaap_AccountsPayableCurrent_c85da602-2709-47ae-a1e7-a4ca9a59faeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedClinicalTrialExpenses_ec552543-eafd-4dea-819c-f9a7a02b3060" xlink:href="insm-20240630.xsd#insm_AccruedClinicalTrialExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3fe61282-b865-4499-8058-b1b3d6be1da8" xlink:to="loc_insm_AccruedClinicalTrialExpenses_ec552543-eafd-4dea-819c-f9a7a02b3060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_0dd42099-ddf9-427b-aa10-75d0734a5352" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3fe61282-b865-4499-8058-b1b3d6be1da8" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_0dd42099-ddf9-427b-aa10-75d0734a5352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedTechnicalOperationExpenses_896b41a8-2955-4d47-8a26-b051279a90f7" xlink:href="insm-20240630.xsd#insm_AccruedTechnicalOperationExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3fe61282-b865-4499-8058-b1b3d6be1da8" xlink:to="loc_insm_AccruedTechnicalOperationExpenses_896b41a8-2955-4d47-8a26-b051279a90f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f348a10a-3f89-41c2-8843-a19453aa71a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3fe61282-b865-4499-8058-b1b3d6be1da8" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f348a10a-3f89-41c2-8843-a19453aa71a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_727458e1-7d08-415e-bcc8-d00f08040295" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3fe61282-b865-4499-8058-b1b3d6be1da8" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_727458e1-7d08-415e-bcc8-d00f08040295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_bd7b76b1-d7f6-4bee-b653-685a914a84f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3fe61282-b865-4499-8058-b1b3d6be1da8" xlink:to="loc_us-gaap_InterestPayableCurrent_bd7b76b1-d7f6-4bee-b653-685a914a84f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_RevenueInterestPaymentsPayable_f41b1361-d183-40a0-b8ec-b7ad6c55a8d6" xlink:href="insm-20240630.xsd#insm_RevenueInterestPaymentsPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3fe61282-b865-4499-8058-b1b3d6be1da8" xlink:to="loc_insm_RevenueInterestPaymentsPayable_f41b1361-d183-40a0-b8ec-b7ad6c55a8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedSalesAllowancesAndRelatedCosts_ede2d837-5432-4436-871c-6f4332dd008a" xlink:href="insm-20240630.xsd#insm_AccruedSalesAllowancesAndRelatedCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3fe61282-b865-4499-8058-b1b3d6be1da8" xlink:to="loc_insm_AccruedSalesAllowancesAndRelatedCosts_ede2d837-5432-4436-871c-6f4332dd008a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_e8d7924c-3ef1-42a3-bb28-67340bb69f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3fe61282-b865-4499-8058-b1b3d6be1da8" xlink:to="loc_us-gaap_ContractWithCustomerRefundLiabilityCurrent_e8d7924c-3ef1-42a3-bb28-67340bb69f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationDeferredPaymentsCurrent_f792def3-0dca-4b4f-89c4-3dd9fca11e04" xlink:href="insm-20240630.xsd#insm_BusinessCombinationDeferredPaymentsCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3fe61282-b865-4499-8058-b1b3d6be1da8" xlink:to="loc_insm_BusinessCombinationDeferredPaymentsCurrent_f792def3-0dca-4b4f-89c4-3dd9fca11e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedMilestonePaymentCurrent_efa4b9c7-e019-4bc6-89ee-3ccc3ebe34b0" xlink:href="insm-20240630.xsd#insm_AccruedMilestonePaymentCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3fe61282-b865-4499-8058-b1b3d6be1da8" xlink:to="loc_insm_AccruedMilestonePaymentCurrent_efa4b9c7-e019-4bc6-89ee-3ccc3ebe34b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_da22ad93-cecf-474c-8090-1b20d288c24f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3fe61282-b865-4499-8058-b1b3d6be1da8" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_da22ad93-cecf-474c-8090-1b20d288c24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_936d37cd-d999-473e-983f-4e450f422d33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3fe61282-b865-4499-8058-b1b3d6be1da8" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_936d37cd-d999-473e-983f-4e450f422d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8e2fbf0b-094a-4b54-a95e-fda7baf31179" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_8631ac57-84b6-49f0-8121-bc640b1ae3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8e2fbf0b-094a-4b54-a95e-fda7baf31179" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_8631ac57-84b6-49f0-8121-bc640b1ae3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_acfaeb1b-3792-47d4-9c13-63ddfd1eafbe" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8631ac57-84b6-49f0-8121-bc640b1ae3f4" xlink:to="loc_srt_RangeAxis_acfaeb1b-3792-47d4-9c13-63ddfd1eafbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9c918e91-fa5f-4f97-b133-afe21538b5f4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_acfaeb1b-3792-47d4-9c13-63ddfd1eafbe" xlink:to="loc_srt_RangeMember_9c918e91-fa5f-4f97-b133-afe21538b5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2fcd97eb-fc1e-4879-9d29-f6f9f6bfd059" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9c918e91-fa5f-4f97-b133-afe21538b5f4" xlink:to="loc_srt_MinimumMember_2fcd97eb-fc1e-4879-9d29-f6f9f6bfd059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_89d44d0f-338b-48e8-b245-ea5676047a0c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9c918e91-fa5f-4f97-b133-afe21538b5f4" xlink:to="loc_srt_MaximumMember_89d44d0f-338b-48e8-b245-ea5676047a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_386dd8d5-e488-4413-8e72-c6edff981b92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8631ac57-84b6-49f0-8121-bc640b1ae3f4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_386dd8d5-e488-4413-8e72-c6edff981b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LeaseRemainingLeaseTerm_8098aa42-2ca7-464c-b811-a4e3180f5dc9" xlink:href="insm-20240630.xsd#insm_LeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_386dd8d5-e488-4413-8e72-c6edff981b92" xlink:to="loc_insm_LeaseRemainingLeaseTerm_8098aa42-2ca7-464c-b811-a4e3180f5dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_f6059b93-241f-44f6-bfe0-c4b2520cfb22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_386dd8d5-e488-4413-8e72-c6edff981b92" xlink:to="loc_us-gaap_VariableLeaseCost_f6059b93-241f-44f6-bfe0-c4b2520cfb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_2a603f20-7715-4c7b-af40-a8dae1d22a78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_386dd8d5-e488-4413-8e72-c6edff981b92" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_2a603f20-7715-4c7b-af40-a8dae1d22a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesScheduleofSupplementalNoncashDisclosuresDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#LeasesScheduleofSupplementalNoncashDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/LeasesScheduleofSupplementalNoncashDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f66a9f99-15da-4aa9-801b-648a273b12b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_0ab17eb3-6530-4559-9bd1-373bbafaf217" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f66a9f99-15da-4aa9-801b-648a273b12b7" xlink:to="loc_us-gaap_LeaseCostAbstract_0ab17eb3-6530-4559-9bd1-373bbafaf217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_d11dd25e-3f5f-4fdc-8c47-d71075a46ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_0ab17eb3-6530-4559-9bd1-373bbafaf217" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_d11dd25e-3f5f-4fdc-8c47-d71075a46ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5de82c9d-1151-4a53-b79c-00239fdc07b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_0ab17eb3-6530-4559-9bd1-373bbafaf217" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5de82c9d-1151-4a53-b79c-00239fdc07b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_54d19a63-9906-49df-86df-cfc00410b62d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7ff6851d-c96e-4e02-b890-7fd98441712a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_54d19a63-9906-49df-86df-cfc00410b62d" xlink:to="loc_us-gaap_DebtInstrumentTable_7ff6851d-c96e-4e02-b890-7fd98441712a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_79894c7a-df6a-4e91-88c7-bc5577495c64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7ff6851d-c96e-4e02-b890-7fd98441712a" xlink:to="loc_us-gaap_DebtInstrumentAxis_79894c7a-df6a-4e91-88c7-bc5577495c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_405b01cf-f018-413c-baa9-ca24d3bec93d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_79894c7a-df6a-4e91-88c7-bc5577495c64" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_405b01cf-f018-413c-baa9-ca24d3bec93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_85311f46-0cef-4d83-a853-c13835c355b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_405b01cf-f018-413c-baa9-ca24d3bec93d" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_85311f46-0cef-4d83-a853-c13835c355b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_TermLoanMember_7bec8927-61f0-4233-9f42-31efa35210ee" xlink:href="insm-20240630.xsd#insm_TermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_405b01cf-f018-413c-baa9-ca24d3bec93d" xlink:to="loc_insm_TermLoanMember_7bec8927-61f0-4233-9f42-31efa35210ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_aae694a3-03e3-4e44-9677-e80945f5fce0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7ff6851d-c96e-4e02-b890-7fd98441712a" xlink:to="loc_us-gaap_DebtInstrumentLineItems_aae694a3-03e3-4e44-9677-e80945f5fce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e4d23395-056a-416d-ae23-0f7ae30ebc65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aae694a3-03e3-4e44-9677-e80945f5fce0" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e4d23395-056a-416d-ae23-0f7ae30ebc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ee21548a-a508-42a6-b7e9-b352b6a76023" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aae694a3-03e3-4e44-9677-e80945f5fce0" xlink:to="loc_us-gaap_LongTermDebtCurrent_ee21548a-a508-42a6-b7e9-b352b6a76023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_397b42e7-8e11-42e7-b105-e5c21c276043" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aae694a3-03e3-4e44-9677-e80945f5fce0" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_397b42e7-8e11-42e7-b105-e5c21c276043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9bfc53bc-5a2b-4f62-a391-01d0a8e01cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9bfc53bc-5a2b-4f62-a391-01d0a8e01cdf" xlink:to="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5023e02e-874c-4efe-8bcb-be040316e89f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5023e02e-874c-4efe-8bcb-be040316e89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a5fd39be-02bd-4ce2-a09c-6e0b77b6b9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5023e02e-874c-4efe-8bcb-be040316e89f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a5fd39be-02bd-4ce2-a09c-6e0b77b6b9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_e59c90e4-0551-4c8d-bc01-c07e7f31f5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a5fd39be-02bd-4ce2-a09c-6e0b77b6b9ab" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_e59c90e4-0551-4c8d-bc01-c07e7f31f5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4e27202f-7807-4740-a832-16e3e9b17749" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_us-gaap_DebtInstrumentAxis_4e27202f-7807-4740-a832-16e3e9b17749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8958c383-342f-4eff-bf9f-f1ba02449ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4e27202f-7807-4740-a832-16e3e9b17749" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8958c383-342f-4eff-bf9f-f1ba02449ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_cc4941d4-118d-443a-a8ea-8df4b60a8052" xlink:href="insm-20240630.xsd#insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8958c383-342f-4eff-bf9f-f1ba02449ae0" xlink:to="loc_insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member_cc4941d4-118d-443a-a8ea-8df4b60a8052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_0e90f566-9626-4fa0-8683-502dabd9f8cb" xlink:href="insm-20240630.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8958c383-342f-4eff-bf9f-f1ba02449ae0" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_0e90f566-9626-4fa0-8683-502dabd9f8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_RedemptionOfThe2025ConvertibleNotesMember_e31c8ef3-8245-44b7-a323-a8dd028a3686" xlink:href="insm-20240630.xsd#insm_RedemptionOfThe2025ConvertibleNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8958c383-342f-4eff-bf9f-f1ba02449ae0" xlink:to="loc_insm_RedemptionOfThe2025ConvertibleNotesMember_e31c8ef3-8245-44b7-a323-a8dd028a3686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_TermLoanMember_b73aead9-14d0-4f17-bd5b-7edcf7a7b3fd" xlink:href="insm-20240630.xsd#insm_TermLoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8958c383-342f-4eff-bf9f-f1ba02449ae0" xlink:to="loc_insm_TermLoanMember_b73aead9-14d0-4f17-bd5b-7edcf7a7b3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermAxis_a40144b6-f4d7-4085-9749-c35a48c07f98" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_insm_DebtInstrumentConversionTermAxis_a40144b6-f4d7-4085-9749-c35a48c07f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermDomain_ccae5843-0fa3-4131-89a5-6fa76d0665de" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermAxis_a40144b6-f4d7-4085-9749-c35a48c07f98" xlink:to="loc_insm_DebtInstrumentConversionTermDomain_ccae5843-0fa3-4131-89a5-6fa76d0665de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermOneMember_03351cbd-652a-43b1-a0e7-1fbc313b3b9d" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_ccae5843-0fa3-4131-89a5-6fa76d0665de" xlink:to="loc_insm_DebtInstrumentConversionTermOneMember_03351cbd-652a-43b1-a0e7-1fbc313b3b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermTwoMember_e032a8b4-a10c-4708-9f73-77f014219c7f" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_ccae5843-0fa3-4131-89a5-6fa76d0665de" xlink:to="loc_insm_DebtInstrumentConversionTermTwoMember_e032a8b4-a10c-4708-9f73-77f014219c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermThreeMember_793591f1-67a7-4a41-a3a6-82f29657b242" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_ccae5843-0fa3-4131-89a5-6fa76d0665de" xlink:to="loc_insm_DebtInstrumentConversionTermThreeMember_793591f1-67a7-4a41-a3a6-82f29657b242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermFourMember_112e8b83-b837-40fe-9152-09bbdb771070" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConversionTermFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_ccae5843-0fa3-4131-89a5-6fa76d0665de" xlink:to="loc_insm_DebtInstrumentConversionTermFourMember_112e8b83-b837-40fe-9152-09bbdb771070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_92e92df1-155a-4824-ae18-30712245013c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_us-gaap_CreditFacilityAxis_92e92df1-155a-4824-ae18-30712245013c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_495f8daa-769e-42c2-8341-389b8665d178" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_92e92df1-155a-4824-ae18-30712245013c" xlink:to="loc_us-gaap_CreditFacilityDomain_495f8daa-769e-42c2-8341-389b8665d178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_64eca65b-66a1-4e8e-ba4d-b2e533e2bd80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_495f8daa-769e-42c2-8341-389b8665d178" xlink:to="loc_us-gaap_SecuredDebtMember_64eca65b-66a1-4e8e-ba4d-b2e533e2bd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83d18cb7-c2a3-4534-aa05-427f1a2f170d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83d18cb7-c2a3-4534-aa05-427f1a2f170d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4b5feab2-c7dc-449a-8639-69098596ac8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_83d18cb7-c2a3-4534-aa05-427f1a2f170d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4b5feab2-c7dc-449a-8639-69098596ac8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_72bcc919-e674-4428-9281-8caa80db7a78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4b5feab2-c7dc-449a-8639-69098596ac8c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_72bcc919-e674-4428-9281-8caa80db7a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_da09a517-7d3f-42d7-aef3-b92177263141" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_da09a517-7d3f-42d7-aef3-b92177263141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2c625107-e5d2-4b8f-b5a3-bdc84897ffdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_da09a517-7d3f-42d7-aef3-b92177263141" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2c625107-e5d2-4b8f-b5a3-bdc84897ffdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c6ad58ca-a636-41f0-9881-6f6ba51ee3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2c625107-e5d2-4b8f-b5a3-bdc84897ffdd" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c6ad58ca-a636-41f0-9881-6f6ba51ee3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b3a9abc8-3149-483d-a290-37cedf5967df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_c6ad58ca-a636-41f0-9881-6f6ba51ee3b2" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_b3a9abc8-3149-483d-a290-37cedf5967df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eb0ed8a4-da2f-490f-9347-eb1c6652fa4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eb0ed8a4-da2f-490f-9347-eb1c6652fa4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_768c367a-b603-4c91-a125-1ada02f0d115" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eb0ed8a4-da2f-490f-9347-eb1c6652fa4e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_768c367a-b603-4c91-a125-1ada02f0d115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2ba9f40e-c8dc-4801-9cf2-19fedb89f428" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_768c367a-b603-4c91-a125-1ada02f0d115" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2ba9f40e-c8dc-4801-9cf2-19fedb89f428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2a378992-b2fe-4981-b9df-8b0490a12c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2a378992-b2fe-4981-b9df-8b0490a12c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_db222ba0-1ced-46d4-a153-b4a3aea5f5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2a378992-b2fe-4981-b9df-8b0490a12c2c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_db222ba0-1ced-46d4-a153-b4a3aea5f5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_26c4903c-2b52-4ae2-a7a9-2ad857d7406f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_db222ba0-1ced-46d4-a153-b4a3aea5f5c4" xlink:to="loc_us-gaap_SubsequentEventMember_26c4903c-2b52-4ae2-a7a9-2ad857d7406f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_c5c1db20-321f-4bcb-b130-7823f25c11e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_us-gaap_VariableRateAxis_c5c1db20-321f-4bcb-b130-7823f25c11e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_4977d046-383d-4431-93c6-50dff815de99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_c5c1db20-321f-4bcb-b130-7823f25c11e2" xlink:to="loc_us-gaap_VariableRateDomain_4977d046-383d-4431-93c6-50dff815de99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_2c51a10f-5568-42ae-876b-d2f7c74d54e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_4977d046-383d-4431-93c6-50dff815de99" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_2c51a10f-5568-42ae-876b-d2f7c74d54e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c2a828e4-5785-43eb-8454-9470547a6721" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0f7ec4cd-0033-450d-affa-4b903a964df7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0f7ec4cd-0033-450d-affa-4b903a964df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_2c9efa58-dbbb-4f52-9f68-5861c9ed2e8b" xlink:href="insm-20240630.xsd#insm_DebtInstrumentOptionToPurchaseAdditionalDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_2c9efa58-dbbb-4f52-9f68-5861c9ed2e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_16df2cd5-2bc5-4919-9dbb-2742ff84586a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_16df2cd5-2bc5-4919-9dbb-2742ff84586a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_ff5ff064-ad19-46e5-8086-ed25817184dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_ff5ff064-ad19-46e5-8086-ed25817184dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_ea4c7c83-dad8-4cbf-9024-e3de69825446" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_ea4c7c83-dad8-4cbf-9024-e3de69825446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3f1cf216-5851-4465-b9b0-a3bab89d2447" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3f1cf216-5851-4465-b9b0-a3bab89d2447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_a7aafbf7-28f7-4996-b0bc-d9a92dc4cadc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_a7aafbf7-28f7-4996-b0bc-d9a92dc4cadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_09dd1190-2ee3-4920-9c7a-0dab13999b50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_09dd1190-2ee3-4920-9c7a-0dab13999b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_7e6a975c-53c1-4330-828d-85469f521ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_7e6a975c-53c1-4330-828d-85469f521ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c5156973-2c4f-407f-8225-fba3dd41da31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c5156973-2c4f-407f-8225-fba3dd41da31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f36ee58f-18b8-46d5-94bf-70458e1f12d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f36ee58f-18b8-46d5-94bf-70458e1f12d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_3a7ba367-57b7-4791-967c-1c3bb0d8239a" xlink:href="insm-20240630.xsd#insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_3a7ba367-57b7-4791-967c-1c3bb0d8239a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_6ae2558e-7f0f-44c6-94ed-745213eff3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_6ae2558e-7f0f-44c6-94ed-745213eff3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_f3b5b265-3d1b-4471-9e40-915303d33f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_f3b5b265-3d1b-4471-9e40-915303d33f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_47566403-9951-4a13-9ef5-b31e9081643f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_47566403-9951-4a13-9ef5-b31e9081643f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining_1454ca1b-6f5c-4761-bc47-2133a31bce01" xlink:href="insm-20240630.xsd#insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining_1454ca1b-6f5c-4761-bc47-2133a31bce01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_90b2d62b-9a48-4c5c-a652-fc1f3750a09f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_90b2d62b-9a48-4c5c-a652-fc1f3750a09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentRedemptionPricePerShare_dcb90902-7f14-4d1f-a069-22a778c90ce8" xlink:href="insm-20240630.xsd#insm_DebtInstrumentRedemptionPricePerShare"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_insm_DebtInstrumentRedemptionPricePerShare_dcb90902-7f14-4d1f-a069-22a778c90ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_90afc105-95a8-469e-8d47-e1fa8be0bca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_90afc105-95a8-469e-8d47-e1fa8be0bca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentPercentOfInterestPayable_fdab0d2e-934c-4655-88db-28a8848875c6" xlink:href="insm-20240630.xsd#insm_DebtInstrumentPercentOfInterestPayable"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_insm_DebtInstrumentPercentOfInterestPayable_fdab0d2e-934c-4655-88db-28a8848875c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_cccde346-6d37-4667-8340-dd551c94434a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_DebtInstrumentTerm_cccde346-6d37-4667-8340-dd551c94434a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLoans_51103bb3-7487-471c-a293-231453a986b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLoans"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_ProceedsFromLoans_51103bb3-7487-471c-a293-231453a986b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_cb098e5a-3c21-4c5c-892f-eb7aa0917147" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b46eee90-fc1e-4939-8101-2d6978414b50" xlink:to="loc_us-gaap_PaidInKindInterest_cb098e5a-3c21-4c5c-892f-eb7aa0917147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_718bd735-ec96-4718-8962-a74703e035f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ca474614-4f15-4e1c-b075-c9fad4685477" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_718bd735-ec96-4718-8962-a74703e035f4" xlink:to="loc_us-gaap_DebtInstrumentTable_ca474614-4f15-4e1c-b075-c9fad4685477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b347d0da-374b-4e64-b2bc-e20481da0b97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ca474614-4f15-4e1c-b075-c9fad4685477" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b347d0da-374b-4e64-b2bc-e20481da0b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d42e00de-6b33-4962-aca8-d43e022c5713" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b347d0da-374b-4e64-b2bc-e20481da0b97" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d42e00de-6b33-4962-aca8-d43e022c5713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_eadc6185-fec9-4cea-a668-98ba16e2c5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d42e00de-6b33-4962-aca8-d43e022c5713" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_eadc6185-fec9-4cea-a668-98ba16e2c5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4a1581a4-0b04-4dff-bf97-f8a43d8a0a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ca474614-4f15-4e1c-b075-c9fad4685477" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4a1581a4-0b04-4dff-bf97-f8a43d8a0a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_fd817c96-05be-4fcc-acd1-4f82ae79b1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a1581a4-0b04-4dff-bf97-f8a43d8a0a7b" xlink:to="loc_us-gaap_SecuredDebt_fd817c96-05be-4fcc-acd1-4f82ae79b1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_e3b57915-e06e-41d9-9d69-633b8f41813c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a1581a4-0b04-4dff-bf97-f8a43d8a0a7b" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_e3b57915-e06e-41d9-9d69-633b8f41813c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_754fbc00-2ba1-4773-b7ae-b01d8aba948a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a1581a4-0b04-4dff-bf97-f8a43d8a0a7b" xlink:to="loc_us-gaap_LongTermDebtCurrent_754fbc00-2ba1-4773-b7ae-b01d8aba948a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_dc5b8d61-3b36-4777-8daf-137c4f134bda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a1581a4-0b04-4dff-bf97-f8a43d8a0a7b" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_dc5b8d61-3b36-4777-8daf-137c4f134bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#DebtScheduleofCarryingValueofTermLoanBalanceDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_377042b0-57dd-4380-8e11-8397ced4f599" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a111a798-e91e-4ca6-aa52-afb08eb08ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_377042b0-57dd-4380-8e11-8397ced4f599" xlink:to="loc_us-gaap_DebtInstrumentTable_a111a798-e91e-4ca6-aa52-afb08eb08ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_784dd5b3-5dcb-47d9-8a4c-b5d2c4a1b6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a111a798-e91e-4ca6-aa52-afb08eb08ac2" xlink:to="loc_us-gaap_CreditFacilityAxis_784dd5b3-5dcb-47d9-8a4c-b5d2c4a1b6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9d33ee6f-9896-4be6-a6ae-b591653f9640" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_784dd5b3-5dcb-47d9-8a4c-b5d2c4a1b6d6" xlink:to="loc_us-gaap_CreditFacilityDomain_9d33ee6f-9896-4be6-a6ae-b591653f9640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_e9449c15-d1eb-4ee9-b082-613da344a8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_9d33ee6f-9896-4be6-a6ae-b591653f9640" xlink:to="loc_us-gaap_SecuredDebtMember_e9449c15-d1eb-4ee9-b082-613da344a8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e3905fbb-13a7-4963-b330-bb4eb1881c48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a111a798-e91e-4ca6-aa52-afb08eb08ac2" xlink:to="loc_us-gaap_DebtInstrumentAxis_e3905fbb-13a7-4963-b330-bb4eb1881c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d609d5dc-cc05-4301-a9d3-ea40cc4ed628" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e3905fbb-13a7-4963-b330-bb4eb1881c48" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d609d5dc-cc05-4301-a9d3-ea40cc4ed628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_TermLoanMember_3c06ed09-05a7-4edf-bcde-4f36fa0d7a43" xlink:href="insm-20240630.xsd#insm_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d609d5dc-cc05-4301-a9d3-ea40cc4ed628" xlink:to="loc_insm_TermLoanMember_3c06ed09-05a7-4edf-bcde-4f36fa0d7a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_820f2bd6-c26c-45b3-b764-0e221b0fee0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a111a798-e91e-4ca6-aa52-afb08eb08ac2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_820f2bd6-c26c-45b3-b764-0e221b0fee0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4fec98da-294f-4e99-a46c-930ddc6a404b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820f2bd6-c26c-45b3-b764-0e221b0fee0a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4fec98da-294f-4e99-a46c-930ddc6a404b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedCapitalizedInterestCosts_cfb0e858-7620-46f6-a391-7c8629ace071" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedCapitalizedInterestCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820f2bd6-c26c-45b3-b764-0e221b0fee0a" xlink:to="loc_us-gaap_AccumulatedCapitalizedInterestCosts_cfb0e858-7620-46f6-a391-7c8629ace071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_c1df24a4-3ef7-4873-923f-ef36551f1391" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820f2bd6-c26c-45b3-b764-0e221b0fee0a" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_c1df24a4-3ef7-4873-923f-ef36551f1391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_14c1ef3e-5692-4e8f-b28f-aec0650dda26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_820f2bd6-c26c-45b3-b764-0e221b0fee0a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_14c1ef3e-5692-4e8f-b28f-aec0650dda26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#DebtScheduleofFuturePrincipalRepaymentsofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_67208003-abe9-4d78-a6eb-181c7783af00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_088f3d08-205a-4416-a906-50706aa1c494" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_67208003-abe9-4d78-a6eb-181c7783af00" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_088f3d08-205a-4416-a906-50706aa1c494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0a1dc019-a6f4-4134-b332-176f664ed22f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_088f3d08-205a-4416-a906-50706aa1c494" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0a1dc019-a6f4-4134-b332-176f664ed22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5c8cc7da-0adc-4f61-bd50-0f25397d9f69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_088f3d08-205a-4416-a906-50706aa1c494" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5c8cc7da-0adc-4f61-bd50-0f25397d9f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3217b8d2-5b71-4cda-9775-edc27d0108ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_088f3d08-205a-4416-a906-50706aa1c494" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3217b8d2-5b71-4cda-9775-edc27d0108ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_07ccc7af-97b6-495a-a958-7f9fe57ad5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_088f3d08-205a-4416-a906-50706aa1c494" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_07ccc7af-97b6-495a-a958-7f9fe57ad5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_0713e049-e866-4da1-91dc-9c0e8fcb48c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_088f3d08-205a-4416-a906-50706aa1c494" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_0713e049-e866-4da1-91dc-9c0e8fcb48c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LongTermDebtMaturityAfterYearFourAndThereafter_81965e07-fa85-4783-8977-89ff9010ee66" xlink:href="insm-20240630.xsd#insm_LongTermDebtMaturityAfterYearFourAndThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_088f3d08-205a-4416-a906-50706aa1c494" xlink:to="loc_insm_LongTermDebtMaturityAfterYearFourAndThereafter_81965e07-fa85-4783-8977-89ff9010ee66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_26c44085-8be4-4f40-9c89-d76116395e86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_088f3d08-205a-4416-a906-50706aa1c494" xlink:to="loc_us-gaap_LongTermDebt_26c44085-8be4-4f40-9c89-d76116395e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4486f384-edc9-4e2a-9b6a-fcdd926638f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8a0cd99b-7758-4923-a851-4826d120f3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4486f384-edc9-4e2a-9b6a-fcdd926638f4" xlink:to="loc_us-gaap_DebtInstrumentTable_8a0cd99b-7758-4923-a851-4826d120f3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_22a6de24-b341-4ec1-a66c-b1d8bef8eeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8a0cd99b-7758-4923-a851-4826d120f3d0" xlink:to="loc_us-gaap_DebtInstrumentAxis_22a6de24-b341-4ec1-a66c-b1d8bef8eeb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_48c57815-cff3-4c95-ae05-e4bdc9b6be81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_22a6de24-b341-4ec1-a66c-b1d8bef8eeb1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_48c57815-cff3-4c95-ae05-e4bdc9b6be81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_5936ab56-91e5-40d0-aaf6-44232808053d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_48c57815-cff3-4c95-ae05-e4bdc9b6be81" xlink:to="loc_us-gaap_ConvertibleDebtMember_5936ab56-91e5-40d0-aaf6-44232808053d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_TermLoanMember_b2bb66ca-cf61-480a-9542-3f0365529e7f" xlink:href="insm-20240630.xsd#insm_TermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_48c57815-cff3-4c95-ae05-e4bdc9b6be81" xlink:to="loc_insm_TermLoanMember_b2bb66ca-cf61-480a-9542-3f0365529e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember_99bc963e-b66a-44b3-a68f-143121ab8891" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_48c57815-cff3-4c95-ae05-e4bdc9b6be81" xlink:to="loc_us-gaap_RoyaltyAgreementsMember_99bc963e-b66a-44b3-a68f-143121ab8891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fda6b47c-994a-4110-849c-455c01334264" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8a0cd99b-7758-4923-a851-4826d120f3d0" xlink:to="loc_us-gaap_DebtInstrumentLineItems_fda6b47c-994a-4110-849c-455c01334264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_1a351226-2a4e-40fd-9682-ce0688f8d6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fda6b47c-994a-4110-849c-455c01334264" xlink:to="loc_us-gaap_InterestExpenseDebt_1a351226-2a4e-40fd-9682-ce0688f8d6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_1a8f1675-80f1-454a-9d38-1ebcc2224b92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fda6b47c-994a-4110-849c-455c01334264" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_1a8f1675-80f1-454a-9d38-1ebcc2224b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_312896e4-581c-4d37-a978-ad99caae8544" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fda6b47c-994a-4110-849c-455c01334264" xlink:to="loc_us-gaap_InterestIncomeOther_312896e4-581c-4d37-a978-ad99caae8544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InterestExpenseExcludingFinanceLeaseInterestExpense_88e01f8c-a0c7-4fa8-afce-419dc76575a0" xlink:href="insm-20240630.xsd#insm_InterestExpenseExcludingFinanceLeaseInterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fda6b47c-994a-4110-849c-455c01334264" xlink:to="loc_insm_InterestExpenseExcludingFinanceLeaseInterestExpense_88e01f8c-a0c7-4fa8-afce-419dc76575a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_f87063ac-cfdb-4e27-a084-e520d5b6a051" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fda6b47c-994a-4110-849c-455c01334264" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_f87063ac-cfdb-4e27-a084-e520d5b6a051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0f6867d3-2019-40a2-9899-ee012322ddae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fda6b47c-994a-4110-849c-455c01334264" xlink:to="loc_us-gaap_InterestExpense_0f6867d3-2019-40a2-9899-ee012322ddae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#RoyaltyFinancingAgreementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_41a95243-6a47-4bdd-8f9a-fbac1877485b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ad5cc248-428b-46a2-9200-e011d9c03e46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_41a95243-6a47-4bdd-8f9a-fbac1877485b" xlink:to="loc_us-gaap_DebtInstrumentTable_ad5cc248-428b-46a2-9200-e011d9c03e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f3ea2b51-d68f-4a76-bd87-c8f219f7647f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ad5cc248-428b-46a2-9200-e011d9c03e46" xlink:to="loc_us-gaap_CreditFacilityAxis_f3ea2b51-d68f-4a76-bd87-c8f219f7647f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5c3d926f-82e3-4b3f-b580-33f2a2f218c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_f3ea2b51-d68f-4a76-bd87-c8f219f7647f" xlink:to="loc_us-gaap_CreditFacilityDomain_5c3d926f-82e3-4b3f-b580-33f2a2f218c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_39d53bb4-eaf6-4561-9dbc-068ed2d04279" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5c3d926f-82e3-4b3f-b580-33f2a2f218c4" xlink:to="loc_us-gaap_SecuredDebtMember_39d53bb4-eaf6-4561-9dbc-068ed2d04279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_07c584bf-17eb-4faf-928e-c589df9557bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ad5cc248-428b-46a2-9200-e011d9c03e46" xlink:to="loc_us-gaap_DebtInstrumentAxis_07c584bf-17eb-4faf-928e-c589df9557bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6649960b-0d85-4d13-a173-b2ddfdc1b811" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_07c584bf-17eb-4faf-928e-c589df9557bb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6649960b-0d85-4d13-a173-b2ddfdc1b811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember_912439c3-3157-4e47-9302-73ee627c0a75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6649960b-0d85-4d13-a173-b2ddfdc1b811" xlink:to="loc_us-gaap_RoyaltyAgreementsMember_912439c3-3157-4e47-9302-73ee627c0a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6ee47b25-168b-411c-8660-b78d2d1d09c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ad5cc248-428b-46a2-9200-e011d9c03e46" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6ee47b25-168b-411c-8660-b78d2d1d09c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d0f1b273-5f41-4d68-b0de-54173df62ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6ee47b25-168b-411c-8660-b78d2d1d09c8" xlink:to="loc_us-gaap_SegmentDomain_d0f1b273-5f41-4d68-b0de-54173df62ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ARIKAYCEGlobalNetSalesMember_b8589829-02fd-4ea9-b252-2b425ba6c37f" xlink:href="insm-20240630.xsd#insm_ARIKAYCEGlobalNetSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d0f1b273-5f41-4d68-b0de-54173df62ba0" xlink:to="loc_insm_ARIKAYCEGlobalNetSalesMember_b8589829-02fd-4ea9-b252-2b425ba6c37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BrensocatibGlobalNetSalesMember_2a02e53f-ca2c-4888-93f3-3ad85930f3e4" xlink:href="insm-20240630.xsd#insm_BrensocatibGlobalNetSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d0f1b273-5f41-4d68-b0de-54173df62ba0" xlink:to="loc_insm_BrensocatibGlobalNetSalesMember_2a02e53f-ca2c-4888-93f3-3ad85930f3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f8b43ca5-cacb-481d-bd92-a3d801f105b9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ad5cc248-428b-46a2-9200-e011d9c03e46" xlink:to="loc_srt_RangeAxis_f8b43ca5-cacb-481d-bd92-a3d801f105b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a07f18b-23d3-4d7a-9914-696bff912766" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f8b43ca5-cacb-481d-bd92-a3d801f105b9" xlink:to="loc_srt_RangeMember_5a07f18b-23d3-4d7a-9914-696bff912766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8b6fd4ec-5a34-4f3e-8c6b-ccdb2117bb75" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5a07f18b-23d3-4d7a-9914-696bff912766" xlink:to="loc_srt_MinimumMember_8b6fd4ec-5a34-4f3e-8c6b-ccdb2117bb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4f137271-7c5f-4dce-aa03-4cf6b8c906a3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5a07f18b-23d3-4d7a-9914-696bff912766" xlink:to="loc_srt_MaximumMember_4f137271-7c5f-4dce-aa03-4cf6b8c906a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_110a2bcd-88b8-4b9c-9375-5f903f5230e9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ad5cc248-428b-46a2-9200-e011d9c03e46" xlink:to="loc_srt_StatementScenarioAxis_110a2bcd-88b8-4b9c-9375-5f903f5230e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bb1c64e7-46c8-404e-8404-f63f01f2dec2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_110a2bcd-88b8-4b9c-9375-5f903f5230e9" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bb1c64e7-46c8-404e-8404-f63f01f2dec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_a79fa5fc-c850-43f2-8b96-90d4dcc7b1ec" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_bb1c64e7-46c8-404e-8404-f63f01f2dec2" xlink:to="loc_srt_ScenarioForecastMember_a79fa5fc-c850-43f2-8b96-90d4dcc7b1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ad5cc248-428b-46a2-9200-e011d9c03e46" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ProceedsFromRoyaltyFinancing_abcd8085-62d4-4b80-8324-3fafdf725347" xlink:href="insm-20240630.xsd#insm_ProceedsFromRoyaltyFinancing"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_insm_ProceedsFromRoyaltyFinancing_abcd8085-62d4-4b80-8324-3fafdf725347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentRoyaltyStatedPercentage_a2a0ab1c-ca6d-4267-86da-015c2533b046" xlink:href="insm-20240630.xsd#insm_DebtInstrumentRoyaltyStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_insm_DebtInstrumentRoyaltyStatedPercentage_a2a0ab1c-ca6d-4267-86da-015c2533b046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_95eab147-d60e-48ab-946c-34ec5611169f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_95eab147-d60e-48ab-946c-34ec5611169f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_0cfbf8a6-beaf-447e-b12c-678455782897" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_0cfbf8a6-beaf-447e-b12c-678455782897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentRoyaltyPayableMaximum_ba7063ba-7a4d-4361-8205-5db959dfa920" xlink:href="insm-20240630.xsd#insm_DebtInstrumentRoyaltyPayableMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_insm_DebtInstrumentRoyaltyPayableMaximum_ba7063ba-7a4d-4361-8205-5db959dfa920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_c0e93287-f1e0-4fe4-8e41-f2cd194d83ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_c0e93287-f1e0-4fe4-8e41-f2cd194d83ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ProceedsFromRoyaltyFinancingAgreementNet_9a9b4a07-d399-41e7-abfe-d799bc4a0efc" xlink:href="insm-20240630.xsd#insm_ProceedsFromRoyaltyFinancingAgreementNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_insm_ProceedsFromRoyaltyFinancingAgreementNet_9a9b4a07-d399-41e7-abfe-d799bc4a0efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6b10293f-bba9-46e6-8f70-d7ab294a105e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6b10293f-bba9-46e6-8f70-d7ab294a105e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_356e1e35-5e18-4802-ab2b-19e18035cd44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c58561b9-14ce-4b70-8713-358b7565e6b3" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_356e1e35-5e18-4802-ab2b-19e18035cd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_abbce1be-7f6e-4c12-ae61-5ef87ca4f9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b8f212f0-faa8-4f01-901d-a6036cfac9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_abbce1be-7f6e-4c12-ae61-5ef87ca4f9b8" xlink:to="loc_us-gaap_DebtInstrumentTable_b8f212f0-faa8-4f01-901d-a6036cfac9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c57e17b3-8fbc-419a-8eac-1143a05ec316" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b8f212f0-faa8-4f01-901d-a6036cfac9f1" xlink:to="loc_us-gaap_CreditFacilityAxis_c57e17b3-8fbc-419a-8eac-1143a05ec316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ffa231d4-d919-4200-82f1-6b92b9bf797d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_c57e17b3-8fbc-419a-8eac-1143a05ec316" xlink:to="loc_us-gaap_CreditFacilityDomain_ffa231d4-d919-4200-82f1-6b92b9bf797d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_3963b636-488e-45b6-ae03-71cb075c0f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_ffa231d4-d919-4200-82f1-6b92b9bf797d" xlink:to="loc_us-gaap_SecuredDebtMember_3963b636-488e-45b6-ae03-71cb075c0f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3938653c-c21a-4b51-9629-c4afabcf8f51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b8f212f0-faa8-4f01-901d-a6036cfac9f1" xlink:to="loc_us-gaap_DebtInstrumentAxis_3938653c-c21a-4b51-9629-c4afabcf8f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_09f8c5b9-933a-4a3b-95f5-72d7bff01e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3938653c-c21a-4b51-9629-c4afabcf8f51" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_09f8c5b9-933a-4a3b-95f5-72d7bff01e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember_48a935cd-970a-41c6-9aa1-4fc09f875d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_09f8c5b9-933a-4a3b-95f5-72d7bff01e6b" xlink:to="loc_us-gaap_RoyaltyAgreementsMember_48a935cd-970a-41c6-9aa1-4fc09f875d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a4218046-add1-49cf-9f31-f5fb23f44623" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b8f212f0-faa8-4f01-901d-a6036cfac9f1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a4218046-add1-49cf-9f31-f5fb23f44623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:href="insm-20240630.xsd#insm_RoyaltyFinancingAgreementRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a4218046-add1-49cf-9f31-f5fb23f44623" xlink:to="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_58a33f47-2825-4914-8be7-4080560ab50b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_58a33f47-2825-4914-8be7-4080560ab50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_34ebfb06-5253-4af2-9a5a-c828ce166c60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:to="loc_us-gaap_PaymentsForRoyalties_34ebfb06-5253-4af2-9a5a-c828ce166c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_7939a87e-7fee-4c91-abce-18b86f9cb0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:to="loc_us-gaap_InterestExpenseDebt_7939a87e-7fee-4c91-abce-18b86f9cb0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_7c889cd4-5c71-452e-9425-b62f1c8f620b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_7c889cd4-5c71-452e-9425-b62f1c8f620b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_22a4b6fa-edbd-4c9b-b679-457759bd3a96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_22a4b6fa-edbd-4c9b-b679-457759bd3a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_be6c1565-0238-4fc7-b815-265385737136" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_be6c1565-0238-4fc7-b815-265385737136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtIssuanceCostsOther_a6a1432f-e308-4055-abe4-706e874df87d" xlink:href="insm-20240630.xsd#insm_DebtIssuanceCostsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:to="loc_insm_DebtIssuanceCostsOther_a6a1432f-e308-4055-abe4-706e874df87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_5f9b1587-2909-4955-b763-e4c00a02362a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_5f9b1587-2909-4955-b763-e4c00a02362a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_1689d570-9bb2-4d8a-a553-884bab0bb57b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_RoyaltyFinancingAgreementRollForward_1819a752-052c-4949-adfb-937b719aed35" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_1689d570-9bb2-4d8a-a553-884bab0bb57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#ShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7936fb5e-13be-4e76-a644-1dd062594638" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_51d9b9d6-27c0-4620-862f-d4321f33d4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7936fb5e-13be-4e76-a644-1dd062594638" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_51d9b9d6-27c0-4620-862f-d4321f33d4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bd78e5f4-e7f0-4c09-82d6-c6f16ad50a77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51d9b9d6-27c0-4620-862f-d4321f33d4d8" xlink:to="loc_us-gaap_AwardTypeAxis_bd78e5f4-e7f0-4c09-82d6-c6f16ad50a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe207717-6b6d-4186-a502-b5b887f03794" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bd78e5f4-e7f0-4c09-82d6-c6f16ad50a77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe207717-6b6d-4186-a502-b5b887f03794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6ea4d208-a659-452a-9fb7-1d7cae2ca8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe207717-6b6d-4186-a502-b5b887f03794" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6ea4d208-a659-452a-9fb7-1d7cae2ca8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e5583a98-fcee-41cf-991e-076c55cfceed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe207717-6b6d-4186-a502-b5b887f03794" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e5583a98-fcee-41cf-991e-076c55cfceed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_8916051c-a019-4b38-8a17-82d1df635fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe207717-6b6d-4186-a502-b5b887f03794" xlink:to="loc_us-gaap_PerformanceSharesMember_8916051c-a019-4b38-8a17-82d1df635fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fa5fb8f8-6d34-4f9d-8c02-5b234fdce21a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51d9b9d6-27c0-4620-862f-d4321f33d4d8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fa5fb8f8-6d34-4f9d-8c02-5b234fdce21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fa592b94-e245-45ea-b2ef-5983186069f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fa5fb8f8-6d34-4f9d-8c02-5b234fdce21a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fa592b94-e245-45ea-b2ef-5983186069f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_845987eb-0b41-42ec-ab13-3a491ca14ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_fa592b94-e245-45ea-b2ef-5983186069f7" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_845987eb-0b41-42ec-ab13-3a491ca14ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4f259020-92fc-456a-9411-15abf61ee9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51d9b9d6-27c0-4620-862f-d4321f33d4d8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4f259020-92fc-456a-9411-15abf61ee9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b00945cd-40df-4c79-b21b-6af6db06c9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4f259020-92fc-456a-9411-15abf61ee9a2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b00945cd-40df-4c79-b21b-6af6db06c9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncMember_7c754e6f-ad3b-427a-b97d-41c8c0649be1" xlink:href="insm-20240630.xsd#insm_MotusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b00945cd-40df-4c79-b21b-6af6db06c9d5" xlink:to="loc_insm_MotusBiosciencesIncMember_7c754e6f-ad3b-427a-b97d-41c8c0649be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AdrestiaTherapeuticsLtdMember_4ee687a5-7f57-4652-8d14-0b1755d637f4" xlink:href="insm-20240630.xsd#insm_AdrestiaTherapeuticsLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b00945cd-40df-4c79-b21b-6af6db06c9d5" xlink:to="loc_insm_AdrestiaTherapeuticsLtdMember_4ee687a5-7f57-4652-8d14-0b1755d637f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_VertuisBioIncMember_a0f096c2-387b-4edf-b94e-3057964e9bf1" xlink:href="insm-20240630.xsd#insm_VertuisBioIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b00945cd-40df-4c79-b21b-6af6db06c9d5" xlink:to="loc_insm_VertuisBioIncMember_a0f096c2-387b-4edf-b94e-3057964e9bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_913b10a9-c7de-4c89-899d-40c94d5699a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51d9b9d6-27c0-4620-862f-d4321f33d4d8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_913b10a9-c7de-4c89-899d-40c94d5699a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3ee36f30-88da-4ec3-9d93-3704432e3966" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_913b10a9-c7de-4c89-899d-40c94d5699a2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3ee36f30-88da-4ec3-9d93-3704432e3966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PublicStockOfferingMember_e9b461e9-ece0-470a-888c-1a5ec6db3172" xlink:href="insm-20240630.xsd#insm_PublicStockOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3ee36f30-88da-4ec3-9d93-3704432e3966" xlink:to="loc_insm_PublicStockOfferingMember_e9b461e9-ece0-470a-888c-1a5ec6db3172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AtTheMarketAgreementMember_abb48e92-77f5-4a17-9208-84b7e514f9bc" xlink:href="insm-20240630.xsd#insm_AtTheMarketAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3ee36f30-88da-4ec3-9d93-3704432e3966" xlink:to="loc_insm_AtTheMarketAgreementMember_abb48e92-77f5-4a17-9208-84b7e514f9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_a36b827a-9044-4944-b328-7958c3e6389b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3ee36f30-88da-4ec3-9d93-3704432e3966" xlink:to="loc_us-gaap_OverAllotmentOptionMember_a36b827a-9044-4944-b328-7958c3e6389b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_51d9b9d6-27c0-4620-862f-d4321f33d4d8" xlink:to="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8e01c7d4-1a9d-4128-87b6-e78de9a7ab58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8e01c7d4-1a9d-4128-87b6-e78de9a7ab58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f66b9667-158f-48b3-a2bf-327fac98eed4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f66b9667-158f-48b3-a2bf-327fac98eed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5a413689-8ba0-4c6c-a79c-84bba097c5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_CommonStockSharesIssued_5a413689-8ba0-4c6c-a79c-84bba097c5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1157ef2c-e74b-4ccc-ae8b-14033d752501" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1157ef2c-e74b-4ccc-ae8b-14033d752501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e3fe8eb2-efbb-4b69-b9ab-eab5b52d1668" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e3fe8eb2-efbb-4b69-b9ab-eab5b52d1668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_21ec87f7-48a2-452a-a94a-97dd6e4c1718" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_21ec87f7-48a2-452a-a94a-97dd6e4c1718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_16f7980e-de74-4c3e-8752-da4937ad184a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_16f7980e-de74-4c3e-8752-da4937ad184a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7cfeb04b-10d4-40ce-8a3b-a4b767757260" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7cfeb04b-10d4-40ce-8a3b-a4b767757260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_6f59240e-a889-42b2-af27-9f1db4355223" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_6f59240e-a889-42b2-af27-9f1db4355223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_8e89049b-cb97-4d68-841f-bd85a5385c18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_8e89049b-cb97-4d68-841f-bd85a5385c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_86d11532-ec91-4d70-ad2d-4edf0099889d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_86d11532-ec91-4d70-ad2d-4edf0099889d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CommonStockAuthorizedAggregateGrossSalesProceeds_cf70bd9f-1f98-4b6b-b7ce-b1163a3e29c1" xlink:href="insm-20240630.xsd#insm_CommonStockAuthorizedAggregateGrossSalesProceeds"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_insm_CommonStockAuthorizedAggregateGrossSalesProceeds_cf70bd9f-1f98-4b6b-b7ce-b1163a3e29c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6beeca01-a658-4092-9861-bc25bcbc8dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6beeca01-a658-4092-9861-bc25bcbc8dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_20cd7803-c865-4823-9a54-9b4efe44c222" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_20cd7803-c865-4823-9a54-9b4efe44c222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f60e0b2c-226a-4c99-b888-20e021e41777" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f60e0b2c-226a-4c99-b888-20e021e41777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3ea47697-b3c1-40bd-bd72-5ba0321c58de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6903d6bf-94f2-4910-bbba-02ff7414f360" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3ea47697-b3c1-40bd-bd72-5ba0321c58de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1de05009-d62b-4aae-859e-1c4b414442b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c58010b9-44a6-4a0d-9bc8-442123223d64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1de05009-d62b-4aae-859e-1c4b414442b7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c58010b9-44a6-4a0d-9bc8-442123223d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d95cbb9d-1e60-4298-8770-cdf684d936e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c58010b9-44a6-4a0d-9bc8-442123223d64" xlink:to="loc_us-gaap_PlanNameAxis_d95cbb9d-1e60-4298-8770-cdf684d936e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cc60804e-7edd-4e57-82d5-2776a0aaf5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d95cbb9d-1e60-4298-8770-cdf684d936e2" xlink:to="loc_us-gaap_PlanNameDomain_cc60804e-7edd-4e57-82d5-2776a0aaf5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2019IncentivePlanMember_3f03c446-0f24-435c-9259-269ebeb6119c" xlink:href="insm-20240630.xsd#insm_A2019IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cc60804e-7edd-4e57-82d5-2776a0aaf5f4" xlink:to="loc_insm_A2019IncentivePlanMember_3f03c446-0f24-435c-9259-269ebeb6119c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2019IncentivePlanThirdAmendmentMember_3d7e5c00-e172-423a-af8d-f6d6386e8e04" xlink:href="insm-20240630.xsd#insm_A2019IncentivePlanThirdAmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cc60804e-7edd-4e57-82d5-2776a0aaf5f4" xlink:to="loc_insm_A2019IncentivePlanThirdAmendmentMember_3d7e5c00-e172-423a-af8d-f6d6386e8e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EmployeeStockPurchasePlan2018Member_93fc3ea7-a030-4b66-b9eb-9b7fbf0bfd3e" xlink:href="insm-20240630.xsd#insm_EmployeeStockPurchasePlan2018Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cc60804e-7edd-4e57-82d5-2776a0aaf5f4" xlink:to="loc_insm_EmployeeStockPurchasePlan2018Member_93fc3ea7-a030-4b66-b9eb-9b7fbf0bfd3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_80486006-08a2-4bb5-8f70-a102e4bc620b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c58010b9-44a6-4a0d-9bc8-442123223d64" xlink:to="loc_us-gaap_AwardTypeAxis_80486006-08a2-4bb5-8f70-a102e4bc620b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9fd59c1-fc59-4b7e-a5dc-f7f31fbeb021" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_80486006-08a2-4bb5-8f70-a102e4bc620b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9fd59c1-fc59-4b7e-a5dc-f7f31fbeb021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_252677e4-8989-47a6-ab91-99308d5a15ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9fd59c1-fc59-4b7e-a5dc-f7f31fbeb021" xlink:to="loc_us-gaap_EmployeeStockOptionMember_252677e4-8989-47a6-ab91-99308d5a15ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_57618cb4-fe80-4b79-9dbf-a6e6612e11f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9fd59c1-fc59-4b7e-a5dc-f7f31fbeb021" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_57618cb4-fe80-4b79-9dbf-a6e6612e11f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_01e0c350-9c96-4a0f-b612-c07302f9c7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9fd59c1-fc59-4b7e-a5dc-f7f31fbeb021" xlink:to="loc_us-gaap_PerformanceSharesMember_01e0c350-9c96-4a0f-b612-c07302f9c7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b50ec1ad-46fc-4fa9-8072-525c247aebb6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c58010b9-44a6-4a0d-9bc8-442123223d64" xlink:to="loc_srt_RangeAxis_b50ec1ad-46fc-4fa9-8072-525c247aebb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_845763f2-e994-4dc6-866d-1fac67b3b64d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b50ec1ad-46fc-4fa9-8072-525c247aebb6" xlink:to="loc_srt_RangeMember_845763f2-e994-4dc6-866d-1fac67b3b64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_44d6ddb7-de66-4d7c-b4ad-569201466fa3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_845763f2-e994-4dc6-866d-1fac67b3b64d" xlink:to="loc_srt_MinimumMember_44d6ddb7-de66-4d7c-b4ad-569201466fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7fb59bb5-380a-42d5-bdee-6d2058703ea4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_845763f2-e994-4dc6-866d-1fac67b3b64d" xlink:to="loc_srt_MaximumMember_7fb59bb5-380a-42d5-bdee-6d2058703ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c58010b9-44a6-4a0d-9bc8-442123223d64" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_13ce6276-6e0b-4795-b5d3-70560909be73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_13ce6276-6e0b-4795-b5d3-70560909be73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ea261d53-1cd2-4040-9897-a5fed38fe029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ea261d53-1cd2-4040-9897-a5fed38fe029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_3623a9fe-8fe7-4fff-98e0-b1eea7d5a100" xlink:href="insm-20240630.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_3623a9fe-8fe7-4fff-98e0-b1eea7d5a100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b6febf69-93c4-4d17-9ca6-397c37acd2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b6febf69-93c4-4d17-9ca6-397c37acd2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_d75a34a0-3a0b-469b-9190-027da29c7ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_d75a34a0-3a0b-469b-9190-027da29c7ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_eadd4aef-e46d-4aef-b214-78aaeef92792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_eadd4aef-e46d-4aef-b214-78aaeef92792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_db4057b1-b2cb-426c-9406-936ec4ad35dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_db4057b1-b2cb-426c-9406-936ec4ad35dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b8dff16f-0d49-4f1e-b574-bbe5edb7a2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b8dff16f-0d49-4f1e-b574-bbe5edb7a2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2460ba75-406e-4ae3-8cb0-e9cc8f3e1f75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2460ba75-406e-4ae3-8cb0-e9cc8f3e1f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d3b2e46f-7f23-46bb-b393-5f5c9ff0a1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d3b2e46f-7f23-46bb-b393-5f5c9ff0a1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2ad620f9-38a9-4ce1-9510-4483cd2ac4da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_2ad620f9-38a9-4ce1-9510-4483cd2ac4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_03292309-e192-4b62-9b55-2696eceb6789" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0687efd6-1b8b-4b15-a334-e9751543a7c3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_03292309-e192-4b62-9b55-2696eceb6789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53642789-9a83-48d0-8949-83033d6c0d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec1aeff2-a0fb-4a09-a3a5-46f410fcc515" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_53642789-9a83-48d0-8949-83033d6c0d6a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec1aeff2-a0fb-4a09-a3a5-46f410fcc515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d241290c-4e13-4fbc-80a1-7ede79e5aa69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec1aeff2-a0fb-4a09-a3a5-46f410fcc515" xlink:to="loc_us-gaap_AwardTypeAxis_d241290c-4e13-4fbc-80a1-7ede79e5aa69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fa06787-0cff-4866-afc2-984de89376df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d241290c-4e13-4fbc-80a1-7ede79e5aa69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fa06787-0cff-4866-afc2-984de89376df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_StockOptionsAndRestrictedStockUnitsMember_901db12b-6628-4621-805f-e0a2c4128582" xlink:href="insm-20240630.xsd#insm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fa06787-0cff-4866-afc2-984de89376df" xlink:to="loc_insm_StockOptionsAndRestrictedStockUnitsMember_901db12b-6628-4621-805f-e0a2c4128582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bee6ad8a-9a3e-4d42-b985-d34d41fac990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec1aeff2-a0fb-4a09-a3a5-46f410fcc515" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bee6ad8a-9a3e-4d42-b985-d34d41fac990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8a3b544f-5f8a-44c5-87f1-4c6344b3ebce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bee6ad8a-9a3e-4d42-b985-d34d41fac990" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8a3b544f-5f8a-44c5-87f1-4c6344b3ebce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1ea1af6b-0573-4b31-a5cf-120125a569b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8a3b544f-5f8a-44c5-87f1-4c6344b3ebce" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1ea1af6b-0573-4b31-a5cf-120125a569b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e65f35fa-b300-4014-a02e-f05d9c5f43c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8a3b544f-5f8a-44c5-87f1-4c6344b3ebce" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_e65f35fa-b300-4014-a02e-f05d9c5f43c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd04c11b-a23f-4fba-ae39-05fa29ca75f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ec1aeff2-a0fb-4a09-a3a5-46f410fcc515" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd04c11b-a23f-4fba-ae39-05fa29ca75f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_cdbbc3f4-c9b5-452e-bf5d-293184b1b938" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd04c11b-a23f-4fba-ae39-05fa29ca75f2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_cdbbc3f4-c9b5-452e-bf5d-293184b1b938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_466ea5bd-3981-45d5-a0b8-4deff69bdb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_21141211-358a-4c0d-9158-ef3c108fce19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_466ea5bd-3981-45d5-a0b8-4deff69bdb6b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_21141211-358a-4c0d-9158-ef3c108fce19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_47dc922e-e9ba-4cdf-90f4-4bc445290ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_466ea5bd-3981-45d5-a0b8-4deff69bdb6b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_47dc922e-e9ba-4cdf-90f4-4bc445290ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4a9658a1-bb2d-4b25-ae28-4892fd1db47e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_466ea5bd-3981-45d5-a0b8-4deff69bdb6b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4a9658a1-bb2d-4b25-ae28-4892fd1db47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1c16406b-b534-49ed-821a-3fc7271bcff8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b8e729fe-ada5-4bd7-9b85-d46e12eb6cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1c16406b-b534-49ed-821a-3fc7271bcff8" xlink:to="loc_us-gaap_OperatingLeaseCost_b8e729fe-ada5-4bd7-9b85-d46e12eb6cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_52b32250-765f-4ae6-830b-74afabfe31e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7def9dc-1637-41e1-98eb-d28f8020aed4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_52b32250-765f-4ae6-830b-74afabfe31e8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7def9dc-1637-41e1-98eb-d28f8020aed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_5759e2e0-fd92-4613-aa74-384d29c2d8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7def9dc-1637-41e1-98eb-d28f8020aed4" xlink:to="loc_us-gaap_AssetAcquisitionAxis_5759e2e0-fd92-4613-aa74-384d29c2d8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_76317e2c-0959-482b-a6d4-13dbf1c557c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_5759e2e0-fd92-4613-aa74-384d29c2d8b7" xlink:to="loc_us-gaap_AssetAcquisitionDomain_76317e2c-0959-482b-a6d4-13dbf1c557c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AdrestiaTherapeuticsLtdMember_af26597f-bdb1-4505-9482-8a57b1d4b27b" xlink:href="insm-20240630.xsd#insm_AdrestiaTherapeuticsLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_76317e2c-0959-482b-a6d4-13dbf1c557c2" xlink:to="loc_insm_AdrestiaTherapeuticsLtdMember_af26597f-bdb1-4505-9482-8a57b1d4b27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_VertuisBioIncMember_bc9a8841-e6f0-46f0-a156-8ff2f73ce795" xlink:href="insm-20240630.xsd#insm_VertuisBioIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_76317e2c-0959-482b-a6d4-13dbf1c557c2" xlink:to="loc_insm_VertuisBioIncMember_bc9a8841-e6f0-46f0-a156-8ff2f73ce795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_TriggeringEventAxis_d193ef08-6078-45d9-b29d-e74d98a99608" xlink:href="insm-20240630.xsd#insm_TriggeringEventAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7def9dc-1637-41e1-98eb-d28f8020aed4" xlink:to="loc_insm_TriggeringEventAxis_d193ef08-6078-45d9-b29d-e74d98a99608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_TriggeringEventDomain_94871098-1c9c-41e0-8c31-6a6a36589ac4" xlink:href="insm-20240630.xsd#insm_TriggeringEventDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_TriggeringEventAxis_d193ef08-6078-45d9-b29d-e74d98a99608" xlink:to="loc_insm_TriggeringEventDomain_94871098-1c9c-41e0-8c31-6a6a36589ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestoneEvent1Member_b0456ce1-2e3b-4871-858c-2eeb987759ec" xlink:href="insm-20240630.xsd#insm_MilestoneEvent1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_TriggeringEventDomain_94871098-1c9c-41e0-8c31-6a6a36589ac4" xlink:to="loc_insm_MilestoneEvent1Member_b0456ce1-2e3b-4871-858c-2eeb987759ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestoneEvent2Member_753429d4-41fe-494e-998f-d2a071f8bd1d" xlink:href="insm-20240630.xsd#insm_MilestoneEvent2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_TriggeringEventDomain_94871098-1c9c-41e0-8c31-6a6a36589ac4" xlink:to="loc_insm_MilestoneEvent2Member_753429d4-41fe-494e-998f-d2a071f8bd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_caf79f89-700a-4966-8fc6-8aaf1beedf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7def9dc-1637-41e1-98eb-d28f8020aed4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_caf79f89-700a-4966-8fc6-8aaf1beedf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3dde47e8-3fc9-4bb1-95bc-57f6a13d71f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_caf79f89-700a-4966-8fc6-8aaf1beedf8a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3dde47e8-3fc9-4bb1-95bc-57f6a13d71f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember_7871e191-eaad-4cde-a6a1-c3ac49f64d0b" xlink:href="insm-20240630.xsd#insm_MotusBiosciencesIncAndAlgaeneXIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3dde47e8-3fc9-4bb1-95bc-57f6a13d71f6" xlink:to="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember_7871e191-eaad-4cde-a6a1-c3ac49f64d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MotusBiosciencesIncMember_4b54cfb9-0767-473b-9f0c-a1c291f8587f" xlink:href="insm-20240630.xsd#insm_MotusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember_7871e191-eaad-4cde-a6a1-c3ac49f64d0b" xlink:to="loc_insm_MotusBiosciencesIncMember_4b54cfb9-0767-473b-9f0c-a1c291f8587f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AlgaeneXIncMember_da7ce1e2-e1e9-416c-834e-f1e8cf152671" xlink:href="insm-20240630.xsd#insm_AlgaeneXIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_MotusBiosciencesIncAndAlgaeneXIncMember_7871e191-eaad-4cde-a6a1-c3ac49f64d0b" xlink:to="loc_insm_AlgaeneXIncMember_da7ce1e2-e1e9-416c-834e-f1e8cf152671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_102f6e11-a598-4b80-a1a9-063bcd30b5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7def9dc-1637-41e1-98eb-d28f8020aed4" xlink:to="loc_us-gaap_VestingAxis_102f6e11-a598-4b80-a1a9-063bcd30b5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_74998a61-78d2-418b-9468-d298208a89ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_102f6e11-a598-4b80-a1a9-063bcd30b5e1" xlink:to="loc_us-gaap_VestingDomain_74998a61-78d2-418b-9468-d298208a89ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3530f994-50ba-4b05-979d-443f35ffda3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_74998a61-78d2-418b-9468-d298208a89ab" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3530f994-50ba-4b05-979d-443f35ffda3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_57c8a12a-974d-49c8-b6d1-ee2831afbf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_74998a61-78d2-418b-9468-d298208a89ab" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_57c8a12a-974d-49c8-b6d1-ee2831afbf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_5103be6a-8e94-4517-baf3-24023acba6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_74998a61-78d2-418b-9468-d298208a89ab" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_5103be6a-8e94-4517-baf3-24023acba6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_dc8e5d08-142c-4224-a7b7-fefffddb07ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7def9dc-1637-41e1-98eb-d28f8020aed4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_dc8e5d08-142c-4224-a7b7-fefffddb07ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_13c409a7-4ed3-40dc-aef3-825952a97840" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_dc8e5d08-142c-4224-a7b7-fefffddb07ab" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_13c409a7-4ed3-40dc-aef3-825952a97840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_903edcda-149e-4b45-9a2e-cce67894c110" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_13c409a7-4ed3-40dc-aef3-825952a97840" xlink:to="loc_us-gaap_SubsequentEventMember_903edcda-149e-4b45-9a2e-cce67894c110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d7def9dc-1637-41e1-98eb-d28f8020aed4" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1878cf4f-59ab-4c30-807d-940ad0cfae5f" xlink:href="insm-20240630.xsd#insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_1878cf4f-59ab-4c30-807d-940ad0cfae5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_70b7778f-cb68-486a-acc5-ed26a617fd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_SharePrice_70b7778f-cb68-486a-acc5-ed26a617fd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_ec360ae3-9c57-43cd-993c-2dce59ae86d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_ec360ae3-9c57-43cd-993c-2dce59ae86d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_c088874d-7d84-4d19-8e77-61b618fc0f29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_c088874d-7d84-4d19-8e77-61b618fc0f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_835e698f-1b7e-4221-8997-5675c6552a33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_835e698f-1b7e-4221-8997-5675c6552a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_056e4bb6-5eef-47e5-a45d-ed2d33e9138c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_056e4bb6-5eef-47e5-a45d-ed2d33e9138c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_76bbf84e-e2d9-451b-b19b-932bd47ba079" xlink:href="insm-20240630.xsd#insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares_76bbf84e-e2d9-451b-b19b-932bd47ba079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_edb82742-890a-4638-a2f4-f09bbfed488d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_edb82742-890a-4638-a2f4-f09bbfed488d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_54d326ff-9b38-4fa5-9486-a273506f9372" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_54d326ff-9b38-4fa5-9486-a273506f9372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_f19c738b-a502-414e-b0a3-559c89f1bc04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_f19c738b-a502-414e-b0a3-559c89f1bc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BusinessAcquisitionConsecutiveTradingDayPeriod_f7e4c8dc-3b16-4ed8-aba9-2dc17a7980d5" xlink:href="insm-20240630.xsd#insm_BusinessAcquisitionConsecutiveTradingDayPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_insm_BusinessAcquisitionConsecutiveTradingDayPeriod_f7e4c8dc-3b16-4ed8-aba9-2dc17a7980d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_93a88dce-9a47-4b62-a7a5-ab1b830ea00b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_36cc1112-adb2-44b4-9364-8eb480c4cd74" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_93a88dce-9a47-4b62-a7a5-ab1b830ea00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#AcquisitionsScheduleofPurchasePriceDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_adfa1a9c-6a25-4c4b-bc01-e4a22c2db344" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6bdf1e06-6693-40d6-9927-1aabfc64462f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_adfa1a9c-6a25-4c4b-bc01-e4a22c2db344" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6bdf1e06-6693-40d6-9927-1aabfc64462f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_e357906c-2f7e-40a8-bedc-ed3c0b38ecdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6bdf1e06-6693-40d6-9927-1aabfc64462f" xlink:to="loc_us-gaap_AssetAcquisitionAxis_e357906c-2f7e-40a8-bedc-ed3c0b38ecdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_602599f6-94c4-4efd-9bcd-3b4eaf3766f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_e357906c-2f7e-40a8-bedc-ed3c0b38ecdd" xlink:to="loc_us-gaap_AssetAcquisitionDomain_602599f6-94c4-4efd-9bcd-3b4eaf3766f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_VertuisBioIncMember_03fa4271-6a91-4edf-ae62-dcde77fe4fc3" xlink:href="insm-20240630.xsd#insm_VertuisBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_602599f6-94c4-4efd-9bcd-3b4eaf3766f1" xlink:to="loc_insm_VertuisBioIncMember_03fa4271-6a91-4edf-ae62-dcde77fe4fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_17280f25-870d-4f81-88b9-1c000a58ca24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_6bdf1e06-6693-40d6-9927-1aabfc64462f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_17280f25-870d-4f81-88b9-1c000a58ca24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_599a7ee4-c920-4e2c-87b6-cfcbe6298118" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17280f25-870d-4f81-88b9-1c000a58ca24" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_599a7ee4-c920-4e2c-87b6-cfcbe6298118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_9522340f-5e95-41cd-8f89-558fb28e3c65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17280f25-870d-4f81-88b9-1c000a58ca24" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_9522340f-5e95-41cd-8f89-558fb28e3c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_bb580c39-26a5-481c-be6d-b462ecb24108" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17280f25-870d-4f81-88b9-1c000a58ca24" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_bb580c39-26a5-481c-be6d-b462ecb24108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="insm-20240630.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_7fbe1038-6e4e-4dfb-898f-9686cadda71e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_0fa8926c-762f-4527-b87e-78bfb854bbd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_7fbe1038-6e4e-4dfb-898f-9686cadda71e" xlink:to="loc_us-gaap_SubsequentEventTable_0fa8926c-762f-4527-b87e-78bfb854bbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_25a50b2c-83e0-4bd0-8e3a-1f8208fe358a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0fa8926c-762f-4527-b87e-78bfb854bbd3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_25a50b2c-83e0-4bd0-8e3a-1f8208fe358a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_66c4d3a6-e3d0-4158-823f-c2a7a8a9d196" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_25a50b2c-83e0-4bd0-8e3a-1f8208fe358a" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_66c4d3a6-e3d0-4158-823f-c2a7a8a9d196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_79086a50-19aa-49c0-80c8-28e9ffffb54d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_66c4d3a6-e3d0-4158-823f-c2a7a8a9d196" xlink:to="loc_us-gaap_SubsequentEventMember_79086a50-19aa-49c0-80c8-28e9ffffb54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d23ea7b3-0f4a-4988-be83-b755d61555b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0fa8926c-762f-4527-b87e-78bfb854bbd3" xlink:to="loc_us-gaap_DebtInstrumentAxis_d23ea7b3-0f4a-4988-be83-b755d61555b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3444f060-33d3-47ed-99d2-6caf98444387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d23ea7b3-0f4a-4988-be83-b755d61555b9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3444f060-33d3-47ed-99d2-6caf98444387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2025ConvertibleNotesMember_d656ca9b-1d94-40b8-859f-55cda201b328" xlink:href="insm-20240630.xsd#insm_A2025ConvertibleNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3444f060-33d3-47ed-99d2-6caf98444387" xlink:to="loc_insm_A2025ConvertibleNotesMember_d656ca9b-1d94-40b8-859f-55cda201b328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2028ConvertibleNotesMember_4c01e62e-8bde-40ae-8a33-2a63abb615c0" xlink:href="insm-20240630.xsd#insm_A2028ConvertibleNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3444f060-33d3-47ed-99d2-6caf98444387" xlink:to="loc_insm_A2028ConvertibleNotesMember_4c01e62e-8bde-40ae-8a33-2a63abb615c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a13af623-d005-4d25-b8c6-4730082f620f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0fa8926c-762f-4527-b87e-78bfb854bbd3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a13af623-d005-4d25-b8c6-4730082f620f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_819f9c19-9176-4625-bae2-08efe7d9fe90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a13af623-d005-4d25-b8c6-4730082f620f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_819f9c19-9176-4625-bae2-08efe7d9fe90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_461f068f-4fc6-4cd8-9e61-5b79b10432c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_819f9c19-9176-4625-bae2-08efe7d9fe90" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_461f068f-4fc6-4cd8-9e61-5b79b10432c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_6800dae0-d08c-47df-a46b-c7974e9478f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0fa8926c-762f-4527-b87e-78bfb854bbd3" xlink:to="loc_us-gaap_AssetAcquisitionAxis_6800dae0-d08c-47df-a46b-c7974e9478f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_0162a48b-14cf-4855-89b9-3510622ef37c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_6800dae0-d08c-47df-a46b-c7974e9478f0" xlink:to="loc_us-gaap_AssetAcquisitionDomain_0162a48b-14cf-4855-89b9-3510622ef37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_VertuisBioIncMember_59c7e37c-1c9e-4f27-b9c5-7171a6ed5e19" xlink:href="insm-20240630.xsd#insm_VertuisBioIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_0162a48b-14cf-4855-89b9-3510622ef37c" xlink:to="loc_insm_VertuisBioIncMember_59c7e37c-1c9e-4f27-b9c5-7171a6ed5e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_7e240d89-449f-4321-88e7-82367f382ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0fa8926c-762f-4527-b87e-78bfb854bbd3" xlink:to="loc_us-gaap_SubsequentEventLineItems_7e240d89-449f-4321-88e7-82367f382ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_9f6ecd65-4965-4f0f-84c2-877fb67e94ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7e240d89-449f-4321-88e7-82367f382ae3" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_9f6ecd65-4965-4f0f-84c2-877fb67e94ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_c5508656-1fce-436d-9b37-ecedd9fce21d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7e240d89-449f-4321-88e7-82367f382ae3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_c5508656-1fce-436d-9b37-ecedd9fce21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d41563b8-e7e8-4a4a-ad66-72717a1ce3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7e240d89-449f-4321-88e7-82367f382ae3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_d41563b8-e7e8-4a4a-ad66-72717a1ce3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_e6c9fc4d-2570-4685-a9c6-472433ed987e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7e240d89-449f-4321-88e7-82367f382ae3" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_e6c9fc4d-2570-4685-a9c6-472433ed987e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_a77c69af-cbff-45ca-a186-6984efaaf497" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7e240d89-449f-4321-88e7-82367f382ae3" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_a77c69af-cbff-45ca-a186-6984efaaf497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_3c1acab0-b4e4-41eb-a3e3-d977c74a8e93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7e240d89-449f-4321-88e7-82367f382ae3" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_3c1acab0-b4e4-41eb-a3e3-d977c74a8e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_a29fc3d0-3475-42ed-b522-107f4b95f9bd" xlink:href="insm-20240630.xsd#insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7e240d89-449f-4321-88e7-82367f382ae3" xlink:to="loc_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_a29fc3d0-3475-42ed-b522-107f4b95f9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:href="insm-20240630.xsd#insm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_S.NicoleSchaefferMember" xlink:href="insm-20240630.xsd#insm_S.NicoleSchaefferMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_insm_S.NicoleSchaefferMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_S.NicoleSchaeffer2Member" xlink:href="insm-20240630.xsd#insm_S.NicoleSchaeffer2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_insm_S.NicoleSchaeffer2Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MartinaFlammerMember" xlink:href="insm-20240630.xsd#insm_MartinaFlammerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_insm_MartinaFlammerMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MichaelSmithMember" xlink:href="insm-20240630.xsd#insm_MichaelSmithMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_insm_MichaelSmithMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_01a.jpg
<TEXT>
begin 644 image_01a.jpg
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MQ^?XG/O@<^Y#O,#GZ[T/^3\ !  $L9W8#@ ! ,$^)UZP=@ @ "#&>_'? !
M$--.@#@,.<3P.6L'GP- T "=?P.4?4YLQ^?XG/O@<^Y#O,#GZ[T/^3\ !  $
ML9W8#@ ! ,$^)UZP=@ @ "#VYXC (3'+Y\H6&$(((8000@@AA!!"""&$$$((
MH35+Y\C9OZ^OSEGS4F?L ! S6K@((8000@@AA!!"""&$$$(((836+0"(OPL
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MS3#R GR.S\D+\#D^)__'YP 0Y/\ $  0Y 7X'  "  (  @ "  (  @ "  (
M@H$)C1$*'7Q. Q2? T#0 .4\IQE&7H#/\3EY 3['Y^3_^!P @OP? ()<D+P
MGP-  $  0 ! D/\#0 !  $  0# PH3%"H8//28#P.8U+&J"<YS1 R0OP.3XG
M+\#G^)S\'Y\#0)#_ T"0"Y(7 $  0) 7 $  0 !  $  0 !  $ P,*'0H1E&
M,PR?4R33 .4\!X#@C* !BL_)"_ Y/B?_Q^< $.3_ !  $.0%Y/\ $  0 !
M$  0 !  $+/15\"E"D"X!;?9;!)SFT\7T\?'1V:?GY^);;?;S*I=(\_5=0]W
M'[W'_VPKMH1KME6N&<I78]['O;]::V=*]UF"K_!Y_?O@\^7Y?*SXOXQK.//7
M=D:L);:3%^!S<D%\CL_)__$Y/N_SCLG_Z?DMM8X@%R3_7VYO9[W]'_*"?OMJ
M^^>_MVT;^JPNJS7GLVO[\T.L__=Q]]5!=^2^'[O/5_/[L8(_R?__W^[N[C([
M.CI*3'^P[P&(=0@  @ "  ( @@2(9AC-,'Q.D0P 00.49ACQ I_C<_("?([/
MR?_Q.3XG_Z?G!P!!7D#^#P !  $  0 !  $  0 !  $ 03%$8X1"!Y_3 ,7G
M ! T0 $@:(:1%^!S?$Y>@,_Q.?D_/@> (/\'@" 7)"_ YP 0 !  $  0 !
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M7$,"A,_Q.=?@<WS.NL#G^)QU@<_Q.>L"G^-SU@4^Q^>L"WR.SUD7^!R?LRX
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M6'U#<0YY5(V8!P!1/T<:*@8#0-2O/0 @1JHUO@$@ "#0&CM+ !  $&C\&AX
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MAN(<\J@:,0\ HGZ.-%0,!H"H7WL 0(Q4:WP#0 ! H#5VE@ @ "#0^#4\  0
MQ+X% -%/!ZL)8(&#[7/[F=CEU65F&JQN;FXR6^LFGN-!/&:!-R;H@7[FAQI
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M;\T' #& OP @ ""*OB\ Q)2]"0"!$-I_7X3\^V?Y&0#$T *  (!8B@ @^@D
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MF0P 45[8 $  0*!ABDD " "(.31DQWCG !#S\M528L$2ZKFQX@X !  $  0
M!$)37.L $/WS8@ (5*-/"  ! #%% 4#T$P!$NQ #@/B1KP @]G,? (B>"2L
M! #$@LMD (CRP@8  @ "#5-, D  0,RA(3O&.P> F)>OEA(+EE#/C15W "
M(  @ " 0FN):!X#HGQ<#0* :?4( " "(*0H HI\ (-J%& #$CWP% +&?^P!
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M70&)/Y#$X28Q!S?HWT1@$/<#<WIJ/]/CTV-FZH?3TY/$7E]?,UN+ ""2@ 8
M\=?"#  " &*I23D ! #$T.L)  (  @!B='\"0.Q' ! (S;U9#0 ! !'U%0#$
M3]XQ  0 A*NS " 00LO)*0$@QN@7HQ_VE0 @ "!F* "(?@* 2 (: ,1?"S,
M" "(I2;E !  $$.O)P (  @ B-']"0"Q'P% (#3W9C4 ! !$U%< $#]YQP 0
M !"NS@* 0 @M)Z<$@!BC7XQ^V%<"@ " F*$ (/H) "():  0?RW, "  ()::
ME -  $ ,O9X (  @ "!&]R< Q'X$ ('0W)O5 !  $%%? 4#\Y!T#0 ! N#H+
M  (AM)R<$@!BC'XQ^F%?"0 " &*& H#HI\D!$*%A8*5KN@*:VZ *0+@BH:0A
M5-K$K3'TC+P_%SPU2&N :RSROK1('O1@DV>/%(%:@-KA<Z!-HI_M"E<%;G2
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MP$-W;S.2Y[F]5JLW'(+!"];%U/7X^)"9^D%C'@#$A!N#0UZC H#X^_L#@ "
M (  @ " &.?< X 81@ 0 !  $,,+ *)?G : Z,C7 "!ZW0<  @"B5K]EU+@(
M  $  0 !  $  0 Q@_L 0/S[[ & &#[/8Y__[#X $  0 !  $)-L# YYC0H
MXN_O#P "  (  @ " &*<<P\ 8A@!0 !  $ ,+P"(?G$: *(C7P. Z'4?  @
MB%K]EE'C(@ $  0 !  $  0 Q SN P#Q[[,' &+X/(]]_K/[ $  0 !  $!,
MLC$XY#4J (B_OS\ "  (  @ " "(<<X] (AA!  !  $ ,;P (/K%:0"(CGP-
M *+7?0 @ "!J]5M&C8L $  0 !  $  0 ! SN \ Q+_/'@"(X?,\]OG/[@,
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MO\8$ $3U)ND^&[W[7J<U3D< "  (  @ B*@ (  @QCXOT7\"@%AV W;RWQ<
MXI_?#P " ,()  (A-,\<!0 " &(=^3< ! #$% 4 T4\ $"T!0+3>!0 $ ,28
M#3( B/\:$P 0U9ND^VST[GN=UC@= 2  (  @ ""B H  @!C[O$3_"0!BV0W8
MR7]? (A_?C\ "  ()P (A- \<Q0 " "(=>3? !  $%,4 $0_ 4"T! #1>A<
M$  08S;( "#^:TP 0%1ODNZST;OO=5KC= 2  (  @ " B H  @!B[/,2_2<
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M9K86 4#\(S@!0 !  $  0 !  $#T>08 "  (  @ B-+&+P $ ,3W-P $  0
M! !$>;,UE%,"0 ! V/4%  $  0 QE^$S $3]^P! _/P= T  0$S]/@ 0_WX7
M !#S$0!$/P% _",X 4  0 !  $  0 ! ]'D&  @ "  ( (C2QB\ ! #$]S<
M!  $  0 1'FS-913 D  0-CU!0 !  $ ,9?A,P!$_?L 0/S\'0-  $!,_3X
M$/]^%P 0\Q$ 1#\!0/PC. %  $  0 !  $  0/1Y!@ (  @ " "(TL8O  0
MQ/<W  0 !  $ $1YLS644P)  $#8]04  0 ! #&7X3, 1/W[ $#\_!T#0 !
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M"S1G=0Y*'F26[YG<(GM$/VLI /98>GQZS$S?\>FNWFC;D#]*!(  @ "  (
M@ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ " 0 @  @ "
M  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
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M!:*[/1O)D2*-./6GPNN-9?O!O(M(WJ[/X/9("!Z0\\GU+[K.FM)U6^M'#-H
MC?A+\]#&=&V[6C9_KL/$7'VN[].=A5H+N2%V23T7B?^N 3I48_SV]VUBKC&>
M#;),3NGJ!C7-.]V/=A2L=O%"Z\1(K:TQT.9G\DQNH!_)SS1G<G%18XS+>2/Q
M(Q]L=+^+" "A/0^7%Z@_;=R6O7>\NTXM$NMU#934^1'@IE9-6JL7/-1]OKG/
M*+X:ZCF'ZI,XX.Q\%XO:9NO?!E;HL+SGEU\3R>NZKHGD&]$<LB]\X6*5RYV'
MZVNQSZ<PGZO5@RFYC^O;:(X9^=%P! !R=;[V*/<[BYZ6ST, Q.-#9NH'S;T
M(  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
M "  (+@/  0 !  $^QP  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M @ "  (  @ "  (  @ "  (  @ "  ( @L$H  0 !  $  0 !  $  0 !  $
M  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0
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M\@CTJV=C*.X8,%+?ESZG>Q?Z_G2_-A89$NOW=;"*WM?E!?GP+1\,/3T_)>8
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M3@S]?):K8+?FDP 0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M$  0 !  $  0 !  $ @!0 !  $ @  @ "  (  @ "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (A  @ "  (!  !  $  0
M!  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M  0"@ "  (  @$  $ @ 8CD 1.C0KW1-#D"D2; K+'3CN^)VZ@"$OAL['-<A
MFBE<M5GA5#)@===HH(X5[7GS7!N,7<UKUY1W 4-]K@!"8]>[Y*5MKL#L*M;^
M%/_O[XFYI%>;,JX9K&M9BTG79(@,@/4 =<^9!6%IB#:FNKN_RTSAALC 7)O.
M;IWH,SF8H*NYTMC#XT-B3@H-.?!$G\DU1G0_.M_H.M%U'-F?[OOI,[@UV35
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M]R7(U2/J&ZVG(K,W  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
M"  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (!  !  $  0 !
M  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M 0 !  $  0 ! ($ (  @ " 0  0 !  $  0 !  $  0 !  $  0 !  $  0
M!  $  0 !  $  0 !  $  0 !  $  0 !  $  0"@ "  (  @ "  (  @ "
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M4=^<[FKKMKF:#P "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M @ "  (  @ "  (  @ " 4  0 ! (  (  @ "  (  @ "  (  @ "  (  @
M"  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "(0 (  @ " 0  0 !  $
M  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0
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M*@#Q^)"9^D_] @ !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M 0 !  $  0 !  $  0#!8!0  @ "  (  @ "  (  @ "  (  @ "  (  @ "
M  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "
M  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
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M'X !0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M0 !  $ @  @ "  (  @$  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M  $  0 !  $  0 !  $  0 !  $  0"! "  (  @ " 0  0"@ "  (  @ "
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M'G9)[_W#?6+##F7':4^X9X@ 9UT#Z^A0L49SWZW_6@.G#,8S9Y@]X\4TUD<
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MU\P (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "
M(  @ "  (!B> D  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M $  0 !  $  0 !  $  0 !  $  0 !  $ @  @ "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
M" 0  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
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M !  $  0 ! (  (  @ "  (  @ " 4  0 !  $  0 !  $  0 !  $  0 !
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M8.WD8F=7P]@-$".%3@Z/_<XL>S=F?SX\W"?FI._+#1[ULS2^N7V>^S=_%UU
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M=+_+(=5*UK8%(#I^2.-F#PJUEOY88TJQ?;$ A,P8&]-UDL'] !  $  0 !
M$  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0
M !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M$  0 !  $  0 !  $  0"  "  (  @ "  (  @ "  (  @ "  (  @ "  (
M @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "
M  (  @%  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
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M^87SC<9.-VN8$CR ^L44UU_7'P&Z'E')?M!ZV/5G\>^< (B\_Z,YG-:  !
M$  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0
M ! ,*P$@ "  (  @ " 0  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M  0 !  $  0 !  $  0 !  $  0"@ "  (  @$  $ @  @ "  (  @ "  (
M @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @%  $  0 !
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M  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M @ "  (  @ "  (  @ " 4  0 !  $  0 ! (  (  @ "  (  @ "  (  @
M"  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
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M $2_V#Z_G 0 8HS&+@#$ /<!@/CKO@:  ( 8LKX$@ " 6$[\!X  @!BJ+@2
M0*BO "  (  @4", B.'S_]6<*P 0O00 T1( Q$^+G_D%- "(GS;, "  ($9^
M[P 0>VAT#=. W'?R# #1+[;/+R<!@!BCL0L ,<!] "#^NJ\!(  @AJPO 2
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M_?@%  $  0 QG;[@J+TG (@!8C( !  $  0 Q!S[<  0 !#3%P!$/P% M 0
M,8U"!P!B#:&ZCL_'.PP!(&K';0"(G]\' &+X=S&UN#C6&0$ T;,9!@ !  $
MT3\O (#XD6\ (  @ "#JQR\ "  ( (CI] 5'[3T!0 P0DP$@ "  (  @YMB'
M X  @)B^ "#Z"0"B)0"(:10Z !!K"-5U?#[>80@ 43MN T#\_#X $,._BZG%
MQ;'." "(GLTP  @ " "(_GD! ,2/? ,  0 ! %$_?@%  $  0$RG+SAJ[PD
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M_WUHINQ_'0- 5'AV  ARZ87F*0 0\UD7 ! (_3S& 4  0 ! H+\) (*:O98
M(/II<@!$9$/4ND;UN=TFY@X-/;"NKZ\S*P$@:@4#_6SW^:'W5^DPG-JAVMEL
M&K"Y,QS$D1>8>M_MUS:S_35ROD:.*?_^Y#$;>O4&P,/=9ZBDI&0%N.]3"S"K
MTK@?,6[7^CZ1AOO4$E/WC8:(*'-,RH>*!<77C'A^UE#D;)SCT">&O73OJ\@^
M4^BP=$U&/JL:)-3Y[%]%UZ!_O..]@LSCQ9BOXM55Y_O4>,_CPLW=M5CYF562
M=Z;FSHBIC?3&0ASMO0M\5?I]0QEKX/MHOEUKGQ7U9$;L!>0@[G _7!DSIM2H
M8T+/,,,SZZM2!36E']]\?T\M)Q\3N)D6"CZU^^QS[ST_/R?FAI61H;\.S+UU
M#_B[8 LW-%-]?GYFUC68;_3R\I*8#N8;ZWJF_UDW#!*[YN?01.R:;M^Y=7%_
M_Y"8DT(F[ITJY.+ $_ULA73>/]XS6V:-NM\9@>:&&C\:>WQZ2LQ>8_:QVO-N
M#[:M6B^]5MX^4#VWA+,F(H6:&M/8I%#,Z]MK9FL1 $3[D > J%[H $#4;4J6
M%H8 $  00S6-ADPX "#J?Q\ B.']N=]W P#1:^\!0 !  $",$YL (+X!(()Y
M* !$]7@_V.< 0 !  $!,]LP"@%A6GPL 8B+Y+0 $  0 Q,QK5  ( (AE" "B
MGP @VH<\ $3U0@< HFY3LK0P!(  @!BJ:31DP@$ 4?_[ $ ,[\_]OAL B%Y[
M#P "  ( 8IS8! #Q#0 1S$,!(*K'^\$^!P "  ( 8K)G%@#$LOI< ! 3R6\!
M(  @ "!F7J,"0 ! +$, $/T$ -$^Y $@JA<Z !!UFY*EA2$ ! #$4$VC(1,.
M (CZWP< 8GA_[O?= $#TVGL $  0 !#CQ"8 B&\ B& >"@!1/=X/]CD $  0
M !"3/;, ();5YP* F$A^"P !  $ ,?,:%0 " &(9 H#H)P"(]B$/ %&]T &
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M*A#AH(C7U]?,]#[N771!'/7LV%CWWRD0L=D<9G9Z^BNQ"'CB='-SDU@$!G&
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M &(=^VKJ-<Q::CP "  ( (BY[W, B"7EV_L_LP @T/P%  $  0"QONH.  (
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M!$((<48,VY>I]3< $  0 !  $)%>)P $ ,38 H#H)P"(E@ @T%)+)@ (  @
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M\VDS7+R8TOD)  $ @1!"Y/94UF1P""&$$-IG=@$  0 !  $ 45, $  04Q,
M1#\!0+0$ (&&78, $%,HAN;8) 6 F/-I,UR\F-+Y"0 ! ($00N3V5-9D< @A
MA!#:9W8!  $  0 ! %%3 !  $%,3 $0_ 4"T! "!AEV# !!3*(;FV"0%@)CS
M:3-<O)C2^0D  0"!$$+D]E369' ((800VF=V 0 !  $  0!14P 0 !!3$P!$
M/TT.@ @-B2M=H_K<!;&V75Y>9*8'@AY8C=4*C&CAR?U7S<'9O-I^L3TL9MY7
MR3>.'=_#%%!#KIT:SX6&7^M?07S ^K@C7I2 "N,V,.K  \-""&/YO/N-U<L+
M^D<P]]G;KVUBM58!0@B1DP\5_\<[X:>65=9X?].KU1!""*$E]4JZ,Z"B^Q2<
MWUKK-J:]?C<DUD%R9(BML,/?@(<<@$@_^^3D)#.%!U1NX-H-6C3/=I38P<%!
MISG X/[^/K&/CX_,(M*Y2PYZ?'Z_O[__T]QG;[=?B97FBPK/*%C1F*X=]PZ+
M )OCW+KN<WBXR4R_BT(GC76MMUHY>7E4T7W^E5FHWQAX!OU1]=UN?:OI^W/^
MB^RMR-K1>*&?[0;H0_V@V_<7_^T']&\]/#YDIFM)SX?7M]?,UB( B"18 4"@
M-35;^R4*X^]S (@^:P< 8JI%/0 $  0 !  $0HB<?!_Q?[P3'@ "(8000K7[
M!47W 8  @ "  (  @ " 6+  (/H) "()5@ 0:$W-UGZ)POC[' "BS]H!@)AJ
M40\  0 !  $ @1 B)]]'_!_OA > 0 @AA%#M?D'1?0 @ "  (  @ "  (!8L
M (A^ H!(@A4 !%I3L[5?HC#^/@> Z+-V ""F6M0#0 !  $  0""$R,GW$?_'
M.^$!(!!"""%4NU]0=!\ "  (  @ "  ( (@%"P"BGP @DF % ('6U&SMERB,
MO\\!(/JL'0"(J1;U !  $  0 ! ((7+R?<3_\4YX  B$$$((U>X7%-T'  (
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MQ98.\_]V !#+*CA1O_4. #'$.^V?A)?&*@ (A!!"/SEK "  (!!""*%EU^L
M$  0 !  $/.KW0 @*M1= !"]! #13P 0[8,.  (MMG28_[<#@%A6P8GZK7<
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MM@ @9M9L H! 2VRL D!,]S <LA$- #'?=P$  0 QS7,$T;AD2$:1C/:1JP)
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M  0 !  $  0 !  $ ,10 H#HIX.U/&AD,7]N/Q.[O+K,;+,+\&V[N;G)K 2
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M5S0#@ " J-?&0@BAD<]X (CJ<1L  B&$$$)]L@L "  (  @ B"'G$1$!0 !
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MDIC^Z*ZQM0@ HB4 "#2] @  HD^!Y 0  0 Q^7T.  $  0"!$$*3/INK-2L
M('HU'0$@$$((H97D7M\ $  0 !  $,/5(R6U"  $ ,04!0#13P 0+0% H.D5
M   0?0HD)P ( (C)[W, "  (  B$$)KTV5RM60$ T:OI" "!$$((K23W^@:
M (  @ " &*X>*:E% "  (*8H (A^ H!H"0 "3:\  (#H4R Y 4  0$Q^GP-
M $  0""$T*3/YFK-"@"(7DU'  B$$$)H);G7-P $  0 ! #$</5(22T"  $
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M  0 ! !$K7X!  0 Q!P$ -%/ ! M 4  0.S[.0$@ZL<+  @ B+&^"P $  0
MQ##[" #BYY\% #%??R[A^ZPYMU<!0/1[[P 0/3\? ()&*D((K:S7"@ !  $
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MT@ "@.AS  ! Q)N) !  $'_=6P 0 !  $  0 !  $,$\#P"B7RP"@/A9O@T
M\7/?1=XI  0 !  $#5&$$$)E H  @ "  ( 8<OX%  $ ,34!0/03 $32  *
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M  @ "  (  @ "  (  @ "  (A!!" !  $  0 !  $  0"  "  (  @ "  (
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M9BWJ>]]$\__4X]-C9CJ?)R?'B=76_P$@ "  (  @ "  (  @ "  (  @ "
M(  @ "  (  @ "  (  @ " 00@@!0 !  $  0 !  $  0 !  $  0 !  $
M0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0""$$ *  (  @ "  (
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M  @ "  (  @ "  (  @ "  (  @:FC3#N0YSSIP#0 !  $  0 !  $  0 !
M $  0.)>C-L  (  241!5 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M0 !  $  0-#0I!G.VF'.F7, "  (  @ "  (  @$  $  0 !  $  0 !  $
M 0 !  $  0 !  $  0 !  $  0 !  $  0!!$YMF.&N'.0>  (  @ "  (
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M=8N I&Z\=&Z<O]#W<O=24U\:*>*Z\SP2A^H[6=A(YLH5*K,"LOE7RAG<^$5
MW$A^KD52_3CBYP,)6>LN_A^JOH(00FC>4O]_>7F5F4()AX='F>6YAOY-70-X
M;V\_,=LPO+M/S,4V>NZYL_FH?X\UBS2DLUJQ^SA.SO>+BU5FD;PF\GQ5#?V(
M'00!C$VO<[B\ZQP9:_8\%4"$[CW[(;'TL<:$OB+2'#GRL:JKG>A81/((E[/H
M\T2@C4C^%(*O*^K%0!)# !!Y_?_P\" QK8D 0 !  $  0 !  $  0 !  $
M0 !  $  0 !  $  0 !  $  0 ! ((00 H  @ "  (  @ "  (  @ "  (
M@ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (! ""$$  $  0 !
M  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
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M/V76ZI2HZ=NBM9J6^8!)]U[6AS0]1@ (  @ "  (  @ "  (  @ "  (  @
M"  (  @ "  (  @ "  (  @:HS3#F7/FG#D'@ "  (  @ "  (  @ "  (
M@ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @* Q2C.<.6?.
MF7, "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
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M%!FO""01N4[)Y[EYT'I:),]Q_3DTO+0VUEO^@?)Q8I$/L0$@ "  (  @ "
M(  @ "  (  @ "  (  @ "  (  @ "  (  @ " 00@@!0 !  $  0 !  $
M0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0""$
M$ *  (  @ "  (  @$  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M$  0 !  $  0""&$ "  (  @ "  (  @ "  (  @E@% 1!I,K7Z3 Q!?B7D
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M0FVH]Z8^T(WQIJ#17\\161<1V"@RILX7Z-SH'M;]T)OZ_UH 6M>Z:_KK>>
MB,.CP\3<G.OZUW%PL4W$%^A^B,!MK>*+")!AYUQ T@S<#%S7[;T:?^OBXE8
M1 L?TZINT^Y>K2#N-@V";;S.-]=AS@>\3NV]LK\+Q+RQFG+Y6<;\30T H?'0
MW^H,I5IPK*%?SKU;_28W!U*4(>37E]?$:L9XM;K,+*\M'A:MMNE?&K_X=0K/
M<U"^3NB]9G>=@]Q*OSD\K/I-9*ZR>KO)?[6&6UL7'^)OPF>"7-?%]NJ[W!Z.
M^*H(C*)CK/?>EF9X+";_]^?ED?F<'0#Q^)"9K@&M@0!  $  0 !  $  0 !
M $  0 !  $  0 !  $  0 !  $  0 !  $  0- ,YSK,.0 $  0 !  $  0
M!  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M  0 !,UP  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
M"  (  @ "  (  @ "  (  @ "  (  B:V  0K!T "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
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MEXLOL@3X\""SL_.SQ!Q@4Y)[OA)TU5O6E#7[4_]==F>46C:&!N;)&\"!PG,
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MULF7>/;,'X#(U\7AX4%B&2 '  $  0 !  $  0 !  $  0 !  $  0 !  $
M 0 !  $  0 !  $  0"!$ *  (  @ "  (  @ "  (  @ "  (  @ "  (
M@ "  (  @ "  (  @ "  (  @ "  (  @ "  ("@Z8D0PA< 0 !  $  0 !
M $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
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M6XQ%Y-Y?7[E%[M/J.I'X7^?A^_LKLVV4?DS;F^Z]_".5O,<(  $  0 !  $
M 0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0"!$ *  (  @ "  (
M@ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "
M (! ""$ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (A! "@ "  (  @ "  (  @ "  (  @ "  (
M@ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ " 0 @!0 !  $  0 !
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M(=\^X'4BM3GU>>Z#T59]VCGI\>DQ,]U[)R?'B;7ZH ,  @ "  (  @ "  (
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M[U ^I95%?*6K7T3RP,4!$-V9KJ;GG-:' "  (  @ "  (  @ "  (  @ "
M(  @ "  (  @ "  (  @ "  (  @:(9S'>8<  (  @ "  (  @ "  (  @ "
M  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @""9C@
M!  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M  0 !  $  0 !  $  0 !$UL  @ "  (  @ "  (  @ "  (  @ "  (  @
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M>"8%8QP ,58?<EP (L^A#G_.WO^9?C0   $  0 !  $  0 !  $  0 !  $
M 0 !  $  0 !  $  0 !  $  0"!$ *  (  @ "  (  @ "  (  @ "  (
M@ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @$ ( 4  0 !
M $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
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M,>8>1P% 3..'VN4Y !!+.8]:^78 "  ( (AQ<B$ "(30I.<>  0 !  $  0
M!  $  0 Q"\% +&9 "#^430"@)BF<#]F$6;,YP. 6&Y#"0!B!XL5 !"S;3@!
M0#187P 0OVIBS#V. H"8Q@^URW, ()9R'K7R[0 0 !  $./D0@ 0"*%)SST
M"  (  @ "  (  @ " "(7PH 8C,!0/RC: 0 ,4WA?LPBS)C/!P"QW(82 ,0.
M%BL (&;;< * :+"^ "!^U<28>QP% #&-'VJ7YP! +.4\:N7; 2  (  @QLF%
M " 00I.>>P 0 !  $  0 !  $  0 !"_% #$9@* ^$?1" !BFL+]F$68,9\/
M &*Y#24 B!TL5@! S+;A! #18'T!0/RJB3'W. H 8AH_U"[/ 8!8RGG4RK<#
M0 !  $",DPL!0""$)CWW "  (  @ "  (  @ "  ('XI (C-M$=(^C]]?GTF
MYC:-;JSKZ^O,9E]\FK"1-K?F;LVSZ/R&(9=&Q:86!9<AP9BE-6OFUBAJU6 :
MZF^FWH]C%<&7Z!=KBB=S&XM:_SI60V)NY]$VW'N1>W;,=5'1,)S;WM/K7G6Q
MLIH6*XZ.CC)[?'Q,;(G X-+BC3&;E:WBL;DUS-O!8]L' <PM!F\&O_[933!]
M;CZ%N4((+>7L&PHD?7EY24P!Y.N;:V,W8OEOJJYC:N<WMS>I&4C:_9W:[>UM
M8I&_<?<JW7MNO]'WCKY[S5C<W-PF9J]S?9-8_;W*:Z#%;Y8XY[6_N?F9GS4;
M:8RMW02LT;UJUU<+JUGKX?D,^$ZMMU2-3:7_'^PWYCTN+R\3>WAXR&P;/S)5
MP+$W!2!.3HX3>WU]S6Q7! "Q)@ ( (@AFP0 $/,L@ )  $!,[:L ('[O7[>A
M, X L: ]^P< XC?7!H  @!@R'@. 6'83:!MR9)KJ\_ IS!5":"EG'P $  0
M!  $  0 !  $ $14 !";"0!B30 0 !!#-@D (.99  6  ("8VE<!0/S>OVY#
M81P 8D%[]@\ Q&^N#0 ! #%D/ 8 L>PFT#;DR#35Y^%3F"N$T%+./@ (  @
M"  (  @ "  ( (BH " V$P#$F@ @ ""&;!( 0,RS  H  0 QM:\"@/B]?]V&
MPC@ Q(+V[!\ B-]<&P " &+(> P 8ME-H&W(D6FJS\.G,%<(H:6<?0 0 !
M$  0 !  $  0 !!1 4!LIKVY!X-#_D;U^?65V&JURDP!B*NKJ\RJFN-;TH1%
M""&$$$([4L0-)),?GQ^)N=@Y R".CS)[>+A/#"&$4)7G_@.6@Q!"Q.WVWW>%
MC7F=H7[S7?F;FO>:\CK;,%=_1GRO[QVYSI\=^<TWOUG4?([4(Y[;!Q01/3X^
M9*8 Q/'Q<6( $+-*QP$@ " 00@@AA-#2"JE. ! ((30KS_T'  (AA(C; 2
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M1'8$  $ ,9-%"0!!\1<AA!!"""T_G6P7_R.$$-K4)P- ((000@@AA,B. "
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M(G>$$$(((830G#(6 (B_"0!B,^WMSJ8II^B?7Y^)K2Y7F>WO[R5V?7V=60T
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M! "!$-J>Y!8  B&$T S.(P (SO.97P<  N$QB-P10FC[3PB:X0 0S/FNS3D
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M0(SCSP @-O5? !#_&Q\ " "(Z>(\ (C?GQ$ $+^M%P!  $  0/SK7@ 0 !
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M'0V1&XWY(1ZU5812/3X^9G9X>)#8R<E)8@ 0NU"0_0,  0 ! +%MR<90R2T
M! !$[7SB+_Y^\@)  $  0'">S[/$,K=S! !B#@4S (AYS,/<UR0 Q&8"@)C'
M>@>  (  @)CO^;G$6 L  @!BZE@0 &)X?P$ @=!\! "QF0 @_A&X $  0,RQ
MH+&5^Q, 8H  $0!BBJ0!?_'WDQ<  @ " (+S?)XEEKF=(P 0<RB8 4#,8Q[F
MOB8!(#83 ,0\UCL !  $ ,1\S\\EQEH $  04\>" !##^PL "(3F(P"(S00
M\8_ !0 " &*.!8VMW)\ $ ,$B  04R0-^(N_G[P $  0 !"<Y_,LL<SM' &
MF$/!# !B'O,P]S4) +&9 "#FL=X!(  @ "#F>WXN,=8"@ " F#H6!( 8WE\
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MYM;N[^9?=T!HH!A./K+H37NIQ\?'B2DLWMNN" !B/=$!@ " :);H $  0 !
M;);FM$N8ICJO ""F2Z0!(  @AKH.  0 !  $  0 Q'AY_IBQZ7#G^>:_ 8
M@ " ^/?S $ ,4#P'@ " &#7' H  @ CFC@ 0@]>1!JNQ 4 @-(H (#83 ,1Z
MH@,  0#1+-$!@ "  (#8+,UIES!-=5X!0$R72 -  $ ,=1T "  (  @ " "(
M\?+\,6/3X<[SS7\#  $  0#Q[^<!@!B@> X  0 Q:HX%  $ $<P= 2 &KR,-
M5F,#@$!H% % ;"8 B/5$!P " *)9H@,  0 ! +%9FM,N89KJO * F"Z1!H
M@!CJ.@ 0 !  $  0 !#CY?ECQJ;#G>>;_P8  @ " .+?SP, ,4#Q'  " &+4
M' L  @ BF#L"0 Q>1QJLQ@8 @= H H#83  0ZXD.  0 1+-$!P "  ( 8K,T
MIUW"--5Y!0 Q72(-  $ ,=1U "  (  @ "  (,;+\\>,38<[SS?_#0 $  0
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M#10-%-[>WS*+/)\6+PZ[^ZMI8<2.>Z P6!IC]WR1XJ9>UQ6Q6AW>)8CC.US
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MA37U]FV\SA^NTWR,1P4@Y%SI30&(TH?L !  $  0 !  $  0 !  $  0 !
M$  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0
M !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M$  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0
M !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0@ L $  0 !
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M H  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
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M  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0
M!  $  0 !  $  0 !$( $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M$  0 !  $  0 !  $  0 !  $  0 !  $  0 ! ( 4  0 !  $  0 !  $
M0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
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M "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "
M(  @ "  (! "@ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
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MXJ=U_-RU2V=-Q'\XWYY!50:,R8&N?+QTC/7L[DWO==N-CUHI^>Y-BT;JET(
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MTZT?M4C]IU0O\P#)O\?/Q3*/G3]5:]7KJO&W0T' "$T.0!A@J@1> 4  0 !
M $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M0 !  $  0 ! ( 0  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M  $  0 !  $  0 !  $  0 !  $  0 !  $ @1  !  $  0 !  $  0 !  $
M  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0
M!$( $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
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M][$&0@ 0ZZ9G!@ $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0
M!  $  0 !  $  0 !  $  0 !  $  0 !$( $  0 !  $  0 !  $  0 !
M$  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $ @!
M0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
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M !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M$  0 !  $  0 ! ( 4  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M0 !  $  0 !  $  0 !  $  0 !  $  0 !  $ @!  !  $  0 !  $  0 !
M  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
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ML[Y5HP]W 2  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "
M(  @ "  (  @ "  (  @ "  (  @$ *  (  @ "  (  @ "  (  @ "  (
M@ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ " 0 @  @ "
M  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
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MZSI_N$[S,1ZU/R?GB@-92S4:  @ "  (  @ "  (  @ "  (  @ "  (  @
M"  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
M"  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (P 4 "  (  @ "  (  @
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MR64#@('Z G>FJKD\!R&T&0!1@A<!(  @ "  (  @ "  (  @ "  (  @ "
M(  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ " 0 H  @ "  (
M@ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "
M (  @ "  (! "  "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
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M]>TU,P (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
M"  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
M"  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
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M "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @$ *
M (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
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M7P)  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
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M[T< "  (  @ B&CB# #1_@0 @ " F+HX!P QCS@/ &)X/]/LS " F"8G!8
M@!@P\@2 ^-T9"P#Q=_]5.U< $+]<[P 0BYE/  @ "  (A(81 ,1F H!8$P $
M $2K  @  @!BZOT(  $  0 ! !%-G $@VI\  !  $%,7YP @YA'G 4 ,[V>:
MG1D $-/DI  0 ! #1IX $+\[8P$@_NZ_:N<* .*7ZQT 8C'S"0 !  $ @= P
M H#83  0:P*  (!H%0 !0 ! 3+T? 2  (  @ ""BB3, 1/L3   " &+JXAP
MQ#SB/ "(X?U,LS,# &*:G!0  @!BP,@3 .)W9RP Q-_]5^U< 4#\<KT#0"QF
M/@$@ "  (! :1@ 0FVEV $3L(&GS&Y4"$!>K56;[^_N)75U=958#0+1J'K4J
M!,8.ZV$.]%T)!J=,;JL=[.-C8@<'!YEI8;S5'@D5T6P@U;YIC*9+].<D;?#T
M=G9VEICNA]X4DGA^><YL.Q+#\7Q7JS-K[N=1J<$_Y'N5H+[O[^^&#<-Q?'+$
M5\VOR-9JUN>](WP+K+PN\L+]=&=\NR;V>+.E (0">[WIF79\<IS9R\M+8FXL
MIBP&5^5<?R(@8J/=N25-NCGGA=LZQKN=?PQ3(VIWABTK#IU:7]]?B6W'.Y4_
MDFD7Y97C'];I/\9BPH^IJD']P/RUBKUJ<N_9@1216N) ]?:YK__I:SN!\WQ'
M8CC]X,K5U[4&>7ATE)GF;]K;NKFYR4S!BD74"XCMT8Y(^W.]*0!Q?'R<& #$
M%B:N !  $-M0# . V#!9!( @$!TS&0& ^/4YLJU)^U#G$0#$^+X* &)&YP@
M! #$B&=&S3P 0,S#M^_R&.]V_@$ L4T"@ " F#3N!(!HGGL#0"QG_4]?VP&
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M\<RHF0< B'GX]ET>X]W./P @MDD $  0D\:= !#-<V\ B.6L_^EK.P 0_R<
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M (CM.C0 ((:_%P $  0 Q+\% %$J5@! 3.';ZPHU !"M=P  !  $  0 1%0
M$  04S_/F&<" ,3O8EX B'^-%P $  0 !  $  0 1'TM$0 "  *A)0@ 8C,!
M0*P)  ( 8F[O->6] "  (  @_BT B%*Q @!B"M]>5Z@!@&B] P @ "  (  @
MH@*  ("8^GG&/!, ('X7\P) _&N\ "  (  @ "  (  @ZFN) !  $ @M00 0
MFPD 8DT $  0<WNO*>\%  $  0#Q;P% E(H5 !!3^/:Z0@T 1.L=   !  $
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M0!P?'R<& +&P0 H  LV]. <  0"Q+4DR ,0_DA$ "  (-)MU4;>6 "#&F%$
MB.7$E  0O]UI !!+>2_._/GN*[0+D1X Q&9Y#P#$4GT3 ,1\G@<  @!BB0*
MF,(G T  0 ! ;)L ()*B'P#$HI-.  @ B('6"0 $ (1-1@ @ "#0;-9%W5H"
M@!AC1@$@EA-3 D#\=J<!0"SEO3CSY[NOT"Y$>@ 0F^4] !!+]4T $/-Y'@ (
M (@E"@!B"I\,  $  0"Q;0* 2(I^ !"+3CH!(  @!EHG !  $#89 8  @$"S
M61=U:PD 8HP9!8!83DP) /';G08 L93WXLR?[[Y"NQ#I 4!LEO< 0"S5-P%
MS.=Y "  ()8H (@I?#( !  $ ,2V"0 B*?H!0"PZZ02  ( 8:)T 0 ! V&0$
M  (  LUF7=2M)0"(,684 &(Y,24 Q&]W&@#$4MZ+,W^^^PKM0J0' +%9W@,
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MI\?,%( X.3E)# !B)PX6 (BA#S$ "  ( (AE^<&Y%SUJD@8 B/9S#@#1X(P
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M%M?4;I3$MYKS,9^G:GP6D.B0B/VNP-*N8=BFV$1D,,]]55\\G,^<1V"MN16
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MP9C^ @#B]_,)  $ 414O D",$GL!0"#47@ 0FPD 8DT $&AN2?*PA1$ B%X
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M#7X> 4 @Q%I&",W&7VS+O="2UB  !$)H>;DC0L2"""&$T+0"@-A, !!K H!
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M  $  0 ! $%<   ! $'1&P "  (  @ "  (  @ "  ( @E@0  (  @ "  (
M @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ " X  @ "
M (  @ " 8)\#0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 ! 8  0
M !  $  0 !  $  0 !  $  0-$;Q.P 0 !#L<P (  @ "  (  @ "  (  @
M"  (C 8%  0 !  $  0 !  $  3G.0 $  0 !  $  0 !.#"_VO?[I';UMDP
M@*I4R5);2*E2K;>2,MM1J3:EEY#66TFIDB63R8SC\"<CF )  #S'@^9^"'(_
M R!?@,\5@!" $( 0@'"W(P A "$ P5]! 8C#8=1.I].L75XNXW9YW,Z7\ZRM
M^7-K^H3\W6%]YJVV/I>D?4+F]SQI6XYS?CA.V+HM?9P:YNKQ^@I[7CP_SKFX
M<=*LG?+W9[ZU<][)VFEGSI\?IXUG^]F<%SKGI?=)56_;YX_&*?M=<]E\G#QK
ML(4]W$[][\R7^[ESV?R^($^?L'L2M>"S^[.V/CGO!;W/U8+N!<UY#>>(RVZ>
M._:Y^M^]8$US_N7\9=:FWZRG 8BE\,5>"$ (0 A "$ H@ 0@!" $( 0@? QW
MT#'G A "$ (0 A "$"Y !2 $(-2" A "$ (0[@6=^00@!"#L<_6_6E  0@!"
M $( 0@!" $(!)  A "$ (0#A8L1!QYP+0 A "$ (0 A ./,)0 A J 4%(+S/
M!2#<"YIS 0@!"/M<_>]>4 !" $( 0@!" ,++4 $D "$ (0 A .%BQ$%' $(
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MRK[<1P!" $( 0@#"RU !)  A "$ (0#A8D0 0@!" ,(^]S%$ $( PIE/ $(
M0@!" $( 0BWH7M"<"T (0-CGZG\!" $( 0@!" $( 0@O0P$( 0@!" $( 0@7
M(P(0 A "$ (0 A "$"Y G?D$( 0@!" $( 0@G/E\&#7G A "$/:Y^E\ 0@!"
M $( 0@!" ,++4 !" $( 0@#"0<=EF#D7@!" $( 0@!" < 'J E0 0@!" $(
M0@#".\*93P!" $( 0OWO7E  0@!" $( 0@!" ,)!1P!" $( 0@#"Q8A+;W,N
M "$ (0 A "$ X0)4 $( 0@!" $( 0OWO7M"<"T (0 A J/\%( 0@!" J,0U
M_'C[,6O7ZW7<;K=YF_2Y_?YGL_9]W&;C_N_/3=KU=AVU-7VF__OZ/O-66Y];
MPCZW/[^S?]NZ^8PU3KYU47:?.N8J9 T^/T[([R_LN12Z)_*,,Y^':Z1QRE\[
MM<U5SG%B/"=;[;/GYW^-[X@XXSQ^3EH7]GG*/EN^(VX5C./Y;Y^W,.>QWC7Q
MWEGY[@)*ZA/V+"UKKM*-XUG0TON\CKJ@O?J_A7&<^6J?\S;K_WSCI+HSM<]+
M'6<OS_:4M6"\[P@KQOG^^-ORZ^OKJ/V\_YRUL !$_00@!" $( 0@7( *0 A
M"$ (0.CC^>\R3 #"/A> $("PSST+!" $(%QZ>Q8(0 A "$ X\PE "$ (0 A
MJ 4%( 0@!" $( 0@!" $( 0@!" $( 0@7( *0+@,\V'4/A> $("PSST+!" $
M( 0@!" $( 0@!"#,N0"$ (1]+@ A "$ (0 A "$ (0 A "$ (0 A "$ (0#A
MPZ@ A "$#Z,"$ (0UH5]+@ A "$ (0 A "$ X6.X#Z/F7 !" ,(^%X 0@!"
M$(!8UD_:<I\'/PN3/OV)]N_;Z (#        ()WI?^@?0@"B,@(0
M +1. .*# (0 !         "5$H#X(  A  $       ! I00@/@A "$
M    4"D!B \'RV$;(0$-         (AM&II8"D[4&)(0@-B(  0
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M#@! RW6H ,0[ 8@G)SDE 8C\XVQ]* 4 4).K!<&9S\<VVMA7I8UC7UD[U@X
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;[0  0'Z_ ,W(POD8DF=      $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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MQ^?XG/O@<^Y#O,#GZ[T/^3\ !  $L9W8#@ ! ,$^)UZP=@ @ "#&>_'? !
M$--.@#@,.<3P.6L'GP- T "=?P.4?4YLQ^?XG/O@<^Y#O,#GZ[T/^3\ !  $
ML9W8#@ ! ,$^)UZP=@ @ "#VYXC (3'+Y\H6&$(((8000@@AA!!"""&$$$((
MH35+Y\C9OZ^OSEGS4F?L ! S6K@((8000@@AA!!"""&$$$(((836+0"(OPL
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MS3#R GR.S\D+\#D^)__'YP 0Y/\ $  0Y 7X'  "  (  @ "  (  @ "  (
M@H$)C1$*'7Q. Q2? T#0 .4\IQE&7H#/\3EY 3['Y^3_^!P @OP? ()<D+P
MGP-  $  0 ! D/\#0 !  $  0# PH3%"H8//28#P.8U+&J"<YS1 R0OP.3XG
M+\#G^)S\'Y\#0)#_ T"0"Y(7 $  0) 7 $  0 !  $  0 !  $ P,*'0H1E&
M,PR?4R33 .4\!X#@C* !BL_)"_ Y/B?_Q^< $.3_ !  $.0%Y/\ $  0 !
M$  0 !  $+/15\"E"D"X!;?9;!)SFT\7T\?'1V:?GY^);;?;S*I=(\_5=0]W
M'[W'_VPKMH1KME6N&<I78]['O;]::V=*]UF"K_!Y_?O@\^7Y?*SXOXQK.//7
M=D:L);:3%^!S<D%\CL_)__$Y/N_SCLG_Z?DMM8X@%R3_7VYO9[W]'_*"?OMJ
M^^>_MVT;^JPNJS7GLVO[\T.L__=Q]]5!=^2^'[O/5_/[L8(_R?__W^[N[C([
M.CI*3'^P[P&(=0@  @ "  ( @@2(9AC-,'Q.D0P 00.49ACQ I_C<_("?([/
MR?_Q.3XG_Z?G!P!!7D#^#P !  $  0 !  $  0 !  $ 03%$8X1"!Y_3 ,7G
M ! T0 $@:(:1%^!S?$Y>@,_Q.?D_/@> (/\'@" 7)"_ YP 0 !  $  0 !
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M7$,"A,_Q.=?@<WS.NL#G^)QU@<_Q.>L"G^-SU@4^Q^>L"WR.SUD7^!R?LRX
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M6'U#<0YY5(V8!P!1/T<:*@8#0-2O/0 @1JHUO@$@ "#0&CM+ !  $&C\&AX
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MAN(<\J@:,0\ HGZ.-%0,!H"H7WL 0(Q4:WP#0 ! H#5VE@ @ "#0^#4\  0
MQ+X% -%/!ZL)8(&#[7/[F=CEU65F&JQN;FXR6^LFGN-!/&:!-R;H@7[FAQI
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M;\T' #& OP @ ""*OB\ Q)2]"0"!$-I_7X3\^V?Y&0#$T *  (!8B@ @^@D
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MF0P 45[8 $  0*!ABDD " "(.31DQWCG !#S\M528L$2ZKFQX@X !  $  0
M!$)37.L $/WS8@ (5*-/"  ! #%% 4#T$P!$NQ #@/B1KP @]G,? (B>"2L
M! #$@LMD (CRP@8  @ "#5-, D  0,RA(3O&.P> F)>OEA(+EE#/C15W "
M(  @ " 0FN):!X#HGQ<#0* :?4( " "(*0H HI\ (-J%& #$CWP% +&?^P!
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M70&)/Y#$X28Q!S?HWT1@$/<#<WIJ/]/CTV-FZH?3TY/$7E]?,UN+ ""2@ 8
M\=?"#  " &*I23D ! #$T.L)  (  @!B='\"0.Q' ! (S;U9#0 ! !'U%0#$
M3]XQ  0 A*NS " 00LO)*0$@QN@7HQ_VE0 @ "!F* "(?@* 2 (: ,1?"S,
M" "(I2;E !  $$.O)P (  @ B-']"0"Q'P% (#3W9C4 ! !$U%< $#]YQP 0
M !"NS@* 0 @M)Z<$@!BC7XQ^V%<"@ " F*$ (/H) "():  0?RW, "  ()::
ME -  $ ,O9X (  @ "!&]R< Q'X$ ('0W)O5 !  $%%? 4#\Y!T#0 ! N#H+
M  (AM)R<$@!BC'XQ^F%?"0 " &*& H#HI\D!$*%A8*5KN@*:VZ *0+@BH:0A
M5-K$K3'TC+P_%SPU2&N :RSROK1('O1@DV>/%(%:@-KA<Z!-HI_M"E<%;G2
MV%CD<*[5\,RLTG!WS %PC<;<F T]EX3K&G!P5DES0M>_2X!T3Y]?7&0VY@$:
M\_G/SXA:Q=J8A:&[3_Z^^J]D!ZYI N[BOUZS;P!."^+(,QQLQ,PU706+*VST
M;&S,?GZ'G9V=9:;/Z<Z:K@+%G86UF@&1/1S)4_2:\_/SS Z:]]JRH^.CQ);:
M3-^G]%QI+++6=1UK3OZYW2[B_6B,UIS.Y74EN5>U(6>EO*DX#XT,7,=Z-[7.
MZDI#?W>?DAI!:QI7\^D@TNWS6D-:O4]H\&[?Q<^_3^0=#[;WOL;+._<>%_4=
MNT%'I1^8=.7%0_I!@<O[^[O,M/<4R5-*8E,I6*'OQOUX1'\D$VF,1TQARL8B
MS] 54R)=D"'7A=9&IZ>GF44&"0J?NB?Y?7>7F.;)KC[1=UY<>T^HCS0Y6*O2
M]QGJ/M_<9S:^&M/G[NRI<:XT]OSRG)B>*XUI;NJ&Q-K;/#DY2<S%V_.+\\3<
MCRBTMS)FGL<^_]E]:L&[KF^? 1$-'""6G;M-;U!,?Y3E^J@E>;$"0?=W]YGE
MP$-W;S.2Y[F]5JLW'(+!"];%U/7X^)"9^D%C'@#$A!N#0UZC H#X^_L#@ "
M (  @ " &.?< X 81@ 0 !  $,,+ *)?G : Z,C7 "!ZW0<  @"B5K]EU+@(
M  $  0 !  $  0 Q@_L 0/S[[ & &#[/8Y__[#X $  0 !  $)-L# YYC0H
MXN_O#P "  (  @ " &*<<P\ 8A@!0 !  $ ,+P"(?G$: *(C7P. Z'4?  @
MB%K]EE'C(@ $  0 !  $  0 Q SN P#Q[[,' &+X/(]]_K/[ $  0 !  $!,
MLC$XY#4J (B_OS\ "  (  @ " "(<<X] (AA!  !  $ ,;P (/K%:0"(CGP-
M *+7?0 @ "!J]5M&C8L $  0 !  $  0 ! SN \ Q+_/'@"(X?,\]OG/[@,
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MO\8$ $3U)ND^&[W[7J<U3D< "  (  @ B*@ (  @QCXOT7\"@%AV W;RWQ<
MXI_?#P " ,()  (A-,\<!0 " &(=^3< ! #$% 4 T4\ $"T!0+3>!0 $ ,28
M#3( B/\:$P 0U9ND^VST[GN=UC@= 2  (  @ ""B H  @!C[O$3_"0!BV0W8
MR7]? (A_?C\ "  ()P (A- \<Q0 " "(=>3? !  $%,4 $0_ 4"T! #1>A<
M$  08S;( "#^:TP 0%1ODNZST;OO=5KC= 2  (  @ " B H  @!B[/,2_2<
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M9K86 4#\(S@!0 !  $  0 !  $#T>08 "  (  @ B-+&+P $ ,3W-P $  0
M! !$>;,UE%,"0 ! V/4%  $  0 QE^$S $3]^P! _/P= T  0$S]/@ 0_WX7
M !#S$0!$/P% _",X 4  0 !  $  0 ! ]'D&  @ "  ( (C2QB\ ! #$]S<
M!  $  0 1'FS-913 D  0-CU!0 !  $ ,9?A,P!$_?L 0/S\'0-  $!,_3X
M$/]^%P 0\Q$ 1#\!0/PC. %  $  0 !  $  0/1Y!@ (  @ " "(TL8O  0
MQ/<W  0 !  $ $1YLS644P)  $#8]04  0 ! #&7X3, 1/W[ $#\_!T#0 !
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M"S1G=0Y*'F26[YG<(GM$/VLI /98>GQZS$S?\>FNWFC;D#]*!(  @ "  (
M@ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ " 0 @  @ "
M  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
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M!:*[/1O)D2*-./6GPNN-9?O!O(M(WJ[/X/9("!Z0\\GU+[K.FM)U6^M'#-H
MC?A+\]#&=&V[6C9_KL/$7'VN[].=A5H+N2%V23T7B?^N 3I48_SV]VUBKC&>
M#;),3NGJ!C7-.]V/=A2L=O%"Z\1(K:TQT.9G\DQNH!_)SS1G<G%18XS+>2/Q
M(Q]L=+^+" "A/0^7%Z@_;=R6O7>\NTXM$NMU#934^1'@IE9-6JL7/-1]OKG/
M*+X:ZCF'ZI,XX.Q\%XO:9NO?!E;HL+SGEU\3R>NZKHGD&]$<LB]\X6*5RYV'
MZVNQSZ<PGZO5@RFYC^O;:(X9^=%P! !R=;[V*/<[BYZ6ST, Q.-#9NH'S;T
M(  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
M "  (+@/  0 !  $^QP  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M @ "  (  @ "  (  @ "  (  @ "  ( @L$H  0 !  $  0 !  $  0 !  $
M  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0
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M\@CTJV=C*.X8,%+?ESZG>Q?Z_G2_-A89$NOW=;"*WM?E!?GP+1\,/3T_)>8
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M3@S]?):K8+?FDP 0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M$  0 !  $  0 !  $ @!0 !  $ @  @ "  (  @ "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (A  @ "  (!  !  $  0
M!  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M  0"@ "  (  @$  $ @ 8CD 1.C0KW1-#D"D2; K+'3CN^)VZ@"$OAL['-<A
MFBE<M5GA5#)@===HH(X5[7GS7!N,7<UKUY1W 4-]K@!"8]>[Y*5MKL#L*M;^
M%/_O[XFYI%>;,JX9K&M9BTG79(@,@/4 =<^9!6%IB#:FNKN_RTSAALC 7)O.
M;IWH,SF8H*NYTMC#XT-B3@H-.?!$G\DU1G0_.M_H.M%U'-F?[OOI,[@UV35
M;"SR6;JV77-?GSL2X]3<WNOR76-=9X9K>KO/TONZ=:I-(C=(UL13WV<$/E(X
ML+&KZZO$W'.6?):#&\8JZDN*B,;4=W9(H,-*,R08ZCDU-C36-?!RL4#OH>?>
MG[-/_!N*G>9]Z=J.G/&N@.L:W+HA1@;#!G)!-PS49W#K7Y_A85>TJ&GCV0UA
M-5XXW]0 A4L!B$BNI>_8Q;RN<Z6QR&?I@*(D+[#K0O, L[:U2(T,$DIABZYX
MZP;QD:&C[FFWWKK@0#?0=\^@W\_F49(#N-JL*R:[=Z%K(!+/7"R(Y&?Z_MSW
MR6*!R8LC^5A7WKDQT)ZN"P>T=-4,I76A>Z<: QW E>6X DU$SNH(].L^^^8/
M#/^?12##2%[@:M (8':^\VO;(HTOO4;OT5@.@Y]D%@$:=2TYGT=@P$B\R.#)
MB_/$W/O3^*OU76-?.[^W+50C!SY+]WUC^3[?9C:4-$=ZW#V[6C:\-S7RV6X/
MMLV!=.XLSO(FB:^7EQ>97>_JE+:]O;\E%JG/=9VXM>+Z+9$>5@:-&MBB"^)P
M=9:3QLZ2V!1IPI?&/(T[SN?ZOMQYI'LFLK9*<N QA\]HFKUT-VLHO<;]58W:
M+*]IWC-[?_](+)07!'Y\$ ,#CC([.CI.K 0F^&/-?V]; %+HO$?P/L>[_]XV
M=TWHAPY/SXFAG^[A*?V4ZKOHARO1^9>>C;]VZZEMD1_EEL,^:1_:U>>::XWI
M]R7(U2/J&ZVG(K,W  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
M"  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (!  !  $  0 !
M  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M 0 !  $  0 ! ($ (  @ " 0  0 !  $  0 !  $  0 !  $  0 !  $  0
M!  $  0 !  $  0 !  $  0 !  $  0 !  $  0"@ "  (  @ "  (  @ "
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M4=^<[FKKMKF:#P "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M @ "  (  @ "  (  @ " 4  0 ! (  (  @ "  (  @ "  (  @ "  (  @
M"  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "(0 (  @ " 0  0 !  $
M  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0
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M*@#Q^)"9^D_] @ !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M 0 !  $  0 !  $  0#!8!0  @ "  (  @ "  (  @ "  (  @ "  (  @ "
M  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "
M  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
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M'X !0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M0 !  $ @  @ "  (  @$  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M  $  0 !  $  0 !  $  0 !  $  0"! "  (  @ " 0  0"@ "  (  @ "
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M'G9)[_W#?6+##F7':4^X9X@ 9UT#Z^A0L49SWZW_6@.G#,8S9Y@]X\4TUD<
M"&VF-]8%4[H"0/W@F@RZ]]R 0N.B[IG&LF:PB?\1>$"'4"XVE>R8DEWEXEE7
MO(WF6MG9;/91#MGF0WX]FT, A,1_%_.Z!OR-Z8 S FB[H4\7^.$ C,A:RH9O
M,KQL+"+=#VZ(T340:TP_V[T+-9>_:BVD_]_M<UT7[K[9WF_B@9C&&/=.([$@
M;W#G_M,<Q.TCS>5+AK*E(+K&0#<PU,]VYU%7?'-G1!=<_+^&7OI=2O,S]:<[
MY_2S73S3WD0$!K<POPP9=?#G]I'N![?^]=TXJ##2%]$S7W\<X7X@X=Z7?M97
MX%_$5QK'%0)N3._K]EZD%M*F<NE>JY'CE@ZZ(V?-V=FOQ#X^/S+[VL6GMKDU
MV%6WNKHK N5D=:R =HWI.M$Z]MC$D% ]9^)BY+R,Q$7-?R(Y>00TTL]VL4"?
MTZT=/2_=^M>ZR_4I]1DT_R^%'H?:1VB^0,17\7V^.F<6#P^/F9V>_DK,YFP9
M*)#:H0$,\J%_#AQL-H>)N=P^!%L$+ *59\-;>\V_@8,(E!"[IAN<B, @FX--
M9GK.E?YX"M7=PT-*>PS%>Z3H;](!NCMC]?N50CECGI=3]WE1G]?4(UW]G]>W
MU\P (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "
M(  @ "  (!B> D  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M $  0 !  $  0 !  $  0 !  $  0 !  $ @  @ "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
M" 0  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
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M !  $  0 ! (  (  @ "  (  @ " 4  0 !  $  0 !  $  0 !  $  0 !
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M8.WD8F=7P]@-$".%3@Z/_<XL>S=F?SX\W"?FI._+#1[ULS2^N7V>^S=_%UU
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M=+_+(=5*UK8%(#I^2.-F#PJUEOY88TJQ?;$ A,P8&]-UDL'] !  $  0 !
M$  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0
M !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M$  0 !  $  0 !  $  0"  "  (  @ "  (  @ "  (  @ "  (  @ "  (
M @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "
M  (  @%  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
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M^87SC<9.-VN8$CR ^L44UU_7'P&Z'E')?M!ZV/5G\>^< (B\_Z,YG-:  !
M$  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0
M ! ,*P$@ "  (  @ " 0  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M  0 !  $  0 !  $  0 !  $  0"@ "  (  @$  $ @  @ "  (  @ "  (
M @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @%  $  0 !
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M  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M @ "  (  @ "  (  @ " 4  0 !  $  0 ! (  (  @ "  (  @ "  (  @
M"  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
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M $2_V#Z_G 0 8HS&+@#$ /<!@/CKO@:  ( 8LKX$@ " 6$[\!X  @!BJ+@2
M0*BO "  (  @4", B.'S_]6<*P 0O00 T1( Q$^+G_D%- "(GS;, "  ($9^
M[P 0>VAT#=. W'?R# #1+[;/+R<!@!BCL0L ,<!] "#^NJ\!(  @AJPO 2
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M_?@%  $  0 QG;[@J+TG (@!8C( !  $  0 Q!S[<  0 !#3%P!$/P% M 0
M,8U"!P!B#:&ZCL_'.PP!(&K';0"(G]\' &+X=S&UN#C6&0$ T;,9!@ !  $
MT3\O (#XD6\ (  @ "#JQR\ "  ( (CI] 5'[3T!0 P0DP$@ "  (  @YMB'
M X  @)B^ "#Z"0"B)0"(:10Z !!K"-5U?#[>80@ 43MN T#\_#X $,._BZG%
MQ;'." "(GLTP  @ " "(_GD! ,2/? ,  0 ! %$_?@%  $  0$RG+SAJ[PD
M8H"8#  !  $  0 QQSX<  0 Q/0% -%/!VMYT,AB_MQ^)G9Y>9G9P>8@L9N;
MF\QJ-7?V623OM?GZ]55D^QRRC/G.]YMP=(U8]EL8;K^^,EM/C-L/-#'H9TUL
MGZ_5YU-;._62TQ$'5])8';0 R/9,Q):0Q2USGW,^+2LN+F%(,+7OLT0 ;O+K
M8L\ Z"+?X<37\E)]-;UWOKP\95RH=KP<=]RULY]G^EKQ#W00*HUQOW__SDP'
MFC&XH7M@KL.MQO1O#@XVB5U<7&2F _6(W"#^ZNHJ,3>HS8&,XTY8H!:H,*:I
M/_6Y&SL]/4W,P3.JAX?'S!2PN;B\R.SA\2&QM>;?^Y:"*6<[?ZGIGM9UTICN
M&1<++BXO$ZL!Q2REI[ $/3X^9G9T=)B8KAL B#4D)=\ $--XRV7/  "QG\_J
M>A< $.MKX % K,_G4UL[ !!]SP@ B#GO<\ZG9<5% (CZWX=FRO[7,0!$A6<'
M@""77FB> @ QGW4! ('0SV,<  0 !  $^IL (*C9:PD HI\ (%H"@!CC+9<]
M P#$?CZKZUT 0*RO@0< L3Z?3VWM $#T/2, (.:\SSF?EA47 2#J?Q^:*?M?
MQP 0%9X= ()<>J%Y"@#$?-8%  1"/X]Q !  $  0Z&\"@*!FKR4 B'X"@&@)
M &*,MUSV#  0^_FLKG<! +&^!AX Q/I\/K6U P#1]XP @)CS/N=\6E9<!("H
M_WUHINQ_'0- 5'AV  ARZ87F*0 0\UD7 ! (_3S& 4  0 ! H+\) (*:O98
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M !"3/;, ();5YP* F$A^"P !  $ ,?,:%0 " &(9 H#H)P"(]B$/ %&]T &
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M*A#AH(C7U]?,]#[N771!'/7LV%CWWRD0L=D<9G9Z^BNQ"'CB='-SDU@$!G&
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M &(=^VKJ-<Q::CP "  ( (BY[W, B"7EV_L_LP @T/P%  $  0"QONH.  (
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M!$((<48,VY>I]3< $  0 !  $)%>)P $ ,38 H#H)P"(E@ @T%)+)@ (  @
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M\VDS7+R8TOD)  $ @1!"Y/94UF1P""&$$-IG=@$  0 !  $ 45, $  04Q,
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MO\\!(/JL'0"(J1;U !  $  0 ! ((7+R?<3_\4YX  B$$$((U>X7%-T'  (
M @ "  (  @!BP0* Z*<#ELS?@]7EU65F&D!N;FXR&RI@(%3KT)_CMQNS&;S/
M(?&T"E"T/U_H6B_S#O[\6>&U1$!C:O$6(816?^8'SH@IQ>1Q ;TZV>G4:P^$
M$$)H]?G0B/T+';XY,.#TUZ_$W)!1!TX.@-!AI;/\;XZ,I7]S=W>7F>:4.I]P
M0^S8]SM)S UN]6\<,')T=)S8V=EY9OI,+R\OF0W57_G\W":F _[&=)U<75UE
MIOX\.-ADIOYU0$O)VK%K\.@PL2Y(Y\\@?G.0F ,K\O6WS6P-M5MCOW__3LSY
M,XLAF]PRR*K96V+')\>)N<_2^^AGNW5R_W"?F .+!JN[ ,][Z?'I,3/=PZ>G
M)XF]OKYFMA8!0+0/.@ (M-C28?[?#@!B604GZK?> 2"&>*?]D_#26 4 @1!"
MZ"=G#0 $  1"""&T['H=  (  @ " &)^M1L 1(6Z"P"BEP @^@D HGW0 4"@
MQ98.\_]V !#+*CA1O_4. #'$.^V?A)?&*@ (A!!"/SEK "  (!!""*%EU^L
M$  0 !  $/.KW0 @*M1= !"]! #13P 0[8,.  (MMG28_[<#@%A6P8GZK7<
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MM@ @9M9L H! 2VRL D!,]S <LA$- #'?=P$  0 QS7,$T;AD2$:1C/:1JP)
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M  0 !  $  0 !  $ ,10 H#HIX.U/&AD,7]N/Q.[O+K,;+,+\&V[N;G)K 2
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M5S0#@ " J-?&0@BAD<]X (CJ<1L  B&$$$)]L@L "  (  @ B"'G$1$!0 !
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MDIC^Z*ZQM0@ HB4 "#2] @  HD^!Y 0  0 Q^7T.  $  0"!$$*3/INK-2L
M('HU'0$@$$((H97D7M\ $  0 !  $,/5(R6U"  $ ,04!0#13P 0+0% H.D5
M   0?0HD)P ( (C)[W, "  (  B$$)KTV5RM60$ T:OI" "!$$((K23W^@:
M (  @ " &*X>*:E% "  (*8H (A^ H!H"0 "3:\  (#H4R Y 4  0$Q^GP-
M $  0""$T*3/YFK-"@"(7DU'  B$$$)H);G7-P $  0 ! #$</5(22T"  $
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M  0 ! !$K7X!  0 Q!P$ -%/ ! M 4  0.S[.0$@ZL<+  @ B+&^"P $  0
MQ##[" #BYY\% #%??R[A^ZPYMU<!0/1[[P 0/3\? ()&*D((K:S7"@ !  $
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MT@ "@.AS  ! Q)N) !  $'_=6P 0 !  $  0 !  $,$\#P"B7RP"@/A9O@T
M\7/?1=XI  0 !  $#5&$$$)E H  @ "  ( 8<OX%  $ ,34!0/03 $32  *
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M  @ "  (  @ "  (  @ "  (A!!" !  $  0 !  $  0"  "  (  @ "  (
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M9BWJ>]]$\__4X]-C9CJ?)R?'B=76_P$@ "  (  @ "  (  @ "  (  @ "
M(  @ "  (  @ "  (  @ " 00@@!0 !  $  0 !  $  0 !  $  0 !  $
M0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0""$$ *  (  @ "  (
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M  @ "  (  @ "  (  @ "  (  @:FC3#N0YSSIP#0 !  $  0 !  $  0 !
M $  0.)>C-L  (  241!5 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M0 !  $  0-#0I!G.VF'.F7, "  (  @ "  (  @$  $  0 !  $  0 !  $
M 0 !  $  0 !  $  0 !  $  0 !  $  0!!$YMF.&N'.0>  (  @ "  (
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M=8N I&Z\=&Z<O]#W<O=24U\:*>*Z\SP2A^H[6=A(YLH5*K,"LOE7RAG<^$5
MW$A^KD52_3CBYP,)6>LN_A^JOH(00FC>4O]_>7F5F4()AX='F>6YAOY-70-X
M;V\_,=LPO+M/S,4V>NZYL_FH?X\UBS2DLUJQ^SA.SO>+BU5FD;PF\GQ5#?V(
M'00!C$VO<[B\ZQP9:_8\%4"$[CW[(;'TL<:$OB+2'#GRL:JKG>A81/((E[/H
M\T2@C4C^%(*O*^K%0!)# !!Y_?_P\" QK8D 0 !  $  0 !  $  0 !  $
M0 !  $  0 !  $  0 !  $  0 ! ((00 H  @ "  (  @ "  (  @ "  (
M@ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (! ""$$  $  0 !
M  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
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M/V76ZI2HZ=NBM9J6^8!)]U[6AS0]1@ (  @ "  (  @ "  (  @ "  (  @
M"  (  @ "  (  @ "  (  @:HS3#F7/FG#D'@ "  (  @ "  (  @ "  (
M@ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @* Q2C.<.6?.
MF7, "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
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M%!FO""01N4[)Y[EYT'I:),]Q_3DTO+0VUEO^@?)Q8I$/L0$@ "  (  @ "
M(  @ "  (  @ "  (  @ "  (  @ "  (  @ " 00@@!0 !  $  0 !  $
M0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0""$
M$ *  (  @ "  (  @$  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M$  0 !  $  0""&$ "  (  @ "  (  @ "  (  @E@% 1!I,K7Z3 Q!?B7D
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M0FVH]Z8^T(WQIJ#17\\161<1V"@RILX7Z-SH'M;]T)OZ_UH 6M>Z:_KK>>
MB,.CP\3<G.OZUW%PL4W$%^A^B,!MK>*+")!AYUQ T@S<#%S7[;T:?^OBXE8
M1 L?TZINT^Y>K2#N-@V";;S.-]=AS@>\3NV]LK\+Q+RQFG+Y6<;\30T H?'0
MW^H,I5IPK*%?SKU;_28W!U*4(>37E]?$:L9XM;K,+*\M'A:MMNE?&K_X=0K/
M<U"^3NB]9G>=@]Q*OSD\K/I-9*ZR>KO)?[6&6UL7'^)OPF>"7-?%]NJ[W!Z.
M^*H(C*)CK/?>EF9X+";_]^?ED?F<'0#Q^)"9K@&M@0!  $  0 !  $  0 !
M $  0 !  $  0 !  $  0 !  $  0 !  $  0- ,YSK,.0 $  0 !  $  0
M!  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M  0 !,UP  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
M"  (  @ "  (  @ "  (  @ "  (  B:V  0K!T "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
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MEXLOL@3X\""SL_.SQ!Q@4Y)[OA)TU5O6E#7[4_]==F>46C:&!N;)&\"!PG,
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MULF7>/;,'X#(U\7AX4%B&2 '  $  0 !  $  0 !  $  0 !  $  0 !  $
M 0 !  $  0 !  $  0"!$ *  (  @ "  (  @ "  (  @ "  (  @ "  (
M@ "  (  @ "  (  @ "  (  @ "  (  @ "  ("@Z8D0PA< 0 !  $  0 !
M $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
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M6XQ%Y-Y?7[E%[M/J.I'X7^?A^_LKLVV4?DS;F^Z]_".5O,<(  $  0 !  $
M 0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0"!$ *  (  @ "  (
M@ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "
M (! ""$ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (A! "@ "  (  @ "  (  @ "  (  @ "  (
M@ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ " 0 @!0 !  $  0 !
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M(=\^X'4BM3GU>>Z#T59]VCGI\>DQ,]U[)R?'B;7ZH ,  @ "  (  @ "  (
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M[U ^I95%?*6K7T3RP,4!$-V9KJ;GG-:' "  (  @ "  (  @ "  (  @ "
M(  @ "  (  @ "  (  @ "  (  @:(9S'>8<  (  @ "  (  @ "  (  @ "
M  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @""9C@
M!  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M  0 !  $  0 !  $  0 !$UL  @ "  (  @ "  (  @ "  (  @ "  (  @
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M>"8%8QP ,58?<EP (L^A#G_.WO^9?C0   $  0 !  $  0 !  $  0 !  $
M 0 !  $  0 !  $  0 !  $  0"!$ *  (  @ "  (  @ "  (  @ "  (
M@ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @$ ( 4  0 !
M $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
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M,>8>1P% 3..'VN4Y !!+.8]:^78 "  ( (AQ<B$ "(30I.<>  0 !  $  0
M!  $  0 Q"\% +&9 "#^430"@)BF<#]F$6;,YP. 6&Y#"0!B!XL5 !"S;3@!
M0#187P 0OVIBS#V. H"8Q@^URW, ()9R'K7R[0 0 !  $./D0@ 0"*%)SST
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M, X L: ]^P< XC?7!H  @!@R'@. 6'83:!MR9)KJ\_ IS!5":"EG'P $  0
M!  $  0 !  $ $14 !";"0!B30 0 !!#-@D (.99  6  ("8VE<!0/S>OVY#
M81P 8D%[]@\ Q&^N#0 ! #%D/ 8 L>PFT#;DR#35Y^%3F"N$T%+./@ (  @
M"  (  @ "  ( (BH " V$P#$F@ @ ""&;!( 0,RS  H  0 QM:\"@/B]?]V&
MPC@ Q(+V[!\ B-]<&P " &+(> P 8ME-H&W(D6FJS\.G,%<(H:6<?0 0 !
M$  0 !  $  0 !!1 4!LIKVY!X-#_D;U^?65V&JURDP!B*NKJ\RJFN-;TH1%
M""&$$$([4L0-)),?GQ^)N=@Y R".CS)[>+A/#"&$4)7G_@.6@Q!"Q.WVWW>%
MC7F=H7[S7?F;FO>:\CK;,%=_1GRO[QVYSI\=^<TWOUG4?([4(Y[;!Q01/3X^
M9*8 Q/'Q<6( $+-*QP$@ " 00@@AA-#2"JE. ! ((30KS_T'  (AA(C; 2
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M1'8$  $ ,9-%"0!!\1<AA!!"""T_G6P7_R.$$-K4)P- ((000@@AA,B. "
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M(G>$$$(((830G#(6 (B_"0!B,^WMSJ8II^B?7Y^)K2Y7F>WO[R5V?7V=60T
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M! "!$-J>Y!8  B&$T S.(P (SO.97P<  N$QB-P10FC[3PB:X0 0S/FNS3D
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M0(SCSP @-O5? !#_&Q\ " "(Z>(\ (C?GQ$ $+^M%P!  $  0/SK7@ 0 !
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M'0V1&XWY(1ZU5812/3X^9G9X>)#8R<E)8@ 0NU"0_0,  0 ! +%MR<90R2T
M! !$[7SB+_Y^\@)  $  0'">S[/$,K=S! !B#@4S (AYS,/<UR0 Q&8"@)C'
M>@>  (  @)CO^;G$6 L  @!BZE@0 &)X?P$ @=!\! "QF0 @_A&X $  0,RQ
MH+&5^Q, 8H  $0!BBJ0!?_'WDQ<  @ " (+S?)XEEKF=(P 0<RB8 4#,8Q[F
MOB8!(#83 ,0\UCL !  $ ,1\S\\EQEH $  04\>" !##^PL "(3F(P"(S00
M\8_ !0 " &*.!8VMW)\ $ ,$B  04R0-^(N_G[P $  0 !"<Y_,LL<SM' &
MF$/!# !B'O,P]S4) +&9 "#FL=X!(  @ "#F>WXN,=8"@ " F#H6!( 8WE\
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MYM;N[^9?=T!HH!A./K+H37NIQ\?'B2DLWMNN" !B/=$!@ " :);H $  0 !
M;);FM$N8ICJO ""F2Z0!(  @AKH.  0 !  $  0 Q'AY_IBQZ7#G^>:_ 8
M@ " ^/?S $ ,4#P'@ " &#7' H  @ CFC@ 0@]>1!JNQ 4 @-(H (#83 ,1Z
MH@,  0#1+-$!@ "  (#8+,UIES!-=5X!0$R72 -  $ ,=1T "  (  @ " "(
M\?+\,6/3X<[SS7\#  $  0#Q[^<!@!B@> X  0 Q:HX%  $ $<P= 2 &KR,-
M5F,#@$!H% % ;"8 B/5$!P " *)9H@,  0 ! +%9FM,N89KJO * F"Z1!H
M@!CJ.@ 0 !  $  0 !#CY?ECQJ;#G>>;_P8  @ " .+?SP, ,4#Q'  " &+4
M' L  @ BF#L"0 Q>1QJLQ@8 @= H H#83  0ZXD.  0 1+-$!P "  ( 8K,T
MIUW"--5Y!0 Q72(-  $ ,=1U "  (  @ "  (,;+\\>,38<[SS?_#0 $  0
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M#10-%-[>WS*+/)\6+PZ[^ZMI8<2.>Z P6!IC]WR1XJ9>UQ6Q6AW>)8CC.US
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MA37U]FV\SA^NTWR,1P4@Y%SI30&(TH?L !  $  0 !  $  0 !  $  0 !
M$  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0
M !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M$  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0
M !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0@ L $  0 !
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M H  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
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M  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0
M!  $  0 !  $  0 !$( $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M$  0 !  $  0 !  $  0 !  $  0 !  $  0 ! ( 4  0 !  $  0 !  $
M0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
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M "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "
M(  @ "  (! "@ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
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MXJ=U_-RU2V=-Q'\XWYY!50:,R8&N?+QTC/7L[DWO==N-CUHI^>Y-BT;JET(
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MTZT?M4C]IU0O\P#)O\?/Q3*/G3]5:]7KJO&W0T' "$T.0!A@J@1> 4  0 !
M $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M0 !  $  0 ! ( 0  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M  $  0 !  $  0 !  $  0 !  $  0 !  $ @1  !  $  0 !  $  0 !  $
M  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0
M!$( $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
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M][$&0@ 0ZZ9G!@ $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0
M!  $  0 !  $  0 !  $  0 !  $  0 !$( $  0 !  $  0 !  $  0 !
M$  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $ @!
M0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
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M !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M$  0 !  $  0 ! ( 4  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M0 !  $  0 !  $  0 !  $  0 !  $  0 !  $ @!  !  $  0 !  $  0 !
M  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
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ML[Y5HP]W 2  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "
M(  @ "  (  @ "  (  @ "  (  @$ *  (  @ "  (  @ "  (  @ "  (
M@ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ " 0 @  @ "
M  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
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MZSI_N$[S,1ZU/R?GB@-92S4:  @ "  (  @ "  (  @ "  (  @ "  (  @
M"  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
M"  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (P 4 "  (  @ "  (  @
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MR64#@('Z G>FJKD\!R&T&0!1@A<!(  @ "  (  @ "  (  @ "  (  @ "
M(  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ " 0 H  @ "  (
M@ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "
M (  @ "  (! "  "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
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M]>TU,P (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
M"  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
M"  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
M  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @
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M "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @$ *
M (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (
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M7P)  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
M $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $
M0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 !
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M[T< "  (  @ B&CB# #1_@0 @ " F+HX!P QCS@/ &)X/]/LS " F"8G!8
M@!@P\@2 ^-T9"P#Q=_]5.U< $+]<[P 0BYE/  @ "  (A(81 ,1F H!8$P $
M $2K  @  @!BZOT(  $  0 ! !%-G $@VI\  !  $%,7YP @YA'G 4 ,[V>:
MG1D $-/DI  0 ! #1IX $+\[8P$@_NZ_:N<* .*7ZQT 8C'S"0 !  $ @= P
M H#83  0:P*  (!H%0 !0 ! 3+T? 2  (  @ ""BB3, 1/L3   " &+JXAP
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M%B:N !  $-M0# . V#!9!( @$!TS&0& ^/4YLJU)^U#G$0#$^+X* &)&YP@
M! #$B&=&S3P 0,S#M^_R&.]V_@$ L4T"@ " F#3N!(!HGGL#0"QG_4]?VP&
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M\<RHF0< B'GX]ET>X]W./P @MDD $  0D\:= !#-<V\ B.6L_^EK.P 0_R<
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M (CM.C0 ((:_%P $  0 Q+\% %$J5@! 3.';ZPHU !"M=P  !  $  0 1%0
M$  04S_/F&<" ,3O8EX B'^-%P $  0 !  $  0 1'TM$0 "  *A)0@ 8C,!
M0*P)  ( 8F[O->6] "  (  @_BT B%*Q @!B"M]>5Z@!@&B] P @ "  (  @
MH@*  ("8^GG&/!, ('X7\P) _&N\ "  (  @ "  (  @ZFN) !  $ @M00 0
MFPD 8DT $  0<WNO*>\%  $  0#Q;P% E(H5 !!3^/:Z0@T 1.L=   !  $
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M0!P?'R<& +&P0 H  LV]. <  0"Q+4DR ,0_DA$ "  (-)MU4;>6 "#&F%$
MB.7$E  0O]UI !!+>2_._/GN*[0+D1X Q&9Y#P#$4GT3 ,1\G@<  @!BB0*
MF,(G T  0 ! ;)L ()*B'P#$HI-.  @ B('6"0 $ (1-1@ @ "#0;-9%W5H"
M@!AC1@$@EA-3 D#\=J<!0"SEO3CSY[NOT"Y$>@ 0F^4] !!+]4T $/-Y'@ (
M (@E"@!B"I\,  $  0"Q;0* 2(I^ !"+3CH!(  @!EHG !  $#89 8  @$"S
M61=U:PD 8HP9!8!83DP) /';G08 L93WXLR?[[Y"NQ#I 4!LEO< 0"S5-P%
MS.=Y "  ()8H (@I?#( !  $ ,2V"0 B*?H!0"PZZ02  ( 8:)T 0 ! V&0$
M  (  LUF7=2M)0"(,684 &(Y,24 Q&]W&@#$4MZ+,W^^^PKM0J0' +%9W@,
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MI\?,%( X.3E)# !B)PX6 (BA#S$ "  ( (AE^<&Y%SUJD@8 B/9S#@#1X(P
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M%M?4;I3$MYKS,9^G:GP6D.B0B/VNP-*N8=BFV$1D,,]]55\\G,^<1V"MN16
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MP9C^ @#B]_,)  $ 414O D",$GL!0"#47@ 0FPD 8DT $&AN2?*PA1$ B%X
M$,L*GN>TAP$@ ""VY8P:M1#Q!P " &+>9P0 Q&;[=8G^;,K="0 QCM]96BRX
MM?$& ,0LSBP:"_/PVP 0RXD+QO07 !"_GT\ " "(JG@1 &*4V L  J'V H#8
M3'N[\J*1("0#("XO,U, XOKZ.K.OKZ_$$$((H;\E8G,_&Q':EC@/(83^C.PK
M\$O(KXMM!/T00MN>.R)$+(@00@A-J\>GI\P4@#@Y.4D, &('@QL "(000I.<
M1P 0"+&6$4*S\1?;<B^TI#4( ($06E[NB!"Q($(((32M " V$P#$F@ @$$((
M#7X> 4 @Q%I&",W&7VS+O="2UB  !$)H>;DC0L2"""&$T+0"@-A, !!K H!
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M  $  0 ! $%<   ! $'1&P "  (  @ "  (  @ "  ( @E@0  (  @ "  (
M @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ "  (  @ " X  @ "
M (  @ " 8)\#0 !  $  0 !  $  0 !  $  0 !  $  0 !  $  0 ! 8  0
M !  $  0 !  $  0 !  $  0-$;Q.P 0 !#L<P (  @ "  (  @ "  (  @
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M!2#<"YIS 0@!"/M<_>]>4 !" $( 0@!" ,++4 $D "$ (0 A .%BQ$%' $(
M0@#"!Q,!" $(9SX!" $( 0@!" $(9S[W@N9< $( PCY7_[L7%(!H+0#13W[6
MCS-N(7_7O;^/VM=OWV:M.W6C=NR.LS;M<S@>9ZWKNE$[' ^SUIU.HW;\_>=F
MK0MIW;C%&&-QG ;Z+/Z.X_3ING%;[C->%UN.,QUC:9SI&#6.4\=<Y>D3]CO>
MN,_T>9NHS^*SO<&U4\6<)^M3US,YYS@M/-O-^39S'J^FW'"<5/6V?5[L.Z+T
M^BSO6BY\?^ZJ_G?F2__.RG<74%2?1/MJ3[5@:?5%2?>"WOG.?.X%S7D-YX@:
MZO]5?4+N,C/=J]KGZO]F:L$5^RIEGZ7_('_Z_^'EY3)J;V]OLS;[5M[WLS;]
MRK[<1P!" $( 0@#"RU !)  A "$ (0#A8D0 0@!" ,(^]S%$ $( PIE/ $(
M0@!" $( 0BWH7M"<"T (0-CGZG\!" $( 0@!" $( 0@O0P$( 0@!" $( 0@7
M(P(0 A "$ (0 A "$"Y G?D$( 0@!" $( 0@G/E\&#7G A "$/:Y^E\ 0@!"
M $( 0@!" ,++4 !" $( 0@#"0<=EF#D7@!" $( 0@!" < 'J E0 0@!" $(
M0@#".\*93P!" $( 0OWO7E  0@!" $( 0@!" ,)!1P!" $( 0@#"Q8A+;W,N
M "$ (0 A "$ X0)4 $( 0@!" $( 0OWO7M"<"T (0 A J/\%( 0@!" J,0U
M_'C[,6O7ZW7<;K=YF_2Y_?YGL_9]W&;C_N_/3=KU=AVU-7VF__OZ/O-66Y];
MPCZW/[^S?]NZ^8PU3KYU47:?.N8J9 T^/T[([R_LN12Z)_*,,Y^':Z1QRE\[
MM<U5SG%B/"=;[;/GYW^-[X@XXSQ^3EH7]GG*/EN^(VX5C./Y;Y^W,.>QWC7Q
MWEGY[@)*ZA/V+"UKKM*-XUG0TON\CKJ@O?J_A7&<^6J?\S;K_WSCI+HSM<]+
M'6<OS_:4M6"\[P@KQOG^^-ORZ^OKJ/V\_YRUL !$_00@!" $( 0@7( *0 A
M"$ (0.CC^>\R3 #"/A> $("PSST+!" $(%QZ>Q8(0 A "$ X\PE "$ (0 A
MJ 4%( 0@!" $( 0@!" $( 0@!" $( 0@7( *0+@,\V'4/A> $("PSST+!" $
M( 0@!" $( 0@!"#,N0"$ (1]+@ A "$ (0 A "$ (0 A "$ (0 A "$ (0#A
MPZ@ A "$#Z,"$ (0UH5]+@ A "$ (0 A "$ X6.X#Z/F7 !" ,(^%X 0@!"
M$(!8UD_:<I\'/PN3/OV)]N_;Z (#        ()WI?^@?0@"B,@(0
M +1. .*# (0 !         "5$H#X(  A  $       ! I00@/@A "$
M    4"D!B \'RV$;(0$-         (AM&II8"D[4&)(0@-B(  0
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M#@! RW6H ,0[ 8@G)SDE 8C\XVQ]* 4 4).K!<&9S\<VVMA7I8UC7UD[U@X
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;[0  0'Z_ ,W(POD8DF=      $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_0b.jpg
<TEXT>
begin 644 image_0b.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '9"$ # 2(  A$! Q$!_\0
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MI:/BW&%(1F@YI:-]& E!H- H\A *6DH&:-M  #%+12<YHVT0!CG-+12<YHV
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M D5NC _C7YXC_@H%\0U4J-&\,X/_ $ZW'_Q^A?\ @H%\0X\XT;PSSZVMQ_\
M'Z;OJ'.C]#A(K=&!_&CS%)P&&?K7YXK_ ,% OB''G&C>&>?6UN/_ (_0/^"@
M7Q#5BPT;PSD_].MQ_P#'Z3;U#G1^AWF+G&X9],T>8H."PS]:_/*3_@H%\0UC
M,PT;PSN]/LMQCT_Y[TD/_!0+XASH9&T;PR&4\8M;C'_H^GJ5?J?H<9%7JP'X
MT&15ZL!^-?GH/^"@'Q"G^]HWAD8]+6X_^/U##_P4&^(ETQ1]&\,  9^6UN?_
M (_23;!.ZN?HCYBXSN&/K1YBXSN&/K7YZ?\ #P+XAL?+.C>&=O3_ (];C/\
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M^@+ZV/T+,BKU8#\:/,4#)88^M?GA!_P4$^(EUNWZ-X8&WIMM;C_X_4G_  \
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MZU^>$_\ P4$^(EKMV:-X8.[KNM;C_P"/T]?^"@'Q#5%D&C>&=S#G_1;C'/\
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M^$HSSG_D'_\ VVOW1'P!\&^20W@WPRTF#\QTN'_XW20_ #P9&I#^#/##'/\
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MW7^S(1G_ ,ATT:1/PWA_93\[/_%4;<?]0_\ ^VT0_LJ^<Q7_ (2C'&?^0?\
M_;:_<P_ 3P8/N>#?#*^N-+A'_M.F2_ /P:5_=^#O#*-GJ-+A'_M.A;LH_#8?
MLJ[IC'_PE&.2,_V?_P#;:#^RKMF$?_"49Y S_9__ -MK]RU^ ?@P*/\ BC?#
M._'+?V7#_P#&Z&^ ?@PJ?^*-\,[\<-_9</\ \;H^U<#\-9/V4_+D5/\ A*,[
MN_\ 9_\ ]MI)OV4_)Q_Q5&[/_4/_ /MM?N3'\ _!RJ=_@[PRS]F_LN$_^TZ>
M/@)X,/W_  ;X9;TSI<)_]IT->\F%^A^&TW[*/DJ&_P"$ISSC_D'_ /VVFM^R
MCMC\S_A*<\9Q_9__ -MK]QHO@#X0#?O/!_AEUQT.F0G_ -IU)_PH7P;G!\&^
M&2OI_9</_P ;I26P'X;K^RCNA\S_ (2G'!./[/\ _MM-B_91\Y=W_"4XYQ_R
M#_\ [;7[C-\ ?"'F97P?X9$>?N_V9#_+RZD/P%\&C[O@WPRH]M+A'_M.G)70
M7L?AM!^RGYV[_BJ-N/\ J'__ &VD7]E/S)&3_A*,;>_]G_\ VVOW'F^ 7@XX
M\KP=X93UQID(S_Y#IX^ ?@P*,>#?#(?NW]EP\_\ D.G+8#\-$_95W3>7_P )
M1CDC/]G_ /VVA_V5=LWE_P#"49Y S_9__P!MK]RI/@'X,*';X-\,J_\ >_LN
M'_XW1'\ _!@0;O!OAEG_ +W]EP__ !NCH!^&DO[*ODMM_P"$HSQG_D'_ /VV
MGS_LI^3M_P"*HW9_ZA__ -MK]RA\!/!9^]X,\,L??2X3_P"TZCA^ 7@X9\WP
M=X9?TSID)Q_Y#I1V _#=_P!E/RXU?_A*,[NW]G__ &VG?\,I_P"C^;_PE'X?
MV?[X_P">M?N5_P *$\&9Y\&^&2O8?V7#_P#&ZC_X4%X.\[/_  AWAGRO[O\
M9D..GIY=$=$!^&Z?LI^9&S_\)1C;V_L__P"VTZ#]E/SMW_%4;<?]0_\ ^VU^
MY7_"A/!F>/!OAD+W']EP_P#QNHYO@%X../*\'>&4]<:9",_^0Z%NPN?AO#^R
MGYV?^*HVX_ZA_P#]MI8_V4_,D9/^$HQM[_V?_P#;:_<L_ 3P8/N>#?#*^N-+
MA'_M.F2? /P<RC9X.\,J_=O[+A'_ +3I)>\V!^&[?LI_OO*_X2C\?[/]L_\
M/6AOV4_+D5/^$HSN[_V?_P#;:_<E/@'X-6,;O!WADR?WO[+A_P#C=*?@'X,*
MG/@WPR7[-_9</'_D.G;WKA?H?AM/^RGY.W_BJ-V?^H?_ /;:27]E'R5W?\)3
MGG'_ "#_ /[;7[CP_ +P<,^;X.\,OZ9TR$X_\AT\? 7P:?O>#?#+#WTN$_\
MM.DUJ@/PW;]E';#YG_"4YX!Q_9__ -MIJ_LH[H_,_P"$IQQG']G_ /VVOW&7
MX ^$/,RW@_PR8\_=_LR'^7EU)_PH7P;G \&^&0OI_9</_P ;IR5PO8_#:/\
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MN'_XW2M[UP\C\-IOV4_+D"?\)1G<.O\ 9_\ ]MI\'[*?D[O^*HW9_P"H?_\
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M"X?_ (W1;2P)/L?AV?V5=T(C_P"$HQP!G^S_ /[;5=OV5=K>7_PE&>V?[/\
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MN'_XW2GX!^#-A_XHWPSOQPW]EP__ !NGU+5[GX:3?LJ^2P7_ (2C/&?^0?\
M_;:)OV4_)Q_Q5&[/_4/_ /MM?N3%\ _!H7]YX.\,NV>ITN$_^TZ>/@)X,/W_
M  ;X9;TSI<)_]IT/=%GX:R?LI^7$K_\ "49W=O[/_P#MM-_X93_<^;_PE'X?
MV?[X_P">M?N0GP"\'>8V_P '>&63LO\ 9D)Q_P"0ZD_X4)X,SC_A#?#.S^[_
M &7#_P#&Z)= /PUC_93\R)G_ .$HQM[?V?\ _;:;#^RGYV?^*HVX_P"H?_\
M;:_<A_@%X.\Q=G@[PRJ=U_LR$9_\AU(?@)X,'W/!OAE?7&EPC_VG1+5 ?AK!
M^RGYV[_BJ-N/^H?_ /;:1?V4_,D9/^$HQM[_ -G_ /VVOW'F^ 7@XX\KP=X9
M3UQID(S_ .0Z>/@'X,"C'@WPR'[M_9<//_D.G+8#\-5_93_?>5_PE'X_V?[9
M_P">M$G[*?ER*G_"49W=_P"S_P#[;7[DO\ _!K1G;X.\,B3^]_9</_QNDC^
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M\]:='^RGYD3/_P )1C;V_L__ .VU^Y7_  H3P9G'_"&^&=G]W^RX?_C=1O\
M +P=YB[/!WAE4[K_ &9",_\ D.B/4#\-X?V4_.S_ ,51MQ_U#_\ [;1#^RKY
MS%?^$HQQG_D'_P#VVOW,/P$\&#[G@WPROKC2X1_[3IDOP#\&E?W?@[PRC9ZC
M2X1_[3H6[ _#8?LJ[IC'_P )1CDC/]G_ /VV@_LJ[9A'_P )1GD#/]G_ /VV
MOW+7X!^# H_XHWPSOQRW]EP__&Z&^ ?@PJ?^*-\,[\<-_9</_P ;H^U<#\-9
M/V4_+D5/^$HSN[_V?_\ ;:2;]E/R<?\ %4;L_P#4/_\ MM?N3'\ _!RJ=_@[
MPRS]F_LN$_\ M.GCX">##]_P;X9;TSI<)_\ :=#7O)A?H?AM-^RCY*AO^$IS
MSC_D'_\ VVFM^RCMC\S_ (2G/&<?V?\ _;:_<:+X ^$ W[SP?X9=<=#ID)_]
MIU)_PH7P;G!\&^&2OI_9</\ \;I26P'X;K^RCNA\S_A*<<$X_L__ .VTV+]E
M'SEW?\)3CG'_ "#_ /[;7[C-\ ?"'F97P?X9$>?N_P!F0_R\NI#\!?!H^[X-
M\,J/;2X1_P"TZ<E=!>Q^&T'[*?G;O^*HVX_ZA_\ ]MI%_93\R1D_X2C&WO\
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M"^#NW@[PS_X*X?\ XW0E9W!IL_#)?V4_._YFC;C_ *A__P!MJ=OV4_,C5/\
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MB//W?[,A_EY=**L!^'"?LI^9&S_\)1C;V_L__P"VTZ#]E/SMW_%4;<?]0_\
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ML/[+A_\ C=#W0'X;-^RCMA\S_A*<\ X_L_\ ^VTU?V4=T?F?\)3CC./[/_\
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MDR[]#\-IOV4?)4-_PE.><?\ (/\ _MM-;]E';'YG_"4YXSC^S_\ [;7[C1?
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M!.W..:%)(Y&*+A<=1358MG(Q0K'<01Q1<+CJ*8&;=C'%!9MV,<47"X^BF,S
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MX>-7L7W=1\#G/_3=O_DBCFT%?2Y^E,%U%=;O+;=MZ\$5-7P+H/\ P4-=O/\
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MM+A=N[=C[R#^Z>GI7XZ_MB?&3QCX?^)NF6]CJ_V>!M(BD9?LL+<^=."<E#V
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M !]?^TJ_%#X@L_\ PNKQV4R6_MB_S@9_Y>6J.K%;6Y^PO[)K+_PA7PQ!^_\
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MV8RK'.<'^[^M EW-F:0QQLPZCUK-N-6FAD "H1C/(/\ C7P=^UI^V3_P@O\
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M..*_+W]IK]J3_A#?B?XJL/\ A&?MGV2*)O,^W[-V;6-^GE''7%<9\*_V[_\
MBG[C_BA_^7IO^8M_L)_TPH!7ZGZXP7#2;L@<>E9USK4\,CJJQD*Q'(/^-?D#
M\7/^"AGV3^RO^* W[O-_YC./[G_3O7C%U^UG_:EU->?\(KY7VAVFV?VCG;N.
M<9\KGK0]A:W9^]5CJDMU<1QLJ -G.T'TSZUJU^0_P-_X*#?9/$7AO3?^$"W^
M1;F'S?[9QNVP,,X\CC./6O7OB%^WINT'7Y/^$&_Y<9CC^U_^F1_Z84(&['Z(
MW%PT,@  (QGFLW^VY_[D?Y'_ !K\)O&7[:7]O:I%<?\ "'>1MA$>W^U-W1F.
M?]2/6CP7^UY_9?VS_BD_-\S9_P Q+&,;O^F7O0.Y^^$$ADAC<]64$X^E),?+
M5I!U'K7PK^Q3^UQ_PL[Q,NA?\(I_9OV30/M'VC^T?-W;7@3&WREQG?G.>U?<
MFE7_ /:=A%<^7Y>_/RYSC!(Z_A0,FMY3-&20 <XXJ6O/_B[\1/\ A!?#.N3_
M -G_ &[[/I4]WM\[R]VU'.W[IQ]WK[U^;_QH_;P^P_V/_P 4/OW>=_S%\=-G
M_3#WH _5"/4)&SE5_(U/;W#32$$ #&>*_GXO/VP/[8V?\4EY/EY_YB6[.?\
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MI3NMPYEN?K4;Z3T7\C1]ND]%_*OY_O\ AK3_ *E7_P J/_VJIX_VOO[*_?\
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ML]"U'4M,BU!/,C7PC$V,R#YMUJ/X?J:7D3=+0T_!?[#>NV_@>S@8>%C N_\
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M3?;''W+(#.WS.VWT[5-NY*U/S5_9O_:)O?"'C?PM9S:OX@\N37[69DM[EMC
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MOTK_ &%-*MK?_A-]D6W=]AS\Q/\ S\>]-;BM8^X=!A:'P_ID1(W);1*2.G"
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MNVW%O'*/,^]AE!Y]^:O5P/P@\56^M_#WP<PNO.FN-(M)#^[*[B8%8GH,5WU
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M6J.HM;G[!?LFQG_A#?ADXP%.@6A _P"W(5]15\N?LF2$^#?ADH/R?V!:8_\
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MBCQA]G^*FJM]DW?\264?ZS'_ "W@]J8==#Z?_:NM5F^ WBH1[I)2;7"+R?\
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M_P"$?\-:Q<_8_M'V>PFGV^;MW;48XSM..G6OB/XI?M>?V7_9G_%)^;YGF_\
M,2QC&S_IE[U8T[['!?L_?L;VWA/^WO-LO%%O]H^SX^U1!<[?,Z?N1_>_E7Z7
M^$_!FCZ;\.?#%E=WLMK';:?:P@S2HC96%1@Y'7@_E7S5\%_VA_\ A:7]L?\
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M\?Z;;R>$+])9&2/]WEMP'_+1?:OF?]FGQY_Q7=__ *#_ ,PV3_EM_P!-8O\
M9KZ(\>:Q_:/@N\7R?+\Q8F^]G'SJ?2@$N5:'XY_MP):6_P :/B!!'<*R"UA
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MC/W/^H>WO7Z/6]I]GA6/?NQWQCO2=QZ]#XH_X*&:3;WUCXAGED==GA"X&58
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MMH5=M+0)(****"@HHHH \&_:DQ_Q3&3C_CZ_]HU^*?CY5D^-7CL.VU?[8O\
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M2=/&B6>F?9'=O(MXXE6/,K/D!..^>/6O1^&YZT<O0;6EC\J_V_+Y-:_X03R
MR^7]OSY@QU^S^F?2OBGX$^'KFZ^+WB,(\0_T>Y;YB?\ GXC]J_:OXK_ 6+QG
M_9>WP?I>I_9O-_U\%N=F[9TW^NWMZ5Y5X!_9/_L/QIJEY_PKS0[42QRKYL=O
M9@MF13C@Y[?I5:7V)ZGK7[/<+6OAGP*CD$QZ1;J=OM; 4_\ :,N%E\#_ ! M
MP#O?1+M 3TR;5J];\+^&[71='TN!=/MK26VMHXML4:#80@4@8_+BJOC3PK#X
M@T36;?\ LVWO);NTEA"RQH?,+1E0IW?ES1JQI/H?SO?'SPY<_P#"86?SQ?\
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MT>UM/.\O&Q(_FQN_N_7]:]$DD6-<L<#I5)65A^H22"-"QZ#TKX4_;2M7O/\
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M2?\ IW]J_+?0;5[;XM^*MQ4XFNUX_P"O@5^_7Q@^%\/CC^R<>'['5?LOG?\
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M?K4,3V=_:WGF1B4?9YE<%2!\PP3QR.?>J4KD/78O;E'>EW C/:F.H"DTL?\
MJQ1UL";V8X'/2FA5;IS3AA>,UR>I_$[PIH_E^=XHT2#S,X\[4(ESC'3+>] /
MS.J6%$8LHP3[T&1&?RR?F]*Y&'XR> IL*/&_ALR8RRC5K?(]>-]5)/C%X%CU
M @^-?#@^NJP>G^_1=%75CN/)0L&V\CIS3FW<;:Y%/C#X$=21XU\.GZ:K!_\
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MDGTH)>USH/$/CCQAX]U*\%Q>_;H)+A[I?W4,><L<-PH/1NGO6[X1_9I^(?Q
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M!(DM@<9;IQ5VTLAV:V/V!4^;$IZ;@#3E7:N*QM U"/5/#NFO$&436L3KO &
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MPA/Q*\4V?_"/_;?LOV7Y_MOE[MT,)Z>6<8W?I7@MK^VU]DQ%_P (9OW-G/\
M:F.O'_/&NC_;6O$N/C%XR@4,';['R>G_ ![P&OEK4-+EDC=PR85#W/O[55NX
M6ON?H+^R_P#M<?V]_P )-_Q2GD>5]F_YB.[.?-_Z9#TK]8=#U3[;=NGE;,(6
MSNSW'M7\['P!OH]&_M[SPS>9Y&/+ /3S/7'K7[O?!K5X=0\474<:R!A9LWS
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M16#;9%<G;N^4#_'VJK#XFM9L[8YACU4?XT-::AS(UZC+;B5Z54@UF&X8JJR
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M -56[B(S1@# .<\T 2T5$\1:W\L8S@"EAC,<:J>H]* )**** "BBB@ HHHH
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M;7[:AN-^SRSC;C.<<]:;-#YV.<8]J)$.\/V6HY%^TXV\;?6A;W06T&_\?O\
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MB^'[XG'M:-0,_$/]I_Q1_P )9X^L+O[-]EV:9'%L\S?G$LISG _O?I57P/\
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MHP"-8OSS_P!?+5'45M;G["_LFR8\%_#*/'30+09^ED*^H:^6?V2UV^#_ (9
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M-=-)DQL!UQQ7YX_LC_';4M>U;X?6-UXGL[AYM,3S(5^SABPLV8\ 9&"/TK]
MM$O#J&EPSF192^[YUQ@X8CM]* +%NCJA\SEL]SFGR2K'C<<9IS=#BH_+$W^L
M&<=.U+J+J2US?C+4CH>@WM]-.]M!$5S(I.1EP!TY[BM/3I[J29A/NV;<C<F.
M<CVKR']I3QQ%HWPI\3.-7M;9X7A7]Y)&-O\ I,8P<_ES3 _./]M[XN+<?$+X
MC6=OXBOBLNGK&L(DF"DM8QC&.G)-?&'P[\&ZWXPT6>]M[0Z@D=PT)EEE3((5
M3CYFS_%^M=/^TEXRO/$7QT\0(E_'?6]TUK%^Y",) ;:)2 5'U'%?1O[&_P )
MXM7^&.IS/X?O+@KK$J;E2;'^H@..#[T7?0BUUH>&?%+X3ZKX8_LSS=$@LO/\
MW'EM#\VW9UVGMGOZU'^S;XT/A;XD:JLFJ7%BT>GRP'RGDX(FB^7Y>W'TXK[R
M_:^^"<=K_P (E]A\,:A\WVO?LCG?_GCCN?>OS!U:34O!?Q(\3-%'-II6]N;?
M,T6, 3'Y?G'7Y?KQ3*MT/Z!O@1XNMM:\'^"$6_DN99M(MF^??\W^C DDD?CS
M7L$S;8G/3"FOS]_8W^+$VH-\--/FU^SE8Z-$K0!H0V5L2<8 SD8_2OOBRN/M
MVEB4.)=ZM\RX(/)':I3N-/09%,C+ESN.>XS7X(_MN0W8_P"$+W%O^7W^/_KA
M[U^\W$/RO\AZX;BOPF_;(8W7_"(><=VW[9CM_P \*+=25T9I_L1+!%XXF;4$
M5X?[!8 2+O&[S8.W/;-?L-\#+7P_<?"K1&-E9N&\_EK4<_OY/]FOP@^"_P 1
M+OP?XBGECU:#3E^Q- 'F\L#&]#M^8=?E^O%?9OP]_;.U[P[X/L+./XBZ39V\
M/F8CD-E\N9&/)9<]3^M*ZN.ZN?J8;'P['&W_ !+[(+C)_P!%7_XFHH[7PQ-G
M986)QU_T,?\ Q-?FR?VZM;DC;_BZ&AE<8/SV'_Q-5)/VYM;AQY'Q/T3G[VU[
M _\ LM-WZ#=^A^GVFZ3HB^9]BT^SBZ;_ "K94SUQGCGO7"_M!1LO@FQ2$;0M
M_& %XP/*DK%^ OQ"NO&?]N^9JT&I?9O(QY/EG9N\SKL'?;W]*V?V@'D_X0>P
M9,EC?QYP,_\ +*2F"/QE_;2C=?BKXQ(XF_T/Y@>?]1!W^E?/FC:;>:A9R (9
MF9R@W./0<<GWKZ$_;.N%_P"%M>,%DD42?Z'E20#_ *B#M7/? KP;9>(_"%Y>
MR6$EY-%?.BR1E\#$<9 ^4XZG]: ;L>76=K=^$]_VK=8_:,;?+<'=MZ_=/;<.
MOK7[)?L@^-8=4^)6I12:E-<A=(E;;(9"!^^A&>1[U^4_QZ\._P!B?V%MLI;7
MS?/_ -8&^;'E^OU_6OLS]A3Q]=-\7-7%SJD*Q_V'-C=Y:C/VBW]J2=PO=:'V
MY^U)XF33?@OXIN/MTL"(UOAT+C&;J(=OK7XA?'S6;C7OC!KC0WD]U'<&W0;Y
M&^?]Q&N#N_+FOU)_:\\?/)\"O&$:ZO;,-]L H:,_\OD-?E3<6-QX@^)UG,;>
M6\AN+VV0R1(2KCY%(!7Z8XJFC/5ZF5:^%[RWT2\DDM%5$5V8[DX 7GO3/!</
MF?;/*4<;,XX_O5[7XZ\*QZ+X=U94L9;918S2'>'_ +C<\_2O$O LK_Z=Y1W?
M<SMY_O5&M[%)OJ?O=\#\?\)9=X_Y\G_]&1U[?@=<<UXC\#U \67>/^?)_P#T
M9'7M]44O,3'M3)((Y&R\:N>F64&I**!G+>-/'^B>"?L?]KZ@;+[5O\K$4C[M
MNW/W5.,;AU]:^$OC?^V%H6CZIJL=M\0=5LQ'JLL06#[:@50T@VC"]..GM6E^
MVU\5O$&C_P#"&;-72W\S[;G?%%SCR/5?>OR]NO$VJ^//B/XDM-4N#J-LMW<W
M"HD:K\WG8#90 ]&/MS2UL+4^C]<_;2O&OKXV_P 4_$HC,SE-M[?*-N[C'IQ5
M;3?VR=4%Y;33?%+Q,;99%:3=?WQ&T'G([\9K>^%O[)OA+Q9_8$FH>";V\2]M
M5FE99;M1(QAW[AM<=^>*M?$O]CO1-#375T7X>ZLD5O:L]OY8O9 &\K=P2QS\
MV:-1-V/6/AG^VYX?DT&<W7Q)UB63[2P!D-\QQL3OM^M?H/\ #OXF:%XX_M#^
MR]4:_P#LOE^9NBE79NW8^^HZ[3T]*_G[U[X;^/\ PS>):Z/X1\006SH)65=)
MFD^<D@G+(3T K]1/V,=9\;P_\)A_:4%];Y^Q^7Y]@(\_Z_.,H,]J730F]]C[
M#^*^O'0_#=K=)=RV>^Z5/,A9E)RCG'R\]OTKX _:*_:I7P?X@\060\?ZUIL]
MO]G_ '=O/=KLW)$>"HQR&[>M?;?QH+W'PUT1YP3*UQ SY&#N,,F>*_&/]N)I
M(_BIXU5<B,?8NW'^HMZ=NH^I]@_LT?M1-XTU#2(F\?:UJCSZY#:A;FXNVW;C
M$-AWCH=W?CFOT6\*WSWGVK=,\VW;]\DXSGUK\.?V#\R:]X9)Y;_A++4#_ONW
MK]NO J,GV[<I7[G4?[U,I7ZG)_&3Q9)X3_LCS-2N-/\ M'G8\EW&_;LZ[?3=
MW]:_-WXL_M?MH'BS7H#\2=>M!#JMQ $CN;T!<2.-HVCH,=N.*^^_VIHTD_X1
MCS!T^U8R<?\ /&OPF_:$NI)/BAXTA+9B3Q!>[5P.,3R 4 G<_7+]CGXY-\1E
M\([?%FIZT;S[9_Q]37#>9L\_KYGIL[^@KZ_\6:D=)\ ^([^6=X!:V%S.9E)W
M1A8F;<,<Y&,\<U^7G_!+MIY-9^&<;!C;?\3/^'C[MV>OUK],_C.%A^#?CM4X
M8Z#?D+GDG[.]+K<+'YX_M!?M86GAW^P?+\?ZQ8^=]HSY,MXN['E]=H[9_6N@
M\"_MBZ!)JTPF^(.J.OD' ;[:1G<O^S7P9^U?#?S?\(MY<$SX^U9VQ$X_U/M7
ME_@3Q/XCN=7F6"2:9Q 25CMU8XW+SPM4*R2/T?\ B5^VKI:Z5K$=A\2];BN%
MFQ'Y4E\A&)1D [1CC->%7'[:DT>JAI?BEXCPKJ6)N[X\<>U4/ _[/>L>-O[*
MDO\ P-KFH0:A MQ))'97(64M'OW H!P3@\<50^)W[),NB6?B"YMOASKT#VMG
M)-&YM;PA&6+<#SQP?6D*UUJ?6/[-_P"V5H>M0VD%[\1-6OIIM82%5N#>R;@1
M$-N67IDG\Z^[/ /Q)T7Q-]O^RZH]WY'E[M\<HV[MV/O+['IZ5_.MX8UOQ1\,
MO%&CVZK<Z&!>0W>R[M0I^^!O_>+T^3Z<&OTF_8K^/&KZ]_PF7]H^)[2;ROL?
MEY%NF,^?GHH]!0/6Y^GLUQ';J&D;:N<=":\5^,WQX\+>%?".NO+XAFL9[25(
MW>*&?<C><JD JGX<5W7Q,\3P:%H,%P-1M[0M<JF^21 #E'..?I^E?C!^U!^T
M+XIU#Q%\0]'@\307%H-:N(X[>*&W8E$NR5 (3)P%'?M0#=CW/XG?ML:5;ZMK
M,%G\2];@40XC2*2^0 F(=,+QS7B<W[9U[(P,7Q2\2;<8XO;X5X5X%\!^(?B3
MKNASW/A_5-9AU.\B@DDM[.7;,ID$94&,#L-O'.1ZU]7Z/^PG9SVK,_PI\0L=
MY'^HU#T'^U0[V%Z'<?#']MC2)O[2^U?$O6I<>5M\Q[YL??SCY?I7WQ\$/CGX
M6^(FGZ9:Z;K\NJ7PTJ*YE$L$ZDC$8+%G09.6'?/-?A3\4_ /B#X8?V9_9GA[
M5-'^W>;YGG6<I\S9LQCS >F\]/6O=/V&_P!H3Q=I/Q&O+*\\20V<-MH+PB.X
M@MT*%9K<;3E,Y !Z\\4#;MJ?MEK=R(='EG1RG"D.N0>6%?#7[1W[0$7@[Q9X
MMLG\7ZEILMI:A_*@DN0(\VRN"-@QWSQZU]AZ7JC:Y\*]'OGG6ZGN].M)VDCQ
MB0LJ,6&..<YXXK\H/V[)I8_BY\1XP<'[%'A<<_\ 'A%0/H=G\.?VT-+71)Q>
M_$G6GE^T-@R27SG&U>^WZUO?%K]M/P^/[*^R?$;5X_\ 6[O+^W+G[F/X?K7Y
M?Z?JVJ64+) SHA;<1Y0/.!ZBO5/"W@#Q;X_^U?:/#6L:K]DV[?(T^7]WOSG.
MQ>^WOZ4EL);'T/IG[8MW?Z]>QP_$[Q%)""[(GVR^"A=XQ@'IP:ZG_AK:^L=,
M^TS?$GQ"D"]6^V7IQEL=![FO./@S^RO=:AXAG^W_  ]UYE-DS_-:WB?-O3TQ
MZFNM^-7[.D'A;X8ZS<Q^#=3L7@\G#RQW.%W3QCG<>^>_K0E;1BB>A?"_]L2+
M6/$FBV[?$C7;I9M2AA,<D]Z0V70;3D=#GOZU^A/P8\<6_C#^V/)U.;4/L_DY
M\[S/DW;^FX=]O;TK^?[2[^^\$_%3PG;Q,VF6_P!NM+AUG0#_ );@%B7' POT
MXK]8?V,_BDUU_P )AMUZSEV_8_NO"<?Z_P!*-BGHM#[JD#'&*^0?VO/CG!X#
M\,[H_%6H:/,FM_96:T>X0C"393*#IE?IP*^I?$VL-I/V;;<I;^9N^^5YQCU^
MM?CG^WS\5)]7N-<TV/7;2Z:W\5S_ .CQ-"SIM-PO( SQG'/K1MJ)Z:G7:7^V
M$VM^+HM%M_B5K]Q=RYVVS7-Z <1ESR1MZ#/6ONC]EGQE=^)/@YXAU"[U:\U%
MX;^X3[1<RR.ZJ+>%L MS@9)X]:_&?]EWPG?>,?C]X9D?2KS4H;C[5EX87*OM
MM)>A0=BO;TK]HOV=_"2>$?@AXJM'T^;37>YNIA#<!U8YMHAN ;G'RX_"DEU!
M+J>*?M5?&C0_!O\ PB_]JZ_/9?:?M7EX2=]VWR<_=4XQN'7UKP/]G_\ :.T/
MQ#XRO+:U\6WMS(M@\A1EN1@"2,9^9?<?G6+_ ,%)Y)D_X5UY0;_F(YPN?^?6
MOFC]B.,7'Q6U59QE/[%E(SQSY\%4#9_0#X"O%O\ P)X<NUD,J3:;;2B1LY8-
M$IR<\\Y[UY=\7OC+HW@N\\0P7FO7&GRV5J976-)CY8\D/D;%/8YXKJM#U1M
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MV[RMN\S/MD8I-K?J!>MYAO/G-N7'\7/-9?A_1]2U[QDMG!&US'-++LA:0;2
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M_P"Y7=?L;:+_ ,)+XXN+'SOLWE:(TGF;=V<2P+C&1ZU^M/P4^"OVOX6Z,_\
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M+&267Y664K\G Q@'^M?LA^QE\%=$U3_A,/-NM07R_L>-DB#KY_\ L>U?D?\
M#.;SM!G;&/\ 26'_ (ZE?O3^SKIG]D_\)!^\\WS/L_\ #C&/-]_>C;4IVZG<
M>'_A9I/ANY,]M<7CN8_*Q*Z$8R#V4<\"O+_VIO!5CJOPI\3P2RW"I)]ER490
M>)X3W7VKZ!'(!K!\>:;_ &MX4OK3S/*\SR_GV[L8D4],^U,--S\ _P!JCPI:
M>$_BEHQM))I/+TV&X'G,#\PGFXX X^45[#^Q%\1-2L_^$TV06IW?8L[D;MY_
M^U7JW_!03X?_ &?7KJ3[?NV>%V;'DXSA[G_:KX7^#VK?\(A_:_[K[7]H\G^+
M9MV[_8Y^]^E )WV/W:_:(\87OA__ (1_[/% _G?:-WFJQZ>5C&"/6OPE_:"\
M27.O?%SQTEQ'"@_X2*_D_=@CG[1)ZD\<U]N_M,?'O[?_ ,(W_P 2+9M^T_\
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M@Q*-GEK<<?-7ZN?$K4I=0_L[S%5=GF8V@]]OO[5^.7[!ZY\6^$3_ -3=:?\
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MLR^EN?M7F[,?+Y>,Y '7/O0!^UUG^TEXFNHS<O8Z2'C;@+#+CCG_ )Z5Y?\
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M;A0N+8-\H$8P?ZU\/2P7%FVR"7R$(R5C8J,^O%?1GQ4_:<UKXE:IK@L_$O\
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M?VEKJU_YT BN/%LQ4*[;AN%RPSQ7V3^Q'$\?_"9[AC/V+_VO5#]M3X"0>/?
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MUMFA\Y0N<<YZ4L4?EQA<YQ0-'PWHO[!'AK3O!.L6RR>*_.D68I&[1;F)B
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M\?C7UTR]_2A6W4Q)]&?E;\./^">MII?]H^=IOC:#S/+QYT 7.-W3-O[U]Y_
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MK>*&+A 3\QQZ'VK?A\JVA""0;5[LP^M>]VG[(GVJX2+_ (2S;NSS_9N>V?\
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MVG=,ZMV7</\ "OI7_ACC]YYW_"7_ / ?[,_#_GM2O^QSYKB3_A+\;>W]F?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0&^@+G'-!Z4,<#-(K;A0'D"YYS3J**!K0****!A1110 4444 %%%% !1110
M4444 %%%% !1110 44E -*^M@ 9I:*3/-+;0 YS2T44P"BBBF 4444 %%%%
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M]:;#NC&USN8GKG-.X$U1S3>2H;&><5)32H;[P##WH ;&N[#^O.*>> 31TX'
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MOH?6ND^.?[4\W_0O*\O'_+7.<Y_V?:NJK\._"O[?$UO]JWZYXV.[;C%V??\
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MN]F&O4_H=^$?QITGQMX;N;Z#6?MJ1W;0F3[*\>"$1L8*#^]^M>LW#2+M\O\
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MUESNG_\ '&_PJU#<Q7&#"VXD;NA''XU^;U[_ ,%$GM]GEZQX&;.<_P"E9_\
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M *C5O LF>O\ I)./RN*5U8$[['Z.PWEJTA*/\QY/!JPMQ&[!5;)^AK\VM/\
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MM8+W/Z"](:%O-\KVSU]_6OC;]OZ[N4^'EL&?$0\1*%X'_/&XQ5GX"_MIW7Q
M_MSSKWPJWV3R,?8Y2?O^9][,Q_N_SK._;FO(-8^"V@ZBTT>Z[UJWG)C<;,O;
M7#?+UXY]:2E=$W/R,\?/-<?&>^ .Y6\OT'_+LM?HO_P37MIE\'Q';\H\6 GD
M?\\[6OSQ\;+%#\8KV5I L V?O&("_P#'NHZ].M?9O[&OQJL?AQX-E5=5T6(Q
MZX;P"^N%4\1P<GYU^7Y/YT[WW"]]S]?F8+UK+BUS3%;*38./[C?X5\-^/?\
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M<WA_4-2A;5/!4<EK</"4GN"&4ARI##SQ@UZ'\)?VO(?B GAZ675_"SRZC=K
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M_M,0^5_PC?.<_:>W_7*OW3_:$/\ Q:OQM_V+U]_Z(DK\*/VEFV_\(Y_V\_\
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MQ%\1O$PNM-O=+@C_ +$^RXNI9%.[?,<_+&W'SC]:5K,?DCX'_9)^/7_",_\
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M_P#VZOHC]@W_ (I_2;/[1\^WQ,DQ\KG@+;^N.>*_2ZV^)NEP[MT%X<^B)_\
M%4M$%C^?W4-#_P"$+A6^\[[9YC>3Y>SR\9!.<Y/]W]:^U?V1/VA/.\=>!-&_
ML#'EV30^?]LZ[+-^=OE]]OKWJE^UU<+JWPVTV&$%675HW^?@8\F8=OK7QO\
M!0?V7\=M.GE^9(Y[L$)R>891_6AW>EP]3^BCP3KO]H^!;;5/(\OY)G\K?G[K
MN,9QWQZ5\[?M"_&C^P?&EE;_ -C^?NT])-WVK;UDD&/N'TKIOV<?&%E'^R_I
M(,4_%K?_ ,*_\_$_O7YU_M^>)K6\^,6CND<P T&$?,!_S\7'O5+0''2S/D/X
MI?%K_A/?[,_XE7V'[)YO_+QYF[=L_P!@8QM_6N@^&GP*_P"%CS1K_;?]G>99
MB\_X]/-QDI\OWU_O]?;I6#\$_"UWXE_MG[+)#'Y/D[O.8C.?,QC /H:_;?\
M8]\ :AX?\*^&+JXFM7CD\,VJ 1,Q.2D)[J/2IM;8GEML?E!XD^#/_"%^'Y[C
M^V/MGV()'M^R^7O^8)G.\XZYKS#6M:^SV%[:>3N_<LN_=CJI[8]Z_H/^.WA^
MY\3?"/6]*M7BCN)A;A6F)"?+/&QR0">BGM7XA?M8> =0\-_&'Q>MS-;2&UB@
MD?R68Y M(FXRH[4UH+E1Y-\/[OR]&F&S/^D-W_V5K^@SX/Z)_9?]K?OO-\SR
M?X,8QO\ ?WK^?WX>W27>BS.@8 7##YO]U:_?WX)V,EE_;.\J=WDXVD]O,HZ6
M95K[GYP?\%';O[#INIOLW_\ %72KC./X;G_"OCC]GVW_ +1^/&@W&[R]_P!H
M^7&<8M9!_2OM#_@H]HL\>E:C.7CV2>+I"!DYY6Z/I7QO^SS9O%\?M <E<#[1
MT_Z]9*7*K6!1TL?LC^QW8^3X%NOGSC6F/3_IE!7O7B^/S/LG./O_ /LM>(_L
M@_\ (AW?_89?_P!%0U]#7W\'X_TIVZ!96L?@Y^V2WG?\(A_#C[9_[0IG[$]M
M]L^)NHQ;MFW1)#G&?^6T JM^V-_IG_"([.-OVS.[W\BM']C6W:;QU<H" 5T1
MNO\ UU@HY>PE'L?LA\&+?[/\ ]'BW;L>=\V,?\O3FOA'_@I!QXBNXO[_ (3<
M;O3+W0K[T^ -NR_ W0HLC=^_^G_'U(:^)_\ @I;^YUC486Y9_!\F".G+70I2
MC=C<5U/RN\-P?8/M'S;]VWMC&,_XU_1E\-=-^QZY._F;\VS#&W'\2^]?SD^$
M[&3_ $KE?X.Y_P!JOZ._AW_R&Y_^O=O_ $):.7J+EUN?$W[>UMY/PJ^)DV[/
M_$P0[<>NH15^4#S;?$D,N,[9HVQGTVU^M/[;D@C^'_Q&8]!J"]/^OZ.OR=UB
MS?4OB-$D153-<VZ+O]2$'-"C8+)'27EO_P )!<(F[[/Y@$.<;L9/7MZUJ:'\
M$_[0\_\ XG/E[-O_ "ZYSG/^W[5]]_L$?"C5[KP6TR7%D%7Q'@AG?/$=N?[E
M?>D?P[U*SSOGM3NZ;7;M_P !I<JZ@MK,^=/AGI?_  B>O3W?F_:M]LT6S;LQ
MED.<Y/\ =_6OCS]J[XU?:-+\>Z3_ &-MVZDT7G?:L_=O%YQL[X]>]?9?[:?B
M2VC^%NEDQS?\AF+L/^>$_O7XUWVFRZS\8M9$#(IGU.\=?,)&!ND/. >U/?8=
M]#1T/P/_ ,+ U*QN/MOV#^T)TAV^5YGE_,(\YW#/3/:O5[?]D?RD(_X2O/.?
M^0=_]MKZL_9+;_A'?!_@6*Y^=K>^+OY7((^V.W&<=C7Z Z-\8-&TZU:.2VOF
M8N6^6-,=!_M^U"74?0_G_P!>'_"K?(_YB?V[=_TRV;,?[V<[_;I7W=^PG^T+
M]L\1PV']@;/L_AP#S/MF=VU[=>GE\5S'[9FH1ZQ_PA_DJR^7]LSY@ Z^1Z?2
MOEG]G_4HO#OQ>\1W-RKO&]K<Q@1 $Y-Q&>Y'I5"N?T)Z?KF/!NGZKY'^LM(9
M?)W]-ZKQG';/I7PW^UY\<O[%NOB+;_V)YWE:3(=WVO;G-D#TV'UKWOP_XLM+
M_P#9\\,QQQSAI-$TXC<HQ_JXCZU^2O[;$+7'QT\=2J0%,%OUZ_\ 'E#0Q;[G
MSMX^\7?\+$UB'4OLG]G^5 MOY7F>;G#,V<X'][ICM7JOAK]F+_A)OM/_ !4O
MV;R-O_+AOW;L_P#30>E5O@3X0O-:\(WD\$L"(M\Z$2,P.?+C/8'UK]X_@WX5
MN_#/]K_:I(9//\G;Y+$XV[\YR!ZBEN/<_#[4OAC_ ,*]M(Y/[2^W[&%KCR/+
MS@'YOO'^[T]Z\N\7:_YFI7>G>1C[G[S?_LJW3']:_?/]H_P5?>)O"-M#:RV\
M;?VDLO[YF QY<H[*>>17XS?MD>%[KP[\5O%]O<R0N\/V/<8F)',$!&,@>M3R
MKJ):,P/V;;/[1\3/!9W[?^*BLATS_P MHJ_<'X&P_P!G_P!M\^9O\CMC&/,_
MQK\.OV7U+_$'P>!W\1V8_P#(L5?N%\!/]#_MW?SN\C&WV\RCE^X.NA['55[/
M<S-OQDYZ5:HJRCP;]K#P_L^#7BF^^T9_X]?W>S_IXA'7-?C5^TSX-_M;QC:Z
MK]L\K[+I:_N?*SNVR2MUSQG..E?T'5\:_M\Z7+>:/XDE1D"KX2N0=Q.?NW!]
M*EKJ3YGXG0W?V?/R;MWOBNUT/P5_;MV\'VSR-J%]WE;NA Q]X>M<9XJL9+?[
M+N*G=NZ$^U?J'^QEX7NM:^*&J0020JZZ/*Y,C$#'GP#L#ZU&K>H;^AG?L=_"
MC^R_B)X#O/[4\W99/\GV?&<V4@Z[O>OHC]H[]H/_ (5[X+^('A?^P/M_V71+
MI?M7VSR]WF6I?[GEG&-^.O:OHGQF?[$^%KK/\YM[>WC?R^<D/&O&<=Z_%']M
M[Q';77QV\>PJDH:2"W0%@,9-C"/6JW8MV>+^/OBM_P )OK,,/]E_8OM$"VF[
M[1YFW<S#=]T9^]T]JN_#[X+?\)3]O_XG/V7R/+_Y==^[=N_VQCI^M:7[+?PX
MU/Q5X[\)2VD]K&O_  D=I#^^=@=WFQ'/"GCYA7[:?!'X2ZOX2_MK[9<V4GVC
MR=OD.YQM\S.<H/[PJK:W*MK<_$?QU^SO_P (?I,-Y_PD'VOS)Q#L^Q;,95CG
M/F'^[^M<UX-\;?\ "'^)K1OL7VO[$7A_UNS?A&3/W3CU[U_0?\1/!%]KFB00
M02VZ.MPKDR,P&-K#LI]:_&7]K+X6ZMH^H_$>\FN+-HH]9GR(W<MS>8[K[TFA
M+O8^P/V2?VA?M?A'P':_V!L\V_\ +W_;,XS>.,X\OWK]#]!UC^W+-Y_)\G;(
M4V[MW8'/0>M?SI? [6(=)\:>"K299&DCU>VR4 (YN%/<^]?NG^R5?QZC\.=2
MDC#*HU:1?F S_J8?\:$K#/RQ_;=O-G_"%_)G_C][_P#7"OD31[[[;KEY%LV;
M=YW9S_$!7V7^WM:O)_P@N"O'V[K_ -N]?*_PKT&XU[QEJ-K;O&DD=O(Y,A(&
M!(@[ ^M.R6@NFI#'X6_X2*;[!]J^S^<3^\\O=C'S=,CTKV#X*_!O['XJ\'_\
M3??Y>JV[?\>V,_Z0#_?K]+/V<O@_K,&@^!+IKFQ,?]D6[8$CYYM1_L>]?36G
M^#;VT2$/+;DHV3M9O7/I4N_0'MH<=^S7X=_LGP+?0_:/-W:E(^[9C_EE$/7V
MKV%FVXXS5;3[1[6%D<J26S\OT%6Z?D.VFA2U2/SK9!G'S _H:_*3_@I%\*_M
MWB+XB:]_:FS=_9W^C_9\XPEJGWMWMGI7ZT5Y-^T9ITK?#'Q#<[E\O_1^,G/^
MOB'I0[@?SOIH/]EPO'Y_FYR^=F.W3K[59T?PQ_;WG?Z3Y'E8_P"6>[.<^X]*
M]J_;F@8?%32Y,C"Z'$3^$]Q4W[%ENVI_\)CY1"[/L>=_'7S_ /"BUUYAYGN/
M[#/P6_Y';_B<_P#/C_RZ_P#7Q_MU],?MD:3]G^ 'A.Q\W=]GU*TC\S;C=MM)
MQG&>*^U_"FE2Z9]J\UD;?MQL)/3/M[U\L_M^7B3?#.RB4,&7Q"F<].(;@4MM
M!:I61^.GQ:M/LOB_56W[MOE=L?\ +-*M?#.?[98_8-NS[3=^5YF<[=P1<X[X
MK'^+-C)J7QFU6VB*J[^5@N3CBW0_TK[C_P""=O@:_;PW; 2V^3XJ4?>;^Y;?
M[-58=CY_;]FW_A-,?\5%]C^S?].._=N_[:#&-OZUY7XS^#?_  KK2XM2_M?^
MT/-F%OY7V;RL95FSG>W]WICO7]$_AGPM=Z-]I\^2%O,VX\MB>F?4#UK\_P#]
MO/P]<VOP@T=W>(@Z["/E)_Y][CVI--]1V9\$?LY?%7[!\5O#=I_9?F>0DT6_
M[1C.VVD&<;?:OVQ_9I\4_P!M_"3PS-]E\GSGG7;YF['^DR#T'I7X!>';5XOB
MD[$J0+JYZ?1Z_9O]AVW9O@C\/Y 1C[3.?_)Z6A*PK6'?M_>&?MWA_P 4ZC]I
MV?9_"%T?+\O.[:EPW7/'7TK\2-4F\SRN,=?Z5^XO[>*DZ%XF/_4IW7_H-Q7X
MD>-H6F^Q;2!C?U_X#3<1V/U\_8'C_P"+PZQS_P P&;_THMZ]@_:N\?\ ]B_"
M7QA_H'G>1-"G^NV[L7<8S]TXKRK]B"!KCXKZLJD _P!B2GG_ *[P5B_MR>$;
MR]^$WQ%5)( 7O8R-S-_S_P 1]*F*L3:ST/S4^,'C_P#X23XK:G9_8/LWVU[>
MWW^=NV;H8USC:,XSG%>@_"G]FC_A,/#MQ>?\)']D\NZ:'9]AWYPB'.?,'][]
M*^?)HSX5^*%B;O\ >?8[VVFD\GG(!1N,XYQ7WY\ /VI_"GAGP;>6MUI^LR2/
M?O*##!$1@QQCO*.>#5/N-]SR;XH?L9_V/_9G_%8>=YGF_P#,,VXQL_Z;'UKY
M\CC_ .%>>)=2@S_:'V:22RW?ZO=M?&[OC[O3WZU^QUM^UQX/DW8TW7./^F$/
M_P =KE;G3Y/'VI7-]I[+#%>2->QK<DJP1SD [<\X8>WO4[:BZ7.)_8]^*?VC
MQ!\/(/[,V_\ $L4;OM&>EDW^S[5^C.@7_P#:FD07.SRO,W?+G.,,1U_"O"_A
M7\*=6TG5=#U":XLFA6#)5'<M\T) ZK[^M>_6<#6]JD3$%AGITZU2\QJY(T>[
MO3)X/.V_-MQ[5'-:O(P(*],<U);W2W&[:&&WUHLEL"*VJ7G]FV<;[/,^8)C.
M.QY_2OSB_;\^,G]E'QWIO]D>;Y?V#][]IQG/V=NFSW]:_1W6;"34;58XRJL'
M#?,3CH?\:^=/BW^SUXC\7ZUJMY9WNEQ17'E;!/+(&&U4!SB,_P!TT<J>X65S
M\//$%W_PLOQ7IJ;/[-\_RK+.?-V[I#\W\.?O]/;K7J/@W]C/_A)?MG_%8?9O
M)V?\PS=G.[_IL/2OTST?X%:_X&U6R:_N]-F$,Z73?9Y9&^4,,@90<_*:]H\.
M?%#2O ?VC^T+>\F^U;=GV9$;&W.<Y8?WA3Y>B*:OH?AIX\^!'_"$?8?^)Y]M
M^U>9_P NGE[=NW_;.<[OTJ_\!/B9_P (3XWOX_[-^V^38R6N?/\ +SB6/YON
MG^[T]Z^QOVLOCUX?\2?\(K]FL]2C\G[5N\Z*,9SY.,8D/H:_/RWF&J?$3Q#/
M$"J33W$JA^#@S9&??FIU'R[G[D?L7_$'_A+OAIX.?[!]D^T?;./.W[=LT_\
MLC/W?UKT#]H/QI_PB/A[79_L?VOR-%GN=OF[-VU)#M^Z<?=Z^]?/_P#P3ND%
ME\&?A^S\A?[0SM][FYK$_P""BWC.RMI-9L&BN#-<>$)@K!5VC=]I49Y]:HD^
M+/VFOVA/^$K_ .$;_P")!]E^S_:?^7S?NW>5_P!,QC[OZU\X>'_#/_"=7CV'
MVG[#Y<9G\SR_,S@A<8R/[WZ5RNH:?)?>7Y;*-N<[B>^/\*_9K]F'X:ZG-X^O
MP)[0'^S)#R[?\]8O]FER]16/S=NOV7?+\,QWG_"39W11OL^P>NWC/F^]>1:E
MH_\ P@?CR*T\W[=]@N()=^WR]_"OC&3CKCO7](>K>%;N^\)#2XY(1<>5$FYF
M.S*E2><9['M7P=^T9^Q[XS\7^-_%5_9ZGH44-U;HJ+/<3!ABV1><0GN*+ >+
M_L@_&[=#8:1_8O\ Q^Z_'%YWVK[F\0KG&SG'7K7N'[8/A/\ X2C_ (1+_2OL
MWD?:_P#EGOW;O)]QCI^M<S^S3^QGXU\'W6ERWFJ:#*L.MQ7+>1<3D[08B0,P
MCGY37W[H?@+4-,\_S9K9M^W&QF/3/^S[TK:IE'\X>O>$?^$0LTO/M?VOS)!#
ML\O9C()SG)_N_K6W9>%O^$ATNVA^U?9_M$2/N\O=MX#8ZC/2O>/VH/"%YX7\
M Z?=W<L$D;ZG'$!"S$Y,4I[@<<&O+_V683J'Q[\,PQD*SFZP6Z?\>LQIVZB2
M6YW_ .S[\$_)\?> ;O\ MG/EZW:2;/LO7%TIQG?[5^P/@WPU]FTN5?M.[,Q/
MW,?PK[UM_LY:/-:_"/PYN:,[&G)VD_\ /S(?2ND\<?\ (6B_ZX#_ -":ER]A
MM+<_G=^-D?E_V-SG/G?^TZ^U_P#@FEHG]K^/FB\[RL>%-^=F[_EK:C'7WKXB
M^+*FZ_LK9QM\W.[_ (!7W7_P33M7G\=>6I4%?"G.?^NMK1K;4C6VI]"_MA?#
M?'P$\8R?VCU>V./(_P"GR'_:K\A-:L_^$=^+5NV_[1]EO+67IMW8$;8[XK^A
M[XG:'<:C\([NUC>-9&AML%B<<21GT]J_$3]L?X>ZC8_'KQG>R36IB@CMI657
M;<0MG"3CY>O%+E"W8^V?V+?B)]L^%NJ/_9^S&LRC'G9_Y80?[-?I-=77V;;\
MN[=GOBOP9_99\:V.E?#_ %"*6*X9FU21_D52,>5".[>U?M#=>.;"UV[XK@[N
MFU5_^*IJ-D%^B/C;_@H)XT_L[P<3]C\S'B;9_K<?\L[GG[OM7YA>9_PF'QMV
M8^R?:._W]NVV_#/W?UKZ*_;P\?:?JVH^(+>&&Y5T\5W#$NJ@<&X'9O>N+_8R
M\)7GB#XO^#[VVD@2*;[9M$K$-Q;S@YP#Z4^70+H^Z_\ @G_\.?LWP[N;C^T-
MWE>(V?;Y&,XAMCC[U=!_P4 T_/\ P@?[S_G_ .W_ %[5])? ?0Y_#_PRUNWN
M'C=VNIY 8B2,&&,=P/2OF?\ ;:A:;_A#-I Q]MZ_]L*5KH:[GY5_!'1_M']M
M?OMNWR?X<_\ /3WK]H?@]9_;O@_X&M-^SRM"L?GQG.+=!T_&OQ:^ _\ S'/^
MV'_M2OWD_9;;/PO\$#_J6;'_ -$14<MP9^3/[>?P^_L_X]>.=>^W^9L^P_Z/
MY.,YM;=/O;O?/2OEE=-_M:>,^9Y62$^[GOUZ^]?L#_P4DM7E^&'Q$8%<'^SN
MO_7>UK\AX;-V\::)%E=SW$ 'IS)BBUA>9T?AOP;]G^T?Z9NW;?\ EECU]Z_2
M_P"&WP+\O7)S_;>?]&;_ )=/]I?]NL7_ ()Z^'[B/_A/LO%S_9_0G_IY]J_3
M*XB,T8 P#G/-/<>C1_.?^T1X:_LSXA_$&'[3YGD:[>1[MF-V+IAGK7>_LH>.
M/[%\3_#72_L7G;-=M5\WS=N=UX#TVGU]>U?3W[<WA*\C\*_$^[,D'EG5BV Q
MS@WZ8[>]?G]X"UB'2_B-X:M95D:2/5+7)0 CF5#Z^]#2V)^+0_HF^&VK?;/"
M][=>5L\N=_EW9SA%/7%>?_'/QAY?]B?Z)G/G_P#+3_KG[5QW[&.NV\OPAUN8
M))M35Y\Y SQ;P'UKR'_@H%XRLH_^$#S%<<_;^BK_ -.WO1;2P:?"?E1\1_%G
M_"2:'!;?9?L^VY63=YF[.%88Q@>M?;?["?PYW?$CX:7_ /:/^LTYI/+\CINL
M).,[O>O@SX2Z7+J_B.YAA9%9;1G)D) QO0=A[U^W'[)GA.\T_2?AO<R20,B:
M+;Y"L<\V>/3WI-7%),^H/#>D_8=)MH_-W["QSMQGYB?6MAI-IQBH_/6-Q&0=
MV<>U3T^A?0*:J[6)S45M"T.[<0<^E.N(C-& , YSS0!+138UVQJ#U Q3J8PH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \'_:BM_M
M'_",_-MQ]J[?]<J_%+X@0;OC5X[3=C;K%_SC_IY:OVM_:C_YEG_MZ_\ :5?B
ME\0(C-\:?'8& ?[8OSS_ -?+5-M;BMK<_83]DV3'@OX91XZ:!:#/TLA7U#7R
MS^R6NWP?\,@>HT"T'_DD*^IJ:5@V"BBBF,**** "BBB@ HHHH **** &2!CC
M%*^2.*20L,8I7SCBI[D]P.=F.]"K\HSUH.=GO0K?*,]:.H:7/,?VA.?A7XV
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MM3*()!(\R%"=G&>?>O$_VGED;_A&O+S_ ,O.<''_ #RKW-5"]*\/_::D\O\
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MV^N._I7V9_P3O\'O?>,PTNF7$D3>%]ZL$< YDML$$?6I^T966Q]C?M-12?\
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MZX>U?B3\7+69OB?XP>V7:&UJ\(*$+\OGO_\ 6K]3?VX?BM /^$*^R^(]/?\
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MYBO_ &R_]GK^>?X:RW=IH<Z('0&Y8X*?[*^HK^A+X.M(W]K^9G_ECC(Q_?H
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MN?MWD>;_ *E%.W=LZ[1WQW]*=Q65[GJ_[('PRU/5?B5J<3Z1#<A=(E?;(T1
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MQWH/]M_8?W_D^5YG\&[.=ON/2@H_G*^)6E1:!XMUZTMV=X[?4IX$,A!)59&
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M_P"FQS][]*^V_"^B_P#".Z#IECYWVC[+:Q6_F;=N[:@7=C)QG'2@72[/FO\
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MO^$]\S[3J<I\K^Q\;=S.W7S^>GI2L*QP^F_MN>.;/18]FE>'CMSC=;3]V/\
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MQ77P4T2%F<+(MRA*D9P;B4>E?-'[8?P@T;4OB9IDLMS?*PTB)?ED3'^NG/\
M<]Z^Y;6#[+;K'NW;<\XQWS5'5-$_M*X67SO+PNW&S/<GU]Z99_,G]ND\&_\
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M3GRNO_ Z_G=^'=S_ ,22?Y?^7AN_^RM?T+_"'_F+?]L?_9Z5^EB5>^I\)_\
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M_P#A//M/V/5;:Y\O^Q]F_9*C;<^><9QUK]%?A_X)_P"$1^W_ .F_:_M'E_\
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MS,5C9NX&:P/ ^@_V#X3T&Q\_S_L=A!!YFS;OVQJN<9.,XZ5T-(LBMY3-&20
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MA6*D%&3G!'8U^W/[3?[*?_"R_ =AI?\ PE']F^3J<=SYO]G^;G$4J[<>:O\
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M62.?[Z*^.FX T\#'2A5"]* U*,V@:9<$F73;20DY.^!3D^O2HAX5T4-N&CV
M;^]]E3/\JU*9+O\ +.S[W:@94CTR*S799Q16L1.2D2A 3ZX Z]/RJQ!')'NW
MMNSTYS21RE?EE.')X_R*GH KW:P-L\Z)9>N-R@X_.LV[\'>']43-WH6FW08^
M9B>SC?YO7D=>3^=:\D2R8W#.*<H"J .@XH Y63X6^$O,,L7A70XYNT@TZ$,.
MW7;Z5;L?!>E:>R&#2M/@VN'_ '5NB\\<\+UXK?)QR:%8-TI$V5QL<,<.?+C5
M,]=J@9I5;=4<_F_+Y?X]*E"@=*8]>@GEJ&R%&?7%(RL6X.!3MPSCO2/G:VW[
MV.*30:,%4[2&YKPO]IWRX_\ A&OD'/VGH!_TRKW&'S/+._[V>.E>/_M!^'[S
M7/[ ^SP>?Y7VC=\ZKC/E^I'I1Y!Y'\]>L:R?LR^8\SC>."<]C[U^EW["MQ;W
M?C+X8I+%YL;:4"4D4$'_ $!SR#7R+JO[)'C*2W4#PIGY\_\ (1A]#_TUK[O_
M &-O@[XC\)^-OA]-J&D?9;2TT\QR-]IC?9_H3J!\KDGD@4UJ3=+4^\$\&Z)J
M4?FS:-ITR2<,);5&W#H0<CFG)\-?",8PGA715'HNG0C_ -EK7MXY8515&(@?
M;UYJ69I68>5]W'M045K>QT_3-WV:Q@M_,^]Y,2KG'3./K5Y&5E&!@8XJNL#O
MGS%SZ<U/N2% 6^4=*2\Q:[#)(8+@&.2%)%/564$&J4OA?1II#(^D6+R'^-K9
M"?SQ6C@$;E[\BEW<8_BIJXO4JVNCV-G&4ALK>%2<E8XE49]>!5RFKG'S=:=0
M4B.9'D4!&VG/KBEB5EC 8Y;UIQ..M&X8SVH"Y6O-,M-05EN;6"X#*4/G1ALK
MZ<CIR:P+SX;^&[S9O\.Z.^W.-]C$?_9:Z?))XZ4ZBVMQ:2.;C^&OA"+.SPKH
MB9Z[=.A'_LM:6GZ#9:;)_HUE:V\878JPQ*H5>,  #@<=*FO/M?R?9_?=T_#K
M4\;/Y2!O]9@;OKWH"^@_:%3"C:/:H_.5752"6/2I.O!ZTUH49@V/F'3FF+=W
M%DA27&]%?'3<,UAS>"](U!1'J&D:?>P@[A'/;)(H;UPR]<$_G6YNV_>I)O,V
MCR_O9I#TD<V_PN\&NI!\):$<^NFP_P#Q-+;_  Y\-V<L9M_#VD0)&P95CLHU
MV\YXPO'-;\7G^8-_W>_2K% _,KVNGVMDNVWMH8%SNVQ1A1GUXJQ110,^ /\
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MU-&C'$RKKP7X?OI!)<Z%IEQ(!M#2V<;$#TR5]S61'\)?!RYW>$M /_<-A_\
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MY[9K]1_@W\&[+P#_ &QNTC[!]K\G_EY:3=MW_P"V<8W?K4+N-:ZGK"QJO(4
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M-'QK34E!T:["[UR/[8M\=O\ IM5F^_9G^-<DP,.BW87;SMUBV'.3_P!-J<=
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MB76[_L+VW_QZ@?LS_&G;@Z+=;O\ L+VW_P >J!+>Y]VM^W;X!'R_V1XDR?\
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M / :W_\ C]-_X;N\ YQ_9'B3_P !K?\ ^/U\'-^S1\:C!M&C7?F8'_,8MO\
MX]0G[,OQK^SX.BW?F8/_ #&+;/\ Z.IAOL?>?_#=G@+_ *!'B/\ \!K?_P"/
MTC?MW> 5_P"81XD_\!K?_P"/U\&V_P"S1\:D0B31KO=GOK%L?_:U-M_V9?C8
MN[S-%NSZ9UBV/_M:@/0^]/\ ANSP%_T"/$?_ (#6_P#\?H/[=O@$<_V1XD_\
M!K?_ ./U\%Q_LS_&Q9G+:-=[.<?\3BV]?^NU'_#,WQL-QN_L6[\O_L,6V.GI
MYU >1]Z+^W=X!;_F$>)/_ :W_P#C]+_PW9X"_P"@1XC_ / :W_\ C]?!4O[,
MOQL\Y"NBW83C.-8MO7_KM1<?LS_&Q]OEZ-=^^-8MA_[6H#U/O>3]O+P!-C;H
M_B08];:W_P#C],_X;M\ _P#0(\2?^ UO_P#'Z^"9OV9_C6V/*T6[]\:Q;#_V
MM3I/V9_C6T*JFC7?F#&?^)Q;?_'JB.R!:*Q][_\ #>7@#R_+_L?Q)N_Z]K?'
M_H^F?\-V^ ?^@1XD_P# :W_^/U\$_P##,_QK\G;_ &+=^;_V&+;/7U\ZG1_L
MS_&M865]&N_,.<?\3BV_^/4+J"T/O>/]O+P!#G=H_B0Y]+:W_P#C],_X;L\
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M'_$XMO\ X]4<?[,OQL7/F:+=^V=8MC_[6H^R'0^\E_;J\!1')TCQ'Z<6UO\
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M (9G^-GV?;_8UWYG_88ML]?7SJ(_V9?C8(7#:+=[^<?\3BV]/^NU >A]Z_\
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M#8_V9_C6  VBW>[_ +#%M_\ 'JD/[,_QI'WM%NL_]A>V_P#CU'5CVV/O6/\
M;R\ 0YW:/XD.?2VM_P#X_36_;N\ L2W]D>),'G_CVM__ (_7P1#^S/\ &M<^
M;HMW[9UBV/\ [6I8_P!F?XUK*Q?1KO8>G_$XMO\ X]1U9IUN?>Z?MX> 8V#'
M2/$F/^O:W_\ C]#_ +>'@&1BPTCQ)C_KVM__ (_7P.O[,WQM\XLVC7?EY/\
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M;Y]O^6U"UU#;<^\F_;O\ KP=(\2?^ UO_P#'Z/\ ANSP$O\ S"/$?_@-;_\
MQ^O@R']F7XUJI\S1;LMGOK%L?_:U%O\ LS_&N/=YNC7?MG6+8_\ M:C=^@;;
MGWFW[=W@%1G^R/$G_@-;_P#Q^@?MV^ 3\W]D>),?]>UO_P#'Z^"X_P!F7XV>
M:Q;1;LH>F=8MO_CU'_#,WQK6XW?V+=^5_P!ABVQT]/.HW=@\S[U_X;M\ ]?[
M(\2?^ UO_P#'Z%_;N\ M_P PCQ)_X#6__P ?KX+D_9G^-;3(4T:[V<9_XG%L
M._\ UVHN/V9?C8VWR]%NQZXUBV'_ +6K1;"/O7_ANSP%_P! CQ'_ . UO_\
M'Z3_ (;N\ DX_LCQ)_X#6_\ \?KX+N/V9_C8^WR]&N_?&L6P_P#:U$G[,OQL
M,*!=%N]_&?\ B<6WI_UVH#T/O7_ANSP%_P! CQ'_ . UO_\ 'Z3_ (;N\ @X
M_LCQ)_X#6_\ \?KX+_X9G^-GV?;_ &-=^9_V&+;/7U\ZB/\ 9E^-@A<-HMWO
MYQ_Q.+;T_P"NU >A]Z_\-V> O^@1XC_\!K?_ ./TC?MW> 5_YA'B3_P&M_\
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M.L6Q_P#:U)'^S+\;/-8MHMV4/3.L6W_QZCX4!]Z#]NWP"?F_LCQ)C_KVM_\
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M*OQ*M_%=_->^%5*/#)\SWUJV6,BG_GH?>G<KJ?JQ^R.A_P"$1^&)[?V!:?\
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M9_\  )ZZ#_Y.7'_QR@_L_P#@$]=!_P#)RX_^.5Z"K;A0K;LTPT^\\^_X9_\
M /3^P?\ R<N/_CE'_#/_ (!QC^P>/^ORX_\ CE>@ALL11N^;%(+H\^_X9_\
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M_P##/O@'.?[!Y_Z_+C_XY0W[/O@%NN@_^3EQ_P#'*]$HH \\;]G[P"W70?\
MR<N/_CE'_#/W@$C']@\?]?EQ_P#'*]#HH \\_P"&?_ 73^P?_)RX_P#CE'_#
M/_@+I_8/_DY<?_'*]#HIC//%_9_\ KTT'_R<N/\ XY1_PS_X"_Z /_DY<?\
MQRO0Z* ///\ AG[P"#G^P>?^ORX_^.4?\,_^ <Y_L'G_ *_+C_XY7H=% CSS
M_AG[P"3G^P>?^ORX_P#CE!_9_P# )ZZ#_P"3EQ_\<KT.B@#SQOV?O +==!_\
MG+C_ ..4?\,_^ O^@#_Y.7'_ ,<KT.B@9YY_PS_X"/\ S ?_ "<N/_CE _9_
M\!#IH/\ Y.7'_P <KT.B@#SW_A0'@+_H _\ DY<?_'*0?L_^ 1TT'_R<N/\
MXY7H=% 'GO\ PH#P%_T ?_)RX_\ CE)_PS_X"_Z /_DY<?\ QRO0Z* //?\
MA0'@+_H _P#DY<?_ !RD_P"&?_ 7_0!_\G+C_P".5Z'10!YY_P ,_P#@+_H
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M_DY<?_'*/^&?O .[/]@\_P#7Y<?_ !RO0Z*0'GG_  S_ . O^@#_ .3EQ_\
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M_CE'_#/_ ("QC^P?_)RX_P#CE>@JQ8T;CNQ0*Z//O^&?_ 6,?V#_ .3EQ_\
M'*!^S_X"'30?_)RX_P#CE>@[CNQ0S%30%T>?#]G_ , CIH/_ ).7'_QRC_AG
M_P  ]?[!_P#)RX_^.5Z"S;<4%L*#2'='GW_#/_@'.?[!_P#)RX_^.4?\,_\
M@+_H _\ DY<?_'*]"'2EH*7D>=M^S[X!;KH/_DY<?_'*7_AG_P !?] '_P G
M+C_XY7H=%(#SP_L_^ 6X.@_^3EQ_\<H_X9_\ @8_L'C_ *_+C_XY7H=% 'GG
M_#/_ ("Z?V#_ .3EQ_\ '*%_9^\ KTT'_P G+C_XY7H=% 'GG_#/_@+_ * /
M_DY<?_'*/^&?O (.?[!Y_P"ORX_^.5Z'36;:*=A/NSS[_AG[P#NS_8//_7Y<
M?_'*/^&?O ).?[!Y_P"ORX_^.5Z#N^7- ;*DT6%='GS?L_> 6ZZ#_P"3EQ_\
M<H;]G_P"W70?_)RX_P#CE>@JV[-"L6-%@NCS[_AG_P  XQ_8/'_7Y<?_ !RC
M_AG_ , XQ_8/'_7Y<?\ QRO0=QW8HW'=BBP<R//O^&?O (&/[!X_Z_+C_P".
M4+^S]X!7IH/_ ).7'_QRO02V& H9MN*+!='GJ_L^^ 5Z:#_Y.7'_ ,<IW_"@
M/ 7_ $ ?_)RX_P#CE>A44%'GG_#/_@'.?[!_\G+C_P".4O\ PH#P%_T ?_)R
MX_\ CE>A44 >>']G_P  GKH/_DY<?_'*7_AG_P !?] '_P G+C_XY7H5% 'G
MG_#/_@(_\P'_ ,G+C_XY1_PS_P" A_S ?_)RX_\ CE>AT4 >>_\ "@/ 7_0!
M_P#)RX_^.4@_9_\  (Z:#_Y.7'_QRO0Z* ///^&?_ 7_ $ ?_)RX_P#CE'_#
M/W@'=G^P>?\ K\N/_CE>AT4@///^&?\ P%_T ?\ R<N/_CE#?L_> 6ZZ#_Y.
M7'_QRO0Z* ///^&?_ 7_ $ ?_)RX_P#CE!_9_P# +<'0?_)RX_\ CE>AT4 >
M>?\ #/\ X! Q_8/'_7Y<?_'*/^&?_ 73^P?_ "<N/_CE>AT4 >>+^S]X!7IH
M/_DY<?\ QRC_ (9_\!?] '_R<N/_ (Y7H=%%@/._^&?? .<_V#S_ -?EQ_\
M'*7_ (9_\!?] '_R<N/_ (Y7H=%%D!YY_P ,_> 2<_V#S_U^7'_QRC_AG_P%
M_P! '_R<N/\ XY7H=% 'GC?L_P#@%NN@_P#DY<?_ !RC_AG_ ,!=/[!_\G+C
M_P".5Z'13 \\_P"&?_ 73^P?_)RX_P#CE"_L_P#@%>F@_P#DY<?_ !RO0Z*
M///^&?\ P%_T ?\ R<N/_CE'_#/W@$'/]@\_]?EQ_P#'*]#HI >>?\,_^ O^
M@#_Y.7'_ ,<I/^&?? .<_P!@\_\ 7Y<?_'*]$HHL@///^&?_  %_T ?_ "<N
M/_CE#?L_> 6ZZ#_Y.7'_ ,<KT.BBP'GG_#/_ ("Z?V#_ .3EQ_\ '*/^&?\
MP"1C^P>/^ORX_P#CE>AT4 >>+^S_ . 5Z:#_ .3EQ_\ '*7_ (4!X"_Z /\
MY.7'_P <KT*BF!YX/V?_  ".F@_^3EQ_\<I?^% > O\ H _^3EQ_\<KT*B@#
MSS_AG_P#G/\ 8//_ %^7'_QRE_X4!X"_Z /_ ).7'_QRO0J* //#^S_X!/70
M?_)RX_\ CE+_ ,* \!?] '_R<N/_ (Y7H5% 'GG_  S_ . C_P P'_R<N/\
MXY1_PS_X"'_,!_\ )RX_^.5Z'10!Y[_PH#P%_P! '_R<N/\ XY2?\,_^ O\
MH _^3EQ_\<KT.B@#SW_A0'@+_H _^3EQ_P#'*3_AG_P%_P! '_R<N/\ XY7H
M=% 'GG_#/_@+_H _^3EQ_P#'*1OV?? +==!_\G+C_P".5Z)12L@///\ AG_P
M%_T ?_)RX_\ CE!_9_\  +<'0?\ R<N/_CE>AT4 >>?\,_\ @+I_8/\ Y.7'
M_P <H_X9_P# 73^P?_)RX_\ CE>AT4P//%_9_P# *]-!_P#)RX_^.4?\,_\
M@+_H _\ DY<?_'*]#HH \\_X9^\ @Y_L'G_K\N/_ (Y1_P ,_P#@+_H _P#D
MY<?_ !RO0Z*0'GG_  S]X!)S_8//_7Y<?_'*/^&?_ 7_ $ ?_)RX_P#CE>AT
M4 >>-^S]X!;KH/\ Y.7'_P <H_X9_P# 73^P?_)RX_\ CE>AT4 >>?\ #/\
MX!(Q_8/'_7Y<?_'*!^S_ . 5X&@_^3EQ_P#'*]#HH \\_P"&?_ 7_0!_\G+C
M_P".4B_L^^ 5Z:#_ .3EQ_\ '*]$HHL!YY_PS_X"_P"@#_Y.7'_QRD_X9]\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:R[ACI3J*
A(([79-OW9YZ8J>BB@!C1[CG.*?112$%%%%,84444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634075325696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Aug. 02, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INSMED INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">54-1972729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">700 US Highway 202/206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bridgewater<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">977-9900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INSM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,849,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001104506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634079035440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,246,799<span></span>
</td>
<td class="nump">$ 482,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">298,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">40,300<span></span>
</td>
<td class="nump">41,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">90,063<span></span>
</td>
<td class="nump">83,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">41,022<span></span>
</td>
<td class="nump">24,179<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,418,184<span></span>
</td>
<td class="nump">929,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">72,777<span></span>
</td>
<td class="nump">65,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">19,629<span></span>
</td>
<td class="nump">20,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">16,406<span></span>
</td>
<td class="nump">18,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">61,178<span></span>
</td>
<td class="nump">63,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">136,110<span></span>
</td>
<td class="nump">136,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">85,834<span></span>
</td>
<td class="nump">96,574<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,810,118<span></span>
</td>
<td class="nump">1,329,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">290,844<span></span>
</td>
<td class="nump">214,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">224,448<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">2,782<span></span>
</td>
<td class="nump">2,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">6,077<span></span>
</td>
<td class="nump">8,032<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">524,151<span></span>
</td>
<td class="nump">225,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, long-term</a></td>
<td class="nump">946,825<span></span>
</td>
<td class="nump">1,155,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalty financing agreement</a></td>
<td class="nump">158,377<span></span>
</td>
<td class="nump">155,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">101,500<span></span>
</td>
<td class="nump">84,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, long-term</a></td>
<td class="nump">25,588<span></span>
</td>
<td class="nump">27,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, long-term</a></td>
<td class="nump">11,666<span></span>
</td>
<td class="nump">11,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">3,193<span></span>
</td>
<td class="nump">3,145<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,771,300<span></span>
</td>
<td class="nump">1,661,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 500,000,000 authorized shares, 166,666,599 and 147,977,960 issued and outstanding shares at June&#160;30, 2024 and December&#160;31, 2023,&#160;respectively</a></td>
<td class="nump">1,667<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">3,943,826<span></span>
</td>
<td class="nump">3,113,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(3,903,845)<span></span>
</td>
<td class="num">(3,446,145)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,830)<span></span>
</td>
<td class="num">(745)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity (deficit)</a></td>
<td class="nump">38,818<span></span>
</td>
<td class="num">(331,923)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 1,810,118<span></span>
</td>
<td class="nump">$ 1,329,837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634076002608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares (in shares)</a></td>
<td class="nump">166,666,599<span></span>
</td>
<td class="nump">147,977,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares (in shares)</a></td>
<td class="nump">166,666,599<span></span>
</td>
<td class="nump">147,977,960<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634076135376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible List]</a></td>
<td class="text">Product [Member]<span></span>
</td>
<td class="text">Product [Member]<span></span>
</td>
<td class="text">Product [Member]<span></span>
</td>
<td class="text">Product [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues, net</a></td>
<td class="nump">$ 90,340<span></span>
</td>
<td class="nump">$ 77,229<span></span>
</td>
<td class="nump">$ 165,840<span></span>
</td>
<td class="nump">$ 142,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList', window );">Cost, Product and Service [Extensible List]</a></td>
<td class="text">Product [Member]<span></span>
</td>
<td class="text">Product [Member]<span></span>
</td>
<td class="text">Product [Member]<span></span>
</td>
<td class="text">Product [Member]<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product revenues (excluding amortization of intangible assets)</a></td>
<td class="nump">$ 20,964<span></span>
</td>
<td class="nump">$ 16,594<span></span>
</td>
<td class="nump">$ 38,421<span></span>
</td>
<td class="nump">$ 30,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">146,748<span></span>
</td>
<td class="nump">196,969<span></span>
</td>
<td class="nump">267,831<span></span>
</td>
<td class="nump">324,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">106,569<span></span>
</td>
<td class="nump">84,431<span></span>
</td>
<td class="nump">199,671<span></span>
</td>
<td class="nump">164,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">2,526<span></span>
</td>
<td class="nump">2,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of deferred and contingent consideration liabilities</a></td>
<td class="nump">103,700<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
<td class="nump">91,800<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">379,244<span></span>
</td>
<td class="nump">312,757<span></span>
</td>
<td class="nump">600,249<span></span>
</td>
<td class="nump">526,129<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(288,904)<span></span>
</td>
<td class="num">(235,528)<span></span>
</td>
<td class="num">(434,409)<span></span>
</td>
<td class="num">(383,686)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Investment income</a></td>
<td class="nump">10,285<span></span>
</td>
<td class="nump">11,172<span></span>
</td>
<td class="nump">19,068<span></span>
</td>
<td class="nump">21,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(21,267)<span></span>
</td>
<td class="num">(20,619)<span></span>
</td>
<td class="num">(42,309)<span></span>
</td>
<td class="num">(40,622)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of interest rate swap</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">2,746<span></span>
</td>
<td class="num">(349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(269)<span></span>
</td>
<td class="num">(488)<span></span>
</td>
<td class="num">(1,369)<span></span>
</td>
<td class="num">(599)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(299,771)<span></span>
</td>
<td class="num">(244,279)<span></span>
</td>
<td class="num">(456,273)<span></span>
</td>
<td class="num">(403,560)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">838<span></span>
</td>
<td class="nump">530<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (300,609)<span></span>
</td>
<td class="num">$ (244,809)<span></span>
</td>
<td class="num">$ (457,700)<span></span>
</td>
<td class="num">$ (404,573)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (1.94)<span></span>
</td>
<td class="num">$ (1.78)<span></span>
</td>
<td class="num">$ (3.02)<span></span>
</td>
<td class="num">$ (2.95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (1.94)<span></span>
</td>
<td class="num">$ (1.78)<span></span>
</td>
<td class="num">$ (3.02)<span></span>
</td>
<td class="num">$ (2.95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average basic common shares outstanding (in shares)</a></td>
<td class="nump">154,702<span></span>
</td>
<td class="nump">137,553<span></span>
</td>
<td class="nump">151,579<span></span>
</td>
<td class="nump">136,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average diluted common shares outstanding (in shares)</a></td>
<td class="nump">154,702<span></span>
</td>
<td class="nump">137,553<span></span>
</td>
<td class="nump">151,579<span></span>
</td>
<td class="nump">136,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss, basic</a></td>
<td class="num">$ (300,609)<span></span>
</td>
<td class="num">$ (244,809)<span></span>
</td>
<td class="num">$ (457,700)<span></span>
</td>
<td class="num">$ (404,573)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss, diluted</a></td>
<td class="num">(300,609)<span></span>
</td>
<td class="num">(244,809)<span></span>
</td>
<td class="num">(457,700)<span></span>
</td>
<td class="num">(404,573)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation losses</a></td>
<td class="num">(1,194)<span></span>
</td>
<td class="num">(2,202)<span></span>
</td>
<td class="num">(2,049)<span></span>
</td>
<td class="num">(2,373)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(132)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (301,803)<span></span>
</td>
<td class="num">$ (247,143)<span></span>
</td>
<td class="num">$ (459,785)<span></span>
</td>
<td class="num">$ (406,580)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of cost from product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfCostGoodOrServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634073499744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (Deficit) (unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 87,951<span></span>
</td>
<td class="nump">$ 1,357<span></span>
</td>
<td class="nump">$ 2,782,416<span></span>
</td>
<td class="num">$ (2,696,578)<span></span>
</td>
<td class="nump">$ 756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(404,573)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(404,573)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(2,007)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,007)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options and ESPP shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options and ESPP shares</a></td>
<td class="nump">8,422<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">8,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">38,014<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">37,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for asset acquisitions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock for asset acquisitions</a></td>
<td class="nump">81,640<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">81,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">34,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="num">(155,745)<span></span>
</td>
<td class="nump">$ 1,428<span></span>
</td>
<td class="nump">2,945,229<span></span>
</td>
<td class="num">(3,101,151)<span></span>
</td>
<td class="num">(1,251)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="num">(44,653)<span></span>
</td>
<td class="nump">$ 1,364<span></span>
</td>
<td class="nump">2,809,242<span></span>
</td>
<td class="num">(2,856,342)<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(244,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(244,809)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(2,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options and ESPP shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options and ESPP shares</a></td>
<td class="nump">7,283<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">7,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">38,014<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">37,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for asset acquisitions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock for asset acquisitions</a></td>
<td class="nump">72,390<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">72,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">18,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="num">(155,745)<span></span>
</td>
<td class="nump">$ 1,428<span></span>
</td>
<td class="nump">2,945,229<span></span>
</td>
<td class="num">(3,101,151)<span></span>
</td>
<td class="num">(1,251)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="num">(331,923)<span></span>
</td>
<td class="nump">$ 1,480<span></span>
</td>
<td class="nump">3,113,487<span></span>
</td>
<td class="num">(3,446,145)<span></span>
</td>
<td class="num">(745)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(457,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(457,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(2,085)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,085)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options and ESPP shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options and ESPP shares</a></td>
<td class="nump">72,623<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">72,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">713,158<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">713,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">44,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">38,818<span></span>
</td>
<td class="nump">$ 1,667<span></span>
</td>
<td class="nump">3,943,826<span></span>
</td>
<td class="num">(3,903,845)<span></span>
</td>
<td class="num">(2,830)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2024</a></td>
<td class="num">(464,808)<span></span>
</td>
<td class="nump">$ 1,486<span></span>
</td>
<td class="nump">3,138,578<span></span>
</td>
<td class="num">(3,603,236)<span></span>
</td>
<td class="num">(1,636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(300,609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300,609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(1,194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options and ESPP shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options and ESPP shares</a></td>
<td class="nump">68,571<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">68,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">713,567<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">713,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">23,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">$ 38,818<span></span>
</td>
<td class="nump">$ 1,667<span></span>
</td>
<td class="nump">$ 3,943,826<span></span>
</td>
<td class="num">$ (3,903,845)<span></span>
</td>
<td class="num">$ (2,830)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634075724112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (457,700)<span></span>
</td>
<td class="num">$ (404,573)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">3,024<span></span>
</td>
<td class="nump">2,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">2,526<span></span>
</td>
<td class="nump">2,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">44,736<span></span>
</td>
<td class="nump">34,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">3,651<span></span>
</td>
<td class="nump">3,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Paid-in-kind interest capitalized</a></td>
<td class="nump">12,571<span></span>
</td>
<td class="nump">11,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Royalty financing non-cash interest expense</a></td>
<td class="nump">9,715<span></span>
</td>
<td class="nump">3,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_AccretionOfDebtDiscountMarketableSecurities', window );">Accretion of discount on marketable securities, net</a></td>
<td class="num">(1,963)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance lease amortization expense</a></td>
<td class="nump">1,356<span></span>
</td>
<td class="nump">1,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_NoncashOperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">1,611<span></span>
</td>
<td class="nump">7,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of deferred and contingent consideration liabilities</a></td>
<td class="nump">91,800<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of interest rate swap</a></td>
<td class="num">(2,746)<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,080)<span></span>
</td>
<td class="num">(2,291)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(8,353)<span></span>
</td>
<td class="num">(8,081)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(17,823)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">15,699<span></span>
</td>
<td class="num">(7,458)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">2,737<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(6,748)<span></span>
</td>
<td class="num">(5,158)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(306,987)<span></span>
</td>
<td class="num">(269,095)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(11,462)<span></span>
</td>
<td class="num">(8,281)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(292,690)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_ProceedsFromCashAcquiredInAssetAcquisition', window );">Cash acquired in asset acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">288,538<span></span>
</td>
<td class="num">(232,554)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options and ESPP</a></td>
<td class="nump">72,623<span></span>
</td>
<td class="nump">8,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">713,158<span></span>
</td>
<td class="nump">38,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments of finance lease principal</a></td>
<td class="num">(1,266)<span></span>
</td>
<td class="num">(1,291)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,218)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">784,515<span></span>
</td>
<td class="nump">43,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash and cash equivalents</a></td>
<td class="num">(1,641)<span></span>
</td>
<td class="num">(3,432)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">764,425<span></span>
</td>
<td class="num">(461,154)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">482,374<span></span>
</td>
<td class="nump">1,074,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">1,246,799<span></span>
</td>
<td class="nump">612,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">16,695<span></span>
</td>
<td class="nump">19,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">1,562<span></span>
</td>
<td class="nump">1,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=insm_VertuisBioIncMember', window );">Vertuis Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_NoncashAcquisitionRelatedExpense', window );">Vertuis acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_NoncashAcquisitionRelatedExpense', window );">Adrestia acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=insm_AdrestiaTherapeuticsLtdMember', window );">Adrestia Therapeutics Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_NoncashAcquisitionRelatedExpense', window );">Vertuis acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">76,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_NoncashAcquisitionRelatedExpense', window );">Adrestia acquisition</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 76,481<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccretionOfDebtDiscountMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion Of Debt Discount, Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccretionOfDebtDiscountMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_NoncashAcquisitionRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Acquisition Related Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_NoncashAcquisitionRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Operating Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ProceedsFromCashAcquiredInAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Cash Acquired In Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ProceedsFromCashAcquiredInAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=insm_VertuisBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=insm_VertuisBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=insm_AdrestiaTherapeuticsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=insm_AdrestiaTherapeuticsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634075836896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Company and Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.      The Company and Basis of Presentation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company's first commercial product, ARIKAYCE, is approved in the United States (US) as ARIKAYCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mycobacterium avium complex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis (CF). In March 2021, Japan's Ministry of Health, Labour and Welfare (MHLW) approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. NTM lung disease caused by MAC (which the Company refers to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's pipeline includes clinical-stage programs, brensocatib and treprostinil palmitil inhalation powder (TPIP), as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP) and hidradenitis suppurativa (HS). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH). The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, artificial intelligence-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in the Commonwealth of Virginia on November&#160;29, 1999 and its principal executive offices are located in Bridgewater, New Jersey. The Company has legal entities in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom (UK), and Japan.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements have been prepared pursuant to the rules&#160;and regulations for reporting on Form&#160;10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the US (GAAP) for complete consolidated financial statements are not included herein. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000110450624000008/insm-20231231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Report on Form&#160;10-K for the year ended December&#160;31, 20</a>23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any references in these notes to applicable accounting guidance are meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. The unaudited interim consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;The Company had $1,246.8 million in cash and cash equivalents as of June&#160;30, 2024 and reported a net loss of $457.7 million for the six months ended June&#160;30, 2024. The Company has funded its operations through public offerings of equity securities, de</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bt financings and revenue interest financings. The Company expects to continue to incur consolidated operating losses, including losses in its US and certain international entities, while funding research and development (R&amp;D) activities for ARIKAYCE, brensocatib, TPIP and its other pipeline programs, continuing commercialization and regulatory activities for ARIKAYCE and pre-commercial, regulatory and, if approved, commercialization activities for brensocatib, and funding other general and administrative activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects its future cash requirements to be substantial. While the Company currently has sufficient funds to meet its financial needs for at least the next 12 months, the Company may raise additional capital in the future to fund its operations, its ongoing commercialization and clinical trial activities, and its future product candidates, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company&#8217;s commercial, regulatory and development activities. Any future financing will also be contingent upon market </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiarie</span>s,  Adrestia Therapeutics Inc., Celtrix Pharmaceuticals,&#160;Inc., Insmed France SAS, Insmed Gene Therapy LLC, Insmed Germany&#160;GmbH, Insmed Godo Kaisha, Insmed Holdings Limited, Insmed Innovation UK Limited, Insmed Ireland Limited, Insmed Italy S.R.L., Insmed Limited, Insmed Netherlands&#160;B.V., Insmed Netherlands Holdings B.V., and Insmed Switzerland GmbH.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634076333088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.      Summary of Significant Accounting Policies</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company&#8217;s complete listing of significant accounting policies is set forth in Note 2 of the notes to the consolidated financial statements in the Company's </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000110450624000008/insm-20231231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">. Selected significant accounting policies are discussed in detail below.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, acquisition related intangibles including in process research and development (IPR&amp;D) and goodwill, fair value of contingent consideration, and accounting for research and development costs. Actual results could differ from those estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for uncollectible trade receivables. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the six months ended June&#160;30, 2024 and their respective percentages for the six months ended June&#160;30, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.116%"><tr><td style="width:1.0%"></td><td style="width:33.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.934%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.936%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturers, or an adverse change in their business, could materially impact future operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finite-lived Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Finite-lived intangible assets are measured at their respective fair values on the date they were recorded. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6 - Intangibles, Net and Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Assessment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing the carrying value of the assets to the fair value of the assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations and Asset Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for the Company&#8217;s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets&#8217; carrying amounts on the acquiring entity&#8217;s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. If the in-licensed agreement for IPR&amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as acquired IPR&amp;D expense in its consolidated statements of comprehensive loss. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable, unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. None of the Company's contingent consideration met the definition of a derivative as of June&#160;30, 2024. Upon recognition of a contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-lived Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Indefinite-lived intangible assets consist of IPR&amp;D. IPR&amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&amp;D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&amp;D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#8217;s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company&#8217;s outlook and market performance of the Company&#8217;s industry and recent and forecasted financial performance. The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#8217;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. As of June&#160;30, 2024 and December&#160;31, 2023, the Company continues to operate as one reporting unit. The Company performs an impairment test for goodwill annually as of October 1. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6 - Intangibles, Net and Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9 - Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Unamortized debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the UK, and Japan. The results of the Company's non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in total s</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hareholders' equity (deficit),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a component of accumulated other comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company realizes foreign currency transaction gains and losses in the normal course of business based on movements in the applicable exchange rates. These gains and losses are included as a component of other expense, net.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In the normal course of business, the Company is exposed to the effects of interest rate changes. The Company may enter into derivative instruments, including interest rate swaps and caps, to manage or hedge interest rate risk. Derivative instruments are recorded at fair value on the balance sheet date. The Company has not elected hedge accounting treatment for the changes in the fair value of derivatives. Changes in the fair value of derivatives are recorded each period and are included in change in fair value of interest rate swap in the consolidated statements of comprehensive loss and consolidated statements of cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Cost of Product Revenues (excluding amortization of intangible assets)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Inventory is stated at the lower of cost and net realizable value. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. Inventory used for clinical development purposes is expensed to R&amp;D expense when consumed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&#160;Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock (RS), restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three and six months ended June&#160;30, 2024 and 2023: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300,609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244,809)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404,573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of basic net loss per share:</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RS and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,702&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,553&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,957&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.94)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.78)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.02)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.95)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of June&#160;30, 2024 and 2023, respectively, as their effect would have been anti-dilutive (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:66.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.553%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.555%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RS and RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements (Not Yet Adopted)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In December 2023, the FASB issued ASU 2023-09, Income Taxes&#8212;Improvements to Income Tax Disclosures, in order to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires greater disaggregation of income tax disclosures related to the income tax rate </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reconciliation and income taxes paid. ASU 2023-09 will be effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of adoption of ASU 2023-09 on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634075211008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3.      Fair Value Measurements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:36.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June&#160;30, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:36.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2024, $300.0&#160;million of marketable securities, consisting of US Treasury Notes, matured. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. The collateral for interest rate swap and the interest rate swap are recorded in other assets and accounts payable and accrued liabilities, respectively, in the consolidated balance sheet as of June&#160;30, 2024 and December&#160;31, 2023. The collateral for interest rate swap is cash, a Level 1 asset. The interest rate swap is a Level 2 liability as it uses observable inputs other than quoted market prices in an active market. There were no transfers in or out of Level 1, Level 2 or Level 3 during the six months ended June&#160;30, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company held no available-for-sale securities. Marketable securities maturing in one year or less are classified as current assets and marketable securities maturing in more than one year are classified as non-current assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2) whether the security was rated below investment grade; (3) failure of the issuer to make scheduled interest or principal payments; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover. The Company has determined that there were no other-than-temporary impairments during the six months ended June 30, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred consideration arose from the acquisition of Motus Biosciences, Inc. (Motus) in August 2021. The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company&#8217;s common stock on each of the first, second and third anniversaries of the closing date, subject to certain reductions. During August 2022 and August 2023, the Company fulfilled the payments due on the first and second anniversaries of the closing date by issuing 171,427 shares and 177,203 shares of the Company's common stock, respectively, after certain reductions. A valuation of the deferred consideration is performed quarterly with gains and losses included within change in fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss. As the deferred consideration is settled in shares, there is no discount rate applied in the fair value calculation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred consideration has been classified as a Level 2 recurring liability as its valuation utilizes an input, the Insmed share price, which is a directly observable input at the measurement date and for the duration of the liabilities' anticipated lives. Deferred consideration expected to be settled within twelve months or less is classified as a current liability within accounts payable and accrued liabilities. As of June&#160;30, 2024, the fair value of deferred consideration included in accounts payable and accrued liabilities was $12.4 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following observable input was used in the valuation of the deferred consideration as of June&#160;30, 2024:</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.111%"><tr><td style="width:1.0%"></td><td style="width:21.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of June&#160;30, 2024 (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Observable Input</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12.4</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed share price as of June&#160;30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$67.00</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities arose from the acquisitions of Motus and AlgaeneX, Inc. (AlgaeneX) (together, the Business Acquisition) in August 2021 (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16 - Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The contingent consideration liabilities consist of developmental and regulatory milestones, a priority review voucher milestone and net sales milestones. Upon the achievement of certain development and regulatory milestone events, the Company is obligated to issue to Motus equityholders up to 5,348,572 shares in the aggregate and AlgaeneX equityholders up to 368,867 shares in the aggregate. The fair value of the development and regulatory milestones are estimated utilizing a probability-adjusted approach. At June&#160;30, 2024, the weighted average probability of success was 42%. The development and regulatory milestones will be settled in shares of the Company's common stock. As such, there is no discount rate applied in the fair value calculation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company were to receive a priority review voucher, the Company is obligated to pay to the Motus equityholders a portion of the value of the priority review voucher, subject to certain reductions. The potential payout will be either 50% of the after tax net proceeds received by the Company from a sale of the priority review voucher or 50% of the average of the sales prices for the last three publicly disclosed priority review voucher sales, less certain adjustments. The fair value of the priority review voucher milestone is estimated utilizing a probability-adjusted discounted cash flow approach. This obligation will be settled in cash. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities for net sales milestones were valued using an option pricing model with Monte Carlo simulation. As of June&#160;30, 2024, the fair value of these net sales milestones were deemed immaterial to the overall fair value of the contingent consideration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration liabilities have been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the inputs to the valuation approach, the estimated fair value could be significantly different than the fair value the Company determined. Contingent consideration expected to be settled within twelve months or less is classified as a current liability within accounts payable and accrued liabilities. Contingent consideration expected to be settled in more than twelve months is classified as a non-current liability. As of June&#160;30, 2024, the fair value of the current and non-current contingent consideration was $68.2&#160;million and $101.5&#160;million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation of the contingent consideration liabilities is performed quarterly with gains and losses included within change in fair value of contingent consideration liabilities in the consolidated statements of comprehensive loss. The following significant unobservable inputs were used in the valuation of the development and regulatory milestones and the priority review voucher milestone as of June&#160;30, 2024:</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"></td><td style="width:25.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.350%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of June&#160;30, 2024 (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$161.8</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probabilities of success</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14% - 97%</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority review voucher milestone</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.2</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4%</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4%</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the six months ended June 30, 2024 and 2023 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.391%"><tr><td style="width:1.0%"></td><td style="width:38.143%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred<br/>&#160;Consideration <br/>(Level 2 Liabilities)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration<br/>&#160;(Level 3 Liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the convertible notes, which differs from their carrying value, is influenced by interest rates, the Company's stock price and stock price volatility (collectively, the Current Market Factors), and is determined by prices for the convertible notes observed in market trading which are Level 2 inputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company's 0.75% convertible senior notes due 2028 (the 2028 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of June&#160;30, 2024 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.2 billion, deter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mined using Current Market Factors and the ability of the Company to obtain debt on comparable terms to the 2028 Convertible Notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company's 1.75% convertible senior notes due 2025 (the 2025 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of June&#160;30, 2024 wa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s $384.5 million, determined using Current Market Factors, and the ability of the Company to obtain debt on comparable terms to the 202</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 Convertible Notes. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10 - Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Synthetic Royalty Financing Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the Company entered into a revenue interest purchase agreement (the Royalty Financing Agreement) with OrbiMed Royalty &amp; Credit Opportunities IV, LP (OrbiMed). Under the Royalty Financing Agreement, OrbiMed paid the Company </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$150 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% of ARIKAYCE global net sales on or after September 1, 2025, as well as 0.75% of brensocatib global net sales, if approved (the Revenue Interest Payments). In the event that OrbiMed has not received aggregate Revenue Interest Payments of at least </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$150 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on or prior to March 31, 2028, the Company must make a one-time payment to OrbiMed for the difference between the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$150 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the aggregated Revenue Interest Payments that have been paid. In addition, the royalty rate for ARIKAYCE will be increased beginning March 31, 2028 to the rate which would have resulted in aggregate Revenue Interest Payments as of March 31, 2028 equaling </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$150 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The total Revenue Interest Payments payable by the Company to OrbiMed are capped at 1.8x of the purchase price or up to a maximum of 1.9x of the purchase price under certain conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company&#8217;s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective interest method over the life of the arrangement, in accordance with ASC 470, Debt and ASC 835, Interest. The Company will utilize the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and will update the effective interest rate on a quarterly basis. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11 - Royalty Financing Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634079794384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenues, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product Revenues, Net</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">4.      Product Revenues, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract to determine which are performance obligations and to assess whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net consist of net sales of ARIKAYCE. The Company's customers in the US include specialty pharmacies and specialty distributors. In December 2020, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Europe. In July 2021, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Japan. Globally, product revenues are recognized once the Company performs and satisfies all five steps of the revenue recognition criteria mentioned above.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a geographic summary of the Company's product revenues, net, for the three and six months ended June&#160;30, 2024 and 2023 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:24.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe and rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total product revenues, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,340&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,229&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,840&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,443&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer credits: Certain of the Company's customers are offered various forms of consideration, including prompt payment discounts. The payment terms for sales to specialty pharmacies and specialty distributors for prompt payment discounts are based on contractual rates agreed with the respective specialty pharmacies and distributors. The Company anticipates that its customers will earn these discounts and, therefore, deducts the full amount of these discounts from total gross product revenues at the time such revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates: The Company contracts with certain government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accounts payable and accrued liabilities on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.</span></div>The Company also recognizes revenue related to various early access programs (EAPs) in Europe. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634177332720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">5.      Inventory</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's inventory balance consists of the following (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"></td><td style="width:49.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,063&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,248&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company has not recorded any significant inventory write-downs. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634075208880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles, Net and Goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangibles, Net and Goodwill</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">6.      Intangibles, Net and Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangibles, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finite-lived Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company's finite-lived intangible assets consisted of acquired ARIKAYCE R&amp;D and the milestones paid to PARI for the license to use the Lamira&#174; Nebulizer System (Lamira) for the delivery of ARIKAYCE to patients as a result of the US Food and Drug Administration (FDA) and EC approvals of ARIKAYCE in September 2018 and October 2020, respectively. The Company began amortizing its acquired ARIKAYCE R&amp;D and PARI milestone-related intangible assets in October 2018, over ARIKAYCE's initial regulatory exclusivity period of 12 years. Amortization of these assets during each of the next five years is estimated to be approximately $5.1 million per year.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indefinite-lived Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company's indefinite-lived intangible assets consisted of acquired IPR&amp;D from the Business Acquisition (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16 - Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Indefinite-lived intangible assets are not amortized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the Company's intangible assets for the six months ended June 30, 2024 and June&#160;30, 2023 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"></td><td style="width:24.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,425)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,704&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,526)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,178&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,425)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,756&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,526)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's goodwill balance of $136.1 million as of June&#160;30, 2024 and December&#160;31, 2023, resulted from the August 2021 Business Acquisition. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16 - Acquisitions </span>for further details.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634079126784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets, Net</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">7.      Fixed Assets, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:33.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.398%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.401%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-10</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,119&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,012&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,342)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,628)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,777&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,384&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634076512272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">8.      Accounts Payable and Accrued Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"></td><td style="width:57.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accrued operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued technical operation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty and milestones payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interest Payments payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales allowances and related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued France ATU reimbursement payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred and contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued milestone payment to AstraZeneca</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,844&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,987&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> milestone commitment became payable to AstraZeneca upon the Company's release of an official public statement that it intends to file a new drug application (NDA) for brensocatib.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634074990768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9.      Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $3.2 million and $4.1 million for the three months ended June&#160;30, 2024 and 2023, respectively, and $8.1 million and $4.2 million for the six months ended June&#160;30, 2024 and 2023, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:33.469%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.483%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f $54.4 million and $49.1 million incurred by the Company under these additional agreements have been classified within</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other assets in the Company's </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated balance sheet as of June&#160;30, 2024 and December&#160;31, 2023, respectively. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9.      Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $3.2 million and $4.1 million for the three months ended June&#160;30, 2024 and 2023, respectively, and $8.1 million and $4.2 million for the six months ended June&#160;30, 2024 and 2023, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:33.469%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.483%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f $54.4 million and $49.1 million incurred by the Company under these additional agreements have been classified within</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other assets in the Company's </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated balance sheet as of June&#160;30, 2024 and December&#160;31, 2023, respectively. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634074989184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10.      Debt</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of long-term debt and debt, long-term consists of the following commitments as of June&#160;30, 2024 and December&#160;31, 2023 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.608%"><tr><td style="width:1.0%"></td><td style="width:46.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946,825&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155,313&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Convertible Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company completed an underwritten public offering of $575.0 million aggregate principal amount of the 2028 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $75.0 million in aggregate principal amount of 2028 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $15.7&#160;million, were approximately $559.3 million. The 2028 Convertible Notes bear interest payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2021. The 2028 Convertible Notes mature on June 1, 2028, unless earlier converted, redeemed, or repurchased. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company completed an underwritten public offering of $450.0 million aggregate principal amount of the 2025 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $50.0 million in aggregate principal amount of 2025 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $14.2 million, were approximately $435.8 million. The 2025 Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The 2025 Convertible Notes would have matured on January 15, 2025 but, on June 27, 2024, the Company called the outstanding 2025 Convertible Notes for redemption, with a redemption date of August 9, 2024. See </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redemption of the 2025 Convertible Notes </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below for further details.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the net proceeds from the 2028 Convertible Notes was used to repurchase $225.0 million of the Company's outstanding 2025 Convertible Notes. The Company recorded a loss on early extinguishment of debt of $17.7 million, primarily related to the premium paid on extinguishment of a portion the 2025 Convertible Notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after March 1, 2028, until the close of business on the second scheduled trading day immediately preceding June 1, 2028, holders may convert their 2028 Convertible Notes at any time. The initial conversion rate for the 2028 Convertible Notes is 30.7692 shares of common stock per $1,000 principal amount of 2028 Convertible Notes (equivalent to an initial conversion price of approximately $32.50 per share of common stock). Upon conversion of either the 2025 Convertible Notes or the 2028 Convertible Notes, holders may receive cash, shares of the Company's common stock or a combination of cash and </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of the Company's common stock, at the Company's option. The conversion rates will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their 2028 Convertible Notes prior to March 1, 2028, only under the following circumstances, subject to the conditions set forth in the indenture: (i) during the five business day period immediately after any five consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of the 2028 Convertible Notes, as determined following a request by a holder of such notes, for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than 45 days from the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company's assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding 10% of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the 2028 Convertible Notes may be surrendered by a holder for conversion at any time from or after the date that is 30 scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on June 30, 2021 (and only during such calendar quarter), the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day (each, a Stock Price Convertibility Trigger), or (v) if the Company sends a notice of redemption, a holder may surrender all or any portion of its 2028 Convertible Notes to which the notice of redemption relates for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a)&#160;the second business day immediately preceding the related redemption date or (b)&#160;if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid. As of June&#160;30, 2024, there have not been any holder-initiated conversion requests for either series of convertible notes. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each series of convertible notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in both series of convertible notes are not required to be separately accounted for as a derivative. However, since the convertible notes are within the scope of the accounting guidance for cash convertible instruments, the Company is required to separate each series of convertible notes into liability and equity components. The carrying amount of the liability component of each series of convertible notes as of the date of issuance was calculated by measuring the fair value of a similar liability that did not have an associated equity component. The fair value was based on data from readily available pricing sources which utilize market observable inputs and other characteristics for similar types of instruments. The carrying amount of the equity component representing the embedded conversion option for each series of convertible notes was determined by deducting the fair value of the liability component from the gross proceeds of the applicable convertible notes. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in the accounting guidance for contracts in an entity&#8217;s own equity. The fair value of the liability component of the 2025 Convertible Notes on the date of issuance was estimated at $309.1&#160;million using an effective interest rate of 7.6% and, accordingly, the residual equity component on the date of issuance was $140.9&#160;million. The fair value of the liability component of the 2028 Convertible Notes on the date of issuance was estimated at $371.6&#160;million using an effective interest rate of 7.1% and, accordingly, the residual equity component on the date of issuance was $203.4&#160;million. The respective discounts were amortized to interest expense over the term of the applicable series of convertible notes through December&#160;31, 2022, prior to the adoption of ASU 2020-06. The 2028 Convertible Notes have a remaining term of approximately 3.92 years. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $566.1 million carrying value of the 2028 Convertible Notes as of June&#160;30, 2024 is net of $8.9 million of </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unamortized debt issuance costs. The $224.4 million carrying value of the 2025 Convertible Notes as of June&#160;30, 2024 is net of $0.6 million of unamortized debt issuance costs. The 2028 Convertible Notes and 2025 Convertible Notes are long-term and current liabilities, respectively, as of June&#160;30, 2024. The following table presents the carrying value of the Company's convertible notes balance (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"></td><td style="width:55.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.755%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of outstanding convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term convertible notes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566,105&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,909&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redemption of the 2025 Convertible Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 27, 2024, the Company issued a redemption notice for its 2025 Convertible Notes with a redemption date of August 9, 2024 (the Redemption Date). All then outstanding 2025 Convertible Notes will be redeemed at a redemption price equal to 100% of the principal amount of the 2025 Convertible Notes, plus accrued and unpaid interest on the 2025 Convertible Notes to, but excluding, the Redemption Date (the Redemption Price). For each $1,000 principal amount of 2025 Convertible Notes, the Redemption Price will be equal to approximately $1,001.17. The Company has elected to settle any conversions of the 2025 Convertible Notes that occur on or before the business day prior to the Redemption Date in shares of common stock. As of June&#160;30, 2024, none of the 2025 Convertible Notes converted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Secured Senior Term Loan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, the Company entered into a $350&#160;million senior secured term loan agreement with Pharmakon Advisors LP (Pharmakon), manager of the BioPharma Credit funds (the Term Loan). The Term Loan matures on October 19, 2027 and bears interest at a rate based upon the secured overnight financing rate (SOFR), subject to a SOFR floor of 2.5%, in addition to a margin of 7.75% per annum. Up to 50% of the interest payable during the first 24 months from the closing of the Term Loan may be paid-in-kind at the Company's election. If elected, paid-in-kind interest will be capitalized and added to the principal amount of the Term Loan. The Term Loan, including the paid-in-kind interest, will be repaid in eight equal quarterly payments starting in the 13th quarter following the closing of the Term Loan (i.e., the quarter ending March 31, 2026), except that the repayment start date may be extended at the Company's option for an additional four quarters, so that repayments start in the 17th quarter following the closing of the Term Loan, subject to the achievement of specified ARIKAYCE data thresholds and certain other conditions. Net proceeds from the Term Loan, after deducting the lenders' fees and deal expenses of $15.2 million, were $334.8&#160;million. During the six months ended June 30, 2024, paid-in-kind interest capitalized was $12.6&#160;million. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the carrying value of the Company&#8217;s Term Loan balance as of June&#160;30, 2024 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.169%"><tr><td style="width:1.0%"></td><td style="width:45.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.276%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.277%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original Term Loan balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid-in-kind interest capitalized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,537&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan issuance costs, unamortized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,720&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,404&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, future principal repayments of debt for each of the years through maturity were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.543%"><tr><td style="width:1.0%"></td><td style="width:64.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190,108&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redemption notice the Company issued for its 2025 Convertible Notes, the principal balance of the 2025 Convertible Notes was reclassified to due within the current year.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to debt and finance leases for the three and six months ended June&#160;30, 2024 and 2023 is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.056%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan contractual interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Financing Agreement interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swap interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(710)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(354)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(427)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total debt interest expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,703&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,007&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,168&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,396&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,619&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,309&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,622&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634185503328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Financing Agreement<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock', window );">Royalty Financing Agreement</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11.      Royalty Financing Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2022, the Company entered into the Royalty Financing Agreement with OrbiMed. Under the Royalty Financing Agreement, OrbiMed paid the Company $150&#160;million in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% of ARIKAYCE global net sales on or after September 1, 2025, as well as 0.75% of brensocatib global net sales, if approved. In the event that OrbiMed has not received aggregate Revenue Interest Payments of at least $150&#160;million on or prior to March 31, 2028, the Company must make a one-time payment to OrbiMed for the difference between the $150&#160;million and the aggregated Revenue Interest Payments that have been paid. In addition, the royalty rate for ARIKAYCE will be increased beginning March 31, 2028 to the rate which would have resulted in aggregate Revenue Interest Payments as of March 31, 2028 equaling $150&#160;million. The total Revenue Interest Payments payable by the Company to OrbiMed are capped at 1.8x of the purchase price or up to a maximum of 1.9x of the purchase price under certain conditions. Net proceeds from the Royalty Financing Agreement, after deducting the lenders' fees and deal expenses of $3.8&#160;million were, $146.2&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company&#8217;s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective interest method over the life of the arrangement, in accordance ASC 470, Debt and ASC 835, Interest. The initial annual effective interest rate was determined to be&#160;12.4%. The Company is utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and updates the effective interest rate on a quarterly basis.&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account for the six-month period ended June&#160;30, 2024 and year ended December&#160;31, 2023 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:48.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended <br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing agreement liability - beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interest Payments paid and payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing agreement liability - ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,243&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing issuance costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty issuance costs, unamortized - beginning balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,523)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred issuance costs, unamortized - ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,866)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,128)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Royalty Financing Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,377&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,034&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revenue Interest Payments payable in connection with the royalty financing agreement were $3.6 million and $3.3 million as of June&#160;30, 2024 and December&#160;31, 2023, respectively, which were recorded within accounts payable and accrued expenses on the consolidated balance sheet. Non-cash interest expense is recorded within interest expense in the consolidated statements of comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for repurchase agreements (also known as repos), resale agreements (also known as reverse repurchase agreements or reverse repos), securities borrowed transactions, and securities loaned transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 860<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/860/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634080035696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">12.      Shareholders' Equity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;As of June&#160;30, 2024, the Company had 500,000,000 shares of common stock authorized with a par value of $0.01 per share and 166,666,599 shares of common stock issued and outstanding. In addition, as of June&#160;30, 2024, the Company had reserved 23,430,187 shares of common stock for issuance upon the exercise of outstanding stock options, 3,425,045 shares of common stock for issuance upon the vesting of RSUs and 664,724 shares for issuance upon the vesting of PSUs. The Company has also reserved 23,438,430 shares of common stock in the aggregate for issuance upon conversion of the 2025 Convertible Notes and 2028 Convertible Notes, subject to adjustment in accordance with the applicable indentures. In connection with the Business Acquisition, the Company reserved 9,406,112 shares of the Company&#8217;s common stock, subject to certain closing-related reductions. The shares of the Company&#8217;s common stock reserved in connection with the Motus acquisition were partly issued as acquisition consideration at closing and on the first and second anniversaries of the closing date of the acquisition, and will also be issued upon the third anniversary of the closing date of the acquisition and upon the achievement of certain development and regulatory milestone events, subject to certain reductions. The shares of the Company&#8217;s common stock reserved in connection with the AlgaeneX acquisition will be issued upon the achievement of a development milestone event, subject to certain reductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Of the 9,406,112 shares reserved, subject to certain closing-related reductions, the Company issued 2,889,367 shares of the Company's common stock in connection with the Business Acquisition (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 16 - Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) in the third quarter of 2021, after certain closing-related deductions. In the third quarter of 2022, the Company issued 171,427 shares of the Company's common stock to fulfill the payment required to Motus equityholders on the first anniversary of the Business Acquisition. In the third quarter of 2023, the Company issued 177,203 shares of the Company's common stock to fulfill the payment required to Motus equityholders on the second anniversary of the Business Acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the second quarter of 2023, in connection with the Company's acquisition of Adrestia Therapeutics Ltd. (Adrestia), the Company issued 3,430,867 shares of the Company's common stock as consideration at closing. See </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 16 - Acquisitions</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Company&#8217;s acquisition of Vertuis Bio, Inc. (Vertuis), the Company reserved </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">550,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> shares of the Company&#8217;s common stock, subject to future adjustment. An aggregate of 500,000 of the reserved shares were issued as acquisition consideration at closing. See </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 16 - Acquisitions</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 17 - Subsequent Events</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for further details. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, the Company completed an underwritten offering of 13,750,000 shares of the Company's common stock at a public offering price of $20.00 per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expense of $16.2&#160;million, were $258.8&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2021, the Company entered into a sales agreement with SVB Leerink LLC (now known as Leerink Partners LLC) (Leerink), to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $250.0&#160;million, from time to time, through an &#8220;at the market&#8221; equity offering program (the ATM program), under which Leerink acted as sales agent. In</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> 2023, the Company issued and sold an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6,503,041</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> shares of common stock through the ATM program at a weighted-average public offering price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$24.12</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> per share and received net proceeds of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$152.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2024, the Company entered into a new sales agreement with Leerink to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $500.0 million, from time to time, through a new &#8220;at the market&#8221; equity offering program (the new ATM program), under which Leerink acts as sales agent. In connection with entering into the new ATM program, the Company terminated the ATM program. The Company has not issued any shares under the new ATM program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2024, the Company completed an underwritten offering of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14,514,562</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> shares of the Company's common stock at a public offering price of $51.50 per share. 1,893,203 of the shares of common stock were issued pursuant to the exercise in full of the underwriters' option to purchase additional shares. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and estimated offering expenses of $34.3&#160;million, were $713.2&#160;million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;As of June&#160;30, 2024, the Company had 200,000,000 shares of preferred stock authorized with a par value of $0.01 per share and no shares of preferred stock were issued and outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634075479424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">13.      Stock-Based Compensation</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's current equity compensation plan, the Insmed Incorporated Amended and Restated 2019 Incentive Plan (the 2019 Incentive Plan), was approved by shareholders at the Company's Annual Meeting of Shareholders on May&#160;13, 2024.&#160;The 2019 Incentive Plan replaced the Insmed Incorporated 2019 Incentive Plan. The 2019 Incentive Plan is administered by the Compensation Committee of the Board of Directors of the Company.&#160;Under the terms of the 2019 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards to eligible employees and non-employee directors.&#160;At the May 2024 Annual Meeting of Shareholders, the Company's shareholders approved Amendment No. 1 to the 2019 Incentive Plan, which provides for the issuance of an additional 3,000,000 shares under the plan. As of June&#160;30, 2024, 4,780,711 shares remain available for future issuance under the 2019 Incentive Plan. The 2019 Incentive Plan will terminate on April 3, 2029 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options to new hires, which awards are made pursuant to the Nasdaq's inducement grant exception to the shareholder approval requirement for grants of equity compensation. During the six months ended June&#160;30, 2024, the Company granted inducement stock options covering 899,330 shares of the Company's common stock to new employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2018, the 2018 Employee Stock Purchase Plan (ESPP) was approved by shareholders at the Company's 2018 Annual Meeting of Shareholders. The Company has reserved the following for issuance under the ESPP: (i) 1,000,000 shares of common stock,&#160;plus&#160;(ii)&#160;commencing on January&#160;1, 2019 and ending on December&#160;31, 2023, an additional number of shares to be added on the first day of each calendar year equal to the lesser of (A) 1,200,000 shares of common stock, (B) 2% of the number of outstanding shares of common stock on such date and (C)&#160;an amount determined by the administrator.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;As of June&#160;30, 2024, there was $168.6&#160;million of unrecognized compensation expense related to unvested stock options. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company had performance-conditioned options totaling 114,780 shares outstanding which had not yet met the recognition criteria. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;As of June&#160;30, 2024, there was $72.8&#160;million of unrecognized compensation expense related to unvested RSU awards.</span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Performance Stock Units</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;As of June&#160;30, 2024, there were 265,887 unvested PSUs outstanding with an unrecognized compensation expense of $10.4 million. The PSUs are subject to two performance conditions based on brensocatib milestones. As of June 30, 2024, the Company achieved the first performance condition by issuing a press release announcing certain topline results from the ASPEN trial by June 30, 2024. The potential payout of the awards ranges from 0% to 250% of the target, dependent on a market condition that is based on the Company's total shareholder return compared to the NASDAQ Biotechnology Index, subject to certain adjustments (the Peer Group). During the second quarter of 2024, the Company's total shareholder return was compared to the Company's Peer Group and the potential payout of the awards was determined to be 250% of the target, pending the achievement of the second performance condition, the acceptance of an NDA by the FDA for brensocatib, and satisfaction of the remaining service condition to such awards.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options, RSUs and the ESPP during the three and six months ended June&#160;30, 2024 and 2023 (in thousands):&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:30.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,636&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,686&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,286&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,358&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,736&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,802&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to PSUs during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended June&#160;30, 2024 or June&#160;30, 2023, as the second performance condition associated with the PSU awards was not probable as of either date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634075486976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">14.      Income Taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a provision for income taxes of $0.8 million and $0.5 million for the three months ended June 30, 2024 and 2023, respectively, and $1.4 million and $1.0 million for the six months ended June 30, 2024 and 2023, respectively. The provisions recorded for the three and six months ended June&#160;30, 2024 and 2023 are primarily a result of certain of the Company's international subsidiaries, which had taxable income during the periods. Additionally, the Company is impacted by certain state taxes which effectively impose income tax on modified gross revenues. In jurisdictions where the Company has net losses, there was a full valuation allowance recorded against the Company's deferred tax assets and therefore no tax benefit was recorded.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to US federal, state and international income taxes and the statute of limitations for tax audit is open for the Company&#8217;s federal tax returns for the years ended 2020 and later, generally open for certain states for the years 2019 and later, and generally open for international jurisdictions for the years 2018 and later. The Company has incurred net operating losses since inception, except for the year ended December&#160;31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin. As of June&#160;30, 2024 and December&#160;31, 2023, the Company had recorded reserves for unrecognized income tax benefits against certain deferred tax assets in the US.&#160;However, given the Company&#8217;s valuation allowance position, these reserves do not have an impact on the balance sheet as of June&#160;30, 2024 and December&#160;31, 2023 or the consolidated statements of comprehensive loss for the three and six months ended June&#160;30, 2024 and 2023.&#160;The Company has not recorded any accrued interest or penalties related to uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next twelve months.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Organisation for Economic Co-operation and Development (OECD) recently published a framework to implement a global corporate minimum income tax rate of 15% on income arising in low-tax jurisdictions (Pillar Two). The Pillar Two proposed legislation is applicable to multinational corporations with global revenue exceeding &#8364;750 million for at least two years of the preceding four years. Over 140 countries have agreed in principle to implement Pillar Two and many have, or are in the process of, enacting related legislation. The Pillar Two legislation is not anticipated to be effective for the Company until the Company&#8217;s annual global revenues have exceeded the &#8364;750 million threshold. The Company is still evaluating the potential consequences of Pillar Two on its longer-term financial position.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634076951888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">15.      Commitments and Contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense charged to operations was $2.8 million and $2.1 million for the three months ended June 30, 2024 and 2023, respectively, and $5.9 million and $4.3 million for the six months ended June 30, 2024 and 2023, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634079113888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">16.      Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asset Acquisitions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adrestia Therapeutics Ltd.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the Company acquired all of the issued and outstanding share capital of Adrestia, a privately held, preclinical stage company. At the closing of the transaction, the Company issued an aggregate of 3,430,867 shares of the Company&#8217;s common stock to Adrestia&#8217;s former shareholders (collectively, the Adrestia shareholders). The closing share price on the date of the transaction was $21.10, resulting in a purchase price of $72.4 million. The Adrestia shareholders may also become entitled to receive contingent payments up to an aggregate of $326.5 million in cash upon the achievement of certain development, regulatory and commercial milestone events, as well as royalty payments based upon a low single-digit percentage of net sales of certain products, both subject to the terms and conditions of the agreement.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the Company&#8217;s common stock issued to the Adrestia shareholders were issued pursuant to Section 4(a)(2) of the Securities Act of 1933 (and, with respect to certain Adrestia shareholders, in reliance on Regulation S promulgated under the Securities Act of 1933). The Company did not receive any net proceeds from the issuance of common stock to the Adrestia shareholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the acquisition under ASC 805 and ASU 2017-01 and concluded that substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets and accounted for the transaction as an asset acquisition. The Company determined that the IPR&amp;D acquired did not have any future alternative use and, in accordance with ASC 730, Research and Development, expensed the assets within research and development in the consolidated statement of comprehensive loss as of the date of the acquisition. The Company recognized $76.5 million as IPR&amp;D expense, after adjusting for working capital assumed in connection with the asset acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vertuis Bio, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company acquired Vertuis, a privately held, preclinical stage company. At the closing of the transaction, the Company issued an aggregate of 500,000 shares of the Company&#8217;s common stock to Vertuis&#8217; former stockholders and an individual who are entitled to receive a portion of the acquisition consideration (collectively, the Vertuis equityholders). The closing share price on the date of the transaction was $18.50. The Company is obligated to pay the Vertuis equityholders up to an aggregate of $23.0&#160;million in cash upon the achievement of certain development and regulatory milestone events, and up to an aggregate of $63.8&#160;million in cash upon the achievement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of certain net sales-based milestone events, in each case, subject to certain reductions. See </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 17 - Subsequent Events</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the Company&#8217;s common stock issued to the Vertuis equityholders were issued pursuant to Section 4(a)(2) of the Securities Act of 1933.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the purchase price (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.543%"><tr><td style="width:1.0%"></td><td style="width:72.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of Insmed common stock issued on closing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of Insmed common stock issued in July 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the acquisition under ASC 805 and ASU 2017-01 and concluded that substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets and accounted for the transaction as an asset acquisition. The Company determined that the assets acquired did not have any future alternative use and, in accordance with ASC 730, Research and Development, expensed the assets within research and development in the consolidated statement of comprehensive loss as of the date of the acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combination</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2021, the Company acquired all of the equity interests of Motus and AlgaeneX, each a privately held, preclinical stage company. In connection with the closing of the Company&#8217;s acquisition of Motus, the Company issued an aggregate of 2,889,367 shares of the Company&#8217;s common stock, following certain closing-related reductions, to Motus&#8217;s former stockholders and option holders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, Motus equityholders), subject to certain adjustments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company&#8217;s common stock on each of the first, second and third anniversaries of the closing date and up to 5,348,572 shares in the aggregate upon the achievement of certain development and regulatory milestone </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">events, and to pay to the Motus equityholders an aggregate of $35&#160;million upon the achievement of certain net sales-based milestones and a portion of the value of a priority review voucher (to the extent issued to the Company), in each case, subject to certain reductions. During August 2022 and August 2023, the Company fulfilled the payments due on the first and second anniversaries of the closing date by issuing 171,427 shares and 177,203 shares of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's common stock, respectively, after certain reductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing of the Company&#8217;s acquisition of AlgaeneX, the Company paid $1.5&#160;million in cash to AlgaeneX&#8217;s former stockholders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, the AlgaeneX equityholders). The Company is obligated to issue to the AlgaeneX equityholders an aggregate of 368,867 shares of the Company&#8217;s common stock upon the achievement of a development milestone event and pay to the AlgaeneX equityholders a mid-single digits licensing fee on certain future payments received by the Company in licensing transactions for AlgaeneX&#8217;s manufacturing technology, in each case, subject to certain reductions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of the Company&#8217;s common stock issued to the Motus equityholders and the AlgaeneX equityholders were issued, and the shares issuable in the future will be issued, pursuant to Section 4(a)(2) of the Securities Act of 1933, and the numbers of such issued and issuable shares was calculated based on a per share value of $27.11, which was the weighted average price per share of the Company's common stock preceding the closing of the Business Acquisition for the 45 consecutive trading day period beginning on May 24, 2021. The Company will not receive any proceeds from the issuance of common stock to the Motus equityholders or the AlgaeneX equityholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Business Acquisition under ASC 805 and ASU 2017-01. The Company concluded that substantially all of the fair value of the gross assets acquired is not concentrated in a single identifiable asset or a group of similar identifiable assets. The transaction does not pass the screen test and thus management performed a full assessment to determine if the acquired entities met the definition of a business. For the full assessment, management considered whether it has acquired (a) inputs, (b) substantive processes, and (c) outputs. Under ASC 805, to be considered a business, a set of activities and assets is required to have only the first two of the three elements, which together are or will be used in the future to create outputs. Management determined that the acquired entities met the definition of a business since the Company acquired inputs and substantive processes capable of producing outputs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, the transaction has been accounted for under the acquisition method of accounting. Under the acquisition method, the total purchase price of the acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on the fair values as of the date of the acquisition. The fair value of the consideration totaled approximately $165.5&#160;million. The results of Motus's and AlgaeneX's operations have been included in the Company's consolidated statements of comprehensive loss beginning on the acquisition date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D was capitalized as of the acquisition date and accounted for as indefinite-lived intangible assets until completion or disposition of the assets or abandonment of the associated research and development efforts. Upon successful completion of the development efforts, the useful lives of the IPR&amp;D assets will be determined based on the anticipated period of regulatory exclusivity and will be amortized within operating expenses. Until that time, the IPR&amp;D assets will be subject to impairment testing and will not be amortized. The goodwill recorded related to the acquisition is the excess of the fair value of the consideration transferred by the acquirer over the fair value of the net identifiable assets acquired and liabilities assumed at the date of acquisition. The goodwill recorded is not deductible for tax purposes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634080026848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">17.      Subsequent Events</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conversions of 2025 Convertible Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of August 7, 2024, holders of $224.7&#160;million aggregate principal amount of the outstanding 2025 Convertible Notes elected to convert their notes into shares of the Company's</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> common stock at a conversion rate of 25.5384 shares of common stock per $1,000 principal amount of 2025 Convertible Notes (equivalent to an initial conversion price of approximately $39.16 per share of common stock). These conversions will result in the issuance of an aggregate of 5,739,433 shares of the Company&#8217;s common stock. Unless earlier converted, on the Redemption Date, the remaining $0.3&#160;million aggregate principal amount of 2025 Convertible Notes outstanding will be redeemed by the Company at the Redemption Price. See</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Note 10 - Debt</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Conversions of 2028 Convertible Notes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2024, the 2028 Convertible Notes became convertible by the holders of such notes due to the satisfaction of the Stock Price Convertibility Trigger applicable to such notes. The current conversion rate for the 2028 Convertible Notes is </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.7692 shares of common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $32.50 per share of comm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on stock). The Company has elected to settle any conversions of the 2028 Convertible Notes in shares of common stock.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of August 2, 20</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24, holders of nine thousand dollars of aggregate principal amount of 2028 Convertible Notes elected to convert their notes, resulting in an issuance of an aggregate of 276 shares of the Company&#8217;s common stock. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The 2028 Convertible Notes will only be convertible during the third quarter of 2024 unless another triggering event occurs. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Note 10 - Debt </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vertuis Deferred Consideration</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, the Company issued the Vertuis equityholders an additional $1.0&#160;million of shares of the Company's common stock, or 14,773 shares of common stock, based on the closing share price on June 28, 2024. See Note 16 &#8211; Acquisitions for further details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634083703120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (300,609)<span></span>
</td>
<td class="num">$ (244,809)<span></span>
</td>
<td class="num">$ (457,700)<span></span>
</td>
<td class="num">$ (404,573)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634075722752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policy governing transactions in our securities by our directors, officers and employees permits our directors, officers and employees to enter into trading plans complying with Rule 10b5-1 under the Exchange Act. The following table describes the written plans for the sale of our securities adopted, modified or terminated by our executive officers and directors during the second quarter of 2024, each of which was entered into during an open trading window and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (each, a Trading Plan).</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.850%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Adoption of Trading Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scheduled Start Date of Trading Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scheduled Expiration Date of Trading Plan (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maximum Shares Subject to Trading Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date Plan Terminated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S. Nicole Schaeffer</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief People Strategy Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/03/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/21/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,734</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">06/07/2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/11/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/10/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/01/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,309</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martina Flammer</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Medical Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/07/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/06/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/29/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,536</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Smith</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Legal Officer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/13/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/13/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/21/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,871</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan&#8217;s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=insm_S.NicoleSchaefferMember', window );">S. Nicole Schaeffer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">S. Nicole Schaeffer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief People Strategy Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">2/27/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">06/07/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">352 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">63,734<span></span>
</td>
<td class="nump">63,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=insm_S.NicoleSchaeffer2Member', window );">S. Nicole Schaeffer2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">6/11/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">04/01/2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">203 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">46,309<span></span>
</td>
<td class="nump">46,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=insm_MartinaFlammerMember', window );">Martina Flammer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Martina Flammer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Medical Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">6/07/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">08/29/2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">357 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">370,536<span></span>
</td>
<td class="nump">370,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=insm_MichaelSmithMember', window );">Michael Smith [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Michael Smith<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Legal Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">6/13/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">05/21/2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">250 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">27,871<span></span>
</td>
<td class="nump">27,871<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=insm_S.NicoleSchaefferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=insm_S.NicoleSchaefferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=insm_S.NicoleSchaeffer2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=insm_S.NicoleSchaeffer2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=insm_MartinaFlammerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=insm_MartinaFlammerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=insm_MichaelSmithMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=insm_MichaelSmithMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634078719120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, acquisition related intangibles including in process research and development (IPR&amp;D) and goodwill, fair value of contingent consideration, and accounting for research and development costs. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</span></div>The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for uncollectible trade receivables.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Finite-lived Intangible Assets and Impairment Assessment</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finite-lived Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Finite-lived intangible assets are measured at their respective fair values on the date they were recorded. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6 - Intangibles, Net and Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Assessment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing the carrying value of the assets to the fair value of the assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock', window );">Business Combinations and Asset Acquisitions</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations and Asset Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration for the Company&#8217;s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets&#8217; carrying amounts on the acquiring entity&#8217;s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. If the in-licensed agreement for IPR&amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as acquired IPR&amp;D expense in its consolidated statements of comprehensive loss. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable, unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. None of the Company's contingent consideration met the definition of a derivative as of June&#160;30, 2024. Upon recognition of a contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Indefinite-lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indefinite-lived Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Indefinite-lived intangible assets consist of IPR&amp;D. IPR&amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&amp;D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&amp;D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#8217;s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company&#8217;s outlook and market performance of the Company&#8217;s industry and recent and forecasted financial performance. The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span>&#8212;Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#8217;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. As of June&#160;30, 2024 and December&#160;31, 2023, the Company continues to operate as one reporting unit. The Company performs an impairment test for goodwill annually as of October 1.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.</span></div>Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Unamortized debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the UK, and Japan. The results of the Company's non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in total s</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hareholders' equity (deficit),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a component of accumulated other comprehensive loss.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company realizes foreign currency transaction gains and losses in the normal course of business based on movements in the applicable exchange rates. These gains and losses are included as a component of other expense, net.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In the normal course of business, the Company is exposed to the effects of interest rate changes. The Company may enter into derivative instruments, including interest rate swaps and caps, to manage or hedge interest rate risk. Derivative instruments are recorded at fair value on the balance sheet date. The Company has not elected hedge accounting treatment for the changes in the fair value of derivatives. Changes in the fair value of derivatives are recorded each period and are included in change in fair value of interest rate swap in the consolidated statements of comprehensive loss and consolidated statements of cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock', window );">Inventory and Cost of Product Revenues (excluding amortization of intangible assets)</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Cost of Product Revenues (excluding amortization of intangible assets)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Inventory is stated at the lower of cost and net realizable value. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. Inventory used for clinical development purposes is expensed to R&amp;D expense when consumed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&#160;Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock (RS), restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements (Not Yet Adopted)</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements (Not Yet Adopted)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In December 2023, the FASB issued ASU 2023-09, Income Taxes&#8212;Improvements to Income Tax Disclosures, in order to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires greater disaggregation of income tax disclosures related to the income tax rate </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reconciliation and income taxes paid. ASU 2023-09 will be effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of adoption of ASU 2023-09 on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combinations And Asset Acquisitions, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory And Cost Of Product Revenues (Excluding Amortization Of Intangible Assets)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634076301744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Percentage of Gross Product Revenue</a></td>
<td class="text">The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the six months ended June&#160;30, 2024 and their respective percentages for the six months ended June&#160;30, 2023.<div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.116%"><tr><td style="width:1.0%"></td><td style="width:33.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.934%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.936%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Reconciliation of the Weighted Average Number of Common Shares Used to Compute Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three and six months ended June&#160;30, 2024 and 2023: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300,609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244,809)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404,573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of basic net loss per share:</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RS and RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,702&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,553&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,957&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.94)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.78)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.02)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.95)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of June&#160;30, 2024 and 2023, respectively, as their effect would have been anti-dilutive (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:66.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.553%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.555%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RS and RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634177731216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis and Carrying Value</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:36.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June&#160;30, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:36.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swap</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Observable Inputs in Valuation of Deferred Consideration, Development and Regulatory Milestones and Priority Review Voucher Milestone and Changes in Fair Value of Valuations for Deferred and Contingent Consideration Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following observable input was used in the valuation of the deferred consideration as of June&#160;30, 2024:</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.111%"><tr><td style="width:1.0%"></td><td style="width:21.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of June&#160;30, 2024 (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Observable Input</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12.4</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed share price as of June&#160;30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$67.00</span></div></td></tr></table></div>The following significant unobservable inputs were used in the valuation of the development and regulatory milestones and the priority review voucher milestone as of June&#160;30, 2024:<div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"></td><td style="width:25.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.350%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value as of June&#160;30, 2024 (in millions)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Values</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$161.8</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probabilities of success</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14% - 97%</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Priority review voucher milestone</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.2</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability-adjusted discounted cash flow</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of success</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4%</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4%</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the six months ended June 30, 2024 and 2023 (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.391%"><tr><td style="width:1.0%"></td><td style="width:38.143%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred<br/>&#160;Consideration <br/>(Level 2 Liabilities)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Consideration<br/>&#160;(Level 3 Liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of June 30, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,400&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634076338816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenues, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Geographic Summary of Product Revenues, Net</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a geographic summary of the Company's product revenues, net, for the three and six months ended June&#160;30, 2024 and 2023 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:24.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,665&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe and rest of world</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total product revenues, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,340&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,229&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,840&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,443&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634074328160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's inventory balance consists of the following (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"><tr><td style="width:1.0%"></td><td style="width:49.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.258%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,063&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,248&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634079958352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles, Net and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Rollforward of Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the Company's intangible assets for the six months ended June 30, 2024 and June&#160;30, 2023 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"></td><td style="width:24.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,425)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,704&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,526)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,178&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,425)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&amp;D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,756&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,526)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,230&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634076338816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Fixed Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:33.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.398%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.401%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Useful Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3-5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-10</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,119&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,012&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,342)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,628)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,777&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,384&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634076991760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"></td><td style="width:57.515%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accrued operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued technical operation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty and milestones payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interest Payments payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales allowances and related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued France ATU reimbursement payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred and contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued milestone payment to AstraZeneca</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,844&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,987&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634076304320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Supplemental Non-cash Disclosures</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:33.469%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.483%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634074840496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Current Portion of Long-Term Debt and Debt, Long-Term</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of long-term debt and debt, long-term consists of the following commitments as of June&#160;30, 2024 and December&#160;31, 2023 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.608%"><tr><td style="width:1.0%"></td><td style="width:46.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,909&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">946,825&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155,313&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Carrying Value of Convertible Notes Balance</a></td>
<td class="text">The following table presents the carrying value of the Company's convertible notes balance (in thousands):<div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"></td><td style="width:55.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.755%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of outstanding convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term convertible notes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566,105&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,909&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account for the six-month period ended June&#160;30, 2024 and year ended December&#160;31, 2023 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:48.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended <br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing agreement liability - beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interest Payments paid and payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing agreement liability - ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,243&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing issuance costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty issuance costs, unamortized - beginning balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,523)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred issuance costs, unamortized - ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,866)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,128)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Royalty Financing Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,377&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,034&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Carrying Value of Term Loan Balance</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the carrying value of the Company&#8217;s Term Loan balance as of June&#160;30, 2024 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.169%"><tr><td style="width:1.0%"></td><td style="width:45.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.276%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.277%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original Term Loan balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid-in-kind interest capitalized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,537&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan issuance costs, unamortized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,720&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366,404&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Principal Repayments of Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, future principal repayments of debt for each of the years through maturity were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.543%"><tr><td style="width:1.0%"></td><td style="width:64.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending December&#160;31:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190,108&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Interest Expense related to Debt and Finance Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to debt and finance leases for the three and six months ended June&#160;30, 2024 and 2023 is as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.056%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,125&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan contractual interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty Financing Agreement interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swap interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(710)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(354)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(427)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total debt interest expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,703&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,007&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,168&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,396&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total interest expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,619&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,309&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,622&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634076299344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Financing Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Carrying Value of Royalty Financing Agreement</a></td>
<td class="text">The following table presents the carrying value of the Company's convertible notes balance (in thousands):<div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"></td><td style="width:55.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.755%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Face value of outstanding convertible notes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,091)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term convertible notes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566,105&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788,909&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the activity within the liability account for the six-month period ended June&#160;30, 2024 and year ended December&#160;31, 2023 (in thousands):</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"></td><td style="width:48.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Twelve Months Ended <br/>December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing agreement liability - beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interest Payments paid and payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing agreement liability - ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,243&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty financing issuance costs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty issuance costs, unamortized - beginning balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,523)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred issuance costs, unamortized - ending balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,866)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,128)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Royalty Financing Agreement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,377&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,034&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634077115664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Aggregate Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options, RSUs and the ESPP during the three and six months ended June&#160;30, 2024 and 2023 (in thousands):&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:30.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.448%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,636&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,686&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,286&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,358&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,736&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,802&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634074189024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Schedule of Purchase Price</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the purchase price (in millions):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.543%"><tr><td style="width:1.0%"></td><td style="width:72.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of Insmed common stock issued on closing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of Insmed common stock issued in July 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total purchase price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634077374960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,246,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,246,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 482,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (300,609)<span></span>
</td>
<td class="num">$ (244,809)<span></span>
</td>
<td class="num">$ (457,700)<span></span>
</td>
<td class="num">$ (404,573)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634083785600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Percentage of Gross Product Revenue (Details) - Sales Revenue, Product Line - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=insm_CustomerAMember', window );">Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=insm_CustomerBMember', window );">Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=insm_CustomerCMember', window );">Customer C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=insm_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=insm_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=insm_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=insm_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=insm_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=insm_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634075903296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details) - reportingUnit<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634082487856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Reconciliation of the Weighted Average Number of Common Shares Used to Compute Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (300,609)<span></span>
</td>
<td class="num">$ (244,809)<span></span>
</td>
<td class="num">$ (457,700)<span></span>
</td>
<td class="num">$ (404,573)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares used in calculation of basic net loss per share (in shares)</a></td>
<td class="nump">154,702<span></span>
</td>
<td class="nump">137,553<span></span>
</td>
<td class="nump">151,579<span></span>
</td>
<td class="nump">136,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Convertible debt securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">154,702<span></span>
</td>
<td class="nump">137,553<span></span>
</td>
<td class="nump">151,579<span></span>
</td>
<td class="nump">136,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (1.94)<span></span>
</td>
<td class="num">$ (1.78)<span></span>
</td>
<td class="num">$ (3.02)<span></span>
</td>
<td class="num">$ (2.95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (1.94)<span></span>
</td>
<td class="num">$ (1.78)<span></span>
</td>
<td class="num">$ (3.02)<span></span>
</td>
<td class="num">$ (2.95)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RS and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634075682016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">23,430<span></span>
</td>
<td class="nump">21,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RS and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">3,425<span></span>
</td>
<td class="nump">2,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">665<span></span>
</td>
<td class="nump">666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">23,438<span></span>
</td>
<td class="nump">23,438<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634072016400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis and Carrying Value (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="nump">$ 12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">12,400,000<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">169,700,000<span></span>
</td>
<td class="nump">84,600,000<span></span>
</td>
<td class="nump">$ 61,700,000<span></span>
</td>
<td class="nump">$ 58,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value | Recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">1,246,800,000<span></span>
</td>
<td class="nump">482,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">298,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Collateral for interest rate swap</a></td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap</a></td>
<td class="num">(1,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue', window );">Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="nump">12,400,000<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">169,700,000<span></span>
</td>
<td class="nump">84,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Recurring Basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">1,246,800,000<span></span>
</td>
<td class="nump">482,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Collateral for interest rate swap</a></td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue', window );">Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Recurring Basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Collateral for interest rate swap</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap</a></td>
<td class="num">(1,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue', window );">Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="nump">12,400,000<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Recurring Basis | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Collateral for interest rate swap</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue', window );">Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 169,700,000<span></span>
</td>
<td class="nump">$ 84,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_BusinessCombinationDeferredLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Deferred Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_BusinessCombinationDeferredLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 30: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateDerivativeAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateDerivativeAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateDerivativeLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634067230896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 04, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>sale </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 01, 2025</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 01, 2022</div></th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member', window );">0.75% Convertible Senior Notes Due 2028 | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original Term Loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member', window );">1.75% Convertible Senior Notes Due 2025 | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original Term Loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements | ARIKAYCE Global Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_DebtInstrumentRoyaltyStatedPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements | Brensocatib Global Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_DebtInstrumentRoyaltyStatedPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements | Forecast | ARIKAYCE Global Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_DebtInstrumentRoyaltyStatedPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_ProceedsFromRoyaltyFinancing', window );">Proceeds from royalty financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original Term Loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Interest payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=insm_MeasurementInputProbabilityOfSuccessMember', window );">Probabilities of success</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Weighted average probability of success</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 3 | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 2 | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 2 | 0.75% Convertible Senior Notes Due 2028 | Convertible notes | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Level 2 | 1.75% Convertible Senior Notes Due 2025 | Convertible notes | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares) | shares</a></td>
<td class="nump">2,889,367<span></span>
</td>
<td class="nump">177,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,203<span></span>
</td>
<td class="nump">171,427<span></span>
</td>
<td class="nump">2,889,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares', window );">Shares issued upon milestone achievements (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,348,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus | Development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage', window );">Proceeds of sale of priority review voucher obligated to pay to equity holders, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage', window );">Average sales prices of publicly disclosed priority review voucher sales obligated to pay equity holders, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders', window );">Number of publicly disclosed sales used to determine average sales price owed to equity holders | sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus | First Anniversary of Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus | Second Anniversary of Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus | Third Anniversary of Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_AlgaeneXIncMember', window );">AlgaeneX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares', window );">Shares issued upon milestone achievements (in shares) | shares</a></td>
<td class="nump">368,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average Sales Prices Of Publicly Disclosed Priority Review Voucher Sales Obligated To Pay Equity Holders, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_BusinessCombinationDeferredLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Deferred Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_BusinessCombinationDeferredLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentRoyaltyStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Royalty, Stated Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentRoyaltyStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Publicly Disclosed Sales Used To Determine Average Sales Price Owed To Equity Holders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ProceedsFromRoyaltyFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Royalty Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ProceedsFromRoyaltyFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds Of Sale Of Priority Review Voucher Obligated To Pay To Equity Holders, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=insm_ARIKAYCEGlobalNetSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=insm_ARIKAYCEGlobalNetSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=insm_BrensocatibGlobalNetSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=insm_BrensocatibGlobalNetSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=insm_MeasurementInputProbabilityOfSuccessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=insm_MeasurementInputProbabilityOfSuccessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=insm_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=insm_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=insm_AlgaeneXIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=insm_AlgaeneXIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634184518096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Observable Inputs in Valuation of Deferred Consideration (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_BusinessCombinationDeferredLiability', window );">Deferred consideration | $</a></td>
<td class="nump">$ 12.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput', window );">Insmed share price (in usd per share) | $ / shares</a></td>
<td class="nump">67.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Deferred Consideration Liability, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_BusinessCombinationDeferredLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Deferred Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_BusinessCombinationDeferredLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634065796464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Valuation of Development and Regulatory Milestones and Priority Review Voucher Milestone (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 169,700<span></span>
</td>
<td class="nump">$ 84,600<span></span>
</td>
<td class="nump">$ 61,700<span></span>
</td>
<td class="nump">$ 58,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=insm_MeasurementInputProbabilityOfSuccessMember', window );">Probabilities of success</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Values</a></td>
<td class="nump">0.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=insm_DevelopmentAndRegulatoryMilestonesMember', window );">Development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 161,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=insm_PriorityReviewVoucherMilestoneMember', window );">Priority review voucher milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=insm_PriorityReviewVoucherMilestoneMember', window );">Priority review voucher milestone | Probabilities of success | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Values</a></td>
<td class="nump">0.164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=insm_PriorityReviewVoucherMilestoneMember', window );">Priority review voucher milestone | Discount rate | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Values</a></td>
<td class="nump">0.164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Development and regulatory milestones | Probabilities of success | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Values</a></td>
<td class="nump">0.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Development and regulatory milestones | Probabilities of success | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Values</a></td>
<td class="nump">0.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=insm_MeasurementInputProbabilityOfSuccessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=insm_MeasurementInputProbabilityOfSuccessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=insm_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=insm_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=insm_PriorityReviewVoucherMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=insm_PriorityReviewVoucherMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634083968496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Changes in Fair Value of Valuations for Deferred and Contingent Consideration Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Deferred Consideration (Level 2 Liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Consideration, beginning balance</a></td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions', window );">Change in Fair Value</a></td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Consideration, ending balance</a></td>
<td class="nump">12,400<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Contingent Consideration (Level 3 Liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Consideration, beginning balance</a></td>
<td class="nump">84,600<span></span>
</td>
<td class="nump">58,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions', window );">Change in Fair Value</a></td>
<td class="nump">85,100<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Consideration, ending balance</a></td>
<td class="nump">$ 169,700<span></span>
</td>
<td class="nump">$ 61,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in fair value from changes in the assumptions or model used to calculate the fair value of a contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634184996896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenues, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues, net</a></td>
<td class="nump">$ 90,340<span></span>
</td>
<td class="nump">$ 77,229<span></span>
</td>
<td class="nump">$ 165,840<span></span>
</td>
<td class="nump">$ 142,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues, net</a></td>
<td class="nump">63,793<span></span>
</td>
<td class="nump">57,665<span></span>
</td>
<td class="nump">120,142<span></span>
</td>
<td class="nump">106,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues, net</a></td>
<td class="nump">21,111<span></span>
</td>
<td class="nump">15,593<span></span>
</td>
<td class="nump">36,002<span></span>
</td>
<td class="nump">28,749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=insm_EuropeAndTheRestOfTheWorldMember', window );">Europe and rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues, net</a></td>
<td class="nump">$ 5,436<span></span>
</td>
<td class="nump">$ 3,971<span></span>
</td>
<td class="nump">$ 9,696<span></span>
</td>
<td class="nump">$ 6,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=insm_EuropeAndTheRestOfTheWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=insm_EuropeAndTheRestOfTheWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634204523616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 24,898<span></span>
</td>
<td class="nump">$ 24,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">36,494<span></span>
</td>
<td class="nump">33,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">28,671<span></span>
</td>
<td class="nump">25,206<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">$ 90,063<span></span>
</td>
<td class="nump">$ 83,248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634075679440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangibles, Net and Goodwill - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets estimated useful life (in years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Amortization of intangible assets, remainder of 2024</a></td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Amortization of intangible assets, 2025</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Amortization of intangible assets, 2026</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Amortization of intangible assets, 2027</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Amortization of intangible assets, 2028</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 136,110<span></span>
</td>
<td class="nump">$ 136,110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634077666000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles, Net and Goodwill - Schedule of Rollforward of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,704<span></span>
</td>
<td class="nump">$ 68,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="num">$ (1,263)<span></span>
</td>
<td class="num">$ (1,263)<span></span>
</td>
<td class="num">(2,526)<span></span>
</td>
<td class="num">(2,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">61,178<span></span>
</td>
<td class="nump">66,230<span></span>
</td>
<td class="nump">61,178<span></span>
</td>
<td class="nump">66,230<span></span>
</td>
<td class="nump">63,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=insm_AcquiredResearchAndDevelopmentMember', window );">Acquired ARIKAYCE R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,738<span></span>
</td>
<td class="nump">37,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,425)<span></span>
</td>
<td class="num">(2,425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">30,313<span></span>
</td>
<td class="nump">35,163<span></span>
</td>
<td class="nump">30,313<span></span>
</td>
<td class="nump">35,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">29,600<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">PARI milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,366<span></span>
</td>
<td class="nump">$ 1,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">$ 1,265<span></span>
</td>
<td class="nump">$ 1,467<span></span>
</td>
<td class="nump">$ 1,265<span></span>
</td>
<td class="nump">$ 1,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=insm_AcquiredResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=insm_AcquiredResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634083736976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fixed Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 120,119<span></span>
</td>
<td class="nump">$ 110,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(47,342)<span></span>
</td>
<td class="num">(44,628)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">$ 72,777<span></span>
</td>
<td class="nump">65,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 24,476<span></span>
</td>
<td class="nump">22,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 6,428<span></span>
</td>
<td class="nump">6,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember', window );">Computer hardware and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 6,252<span></span>
</td>
<td class="nump">6,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember', window );">Computer hardware and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember', window );">Computer hardware and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ManufacturingEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 1,336<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 37,922<span></span>
</td>
<td class="nump">38,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 43,616<span></span>
</td>
<td class="nump">$ 35,449<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634075282720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable and other accrued operating expenses</a></td>
<td class="nump">$ 51,363<span></span>
</td>
<td class="nump">$ 65,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_AccruedClinicalTrialExpenses', window );">Accrued clinical trial expenses</a></td>
<td class="nump">22,581<span></span>
</td>
<td class="nump">23,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued professional fees</a></td>
<td class="nump">16,114<span></span>
</td>
<td class="nump">13,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_AccruedTechnicalOperationExpenses', window );">Accrued technical operation expenses</a></td>
<td class="nump">11,097<span></span>
</td>
<td class="nump">9,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee related costs</a></td>
<td class="nump">42,198<span></span>
</td>
<td class="nump">48,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalty and milestones payable</a></td>
<td class="nump">7,288<span></span>
</td>
<td class="nump">5,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="nump">2,175<span></span>
</td>
<td class="nump">2,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_RevenueInterestPaymentsPayable', window );">Revenue Interest Payments payable</a></td>
<td class="nump">3,613<span></span>
</td>
<td class="nump">3,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_AccruedSalesAllowancesAndRelatedCosts', window );">Accrued sales allowances and related costs</a></td>
<td class="nump">14,479<span></span>
</td>
<td class="nump">10,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent', window );">Accrued France ATU reimbursement payable</a></td>
<td class="nump">17,188<span></span>
</td>
<td class="nump">14,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_BusinessCombinationDeferredPaymentsCurrent', window );">Deferred and contingent consideration</a></td>
<td class="nump">81,600<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_AccruedMilestonePaymentCurrent', window );">Accrued milestone payment to AstraZeneca</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">8,648<span></span>
</td>
<td class="nump">10,360<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued liabilities</a></td>
<td class="nump">$ 290,844<span></span>
</td>
<td class="nump">$ 214,987<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedClinicalTrialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedClinicalTrialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedMilestonePaymentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Milestone Payment, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedMilestonePaymentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedSalesAllowancesAndRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Sales Allowances And Related Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedSalesAllowancesAndRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedTechnicalOperationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedTechnicalOperationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_BusinessCombinationDeferredPaymentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Deferred Payments, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_BusinessCombinationDeferredPaymentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_RevenueInterestPaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Payments Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_RevenueInterestPaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634075283008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease, cost</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount', window );">Lease cost, future right-of-use asset</a></td>
<td class="nump">$ 54.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_LeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_LeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_LeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_LeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecorded obligation to transfer funds in future for fixed or minimum amount or quantity of product and service at fixed or minimum price. Includes, but is not limited to, lease not yet commenced and take-or-pay and throughput contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634182298304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Non-cash Disclosures (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 5,656<span></span>
</td>
<td class="nump">$ 1,881<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634076165360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Current Portion of Long-Term Debt and Debt, Long-Term (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of convertible notes</a></td>
<td class="num">$ (224,448)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term convertible notes</a></td>
<td class="nump">946,825<span></span>
</td>
<td class="nump">1,155,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">790,553<span></span>
</td>
<td class="nump">788,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_TermLoanMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 380,720<span></span>
</td>
<td class="nump">$ 366,404<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634066492272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($) </div>
<div>day</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Paid-in-kind interest capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,571<span></span>
</td>
<td class="nump">$ 11,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member', window );">0.75% Convertible Senior Notes Due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0307692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member', window );">0.75% Convertible Senior Notes Due 2028 | Level 2 | Carrying Value | Recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible senior notes</a></td>
<td class="nump">$ 566,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member', window );">1.75% Convertible Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0255384<span></span>
</td>
<td class="nump">25.5384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member', window );">1.75% Convertible Senior Notes Due 2025 | Level 2 | Carrying Value | Recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible senior notes</a></td>
<td class="nump">224,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_TermLoanMember', window );">Term Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original Term Loan balance</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_DebtInstrumentPercentOfInterestPayable', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Proceeds from loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 334,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_TermLoanMember', window );">Term Loan | Secured Debt | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="nump">9,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | 0.75% Convertible Senior Notes Due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original Term Loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_DebtInstrumentOptionToPurchaseAdditionalDebt', window );">Option to purchase additional debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="nump">8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 559,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Residual equity component of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 203,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining', window );">Remaining discount amortization period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | 0.75% Convertible Senior Notes Due 2028 | Conversion Term (i)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percent of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | 0.75% Convertible Senior Notes Due 2028 | Conversion Term (ii)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percent of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | 0.75% Convertible Senior Notes Due 2028 | Conversion Term (iii)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange', window );">Threshold trading days following fundamental change | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | 0.75% Convertible Senior Notes Due 2028 | Conversion Term (iv)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percent of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | 1.75% Convertible Senior Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original Term Loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_DebtInstrumentOptionToPurchaseAdditionalDebt', window );">Option to purchase additional debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchased amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Residual equity component of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | 1.75% Convertible Senior Notes Due 2025 | Conversion Term (i)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percent of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | 1.75% Convertible Senior Notes Due 2025 | Conversion Term (ii)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percent of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | 1.75% Convertible Senior Notes Due 2025 | Conversion Term (iii)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange', window );">Threshold trading days following fundamental change | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | 1.75% Convertible Senior Notes Due 2025 | Conversion Term (iv)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percent of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes | Redemption of the 2025 Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Redemption price percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_DebtInstrumentRedemptionPricePerShare', window );">Redemption price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1,001.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Debt Instrument, Discount Amortization Period, Remaining</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentOptionToPurchaseAdditionalDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Option To Purchase Additional Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentOptionToPurchaseAdditionalDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentPercentOfInterestPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Percent Of Interest Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentPercentOfInterestPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from principal payments made on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_DebtInstrumentConversionTermFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_RedemptionOfThe2025ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_RedemptionOfThe2025ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634083704080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Carrying Value of Convertible Notes Balance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of convertible notes</a></td>
<td class="num">$ (224,448)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, long-term</a></td>
<td class="nump">946,825<span></span>
</td>
<td class="nump">1,155,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Face value of outstanding convertible notes</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="num">(9,447)<span></span>
</td>
<td class="num">(11,091)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of convertible notes</a></td>
<td class="num">(224,448)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, long-term</a></td>
<td class="nump">$ 566,105<span></span>
</td>
<td class="nump">$ 788,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634074148464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Carrying Value of Term Loan Balance (Details) - Term Loan - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term Loan</a></td>
<td class="nump">$ 380,720<span></span>
</td>
<td class="nump">$ 366,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original Term Loan balance</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedCapitalizedInterestCosts', window );">Paid-in-kind interest capitalized</a></td>
<td class="nump">40,108<span></span>
</td>
<td class="nump">27,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Term Loan issuance costs, unamortized</a></td>
<td class="num">(9,388)<span></span>
</td>
<td class="num">(11,133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term Loan</a></td>
<td class="nump">$ 380,720<span></span>
</td>
<td class="nump">$ 366,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedCapitalizedInterestCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated interest costs capitalized as part of property, plant and equipment cost basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedCapitalizedInterestCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634074463504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Future Principal Repayments of Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Year Ending December&#160;31:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">$ 225,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2026</a></td>
<td class="nump">195,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2027</a></td>
<td class="nump">195,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2028</a></td>
<td class="nump">575,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_LongTermDebtMaturityAfterYearFourAndThereafter', window );">2029 and thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1,190,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_LongTermDebtMaturityAfterYearFourAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturity, After Year Four And Thereafter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_LongTermDebtMaturityAfterYearFourAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634184999184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Schedule of Interest Expense related to Debt and Finance Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 2,004<span></span>
</td>
<td class="nump">$ 3,651<span></span>
</td>
<td class="nump">$ 3,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Swap interest income</a></td>
<td class="num">(710)<span></span>
</td>
<td class="num">(354)<span></span>
</td>
<td class="num">(1,464)<span></span>
</td>
<td class="num">(427)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_InterestExpenseExcludingFinanceLeaseInterestExpense', window );">Total debt interest expense</a></td>
<td class="nump">20,703<span></span>
</td>
<td class="nump">20,007<span></span>
</td>
<td class="nump">41,168<span></span>
</td>
<td class="nump">39,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance lease interest expense</a></td>
<td class="nump">564<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total interest expense</a></td>
<td class="nump">21,267<span></span>
</td>
<td class="nump">20,619<span></span>
</td>
<td class="nump">42,309<span></span>
</td>
<td class="nump">40,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Convertible debt contractual interest expense</a></td>
<td class="nump">2,062<span></span>
</td>
<td class="nump">2,062<span></span>
</td>
<td class="nump">4,125<span></span>
</td>
<td class="nump">4,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_TermLoanMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Convertible debt contractual interest expense</a></td>
<td class="nump">12,658<span></span>
</td>
<td class="nump">11,490<span></span>
</td>
<td class="nump">25,141<span></span>
</td>
<td class="nump">22,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Convertible debt contractual interest expense</a></td>
<td class="nump">$ 4,893<span></span>
</td>
<td class="nump">$ 4,805<span></span>
</td>
<td class="nump">$ 9,715<span></span>
</td>
<td class="nump">$ 9,569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_InterestExpenseExcludingFinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Expense, Excluding Finance Lease Interest Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_InterestExpenseExcludingFinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634078470880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Financing Agreement - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Sep. 01, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalty financing liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,288<span></span>
</td>
<td class="nump">$ 5,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalty financing liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_DebtInstrumentRoyaltyPayableMaximum', window );">Royalty maximum</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_DebtInstrumentRoyaltyPayableMaximum', window );">Royalty maximum</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements | ARIKAYCE Global Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_DebtInstrumentRoyaltyStatedPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements | ARIKAYCE Global Net Sales | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_DebtInstrumentRoyaltyStatedPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements | Brensocatib Global Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_DebtInstrumentRoyaltyStatedPercentage', window );">Royalty percentage</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_ProceedsFromRoyaltyFinancing', window );">Proceeds from royalty financing</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Interest payments</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Lenders fees and deal expenses</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_ProceedsFromRoyaltyFinancingAgreementNet', window );">Proceeds from royalty financing agreement, net</a></td>
<td class="nump">$ 146,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">12.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentRoyaltyPayableMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Royalty Payable, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentRoyaltyPayableMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentRoyaltyStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Royalty, Stated Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentRoyaltyStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ProceedsFromRoyaltyFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Royalty Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ProceedsFromRoyaltyFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ProceedsFromRoyaltyFinancingAgreementNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Royalty Financing Agreement, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ProceedsFromRoyaltyFinancingAgreementNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=insm_ARIKAYCEGlobalNetSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=insm_ARIKAYCEGlobalNetSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=insm_BrensocatibGlobalNetSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=insm_BrensocatibGlobalNetSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634067495072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Financing Agreement - Schedule of Carrying Value of Royalty Financing Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_RoyaltyFinancingAgreementRollForward', window );"><strong>Royalty Financing Agreement [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalty financing agreement liability - beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalty financing agreement liability - ending balance</a></td>
<td class="nump">$ 158,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of issuance costs</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">$ 2,004<span></span>
</td>
<td class="nump">3,651<span></span>
</td>
<td class="nump">$ 3,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalty financing agreement</a></td>
<td class="nump">158,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_RoyaltyFinancingAgreementRollForward', window );"><strong>Royalty Financing Agreement [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense recognized</a></td>
<td class="nump">4,893<span></span>
</td>
<td class="nump">$ 4,805<span></span>
</td>
<td class="nump">9,715<span></span>
</td>
<td class="nump">9,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_RoyaltyFinancingAgreementRollForward', window );"><strong>Royalty Financing Agreement [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_RoyaltyFinancingAgreementRollForward', window );"><strong>Royalty Financing Agreement [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalty financing agreement liability - beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,162<span></span>
</td>
<td class="nump">151,538<span></span>
</td>
<td class="nump">151,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Revenue Interest Payments paid and payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,634)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalty financing agreement liability - ending balance</a></td>
<td class="nump">161,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Royalty issuance costs, unamortized - beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,128<span></span>
</td>
<td class="nump">$ 3,523<span></span>
</td>
<td class="nump">3,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_DebtIssuanceCostsOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Deferred issuance costs, unamortized - ending balance</a></td>
<td class="nump">2,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalty financing agreement</a></td>
<td class="nump">$ 161,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtIssuanceCostsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtIssuanceCostsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_RoyaltyFinancingAgreementRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Financing Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_RoyaltyFinancingAgreementRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_RoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634065736240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 04, 2021</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,666,599<span></span>
</td>
<td class="nump">147,977,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,666,599<span></span>
</td>
<td class="nump">147,977,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=insm_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,514,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 713.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=insm_AtTheMarketAgreementMember', window );">ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,503,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_CommonStockAuthorizedAggregateGrossSalesProceeds', window );">Common stock authorized, aggregate gross sales proceeds (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,893,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,406,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,406,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares)</a></td>
<td class="nump">2,889,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,427<span></span>
</td>
<td class="nump">2,889,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_AdrestiaTherapeuticsLtdMember', window );">Adrestia Therapeutics Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for business acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,430,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_VertuisBioIncMember', window );">Vertuis Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock for business acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,438,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,430,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RS and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,425,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">664,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CommonStockAuthorizedAggregateGrossSalesProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Authorized, Aggregate Gross Sales Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_CommonStockAuthorizedAggregateGrossSalesProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=insm_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=insm_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=insm_AtTheMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=insm_AtTheMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=insm_AdrestiaTherapeuticsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=insm_AdrestiaTherapeuticsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=insm_VertuisBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=insm_VertuisBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634072713584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 12, 2020</div></th>
<th class="th"><div>May 15, 2018</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross', window );">Inducement stock options granted to new employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">899,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,600,000<span></span>
</td>
<td class="nump">$ 168,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,780<span></span>
</td>
<td class="nump">114,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RS and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to unvested RSU awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,800,000<span></span>
</td>
<td class="nump">$ 72,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Options outstanding, nonvested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,887<span></span>
</td>
<td class="nump">265,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Potential award payout</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Potential award payout</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Potential award payout</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=insm_A2019IncentivePlanMember', window );">2019 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=insm_A2019IncentivePlanThirdAmendmentMember', window );">2019 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,780,711<span></span>
</td>
<td class="nump">4,780,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=insm_EmployeeStockPurchasePlan2018Member', window );">2018 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock, maximum authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of inducement share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=insm_A2019IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=insm_A2019IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=insm_A2019IncentivePlanThirdAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=insm_A2019IncentivePlanThirdAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=insm_EmployeeStockPurchasePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=insm_EmployeeStockPurchasePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634072986608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Aggregate Stock-Based Compensation Expense (Details) - Stock options and RSUs - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 23,286<span></span>
</td>
<td class="nump">$ 18,358<span></span>
</td>
<td class="nump">$ 44,736<span></span>
</td>
<td class="nump">$ 34,802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">11,301<span></span>
</td>
<td class="nump">8,787<span></span>
</td>
<td class="nump">21,636<span></span>
</td>
<td class="nump">16,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 11,985<span></span>
</td>
<td class="nump">$ 9,571<span></span>
</td>
<td class="nump">$ 23,100<span></span>
</td>
<td class="nump">$ 18,116<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634204024944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 838,000<span></span>
</td>
<td class="nump">$ 530,000<span></span>
</td>
<td class="nump">$ 1,427,000<span></span>
</td>
<td class="nump">$ 1,013,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest and penalties accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634074681760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent expense charged to operations</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634070950256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 04, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 24, 2021 </div>
<div>days</div>
</th>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.10<span></span>
</td>
<td class="nump">$ 18.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_BusinessAcquisitionConsecutiveTradingDayPeriod', window );">Consecutive trading day period | days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncAndAlgaeneXIncMember', window );">Motus and AlgaeneX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares) | shares</a></td>
<td class="nump">2,889,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,203<span></span>
</td>
<td class="nump">171,427<span></span>
</td>
<td class="nump">2,889,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares', window );">Shares issued upon milestone achievements (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,348,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Share price used to calculate issuable shares (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus | First Anniversary of Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus | Second Anniversary of Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember', window );">Motus | Third Anniversary of Closing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=insm_AlgaeneXIncMember', window );">AlgaeneX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares', window );">Shares issued upon milestone achievements (in shares) | shares</a></td>
<td class="nump">368,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid in acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Share price used to calculate issuable shares (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=insm_AdrestiaTherapeuticsLtdMember', window );">Adrestia Therapeutics Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Shares issued in asset acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,430,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition, consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent payment, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 326,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">IPR&amp;D expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=insm_VertuisBioIncMember', window );">Vertuis Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Shares issued in asset acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition, consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent payment, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=insm_VertuisBioIncMember', window );">Vertuis Bio, Inc. | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Shares issued in asset acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent payment, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=insm_VertuisBioIncMember', window );">Vertuis Bio, Inc. | Milestone Event 1 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent payment, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=insm_VertuisBioIncMember', window );">Vertuis Bio, Inc. | Milestone Event 2 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent payment, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Consideration Transferred, Equity Interest Issued And Issuable, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_BusinessAcquisitionConsecutiveTradingDayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Consecutive Trading Day Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_BusinessAcquisitionConsecutiveTradingDayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncAndAlgaeneXIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncAndAlgaeneXIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=insm_MotusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=insm_AlgaeneXIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=insm_AlgaeneXIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=insm_AdrestiaTherapeuticsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=insm_AdrestiaTherapeuticsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=insm_VertuisBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=insm_VertuisBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_TriggeringEventAxis=insm_MilestoneEvent1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_TriggeringEventAxis=insm_MilestoneEvent1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_TriggeringEventAxis=insm_MilestoneEvent2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_TriggeringEventAxis=insm_MilestoneEvent2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634076254608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Schedule of Purchase Price (Details) - Vertuis Bio, Inc.<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Shares of Insmed common stock issued on closing</a></td>
<td class="nump">$ 9,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Shares of Insmed common stock issued in July 2024</a></td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total purchase price</a></td>
<td class="nump">$ 10,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=insm_VertuisBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=insm_VertuisBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139634067618208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 07, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 02, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=insm_VertuisBioIncMember', window );">Vertuis Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent payment, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Shares issued in asset acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Vertuis Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent payment, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Shares issued in asset acquisition (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Conversion of 2025 Notes | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted outstanding amount</a></td>
<td class="nump">$ 224,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate</a></td>
<td class="nump">0.0255384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 39.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued (in shares) | shares</a></td>
<td class="nump">5,739,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Aggregate principal amount</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Conversion of 2028 Notes | Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0307692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Consideration Transferred, Equity Interest Issued And Issuable, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=insm_VertuisBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=insm_VertuisBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_A2025ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_A2025ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_A2028ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_A2028ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>96
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M ;R?2ZGW-^8?%"?9P_\ 4$L#!!0    ( 'TW"%E#+GTCKP8  -4;   8
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M  !J!P  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;*U576_3,!3]*U9
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M.\"I!SCG#G#K 17U\9Y[)5S$-9\\R.*%R!(-T<H/E?K5:- KR<M">=82?IO
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M:^8#6S@X",GQ&*TKA4F1(#_<^0!W_B;G5NQ6 2[EEC8ETP9(OWOG+I8LA2/
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M'L12-HE3]ABH)FH&%'WR5V#B.7I.G;G')X6S4)CM/>^-T_/OK%5Z7 "77'P
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M2GJS:=70,&"T=/H.Q=E 'P<EH(T943DPM,:H##4H328&CD.W7FC4&F&B@&<
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M8XFT6$CA47EIG7$KH@JDO7*%-#!Q-W\KA<))G&*3D5V:F@E/M BD:[S/U:0
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MCQ^.A$\_(*6;Z&K^T6;A8G057Y;@U<K3 KQ?.I13>T,*^E_Q3O\'4$L#!!0
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M ,?A=#584K"R6 [$\]G0UDYV^E;;EK9%H7"!'>C@68[[0I%14%/P(0L0M/D
M.X^NRK'L0?Q&S!-6*10!CV4O:_,6.*V_L.5#805$G9II()0M ; $ *SSQ<$9
M@3IWCG2+]L&A5G; %A1ZXIW^"CM+TBXX(#84I&GK@GZ(RW+ ==PXT(IZJ#;W
MJ>X 5U1HL=FPZ0U.M\ V $#,C(:G!KT@6:5]]2OF$ ='MH2,$AD9TN>E!O&N
MNZ:;L^"IIAIPG<1"L#NTJM: 3*5!7%"U,^#?(2#<9O8I0%5813B!B[%+9T/#
M]D+?HLLT+6</%(9/(34H5@KD"4U5[\K$AHR:_1((ME9L06W$1N).HN1U+6)+
M7]VP0BM,WV%!#?+?;WLWY#-\9F^P]CXW&'#F^(Z]$D0:%%60185R!U@"NH&;
MQ,RAE5702.YB[:S#.4@VHRRNPA$^0#P:"- 5Q'!N<2M%D(*-!YR#=P&'DGNR
M?F$U!&/*SE%UHY JYTEVYFNQY "=0R (KW4(K[WO,V1@<:]1^R):+@11]\(Y
MA2@*GJ>)P,8Z%&M="G[%17%Z]DUQ>OY-_.EM<7H"/SU-?KHLCI]_4QP_^R;;
M)I W-  =.G5CZT.(JV"#(10:9A#/@^Q:%^0$1EHF(3['K0C/23)0VW+U!4.9
M"TX$EL'"'T#=9D,S __F08JN2Y@SR[P"^R4O4##8P.^PV[,!P160AK/!\XX,
M'%M1+< 1:Q_&L(T$[5B8%=NK^Q$L\1<P&*H&VPP>,(,&^SX='-I>&/?G<0/W
M"&'*80-"4Q<?0\!07'!$%IUH'!7#BA"W 6PQ.Z"8_;8XQJA!MAW"<+1M\ '"
M8FU)ZSH+0B<JEXR'-2"JC^8ZJLXX(HE9"U9G=TP]!_2 L[>0!; ] G;QJ,K8
M:EB"ET/3BSF&YKSG:7&8, J8_@E2(YSP@P1))*VSP5+4RPD&S/\(6!M+5AEY
MZQQ]3!*,J!VW6-(02:G0'R>BC)(^>V WT'=V[5P&R*^(E &S7"FPW"34)F $
MZ+V_95FW.=ULE3&V\.X/Y#!.).!""GL'2 ?UG". "B("<A$]65X1.? (69I6
MZPHW*B@'!%)?-(54E?:J1R2P%N0IWI9"-+!X0YO8L2(QR+;52+T$[ $D>D&,
MW&%W( D>JD7*(90EL=ME9@"89KUKAT+N((P'BP]"H"$%;"G\EMQ164N95XBE
M:7V9 W@U&* #]ULQ#DO/# C5((-%YX<I!RLV19 S\%(N8YF+A"4*,H.YI$WH
M*:<)"8W."165=DEJY<$G(C!=4[*BR"R/DQ81\DJ<IQ$IPF_%F"$64[#B,<(E
MDP190DATW)CZ:(3*JIZ.S)-,SD@=I&C@>-'O0Z9529+=R0:#L&@:!E*$G$(D
MDY&0>I*QG8;43K)*<-PJF&1DC:>"Y)=H2).U*4;U%ER_0L]#KJUPH!)@E0 5
M+SD:Y09R%%1+R5C@/\^[;6YR(.(IKDAU:Q2KF-!P6HT*U<[!>$ $#Y!G1@5+
M@O@"G&'%)2+FU?8P%C(24D;;4#!;;C',N!%.M=LL&8&'_">8B5DEOB@/6<P3
M:AWR;63OTN0E<J1=#2(3DA1[FT>!(PFFJ#8G-.BU(##&63[_OV.GBY5YM@AY
M[!"%@0@+.THJB-(S*BP;)H?Y%F.YE*^@S=I*C2'*%><3A$!,PY7S%HYW_^+Z
M!N*ZXV>'1\?E#LW;_[5;F:IX?G1^\+*X!!$PL[77]'>:7)$DWRI \)P)9:Z
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M2<-6CW.>#G-J,W#3-?=T<&K4;N*P2YW;+2:C.,?2^DZ%_:M=$#]IZBH6=;\
M!M'1OY.$#?OYZ9S?YYCIS^+XVEN]EK-WO,DAY3H\T.#C<>[A!AN-/=^8&W'
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ME<NU[UN0#O&#)8JPH[Y'3$PV!YRLUUJL7<DY6DR3Z60"89GK ,D]Z5"IIJH
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M?V[E")(HA#B*TU?XDL'UQ/,E+_#U'IN3R[PR\-=J;:RF8OG[.9<[QO1Y1M=
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MA_)F=#42N2ID:\)'^_BS2OHPP,P:S[_B,>X]Q>:L]<%6B1@(*EW'__(IV6%
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MC&)PMBB&SJPHI&DMI#!Z%L>Y94FP:T#?I)#5.6PE'J2!!Y8(:%D'I6)(ZS#
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M3?Y\,8J%:GT3;,/?BRQL"+;B2WIQ5HXVX'EA;5C?D(#N Z+;?P-02P,$%
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M)+XTTOG!B!1A9Y]GD5*Q$>L\VS%EE5 \(=>@#DB-2WAO\%/33%]BV#=M9QB
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ME77B&+G*8'0'C8(XM77;"T\&9.Q:E6 AF"*!B#EO2Z.X.RJ*C73B:#P:C)!
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M4 'GR$)_R)DJ2-X^0J5&!7X%5H0D2JQ22!P5"Z=?E8P2"#B&.GB<JP:U#2C
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MWN?-C?/E>'-O_R+L4I)KA0LRI9DQC, V=^'FP9LJW#_GQM-M-OPLZ.\#6CY
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MD13%':,1D[H"_+X10KT^Z :J6[O+_P)02P,$%     @ ?3<(606B9U6Q%P
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MSX-0??&/K\].SU[\NM 5(+Q23I'5P#L]?%5WU@-;&GBUJ6;&*EL;U5:^AR_
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MJQ[R)3] E/6Z'AP9_*1:#J0#L\$V7C3O5CM+:J)0V<$O=?"LQ'VAR$FI:6O
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M+>E/K-&UPQ?@^:P#<N4#;A!_TNSU_P-02P,$%     @ ?3<(6=B3S17,!
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M;.'1G* ^W_II:*!0O;3#R!B]X\"]'N;,(7R8UE^%WM;20(,;@D87DRP /4S
M86%5YZ?.6EFZ5-ZLZ*>!V@70_D8I^[)P!XR_H<5O4$L#!!0    ( 'TW"%EQ
MD$LWF0(  (8%   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;(5446^;
M,!#^*R<V;:M$"P%":98@)>VJ=5*EJNW6AVD/#ER"56,SVS3MO]\94I9):?8"
M=^>[S]_9_FZZ4?K15(@6GFLAS<RKK&TF06"*"FMF3E2#DE962M?,DJO7@6DT
MLK(KJD40A6$:U(Q++Y]VL1N=3U5K!9=XH\&T=<WTRP*%VLR\D?<:N.7KRKI
MD$\;ML8[M-^;&TU>,*"4O$9IN)*@<37SYJ/)(G'Y7<(/CANS8X/K9*G4HW.N
MRID7.D(HL+ .@='O"<]1" =$-'YO,;UA2U>X:[^B7W:]4R]+9O!<B0=>VFKF
M91Z4N&*ML+=J\Q6W_8P=7J&$Z;ZPZ7/CR(.B-5;5VV)B4'/9_]GS]AQV"K+P
MC8)H6Q!UO/N-.I87S+)\JM4&M,LF-&=TK7;51(Y+=REW5M,JISJ;7\DGE%;I
M%_ATSY8"S=$TL(3K5H-BB['H,:(W,%*X5M)6!K[($LM_ZP/B,Y"*7DDMHH.
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M'"8>Z*[E=Q.KZK;-+I2EIMT.U_1*HG8&M+]4RNXFSD'_[D[_!5!+ P04
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M0#73N-D8N7(3<"8-S5.W7-('#"JK0.=S22VZV]@+VD^BR;]02P,$%     @
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MD]Z'LPA,LQP:P>DJ#.12.QKO<"UIGZ+Q!O2^TMIM!1^@V]#9'U!+ P04
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M>@0E#'N<K0'7WHI-+TRY#%HE&%/=6#/)U5>L<#*\3Q 8LC2#] 5 &H,!%%@
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M#1'7#NK[@C&YV6B!:MH,_P)02P,$%     @ ?3<(6721[BH' P  )@P  !D
M  !X;"]W;W)K<VAE971S+W-H965T-# N>&ULK5=K;]HP%/TK5B9-F]21D/!J
M!Y& O3JM$@)M^S#M@YM<P*IC9[8#W;^?[027L(!:*5^('_><W.-[DES&>RX>
MY!9 H<>,,CGQMDKE-[XODRUD6'9X#DSOK+G(L-)3L?%E+@"G%I11/PR"@9]A
MPKQX;-<6(A[S0E'"8"&0++(,B[\SH'P_\;K>86%)-EME%OQXG.,-K$!]SQ="
MSWS'DI(,F"2<(0'KB3?MWLR[%F C?A#8RZ,Q,E+N.7\PD]MTX@4F(Z"0*$.!
M]64'<Z#4,.D\_E2DGKNG 1Z/#^R?K'@MYAY+F'/ZDZ1J._%&'DIAC0NJEGS_
M!2I!?<.7<"KM+]I7L8&'DD(JGE5@G4%&6'G%C]5!' $T3S,@K #A*:!W!A!5
M@,@*+3.SLCY@A>.QX'LD3+1F,P-[-A:MU1!FRKA20N\2C5/QJBP?XFNT(AM&
MUB3!3*%IDO""*<(V:,$I20A(] ZMM(G2@H*)7H!(@"E=:C/[++B4:"%X6B0*
M+6$'K #TY@,H3*A\:["8:HYJY\J%?M/YZ-VY50H"S3DSM +;(B^)?!C[2NLT
MV?I)I6E6:@K/:!J@.\[45J*/+(6TCO?U^;A#"@^'- LO$GXM6 =%P14*@[#7
MD,_\^?#H0CJ1JUED^7IG^-QA39O.YB+6O!5N9(X3F'CZL9<@=N#%KU]U!\'[
M)F$MD=5D]IS,GF6/SLG\SPKHE[7+K8),_F[2WFM3>TMD->U]I[U_N<0U[4)K
MOT*Y>^*:I)=\(\MGWMV[..A$VJR[8TF-07T75$MUX%(=/,^-LZ:T+F)?6I&6
MR&HRAT[FL&TW#MO4WA)93?O(:1^U[,91D]'"$S<V!@V:W7CM4KU^GAOG36E=
MQ+ZT(BV1U61V@Z?O=M"V'RO&EN2WQ5;7?]2W=%OV9$58]UMW=&+*YJCAB2O]
MHXY+NVUC&U&);--4]A5NU36[4]OBG:S/3!-L.[DGFK*#OL-B0YA$%-::,N@,
M]<M;E$UI.5$\MWW=/5?:\G:XU8T\"!.@]]><J\/$W,#]-8C_ 5!+ P04
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M.O1LH 4S&]8]5G@Z%GR'A+'6:&9@M;'>.AK"S&M\5D(_)=I/33]B(M!73'-
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M*0%Y?T6I. R4@:X-./\)4$L#!!0    ( 'TW"%F0"ZJ)AP(  ,D&   9
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;*U574_;,!3]*U:&)B8!2?-%86DD
M:(7&I$D(QGB8]N FMXV%8V>VT\"_G^V$J!33[6$OB:]]S_$YL>]-UG'Q*"L
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M,#?YE<*>V[#$+ .AF11$P7+LG'6'L[ZU+PV^,ECKK3:QF2RDO+6=]_'8\6Q
MP"$REH'B;P43X-P281@_:TZG<6F!V^T-^T69.^:RH!HFDG]CL4G'SJE#8EC2
M@IMKN7X'=3YE@)'DNOR2=6WK.20JM)%9#<8(,B:J/[VK==@"($\[P*\!_BZ@
M]P@@J '!<SWT:D#ON1[Z-:!,W:UR+X6;4D/#D9)KHJPULME&J7Z)1KV8L/MD
M;A3.,L29\".@RIITR!QW8%QP('))YD6><\#=8"@GGZ3H1%2G9,ITQ*4N%-H?
M3L%0QO41(F_F4W)X<$0."!/D2RH+346L1Z[!\*P3-ZI#.:]"\1\))2"74IA4
MDYF((6[!3_?C!WOP+LK2:.-OM#GW]Q)^*,0)";QCXGM^KR6>R?/A05LZ_^9]
M]M?>[XD1-!LE*/F"?1OEF$RD-N3[V4(;A6?\1]LJ5SR]=AY[[PUU3B,8.WBQ
M:5 K<,+7K[H#[VV;Q"])-GU)LMD+D=U;C%ZS&+U][.$%$U1$0)2]!CMRV2DT
M$*HU&$WD D^F@-B>1KB+4BH2(%A0"+<KB-.<)=1>TJU'M/([*/W:&K,*O9&[
MVEZ1)RVF3UK,]EG<$Z3?"-+?*\CG'!0F)9+_($G_24D>6G2#75$>VO0'_<&.
M+BU$IZ?='6G<K=L^ Y6495:32!;"5.>Y&6TJ^5E9P';&S[O#2;=E?(J5ORK4
M?^BK9\,E50D3&G5;HBOOY T&K*I27'6,S,M:LY &*U?93/'U LH:X/Q22K/I
M6 ?->RC\#5!+ P04    " !]-PA9WX+U-P$#   $"P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6RM5EUOFS 4_2L6JZ96:HOY""%9@K0FFM8IDZ*F
MW1ZF/3CD)D$%.[--TOW[V892TE+4:KP$V]QS..=R3#PZ,'XOM@ 2/60I%6-K
M*^5N:-LBWD)&Q"7; 55WUHQG1*HIW]ABQX&L#"A+;1?CP,Y(0JUH9-;F/!JQ
M7*8)A3E'(L\RPO]>0<H.8\NQ'A=NDLU6Z@4[&NW(!A8@[W9SKF9VQ;)*,J B
M811Q6(^MS\YPXF -,!4_$CB(VAAI*TO&[O7D>C6VL%8$*<124Q!UV<,$TE0S
M*1U_2E*K>J8&UL>/[%^,>65F201,6/HS6<GMV HMM((UR5-YPPY?H334TWPQ
M2X7Y18>R%ELHSH5D60E6"K*$%E?R4#:B!G#\5P!N"7#?"O!*@&>,%LJ,K2F1
M)!IQ=D!<5RLV/3"],6CE)J'Z-2XD5W<3A9/1%)827:"%BL<J3P&Q-9KDG .5
M:,ZXZ;1:FC&ZN;@%GB%33^C*#,YK-TZG($F2BC/%=K>8HM.3,W2"$HINMRP7
M"B%&ME2"]6/MN!1W58AS7Q'W+:>7R,/GR,6NWP"?M,.G$"NX8^#>,=Q6;:IZ
MY5:]<@V?U]:K:RHDSS/=H%\S58"N)63B=Y.Y@LUO9M/[<RAV)(:QI3:@ +X'
M*_KXP0GPIR:K'9$=&?<JXUX;>S0#(88JC44N=D^YB!G=@YHM57(HD]#XC@ON
MP'#KK\H^NG!=W_?#D;VO.WQ9AZN*(]E^)=MOE7W+)$E1JB,J=43?I+:@[-54
M#/P@='O/Q+XL<YQ>SW.\9LF]2G*O5?+D+1);*=Z;JX[(CMP&E=N@TPT5=&F\
M([(CX_W*>+]]0U697*D6-%GMO\A7?X!5P)[%L*$L# =XT)S"L)(7MF\<K6S&
M"&U2U@I][TOHB.S(Y:!R.>@T?8,NC7=$=F3<P4]_^O@_\U<2U+_&7HC[+GX6
MP*:Z(/"Q_RR!=NV(HL^'WPG?)%2@%-8*B"_[*L.\.'(5$\EVYM2R9%*=@<QP
MJXZIP'6!NK]FZO-83O1!J#KX1O\ 4$L#!!0    ( 'TW"%E[OA36IQ   !GB
M   9    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;+V=6W/;Q@&%_PI&33O)
M3&(1(,"+*VNF$K"[[B2Q1T[2ATX?8!(2,28!!0#MN-,?7X""M%P"7!'VU^8A
M%BGLMP!YA,6>LY>+3WGQH5PE2>7\L5EGY:NS557=OSP_+Q>K9!.7+_+[)*M_
M<YL7F[BJ7Q9WY^5]D<3+7:'-^MP;C2;GFSC-SBXO=N^]+2XO\FVU3K/D;>&4
MV\TF+CY?)>O\TZLS]^SQC9OT;E4U;YQ?7MS'=\F[I/KU_FU1OSI_HBS339*5
M:9XY17+[ZNQO[DLU]YH"NR-^2Y-/Y=[/3G,I[_/\0_/B]?+5V:@YHV2=+*H&
M$=?_?$RND_6Z(=7G\7L+/7NJLRFX__,C7>PNOKZ8]W&97.?K?Z3+:O7J;';F
M+)/;>+NN;O)/*FDO*&AXBWQ=[O[O?&J/'9TYBVU9Y9NV<'T&FS1[^#?^H_T@
M]@J,QT<*>&T![Z" YQTI,&X+C ]KF!PIX+<%_,,:CA4(V@+!80'_2(%)6V!R
MZC5,VP+34PO,V@*SW;?[\'7LOLLPKN++BR+_Y!3-T36M^6$GB%WI^BM,LT:[
M[ZJB_FU:EZLNP^1]Y?S@_!P71=RHR/DV3*HX79??.=\XYTZYBHND=-+,^35+
MJ_+[^LWZYU]6^;:,LV5Y<5[5Y]"0SA=M?5</]7E'ZG.=G_*L6I5.E"V394]Y
M82\_L90_KZ_]Z0/P'C^ *\\*_/LV>^&,1]\[WLCSG5_?A<ZWW^Q?>\\I7MN)
M;Q95371W1.^1V(,)[9B?XL^/%/?IO);UF]9SBYZYVCA[/#=WMD_M^R:^X(/K
MP<C3,6,+1MDQ8;)X^M"/8 QYC)_^/L8[[MCV]_$Z*ZMB6]^Q*^>?/]8'.*^K
M9%/^JT_]#S2_G]8T1"_+^WB1O#JK6YHR*3XF9Y=_^9,[&?VU3V<D+"1A$0D3
M)$R2, 7!#.7Y3\KS;?3+MW&Z_"'-?OB09LOZIELE=165LXCOTRI>I__NO7E>
M69%#Y4?"0A(6D3#Q )OL8,VCWL=+UPNF[L7YQWU=]1SEUC=1\R@%G9@AF.!)
M,(%5,*,7T^#/SG6>?4R**GV_3IQW29;FA?-S7M5M>+A-FIOCK$\V5O!0V9"P
MD(1%)$R0,$G"% 0S1#AY$N$$;2\GI/)(6$C"(A(F2)@D80J"&<J;/BEO:KW]
MO:X[*&F\=A:[&^!#WSJNDC[164%#14?"P@>8.]YK9D8O1N/1=#+WS*8F(NL5
M)$R2, 7!#$G-GB0U(UI4YS_.C\G'9.UX]4_7=4_Z<YK=.;_%Z_KW_W%NDL6V
M*)IWKN(R[>TR6\]BJ!Y)6$C"(A(F2)@D80J"&8J=/REVCC:_<U)Y)"PD81$)
M$R1,DC %P0SEN2/M)(ZL=\O]^V3Y<)_,FOMDKTDXZG2G@LG$'8W,1N[:7N50
M3:&T"*6)EA8\\XE(M%9%T4S)[)G/KE4R[DD-;-"K("MYZ*T+I84H+4)I J5)
ME*8HFJE&3ZO10QO/%D=)D*2%*"U":0*E292F*)HI09TVN%9+>4@GUDX:K#XT
M:VAIA_U8+PC&,_^@'_MXK+]WK!>\Z!XIT'.4*$U1-%,W.BMP[6'!B0WI5_=4
M[:<Q6'1HPH#2(I0F4)I$:8JBF=+5J84;L*TN&E:@M!"E12A-H#2)TA1%,R6H
M,PO7:DP/Z[E..OTTS_/];L\5#2-06H32Q(F?B$1K513-E(P.&UQ[VO!+4FR<
M'_,XJ]O-=TV[F2R=YD[6*QDT;T!I(4J+4)I :1*E*8IFRD\'$^Z,;331B &E
MA2@M0FD"I4F4IBB:*4&=-+A6._GR39'>I5G=5]6WPO?Q.LX6_;W5>:>1& >C
M4;?9G'>,X;[C0OO)#18-&A"<>*T2K54]_\F9XV.UK^_9??W=O28MRVWSW3J+
MO&S& 6=);U-G1PV]SWC=E, -O(X6T$HCE"90FD1IBJ*9NM+FOV<W_U\_CFD\
MYG#9RP\6TP-M;EI2TVEPJ";4O$=I J5)E*8HFJDF;=Y[5F=6J^D^_AS7';E>
M0:&&?4N;&8+JJ GUX5&:0&D2I2F*9JI)^_">W8??M7E5\V#S;9HYF]V4D[Y9
M"5=VSF!)V<_*\]M3Z7N,1L\D0FD"I4F4IBB:J33MW'MVY_YMD2^29%DZMT6^
M<=;U8W2O[62G#-:9WWU6'/NS[I,5:JFC-('2)$I3%,W4E+;4/?M,@&/FU-[+
M-Q^3(FOF=3JB[L1EBR;UN:F?PYQOW[T1-_VW.M1X1VDA2HM0FD!I$J4IBF8*
M51OO'CM;P$.G"Z"T$*5%*$V@-(G2%$4S):B-?.^Y:0//]4)1][ZE'?1"O4ZW
M ;7E49I :1*E*8IFBDG;\IY]PL!^D'@T0;0S!@L*]>)16H32!$J3*$U1-%-W
MVHOWV&'_'CKN'Z6%*"U":0*E292F*)JY3()."<9<2C#NCG6?^_[T( JR5SA4
M5B@M0FGBI,]#HG6J<4^VXH[F;G]:--:N_MCNZG>:P+K3^14ST^VU#;U3H;00
MI44H3: TB=(413,5JI.",3O,?XRF!B@M1&D12A,H3:(T1=%,">XM*F0W\H>-
MG;##!@N0755HW&E&@FG0&>L0H;4*E"91FJ)HIK1TGC"VYPEO[G=K E:Y<[\M
M%JNX3)QXN4R;-VN]+8\,4;1#!TN,I(4M;?_IJ%=A:+J TB1*4Q3-5)A.%\;V
M=&'0DW[0^>YF\\Z@+WN%@_72K=,-IEV]H"9_2YM8+U2B=2J*9NI F_=C^ZCY
MGY/*N6_3R][O'C7K45K8THQF*YB/NR)!;7B4)E&:HFBFF+0-/QZ\>L]]D=;W
MEV;\Q3)?K^.B=.Z3XF'ER^_J3J5U&<PK>W6#Q8>.N6]IT_WTW3L<.12A=0J4
M)E&:HFBF]+1I/S[=M']N]H\=-5A6J'??THQ!'=/ZX,X]#77E49I$:8JBF<+2
MKOS8/D(^NKU-=DMSZ^4[CX6,=M)@7:&&?$L['#@[FAO_'8H,]=U1FD1IBJ*9
MB\1JW]VW^^XW29DNMW7+F?R^3:O/=0.ZN<^SQM?*;X]V]^S,H7)#::'?-::]
MT;@SG3!":Q4H3:(T1=%,A6E'W[<[^C=)LP=",T!LF9:+?%M+*][D=8/Y[WAG
M-=1/96F^W#VH?4[JQ[3>P6/V.@8K#O7Q45J$TL0SW\WXX2-W7+<=&>RX1U9S
ME^AY*8IF:E)[^+Y]M/]7I$S-RA>ZD_'+PQCO?LVBQC]*"U%:A-($2I,H35$T
M4[?:^/?9[01\U/I':2%*BU":0&D2I2F*9DIP;UL!>T#PRZJFKO+UTJF*>+EK
MUN//S?VSO]VXLN,&2Q"-!OQN-'!HHZ 5"I0F49JB:*:N="S@/S/IX$E7BSPK
MD\5VU_,]46/HU *4%OK=.*&C,31*0&D2I2F*9FI,1PZ^/7+0&JL['8NVDUM6
M^>)#ZQ9717IWEQ2]&D/C")06MC1S*NE\=B@S-(Q :1*E*8IFRDR'$;X]C*![
M%T>Z%VA$@=)"E!:A-('2)$I3%,T4KHXR?'99(!^-,U!:B-(BE"90FD1IBJ*9
M$M2AAV\//09W+]#D Z6%?G<A'[_S[(<&'2A-HC1%T<S-S730$=B#CJ_I7]C1
M0T6&TL*@._C?/<PZT!H%2I,H35$T4V0ZZPCL?OK7=##LZ,$B0R..EF9V,-Q#
ME:')!4J3*$U1-%-E.KT(_K_IQ9$.AOTL!@L2S2]06H32!$J3*$U1-%.Y.K\(
MV/PB0/,+E!:BM BE"90F49JB:*8$=7X1?%%^<9NOU_FGYN7M-EO&C3J;X:2K
M.+M++ ^&:+B!TL*@&VZ,.P^&:+J!TB1*4Q3-5-W>WLKV=(-NLC_VM]CL1LSL
M3LSL5LSL7LSL9LSL;LS_B\@DT)%)P"ZQ%* Q"4H+45J$T@1*DRA-4313@CI.
M"9[9*V&@)6C'#98@&HRT-&.SBTZCC,8=*$VB-$713&'IN".PS]SX*DL0C3Y0
M6MC2[$]^:*"!TB1*4Q3-%)D.-()3 XTOL 31< .EA2UMWQ)T7XP/58:F&RA-
MHC1%T0R5372Z,3E]\^3'_L57[(YKKVVH\%!:B-(BE"90FD1IBJ*9"M71R,1%
M.Q(3- Y!:2%*BU":0&D2I2F*9DI0YR83>VXR;-D<.VRP -'X Z5%+6U_RIS?
ML^&00&N5*$U1-%-:.MB8/+,BTQ<MFV.'#I88&F^@M*BE&:.@^Q2&YA8H35$T
M4V$ZMYC8<XLAR^:TJ/T_Z,X\_FM[?8/E0M*B23>[</W.SEWBE.N4Z)DIBF:J
M0.<($WN.\-RB.?;B@^\H: * TJ))=UZ%/PXZ>Y (M%:)TA1%,\6DO?V)?3K$
M3?+86"V;*=G;K/]F@CKZ*"V<=-=A\KR>Q=W06@5*DRA-43134MJKG]B]^A_S
MLG3J!Z'DCRK-[K9IN=H\LY:$'3A87JA;W]*,18ZGW:7@T$H%2I,H35$T4UW:
ML)]P2RW948-UA1KT*"V:]"S<-)J[W980->E1FJ)HIK"T23_!EEJRDP;K"O7D
M45HTZ5^X:7(H*]251VF*HAFRFFI7?OH_6%S)SAPJ,)06HK1HVK.'@#_J+'LJ
MT%HE2E,4S528=M6GP[=+.#'W.7TA&_LY#%8D:L6CM BE"90F49JB:*9NM14_
M93=1F*)F/$H+45J$T@1*DRA-4313@MJRG]HM^Z'#RNRXP1)$S7J4%DU[S/K#
M)ADUZE&:HFBFKK11/[4;]5\SJLR.'JPQU.%':=&TZ_!W-$96*%&:HFBFQG0,
M,#UUL:3A@\KLZ,$:0R,"E!:U-/NR. *M4Z(T1=%,F>F 8&H/".C>Q9'N!1HP
MH+00I44H3: TB=(413.%JV.(Z93M7J A!$H+45J$T@1*DRA-4313@CJKF)XZ
MN>#$1S\TKT!I(4J+IMWI"8?+X@BT1HG2%$4SA:6SBNFI$PJ^H'^!AA<H+41I
MT;2[]M+ALC@"K5&B-$71#)'-='(Q.W6UI.$=##MZJ,A06HC2HI9F719'H%5*
ME*8HFJDRG5[,_K_IQ9$.AOTL!@L2S2]06H32!$J3*$U1-%.Y.K^8L?G%#,TO
M4%J(TB*4)E":1&F*HID2U/G%[(ORBR];R,9>UV!]HN$&2HMFW7#C<'*T0&N4
M*$U1-%-U.MV8V=,-NLGN7\C&?A*#Y8CF("@M0FD"I4F4IBB:*5P=F<P"ML5&
M8Q*4%J*T"*4)E"91FJ)HI@1UG#([=?N)T]P:.VZP!-%@!*5%+<VV+(Y :Y0H
M35$T4U@Z[IB=ND+2<$O0CAXL,C3Z0&G1K+OV4O?)#PTT4)JB:*;(=* Q.S70
M^ )+$ TW4%J(TJ*69ET61Z!52I2F*)JI,IUNS.SI1E__XB99)IN'"?:UY*I5
MVYW8/_3G8]. [-4-5AZ:>*"T"*4)E"91FJ)HAD3G.AN9C]">Q!S-0U!:B-(B
ME"90FD1IBJ*9$M3!R?RY/;6?[H@/;6_;),=WO7/6YMWM&PY2JFM[A8-EA:8:
M*$V@-(G2%$4S9:53C;E]@:0^63GE*BZ2W?;LRWR];G8+?WKWN[IQ_L8Y?WC1
MV_RV%4Z-&'[DOG"GA_I#(PV4%J$T@=(D2E,4[4%_Y^4J2:HPKN++BTU2W"77
MR7I=UGW4;58US>O>NTZ1W-;Z=%_^S3L[[[Q_Y;Z,W)[WA?M2[MX_U_C+B_OZ
M+OA37-RE6>FLD]NZJF:E]3.G[IZLGEY4^?VKL_JO[7U>5?EF]^,JB9=)T1Q0
M__XVKY\HVQ=-!9_RXL/N<B[_"U!+ P04    " !]-PA92]7>A1D#  "!"@
M&0   'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6RU5EUOFS 4_2L6JZ96:LHW
M@2Y!6A-5Z]1-5;-V#],>''*3H(+-;).T_WZVH8PD-.VT+ _!AGN.S[E<7SQ8
M4_; EP "/>89X4-C*41Q;IH\64*.^1DM@,@G<\IR+.24+4Q>,, S#<HST[&L
MP,QQ2HQXH._=L'A 2Y&E!&X8XF6>8_9T 1E=#PW;>+YQFRZ60MTPXT&!%S !
M<5?<,#DS&Y99F@/A*26(P7QH?+3/1[:E #KB/H4U;XV1LC*E]$%-KF9#PU**
M((-$* HL+RL8098I)JGC5TUJ-&LJ8'O\S'ZIS4LS4\QA1+/OZ4PLAT9HH!G,
M<9F)6[K^!+4A7_$E-./Z'ZWK6,M 2<D%S6NP5)"GI+KBQSH1+8#MO0!P:H#S
M5H!; UQMM%*F;8VQP/& T35B*EJRJ8'.C49+-RE1KW$BF'R:2IR(QS 5J(<F
MLCQF90:(SM$(,_:4D@6ZQUE9W:%D!4RD4QGPE0K@Z )GF"2 CL<@<)KQ$\EQ
M-QFCXZ,3=(12@KXM:<DQF?&!*:1,M9B9U)(N*DG."Y(^E^0,N=8I<BS'ZX"/
M]L/'D$BXK>'N)MR4R6DRY#09<C2?NR]#5X0+5LKR%>C'M0Q 5P)R_K/+7,7F
M=;.I77G."YS T)#;C@-;@1&_?V<'UH<NJP<BVS#N-L;=?>SQ-7!^+FN0,66[
MH$SO.UD.2:L<B"J'KC14W('F5KUD%?<<Q_.\<&"NV@YWXZPF8D.VU\CV]LI6
M[^L4990L>@)8WJ6M(O!;:T9>$#K^EK3=,-OV?==VNP7ZC4!_K\#16]*WE^)O
MJ^A 9!MN@\9M<-#M$QS2^('(-HSW&^/]O:_Y4A*CU7,+E5]0+F0_5'WU3?NG
MOU-\H:5^6S7Z:MB&]K#1'KZZAU#*>:F;?$*YZ-08[BS>BSROOR6Q(\JVK<CN
MEA@U$J/_V)VB74V=W6DW[H7,VM:?#Z[UK_VI9F@W13\(;&N[077$]<,PLJ(M
MC6;K?* .9U\P6Z2$HPSF$FB=]:5!5IUWJHF@A3XR3*F0!Q ]7,HS(C 5()_/
MJ4QL/5&GD.;4&?\&4$L#!!0    ( 'TW"%EF8+0 , ,  &,,   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8P+GAM;*U7:T_;,!3]*U:&)B91\NR+M9$&T30F
M)BH*[,.T#VYRVUHX=F<[+>S7STY"UD>(2M5^:&SGGI-[3GQM9[#BXDG. 11Z
M3BF30VNNU.+"MF4\AQ3+<[X IN],N4BQTETQL^5" $YR4$IMSW$Z=HH)L\)!
M/C82X8!GBA(&(X%DEJ98O%P"Y:NAY5JO W=D-E=FP X'"SR#,:B'Q4CHGEVQ
M)"0%)@EG2,!T:'UQ+Z*^B<\#'@FLY%H;&243SI],YSH96HY)""C$RC!@?5G"
M%5!JB'0:?TI.JWJD :ZW7]F_YMJUE@F6<,7I3Y*H^=#J62B!*<ZHNN.K;U#J
M:1N^F%.9_Z-5&>M8*,ZDXFD)UAFDA!57_%SZL 9P@S< 7@GP]@7X)<#?%Q"4
M@"!WII"2^Q!AA<.!X"LD3+1F,XW<S!RMY1-F7OM8"7V7:)P*(Y@HU$)C/9V2
MC +B4W2%A7@A;(8>,<WRD7L0*;KAF*%+3#&+ 9U&H#"A\I/&_K_;0@_C")V>
M?$(GB#!T/^>9Q"R1 UOI5,T#[;A,Z[)(RWLCK>\9.T>^<X8\QPMJX%?-\ AB
M#7=SN%\#CYKAM[&JX-XFW-;^5B9[E<E>SN<WF7S-I!*9KAB%?MWH '2M()6_
MZ[PIV()Z-K,07,@%CF%HZ4J7()9@A1\_N!WG<YU3QR2+CD2VX:)?N>@WL8?5
M/*NSK(!V<JA9ZI:AWW.ZGC.PE^MFU(1U.H$3;(9%C8D<*#.H9 :-,L<09P(2
M9"9-G=)&]'LGQS')HB.1;;C6KEQK'[7$VL=T\9ADT9'(-ESL5"YV&N?>K2 S
MPC!=6],GQ8I?YV'!U5XOIK:C?ULUMU]8U-DMS<VP#47=2E&W4=$(DZ1%6.N)
ML$3O20JT:0K%>$$4IN0O)'7"NCL9!X[K]+9T[49YW;;?W9+5F-Z!K[-7B>_M
MMV(B(F66;]PQETJ>H8SAE OUE@&]'6FMOM_;-J FRG5=W]]RH#'' QWH5P[T
M#]\S^OOM&35A=7M&8R+OE6FOG>C,\?L'%KHP):(PU?3.>5>[+HHC;=%1?)$?
M\B9<Z2-CWISKKP 0)D#?GW*N7COFW%A]5X3_ %!+ P04    " !]-PA95C3T
M]X("  #*!@  &0   'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6R5E6UOFS 4
MA?^*Q:JIE;9B2" O(TAKLVJ;-"EJVDW[Z, E6#4VLTW2_OO9AJ)L)<WV)=C8
MYSSGQG!)]D(^J!) H\>*<;7P2JWKN>^KK(2*J$M1 S<KA9 5T68JM[ZJ)9#<
MB2KFAQC'?D4H]]+$W5O)-!&-9I3#2B+55!613U? Q'[A!=[SC5NZ+;6]X:=)
M3;:P!GU?KZ29^;U+3BO@B@J.)!0+[V,POYK9_6[#=PI[=3!&MI*-$ ]V\B5?
M>-@& @:9M@[$7'9P#8Q9(Q/C5^?I]4@K/!P_N]^XVDTM&Z+@6K ?--?EPIMZ
M*(>"-$S?BOUGZ.J)K%\FF'*_:-_MQ1[*&J5%U8E-@HKR]DH>N__A0!"&1P1A
M)PA=[A;D4BZ))FDBQ1Y)N]NXV8$KU:E-.,KMH:RU-*O4Z'2ZA(U&[]':'';>
M,$"B0#>-;B2@E:0\HS5AZ!9J\F0.0BN[[!3G2]"$,G6!SA#EZ*X4C2(\5XFO
M32AK[6==@*LV0'@DP->&7Z(1?H="'([1_7J)SL\N_K3Q34U]86%?6.A\1T=\
M?P*1Z!//*=^:R!E4&Y!OWP0Q_C *YD,Q6[OQL)U]-^:J)ADL///P*Y [\-+6
M[Y6PHS[LZ#7WU-8^E*E5Q4YE7Z]=&H81QCCQ=P.T<4\;GZ)%0[16%1W0CH"B
M'A2= L5#H.@%*)A%.!H/T^*>%I^B389H\7_1)CUM<HHV':)-7M"BR?$CF_:T
MZ2G:#)D7#.D23.\M-,@A^/1?3W#6<V>O<N^$)FR(-'OQ9 ;!# =X^A?//VA-
MMLM_(W)+N4(,"J/$EQ,35K:=LYUH4;MNM1':]#XW+,W'!J3=8-8+(?3SQ#;
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M[&C0(>$V4R(I@W4+DBC=_6=?RANQ%^">"O#* .\PH'\BH%<&]-H&],N ?MN
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M3!0-U/LEY_+YIG!0'VN<_@]02P,$%     @ ?3<(6:2>X[3]#0  /M\  !D
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M"U M1+6(TIH957?%M?]35UP\S\7IA7;%4<U -1/5+%2S4<U!-1?5/%3S42U
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M OK[!RG5ZXZI8+?\?O8O4$L#!!0    ( 'TW"%G3I6KNE@,  ( 0   9
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M^3TY_@Z=0S/)EY"2J5]T[&PM R5[QDG5@<4.JJ)NG_BY$^($('BF 4X'<,8
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M<<Z60-67E/$"2]7E"ULL.>#$@(K<=ATGL M,J!4.S=B,AT-6RIQ0F'$DRJ+
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M)*B$$F&:(%5YX%P2=0W@..9EZ]$]#@[VP/ZFZYS,:YU]-MWT2.DJ9^VM>[0
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M"U]5COF_^2%I:H7%6V&3^"C@-5,=Z'7/(8[B'MS/K^#TY.P(;J\]L%Z-VSN
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ML%T2QVGJ1@!S.XAC#('=B".8 _" (7%LGH-[SZ-@\YP*MO]K'O\%4$L#!!0
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M-G\</S[+SC;]6SX;_[YY_@)02P$"% ,4    " !\-PA9!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M 'PW"%F8_Z$G[P   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( 'PW"%F97)PC$ 8  )PG   3
M  "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ?3<(6:F0
M8O+;!0  U1X  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( 'TW"%E#+GTCKP8  -4;   8
M  " @1\.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !]
M-PA9Q#,+L*,"  !J!P  &               @($$%0  >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ ?3<(6;.-X-WN!P  G24  !@
M         ("!W1<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( 'TW"%G;I7D6,0L  )!F   8              " @0$@  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !]-PA9G[D;E;<(  #**0
M&               @(%H*P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ ?3<(63)<AXF8"P  T1L  !@              ("!530  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( 'TW"%GBXOH^:!D
M %Y0   8              " @2-   !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    " !]-PA9FB9RQC81   %.0  &               @('!
M60  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ?3<(69*V
M%#3!"P  ;"$  !D              ("!+6L  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    " !]-PA9 X$;"B@#  "R!@  &0
M    @($E=P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M 'TW"%E/LS59O 0  !P,   9              " @81Z  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ ?3<(6<4E=ZY0 P  Y@8  !D
M             ("!=W\  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    " !]-PA9L0%AH0,$  #<"   &0              @('^@@  >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( 'TW"%E&\#GFS0<
M $PD   9              " @3B'  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ ?3<(66M?0B9G$@  "SH  !D              ("!
M/(\  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !]-PA9
MA:QF.>(&   /$0  &0              @(':H0  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( 'TW"%GV,3017P<   T8   9
M      " @?.H  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ ?3<(622P9[UO"   ,18  !D              ("!B;   'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !]-PA92^R,KUT&  "R#P
M&0              @($ON0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( 'TW"%GV:4=80@,  & '   9              " @<._  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ ?3<(6>SL9O:K
M"P  X"<  !D              ("!/,,  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    " !]-PA9UCYXB[8$  "<#   &0
M@($>SP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( 'TW
M"%G$B5=*?@(  +X'   9              " @0O4  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ ?3<(60)%V*77!P  P2L  !D
M         ("!P-8  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    " !]-PA9!:)G5;$7  #>3   &0              @('.W@  >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( 'TW"%G8D\T5S 0  !\-
M   9              " @;;V  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ ?3<(61DT:"@9!0  ]0X  !D              ("!N?L
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !]-PA9$5+(
M0@8#  "2!@  &0              @($) 0$ >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( 'TW"%EQD$LWF0(  (8%   9
M  " @48$ 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
M?3<(6<J*%MDG P  @P<  !D              ("!%@<! 'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    " !]-PA9_;LQ]%P#  #A!@  &0
M            @(%T"@$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( 'TW"%D/>X-FH0,   H(   9              " @0<. 0!X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ ?3<(6>#Z3NO) @
M;08  !D              ("!WQ$! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    " !]-PA9 .EX)W@&  ""$@  &0              @('?
M% $ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( 'TW"%GR
MMU#6\@,  !X)   9              " @8X; 0!X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ ?3<(6<;;&:HK P  V 8  !D
M     ("!MQ\! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'TW"%D6%Y'.0 4  .,>   9              "
M@?$N 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ ?3<(
M66U<]7FL P  DQ$  !D              ("!:#0! 'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    " !]-PA98,&]L?T&  "[1P  &0
M        @(%+. $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( 'TW"%E@=U 5T10  /IT 0 9              " @7\_ 0!X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ ?3<(6:TFB]JK @  W@8
M !D              ("!AU0! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    " !]-PA98@L(52@%  !W*P  &0              @(%I5P$
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( 'TW"%G2$69.
MZP,  (8/   9              " @<A< 0!X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ ?3<(6>!_$'7$ P  $A0  !D
M ("!ZF ! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " !]
M-PA9D NJB8<"  #)!@  &0              @('E9 $ >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( 'TW"%E&M[V&Y (  '@*   9
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M970U-2YX;6Q02P$"% ,4    " !]-PA99U;B^^4"   ;"0  &0
M    @('O?@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (
M 'TW"%G?@O4W 0,   0+   9              " @0N" 0!X;"]W;W)K<VAE
M971S+W-H965T-3<N>&UL4$L! A0#%     @ ?3<(67N^%-:G$   &>(  !D
M             ("!0X4! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"
M% ,4    " !]-PA92]7>A1D#  "!"@  &0              @($AE@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( 'TW"%EF8+0 , ,
M &,,   9              " @7&9 0!X;"]W;W)K<VAE971S+W-H965T-C N
M>&UL4$L! A0#%     @ ?3<(658T]/>" @  R@8  !D              ("!
MV)P! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " !]-PA9
M[GYR7YP$  !/&   &0              @(&1GP$ >&PO=V]R:W-H965T<R]S
M:&5E=#8R+GAM;%!+ 0(4 Q0    ( 'TW"%E,=K+H$@8  !0X   9
M      " @62D 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%
M  @ ?3<(62KI^ W&!0  XB@  !D              ("!K:H! 'AL+W=O<FMS
M:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " !]-PA9I)[CM/T-   ^WP
M&0              @(&JL $ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+
M 0(4 Q0    ( 'TW"%F=(3ZJV 8  (H_   9              " @=Z^ 0!X
M;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ ?3<(6=.E:NZ6
M P  @!   !D              ("![<4! 'AL+W=O<FMS:&5E=',O<VAE970V
M-RYX;6Q02P$"% ,4    " !]-PA99!7>)? "  !U"@  &0
M@(&ZR0$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( 'TW
M"%D\M+=>G@(  .L'   9              " @>', 0!X;"]W;W)K<VAE971S
M+W-H965T-CDN>&UL4$L! A0#%     @ ?3<(63>D<[[0#   +L0  !D
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !]-PA9EXJ[',     3 @  "P
M            @ '3Z $ 7W)E;',O+G)E;'-02P$"% ,4    " !]-PA9Z-6B
M@&\%  !"+P  #P              @ &\Z0$ >&PO=V]R:V)O;VLN>&UL4$L!
M A0#%     @ ?3<(6:QM4%<\ @  KRH  !H              ( !6.\! 'AL
M+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ ?3<(64!K%[H
M @  QBD  !,              ( !S/$! %M#;VYT96YT7U1Y<&5S72YX;6Q0
52P4&     %  4 #G%0  _?,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>302</ContextCount>
  <ElementCount>336</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>88</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Shareholders' Equity (Deficit) (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (Deficit) (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - The Company and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/TheCompanyandBasisofPresentation</Role>
      <ShortName>The Company and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Product Revenues, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ProductRevenuesNet</Role>
      <ShortName>Product Revenues, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Intangibles, Net and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IntangiblesNetandGoodwill</Role>
      <ShortName>Intangibles, Net and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Fixed Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FixedAssetsNet</Role>
      <ShortName>Fixed Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/AccountsPayableandAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Royalty Financing Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/RoyaltyFinancingAgreement</Role>
      <ShortName>Royalty Financing Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.insmed.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/FairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Product Revenues, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ProductRevenuesNetTables</Role>
      <ShortName>Product Revenues, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/ProductRevenuesNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/Inventory</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Intangibles, Net and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IntangiblesNetandGoodwillTables</Role>
      <ShortName>Intangibles, Net and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/IntangiblesNetandGoodwill</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Fixed Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FixedAssetsNetTables</Role>
      <ShortName>Fixed Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/FixedAssetsNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/AccountsPayableandAccruedLiabilities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/Leases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/Debt</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Royalty Financing Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/RoyaltyFinancingAgreementTables</Role>
      <ShortName>Royalty Financing Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/RoyaltyFinancingAgreement</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/StockBasedCompensation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/Acquisitions</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - The Company and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails</Role>
      <ShortName>The Company and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/TheCompanyandBasisofPresentation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Summary of Significant Accounting Policies - Schedule of Percentage of Gross Product Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Percentage of Gross Product Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of the Weighted Average Number of Common Shares Used to Compute Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Reconciliation of the Weighted Average Number of Common Shares Used to Compute Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis and Carrying Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis and Carrying Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Fair Value Measurements - Schedule of Observable Inputs in Valuation of Deferred Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Observable Inputs in Valuation of Deferred Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Fair Value Measurements - Schedule of Valuation of Development and Regulatory Milestones and Priority Review Voucher Milestone (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Valuation of Development and Regulatory Milestones and Priority Review Voucher Milestone (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Fair Value Measurements - Schedule of Changes in Fair Value of Valuations for Deferred and Contingent Consideration Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Changes in Fair Value of Valuations for Deferred and Contingent Consideration Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Product Revenues, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ProductRevenuesNetDetails</Role>
      <ShortName>Product Revenues, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/ProductRevenuesNetTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/InventoryTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Intangibles, Net and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails</Role>
      <ShortName>Intangibles, Net and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Intangibles, Net and Goodwill - Schedule of Rollforward of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails</Role>
      <ShortName>Intangibles, Net and Goodwill - Schedule of Rollforward of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Fixed Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FixedAssetsNetDetails</Role>
      <ShortName>Fixed Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/FixedAssetsNetTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Leases - Schedule of Supplemental Non-cash Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/LeasesScheduleofSupplementalNoncashDisclosuresDetails</Role>
      <ShortName>Leases - Schedule of Supplemental Non-cash Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Debt - Schedule of Current Portion of Long-Term Debt and Debt, Long-Term (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails</Role>
      <ShortName>Debt - Schedule of Current Portion of Long-Term Debt and Debt, Long-Term (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Debt - Schedule of Carrying Value of Convertible Notes Balance (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.insmed.com/role/DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails</Role>
      <ShortName>Debt - Schedule of Carrying Value of Convertible Notes Balance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Debt - Schedule of Carrying Value of Term Loan Balance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails</Role>
      <ShortName>Debt - Schedule of Carrying Value of Term Loan Balance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Debt - Schedule of Future Principal Repayments of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails</Role>
      <ShortName>Debt - Schedule of Future Principal Repayments of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Debt - Schedule of Interest Expense related to Debt and Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails</Role>
      <ShortName>Debt - Schedule of Interest Expense related to Debt and Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Royalty Financing Agreement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails</Role>
      <ShortName>Royalty Financing Agreement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Royalty Financing Agreement - Schedule of Carrying Value of Royalty Financing Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails</Role>
      <ShortName>Royalty Financing Agreement - Schedule of Carrying Value of Royalty Financing Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/ShareholdersEquity</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Stock-Based Compensation - Schedule of Aggregate Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Aggregate Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/IncomeTaxes</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/CommitmentsandContingencies</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Acquisitions - Schedule of Purchase Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails</Role>
      <ShortName>Acquisitions - Schedule of Purchase Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="insm-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/SubsequentEvents</ParentRole>
      <Position>72</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="insm-20240630.htm">insm-20240630.htm</File>
    <File>insm-20240630.xsd</File>
    <File>insm-20240630_cal.xml</File>
    <File>insm-20240630_def.xml</File>
    <File>insm-20240630_lab.xml</File>
    <File>insm-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="889">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>103
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "insm-20240630.htm": {
   "nsprefix": "insm",
   "nsuri": "http://www.insmed.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "insm-20240630.htm"
     ]
    },
    "schema": {
     "local": [
      "insm-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "insm-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "insm-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "insm-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "insm-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 300,
   "keyCustom": 36,
   "axisStandard": 30,
   "axisCustom": 2,
   "memberStandard": 43,
   "memberCustom": 39,
   "hidden": {
    "total": 22,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://fasb.org/us-gaap/2024": 13,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "contextCount": 302,
   "entityCount": 1,
   "segmentCount": 88,
   "elementCount": 648,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 889,
    "http://xbrl.sec.gov/ecd/2024": 30,
    "http://xbrl.sec.gov/dei/2024": 29
   },
   "report": {
    "R1": {
     "role": "http://www.insmed.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.insmed.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
     "longName": "9952153 - Statement - Consolidated Statements of Comprehensive Loss (unaudited)",
     "shortName": "Consolidated Statements of Comprehensive Loss (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited",
     "longName": "9952154 - Statement - Consolidated Statements of Shareholders' Equity (Deficit) (unaudited)",
     "shortName": "Consolidated Statements of Shareholders' Equity (Deficit) (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-35",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-35",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
     "longName": "9952155 - Statement - Consolidated Statements of Cash Flows (unaudited)",
     "shortName": "Consolidated Statements of Cash Flows (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.insmed.com/role/TheCompanyandBasisofPresentation",
     "longName": "9952156 - Disclosure - The Company and Basis of Presentation",
     "shortName": "The Company and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.insmed.com/role/FairValueMeasurements",
     "longName": "9952158 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.insmed.com/role/ProductRevenuesNet",
     "longName": "9952159 - Disclosure - Product Revenues, Net",
     "shortName": "Product Revenues, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.insmed.com/role/Inventory",
     "longName": "9952160 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.insmed.com/role/IntangiblesNetandGoodwill",
     "longName": "9952161 - Disclosure - Intangibles, Net and Goodwill",
     "shortName": "Intangibles, Net and Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.insmed.com/role/FixedAssetsNet",
     "longName": "9952162 - Disclosure - Fixed Assets, Net",
     "shortName": "Fixed Assets, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.insmed.com/role/AccountsPayableandAccruedLiabilities",
     "longName": "9952163 - Disclosure - Accounts Payable and Accrued Liabilities",
     "shortName": "Accounts Payable and Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.insmed.com/role/Leases",
     "longName": "9952164 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.insmed.com/role/Debt",
     "longName": "9952165 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.insmed.com/role/RoyaltyFinancingAgreement",
     "longName": "9952166 - Disclosure - Royalty Financing Agreement",
     "shortName": "Royalty Financing Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.insmed.com/role/ShareholdersEquity",
     "longName": "9952167 - Disclosure - Shareholders' Equity",
     "shortName": "Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.insmed.com/role/StockBasedCompensation",
     "longName": "9952168 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.insmed.com/role/IncomeTaxes",
     "longName": "9952169 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.insmed.com/role/CommitmentsandContingencies",
     "longName": "9952170 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.insmed.com/role/Acquisitions",
     "longName": "9952171 - Disclosure - Acquisitions",
     "shortName": "Acquisitions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.insmed.com/role/SubsequentEvents",
     "longName": "9952172 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.insmed.com/role/FairValueMeasurementsTables",
     "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.insmed.com/role/ProductRevenuesNetTables",
     "longName": "9954474 - Disclosure - Product Revenues, Net (Tables)",
     "shortName": "Product Revenues, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.insmed.com/role/InventoryTables",
     "longName": "9954475 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.insmed.com/role/IntangiblesNetandGoodwillTables",
     "longName": "9954476 - Disclosure - Intangibles, Net and Goodwill (Tables)",
     "shortName": "Intangibles, Net and Goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.insmed.com/role/FixedAssetsNetTables",
     "longName": "9954477 - Disclosure - Fixed Assets, Net (Tables)",
     "shortName": "Fixed Assets, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesTables",
     "longName": "9954478 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)",
     "shortName": "Accounts Payable and Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.insmed.com/role/LeasesTables",
     "longName": "9954479 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.insmed.com/role/DebtTables",
     "longName": "9954480 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.insmed.com/role/RoyaltyFinancingAgreementTables",
     "longName": "9954481 - Disclosure - Royalty Financing Agreement (Tables)",
     "shortName": "Royalty Financing Agreement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://www.insmed.com/role/StockBasedCompensationTables",
     "longName": "9954482 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.insmed.com/role/AcquisitionsTables",
     "longName": "9954483 - Disclosure - Acquisitions (Tables)",
     "shortName": "Acquisitions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails",
     "longName": "9954484 - Disclosure - The Company and Basis of Presentation (Details)",
     "shortName": "The Company and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails",
     "longName": "9954485 - Disclosure - Summary of Significant Accounting Policies - Schedule of Percentage of Gross Product Revenue (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Percentage of Gross Product Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-56",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-56",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9954486 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportingUnits",
      "unitRef": "reportingunit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportingUnits",
      "unitRef": "reportingunit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails",
     "longName": "9954487 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of the Weighted Average Number of Common Shares Used to Compute Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of the Weighted Average Number of Common Shares Used to Compute Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails",
     "longName": "9954488 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-75",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-75",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails",
     "longName": "9954489 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis and Carrying Value (Details)",
     "shortName": "Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis and Carrying Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "insm:BusinessCombinationDeferredLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-83",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
     "longName": "9954490 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-96",
      "name": "insm:BusinessCombinationDeferredLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.insmed.com/role/FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails",
     "longName": "9954491 - Disclosure - Fair Value Measurements - Schedule of Observable Inputs in Valuation of Deferred Consideration (Details)",
     "shortName": "Fair Value Measurements - Schedule of Observable Inputs in Valuation of Deferred Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "insm:BusinessCombinationDeferredLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-97",
      "name": "insm:BusinessCombinationDeferredConsiderationLiabilityMeasurementInput",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails",
     "longName": "9954492 - Disclosure - Fair Value Measurements - Schedule of Valuation of Development and Regulatory Milestones and Priority Review Voucher Milestone (Details)",
     "shortName": "Fair Value Measurements - Schedule of Valuation of Development and Regulatory Milestones and Priority Review Voucher Milestone (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-121",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-104",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.insmed.com/role/FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails",
     "longName": "9954493 - Disclosure - Fair Value Measurements - Schedule of Changes in Fair Value of Valuations for Deferred and Contingent Consideration Liabilities (Details)",
     "shortName": "Fair Value Measurements - Schedule of Changes in Fair Value of Valuations for Deferred and Contingent Consideration Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-118",
      "name": "us-gaap:LiabilitiesFairValueAdjustment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.insmed.com/role/ProductRevenuesNetDetails",
     "longName": "9954494 - Disclosure - Product Revenues, Net (Details)",
     "shortName": "Product Revenues, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-131",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.insmed.com/role/InventoryDetails",
     "longName": "9954495 - Disclosure - Inventory (Details)",
     "shortName": "Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails",
     "longName": "9954496 - Disclosure - Intangibles, Net and Goodwill - Narrative (Details)",
     "shortName": "Intangibles, Net and Goodwill - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails",
     "longName": "9954497 - Disclosure - Intangibles, Net and Goodwill - Schedule of Rollforward of Intangible Assets (Details)",
     "shortName": "Intangibles, Net and Goodwill - Schedule of Rollforward of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.insmed.com/role/FixedAssetsNetDetails",
     "longName": "9954498 - Disclosure - Fixed Assets, Net (Details)",
     "shortName": "Fixed Assets, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails",
     "longName": "9954499 - Disclosure - Accounts Payable and Accrued Liabilities (Details)",
     "shortName": "Accounts Payable and Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.insmed.com/role/LeasesNarrativeDetails",
     "longName": "9954500 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:VariableLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:VariableLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.insmed.com/role/LeasesScheduleofSupplementalNoncashDisclosuresDetails",
     "longName": "9954501 - Disclosure - Leases - Schedule of Supplemental Non-cash Disclosures (Details)",
     "shortName": "Leases - Schedule of Supplemental Non-cash Disclosures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails",
     "longName": "9954502 - Disclosure - Debt - Schedule of Current Portion of Long-Term Debt and Debt, Long-Term (Details)",
     "shortName": "Debt - Schedule of Current Portion of Long-Term Debt and Debt, Long-Term (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-181",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.insmed.com/role/DebtNarrativeDetails",
     "longName": "9954503 - Disclosure - Debt - Narrative (Details)",
     "shortName": "Debt - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaidInKindInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-205",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.insmed.com/role/DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails",
     "longName": "9954504 - Disclosure - Debt - Schedule of Carrying Value of Convertible Notes Balance (Details)",
     "shortName": "Debt - Schedule of Carrying Value of Convertible Notes Balance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-202",
      "name": "us-gaap:SecuredDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails",
     "longName": "9954505 - Disclosure - Debt - Schedule of Carrying Value of Term Loan Balance (Details)",
     "shortName": "Debt - Schedule of Carrying Value of Term Loan Balance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-183",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-208",
      "name": "us-gaap:AccumulatedCapitalizedInterestCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails",
     "longName": "9954506 - Disclosure - Debt - Schedule of Future Principal Repayments of Debt (Details)",
     "shortName": "Debt - Schedule of Future Principal Repayments of Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails",
     "longName": "9954507 - Disclosure - Debt - Schedule of Interest Expense related to Debt and Finance Leases (Details)",
     "shortName": "Debt - Schedule of Interest Expense related to Debt and Finance Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:InterestIncomeOther",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails",
     "longName": "9954508 - Disclosure - Royalty Financing Agreement - Narrative (Details)",
     "shortName": "Royalty Financing Agreement - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccruedRoyaltiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-234",
      "name": "us-gaap:AccruedRoyaltiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails",
     "longName": "9954509 - Disclosure - Royalty Financing Agreement - Schedule of Carrying Value of Royalty Financing Agreement (Details)",
     "shortName": "Royalty Financing Agreement - Schedule of Carrying Value of Royalty Financing Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-232",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.insmed.com/role/ShareholdersEquityDetails",
     "longName": "9954510 - Disclosure - Shareholders' Equity (Details)",
     "shortName": "Shareholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-256",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
     "longName": "9954511 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.insmed.com/role/StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails",
     "longName": "9954512 - Disclosure - Stock-Based Compensation - Schedule of Aggregate Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Aggregate Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-273",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-273",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.insmed.com/role/IncomeTaxesDetails",
     "longName": "9954513 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.insmed.com/role/CommitmentsandContingenciesDetails",
     "longName": "9954514 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
     "longName": "9954515 - Disclosure - Acquisitions - Narrative (Details)",
     "shortName": "Acquisitions - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-21",
      "name": "us-gaap:SharePrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-21",
      "name": "us-gaap:SharePrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails",
     "longName": "9954516 - Disclosure - Acquisitions - Schedule of Purchase Price (Details)",
     "shortName": "Acquisitions - Schedule of Purchase Price (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-278",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-278",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.insmed.com/role/SubsequentEventsDetails",
     "longName": "9954517 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-278",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-289",
      "name": "us-gaap:DebtConversionConvertedInstrumentAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "insm-20240630.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "insm_A2019IncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "A2019IncentivePlanMember",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Incentive Plan",
        "label": "2019 Incentive Plan [Member]",
        "documentation": "2019 Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "insm_A2019IncentivePlanThirdAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "A2019IncentivePlanThirdAmendmentMember",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Incentive Plan",
        "label": "2019 Incentive Plan, Third Amendment [Member]",
        "documentation": "2019 Incentive Plan, Third Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "insm_A2025ConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "A2025ConvertibleNotesMember",
     "presentation": [
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of 2025 Notes",
        "label": "2025 Convertible Notes [Member]",
        "documentation": "2025 Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "insm_A2028ConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "A2028ConvertibleNotesMember",
     "presentation": [
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of 2028 Notes",
        "label": "2028 Convertible Notes [Member]",
        "documentation": "2028 Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "insm_ARIKAYCEGlobalNetSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "ARIKAYCEGlobalNetSalesMember",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARIKAYCE Global Net Sales",
        "label": "ARIKAYCE Global Net Sales [Member]",
        "documentation": "ARIKAYCE Global Net Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accounts payable and accrued liabilities",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Liabilities",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r76",
      "r82",
      "r992"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesMember",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Liabilities",
        "label": "Accounts Payable and Accrued Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and other accrued operating expenses",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r793"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "insm_AccretionOfDebtDiscountMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "AccretionOfDebtDiscountMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of discount on marketable securities, net",
        "label": "Accretion Of Debt Discount, Marketable Securities",
        "documentation": "Accretion Of Debt Discount, Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "insm_AccruedClinicalTrialExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "AccruedClinicalTrialExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued clinical trial expenses",
        "label": "Accrued Clinical Trial Expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses."
       }
      }
     },
     "auth_ref": []
    },
    "insm_AccruedMilestonePaymentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "AccruedMilestonePaymentCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued milestone payment to AstraZeneca",
        "label": "Accrued Milestone Payment, Current",
        "documentation": "Accrued Milestone Payment, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued royalty and milestones payable",
        "verboseLabel": "Royalty financing liability",
        "label": "Accrued Royalties, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r745"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty financing agreement",
        "periodStartLabel": "Royalty financing agreement liability - beginning balance",
        "periodEndLabel": "Royalty financing agreement liability - ending balance",
        "label": "Accrued Royalties",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "insm_AccruedSalesAllowancesAndRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "AccruedSalesAllowancesAndRelatedCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued sales allowances and related costs",
        "label": "Accrued Sales Allowances And Related Costs",
        "documentation": "Accrued Sales Allowances And Related Costs"
       }
      }
     },
     "auth_ref": []
    },
    "insm_AccruedTechnicalOperationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "AccruedTechnicalOperationExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued technical operation expenses",
        "label": "Accrued Technical Operation Expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedCapitalizedInterestCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedCapitalizedInterestCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid-in-kind interest capitalized",
        "label": "Accumulated Capitalized Interest Costs",
        "documentation": "Amount of accumulated interest costs capitalized as part of property, plant and equipment cost basis."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/FixedAssetsNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r166",
      "r604"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r95",
      "r175",
      "r601",
      "r632",
      "r633"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13",
      "r20",
      "r483",
      "r486",
      "r545",
      "r628",
      "r629",
      "r911",
      "r912",
      "r913",
      "r922",
      "r923",
      "r924",
      "r926"
     ]
    },
    "insm_AcquiredResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "AcquiredResearchAndDevelopmentMember",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired ARIKAYCE R&amp;D",
        "label": "Acquired Research And Development [Member]",
        "documentation": "Acquired Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r793",
      "r1059"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r645",
      "r922",
      "r923",
      "r924",
      "r926",
      "r1000",
      "r1060"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r409"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "insm_AdrestiaTherapeuticsLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "AdrestiaTherapeuticsLtdMember",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adrestia Therapeutics Ltd",
        "label": "Adrestia Therapeutics Ltd [Member]",
        "documentation": "Adrestia Therapeutics Ltd"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r826",
      "r836",
      "r846",
      "r878"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r839",
      "r849",
      "r881"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "insm_AlgaeneXIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "AlgaeneXIncMember",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AlgaeneX",
        "label": "AlgaeneX, Inc. [Member]",
        "documentation": "AlgaeneX, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r840",
      "r850",
      "r874",
      "r882",
      "r886",
      "r894"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocated share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r444"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails": {
       "parentTag": "insm_InterestExpenseExcludingFinanceLeaseInterestExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "verboseLabel": "Amortization of issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r361",
      "r916",
      "r1011"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r763",
      "r764",
      "r916",
      "r1011"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "negatedTerseLabel": "Amortization",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r292",
      "r300",
      "r759"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails",
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r995"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition, consideration transferred",
        "totalLabel": "Total purchase price",
        "label": "Asset Acquisition, Consideration Transferred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r996",
      "r997",
      "r998"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails": {
       "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails",
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent payment, value",
        "verboseLabel": "Shares of Insmed common stock issued in July 2024",
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997",
      "r998"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails": {
       "parentTag": "us-gaap_AssetAcquisitionConsiderationTransferred",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of Insmed common stock issued on closing",
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997",
      "r998"
     ]
    },
    "insm_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in asset acquisition (in shares)",
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued And Issuable, Shares",
        "documentation": "Asset Acquisition, Consideration Transferred, Equity Interest Issued And Issuable, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails",
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Domain]",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r995"
     ]
    },
    "us-gaap_AssetAcquisitionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionTableTextBlock",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Purchase Price",
        "label": "Asset Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in Fair Value",
        "label": "Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions",
        "documentation": "Amount of increase (decrease) in fair value from changes in the assumptions or model used to calculate the fair value of a contract to service financial assets under which the benefits of servicing are expected to more than adequately compensate the servicer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r146",
      "r169",
      "r200",
      "r240",
      "r244",
      "r262",
      "r265",
      "r273",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r478",
      "r480",
      "r516",
      "r599",
      "r677",
      "r755",
      "r756",
      "r793",
      "r817",
      "r957",
      "r958",
      "r1015"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r177",
      "r200",
      "r273",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r478",
      "r480",
      "r516",
      "r793",
      "r957",
      "r958",
      "r1015"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "insm_AtTheMarketAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "AtTheMarketAgreementMember",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Program",
        "label": "At The Market Agreement [Member]",
        "documentation": "At The Market Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "insm_AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average sales prices of publicly disclosed priority review voucher sales obligated to pay equity holders, percentage",
        "label": "Average Sales Prices Of Publicly Disclosed Priority Review Voucher Sales Obligated To Pay Equity Holders, Percentage",
        "documentation": "Average Sales Prices Of Publicly Disclosed Priority Review Voucher Sales Obligated To Pay Equity Holders, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r1026",
      "r1027"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r317",
      "r1026",
      "r1027"
     ]
    },
    "insm_BrensocatibGlobalNetSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "BrensocatibGlobalNetSalesMember",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Brensocatib Global Net Sales",
        "label": "Brensocatib Global Net Sales [Member]",
        "documentation": "Brensocatib Global Net Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r471",
      "r776",
      "r777"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r471",
      "r776",
      "r777"
     ]
    },
    "insm_BusinessAcquisitionConsecutiveTradingDayPeriod": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "BusinessAcquisitionConsecutiveTradingDayPeriod",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consecutive trading day period",
        "label": "Business Acquisition, Consecutive Trading Day Period",
        "documentation": "Business Acquisition, Consecutive Trading Day Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in acquisition (in shares)",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionSharePrice",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price used to calculate issuable shares (in dollars per share)",
        "label": "Business Acquisition, Share Price",
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate value",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r12"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of deferred and contingent consideration liabilities",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r915"
     ]
    },
    "insm_BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued upon milestone achievements (in shares)",
        "label": "Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares",
        "documentation": "Business Combination, Contingent Consideration, Equity Interest Issued And Issuable, Number Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "periodStartLabel": "Consideration, beginning balance",
        "periodEndLabel": "Consideration, ending balance",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r128",
      "r474",
      "r495",
      "r496",
      "r497"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current contingent consideration",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r128"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average probability of success",
        "terseLabel": "Values",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "documentation": "Value of input used to measure contingent consideration liability from business combination."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r496",
      "r497"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "verboseLabel": "Non-current contingent consideration",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r128"
     ]
    },
    "insm_BusinessCombinationDeferredConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "BusinessCombinationDeferredConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insmed share price (in usd per share)",
        "label": "Business Combination, Deferred Consideration Liability, Measurement Input",
        "documentation": "Business Combination, Deferred Consideration Liability, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "insm_BusinessCombinationDeferredLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "BusinessCombinationDeferredLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred consideration",
        "label": "Business Combination, Deferred Liability",
        "documentation": "Business Combination, Deferred Liability"
       }
      }
     },
     "auth_ref": []
    },
    "insm_BusinessCombinationDeferredPaymentsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "BusinessCombinationDeferredPaymentsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred and contingent consideration",
        "label": "Business Combination, Deferred Payments, Current",
        "documentation": "Business Combination, Deferred Payments, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.insmed.com/role/Acquisitions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r472"
     ]
    },
    "insm_BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations and Asset Acquisitions",
        "label": "Business Combinations And Asset Acquisitions, Policy [Policy Text Block]",
        "documentation": "Business Combinations And Asset Acquisitions, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying Value",
        "label": "Reported Value Measurement [Member]",
        "documentation": "Measured as reported on the statement of financial position (balance sheet)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r164",
      "r743"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1001",
      "r1002"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r106",
      "r196"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r106"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r174",
      "r242",
      "r371",
      "r372",
      "r373",
      "r375",
      "r378",
      "r383",
      "r385",
      "r639",
      "r640",
      "r641",
      "r642",
      "r765",
      "r904",
      "r917"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r321",
      "r323",
      "r728",
      "r949",
      "r954"
     ]
    },
    "insm_CommonStockAuthorizedAggregateGrossSalesProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "CommonStockAuthorizedAggregateGrossSalesProceeds",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock authorized, aggregate gross sales proceeds (up to)",
        "label": "Common Stock Authorized, Aggregate Gross Sales Proceeds",
        "documentation": "Common Stock Authorized, Aggregate Gross Sales Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares reserved for issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r808",
      "r809",
      "r811",
      "r812",
      "r813",
      "r814",
      "r922",
      "r923",
      "r926",
      "r1000",
      "r1057",
      "r1060"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, authorized shares (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r665"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, issued shares (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, outstanding shares (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r86",
      "r665",
      "r683",
      "r1060",
      "r1061"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.01 par value; 500,000,000 authorized shares, 166,666,599 and 147,977,960 issued and outstanding shares at June\u00a030, 2024 and December\u00a031, 2023,\u00a0respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r600",
      "r793"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r182",
      "r184",
      "r188",
      "r594",
      "r609",
      "r610"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "insm_ComputerHardwareAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "ComputerHardwareAndSoftwareMember",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer hardware and software",
        "label": "Computer Hardware And Software [Member]",
        "documentation": "Computer Hardware And Software"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r69",
      "r70",
      "r271",
      "r727"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r69",
      "r70",
      "r271",
      "r635",
      "r727"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r69",
      "r70",
      "r271",
      "r727",
      "r908"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r150"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r69",
      "r70",
      "r271"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r37",
      "r69",
      "r132",
      "r727"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r69",
      "r70",
      "r271",
      "r727"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerRefundLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerRefundLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued France ATU reimbursement payable",
        "label": "Contract with Customer, Refund Liability, Current",
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal amount",
        "label": "Conversion of Stock, Amount Issued",
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of stock, shares issued (in shares)",
        "label": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible senior notes",
        "label": "Convertible Debt, Fair Value Disclosures",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006"
     ]
    },
    "insm_ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining discount amortization period (in years)",
        "label": "Convertible Debt Instrument, Discount Amortization Period, Remaining",
        "documentation": "Convertible Debt Instrument, Discount Amortization Period, Remaining"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r340",
      "r341",
      "r351",
      "r352",
      "r353",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt securities",
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails",
      "http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes",
        "label": "Convertible Notes Payable [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r136"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of product revenues (excluding amortization of intangible assets)",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r559"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r955"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r955",
      "r956"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "insm_CustomerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "CustomerAMember",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer A",
        "label": "Customer A [Member]",
        "documentation": "Customer A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "insm_CustomerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "CustomerBMember",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer B",
        "label": "Customer B [Member]",
        "documentation": "Customer B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "insm_CustomerCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "CustomerCMember",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer C",
        "label": "Customer C [Member]",
        "documentation": "Customer C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r271"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted outstanding amount",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r30"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.insmed.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r198",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r328",
      "r329",
      "r339",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r355",
      "r362",
      "r363",
      "r365",
      "r527"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails",
      "http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails",
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails",
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r75",
      "r76",
      "r136",
      "r138",
      "r203",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r791",
      "r918",
      "r950",
      "r951",
      "r952",
      "r1010",
      "r1012"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails",
      "http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-term debt",
        "terseLabel": "Term Loan",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r138",
      "r366"
     ]
    },
    "insm_DebtInstrumentConversionTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "DebtInstrumentConversionTermAxis",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument Conversion Term [Axis]",
        "label": "Debt Instrument Conversion Term [Axis]",
        "documentation": "Debt Instrument Conversion Term [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "insm_DebtInstrumentConversionTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "DebtInstrumentConversionTermDomain",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument Conversion Term [Domain]",
        "label": "Debt Instrument Conversion Term [Domain]",
        "documentation": "[Domain] for Debt Instrument Conversion Term [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "insm_DebtInstrumentConversionTermFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "DebtInstrumentConversionTermFourMember",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion Term (iv)",
        "label": "Debt Instrument, Conversion Term Four [Member]",
        "documentation": "Debt Instrument, Conversion Term Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "insm_DebtInstrumentConversionTermOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "DebtInstrumentConversionTermOneMember",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion Term (i)",
        "label": "Debt Instrument, Conversion Term One [Member]",
        "documentation": "Debt Instrument, Conversion Term One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "insm_DebtInstrumentConversionTermThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "DebtInstrumentConversionTermThreeMember",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion Term (iii)",
        "label": "Debt Instrument, Conversion Term Three [Member]",
        "documentation": "Debt Instrument, Conversion Term Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "insm_DebtInstrumentConversionTermTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "DebtInstrumentConversionTermTwoMember",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion Term (ii)",
        "label": "Debt Instrument, Conversion Term Two [Member]",
        "documentation": "Debt Instrument, Conversion Term Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Residual equity component of debt",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial conversion price (in dollars per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r342"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial conversion rate",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r79",
      "r124",
      "r125",
      "r342"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold consecutive trading days",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold percent of stock price trigger",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold trading days",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold trading days following fundamental change",
        "label": "Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change",
        "documentation": "Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original Term Loan balance",
        "verboseLabel": "Face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r527",
      "r528",
      "r761",
      "r762",
      "r791"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lenders fees and deal expenses",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r368",
      "r527",
      "r528",
      "r791"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest rate (as a percent)",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r341"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails",
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails",
      "http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails",
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r364",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r791",
      "r918",
      "r1010",
      "r1012"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails",
      "http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails",
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails",
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r203",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r791",
      "r918",
      "r950",
      "r951",
      "r952",
      "r1010",
      "r1012"
     ]
    },
    "insm_DebtInstrumentOptionToPurchaseAdditionalDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "DebtInstrumentOptionToPurchaseAdditionalDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to purchase additional debt",
        "label": "Debt Instrument, Option To Purchase Additional Debt",
        "documentation": "Debt Instrument, Option To Purchase Additional Debt"
       }
      }
     },
     "auth_ref": []
    },
    "insm_DebtInstrumentPercentOfInterestPayable": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "DebtInstrumentPercentOfInterestPayable",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest payable",
        "label": "Debt Instrument, Percent Of Interest Payable",
        "documentation": "Debt Instrument, Percent Of Interest Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest payments",
        "label": "Debt Instrument, Periodic Payment, Interest",
        "documentation": "Amount of the required periodic payments applied to interest."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "insm_DebtInstrumentRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "DebtInstrumentRedemptionPricePerShare",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption price per share (in dollars per share)",
        "label": "Debt Instrument, Redemption Price Per Share",
        "documentation": "Debt Instrument, Redemption Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption price percentage",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "documentation": "Percentage of principal amount of debt redeemed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRepurchaseAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchased amount",
        "label": "Debt Instrument, Repurchase Amount",
        "documentation": "Fair value amount of debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "insm_DebtInstrumentRoyaltyPayableMaximum": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "DebtInstrumentRoyaltyPayableMaximum",
     "presentation": [
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty maximum",
        "label": "Debt Instrument, Royalty Payable, Maximum",
        "documentation": "Debt Instrument, Royalty Payable, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "insm_DebtInstrumentRoyaltyStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "DebtInstrumentRoyaltyStatedPercentage",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty percentage",
        "label": "Debt Instrument, Royalty, Stated Percentage",
        "documentation": "Debt Instrument, Royalty, Stated Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails",
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails",
      "http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails",
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r49",
      "r52",
      "r71",
      "r123",
      "r125",
      "r203",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r351",
      "r352",
      "r353",
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r364",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r791",
      "r918",
      "r1010",
      "r1012"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt term (in months)",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "insm_DebtIssuanceCostsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "DebtIssuanceCostsOther",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Debt Issuance Costs, Other",
        "documentation": "Debt Issuance Costs, Other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Issuance Costs",
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs, net",
        "negatedTerseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r960",
      "r1009",
      "r1010",
      "r1012"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax benefit",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r156",
      "r920"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r41"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateral for interest rate swap",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r493",
      "r494",
      "r507",
      "r515",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r671",
      "r672",
      "r715",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r749",
      "r784",
      "r787",
      "r809",
      "r1003",
      "r1004",
      "r1005",
      "r1058"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r61",
      "r62",
      "r63",
      "r66",
      "r202",
      "r217"
     ]
    },
    "insm_DevelopmentAndRegulatoryMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "DevelopmentAndRegulatoryMilestonesMember",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and regulatory milestones",
        "label": "Development And Regulatory Milestones [Member]",
        "documentation": "Development And Regulatory Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DilutiveSecuritiesAbstract",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities:",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.insmed.com/role/ProductRevenuesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.insmed.com/role/ProductRevenuesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r412",
      "r440",
      "r441",
      "r443",
      "r779"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net loss per share (in dollars per share)",
        "verboseLabel": "Basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r219",
      "r222",
      "r234",
      "r235",
      "r236",
      "r239",
      "r469",
      "r477",
      "r490",
      "r491",
      "r595",
      "r611",
      "r751"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net loss per share (in dollars per share)",
        "verboseLabel": "Diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r222",
      "r234",
      "r235",
      "r236",
      "r239",
      "r469",
      "r477",
      "r490",
      "r491",
      "r595",
      "r611",
      "r751"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r238"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rates on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and employee related costs",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense related to unvested RSU awards",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense related to unvested stock options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "insm_EmployeeStockPurchasePlan2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "EmployeeStockPurchasePlan2018Member",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2018 ESPP",
        "label": "Employee Stock Purchase Plan 2018 [Member]",
        "documentation": "Employee Stock Purchase Plan 2018 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r159",
      "r185",
      "r186",
      "r187",
      "r204",
      "r205",
      "r206",
      "r208",
      "r213",
      "r215",
      "r217",
      "r241",
      "r274",
      "r275",
      "r309",
      "r386",
      "r459",
      "r460",
      "r466",
      "r467",
      "r468",
      "r470",
      "r476",
      "r477",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r529",
      "r531",
      "r545",
      "r608",
      "r628",
      "r629",
      "r630",
      "r645",
      "r703"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r826",
      "r836",
      "r846",
      "r878"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r823",
      "r833",
      "r843",
      "r875"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimate of Fair Value Measurement",
        "label": "Estimate of Fair Value Measurement [Member]",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r515",
      "r761",
      "r762"
     ]
    },
    "insm_EuropeAndTheRestOfTheWorldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "EuropeAndTheRestOfTheWorldMember",
     "presentation": [
      "http://www.insmed.com/role/ProductRevenuesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe and rest of world",
        "label": "Europe And The Rest Of The World [Member]",
        "documentation": "Europe And The Rest Of The World"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r507",
      "r784"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r507",
      "r784"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Observable Inputs in Valuation of Deferred Consideration, Development and Regulatory Milestones and Priority Review Voucher Milestone and Changes in Fair Value of Valuations for Deferred and Contingent Consideration Liabilities",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r496",
      "r787"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r492",
      "r494",
      "r495",
      "r496",
      "r497",
      "r506",
      "r507",
      "r509",
      "r549",
      "r550",
      "r551",
      "r761",
      "r762",
      "r773",
      "r774",
      "r775",
      "r784",
      "r787"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class [Axis]",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r508"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Basis [Axis]",
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r761",
      "r762"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r497",
      "r784",
      "r1004",
      "r1007"
     ]
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosureItemAmountsDomain",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement [Domain]",
        "label": "Fair Value Measurement [Domain]",
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r761",
      "r762"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r504",
      "r505",
      "r506",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r592",
      "r784",
      "r788"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r399",
      "r404",
      "r494",
      "r507",
      "r549",
      "r773",
      "r774",
      "r775",
      "r784"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "verboseLabel": "Deferred Consideration (Level 2 Liabilities)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r399",
      "r404",
      "r494",
      "r495",
      "r507",
      "r550",
      "r761",
      "r762",
      "r773",
      "r774",
      "r775",
      "r784"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "verboseLabel": "Contingent Consideration (Level 3 Liabilities)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r494",
      "r495",
      "r496",
      "r497",
      "r507",
      "r551",
      "r761",
      "r762",
      "r773",
      "r774",
      "r775",
      "r784",
      "r787"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r508"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r497",
      "r784",
      "r1004",
      "r1007"
     ]
    },
    "insm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments",
        "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r492",
      "r494",
      "r495",
      "r496",
      "r497",
      "r506",
      "r507",
      "r509",
      "r549",
      "r550",
      "r551",
      "r761",
      "r762",
      "r773",
      "r774",
      "r775",
      "r784",
      "r787"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring Basis",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1007"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails": {
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease interest expense",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r538",
      "r792"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease liabilities",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease liabilities, long-term",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments of finance lease principal",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r541"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease right-of-use assets",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease amortization expense",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r538",
      "r792"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets estimated useful life (in years)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets, 2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r741",
      "r759"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets, remainder of 2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets, 2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r741",
      "r759"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets, 2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r741",
      "r759"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets, 2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r741",
      "r759"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r293",
      "r294",
      "r295",
      "r298",
      "r299",
      "r302",
      "r303",
      "r560",
      "r561",
      "r741"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles, gross",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r299",
      "r561",
      "r759"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r299",
      "r302",
      "r303",
      "r306",
      "r560",
      "r741",
      "r759"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r293",
      "r294",
      "r295",
      "r298",
      "r299",
      "r302",
      "r303",
      "r741"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles, net",
        "verboseLabel": "Intangibles, net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r945"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsRollForward",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-lived Intangible Assets [Roll Forward]",
        "label": "Finite-Lived Intangible Assets [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Finite-Lived Intangible Assets Acquired",
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r840",
      "r850",
      "r882"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r840",
      "r850",
      "r882"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r840",
      "r850",
      "r882"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r840",
      "r850",
      "r882"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r840",
      "r850",
      "r882"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r45",
      "r46"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r687"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/IntangiblesNetandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r279",
      "r593",
      "r756",
      "r758",
      "r785",
      "r793",
      "r935",
      "r936"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r289",
      "r758"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r305",
      "r308"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired IPR&amp;D",
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r945",
      "r946",
      "r947",
      "r948"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r141",
      "r145",
      "r596",
      "r606",
      "r753",
      "r755",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r317",
      "r318",
      "r499",
      "r503",
      "r508",
      "r625",
      "r627",
      "r688",
      "r741",
      "r786",
      "r1028"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318",
      "r499",
      "r503",
      "r508",
      "r625",
      "r627",
      "r688",
      "r741",
      "r786",
      "r1028"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r461",
      "r463",
      "r464",
      "r465",
      "r644",
      "r782"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.insmed.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r157",
      "r216",
      "r217",
      "r240",
      "r252",
      "r265",
      "r449",
      "r450",
      "r462",
      "r612",
      "r782"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r195",
      "r457",
      "r458"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "calculation": {
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt securities (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r236"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r236",
      "r411"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r840",
      "r850",
      "r874",
      "r882",
      "r886",
      "r894"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r898"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r898"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r898"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles, Net and Goodwill",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r304",
      "r307",
      "r740",
      "r741"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-lived Intangible Assets and Impairment Assessment",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r557",
      "r558",
      "r560",
      "r750",
      "r937"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total interest expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r244",
      "r248",
      "r254",
      "r265",
      "r526",
      "r755",
      "r756"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails": {
       "parentTag": "insm_InterestExpenseExcludingFinanceLeaseInterestExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt contractual interest expense",
        "verboseLabel": "Interest expense recognized",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r359",
      "r369",
      "r763",
      "r764"
     ]
    },
    "insm_InterestExpenseExcludingFinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "InterestExpenseExcludingFinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails": {
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total debt interest expense",
        "label": "Interest Expense, Excluding Finance Lease Interest Expense",
        "documentation": "Interest Expense, Excluding Finance Lease Interest Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r914"
     ]
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "presentation": [
      "http://www.insmed.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Interest Expense related to Debt and Finance Leases",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails": {
       "parentTag": "insm_InterestExpenseExcludingFinanceLeaseInterestExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Swap interest income",
        "label": "Interest Income, Other",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r193",
      "r194"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest payable",
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_InterestRateDerivativeAssetsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestRateDerivativeAssetsAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest rate swap",
        "label": "Interest Rate Derivative Assets, at Fair Value",
        "documentation": "Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestRateDerivativeLiabilitiesAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestRateDerivativeLiabilitiesAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate swap",
        "label": "Interest Rate Derivative Liabilities, at Fair Value",
        "documentation": "Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "insm_InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory and Cost of Product Revenues (excluding amortization of intangible assets)",
        "label": "Inventory And Cost Of Product Revenues (Excluding Amortization Of Intangible Assets) [Policy Text Block]",
        "documentation": "Inventory And Cost Of Product Revenues (Excluding Amortization Of Intangible Assets)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.insmed.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/InventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r746"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.insmed.com/role/InventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "totalLabel": "Inventory, net",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r744",
      "r793"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/InventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r748"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/InventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r747"
     ]
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNonoperating",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment income",
        "label": "Investment Income, Nonoperating",
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "country_JP": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "JP",
     "presentation": [
      "http://www.insmed.com/role/ProductRevenuesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Japan",
        "label": "JAPAN"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.insmed.com/role/LeasesScheduleofSupplementalNoncashDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease, Cost [Abstract]",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.insmed.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Supplemental Non-cash Disclosures",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "insm_LeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "LeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.insmed.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease term",
        "label": "Lease, Remaining Lease Term",
        "documentation": "Lease, Remaining Lease Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r543"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://www.insmed.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Finance Leases [Text Block]",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.insmed.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r544"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.insmed.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r544"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.insmed.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r75",
      "r76",
      "r77",
      "r81",
      "r82",
      "r83",
      "r84",
      "r200",
      "r273",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r479",
      "r480",
      "r481",
      "r516",
      "r664",
      "r752",
      "r817",
      "r957",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders\u2019 equity (deficit)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r139",
      "r603",
      "r793",
      "r919",
      "r934",
      "r1008"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and shareholders\u2019 equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r163",
      "r200",
      "r273",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r479",
      "r480",
      "r481",
      "r516",
      "r793",
      "r957",
      "r1015",
      "r1016"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofChangesinFairValueofValuationsforDeferredandContingentConsiderationLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Liabilities, Fair Value Adjustment",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PARI milestones",
        "label": "Licensing Agreements [Member]",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r447",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r945",
      "r946",
      "r947",
      "r948",
      "r994"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r138",
      "r352",
      "r367",
      "r761",
      "r762",
      "r791",
      "r1024"
     ]
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtByMaturityAbstract",
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year Ending December\u00a031:",
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails",
      "http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of long-term debt",
        "negatedTerseLabel": "Less: current portion of convertible notes",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r203",
      "r357"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r203",
      "r357"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r203",
      "r357"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r203",
      "r357"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "insm_LongTermDebtMaturityAfterYearFourAndThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "LongTermDebtMaturityAfterYearFourAndThereafter",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofFuturePrincipalRepaymentsofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029 and thereafter",
        "label": "Long-Term Debt, Maturity, After Year Four And Thereafter",
        "documentation": "Long-Term Debt, Maturity, After Year Four And Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails",
      "http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt, long-term",
        "totalLabel": "Total long-term convertible notes",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r950",
      "r951",
      "r952"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r43",
      "r950",
      "r951",
      "r952"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r768",
      "r802",
      "r806",
      "r961",
      "r1025",
      "r1029",
      "r1030",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "insm_ManufacturingEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "ManufacturingEquipmentMember",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing equipment",
        "label": "Manufacturing Equipment [Member]",
        "documentation": "Manufacturing Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r909"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "insm_MartinaFlammerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "MartinaFlammerMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Martina Flammer [Member]",
        "documentation": "Martina Flammer"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails",
      "http://www.insmed.com/role/FixedAssetsNetDetails",
      "http://www.insmed.com/role/LeasesNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r405",
      "r445",
      "r497",
      "r555",
      "r624",
      "r626",
      "r634",
      "r656",
      "r657",
      "r708",
      "r710",
      "r712",
      "r713",
      "r722",
      "r738",
      "r739",
      "r757",
      "r765",
      "r778",
      "r787",
      "r788",
      "r789",
      "r790",
      "r803",
      "r959",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1004",
      "r1005"
     ]
    },
    "insm_MeasurementInputProbabilityOfSuccessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "MeasurementInputProbabilityOfSuccessMember",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probabilities of success",
        "label": "Measurement Input, Probability Of Success [Member]",
        "documentation": "Measurement Input, Probability Of Success"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Price",
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1004",
      "r1005"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r496",
      "r497",
      "r787"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofObservableInputsinValuationofDeferredConsiderationDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r495",
      "r496",
      "r497",
      "r787"
     ]
    },
    "insm_MichaelSmithMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "MichaelSmithMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Michael Smith [Member]",
        "documentation": "Michael Smith"
       }
      }
     },
     "auth_ref": []
    },
    "insm_MilestoneEvent1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "MilestoneEvent1Member",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Event 1",
        "label": "Milestone Event 1 [Member]",
        "documentation": "Milestone Event 1"
       }
      }
     },
     "auth_ref": []
    },
    "insm_MilestoneEvent2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "MilestoneEvent2Member",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Event 2",
        "label": "Milestone Event 2 [Member]",
        "documentation": "Milestone Event 2"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails",
      "http://www.insmed.com/role/FixedAssetsNetDetails",
      "http://www.insmed.com/role/LeasesNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r405",
      "r445",
      "r497",
      "r555",
      "r624",
      "r626",
      "r634",
      "r656",
      "r657",
      "r708",
      "r710",
      "r712",
      "r713",
      "r722",
      "r738",
      "r739",
      "r757",
      "r765",
      "r778",
      "r787",
      "r788",
      "r789",
      "r803",
      "r959",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "insm_MotusBiosciencesIncAndAlgaeneXIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "MotusBiosciencesIncAndAlgaeneXIncMember",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motus and AlgaeneX",
        "label": "Motus Biosciences, Inc. And AlgaeneX, Inc. [Member]",
        "documentation": "Motus Biosciences, Inc. And AlgaeneX, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "insm_MotusBiosciencesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "MotusBiosciencesIncMember",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motus",
        "label": "Motus Biosciences, Inc. [Member]",
        "documentation": "Motus Biosciences, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r768",
      "r802",
      "r806",
      "r961",
      "r1025",
      "r1029",
      "r1030",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r109"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails",
      "http://www.insmed.com/role/TheCompanyandBasisofPresentationDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r109",
      "r142",
      "r161",
      "r180",
      "r183",
      "r187",
      "r200",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r216",
      "r217",
      "r232",
      "r273",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r469",
      "r477",
      "r491",
      "r516",
      "r607",
      "r685",
      "r701",
      "r702",
      "r815",
      "r957"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss, basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r209",
      "r210",
      "r211",
      "r212",
      "r219",
      "r220",
      "r233",
      "r236",
      "r477"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss, diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r221",
      "r226",
      "r227",
      "r228",
      "r229",
      "r233",
      "r236"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements (Not Yet Adopted)",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r840",
      "r850",
      "r874",
      "r882"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "insm_NoncashAcquisitionRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "NoncashAcquisitionRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vertuis acquisition",
        "verboseLabel": "Adrestia acquisition",
        "label": "Noncash Acquisition Related Expense",
        "documentation": "Noncash Acquisition Related Expense"
       }
      }
     },
     "auth_ref": []
    },
    "insm_NoncashOperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "NoncashOperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash operating lease expense",
        "label": "Noncash Operating Lease Expense",
        "documentation": "Noncash Operating Lease Expense"
       }
      }
     },
     "auth_ref": []
    },
    "insm_NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of publicly disclosed sales used to determine average sales price owed to equity holders",
        "label": "Number Of Publicly Disclosed Sales Used To Determine Average Sales Price Owed To Equity Holders",
        "documentation": "Number Of Publicly Disclosed Sales Used To Determine Average Sales Price Owed To Equity Holders"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportingUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportingUnits",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reporting units",
        "label": "Number of Reporting Units",
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.75% Convertible Senior Notes Due 2025",
        "label": "One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]",
        "documentation": "One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r753",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense charged to operations",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r792"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, long-term",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.insmed.com/role/TheCompanyandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Company and Basis of Presentation",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r130",
      "r636",
      "r637"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r168",
      "r598",
      "r756",
      "r817"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized (loss) gain on marketable securities",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r13",
      "r131"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency translation losses",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r13",
      "r131"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r13",
      "r131",
      "r181",
      "r184",
      "r213"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty financing non-cash interest expense",
        "label": "Other Noncash Expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r838",
      "r848",
      "r880"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r841",
      "r851",
      "r883"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r841",
      "r851",
      "r883"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid-in-kind interest capitalized",
        "label": "Paid-in-Kind Interest",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Revenue Interest Payments paid and payable",
        "label": "Payments for Royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments of stock issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid in acquisition",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r473"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of fixed assets",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PSUs",
        "verboseLabel": "Performance Stock Units",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisandCarryingValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Portion at Fair Value Measurement",
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r371"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r665"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r371"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r665",
      "r683",
      "r1060",
      "r1061"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "insm_PriorityReviewVoucherMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "PriorityReviewVoucherMilestoneMember",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Priority review voucher milestone",
        "label": "Priority Review Voucher Milestone [Member]",
        "documentation": "Priority Review Voucher Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "insm_ProceedsFromCashAcquiredInAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "ProceedsFromCashAcquiredInAssetAcquisition",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash acquired in asset acquisition",
        "label": "Proceeds From Cash Acquired In Asset Acquisition",
        "documentation": "Proceeds From Cash Acquired In Asset Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net proceeds",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock, net",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromLoans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLoans",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from loans",
        "label": "Proceeds from Loans",
        "documentation": "Cash received from principal payments made on loans related to operating activities."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "insm_ProceedsFromRoyaltyFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "ProceedsFromRoyaltyFinancing",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from royalty financing",
        "label": "Proceeds From Royalty Financing",
        "documentation": "Proceeds From Royalty Financing"
       }
      }
     },
     "auth_ref": []
    },
    "insm_ProceedsFromRoyaltyFinancingAgreementNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "ProceedsFromRoyaltyFinancingAgreementNet",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from royalty financing agreement, net",
        "label": "Proceeds From Royalty Financing Agreement, Net",
        "documentation": "Proceeds From Royalty Financing Agreement, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options and ESPP",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r16"
     ]
    },
    "insm_ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds of sale of priority review voucher obligated to pay to equity holders, percentage",
        "label": "Proceeds Of Sale Of Priority Review Voucher Obligated To Pay To Equity Holders, Percentage",
        "documentation": "Proceeds Of Sale Of Priority Review Voucher Obligated To Pay To Equity Holders, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r543"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Assets, Net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r151",
      "r154",
      "r155"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/FixedAssetsNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r165",
      "r605"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.insmed.com/role/FixedAssetsNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets, net",
        "totalLabel": "Fixed assets, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r543",
      "r597",
      "r605",
      "r793"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fixed Assets",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r543"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Life (years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "insm_PublicStockOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "PublicStockOfferingMember",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Stock Offering",
        "label": "Public Stock Offering [Member]",
        "documentation": "Public Stock Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails",
      "http://www.insmed.com/role/FixedAssetsNetDetails",
      "http://www.insmed.com/role/LeasesNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r398",
      "r405",
      "r435",
      "r436",
      "r437",
      "r445",
      "r497",
      "r552",
      "r554",
      "r555",
      "r624",
      "r626",
      "r634",
      "r656",
      "r657",
      "r708",
      "r710",
      "r712",
      "r713",
      "r722",
      "r738",
      "r739",
      "r757",
      "r765",
      "r778",
      "r787",
      "r788",
      "r789",
      "r790",
      "r803",
      "r809",
      "r953",
      "r959",
      "r1004",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsScheduleofValuationofDevelopmentandRegulatoryMilestonesandPriorityReviewVoucherMilestoneDetails",
      "http://www.insmed.com/role/FixedAssetsNetDetails",
      "http://www.insmed.com/role/LeasesNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r398",
      "r405",
      "r435",
      "r436",
      "r437",
      "r445",
      "r497",
      "r552",
      "r554",
      "r555",
      "r624",
      "r626",
      "r634",
      "r656",
      "r657",
      "r708",
      "r710",
      "r712",
      "r713",
      "r722",
      "r738",
      "r739",
      "r757",
      "r765",
      "r778",
      "r787",
      "r788",
      "r789",
      "r790",
      "r803",
      "r809",
      "r953",
      "r959",
      "r1004",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r823",
      "r833",
      "r843",
      "r875"
     ]
    },
    "insm_RedemptionOfThe2025ConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "RedemptionOfThe2025ConvertibleNotesMember",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption of the 2025 Convertible Notes",
        "label": "Redemption Of The 2025 Convertible Notes [Member]",
        "documentation": "Redemption Of The 2025 Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock",
     "presentation": [
      "http://www.insmed.com/role/RoyaltyFinancingAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Financing Agreement",
        "label": "Repurchase Agreements, Resale Agreements, Securities Borrowed, and Securities Loaned Disclosure [Text Block]",
        "documentation": "The entire disclosure for repurchase agreements (also known as repos), resale agreements (also known as reverse repurchase agreements or reverse repos), securities borrowed transactions, and securities loaned transactions."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r553"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPR&amp;D expense",
        "label": "Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff",
        "documentation": "Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r741",
      "r993"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r741",
      "r755",
      "r1023"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r824",
      "r834",
      "r844",
      "r876"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r825",
      "r835",
      "r845",
      "r877"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r832",
      "r842",
      "r852",
      "r884"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "RS and RSUs",
        "terseLabel": "Unvested RS and RSUs",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r126",
      "r602",
      "r631",
      "r633",
      "r643",
      "r666",
      "r793"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r204",
      "r205",
      "r206",
      "r208",
      "r213",
      "r215",
      "r217",
      "r274",
      "r275",
      "r309",
      "r459",
      "r460",
      "r466",
      "r467",
      "r468",
      "r470",
      "r476",
      "r477",
      "r482",
      "r484",
      "r485",
      "r487",
      "r489",
      "r529",
      "r531",
      "r628",
      "r630",
      "r645",
      "r1060"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.insmed.com/role/ProductRevenuesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product revenues, net",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r240",
      "r245",
      "r246",
      "r260",
      "r265",
      "r268",
      "r269",
      "r271",
      "r395",
      "r396",
      "r559"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible List]",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.insmed.com/role/ProductRevenuesNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Revenues, Net",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r397"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.insmed.com/role/ProductRevenuesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Geographic Summary of Product Revenues, Net",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "insm_RevenueInterestPaymentsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "RevenueInterestPaymentsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Interest Payments payable",
        "label": "Revenue Interest Payments Payable",
        "documentation": "Revenue Interest Payments Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/LeasesScheduleofSupplementalNoncashDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance right-of-use assets obtained in exchange for lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r792"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/LeasesScheduleofSupplementalNoncashDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating right-of-use assets obtained in exchange for lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r792"
     ]
    },
    "us-gaap_RoyaltyAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyAgreementsMember",
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Agreements",
        "label": "Royalty Agreements [Member]",
        "documentation": "Contractual arrangement, generally for a defined period of time, entitling the entity to use the rights and property of another party. Examples include, but not limited to, licensing the use of copyrighted materials and leasing the extraction of natural resources."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r447",
      "r938",
      "r939",
      "r940",
      "r941",
      "r943",
      "r945",
      "r947",
      "r948",
      "r994"
     ]
    },
    "insm_RoyaltyFinancingAgreementRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "RoyaltyFinancingAgreementRollForward",
     "presentation": [
      "http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Financing Agreement [Roll Forward]",
        "label": "Royalty Financing Agreement [Roll Forward]",
        "documentation": "Royalty Financing Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "insm_S.NicoleSchaeffer2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "S.NicoleSchaeffer2Member",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "S. Nicole Schaeffer2 [Member]",
        "documentation": "S. Nicole Schaeffer2"
       }
      }
     },
     "auth_ref": []
    },
    "insm_S.NicoleSchaefferMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "S.NicoleSchaefferMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "S. Nicole Schaeffer [Member]",
        "documentation": "S. Nicole Schaeffer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate net proceeds from stock offering",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares sold in offering (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueProductLineMember",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPercentageofGrossProductRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Revenue, Product Line",
        "label": "Revenue, Product and Service Benchmark [Member]",
        "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r406",
      "r925"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r406",
      "r905",
      "r925"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.insmed.com/role/AccountsPayableandAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesExcludedfromComputationsofDilutedWeightedAverageCommonSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r471"
     ]
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "presentation": [
      "http://www.insmed.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Carrying Value of Term Loan Balance",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.insmed.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Current Portion of Long-Term Debt and Debt, Long-Term",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r49",
      "r52",
      "r71",
      "r123",
      "r125",
      "r761",
      "r763",
      "r921",
      "r1010"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://www.insmed.com/role/DebtTables",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Carrying Value of Convertible Notes Balance",
        "verboseLabel": "Schedule of Carrying Value of Royalty Financing Agreement",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Aggregate Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis and Carrying Value",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1001",
      "r1002"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillScheduleofRollforwardofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r299",
      "r302",
      "r303",
      "r306",
      "r560",
      "r741",
      "r759"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.insmed.com/role/IntangiblesNetandGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Rollforward of Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r759",
      "r944"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.insmed.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r92",
      "r93",
      "r94"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.insmed.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Principal Repayments of Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r543"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r410",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r121",
      "r123",
      "r125",
      "r126",
      "r172",
      "r173",
      "r174",
      "r242",
      "r371",
      "r372",
      "r373",
      "r375",
      "r378",
      "r383",
      "r385",
      "r639",
      "r640",
      "r641",
      "r642",
      "r765",
      "r904",
      "r917"
     ]
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of the Weighted Average Number of Common Shares Used to Compute Basic and Diluted Net Loss Per Share",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "insm_ScheduleofEarningsPerShareBasicandDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "ScheduleofEarningsPerShareBasicandDilutedLineItems",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Line Items]",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Line Items]",
        "documentation": "[Line Items] for Schedule of Earnings Per Share, Basic and Diluted [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "insm_ScheduleofEarningsPerShareBasicandDilutedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "ScheduleofEarningsPerShareBasicandDilutedTable",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Table]",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table]",
        "documentation": "Schedule of Earnings Per Share, Basic and Diluted [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Percentage of Gross Product Revenue",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r37",
      "r69",
      "r132"
     ]
    },
    "us-gaap_SecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofConvertibleNotesBalanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Face value of outstanding convertible notes",
        "label": "Secured Debt",
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r138",
      "r1024"
     ]
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredOvernightFinancingRateSofrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredOvernightFinancingRateSofrMember",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Overnight Financing Rate (SOFR)",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r240",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r271",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r306",
      "r319",
      "r320",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r754",
      "r755",
      "r756",
      "r758",
      "r805",
      "r1025",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.insmed.com/role/ProductRevenuesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r649",
      "r652",
      "r654",
      "r709",
      "r711",
      "r714",
      "r723",
      "r726",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r742",
      "r767",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r804",
      "r809",
      "r961",
      "r1025",
      "r1029",
      "r1030",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding, nonvested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425"
     ]
    },
    "insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement stock options granted to new employees (in shares)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Inducement Options Grants In Period Gross",
        "documentation": "Gross number of inducement share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r410",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock, maximum authorized for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Anniversary of Closing Date",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Anniversary of Closing Date",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Anniversary of Closing Date",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in usd per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential award payout",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r197"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r160",
      "r240",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r271",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r306",
      "r311",
      "r319",
      "r320",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r754",
      "r755",
      "r756",
      "r758",
      "r805",
      "r1025",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r86",
      "r89",
      "r90",
      "r159",
      "r185",
      "r186",
      "r187",
      "r204",
      "r205",
      "r206",
      "r208",
      "r213",
      "r215",
      "r217",
      "r241",
      "r274",
      "r275",
      "r309",
      "r386",
      "r459",
      "r460",
      "r466",
      "r467",
      "r468",
      "r470",
      "r476",
      "r477",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r489",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r529",
      "r531",
      "r545",
      "r608",
      "r628",
      "r629",
      "r630",
      "r645",
      "r703"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.insmed.com/role/ProductRevenuesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r649",
      "r652",
      "r654",
      "r709",
      "r711",
      "r714",
      "r723",
      "r726",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r742",
      "r767",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r804",
      "r809",
      "r961",
      "r1025",
      "r1029",
      "r1030",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r241",
      "r531",
      "r559",
      "r638",
      "r646",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r684",
      "r686",
      "r687",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r703",
      "r810"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r406",
      "r905",
      "r906",
      "r925"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r241",
      "r272",
      "r531",
      "r559",
      "r638",
      "r646",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r665",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r684",
      "r686",
      "r687",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r703",
      "r810"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r837",
      "r847",
      "r879"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock for asset acquisitions (in shares)",
        "terseLabel": "Issuance of common stock for business acquisition (in shares)",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r126"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuance of common stock (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r85",
      "r86",
      "r126",
      "r639",
      "r703",
      "r724"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for vesting of RSUs (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r85",
      "r86",
      "r126"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options and ESPP shares (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r85",
      "r86",
      "r126",
      "r421"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for asset acquisitions",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r86",
      "r89",
      "r90",
      "r126"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issuance of common stock",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r85",
      "r86",
      "r126",
      "r645",
      "r703",
      "r724",
      "r816"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for vesting of RSUs",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r126"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options and ESPP shares",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r86",
      "r89",
      "r90",
      "r126"
     ]
    },
    "insm_StockOptionsAndRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationScheduleofAggregateStockBasedCompensationExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options and RSUs",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "documentation": "Represents contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time. It also includes stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquityDeficitunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity (deficit)",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r89",
      "r90",
      "r113",
      "r667",
      "r683",
      "r704",
      "r705",
      "r793",
      "r817",
      "r919",
      "r934",
      "r1008",
      "r1060"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r199",
      "r370",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r386",
      "r488",
      "r706",
      "r707",
      "r725"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r547"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r547"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r547"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r547"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r547"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.insmed.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r548"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosures of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "insm_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "TermLoanMember",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails",
      "http://www.insmed.com/role/DebtScheduleofCurrentPortionofLongTermDebtandDebtLongTermDetails",
      "http://www.insmed.com/role/DebtScheduleofInterestExpenserelatedtoDebtandFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan",
        "label": "Term Loan [Member]",
        "documentation": "Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "insm_TriggeringEventAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "TriggeringEventAxis",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Triggering Event [Axis]",
        "label": "Triggering Event [Axis]",
        "documentation": "Triggering Event"
       }
      }
     },
     "auth_ref": []
    },
    "insm_TriggeringEventDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "TriggeringEventDomain",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Triggering Event [Domain]",
        "label": "Triggering Event [Domain]",
        "documentation": "Triggering Event [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfCostGoodOrServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfCostGoodOrServiceExtensibleList",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost, Product and Service [Extensible List]",
        "label": "Cost, Product and Service [Extensible Enumeration]",
        "documentation": "Indicates type of cost from product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.insmed.com/role/ProductRevenuesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/DebtScheduleofCarryingValueofTermLoanBalanceDetails",
      "http://www.insmed.com/role/RoyaltyFinancingAgreementScheduleofCarryingValueofRoyaltyFinancingAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Term Loan issuance costs, unamortized",
        "periodStartLabel": "Royalty issuance costs, unamortized - beginning balance",
        "periodEndLabel": "Deferred issuance costs, unamortized - ending balance",
        "label": "Unamortized Debt Issuance Expense",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of interest rate swap",
        "negatedTerseLabel": "Change in fair value of interest rate swap",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r697",
      "r698",
      "r699",
      "r700",
      "r717"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, interest and penalties accrued",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r781"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.insmed.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease cost, future right-of-use asset",
        "label": "Unrecorded Unconditional Purchase Obligation",
        "documentation": "Amount of unrecorded obligation to transfer funds in future for fixed or minimum amount or quantity of product and service at fixed or minimum price. Includes, but is not limited to, lease not yet commenced and take-or-pay and throughput contracts."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r1013"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r148",
      "r149",
      "r152",
      "r153"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.insmed.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease, cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r792"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "insm_VertuisBioIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "VertuisBioIncMember",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/AcquisitionsScheduleofPurchasePriceDetails",
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsunaudited",
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vertuis Bio, Inc.",
        "label": "Vertuis Bio, Inc. [Member]",
        "documentation": "Vertuis Bio, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.insmed.com/role/AcquisitionsNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average diluted common shares outstanding (in shares)",
        "totalLabel": "Weighted average common shares outstanding used\u00a0in calculation of diluted net loss per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r236"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLossunaudited",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average basic common shares outstanding (in shares)",
        "terseLabel": "Weighted average common shares used in calculation of basic net loss per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r236"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesScheduleofReconciliationoftheWeightedAverageNumberofCommonSharesUsedtoComputeBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "insm_ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.insmed.com/20240630",
     "localname": "ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member",
     "presentation": [
      "http://www.insmed.com/role/DebtNarrativeDetails",
      "http://www.insmed.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.75% Convertible Senior Notes Due 2028",
        "label": "Zero Point Seven Five Percent Convertible Senior Note Due 2028 [Member]",
        "documentation": "Zero Point Seven Five Percent Convertible Senior Note Due 2028"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "860",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/860/tableOfContent"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-42"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-10"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-27"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>104
<FILENAME>0001104506-24-000026-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104506-24-000026-xbrl.zip
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M'IN6-"N/^+0Z^EVS3M31YM=.X==,-/3QU .MY#Z13]8Y _@Y7USR R[)]/
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M7=>06D45YM_=>S/D@+MXQ$[VE:PGM8H/5,6<BM86I9:>?@624\4ZH]32UZ]
M<JI8<Y1:>?ME93WE9%Y%6<R*4JMX */,J^@@A:+4+V)01NIN7;E7J_#"H8O:
MWI<>L^QX2>DD2JWB$D?E9%GER\OB9*T"&J5QLJG;N<I)A$=JQ5ZE2/:>1("%
M??:R$#)03R*>4S,L9(I0K.B%?%@XB? 1^U@H*>].938 Q8;45:6!F0TML<&6
MJI1AK8)&1XREEZ6=3B+,PXZ/IS(;C!F\(-]:/TQW-9DZW@SCA] S?][2XWWU
M 3>S\9(MQ+['@'?;#+%%R?W#M</@_N%'?0C.; 1C"\'OL#_R_ ER3?PP1O[>
M$ZH,D9K9:,*7*+!=' 0#\\_(#FRB,9:;W7MA%'RQO<"T,5 ]N';-VM!<8]9K
M9XOF<H$+IL:L=\P S=]M%*8^*B@7:+%KS/JWK#%(:4O=U&<Y):,H3U=CUM-E
MC4%J>@:I13*(69]W-X,&%AA,H8T>Q]A'4QR%MAE\"ZUF9F!JS#K*NYGT!_9#
M^!CDJ.Q57RVNXYZB,>LF5TKM' F5A>7D:<PZU0_1,+ M&_FS!^3@VQ'UH9>8
M<Q<-X0EQ(&,TPN74/V.A>H-6NAN>33,4F0.CE>[WUH3).K/.Z#XY'(1@,7Q'
M_D\<+B*XY2=1IM65<)U:&(^8=5X9Y%%%.TXZL_XK&SPJ:2-$9]8K98/L.?;(
MBU-?S#JFM>=187ZISJQ?RIXYKJ4_2J$5>)1"+]V9S;PE4E1/:T6OHS<XOX14
M=1PXCA>21Y>UM\T$ EEP")D@!+.[IG<.<F_0!"\O8HHD&]<N.7]&3J(YI9>%
MD BE924-4]Y=FHLI'68]V51,>1S;OC6 >ZW2#? B-[,[S/JF&ZB^DH5T%_GF
M& 64^.3 <9DD)\>9 >AZ,21GUM6LGN3OCYLO$WW/<?/E2_,I(F9]TH+2E_:^
M[YC'75GPGCK,>KA5<KRL8[%,<)Q9?_D=QZD27LJZ#0:NM2D_M*AS-V#3>!/0
M]D!9,O!OGHG>-C>7$E0Q:1$%8[DD+:"\*;GVZG4*3SM"@XTJZF)UF-V*YH#9
M#9B*,D4ZS(9$.&#87)+JDC7/ 9,K!:<XP# ;Q:H#8'[#+O:1 T,96!-P;F X
MB,1R&FW%=)F-L7'(,&K'=)D-$'+(,&K)=)D-<'+(,&K+=.L2<RT(,G6U'^H2
M*&6$356MV2<6W:SK.GEB,<6ZKDWL1O*" (>,G<I+V_VZ4 ZQ&SK;SJ$3."36
M9>&43DEG$WO,A5+BUD&^_?1$LVBOGO%*5?/OM@,:P7,Q_4(NRJ<A"9;XSX@$
M6\ESU_>JWUU0U'L9D2PM_6%Q>FE!DM5C+BJ3"7T*1U^MT<=L@(>U6A*PZO;
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M]C0V^Q(B*^"*]GKD+-%IF!P),8AY,?4!C_84.0)^Q69$RIK"Q["4XN!$C0L
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M!,XYEM)O91:))1)3-CK@-31HUY)C*?TV7Y%8ZH$#VNF*/36WQ<>QQ""6]NZ
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MLX*E]#EJNO"E.$Q#THV3S8;,#J=*^GQV#5'1BLHZJ;Y5 ^]P=(RC-[E01]J
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MK>EPXG@+3\AV!8#;!/D_,>6G$&"PN>W0/M# WD";FLA@@17@MTG>(K@%LA*
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M'A#,"H21[TT$>TM;7]["MS3+^.#&USV)>I%*427F>.R")7V<QUA>@M0Z:F1
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M0/9@:"$=>)#%S?&#-7%<E.CO0-GKA+"9I:/7ZLO@IG9S*UUNBK,(H#U*MP
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MZ0A,)HXUP*?8J;LQZ2NX36N7:V5M(E.U@O6?Y1&@22J%)8U"6X<K6D?LYF\
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MA41/T1-N#WV,?K;1""9XCIP7- L(1I<!"=A+!F1H9X3L[RFVE2ZC46ETB<4
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M/]3^4<O[-MX=_P6^4?PJ$5;6\)"U+$IH.Z>^MW=+?7\ ^4#Q$B>(PQW?@2B
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ML2[22@S?Y3YBJ@$)YZA*T+_AA0RH/<BJ: AGK$J*8]X\0U)F;Q'$"^XJF=V
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MJ/2+\8H71- &8C%,\Q7(*N.W/WSXB<.R>M?UAJ[E$_WEHSL'7MJO=Z[>:;>
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MO,@['D3"R[UKVBTYV*+.(YN6-8O.I*CRC\4*)N^[+ ^H1R<DNC&Y)O*$19
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M32,/P(:7G7T21^>7C(I6(A 5V<N)<)50M42BB  7PN&)$ </!>]%[5X^A*V
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MG(#ZJ]!KI4?AD.C5 O1J]?1.)ZM(*O0Z"_3*&.B'1*\V<J\&V"E9/Y9"K[-
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M G'V :[$FH &M22;49G!++U"*/#_+G'P6.<!_:;PVWKGNKV=OG,$]68EH_:
M:3ACR[;XN5#\QJ(/7C,W+#,M8E\LV]9&3"078@8AZ-?:Q$)%6ELPP_/A6SBQ
M0[F+R-9C!:/1X:F+-0TS+%%Y-YP%Z!D:Z/8@_P-[H;%GPT8@P\,DA^$G?%RR
M8?)D"/P[N1^\#5 \X!@41"0A/K$<4"\LV) /Q@%736I9$9X6V?E"'&]Z/?/$
MH8LQ(FVNBW\V+.\?<&"6T)1R%.]VCN+=SE>\JT*G+4&A>$*-CJA]908><,8E
M2_(R=H/9_>2SO.<[QP<0)&R8&':=<TE(EN0R!HQ^<CUXVB?,CY'=\'T&'R 1
M T&/@*HI/WG&X6[2%QZ;NQXE'@?:!._FF>Z&DH!9+N$@A1GP'-(HDN7(\(%B
M1]C.6@OG+G_09L_,1M+\/32?\#'<C LK4;*S%4R%5@W6ND]=ZE#1%AL3V<KQ
M;FK:_UC,,[SQ% UBOC88$"_PSZD&A@(H[K =Y!9+6KM!%C]NPP]'OQ-[LH+%
M)ELQ&3 JT#2Y29( #*RU#L Z[<GP1<JXOVD.=2N-;OA/X2NX1M<JX5L* :\;
MKRJ)UYJ+S>[[/%/V,%M(PZ9!EL#%S1?"NT9DS-*EXG6$CF'^'F*&A*[].W3Q
M[N? 7)!F )VYX +@_X'WB0+,0@@3NHE+AL^21 3D@I@QBWF8AK*FIN[ZP'?=
M3-_UI0O7XL'=P!Z7[UD48\"%"S2Y(M1@%CT2,1&\?2?^UPBV_$R6$.(%L94,
M1BS@<U#;GJ8@K#QNR ,C).;"D0J1PRA"&F(@<G$S]"+?!&=,4I3107OO?2K8
M&%MS8F"V-5%(=W"D:Z61#FQJ&RMKX(T&'^,0W=6(^0$H'($UPXN&.WV9&H%$
MBKGA\9M$L<K+<D  (8(BSDJ=E] MC6U%W(=;0V#9^,"_!!Z!<'X"[N9(H>A9
M_A_P"D!Y?$P(>J%EH_1FXZEC_3OD6%GX@)"78LV9:S)[4S2LKEKUR1@CP?X.
ML!9:U6(3@9_0J%)*5*ZBA-9-I+&9&;W)?4&$B=0G/V'%$L@EQ*,+\[GQE'CM
M5"A+@":V[\8^4( GRC1D5J!K&;^L&>R %D.D@Y<E6)VX7CPH:$&97X9.]K<O
M4\ Q#@D\;5)]B_3R!#?S$WQ8>V(.[!D+Z@27UGX^:(''%V-B'V$0P@H3,(Y]
M@#XE.V9D=\J2_"N"VI_2T_0'0@*V1&^?HWZ'9&.1WFBRV3PR>=,ZGR]8,5$F
M9EGR[:/H6+J]=8H%.L8M%$&C!?U^ZMI4TC=)P<<*0GZQJYW,.Y9X1N;2D'!Y
MZ)A?8DP6)IEY[_R0:(L%M#YY G,,T6Z.(=I]W0C0<6H^12'A%-3Y(B80(&-'
MI-B&&PALLY#A>-X"O^"_QC),.)6-B+"B"C-;L),#OL-60?9[M5YCL&T59*M;
M:Y95!=FJ=;K=4JH@&[56/?\E.VRJ7L5-51)2G>[JTM-]ZD6;C>72.('<6U7'
MG6Y!:;IH?/?2TC+*#E]MC4;G'.L?8]_I-E60;Z].]%:*TBRL%(@XB(3BK6J0
M=P-<4P%N-\"]>OUV!4_.#:V2^H2GT:!*7;C5SLK?V9O(TB]RT>R36'NF[>A.
MJ-O<JAYOF<3O]!3OSK+W"E%DZ)CX/Y]B_,A)EM@LN;L;.["P-;3>;'=K5<GN
M/D!?1T4G53K;5G32/A:=]!6=*#HY'3KIO J=Y,Q"39!(>3.>%8DH$GEU$ND>
MGD3ZY8VF/DRC"1D2@XVR8HIZB[]Z"QTZ;C$R&F!> L\(1,<2)F=0 9C_8LSW
MJ=D_-VZ9=\0SXI9K#-2/L(5GJM[CSKX\YM>XN.G6RFKP5X&N(@K;SQ;;UYB9
MFV![4V&[PO;3P/8UQF(6VS=7>%NE*;R*$A0E'-LFW(<2VE6CA%<(K54P]IS(
M[=TI +U)[R+U_.&??POV]YTRN,]*%*V</[:MQ2V1XP?@QK)<&@:1GS)/%'5P
MXF>VO>?F<[Z4+J8(X-@V^,;XO[F*UJV:BJ8(Y(T1R'828HW=OH>$Z"D)H0B@
M\A)BC;7^"A*B7S4)\1;R8S^R"?.PG'2<+.M7R;%O)E.CP!*R''_V[D/H6]@0
M]=:=C2R',$/BBW3]+/(H>8 ].6OMBJ1AJ$PEA?];6T);X/_&$FY0N0PE11J*
M-+8V@?81#8.&$@T*_T\$_PM,H%<1#<VJB8:W$ /B39J?L/'8;N:/<G.<.HVO
M"03ED'F,-*E.>"NE7@ND7G=0ZU7$L:$\?XHD=HX-[402FPO"RJ7R*&)1Q+)S
MF.B5B:6CB$41R^D0RYJ84DG*5K=:RI:J MRG"G#U*,+E?[_U06AQ RPU"$T-
M0E.#T-0@M,,,6-IUWAF-E<H9-M4LGH)&'<!5E^H3[;VLNE1OOBG5I?HUNE3+
M\8"B4W6#.E4OZTVJ4W65R\Y4IVK5J5IUJJX"X%2GZAT!ISI5JT[5:F>J4W5*
M6JM.U6\]XZQ76MO$;%BD=W'3[JO42T4(IT (_5<DA+XB!$4(IT((@\,WTAVH
M7M.*1$Z'1 ;U@Y-(IUZY2JZWD*[_E08=\T >3KK-;3RFTL?.E=#764<Q>CQ$
MV)%'NXV+F^:@7VM4)#],I4PJG-_9$-H4YYL*YQ7.GPK.K[%Y\G%^<]U-M4U6
MU' ZU+#.O-F7&BI7;_4F8CVE#7]1[HL3I^]U5LWZ<1B=>J>4<1C*6:>P_=CV
MS";8WE78KK#]-+!]C26S^\B+3KU7-0^TH@1%"3M;,?M00GE]8ZL;BZE@.N>^
MPU]*RB)4SY?\_%NPO_<8_J)$T8F+HG4&=WYG\P2W6]G>OU/'YL>U9D5$D5+*
M%"7L;(QO1PD;*VR-RB7/*"I15+*S$;^GO&@TE+Q0E' 2E+#.B'\M>:%Z(Q\!
M,?8<#*/R#DZ<V(O,I#VZ_W<:K8N;3F4:\ZFT&X7^6]M&K]#\O].H7 Z.(@U%
M&EL;1'M)AHZ2# K]3P+]BZR@5Y$,E9N:_!:B0WN/A5&>CA.G\74QHE(ZE7<:
MO8N;?KO6K8A70_G^%$7L'"MZU4$7G4;E<GP4L2ABV3ED],K$HOIW*&(Y'6)9
M%U4J1]=JUBNE:ZFA,.4.A4E."E@Q8:&;GK#0E2PB/2O@P!1# Q8^AAYV:@ZF
M3/.M7]H,'ICZ&H-]F=K_A@X3[<KKU*Z\K6M_V8;$&JLI[+OGCADS_<^>.WL
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M3YO1J1:X12O00A_NT1T!7CP3!"QG'@) .*B"*:#:OT,7S\>)0)M[UAB>  C
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M!0 6^F21HHH(/Q2^AS&H-$^H2R4]$/"^Z%TTUJ0@JR)I_.=:^ZA BS&CL"8
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M5&8OVM1#7O0?UJC>'K3: ]/HULVVT1H/1F"^L/IH8C8'C7:G_7] 120^@@2
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MK*=R"2LTNA;OC1Y1@NV[>;/,$N@JW=C,P-&& &7&Y1;G;)>?AM_]JV3S?OR
MR!Q')#I"8-(X9\G7@'D9P ')JD+"Q7P&4W(F/CP1M !T[^*M+<1$2\GJ<1/1
M\SE3)G'8!M+I$P5U^*#3Y4O5LG2VX0#!UFX#!.\<''_N>HN/H)K8+LBJG-;[
M@\X^K?<K8XMTA"T2G7F/B092W[V?1*O=<HY9,+Y@T#V7\04QR[3DT2._IQ@%
M$JDB\:B#4N<+'./H$6D>=KA!;U#K-]O;#C=H#VK-;K>4[OC-5JW9V:[1?O'G
MO4:GM$UU5[_\+;;L'R+AY;5]7G)N-]I\3$<:,I[[LESY^,:Z9LMV_IIJ-[X=
MX*(13*T& 6^KWN.258+T96^E9\</XT5#6\(#Q=%77<M5T\CB-.LU/5LC_1-0
MZJO$J&\LN)_\$+Z-K;.J>Q<WS;;>'_0KWR!2=6A5Q%8JL:WIS_H*Q-8G8NN4
MUN! =6/=!U?^Z7I_@+%Y/?=<]">IOJQ[BR6$Z)WSG<-S/U(94/_"]J!=D>9R
MJG_A,5AO:0C5K=<!H5IZNU]6S:CJ5K@>)3Y;#B_$HHG;JD?AW@Q6 O1O",_]
MZ*%!W3N[JF'<62+4I@RV1(1J D)U]&:]*OWA]E5A2RNDKZ^J)CYWX[)\ )T/
MD6[*]8$NMZ;&%O6TJG</4BR_U06>8@<<1<**A/>2L[N0</OBIM_2F^V]7;.5
M(.'S['H173#F!6(U/N]Z@?D0MOO"/%YRZP>4GX>5S1X#P/Q):07/ABW*VI*I
M%%XR6J1C=_>DDXJGYJ;,JG1:X=3PJ5(\[L$!'R;KT.-$CA?/"A@@X8NSM$:<
M3QYBSP5#LZV9A2<#I!WQ,R6KS60R,Y:6A=C>(/0P"R15C*E=WGZ]]Z\HPY,R
ML!BEV46;R<F 6\:,#9.CNKLF1P6&0_6>V*,F\%?D2'7KG4Q) GR&:YY!YE0W
MRIR2 !$%'(AY:"9@]>+.*:)'(M,TPSQ*I=,2."L(P4)$R8<IFH[ /VQJ)1$?
M3^/T<_))Q)1?HV&6"$<>F2JB+^423Y)@L&(P& 0&R=H9S_@=4^:_&1>;__@O
M8S9__S%*E(>#,#]P'2S$P7H1X)??X<=1W2Q<#3;"P<]#41SS!4[O&;#)7OL]
M''X4@GP!)OVP@+?.M$O^]56T@LEPJ\#^83_1-BCQ7B3E4QL=GM8N4_M^/FB?
M79?7MGSTPB=M:,Y0!@6BN<CEYX_#*_KVTRUOK_.,V>S)-UB.]L#F <\<:=8;
M??KY_3AP^0?-NI[HYF OTA)IQ$"68%4!*!=_4K(]9<VO@B:!+0+GM4PFSMX0
M["S>1J.O:U@4%:U)J8]4X"/3>5%T,FQHYO/,^SBA>Z7$R>B&G'Z^(-XL"9^?
M/IN$]A=KPE(Z(V#R^)T9>@MF>+$LZN*,U66!J>%O0*H/.<0,69' JX'$P4TN
MIT& 3N5%.[!?P.AGQA>@5CU1Z1#O!T77^TOVDOG+[O9N9W. ^,ES?.*]H/X%
M&WR<>HQ%JG,W!DIO'T-\SXU]@W4?7YC]S+["2Z9^WO[Z1]P? NZS&WIY^QH<
M>5^/+V[.MAKU(V[K!YL9*(V\^\EG"[?V+R*_["8;F'6>]::7\0'R,9O:5P%G
M0LK<O4:G,NK#'<!THE0(GEN_!(I-U8B[[U+B176W'T L.6@H#O%'O#F%=NDS
MIKVR]KOE]7]S Z8UNMIU<J/^833T_!U=U;0,3F8O NN T+X6NDBFU'7'RI(5
M/"F_R*3;R-;%PV?[&:&5(1S-<VT;5)\7PS.SY7O96Y'*K6_]TF8D=35>]I7*
M\B:],$..+=1R#%_4K_BKJU>6'1,K7%AOLKE,7S67J<1>5',9U5QF^^8RE5 7
M2W!+'K5FL!KPVJG=CO!BY_BVFX4%W5SIV+ZN\["EE8-.K=X<;%M:V6S7!O7\
MK[:MAVS4VH-F*?60C7ZMT:K<ID!";[G4 3;5K.+U]6K-QNI-;5E#5^:O-JRD
M/8U*Q66/P@95GAO6<IX6'%97;+XA0 QALRD_PYL#0,*_>1 8K$Q[.JH!NTU5
M.%><-BAOWK]2:QWP8(4CI44-B\)MFQ3/JRI-5:6Y6X9=H[TF37:%Z_1OV-]P
MV[R[1NOBIM74>RU5$JV([<T1VYJ$5DYL=F[L5,B'1IK@)M8O9E[_R3PWC];:
MF)O5;S::[Q6Q*6([?6*[+)7:DNHZ=I]+$]S6@JUS<=/4V\U.AM2N%)4I*CLA
M*MN.R#H[ZX\[5&TTNJ ]UO568^_"JW/I\5$!BS7*D]G)5%4M'3:CL^Z![31L
M7370N_6J='10^%0N/JV9.5VV*=(OS111^'2*^+2-LKT:DP8*D\X;D_J'U"B;
M]8K)N0-U+CJ>WI@N'=HD6*C:U.Q*2H/#*HW-QL5-0V]UJ]*D1J%3J>C4J1]4
M9VPVRW9?*WRJEH=V'4*M4QJS*-,"!E3/EHEM[8)5F%(MSM,XJ$[81C'6[&9=
M^97LM;9E'E&>,_\M^.S?FFM^HUASB;I?Y^*FV])[]6U["A\XV*7(X&V1P4:2
MHSR=M;NKSJK(0)'!JRK;ATR&:&+T2.\TLXZ 0DU<X;_"_U<4 [NGN>YB0/1!
M%VKHC=ZV2:ZOG8T@7[1R>MW^9D6>Z1L?;:DWYJ83WM2+-GB1JC [P[JBY0JS
MYEL%A*HP.W2%605AD"PBVVHZIBH?4^F_*OVW9,=\\\!>1IQ<UM,[?54^IHCM
MS1';1D9L:;[,5EV5CREB.R-BVS(Y80VUE>LQ;354^9BBLG.@LNV(;/<H]0Y^
MV583M,>.WMA_;I<J'U/E8R=%9[N7:>YDI[5:%4NK5_A4+CYM5(Y8GBE27B<+
MA4^GB$^EE8^U.@J3SAN3-BIL+4VC[%9,SJGR,95U7QHI[5Z)N9O2V,.\^TZW
M+-]^!=P="IT2Z+11-6)Y.F-Y+0<4/E730[L&H;8N'VL-5/G8B6#*5HC2W:AP
MM2R=L%U',=;N]BK"=O9U):Y+3]SF^77/K)RB_D:# V6"YGR(NG7@W@;MQL5-
MMZ_W.GLW-RCQ/H_D;U!4K*BX'"H^;!>R=GD=)101*R(^9R+>RA(KL??;!H*X
MM75MH:)>1;UOBGJW(=[F07NKM-N@1G?U9JNL@,FQ:)BLZM]H9&)R?'%RAF-%
M9H&NG&2Y/-RSA)/DS:,LGHB9,V@;/FT=:<3R8VH4]I, CC8R;,,9TQ3?O^S>
M@Z6S3%H2^!&==&,ZZ>Q3W[S5F[H7-XU6MY9U>V8^P+B;C3LQ? 1%9M@WGP$N
MRQ7%5V(JGJYYS _M@)G:Q'-G-%!\&#Z%?H!?-[0/H0^WX?O)B?4U[8&QHXU^
MS<>0;V[ M$97NTYNU(\VF:6<8Z#Q"GH#RL)Y[I/0@QOP &D"P[+]6G;C2^PX
MFFV,2ZT??-T>7"2FX<9#W+-=*=*(^MUSY\!R%]^!X(*A8WX"&,]GP$D^6O[8
M=OW08X_P^ ?;'?\1HS HH P0>PX+!5[(+BK">0M1*Y\7]\04YL]HP_*29SZ&
M.7T)Y< S!XK]?:"8Q_6/@?H<> 8!3S,\'()L(-,Q @"5SR=:FVSN ;.DSY'M
M/!$W\@//P(6N<5%MQH*I:^K ^GWX%7)?GTU"6T-GA(\,<.+:MOOB:Y>6 X^[
M(6S:]*_>%0X#SU;5YD#LL'.;^X-:K]O==FYSJU4;-+JE#/ZMU[J-=EESF]OM
M5L4VU:S76H-^]3;5KJ]^^?&ZA7A 44M1R].J3O_D!Z"$ 6/Y[Y'WV\U/SC.^
M6!.F72Z8X?D9'\6V0!J<*&"&J#+FE>OO@F6G<F000J .^V//FK].RX;-6\=L
MWMF@@I#,'QR\(N5O[;G?".!6#R=?DQFPVY#[P__JZ'T_CNKK^V*,-":U^E=+
MAWTM<!Z59E8Z3PL,K.[F)A:7_BC\4UY2V-?XG1EZJ _$QA?8RU'"D'CUC6K>
MHHIO7S,M;HWGOQ"Q=TJ@Z>"DG;;>[I4U'>3X\3E%:HK4-B2U-7V22B8U;";1
MU+O=O8-LYU+G?E1,^1QZ@!NAQ\CY.($[A+]WJUPJ.37W+!2RS8EI&X6LTRQ+
M(5.%FYNQR#7]=DIFD:V+FZ[>;NY=:Z:J@"N)3&OZRI2,3.UJ(=.!BH"/B@Z8
MI1&"I-*FAF>^&$*X^NXDP'\<TP^R*Q17Q0JK*7DS:2;E2-[.Q4UK6?)>K]E*
M]W6VTKVXZ10J 3Q52A6>E\^]UR04E\R]>\B]FYUF1>KU%#*5BTQKNAB4C$PX
M^D.OYQ01GV;QYRFH O>3B35F>P9!E&6=%:J#UQ&JI84ZE#&T&0=<4RJ[C@-F
MF%RW?G'3'U3$V%'(4BJR]-;T2M@>61H50I:W8!E_-9QP E ./<QLK41JP#E)
MQ=[K) !T2_,W*[M@,T9WT.AW%R?3ZZU66<%O9616"YD.&M_MMJN%3&_!R/S"
M#)]-7=O4K-G<<Y\9WEY5@[CGY6?NO4Z$M]NYN&ENZ6?NM5]G*UB#62_1T:R,
MG<W8]IJV^"6S[1X-+QLT]_8T*].YDMBTIHEYR=C4!VSJZ_6VLJT/&75V_, +
M.3)8C@::P)/'_-=K0WUVQG74?TM9MJ_&APX:/NT.+F[:+;W;J(HUHK"I7&PZ
M:/RT5Z<17>W]I5I%;-LRN^=6YOD-E+T]"AQ.FV .FL;::X#AV*SKC4996N#Q
MJVH4 NZ'@ =-?>TU 0$;=;W>*,NHK5"MR0D:*%_ &'FG&>-Q. MM:G 3-;O9
MK '!JYLIK_+\>>II6S5A72-WAC%*?$Q@!/QM,_P#.$&R3VLAE]B:0;3 /.CI
MK7:6/ZBQ&J>-<6L$S=$PK@T8U]:[.>48!\<X93VHEL6J97%53*P=^A7W.A<W
MO:;>Z^T]S:?$JU0]QQ4!GS0![VJB[D+ W8N;;D=O]=LG3L %#<=3^0)+_U[.
M],AV9[VA-H6[-OG%&OE=FM*"9@B #?SOQ@*/@XK@>.R%S/QB&2/+M@*+^:OZ
M_6* 8[EI>*^'[SF#+L!]T058 DD34*+Z5@$G+0&H/9H#/XRGS QM=C_)PO\1
MWYD#^GX.Z/O[@;XJK8,CB,\3$#<$Q.T8- @ W_(#[(&.C8-Y)V!,ME[9"W@+
M:A7;:C=K/6SD.W=YF_%W'@-SRGIFHG^O8+R)!P6,Z_$CQ@AX4!@4/U*!'#""
M/GJP4^!*_'<:=0F=&T_L>N0QXX]K8P*;?6?8+\;"1P:9Q#A +K'XH%U#$"Z?
MOO",D\FKG9'C.8@JUR.+]QT(%^;AKV!/1F7VHDT]Y!?_L9[_]RYNB$T@(=PB
MJZ&,2"-'GN1R@GZ:$_3S<A>.-!;C[MO#UT\?M;MOM_<_OM__&#Y^^GCZA_IV
M__CI07N\UV[OOSW<?[G[B,?2/M]]&WZ[O1M^T1X>X8.OG[X]/FB7MY+'7VUX
M[C.4J,?@@D>;=I$/ND(\B+2-O#$3I(L5?]NG;[=6$)8HZ+"M\@>=6KTYV+95
M?J=7ZS0ZY32X']2:]5Y)O>0[W4%YFUJ]U!H/Z-OJ=;X3%,ZO*[5JYWV,=MYE
MQ;<!BD=R,>4::"[-,9)F&CJ.0-I@X>NO.7/\;)_%==!XFW[*M]J9=7W4/.FI
MN@T];Y>(Y.#BIM/06]U6Y?NQJM;'BL .Z>HOA\#Z=>[D'U2?P Y4*WM4(4V2
M> Q?X8:TP+/@OT7B6!60K9-%EN//W@FHW@J@/B),/PF0;DTMO#UXI[]WDS)5
MAUA!-"K@N.6C41/0J*7W&E5!H[=@_Q!KG7ONA/D^0!H8ZX3MR%1/-TNQ7 4?
M0?H] ='/ %"AAPP=\YOKC'=42K#E2U=O-/;./%#IKQ5$K/6*[:LA%K9_:>G]
M?J<BB/5F=-J C:=<J15^)L 1I=B6H=@^2LC>2\#NK)9TL"))KP_*RMA4VFV5
M<&D#[;9$7.I>W ST1K\JJ%3Y@9UO1@4?NS-$*2X", S!9G/;73"F48X6_<)?
MT1],Z4]K%/-/ IX_.#@3Z1F[^@A[%S?MIMX8[#VE1:GC%42G->IX^>C4!W3J
MZX-662YGI81OR'H]=V'8P8*X+KR&^0$(GR@FK-3P/5TA/PB\>Q &MO?7F_VJ
M#,-2ZO?AO1[[XM"@?G'3T;N]LFIVE&=Y0]YJ8<H3<-2]N.G;4#C6<-,[ <G]
M ML##-7IC5Y5/'U*9ST@,RT)A9K50J&SUU-_L&?FA$R3UX?E!M0L7*FH>WF*
M!5P35$%0%=2Q-5FT+FZP:^7>YIM24RN(1ZN\Q"7C41OQJ-4^$1?Q^:BJ/ER$
MKQE8>FLX8_S3,97SM;R(W /"=QB!=^B8PG=VB[#=FDPP*M?6V[VJ]'55FNR!
MHW(EXQ--S- 'K;WYKE)KM^.[ &>X/VWX^!.XK34;A9Y/LW"4=KNORP!K;7&9
M?UK!]#;TX4S,@R<!3#)<L=C5!NP!M?3TAG+*GB5>K?$CO")>]4FJ=_?/1%/:
M[V9H\9%-&%R52=HNKZY_0N9++6E,D>ZB%-^=%-\/H0]K^_ZM.QM9CFA6RL$M
MC<1=Z61P<=-OZ-UZO2+:BM)^#Z7]OAI2]>I8]*;W*H-3YY><=JHJ>I05@3HY
MZ>:!JPU]4 +^/^:PL:%4]'T<(U\E= 7][DJ^-+I#[^Q/OTHGKR B;> 1V0B1
M)M8O9E[_R3PW#X>:B8%JE4"BLU? [U/M1NR</IQ*Z=[2[T$@S78@W96OMD#7
MUKMME>9[CJBTQM51,BJUR<G<ZIZ(BKVJ&\NJKM7U58VKZ^?5F*4\.)P/46W7
M!"FW7?>N%(8SV =UO=_>-M6SM'LLCZ<K\E/D]_HMDDHEORZ07Z.M#[:N<#PJ
M^16,0D@VFRVU 7VAM70 ;.+MJ!WMJ[&@=IFZ9KQVC^"56_E+HUGKH(?)3@0:
M*@6LA/MK[,YF5D >L!$; U5%G2/3#C$MG+L.]?*_=6=PEL5??4PE8H9/O<WA
M<.YD8HVQC]4<T-P:PV&-@(>]@ZD1:%9 J?..Z>/*$PM[4VH.G,?TPB?-F,_A
M&5XK>OGMX_ *R50; <7Z+GX\JF4G!621><.9')W=9G+@X$C&/EL.1O>_X,G]
MS/2'7CT[_0$^RYG^L,.K[V7GSL*79Z=^P&>E3OTX!.[2JS;OP#T0S<LY5'9N
MQEZ5&1N/*1KC%#9WO6 " L*5@S5\;>Z!Q/+@]4A^1'N\V:MMC'!@@>LM--C]
MF.D:["B<@,@*/6SZ"G\)B:@# ?O,\,93C<GQ0;3$Q&8LT)[9U!H#FZAI0]N6
M@SR6-N9KA@<\Q#9\WYI8&'/U$_UE^4]TC?T:,Y!A2-&Y:\#:5H S0[PY;IUI
M4V:8_PX-+V >3UHTXJV*_2^ FV@/<#L?+?;DZMH+;'::LYL))U?QJIJ&T(5E
M9W[!B33CR6.,)Z,3WYH:SYQ+,EC&U#S#>6+:Q'-G\'N??N-HJXFY-TBY-@E-
M?["983F2E!]A0RG%!'!G_,X,O1?0$7SFQ 0^N+A!KKT 6"Q/1T&VNGHC_7II
M&VG4+VZ F=-&X(;QSQF\;.HO[ZJF@63&VX5+ 7@1C@G(XS7@W\">IYH?PG_H
M!O3DM0#X?<UQ47:,[="DJ#Y@_!QY/@D2.![#%L<>+8?A0T;/\\LT0Y)C^($Q
M\O$&Z84 %W<&\(%%83_6,^"@Q7>YC ,UP54X+@!.VM9DP3'98P:7F[!#0_.G
M0*+7="2Q!J"B:'Q#B&CQ7D8FH2!\O_P )R4\*L">44-(L?,80SDRDXP5PVMJ
MVN?00X_.S/66(&>ZC(/.9W.#R$IL#, %%W3-_X5=&@"C$-WQ5 :0.A$0)TL^
M\F2!Q(R?!8* ,A1LNO0FQ#? )B16RP18:<^&#3?P!*1L ":*#&0K2.P-56*^
MJX7D _2!*5]X3OQ<<\/ =T,/<['QI&G.'#5,(L2^_7H/T/Z)6I?'GBW8BR";
M!(-ZL8(I+80_7KI]QND!6S(AZ@:$=&.1Y^1'5X7-TDVD*W&3B 3P3]3%,$Q:
M(#I2:*"Y(US*Q\L$I0\("K!H0:@DMAP1W ATR0ENF!@H?A5R_1'_+)93RPP!
M_TT&$ +*M#PV!C[MOG#A!0=XP1//0Q G/N<&L=#P\8T($]!AGJ9P'_0]0-YR
M3<)X9$"X#G[LAZB6,B_&5Y(&J=>/IR01\+-8\@$T0-,:\\N4,[#$'CCLEJ0D
M7^_:G5PC0#CJBP0F8!H^8($9_S8Y: M^ZN+88#@38<,J0.+I^;%F$<R!]\_@
MGPD2=<&HY"S4FD1W,_=<DY\GQJ'S(DW#]EV@M#$*.N!;P(#1"$HEC1%N15\)
MS4Q6KB$M@9[CTWU32)+Z3J)DR@*YIOTC_PVR.B/#^O%MQ(8]TD $_0,M_&4;
M/THGY4?I+)L9<E,D\S#I/'*(=&/)W[BX:=6RH\JEP4M8N]6FNB5LJGEQTZYE
MNZQ&FY*Z)] ]8T)5T4!Q %#CJ WNR9'S-N@(.#N"-.0Y<!=0$>R%OOW1&B4<
M#8-UJXZV]:9Z)6P*!XBO0@();]_ZM2.T4R2"!D^"-$#<+3&YA%!$-4K(A,R#
M6>X(Q#K\<??WX;]N/W%+ RT(8T[&YY^"J:)NZ#S#XFA46<M>$"1@]-W1.T:&
M3>:&/P43BJP2F\N&Y\+#\.D<>?2MD\C9=/LZ%TXC!KIXP@82!\A._5ASDLA]
M0PP-U42/3>%!N!S-=OUE[K^E.T.@5OX(S5ZCD_5C-#KG,4*3#%#"A!&S06<!
M88QV_)_,CU4.@CNHSZBFCPU_"O@L1[T6V:U^;"$)4R9UF['ED+C7O69QJMF<
MJ6MMUM5LSDKL1<WF5+,YSVHV9[Y[^Q@\[APF;_)@3/&WJ^9R<AWDY.9R]FN=
M5G_;N9RM5JV]?@3FX8L8-MI\HUUK]_HE30)M#5KE3 (M;U.-6J^YW4HG!ZG^
MZJ7*F1:Z"@M/=;+J(WDXOG*;^U-D<^,PT0WFB)[EL-D'Z]<& 'E]E'J=7Q5&
MY$L<Z3JS3--F1[J^@XW ?0. ;.W+ ]X6N!3>O0K>':@$ZJCIK2)/+#>PQP.F
MW%7'?HD((KK,13[="+;/(\$;X-]A%&XUJU;-JLT$$#.)V#]PV?O)3Y\-$=/O
M!9[?.9\$EG]VO60"9=1=98N*SD:WM(I.-2NZ6IBHZ&^[6/EQZ*^GZ$_1WQNE
MOT8%Z*^OZ$_1WQNEOUX%Z&]P.O1WH'Y.QT*?1@?;C42936=K:F_:#ZA*=[,E
M0\L[XOFPK1+,YG3QWRZ,JUFO6BND$OII*9HY5YHIP=0MI)DL;6"KN=89]9E3
M='&N=%&"";J1+%G?&Z/9I!F$G:XB&T4V52>;$BS'LLBF!;)&[_>S-3U';$AY
MP%XQ!VP)@Y AS,BMIRLH]I]CO:T;^O8B4?<O:X,\-K'9.. &)2ZYMLPB6[Y*
M$7H^2M2-M@C/K-@3%@(M6!!O*%V!FUIQ#!>-I;W+A<+?#=@(P.+GW[4OULS"
M_5Z*SZZ254:6,_9$-1*58[O.$Z]33Q:!&G-CC 6U:$I'!52T.X_.'Q5,I3>*
MQ\\O32[:K2Q4-I9KE:,:L]QRUT5<Q#MGN".JYHK[7(AE:0\ .LNI:31E1W,K
MV;%GLEV)7VMUB=]/AQ>Z,O.G,\;28HZ WT,/>)W/[B.GR =>SO: U6S#&?;8
MRBD&;+9!#6C7LNWI=B]1;!]T_YV+F_9@58FE[-V@C18I8J:J$XF_,1TG4'E%
M2=ZQ\*PPRWZ+I/^CTP,OFA0^ODPAXS&+)(K+0:DYSJ2H O8C&R-_\\17#3VW
M)O:G[,(E!0$Q,WR9CG)K;EABLA^MF5/=3]R0L%! +4)60$O;!ES%I4><,[H:
M\U$OL/SI_\_>FS<WCES[@E\%H;E^EB(@-O>E^XTFU+78NJXJZ9:J[>?Y9P(D
MDR)<($!CD4K^]'.6S$2" $A"HD12A1O7MDHB@5S.OOP.(7RM8!9\O?Z#KX!>
MMOI7A5+PN!&ZZUE@7L.G@7F]%^/XO>ZJS+>@MOOY%M1V?Z=06OOKG&DU94\1
MGL(S^GAO)W,Q33QQ/<,'71'H!<F]@O,<O(7F70DB27A<J!B G5/S: IG0)R
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MK7[+B[].5<'=?>D5=3$]OH4XAM49H7I8D^>P#\QI*R("O&%-K13@!8)%2IW
M;_@S\/\Z@E\2V<,8HB&P.8Q%:)BN*1>)7&"WP/V;V+.8*50(\K5)I%23YB^G
M]_KD4F%U?702GZ_)!2=$D%Q09.J:"CNCP<M#UE7H$7Y[.CY;\=<8*M'F' JN
M% L+..8I!9E9K&%^(.,8VM+N,-](H*Z.0<?WCI<(,B<01S;PG3'LQ; L)(KF
M.'!"DF93%_89!R$L3_S ?!GNN+*J?3[15E>UZYR+LG4^GWRKKW.X'17_Z4DV
M@$S$[):(P58 8\'%'!@\V(_DZ:*1>4^)#925R'2@*!/*RE@ST,$.GAEF.GC0
M#ZG-A?-=G#_ P8G"CTR U"/B&C=#ZBB)@:J=,'Y$WB#SPD![IE4N1 A';IMA
M?9N@GQ.$/L9GPJ]I[\P9>@(1;MI=N' 4YO9LY, H<3AQDUKXF>/FVHZQLKEB
M"?M,.U#/I^")K;(3&6YG"PAL/N#7F):H1(.4&[AUO'&;7_"(<0-;C4M2WZ=%
MST18LA$TK@)?K%X=V%<@#J502?]$_RZU^33)&;BJ:KA3]L)(LL*O\1DND!^^
M"@0L7+]OD8@B(K#5J_ K*SG[TGK)1PYG85O#5$@D8.T)(0D;!K"1'V1C0F<W
MB0&0Z)6FKZ;X>B62HZ ,SA0;J8:[P=C1M^##;,:(LN^=V+F>?4R9XAU13Y$>
MK.R-]_>WV#Y"3FRCM N3QD:(C<POH$5THI'LA%J++F.2@B]EX%/WGL26#);)
M$BJ@&F"0?R<@3*BNEK![Z>^:+G*?TB:#98+DM4 08<4?1OOD.TAZKG[]S*XN
MR,G+B(G5XXJD.7AA$[Z_SODN7-'PI5>$S?+;$%F&M$X?YH*+-4-RX@RS,1-@
M35V]U][U]K9QO[*C]WPJJ;"Z[I9"H,1RCPP&U)Q4$-LJ-G5RW S"_@ZLX5A%
M'U!9P]\\%#.53<CGGV-E$[*_SDTK6^?SJ;'Z.OO%@[S*;=U\48S/@4QGN?3<
M"66QS7L_Q3^"$6'1>BQ:4&HS\.P)N< S-JI8(YB62@3$@08)B  IC,VJ66U8
MH-VAC8X2LP4-GA*S)6-#%KU*5J1%ZRR8P"^T7X1Y/(7/Q@AOA*;ZAB(N,*RY
M]\>HYLHD-\J="550EZLO)DN6G[IR\C,L=25?UWF4S]#?U=>_\GMZIK."G:]B
MWP7W1W_RB->G,AB:WD/N?2 9,*?9L"Y+ ,!M'E&2AA1IG@1-4R$R.>?R+CP(
M,PS+(7N^6UG[E%K?.>2>-]#(\P&9=LT602C[9,:+./;X$ME!RJ:ZU]9IK0;Q
MBI+BMHR*)RNC?S)S;T0ZS<8L4Y,Q:U@:'/?ZW: _B=2 %^V&7%9*NUNB?TTI
MP GUC*A4.@H<(!?WG@K%&M9?@P?PI<%-!%Z;"$,6KKZ%YY5PM>4$_$8E.>7S
MD1OO$O#,\"DD2?"TS$>YZ62 [)&X46;Y:NTL?]=MG@8=Z0D3=.#XG)@[ML#U
MA%?)X@0).+:2 TN_J[^@6R_6GKKV.I4+@ D VCH*/-!'DX2%$GB(G/=2T@I$
M3\BQ,:[M57YSNA1R"Z?NE.Z5V!V[IM)TP>H6>8?&<W$)8^S+LUAL.>R @N$Q
MQ0)DYQZD'TEL%#WD.P1)B+%CED]@!.&<)- [X7<!YS&&D[AW^ :726PV&TWF
M#FI2.*D(1"!+&1T(>%SR\1GWOO8R5O>%'@L8 ()I:SVSI(G'==?VD,UMCA^-
M1JO\W901B$X-W(58JJZK^Q4_I!JQ0+Y^H^ZY"6D]E7@KSL\6TN8]&I%QE#M"
MC%(MT!SXCYK>)5N09!<8?Y-;]Y8\N<QS9QM(,( CVY(&K232EZ3=8[V(!7@[
M@1Q6EONF&TD!)O/#&-?1*38WUC55I*\7.$%GI6)EQE8T/56.5YHX*OZT5D+!
MDY%\2=+B9#',MST2AM7@-[B?!U\^-\=AZ\7'NN)BOUQJP$E1 ?845<IN._96
M^MX^PD[^CAM)9]]$55NX^P/TK(H&9F5ZN"5AX.GFZ2*4QU#5I<AN=P/6Y)5\
MVU=XF0XCI1Y%H?N P-N-_$#3/Z'HLXF>0C0_O4=;6G.1.T4W+D?<Z^[[)1N%
MS?+Z#-;F]0Q(^0,M\YU:9>6K'V%79[-1AI6<:92LRC5%+LQ+<<T&L(,7X)H!
M!B4'K0+:>@6NZ;TLUPQ:R#5Y>;!7KJF$L?*B7#.@4&&G8$)B =>D\]Z,IF]N
ME=Y.S=/(J;Q%LLXZBN=AD-S-BZ=,M>V5@/@TT,VOE[=_X$>:Y\W^6L )MB-0
MTSLN=3.K16:[C]9/'QN-,CF$%1Y-[_*]/+9+/B\R"&XHGOI5O3]?T3=-0NRX
M3N^L ^S:&+57>W&H+_LM>,MX6Y4XJMW,-5(^06CFF0.GA_;[Z\9O:I,WHTS*
MNO/*QJBY#,%0N7^TW=X5)L*@=W(Q+-"=9C/MIEF)/WLK6+MN!3N(M=2M8'4K
M6-T*EF\%:Q>V@G6.HA4L\5,3D^H$M?E-(X79PJMH,[1>Q&;H$U#]NI'CI39#
M46QF]S;#A@'F%6P&$)_- J?1M!FVNK<R<\F?EIX*^!SI$%O*?L@1$,J/I_HJ
M<T"U77J4C0W&_?K1PJ1 \D.%!\,\MPV&^2'-WS(-<;&,@%. .9+%-T748C9#
MKKI,:K)W;@+O2NO^ZG#E(K'!2R[82,4.TD.<XCL<-9HXL+;:%-]>K]$95AN8
M6_:HU@C,X\Z.9N_VFSM<U/HQOL\9)UL/U7V;0U_K:;G'/"UW?R-"$#PT56TF
M0E=.L>ULVF$.#/^-S0FHO/^W,PP &&C].(!;[#@04\9,JS8#8# ZN1@VF]B_
M_-+S. O$V*%/J7K&2(YC)[D-TV.>07+#YJN1W*$,MCI<5?4^[[^6&CIO<_AF
MI:& &T7QLV#[#1YIG5R,[&XW#W2Y_6# >GSK85+0QF' NZ$@! 1OV<U1/M'W
MZB3TY@W^[,36C4;^&Q^4N5N)NH-!J\-./6CUB.AGI^+T>:-6A]TC&[6JXLBP
M4%%.;2_YJ9]I%NRW )$-TJ3-T\,[]83(>D+D;H-"NYD1.>Q1N9C=:M;S76ON
MK;EW'V;+,[BW?W(Q& [M4;.L@^!8N+=DOFMIL6;%DI\C'GOT8I71>Q^==+UV
M4I8$@LQ,NY+]X=AR)OOT"Z=U;3DEB_%@C7MX#Q\[:UB7'K77^]M,Z%+0W&J@
M(R,1YIK2GXI-T6Y6@S=+-T,X"B;<PXWJCN1&C*]RP47])\,!UN_EH_=_VM1I
M63;S<.DET3K<<=6G4G+(B,:%L.;B1P;F;^7F<M=)1P#W^5%UM*Z?_5*X\J)'
MZDO7M[J#H2_E-UV \)2_9OG,;=1'BNDR1!P[.))6HY4/1&?'2B$F(<'+JLYR
M[/EG.";=01QM* ND7EC"AY,H&&,Q8]!5L0*_;?;'K-XR8D44@H"N0WQ YW7#
MZC3\V]-!\ ]AK#A)5IF]LVZ%CR>)AH;U*7#\8^ZRH7GI5[YU/8D#+#WA5JH,
M_#%)$X;O R%<L;(VV]_6WWY\;+7FM>'HY*)3,'XIV[48\<5%\AXI^. %V#E^
M%PH&_B8M=P.<L'"^PS<NI_=N%(21]>G&.M6_/K,M.'.0_Z&B_M_=@/]JO8,G
MNS%A.$8L.S6=G#'SZW_+J9?4/ZK.O\5:=$#R?$Q3.+4X9R6(W,KH"<DRT-/%
M>'HFL)J/]VK-* V"&I8^?WI[_?'K66:L@F/A[ZR9%P3A$[HUV\U^A6[-WYW(
MC6Z7B/!P[?_="5VT2+%ULU6D*$?-DXMV(^\Y_\FF1G@Y*Y<WP0SUI UD&I:[
M.]T =9H."G9 ^+,X:G6!T[^>9+IDEMU>H\ZDF7(]4[VR-SSNM7#%;9PO7&Z:
MY$;&&BAP,S=,D?B*"Z=IU>O.%WFBL-T1]% \3Y>)*8ENKMN1/F1@8F-1OIQV
M':\P'$%DHI4$8O?\.XC>/#X.*63J=+V:*>UL9[^CCT/9+!-G26KD/](2<P@&
M1(]0++;K]+I6Y,+J-.O"5]N&D2RM/HMDNK2?)*0;HE$YCP1N@I"O(:%,2-R)
M5@=DG8)^,RK/UYW@J=L0#580*Q"0/.E%EB[VSQ@E>2DQ<+F?6JZ$%\+N@[P1
M(!6$#RNX#0,_)3N<>Q8D&K@.)\8$_";]%KE?O=E!Y<WFQM" M>N*>Z$&7Z9(
M6Y=?K_YV^<]W'QC-)E:X<'(.-M@_#LHHAJ31P" -4-]%PU>-]Z].VR9X L)9
MB_YLS83LC)@*;%)_ZCCM51W]C#:041<LW][F<=H5U[<!6<(<H(W'5AGT8-0#
MXZ'3+9BIO=+Y_CX5>I'[0XD=)MQ,U7.9N##%1'6P@ W' &^\\O\&[U/ROO(Y
M("IA>Q/VPVI7^1,;9A2  35219?^](,"RM#M51&WU:1:(BKIL$&HR6POS9%9
MX;K7_>G]/QH6*)75JONGM'$LUQ;T+#_FL%IZ!OU&JS^JVM+3[35ZW6K]-F6_
M;S=:S6H=/66+:G<:[4&UEIY76M1@TZ->*S^^9:=(W8^TJ\-Z>]TW==O2B[0M
M[;5(YFD5D7O-AUZ'+J@Z,.AS>GP;FJQ2#U<W3=5-4WEG:[BISOHY =LTQSX:
M4L#V)^J@JMFM9K<\NXU>B=U&;X#=7M1S. :>NMD45-K"1-BR,O[-%\!OT'.7
MDTFR8(ST=^GYJL@:Q4 K\N"PV3RYZ#;M5K,LSEC"@B_#3#4=;"6 7X(.6B<7
M[8'=Z^2K0_9 ![4G5MJFH!VP;*>O;4)9[=HI>^--2A6;W#8(Z3_2>R!#25[3
M!TZ%5>9+'$EN=X9UM]O;(Z0-4G['A-2A)N)6IW.HE%3WJ&TM_)]H4F=CO,6%
M_VMK_]^8U[^[<SALN?2"P;8LY']EH823)H=->U P#G1]!&!G5_>RSDO-<37'
M[3C>]DR.P[*B?M_N-LM&:AP1QSW#8LCWGV6@9^OA 2O# SK9.IQZ>$ ]/* >
M'E /#ZC2O_2BPP/2@>J5BSX_8\,+(;)?S\Q>[>*ZSB'VF!Q_76=Y_]PLP?X?
MHS_ *%Z'KQ!*OAX<*LL]:;*3GH6UX -]E+.W(EE &KU@:>>>3C%K,;UN+2G8
M'[UNIVHM:1\T;F<]?/JVC^IT&NW^LY#8CPDMKKC,[)] ^-8'[C59'0'WZR["
M\'N.>V[E[!3X#3N-RAT& 13OO:@NL\HFC]R?WVJ+;\=5KX#TDEH57[7^-) 9
M>)XB:(CKV4<7O?1_T@C%BL[\ ,$0>[LHH#DL>-"CX/O>3X8%NA]&N?*_P&._
M/0CO7GRFWK;M,1^'S>&183Z^*<78_\G@Q_?%(*@ZOCT$E;4'3B0?@?;H50T%
MU]KC^<PQJ+7'ZS''/!25"R9:S9VQ1ZT[*K/'L-8=K\8>'X.DLNO1:IU<] :U
MZ[$?[A@1Q 9"=PA*M-6ZI"JS$#11 :<\7N)Y*JZX]*??]"%7\#M:[3?J=^R#
M*YX:@ZQ1GI\3P:M1GI^J<RNK4JS,M5NC)W3A' NVLUE;<X3)TBL?J<%G!#9&
M8\2LI[H4<TE[1UK.0R@7("VO1U6V5P#B%&3/>E!5A(X*Q<1SHHCQQ^+ FB:"
MCDO"G:FI2I@N?@/0JZKARI(E^<^ H%*/NO(GP4)<IG!9\M'OW0@!X9)0E%0E
MM+IOH2I!GZ@$CK.HID[2$A8>H-G+,**(.><@M!S2,A(7 MP)^D A#-H*RA1^
M#F%!@"->IT)A_^!3H/0:359\52H&.H-&L[>CV>V=QF"TFX'RS4:GOQ'HJ5X4
M_7[4Z>YN4>OW]QR0IV.%NJ+HHL6Y*:P%,7 7G]OZ?JQ'<@L2>/.![ 81K$K=
M^8$?VW-!OLP=_U2GM@VZUT]Y,#4Y/9^<?@98 =.=(T,;_14,02!JM[MBE;\<
MB-(;"Z7]S"!2K>;ZB-FJ@_N4P%D/N-5N]O/0WD>#'E6#M=5\]DP^:[T\G_5K
M/JOY[&?GLPTS>G?!9X.3BZ[=:C][/&_-9S6?'=#&J_'9ADSK+OAL>$1\]DJ%
M&P<":E?%[:PK @VNZ;X\UV"Y>-ON]W95HW  4^!K$C)(J/?B)-1N$@9==W0H
M-:,U">V6A/HO3T*(4]NS6]U634)ODH0&+T]";>R:M;O-0R&AGR'!\#5X=+SX
MT?JH9P!?ZO'&.S'T?HYJ]G9K SKC+OBC@^[1<)0'BMU/Z7J-.[Q;"MJ -K@+
M"NH2!35WY6#7%'10%-1^^=1>NX>PYX-634%ODX)>/FG5[B,%]?JC Z&@GR&.
M=\EX]8S-I[#BLG,JZB!>*5=LB+^8AXN@0=*.?M*TE_8 6XZ&!].[6SO1NR2D
M#5&8G1+2D$H#*H-)UX1T#(2T04OOE)!P%J#=[QU*3*8FI%T2TH:@WBX)J=-$
M0AJT#R5+M<'N>QJ$_<_PJ9\A*GK[X"S3\*=+S9\_6?2STLRL+5.4W$5[C?@H
M11*B=7(Q:.5-WP,9@U4'%9Y('%LF'S<01QMG$N?-V9HXCILXM@PX98BCHN%!
M,![=?DT[;XUVMDQ);Q LF!-IYZ?KOCIQ_ R!2#;US?_^%L2.)P.2.ZPK? 9$
MU.$QQ0XL,8)56XG>?_@Q\1(\"W;LQ"?$[5CY3&5ABZU?37O0?':2NM)%'D$D
MX:>ER!+S[]4HLD\4V6Q6'*!>4^2;I<@2F_/5*!+;B5IVJ[]C4+F:(H^6(DLL
MV5>CR"$XUR.[,^H?/$7^#-''CR:06EV%N;,PY%J.R3/%Z.2B5Q UJ N=CI]0
M-H0DJQ%*MWERT6_MJ@F_)I1#(I0-X<D=ZN!NB]"&G]\_4]/1 =+1AE#E+NFH
MC734;C_;E*O#FL\.:SX9H"MK1M<P^#4,_FX2\$^5*9V3BS8(E?Z.8VBO#H._
M@WA&S;,US[Z*$_)<GNU2W+O?>G:C1<VS-<_6/%NI7.6I/-O#6@2[TZQYMN;9
MFF=?Q_=^+L_V@6=!S[:?'0#<,\]N,2(*_XUGZ_H)]03PZ!4\"'?<[(XZW='4
MZ3>G7:<S&8V%,Q'-\6S:'K6ZO>[_UP=[Y"D3>+Z*91).YDXD-#!%]%5$< OI
MOV_%1$[3_#T(P^!!3"_]:?I+1# 34V-43VY*3Z_)1 ,;@^_&\G>XF*?/[MG#
M.*0<<#H-[VFU&A;]WQJLCV<.U-GKA*)6CT>!74_B8"Q"'!_4MC/3M0C,7DPQ
M'A/0']:AGM 8L>MP['X6TX;U!^PLW/0=6WW>6CKN-//J_ZID7;2S/D$_DPB^
M"8.)$-/H8Q@LY&+T6K:36OV4X#':W"MK,X7[\7"MKF^)'\![_IW0XYQ(BN#<
MIU!,A'LO; L^Z%C_3IP0#ME[M,9.Y$:V%=(*@?OP*4 /S@)D76R)?R.$('R]
M]%Q@\6.LU%P]FHP8;V=.!OO0K_P(>!1O0Y[-;8P3JFY$B+,,G+LT<W/>3H^A
M#<([=PA_PA[IRZ]7?[O\Y[L/UIT7C&')O@!I"]^/<  ;GD5@W8IE+'"Q5LOF
MZ6LXO:KRQC+(,9T=;0RQ8AIYE(8-6\/V\-"BJ:KYW=DXD.M!>![^;^5=9M!-
MND_9Y384WDQ/ /1-LS$H.8)Q"+H^F( 6&^=.P;;<F>4LEV%PCQ+@BF?DB7L4
M#O'<B36S@U+"67Z*$Z:6<P<2X0[6;7W%CR?"TH/3;N209WPY/ )3^_'!"H?>
M-L*!:44SPV<'M+3585H99N7O(H'-+ISO @1%@*/20/);<NPU?E<=J)(Q4W<V
M@V/#&HBQB!^$X"NH=ER=9O%Q*<,B2W4?P5JY)!%5^;3ZVYR6G N=DLAT#8T0
ME<V=>]P^[!V5"M$A6GCX;#[=4"JD$ D.CT[S]0.\%+Z*C6LAII2F\ _0V3XJ
MK>P]65(ATC,>YB[\Z2%(O"F_'5:5>#$ISJUHVR'R7GD#27Q\\VZHO?CZ0$ZX
MP=2=R*6HI56^R\$6=]FPON%80\KPE)\%D#=-$1P_9EC!H'8G%!88ETO\,:XJ
M4-OM3,C_ZLO'S2+UAI?TV?GA+I)%D<P<PO8;^;+$'VK$J#+%D>UQ\&AH)4O<
MD@/<30_%#U;>2?\%=H*@N(U\&*5L)PF9>1/PC1R7T(Z9T:(&V*<Q?(:%JS4#
MZ;K9&&3].173!%X*?\(O>#CQ,HS^;,T$Z%F4!E,!]",3@\0WSQ)OO0WB33Q1
MNO6Q;;N )++2[0&(WWX>@_>V5F?ZI.%J*F\'[=YNOU'FK"L6/V9_J,W##T$G
M.&YHW3M>HD<$K_-[G)C'M:)NEA^/0UB!O$L<(SPF71+XID3[7__7L-T:_!:!
MIPQ?=6*FY5D2@Z-M. %(Z!,Y,78LI)^4RD(PM5CU>^Y,O]X)0W0]F*FD<H)5
M3 6PUP)V/+62"/< )" F8$])_H0+^0Y,.W5BQXH"X',TZ?CK)'*!K=TI^8.?
M0'I[5@?4VS*)(Y3K;@0K<,:NY\8XE!F6BB]P& =!OY#L03!1X&3NC0+-A8CG
MP39[074ZF03AE,H\+V_?6=U!T[;>JTFZ^)MA!PQNI598Y;C 3BX(#<?WT8DJ
M6 &K\>P9T8'+4%1%HSTK8W*1LZR(46O]"FOXH):VWDOI8ZU*NU'@@?&&T^G8
M5A+#G?Q''3X(Y&@I-R]/';40G"GZF&@+1<DX LL#"9L=6/)#Z>(DG4X5D2ZU
MV46DN7"F(J.FX4*2Y90HN^3BZ=B+W.#&2@APT^!UR<+=-C@NP.;+("(U]"N-
M6X97IA.#_Y0-1DEYU$R_XHRCP$OB\J\8D4&>]K<G267,0N3C,?Y['JK5+(&$
MSL%K<[Z?DWK]U?$>G,<( Y>F= 9!+!\^ O<7WK^Z^](]SF8OMD?6"<!(04AA
MTU_)VL!/P9J<@UF+-0^1[_^OS;%<L))IW#D*MW<H,GP$D',NMM2:PZS6'!:-
MGGS](9,\Z/S+[></[ZVK+^^NO]Y<?[W\]N']\6_JR_6W#[?6MVOKW?67V^M/
M5^]Q6];'JR^77]Y=77ZR;K_!+SY_^/+MUCI]IZ+@9T\V@8XJ\%V^8YVK,#,>
M:<+@O'52]M?!8 A*+B]L#\0J##PO>"!-RF/NY\$#:S94OO=H^& (7&K+U!HR
MM2O^)7)_G"_@C7-K2<ZW)?1$:=9ZG29% +JD01^%$\I/O!<3BBO*3W&<H&.=
MTAN#!/8WC<Y^+26_'%<5F=QR:THY4LX,#MESEI'X5?WPFX(V<GTZ*OK2;UGR
M1AVRDC*CU_&?I7I!73,B#2,+7>6+UX]M[PX;[6:U"?#ED^%[S>*75)TEWVXW
M>MWUL^3WM*C1<P;</ZUE\16_7U"(<( SF%?GQ__O<?C+A9HA;VT[U[H^2Y+%
M#\(#)\(\3HO.4\E'%4+]^:9>*WT]T_K:T?HZ54CG1E1[['CH2S^)^EYB$N*;
M+C.JMOFW4TC4;F_"RYQ,0C DOZJHU[LD#(%F+_WIE\"?\#^JUA?U$;ZJ-[1;
M+S_F]Q!ZQFJ.JSG.Y+@-8W5>A..ZR'$MN]=Y-D#'BW/<S]!=MR['ZG)\5B9;
M7\SX?)M(T97 ]MKM#?.)U*U\#$+-CI59KW=RT;?[G>=@-193^*%#W[QY\NEL
M&$ZT$_+ITRC<=D$M]JO3S\_@IVF)+,L8L!(NN/,Q4[IK3ZS&$MA>$N]@2E-_
M4,_Y>L,4M$D8[X*"L)9L: ^[-1#%X07.A#]];M3L^:U[/YD/7VWS;TG8;!I7
M]!(^/-9_]EMVN_M3 !'7'%=SW)[CU(/FSN+4+\YQ/X-OEC<%L@,_?WTQ#VV+
M[V^^VJ<^^157]C,9E%G:L4'\I#71N\K#/D.__01:[(AT5<6X\@9E]4=*:E1P
M+BGQB7 -@Q:.(6P5C"$\Q@ASS1=OF"\VI#YWS!<X7\WNM?/N4ATY?X6)[%L.
M8Z]#G\^/1K2?,_,VSS<(C;FSTIPZ3'Y8M-+9+:UT3RYZ[4,!^/X9W!<:^E=7
MA;Q^*C)MW9>*C7BB8'[GS/TAIN?_$6%0Q# ]Q-8>MEOMWPYD:GA-/J]3%;*6
M?O)T0G4?^41C;;J^P 6_%S,1$IK:VIC0#E*,=9GP3UPF7%&.;,@Q[MA9'H#1
M;P_[SY$X=3'^8=%;S64'%ZH=/C]46Q?@[WB\S388LJ];1E0C@-<(X!L$UZ8P
MSDN40XRX'*(SJ&?FU)Q<<_*..+G[^IP\I,*FGMTLZ$HZ+DXN0?C/(_K+#92
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MB4'"4L*A\B7UUQB@.UH>QL&>0#Z(1=_OVWWX3V^4AS+?FIY<>CU=1) >U,I
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M1DU,.C4;1;O3A0>95!MLSR^<XQTYGHZ>\\$4C^_6I$$A=S>2E6:4$%#'HPK
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M 'N!6BL4]PX/:\J>K-PVGZ]$,2XX8I2P$4*O9J4 &EDQSHX34I<H?T&CK*)
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M.))YL\+6@Q70Q4^E/$98G&ANS<#PK>'%U\.+#\KAQ2N892-MENT>D[R8\_.
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MI2O!G,,\SE<%/W\M@UHAA;\7,D^<*5-YNV&>*P-KM! *"']5#*..LGO*8_9
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M]#@D0UQU!'-(J&3-1+.X4X-UY3Z-+BG]3?@KJ$AJ"I0/T,D=J0BX:1([></
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M)OS!C_*MV3@9*A*\R&,:[%),+_] )N&3#X5#87!,MV!WG^=,,#**V3RL3V<
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M5,8T$>=3QT6008H\?((OA0[2;28>*6ANG RAH2"CP85Z-@$Q @Y.:L@'L-A
MLX-<-)\BN/\1$B-0T.PQ^(0( P35^H_N>/;<?R<@RS#4-I%EZ'@@P,/NF*T9
M&X?@S0+6= M0:*'C2SY[ /;G*BDQS88^,TVO\L8>CS^(\4U&XN9ZXW0J:7LO
MR<H@!%Z4,67*TB'VF0=G Q^]DG271,J&LFYD+/+T?Z[>WYS1T:UJH(9U+9^9
MOA0?SS$4.-X[$OSXU0B=<P+2(EH7/R8>$!H):*7ZY/K,ECQ\M7XXDH8,$D0K
MJ-@S-!G6/MQ8H?D"=7)W0#UD,@%[QEP>VVH7/U&*G/0I] XNN-,GCB2H"\^/
MGKY20D*AC%0V%L+/0.SRD1CC;PPK V33E/)240D5?:.A2/ AE$*,=YU^Q^9A
M2%HERXR$#]\"[I^ <+X-)J373R^_W9[9:8SX*Q@^KBS\U)_Y\#7S&?5[3/2K
M(,9G%_36V)5ZR"_BC@@>=/ON\]5[.0&NZ!/&H^6:K=.K][>7\!6<#>S?D6U&
M7KK$%I2R/N/I'(K]3?8E6;@X8(:MHDG@8P:2!U[YXHZ_BL,EDX6%D^UQ$ &5
MLU@@[5%[@VGJ_K 60''<V*1?<_Q,4HCSA+)%NVT.SV.EJ@OJ&GB0PICG#FE9
MDF:F.3) XQ!!@\)EZ/IE&6B[<T(]*'::A,H>(;LBB;#\6?T*#EO="%^;:JZ6
M+?E,<=1\S0R);[ -K/25.NF.]>[ZR]\_?/V65J.FZTY[U&3.B]K/I+S.D#@L
M0+.Z9'V9N+!.__+[MS.2I'4]F5E/UJWKR0YC+7NO)]L3!:Y.!9&2!OY9)&'F
M89#<<?964.3 T"T&= -)+T^4/$((I32 8>/S] F4+ W52D!B@!8+_"J)R8.9
M7W-IA.XN98#H+6A%%0IK#:F(,$K&8'20L<W%!!FG3"HDU)L$9/_O!&/915%-
MG$-2$.MT*&LKW1#2/:?NF1SV0<#3VG?5U2^.3F\$..!Q)LZ1XN"QOFO874&8
M0N23@CUUX<$J:^F #^K@YV>))S48(;;*DA<PHS XH"<]:0+F83\B-1+@>!!U
M/^;9(7KX"SE&F#KCXI,4<X7:8Z,D#(.[S.]Y%"&.2W:B /WL1\;@?^0X(#K6
M<9JWDZNTL3%\SNXYXEGJO^O'\O1B1%H)[UT\;XQ4F5&^11".73BE1PJ#9H/-
MJ4VD_:VB*\P0! ]-QN]]DL;J3;!4V&@WL%IL3:1O9,Q?GC82NS,PG>&?[XD<
M3C_=7+X_.Z*0-ZY7-W,Y6!SBT( F8T&XD78+>.0=?#.!U;\#Z1GAC!Z;TWL1
MQR]EW&@NLJ,E9V2&YO<1I>RQCCF,^#D5^O'>EOJ&HGP8.ZW#Q5A:E(["H- ;
M1P\4,QB7#R>!#\+KMME,515<1G&= H.4G7_9J1BD41Y3>Y2N2SNST3QX\"4S
M8B<AEQGP[#T<I>C+\%'"U7%.P6:/WX>YC(C _=10+V)0!HA*" ?:IQB1PVH9
M-O6=48K@#S,7P>J0G[04H7HSD@L*1EVZ2@\R6TU5;'*VY9:/4Y53JZ2P0G4Y
MGD8<?RF,)1<9N&2VEK?W/*&*$/[1S=%Q1: 4. HNZZ,^I7,Y-$D*'XQ;NS'6
M8R%H]]P)F;T0JB.2S9M?K^$I 8.%K"POG?(IT9SDLLS7Z]P'@UNMB')9)Z-J
M]*G9FAMD3?<K=TX@#3##[#IW?A"QF J% L[2JTS#U#HJ0&FGV E9L8,X<0/:
M*H>3R6]4^U7GI@-'QLGGM$:[(Y$:G@0PMPY\):!IW<3<LQ54%2TC_N?ZT_GO
ME$%3@:1I@&V6UD,0?H]2^<!3U+)WNIX <PW$>CH:[)9.%!,\= >F3:06)L?Z
M2-(U%QA- JIR#2G3J ^E=">XY+&H!.A6@\4=9G>>IJ@9:%=<C:J.IXM),[[R
M:E)2FPHT+<F%TQ2VU87QX"9UY$.+S'72^UL1GBYI?RJ^G2H&E(@4C F0Q39[
M%4RQ_7F-7]/:9V4-7R<Q)E65</CC]NCMDC(,?>5&I):"K/_^3SZ:NI=*$/UR
M3%CXP0-*VF6HQRUFZOMENW.FS/T/GV8Y?OCC#,=.^J#31$:&J<J>OV5SNZ%P
M%^,DQ%VH? PU?E@?0RY'^%UX=VZRX(/\(M#G\X"5(EL^CI,:&$;UI\2DM"-4
M>J9X_PL(#73B5<KG4@:&I.UX"^9W0I3Y5P&.SAP4![B-Y(=\!"$)_MA?_O;W
M\]N_GTE #,[JW85"]B5JQ3')ID6XFX.&1I&W#S8&&^XQLC;7-*KBC:P# B?
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M&)!(YHET#]S\/V0>98 T$%)7O?5O!#6DCH)XD/1J ZUT[$ZD8<4]U$A"Z^M
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M8B2U'5&%BM-6I2H-DWS"JB?#.]Y]X(4_>.RHME0TQZ</O*UAG(PN3KMND-.
MH]H-)\V#YS73$I-::[6:OUP:-:O9D:MQNN_4,.MZ)WT!;_61%[0<M9W6.\(9
MU4_1G&^AH(.'U\6(I&)B>JT\;4<W 50)R!)^C]6>^;E-YMRR+>-*&PILIN)'
MU>4MK!6])X''XTE<H][Z97%U$C6PAE%6(;V34W:=9L[M#-3D=AN["LVO\H23
MO:BSU!35@R")+\FH74Y8TJ#N)=2(<NZP%I+&2(.0S9<R!J5$?=)M,!UC>4,#
MWFN]P4EU" *%2S9K#[C-%RS!>@UGYF:29TEQUGX(HM_FW41<>S1^H+RY8]9
MM0$O,F_OTI6CSK&V!W2YH>QK/E_LI:N:&9J4J&PN,A)6=/6?F<)(%-E83FT:
M;:OQ"]^'I<59SKM8@81K7+J0C)^,FV7%-[>F<0N;PIB*J6C0FW)0W*0RIJEP
M08+"4S>Q'/$3SX#8,HEO$682IFFT&M3F:XE&W*:(G#FHN\/:CWJG5V><E[$E
M"&;!9/)NL;$&1:#"#[(>#A?S Q,+9.E8&CJ[?8 =_D!\0*^WK":S;:L#)X#U
MF_)(G#J<T<?T;8CBY"-.M?.ZU<1G6E9-/@/G:L,SY,)6S\UW?TI;F0W)O"$
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M."'\BBH92L_1>MD)GAK9)U$CZ4.3;5LH1:'1JDF#C_UIA-%B>@-&Z)!S,=T
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MZ!NZRN]"KC7ATUYZ3UQ$7[O6UE;A1;9_FIREDY&@>(C'U % T+@RY!(A=:3
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M_UXJ5"HVJIQ:E(0@?22[],D3W\OEE(H!)EXTD/!#FKQSPUY*,;B=4BA56O*
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MF!E=+YDN6UPG0?YVOWIC$4;^5!@S]T'%IWMA%+C_)Z9BX!Y8]UW;,9NU#:L
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MG<+(FV9R:A\M_J&+X9)L7$*>4-&"C@7PB5OA#@< XHA>X0*K<E2^MD++B3Z
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M<(J96[<Y7*,S E%3\I$SZ:/S357A%V);@0-+1&R9&6'2MNI6E>;RPH<2T"<
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MVQ"Y&G#4[I.7<.R$2PI/((SKGVQH=X ]?2?,'=]?_7W\C_-/GP/1?X,OB#_
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MBATM:?/QA=3G:WQ),26=P)K442F,EI#2DNHEMRXRR5$T+^3;&5V? O=C$>E
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M&/ 4%<T1A;<^T7(O?<GD'4JI\Z.2;86S3RE;C\.QARCL$:E%7,%!E%G6%AW
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M4SKX6I\8S<#OZSKE<-R]>F <1N_WY3KE;/4_?[NP$0Z+&N)-Q@:949+AAMJ
MH@V?#D):753.)R,\9[;US();(!WJ6N- /%G'U@;ZZN&:3Z:#+LY/R+,OSA,X
M3[V#3:!VNJ#8 N9A[BJ:JOFJ-]]91QUHM0)@W?@7QOIL>4V2O%;!*T"6*E9)
MKQ6KV9T^HJ,C(;'2.BED$UP'N8+HR9_FRCCP/E2"KHV% A2R(D I4;.ZK02>
M;33D<K*<6C= .=#^LYD;WUZ_.VQ VRBG1W?C4U_N'7XAT)@70E@/UQMGDDOT
M7KE(8LG(P=59$B'PDA(SG&%K)VI+B/OG4S=U7XU&=M15C]O.V7ST.<SQ3=E
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M3Z.LJ>UM DE4HG!T5.C0/,*P!LK#S^C:BA=K3OA=]-/!@5P%JWXYQ657I$T
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MRF.Q65I(^CH!7 <"+!W%#8!ULD[6@CJ,3=)$=;?380>Y]\B,60LP1R%HVV+
MR=T"97)-V=82H@JU9$\7G5J/2M@S(6ZQ-/;+AVW$W9\'RV/+)%J23"#B, B\
MM@JRP8,(V6F;K6*F=;AD)9#]6PV-%'6S^N\@Y0[&P7*,V;LP7Q \Z<3KH':0
MHDXQ&YJ$<<G .B&+H!]R[#4I;HGAL9@#.\GVNJY]2UTOL_PW0-3) +B.YC G
M_VY:ND'E.XBXPQZ_ IGRUF:F#,@:7E5*DE\BDP'-<BF.ZXR^=7^T?2G]EM.]
MM\ZWD6R_C.<W7W$Z'GW\-'\Y&H=QJM%W@OA^4I8U.")I'C@KH+49^KK7_I F
M0A;%)JNR5FC[Y$'?!FW_9_ZN6ER=&]U4!=V[)KX,"4^G/+!B,:F4@3%9T^E8
MAE!*H%>#C)7@C<JE-37683ETXY/7'1IOWU'2?8NBWPR==CY,EJ-'G^7E,-+Z
M.:*JIU-*.\@Q1E"%S%5?B+3:&4X_RK6>[S(E-BJ)O/FI#UOY?87<I85BP2GM
M6XOM:IAK//L-YT?<Y")2UN2E)#*#:W*C)X0@K!*T%RJ"UWZNYDHH#YL0+>7<
MH:7JV^DD(>;92Q+"A49; S-+T:4P0PYO)E2T=@V..0/$2>VXY4[EUN'B&^ \
M#AJTDG>' NG+RWV'7Y;[U>D4J*"234Y"#IGLEA0+>%(?H,QHO!-:*=/5/KB*
MZ'$0HJ'4.Y10_XW$,GL]F<UP]F;\RY]S,F=/1K-/P[%6!M+*PE,1G&QD5YN
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M/9Z)CF.['>WV[)XG15Z0W8Q1DQZ2\MC[ZQ=)D;J28A695:2HF8AIJR4UZTL
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M%H%EI^M$'PF!6PE1Y%QRXM'QMU;F,X@=])'SF'4#7"CI$P6Y7-<V.V5K?Y4
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MB"+(B<M3ZE"<.*Z*G9N3R9E-Y(!E4!>@[)D&PC<$:\&P_*W\N=&;C> 69/G
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M+N/5BH8N2WG$8, YA<CG@?!YQ7$V32,OP"SR'&*>"J?"P<P*VQ'OLA(>MPR
M:LO!!=EP2A KALKF!$XS8+:?+8?EE4C.0,^.!'+'$/@Z#>1E"70Z8,R14*=$
M__42['3@&4VXTUK(L(BI:S_#V7!>Z: X[<W+[B.W^$7^JJT V,B@WN>T/25<
M/^-L+1G[4)2_B&?K51*&#B(.AV&"'(CB*('$23ED+,:>&WF(\U"KMFDF1F>V
M=BU5@'NR3:G3O21\08'37.],S2[^$=Z$GOEL",*&'[ _EG=0A$E>P/!S'>/;
MJJB&=VEHNS=ZO?=&&P$LUDG-#+&M\JFYV%RVJFIFL(^*K>:F9R,\\S'KLL@^
M"1 W92EX6+F$L=1E$733I(G6<$@891 3Y(4X9BE-8O-HS0F*<V>*;>,8ZZ8S
MUCK;)LQ>@761WT.QZ.,E 9Q3*)K$<R[$YL+PSI:Z,(-;^G/%>T9$G27\<XK>
M*T:#1L0?#PZ-/6@TUO*9YQM^DPL5X%7=F:%*_+?I>)<RZGG4%[KOL!BB" <P
MCE,/ABEE8<P<E[@ZLRS':,T>P6V(@YYZO_%7X*FEKS6-<12T<<VW#(6>SI]'
MX=8V"EJ#*&VA83I]TA05W;&3*G).S)H<76+) 9,JLAQ,E51ZQ#CG5J9%?VS;
M)[84NM2W%?&<)/8(@HD?"X<FX5Q:,08#1UXL1R1EOM;U\@BMF:U81[ES9++^
M^]K=3&FGS)Y%3,UYL82#G@GK(>B<EJW.OI_ P"2S=4HZ>]FK9RDMG:$Z)?*)
M+-3)1PS\DFM*RPUGOV9KL5Z1\\Y8O.V<Z]AG+ F]&*9QC(5?XB1"HV,$D>,[
M 0]#SZ=*P7,%6C-K=$<<//;4I3_21"3J ES+NXG_PW-.L<;&/(&=@GMB#Q$]
MW>[!V!+N=^(K\';B.*(-@X9_8@\.,__D ECT'!0U04<=E(DEEG-0U&39<U 4
M'S%S4#KO1P;\WQ9Y<^?XUZQ^>+L1I!YYJ7DEK;C:_">)YJ:J9P%\$SR GHE9
M+K U!;>T0ZM2772WUH3B<.?6?=SP8EQ\:S[A1][-*4L\F:[M1S @(9-37Q.(
M"2:01#%W:$("/]*[]=Y;?N:]6A(#DIKF$+<S6*AINKF$>@JM(9S^K?))&6Q=
M&>\OONQ]\$G!CBY[3W_*\"87K_GGM,G<O"TSROO.X:LT1=PC)((X<5RA6E$(
M21@%,$@8"EGD>@QKJ=8Y0G-'Z].4-XT,GR11\"3VD>;VM+E'9<5ZC<MJ]UO=
M*]5SX*GIH@U(]+2RR0&1MY%M\G1#56&H@?Y-Y(1DMFX2SY%9]B9P0MBCF[RI
MS^MI<C/9HWQ9_?9UQ1EG8LMCT/53>=4FYZ>YE$+N!7$<NIQX+%+1V=V2,VOG
M;U_5%&X@X[AJF7&NIT2_?;JY>_\.?+V[OGM_GG]EG3EF>:0W0O?A5CFZ?^ST
M8K#4(AIPS'K_73_Q%[UO->/9ZGU>9_7+'?Y^P\2!*4LSVAQTVPOM59 02GRQ
M+3D!(N++[E*8..*?GL<CA,*4"<]P]<Q+4DQ]W2=IZ7R7AA25OU(M=2#(@WWZ
M70:)FI9,8S:N/%9QT-,I8P"4U4Q9N!'M$VNTFB=^V&G=],J+**.R@+V.JC]P
M0=5 99(<7RV4&5_-EQ1_)(+-C/CJ%=/ACP0[F0M__"GKO6]^*8NJ6E&7H#3!
M#@RY%T)$20AQ[(O]('$H<SS/2V.]+L\3!&=VB'8TJRMP+PE::US3XJ6FA391
MT-/+T58T I-?1C&QV6]F3]#Y&\NTY/XH'63VA-=H%;/_G&%(HAMXVLS%.4>H
MG<*;>(X;.G$,71?+ 6()@80@'P9^FM*0,1+Z6KF%ZJ1GM@/#&;WC*J$WZM@
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MM%NI.)8^%GF3V=0.W/R\ZZ:P"G!*8S_@D"4IAHCA5-@!ZD+B4BPG'\>1JU3
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M@35L>@OEPLQNVD4;:EWGS%_Q]^QQ\[@*$\HBY!(8$A++*>H48E?XZ FF'+'
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MN%:*WYU[=F93N2,&WBGWI3LKYW2T_U(1]0R>V&B;?N>#PP50E5@K8C\FEE%
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M(^L5<Z(88<:@[\O&=]Q#,"$L@;X;I(F;^)PFJ<Y>/4YNYGUY2[P[;!BW>)@
M3<V,V(-"SV[L4&@(7PUC(QUQ>V9"34A+=F&"V**&0$WP0\U7?,K@LDGV-&ER
MI=KNKU_J_/JQ5KYN.OGTS-K:MF$94 5?>+TI<W#]6&Q44\5'9%>X@KI8;,U+
M*$.)]2Z@1H4RNX(ZO>1REU"C(NU=0XU_\N(JTW82[4W3@WA%4.A21VR;-')D
MN"\BD/@N@IQQ#[L!3F*]\2=GZ,RLAOO5I%U[Y:[-L_%TZ'.0J>V<%H#04\S]
M<M&6YA5HJ<Y2'WI*+/LUH7M47JL.])2H([6?)S]N8\[@H*',G8"ZD@9"WB=P
MNA%G4MXE"+S#+Y6[0DY"W%CXPM3#%"*?>S .J2^\8J'7/J%>K%<S;LS)W%MP
M3[[IF][1!W67*\$$!Y>,)]1!7,TP+(*CGNDX&F XX.H*[  >, ;Z9)1W8P!?
M.-+0 )Q99ASJ\/&*0P\-X!J?@FBRX"4]YJJF<O7(A+HK2@.$DX1"'R,&4>P+
M6Q9',0QI(L[^KB-,G*:7,D9N=F>E)[X=07'5.RN=ZW*!SS**HZKK8@L=70]F
M",R>(S.#'Z,BH]6^=6>)O4(#NRG!3W>RFWQ*_\S__A_UR_6WDE77[&\?<NVN
M%6<>GUF#94OK^J6M!:R (+VIZJ;4ZPI\*(HZ+W123\\A,'WTMR"\GH(JR#U#
M_X@),8VB >?67"P<,"'4,!XP]5'C'9=R.7M)YK%\R:J_W_)2_@+?<W%V"#S*
M$?-@@., HBC%D! WA2RB 4%QPD*D5;T]1FS^W79'&I2"]I5,)^VH:^^NYS%3
MWENM(*&]LPY ^-* <#L-@LFN.BF=O3WU/*FE=]1)H4_LI]//F"GV=MY"UY X
MPIBZ,FG<CY #$?$0))PAZ,=>PD,<A8D7Z.CRP?HSJZ_X-. ]13UM/01"34$O
M$$]_,VW;J=AOQGQ&"$NJ=[CZHMIV1K1#!3OW,7T/]:9-U[TK65/<FO%*#G2Z
M9L53S=F'-;Y7]54G%YH]XZNAOXW<]%PTN1G-D"JVD4>MCB-U#W8:H6E?UBHX
M>HJHB0OX7;)CR;=5%MO(RYU>?3%_5UG0H>>K_I#95GE-Z>9QLY8]&M_)D:0T
MZS+UG]:\Z>*1L^M'V>GUG\WOSTXV6F$W8<A%$8Q<QB"B00!)0 +H!2[C@>-Q
M-PY7.;^7E-1V65NL*:E-TJK-D$'U#9I7U9\!WK$+V(!?O1W;VOM0V^H7Q=C(
M- TX!$,690E1QV1CI89L7H&#L6A7^W/1['D9MO&SY)Y88VM1O\8VF(<.D?7U
M#3O,;4@E_'G9L4Z.=/J8Y?RFYH_5BK&4B(,*@0X-93MZSQ4FU \@8C1!G#.?
MNUK]B,X1FMG)VI'MQGW]+BF#AK1N&[=S4*E9-QL Z%DK,]GU>Z5-"&:K]=DY
M,LMV,IL0]J@QV=3G+0^<_:4LJFKE4I=%3II 1F7)#&8QQ$X4PQBGPBWB48"1
M5MO7<7(SJ_#^--5[2='2/-46+#7UM0>!GA)/S%3]910.>U-5]Z2<>ZYJ2^R/
M,5EU3W#EV:K[3QENS?)>K[W1>[<IQ4GXEI=9P=J;ON&@^_??>4FSBK,50QX*
M ^I G_,0(C>(((G#$%)" TJ\)/&(J[5I:[,P]TU?1V=[4P^*IUTCO/=?;V\O
M3C,T@%W1 9@53$W70*'GZFC+U2O0,2L[V+?L5K* N)7)HG-A#)HMMT.?@64=
M$F. CEP5\Y5LY%+N_&G731+?BUS('!=!E"88QCX-88H9YCY.>>1H91>=H3.S
MJ3I(XKO@X'$.)S6S8T%Z/=MB)/B%F8ES'3K.47G%K,+)(\?4Q_6O7#[A1\Z$
MUK=IAI_3-*-"'PS2@R87FEDG&_I@RP#H.3#)$YH&9?J6Q2H>>EHZ#<4,J4/*
M\AI=KTROOMCUBK*@P^L5]8=F&!737<K[B9^F*4(PX"B%B#$"$Y(&T*.>&V(O
M<F(_M#8P9I&,A07&QF@E-%A&1$_KIT;(S)#[H"'O$A-E7B-'0@,"K>DR5@98
M?Y9MK-M& :O4XTAVTH&)CY(VZ)_0,(7<\2/*4S=)-2OW=VO/K.4-I2Y(J%F7
M/Y!?38,-I=+3U%:@ZW&!]$OKCUFW54<_6'G9HOECD8XJY$]\Q%+9[O6F?BC*
M[)^<K9 7,QS$'*;,B2"*72([WOLP)L0-$AHD:7Q9Z>Z.ULS*M%^^B[=D[9?P
M#N!3TSU+H.CIXJE27K C/&,U[[%T<U7T#BB];E7OL<B3E;TG'C%3[[]RV1&/
ML^MG7N)[WL^7?I>M-^*W+;'/F[JJA?N4Y?<KWZ?<X5X$7=]U( K=$"8)Y3 (
MDC@)0\("I%73JTE_9C/0<P-PRPY@+1^ =O:A581BQY"Y9=!%/N!.Q!TOAC0.
M?7%.D?T L8^A*TRM@T/?88FWJF7GAM='?LN%.?+G$=]4G/W;O[JA\^\">HK7
M=+/>#I/MWU?.:[ NJL$$[^5>E)I9GQ%^/5._1;[C!+2L;.?456# QA7H&+2W
M Q@"86E7T*6^Z$YA",WA[F&ZS 6G*WG#5O('<63+GOE-+I29?Q3J^(G7G],[
M_/U6IGD5^75=EQG9U'(,W5UQBV7WIFV702^-0Q12 GV>"GL7DA3B-.*0,3\(
M';'-.(Z[$A*10NML=CEG.JHXY$_S($2'C(*LX13\((W:CW\V..]9>",:9\5E
M438Y9^YQ"&XZ>"63/UX!V7-5V#_!Z17H> 5#9D%=@);=6;I&6H;0YGG7 E?+
MGY7M07GRG&UQ>?V;JE_SITRVN[S+'CG[4#3,_ 6O=<J"1I:8V=_^]=/MS; %
M:\-!TXE]+T5#,+/1N*<:@V3ZALH2&GHV20<(J^4_"M(:W4R-K;O8G92"<,/;
M*)6/&P[)S?*LYA^%>3AJ53M,>>^"W%_X(\YR)GVT#X(=O)8SU5:)'[A^&H8P
M2%/98S85)V\4B/]):4P)IA@Y2&M<[N4\S6P=AFS([3C;=6_N<V/+GBWY=_D%
MU!RN:^&]J'E%"Z.M9WU:YF##W5&/[*OFIHPV)\2](I\O0^Q;-ILAC1:G[MH#
MS=;\70L<+3N)UQZ$1S-Y+2YM,-MNT!IL/_]'FG#9"':OF*A)[&MY:()IB8L(
M3WR("8XA"IP4$LZ1L*B)E_@Q"SB+E<?:7<+)[*D '1W .EX 'EK5IX:;)C;V
M(MZ':FCL\A<P;C47A57W9F3+%3CJ6MASMF<INPSAWF *[I8"66.2W5)@FPVQ
MFQ5TO?EU-H :'5UW$8'EIM;9P&%O8)V5!0WVD5]QODG%&;Q) #_LV,)#S_,B
MYL HE#6A491"S%,78M]WDBBF?AHHI8=,4IK[H#TDK=O.9AHF!6MN2WC-<_6>
MW!H-;S0!T+"TMH PLZ1G +%D'%5D&S5^HPLL9]Q4Y-@S7DH/F,4.Y*3UNINT
M?B>6N/Z>52N44(S#R('4#X1=BN58YBBBT'4]AI*4>I&G-1SN%)&939(D"27-
M9D>_ I(L^%T2UBP6.0F0VJG\4K'UC%$C\9V>Q-IGYC&1+!V"3Y)8]%0[)N3A
M,77TLP;^PE?ZP-EFS8OT/2ZE\U$)9Z2Y1'V#JXSBG'47JQ^W94N(1RR6,RU<
MET@OPF,P=N4H1^IZ%(7<3=6:61K2GUF1>X9D&*AG2;K?;?K %6C8:M.ON^P,
M_<(P4^05')-Y\=2S$']D*#5<G'DA-7-\AD U%RL&6-_)NSL+MOI"D$8]*(-E
ME_.KS&7>\[8N6.:"Q@3M+*2J;4&]BA(O$@? %+I^[$/ACR&(0]DM*!$N69K0
ML!D(H)Z.=TQBYHR[=HQ6M9OR5/W;O\:>&_U[<SRL7\ /C*<9S6J3;@('6/D\
M"9V40Q;)(@LLRRT<'#:#$D,<>)S[R:H-17ZM<5DO@=@A.67<WO#[+&]"J@2O
MY:#HB^'Q0Y;&/@EAV@89!#*$H$A@A +B^]P-:=#!\SY7[-YG YR>F#(T[]L$
M35NXJ/GPETFJMS^WZU^=R06RW /BI$PV>SSL$UB^A\-) 4_V:#C]20/G_?_P
MLK@MLKS^RI]Y_B%[YEW;ZT'T\2O/LZ+\5-3\W88+Y.(NQA-Z"0ECA\*$)0Y$
MC!,H_IW"(.*!+QS\Q$G4[XPN8&1F=][Y*0K^[^'\)=#R 20C%1"LR(OV6,/9
MO 1T!0=^(2CU+(5D"C1<@88M(/GJ.]Z?0W<+KDE\\A*4-7S[A= V<_(O0]V2
M8V\!H5$/_Y+UEW/U+:"PY_/;6,_,^7_3NC-?'SBO/\I7+Y,Y98S1B?U4N/D!
MY#B0M<-^# E*(HAQ2B,O#3$-$IT@[#E",QO\CBQHZ(*>L%$H]BQ4:JZ<#0 T
M R["P+2MOYH<IER0S\2IZ+:HL@:$G@L9#FA1LAVOG9+9DL-WELRB;M^4L(?.
MW^3GS33Z)A=JPJN^J<"G(B_ZB>(K%+@!"GT"(P_)PUC(81*[$>0T)6Y*'#<(
M [U&ZB/4E+[8E_1&[VD#WA+74^<QG-0T^E+9#<<I=$)W5*_ D*X]U540SI+V
MCE%:5($51#[4895'3+OII;PL9?:A++FXP]\[$F]XSM.L7@4DI@P[#F2.QR#B
MH0?C*$20>4[J4H>XGJ-T8%.D-_,VW5,'-?X.2$M2MZO>.%YJ*FT1!3VUW@+0
M%6L)TMLF/C]TU,_'*@W:[2G)::WMWCBUA=OO*8E^W(9/[3'+#<!W93.[1G2I
M'S'NL1"2-!6NN>=AB.7=:QQ2+T%AX/I(JUA"A_C,=J!M#G[=%4!\XII&0 M&
M-8LP%SAZYF&T;?BPMLIND[]+0)B[J_@ITG^,'N,CH"AW'!];P])$4IDO\JZ0
M2::K!!&>"LL!HQ#+.ZR40L)X!'V7Q21U4>KKM>@=H36S 3D>Q=EE(K74-8_\
M8YBIF0]+2.A9"V,0+I](>BS>7 -)!Y1>=Q[IL<B3XTA//&+L-U#.6?5!L/FQ
MP'FU(DD4X30)8"@'IB&,."0Q)I GOD=]2AV?:_4P.J(PLP+W](!$'JPE16T?
MX  2Y8W>7%#MW7P@X\=1&4WVZM-RV-N0#]9?>M<]+=Z)K?7,!U^E]<LJ#6(<
M>XD'$^2D$ 4\@<1)'>@X;H)Y$+E.H.6U7\C/S&I\JLW+6GO4SZ68JVG^@DCJ
MV0FKS5S^,!U<+-NC2[GY_U/'EG.VSM:RA@T@<%8VS3M^Y5B>6.3YI?K"Z::4
M!2/=+3R.,''$NX-^['@0\<2!B7!1(,:10W#@(S_6ZD2N0G1F&[>EUJ33:IHV
M)=#4[)=M*/2,E*3>]FZ1]:@](O8;C^M(::LA@@K)93L>:(!PU-) YUDS2W!-
MFV)6N2K/GJ6)$=;GK2 @-^.$!D["'1_Z@2<L@$M\F+ TAC'B$4YB%U%&=2S
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MV6Q9H6F"RYH590".[(3ZDX;1HKS.FIDFV3/_*N-0XC3%J_??Z7K#.)/W=M)
M;=HRJ<]'Y? ?M]T;XI1@AZ0N)('3E*L[$"=N D,4I"Y+8\82K!59LL38W%$H
MP2;L^035EE' .T[;^V6ZX[4:CI'YUDW.@)-3:31C6[9>JV(<[!5>EF;,;, A
MV+$(WN^]I@&7I[MVS#1YVS9^ML)NMMA:-D1G&<RC<)[M]4UKC&C)A7OXCK?_
MO<F;&\C/?>W#QPR3;-WPMN(HB+"3<,AHRB$B&$&2<@<&282B($8L<ET=XZQ!
M>Y$<A_6.GFX!DCJ(:J9P)FCTK%W/!/BA9^-'D.6@!6O+"OBH )M!T9(V -:*
MF-0I+US4I W)<9&3_A+F[2#ONG9V*\KC./*P!VDBDY*%&8%)$A*('1='3N#A
MQ*<Z38B&BVM9!L/V0_J-'K>BJZF[J4!Z^KS?V-%N+\=#[BWV<-PNO7COQD.A
M3O5L//J,_FRDV[S*K]G?JMNR_/I,WU9]MU[%N4AG'I]YR[R5V4DRM,G^MJGJ
M)@-!7O;(CG6\?)979V^+2K'H9PR$<06R)+^>'JF);C%Q1D%*H^E'Y]9<;/+1
MA%##J4=3']53.\:SU;NN=TL[YZ-MU?Y!_*Y:><3%E%/AWD9I+/8K[$/B(P2Q
M'W,OC!+?392"E*-49M;/GFX_\J:E#!K2:EHYCM&X7EJ37/-:VD1H9354$FI$
M$<7SK2**'W:*.+[J(JJH)%BOC&H?OMQK_!77W:'X"W]J[RZJSZFPLSG-GO#Z
M)I>3>3Z(;\(J3J.4$LZA%^$((A\%,(YD+PQ"@SA)F4N#0+?+N#87,ZNS>B^S
MR[#4]U=G0>@2Q_8*="R]7#6#OH D/H^WJRW[#&ZQ.@^OYC]KPS3F:.LOIN^1
M7Z_7[[]SV@3GWN*:WQ>EH*?GEH^M,?=UPGH-MK3!CKBZ-SX*P+1+;DMVS>C\
M&;$M>^(JPAFYXZ,++^:3JX@W=,R5/G]A.<HG7K\33L8SED2:GA)]I.JE2X%G
MG_-M GQ3P_%;7I!*',=DHNQ-_K2IQ9^%\.*9MG:W6*\_%*5,AEA1E\:.2SDD
M-!;^ _%#F+@.EX7S-&0>8B[2:I"W#-LSVY!A,8@L3=L)TC;U #]L9?D1]-(
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M]!3B9U8QT8Q(=W!L:8,M\7[4NUTX-()N5F$Q#,/ALGR1M6#/LOX&X*97:?W
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M6GZF$<EHF.<(IZK@+,<1(CSTD2\_RWW&@BCDL%(&9R@Y7I-W=+V.,+0VP3F
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M4%6E+UB!L$AC1*DO4"0B7F"?,LI#V)7((0G7838#P2N4_00NNA<4UT@+O7(
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M(@Q;'B? T5L0[8@,,R(CFC=>1]7[H__7R6GY92$M+7T3A&9=["X+?+B\:8R
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M<^15X36*OK?J8WC;V]WO]_=]\"XTX P*M.8"[A(^X.+>HM47$NF8\3IN;KH
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M0Q;0E&EU_IDFX_I(JZ4[Y,STE 'E2\[#,ZWX]H0&'H.=DO?RP1A$<$"Q%2L
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M?ZF$0'%7?*R*E?RJM+E_^G4+ %,Z5O&>$V]@Q>,;H9HK]MRTS1EW_-R BQU
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MT <A)7' :)9E*(E4W\\X)8@F/$<Q#D.<81QP/7MUGH1C6[2EZ;5$O4#/Z$Q
M,FU0[ @*,Q9',EZ.N=(5EJ_DID?^WNYT' N]1\O!"]:V?9?%Z>R:>JXU5GX2
M^:W!FA@YBS&ZS/E@:#2>A)^#MFWD?SP]_,?JSR_5<_F^:KC\'7J%,3V+:]]%
M$?=^E$]MQ*=DP?OR]?[SMOVW[LVJ!AJ7#SSM 0&S)Q<Q<'"!H2>KT3GGA:EG
M.^;4$W%\RJDYPD9%N'M:W]5MW#C_G2XWXE[4[6' @D5AXE-6(!;'#.&(4[EC
MD1X CUD<%"0M<  JS:M'UK&6'U6(>Z:U]Z(8:,LE\-5R2>O&N"2C)K1Z6Q/[
M@,&LP5'M.,F":L7=,>&U7*A2"ET9!5=UY"[)[:2>W%FB;UA7[A(0T_7E+HXV
MLR7=28NZB)'.1+4>&E^'!:%Q'"*6%])TT(2@/$HBQ+)4,)'Z:9Z"RK.>I.+8
M4O2'?UNBAGVM3P.D9P"N%MOHN!,@,5BU)R6RI,FG:<RJN)-B'NKI],,&&_IM
M7';;E*99WQ7W]8IOV/J;D'_8B.;C7VRYX=+'&]]FJ7CN4_G/.[^5A"*,&"$H
M)>KN V..,I[[*"XX%C&)TX)K:;5+)AT;A2W7?3>GINV^VG/N#:Q[OXB!>8^.
MN%?/EKOR MU=JZ:'X?3-:IQL_ 3O"WJ0.KRJV^%5W9UZ55N^]^YVU;-'E2#^
M!BH!,=_K YS5_ 2OT>RTQ\7KM'1@Y!C3R2,G5[3G.[1RC-[>L9=K6E=U=ONV
M>NT"C$]V(9/^,V.Y=*EY*!*$4Q(AR@MUDYAD?L;2*"2@.NTZ1!TOIAWM5Z]H
MXSK:Q?*A%FWZNE$WMVD ,4N(2(H,A5DN <S3&&6Y1#$C+(["W"<B3Q?/77&Y
M-:W7;P/C(0,VP-S>O+YZR,O%0UE5ZN]YUR+>!=1!'E"2$Y3%!4$X)B'*<RK]
M1A:DTH',DD*P'NJ/%7]+H ?RUF$6%7>+L=X.TC9JP./D_GYZ2]YZ&T(MP>SV
M'YPF^1:-![5 .--Q4&^L80KOJGKX(>HGU4JNGW[!><($CWU$VJ[(+ I1ED8)
M"@(:IZ'P&<.@,)@3-!RO6D/"^K-R$+H]W5(R@>143QZ7;  S=D^ E,<LSOV0
MH4*5+L11AA'U([G;EAAA7T2JGO&B$@_J,.^'>ZQ(A]4106W(5#+IOWOL&#CY
M/7\1\C?EDU>K-30PZ!1V>G;QRJ\-S PJ8DA1\Q2Y7<F#+W2]J2U'[4P(9BNK
M^02%>;.9SXMXE,4\\2C,IK4A./7KXC_O%R+,1)IEL>HX%JKZ?0&B)$Y0D?(T
MY@G'81#HF+#=E(XMUG_29ZJ9@3<2<UJ1S)B'Z<U_WM[??KU>-8Y9G;A,[A_N
M%*'_9:<#HZEF^<H?LSY\PT_\Q2!J@_.V)C]=8C]\.16JK1NX<6DBU[$;6_J>
M9."7E[^-F@8#PC8NPC&M$]:1 'K;$R"XB-O0E=0L=./B[/-%;^@*NA? H3W(
MS+=6*]KGJEG7[5%J5Q._9/?T5?TZI*<O0H*+R/=]%.0)1CC$TN\.I",I/\1%
M%M T3D'U,K2H.K^"Z>LP/'=D@3ZC'G!Z7J1U.& *WW9'W]&_\08.O)Z%FVW1
M"KOMTK5EMM@]_3+-V9NI:\-PJK>Z_F##0V7^7YMFW2K(C]7.&JDTV<_5>_I<
MKNFR#0#):2/X.*GYF^B:]8COHGXIF>CX^]85QU /M/$CBT@EOQ4D0UE[#,U]
MCB@F 6("$Y;)/^(,U%W'-<..S5(;9(-:WE07GEV*N.CJ*@*/ %V_/<WCPY_H
MG0"=H?O/[_O^/NA=^U)Z]?)NZUH^* ;[V&?;%*NZNU0<L6CQM'(F'&V==+IF
M=]Y3TIG /SIAG8NNV0(Q=&J3A/.R:NF^7U7K4NI&M1XBOMN/1QK3O']4/WZN
MNE(7=\69(4-JTFNP*&@>%&F,49!F#.$D25$>%QSA+ P%SXL@#K3:'<S,M^M3
MY)8?E=E7T'*(0%X5'A]";E5\$=LRJ7[<<6F>2CG72]=;7G["5PE;9;8]+4<2
MW'@[AKP]CL9+3R,?VWX%.DG4ZS\W]&:;XVFA^\0;P6]I<9J+ZUG7J)E?Q>%2
M-3=YTU8ZWQ_%<CFTFXO#),),;COR- T0]AE!65:DB =%D =ADB<^AC;G&Q.
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MSOJX'BR^<K/64X(==V0]^91MV]4V+:8;4ZE2:&YCGU,>HP105<@'&4T 284
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MU!U6I,V2WE6UFAT3ZU:RS0+JJ,IMWFHNQIVW;811'#"&,0991&( "4& 0$@
M89$O_PR3+,3VP\U7::L\B!LT>Z?N]\[@5*[L>BZ?0DS?6IF!@Z&/\AJ"&RL(
M9HXQ7Z(_\RD*;SBB?+13\]BC=ANVG2J@%OK.::<C;HF(N.#2[T PDGY'EE*
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MAIJF4H]VV-1>;+V6FZ;R'?3@-'[90GW^6M1/U;N\J&C.I3C5YRWMOKL(4Q'
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M,4X75A$]W\I<N+R[*YO\O3:O%S1<'P8(/MH4M"[W*6H:('^&S\;0:%&<=1]
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MXPV[K2QMI$=>UB_7\J-7<\[54?*HXGC29!)/FR^YX+<9BUC&HP0@K*[MHD2
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ML'/V5HTD+P7NZ\#S8G2L&Y"IT/<7CBM^7>9;FC_B33\HZ=;W&<<!HO+#)AF
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M/\L\;@/@#"9UFZQJZQ16]97XI2A8I2HSV^A-];W8L-LPQ)S&*0=A@J6V"^-
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M0X//T%DZV[.EZI6="E2WA _YAE>U/',J[Q&_J&8PAI5G9Q"+XQC1A""0DD@
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M=] HQ,'VN9,"Z3@-=(.D)RX3;P9')FND3'6V8R![SH6!R$4 10Y@H7"$C/T
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M""4FCAE#0-<80OM3V8E;>R N[A<W#*FD/F"X5;Z1199,ULE4R&DAZE @%HZ
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M/G+:&'PN+$@@<U\S&B.#6##5NE^MC+2^Y-95F/O2N!OPOK>+B$$UU0$2KX>
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M!W(RB#P0,^OK.<9IS2DM0'-1O-%9FM :31W7?@R*J':*Z !5CQ4%).98"76
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M\#5IU <5A.%8+&^>#O =%<. R/[<!L&)PND.7KM#F#Q'D3UP<M- N5(@!IV
M.4G.G.(Z-W=O[J-C6EUWJFP?A,H1C.X +)N14)AKXLVN=KDH3?1S4J&>O'SF
M29G6VF7!;<Z2J1Q4ZR89WQ'1$TR.D>M=G_<D)D^(DM5R??:>&+_)5WB?<!Z6
ML\7FW)"C'RUI4Y!TM]>V@Q9"H5U$4PQQPSBCQ1"4T HW$$)?7:-C[^+#T/$G
M[1W<1B138VI+]V_SU1=,LS*CP[%KO87<<!Y \AI:TEJ!8P(A^<*$4\9'Z5O@
M:A\!TVB>1D)=M.9P)S!YM:#3$U;KJ^H6'DVR!9SS&12J H'<"/"T+:<B^15L
M4!QM($9NKSXA0-J(]!Z0G,#?'DR8W<'9-<M]CQ\W!2V7B>A:\N@8'2"T]6%7
M&7"D6(E!F65K,OUKZX:;#Q(T##]_\N:O[436 _XN:=^U%.(A2"<+T $D.U'7
M09PED-GH$5E!%"$,,HP.,I]O$#"MZ=Q0L-_9T,=R>>K(XXMWK__KQ3]?_O3W
M\T4,Y[_B^GTXOPI=B62#M,5#B+767:@$/M7YS2()ED(4/MW)P-G7N/R!52;&
MQ/&26XS!QJGQ\ ,Q;55_9!;OW8MA2K@:R&1(%[GRF12K10.&#HD)QD7OAI52
M/[+0M"D,C5#1DID=W"4_A/,P3_C^$^+ZY\VVMG-!K%&BM@R&8(HCF\QX(-,_
M0&;.9(^^!-O:C-E'RS!M\B=OI]M$4)T";E=]A\Q;FQBXB%C= &)/)/;8H+07
MNOA4FL^*VDO-Q!-9FDA[ (2.8'T'('J1TJ:B9%MC22>._F5Y@;=/YF4.F>,N
M1=+LP@0.*G(-3NL,Z$SB.>9L<NN6#L.IZP]DQ^!A\23"Z0!V;>?;%Y>U4H6#
ME[4.*O$$@=FX>; NH?BB;&O'K>D&AH'W3]XA=3I(=' >WBX7"3&O7I%PJ@U,
MF_LEK"^6FR:-OX3EOW =-DV#4OTW8LA9<DPF4B!0:NMK97(!KPJ#D)SE*FL;
M0NNT@X.)["0]YND!=;?6<E3I=@#?>_=@40N9'(+V1H+B==H 77V0'3KMLK1)
MM:X".!J$70=MVX#P9!EU@+-[9NK]1'];?WL]IT5PM5Z]7JW(/GJSK/^M>_WU
MHII';\HF=WW[W3.RAK!D.DXI(QE+@C8<5'VH,P*U5=QSW=PC;T+Y\Y^&TP;+
M$^!@\M#C=LLO%Y_C;'[I8>S(V*5NGB4I-?<^ 6.EUF"' %Z40AM*D3,AHT_#
M$F"'K/;\V_J?!L9QQ-(ASEXNYK6"Z+)_Y6I&<@W?G[C+(T5<OO_$G3');"&0
M 1/U95H5"Q%S!N((RXRAYXD?"\T6!#[_IMWCH/G)A=^1F?$X&Z[.^-TN^V?6
MQV@<#U![<H**HB8=TM^"1+*U>-#Z;BU",QOC!+*??]O+M@;&4R'@:-!_Q65<
MM-#[.Q^5SBQYJ&_*V^5L41W4=_AUAK__8W&1/M&!CN>SCV&-^</B;?CV87&I
M!?YS<4[<6&U['(>/>.9-4"EE#;;4J@Z9B?6*A&",L9SQVB'&#%+V+:EZ_GWM
M&FCXR<0\M5WS@DX*T;QY8*9-)R06O+V@C:;S;]L60YCOY<;F5VZS9!]#+-?"
M^5J^5#0Y%-I%<)*^+'3MF530I[M!N7TI(4] [?-O!]3@/'0'BZG/R<YR^XX)
MF_W^MJI;_1%KQU=B_G?<>_-[_?XM/ISIX%6."4%DU*"R".!0<$@Z&"=)7CSI
M08>B.6G/OXJ^P0F85N#/T]I_22*@;]8>/C7%28/VCDP\5@3$K!G0)DWFGOG8
MO G7\=3^"6I$)S/NCQ'X\X0V\3QM-^L$G5KG:K"J7EO<%O"U:9!+='NQ+'3F
MK0M/3R+X3U!<-AG CQ3[I'[K;KNW9ZSL8E+OR"S;Y+3G&Y:8Y,8KD3,8<K]!
M84BTMYKY%;F@PTSW4VJ=*3*<NC]!?4D;_(XDT"[ >F.X0=WF/6UN5V=.)L6-
M]F"07&J5+*O-+#7X9)3SSBK3? ;. ++^!,G#;>#96H13NWPWTU.VHZ5>T;4Q
M3\2V,U2!^X "BI:*?%>9R.(Q=!OH$(23C([=L)#&0ZO\"1+@&L;F3I;#U("Z
MK;^W6_E.=7MEDB[: $/)R$VLCT*;^$A10N4@T!HV"%F#EAL&L3_[ U][R73@
MY=S>U*N0\'),PEER=3 "LQ!0%CHSF91PL@ZBQV)%4*E$.:JU=TW+,/C]!5[6
MF@BK.]#1X9DM\BR]#=]NFJQG23O&,!8P63I0*F0(PEBP4C"M>-96CCN/? ]A
MP^#X)WX,&T^,S;#Y?_[VG7!HS__:?&OSG?I;[[#\K_K?W]Z]OO7Y5=MC_H^T
M^'SYX5<<O_%,O7J?/F&^.,=%>7.[.>!J-J\_O%ES478)3;<B!S_B.LS.5[=W
MO9I]_G+^:(;9:+3\[9HW=[FV)>D[%$_#)_QCC?.,^7\W'^NU>A$)S"&MS[++
M3)6$X"R7=(GG4NO;.##/4U"NJ(*MHW</T=-#Q=!ED4I4R,B 22 2KTJB#JH)
M=*)1,ZF)3Y(W]ZZ;$=])1<6I>!NC]N=PX79@1=QH(7SUU_^<D>I8ID_??JY-
M5"]["3M?YT%HXB@G,]P(#YX,(D"!F"1Y?P);3^\81EDG>'Q:V.SO0]Y*ACTA
M\^9%^/W^=DT@?.!2U?)3K00=?@S@DR@@I"Z)2=2FV+$ .H3 3G#:$"'[0-A<
M7#UA\=+HVG!,; N?.:+T3@C:0 JU\%F"R[6'C @6N5<*>>L7G0?(Z01G[4&P
M#VXG2J0#<-W-V[V:@\Z=$=G3/I2.JA8S,XAH%$1GB6N\#K8NK>L7]]#R_&L8
M3[]FF\BI4[Q=]8H0O@2?P4E1.X9J!QX+!ZNR4)R5*)HWH-M/S;2JK(VT!T#H
M"-9W"*)-G<TF(6_754U;M(&V$HRV=-)(KP<K&&25;3$:/<-!S7A/@-)=FOH#
MU#&R?P12)PFB V"UC<R:D@W64*ROYU2YR@86 YALO>16N.!&BT$]66.6KC,>
M&KJW3XZ(J9^Q!]7VYIH2QR29MY(GLJ(]V;T928,HYD/)R65]Q_,=N^2ZZW#+
MD4@XN.3Z$+%TC+.!I88!?7',<;*'K*'=JIH<PC*D(J(PRC*13P9APP+2KCV5
M<1$Z@D"?Y8/CK6>SJUEAX?Y98?3/]Y9@7?W$>(^1X] Y_D/E$_#W*1XQBR4S
MQ=H 9**3&M<^@DN&@\XNJB2*CW<;FOQE'C$#.E9KK$K-+V5:0<A>DI>!.A>#
M3H36E4=_A4?,0_ VYB/F<.%./.?E79A_O S,:"9"#"Z"UD'4?KH,@E,(RE@?
MI0B,?(TAB'QDM,O5@IV@Z&F%O3B5\SW 91L92=E)+#7-;]/C,$<RM(1C4%C6
M'*V0*@_*PQ@"F*D' !TIK+OB/H)S$PO\E]E\]OGB\ZZEO\+(8TJ05=PDL6MP
M@JS<+%$AJXETI86.N+7HQ$(_1F2+%OR;6O#ACQN$%Q.]<[P.C0DUN3<5B%Y$
MR"E8)XI4,@SJ'?Z8X&\N.HTKVDSP1_.OIRCRO9/14]&6E12!.<R@?'3@?+)D
M<Y62,R;OL?5T@@<)>OXQB^,MB?82ZPE^HPU&-U[4&30<^":\&+0';YRI#;X\
M22 Z$T9[V!AK4YT8U*<#<!^TNT##U,'F&]&@%_='@[973C2*:VEJ2Z]0N[@D
MTB81&>A2I'&%<>>&]7 ;NF(G^.L#)8NQ138U#A\..&XWA(G(CC9#,8Z.O8QD
M *60(/+,I5!HHW.#,#ADM4[,@/[PUUQ4'9@(>_.+= Y2URJO$JPD+J&"J),'
MNGV<YR8%CZU[PY^4]?<LL@^.MTN;R*E3O.W2CP+&8E.F@UB3,W@1X.EK\)&.
M32PE*O\4>:8]&(%MI'U UM\!K)_ZPKR[C;?+1=QJ^3?E_45*N-K9 <A$)O8(
M0)\X<2NXVF]> UJE:K])9?4PTVWXFOWAYA@1+\;G=X>ZJ#Z$U1+\VF!I%[4B
MBS&E(L$65VIG7^):'<#*K"L.== JM?9O'Z=J6@.M,<9&$D8'\!I8[41L<5P;
M <Q+"RK5$8G>*M"BQ*1--EF8QA!K6-/8=2^BIN' 5C+L"9F#ZJ-H2\FR%.DL
M(QT[X7UM3:+H5"-FC\&HYBGT?[Z:QH,0<E)-XR'BZ@F+-RKHY*YF(%DADE/D
M04NZ3T)&\*P. TR6*X62,=[:(WB G$YPUAX$ VH:CY%(3^!JD@>;-=-))@7&
MU, 1Q@"N1'*^<D)KD&461[NIGZR*H^O.;PTO]"='1 ?'X8A^R&>:;BG)N(8D
ME0;EE(+(O -A;=+D)K,H6W<T.(+,3G3STX/J]([7!TGX>8+XN[("X5U$X3Q@
MH(VJ.I+0:29 ERCK(/J84VN3]JF&DG6=GS$9R$]"P+,L+'GYJ29?$:.N?NY&
M,<2J+):[2IPPSX]PC^0[7F').'2.7UCR!/Q]BL(2%DI(V2)D@V30*[1DT-,?
MDI-[&G1,R/58-FW7A24& V<J64@A>7+823>X8@HD4]"0I9G(G^K0V.^]L.00
MO(U76'*(<#LP>0;&F))76$+@D$/4M?^K@^ 276S&^&AT1F5:/]G_M;KC'02;
MXR+)A\BP)V0.BDI99C@ZR<$*4]LO< ,A10Z1*\%D3@IE& N@?YI(\D$(.2F2
M?(BX>L+B/;W8LE16Z6*A%$;F/D,)CMQ;*+E.R9%%J#*:F?.\N^,=!((#NN,=
M(I$N!A8]%!8WSCM=,[(=JR5LS F(/C!P2$>5Q5A<'JTO[9$/%>/'"2:!US$2
MZ0M>3<(KUG@A@^=@N)*@I$-P,=--H:6VGK&LY6C] I[LJ:+K4%=#B_')$='3
M9?XKKG_$Y>PK"?_K)2?N!O4.30M_MS@_?[58_AZ6^2Q(-(E%!SRE JJ$"-YR
M7N537%(!F1XMMV'4G75B8CP]=/<=HGYPU,'I.N:9*$1+=RKW$-.F.R0JNEM1
M@$["%M2&<=,Z(/9\'P([0EN#%\)#1'\TNK]L9@Z]7X?EN@G&;VB<:W64_]_%
M:ETM4G*C0TI9*RB!9]J3K+/=O .K5,%8O]5\^LG#%'5B\O2+W(8"[4 %;UC[
MXGIHZO8]Z?7U>]([7%V<UX-9YV!>?9M^[^+SE\TCTYF,QLJ:"VTD^MH#&L%[
MEVMQB)">2^U<:[>S =F=E'/U"_2GAL;AI\%?GH8Y?JP3,S^T*>RY+W#PW[/U
MI^^XOKK#]CMFXU:(UZIA,QE/9>$"\,(=*"$-^)(C8 F9\>Q4-G?:KNPI!!J/
MQDZR[?L[%3UAHX-[XQC[K3AGL' )7,=0GPPBN.P#:03$0AL.5C\7TWW\]-3^
M3L!3B?Y$T_VG>1XKU^GM<I$O$K'U*\XO<+41T=$)2?L_K$'6T$!*&Z7V;)?9
M6 &$A)IA4;7B2U)NB\^XO,JZ<"+K)+,&[16AP#%"7?)D#5B;@D)=QSXT5@ #
M23MY_/!L%3Y^7%9#A"3UIFR7O8R^RNRD]461+J]3NT/F$")]R;UGSJKH3?-Q
M@0_1,VUL8@RL?#=%N)4T)F[:MYD$7\V#O^/BXS)\^31+X?+UW?' 2_(1,LN2
M[&I%7B:9"\!M=D*GF$L>=)(>:>"WEX!I,=1.OHO6S)X:,?CQ[A:V+YRL%)E9
M0! R9[KQ<P(G@J(O)9><&Y^'964]AIA]!$S7][.18!>MN3PA5#8E[<MO9[^]
M/U..&."=J"0B'9>:QV,"!Y-XJB_?3#YX.:TP_<?'Q=>_;3_Q$AK;+ZZ1<;W>
MA#!H([3%21SL0.;_]^V9%@)52@A&,%4;9"!$U 6R"() 7XJ-#[63.$SF__?M
M=)U?QY'Y@1R<NE/-3Q?+Q1=\,<\?/M6(W?I-H;_\]V)YGG<30FLVBE02Z':4
MU1DLX&SQ4 ++1J)BQ=[)2ML3EGILI6E"KNV!T)ZM'41T]AA5U^_?"DG-66*-
M45@C5+7\6AI%!KHF5]ZC"JIU">9C-$W[6-7<#!U%%!U ZQ&?[Z<_TOE%KOD7
MJQ72__*'\,>9TBJZ2*<QQ=J87W,&+H@"/G-9A%?2- \6'D%FEW[0D3A9/*W0
M^BQG?#VG7==NKB=$]K[[C 8!O8?I:A3'NU[DJF3JNF)*&,,4<X#:UFX'2H"O
M,RO)1>+::$&R'C0RX(#S^  YIVJDJX]^%W[_A=S#Y2R<URAI/4,UA([D'$JA
ME2_R,F%7<4.&0=$.I#!9J<Q82*V[OCQ.U;3ZIA4^[JJ:QM+HX,:[VA$9A/]Z
M/7^[7-3^A+>W%*66:+0&+P,IYVH<A(0&$D<?DHU*\=;)T0/(FM:D&AUAC>31
M$\1>S>:SU2?,?U\L\ITMH1-*L20!98J@D@_@N,MDA :N@Q0QJ-:EF /(FC;S
M9G2(-9)'3Q"C79QADB$Q.AZL#NXE[Y5L250&:JT?YNQ+L*-AB=:?-C%E=- <
MRN'CT;%8A_/QK.=UF'^<D?];@1_FFS/P^^S\_->P7&XR&4XRJX=^>!-[^ZB=
M-#+$=XN]F.=K0BZ+&.X!H,A):H:I=KE%4%(Y<-7IXR6F:$4Q0;2N*CV(P).+
M<$BAKLFK_8IW%_MMA>7B_.=9P3,;A3+50)39F,MN;-%:NL*9PI)3(JXT'P$T
M@*YI#?;Q</1=@4MK&75P_>W?T^K%Y\5R/?N?C2!_^N,+SE>D(VL\F>3YIKPB
MWH;S?V)8GIEBE+': -I,-SZS%D(1Y,84YX14&K5IWFO@=+*G=0)Z0.TX$GYV
MH/Z5+K0/O^/Y5_QE,5]_6ITEX8(SO("RA?[PFHR=K!(@^>6%&U6\:5VO<AK%
MTSH;O4+Y)+D^.Q37<_KA]\49W3ZF>&TA;H8B.5&K\6F[++N@!6IO7?/V&\<0
M.JVOTRMFCY'B\X0J80_/3 K2VQ(!I:S>H,H0,2-([8KGY%H*D:<':R5UVHSY
MKN%ZL"2?)6!?+2Z69]F9HH5#X!DEJ$AG,R17Q]O)8FV,S)GIE6NE=!!<S5\1
MK@?+L0.T[OAYQIA(S&<.J#76PEL'7OL"*%S$37$5:SW&>K?V($39YX^HHWC=
MZSO_GOC>=6O=6B]5+NNE%N4[SHX0QSQPZ3&CG*=P89(8J'%1FZ(T8$)=D^T2
M.$4 5<)+KW3F'%N'_YXT!KH32 T][%7KEYEGZ*5%4RP9Q(SL8QTX1,$,)#(S
ML+ADE&J=N#"<NN<4#ST$4W=5Y4CRZN#"?6 _/WS[)?R_Q?)Z3GSFVCJI.)AH
M%=D2R,"+R("'[+.-)O'F27P'D#<M%L="R' K\"1Q]8W$ZXW]&CY?S85,(29!
M1BUWL:9ZE]J6T7M(TMILA27;YPECE_>1.'';J+&@,AR2)\MMZF*+%^G?%S-:
MLZ9\U :C=-/\6!N"+K[4^H.KR@"6N! &.,::!D)73,C& UTWTFITHL3\F!4Y
M>+5N,76ZK!=C,KX#!7>5J/;@IB)YYCEX!D;(VF,G<7!">W#9H8\B*29:J[5!
MA$W<2>P)@#>>G#H W\^SA/-53?#_N,3+]LG;C:B,5LN8('%/IT@: 0$M?5G0
M&":3*ZYU&X>]Q$S<Q>L)0=9&'AT ZP&F_7Q5N6*$8%8J"UKZZGLE"0[KRR0=
M(NFX#[8T[X@[@*YI==KT+L-Q NH;=#?[(I$:1C)L#5@5:A]XLFB==K5FTWJ5
M,DN2->^@/XBR;JVX(Q$Q''+'BJ=OT/U]N5BMSJ(2W.1@(7+.R200M!]!1JD3
M1F1C&0OM)]$\0E.W0#L:!\.A=KA0N@'9^;W/?%N?B)\%5XS)FGC%;:F/>AZ"
M3AILS $5YE+B.'KM8;JZ=1':@JVA<#H W,W'XS??/0F=1?*P4_2V/A@K4,)P
M\-([NA4,MR[*3'\TAMK#%'7K(K0"64.!3-^#=P#?:JV,T))OLA10;-IV:'?)
M+XG:HR@N6]^Z&<7#%$W<.'?2>_-0@32<=-1VEO'L#\Q76SIEV/"]']1B&O#C
M%#9Z?G];N]LLU]_>GH?Y^L4\_T2WU2::==VAT0@I/)GZ$3FK]GXB%U/R*GOM
M-&=.^-8)7X\2U>Z9?>]2E_ZU3@*#8QYL876PERD0+7D\/!CN?%2L"-%X\T-I
MF]:";XN;_<_J#>73@4VU=S<_?/M '[%Y<M.AI%RS\VTJ"510$H*3ACP4[5F4
M7&(Q3W7>KLGJY1&])1X6XPJG9[S5#6V#U5&*:#W7-<_>5M^DOE?41!@6E8Q<
MJ_)T^OV:K$ZUV[%0& JU(^72 =2NMK!]K4A,)L_107)(3#%<0608@9'UB702
M.4^M&PG=(:%3"!TKXD4[?G< EU<72_(S:AK>/).U6_^V>^=BFM0T)D4^!;%&
MH4QTL,B1-=%C]K*@:C\E<2\UTX:NQ@91(RE,G8WS<O'YRP5]UG^2\TL.<-W-
M^T59U[_NWDY9]#RQ5%OVDMN:!)T.+S+]X4/2(CKD=^SX/:DXCRXU;1AJ+,",
MP.8.E-";4F8)[VI2G[R/+ 1 5ZHFC87X(R08<F9DT5&[T#K'_%Y"I@TUC:UZ
M3N?]U%KGES"_*.3I7M3)/'<WPA4+0CH&)I<(RM$?46?R@U7 6%S(3*5!"N>A
M5::MR!Q5US1C;@=JYF<,*_RT.,^O/W]9+K[>2NHQQ)A-JJ(OLGH13M1N= @I
M^6AETMJRUMT!'R!GVIK)L55.*SET *DZ?VN]O$A5-)NTQ(\DJ]U>0J:-9#H>
M2M<)UIX9B((<54_Z5&!$:T-KC_XA>J8MFQP;5,TD,?%(F7=UK.<FL"$P<.82
M&7'1R=K2W-:A!PHL<T9:S(AJ4+;*(R-DKA;L)=ENA-#B\8SM 0U;$$O%A8Q>
MUJ "J4:C&7A>4^I=X$5GSD(:%) >@H<I(S<G".NNN(_@W,0"_V4VGWV^^+PS
MPT7"1%X^>)UJK\O$P!55*O13\=R1%=YBBM2M12<6^C$B6[3@W]2"#W_<(#R1
M@A/:6S"6=J[J)#[/Z&*TR3/Z3K+2#\KJ>4SP-Q>=;FY0$\$?S;\.S,B]5][/
MU^F^47F5ZLRCH 7I0<,@F)3!%.=8L<$B/MESY,\'Y>>/%F2;]C7R.-'T#+8;
MK4.%CESPG($Q01P3-;VH6 ;6)92>>2=UZ^[3 \CJ]"7I2"0,!=J18ND9:9>9
MWX$)7PRI9N%%?:]-I.6+"H"2##Q;R+ 33Z;2AB?C/_TCT\CX.EP8'4#K14H7
MGR_.:Q+LCTA$I,NAZ_3W<]P(;)YOYNGNW?R90B&"=0)B%J'>#1$<+0="2;(.
M(U.9M6[?THKV3I^XVL!U$@&?FH\]KM;<Y/WF*)@L#')R=?JIC1!8"74W(FD1
M5"RMJ\\?HJ?3M[&1->:A@NAS>@2=L#IA=?4V?*M6<J #E=+R@DB;A3@[GZUG
M>$K?M4,^OD&J]M&[:97 ?;GNZL5VX7"^NDK!E04-%U4%.:/I;O4>'"/;+?(H
MLXG(<VAN3>\GI\'5>Y/3+R^6]:R2RZTS'2\!PI*GI6Q "!PM!)6"#]J7@,T+
MD>ZE9&(OH1$.[KD/3^5ZPSJ0H]OU;([D2_IFG0G\H4Z>VS9$79UATEK4]QD,
M)8/*6*<U^03%!TO6:93,L,>4SJ.K3&SB-P9'6Z;V8=;7O=#-6W"U(JF$\U>(
MJRW:B6V_+N9I"WV6LQ*UG4?.A: OZ@T<.#G#.M?"^*"E;ET3<@!Y$QOGXVFA
M4>0S=0[1=E\?,'W:'*(W9/C=;->\.G.>3$D>'/G'FKB6E:VS=@U$IKFP/GBR
M)@_13ON7FMBF'E%%-6)O!WKJ)[* %]^0;.V-AWK#QMQ=S$4J1V@/((LC]/,D
MP+E:F\"]TC($RYLG?SQ*U,1Y:B/II+:RZ !<V]/R;O$MG-_<AA56:8<<;&:.
MMJ$18DH.,F.%.:98^PK0/:1,G)\V[N5V$M\[@,_K.7T6KM9W/(68;;0F<LBV
MIO1&I%T8+<$X'3Q7P:G2?J+X?91,G(<V$G@:<'UJ(^@=?L7Y!=[8R28S<[NC
MLZ)XY-+05GC-Q&&!$9\P0;0A&W(S@LMFD 7T\#J#X.&>"SQ:,W9JC&QUY/M0
M>71^OO@]S-.&6]O;]^5BM2:O,Z/(3EH@SU,0IZ0!9WD"4Y24(I/B=.$08_GA
MY08AQC\KQ+1G<P<7T\O%?,.6_YZM/[V\6*T7GW'Y#LO%_,IF^[93FU@;F B5
M0&*I$P""A!B% T..(XO1^"):I^,/IVY8@)$]%\"-+)ZI-=8/%ZO9'%>KEXO/
M<3;?/B)>DK%3Q%=^ FTJ8Y' <@IT6:L"SM?2RSH-/(4Z@$(-4EO#UQR&I6<3
MK1Z3XU,#::N3?YD1O]:+.6[W<G4F2E#1)PO(.#F9,9$R]F3NR922Q(A2Q8/"
MUWO6&0:89QG!;L'9#JZY-^M/N/S^\7&WFQR$"#4G.6&J\U])BSKF&? H6!;.
M)=%\7M##% U#U+,+53<40P>@NO/\]^*^Y^W=UKPT6=J4(7M?WP0E@G>2-HE*
MLZ*$R++U&* #R!L&MV<3WQY;0'WFCFQ*.%>_AF4-XW_%$])$]GQ2@XR0(30V
M2OZX7.JZY1J*$@N+P+RJ5HU6$+Q&*#G8&(KDW#:?V'"+@M,KI5<KQ,UG_HBK
MM)Q]J<R_3*9W1O*0M 6GH@'E"P/'!0>ZELGVYP%E\SCB ^1,F^QQ@MR_+XIN
MP_(>"A8WA7LAU=P3'D&2C4]*+BOPB4LP9-N7S#&4.,B%;UJ^.B(2&HGOWHK5
M0WC9 P"NNXAPAYY#"9INM^)KDW<I(1047$L7]3!5\;PJ5@\2UIZ*U4,X-W7A
MXJV*2U%2]A8CE,01E+,>?!8>BBF^F%@R&]8T[/E5K!XDLKT5JX?P;VK!WZJX
M=#ZKFDH/DK9*A".9S76, P9MK&'*AF&C7)Y?Q>K1@C^:?QWXH_??=S]?Y=U+
M9W)VF>A7SI$KQ>MT&BL@F3I@P3L>?>ODO$=(FC;SL[5],(8<I@ZP;G;Q#FLK
MF-G\X^:K#[C\?.:8=R$H 2(%"\JH1 XZYQ 42NY8T3G=N5/V1%;W+-"CY7BD
M!!>-V=F!IOE'6,[J,=ELH+Y[GA5#EV!M$2 4)X6KBH%8D$%246C!4HG-F\%_
M1T2/VN0TS+3A=P> ^6V^Q%0ED'^;I\4\S]:;/.6W%\OTB;;T)I[//FXD]4,X
MK\_J[S\AKE]\KM&[,Q$,DT4PL+9V6TTU9[DH!L'E@#QO*@D;0^L$<J?-,1\3
MA$\EPV9P'2&ZNFMOL2CO+[Y\.=^TR0OG-<$^K#[].%NE\\6J-@H^.?AZZ$+-
M8K,G[7"<T&TQ)OCB/7"= Z@0ZA, ^?)&N2"LC%S$UH..6H=NMVK[:DLL1$X>
MI02C9>V I\FEC)F#I.W$4$(1?)0MW21B:A/K:!G?V[OR:/9V<#N^FWW\M'Y3
M?EM=#I-Z$^EHS>N,J9_^(-5*7NVKQ?+5;%Z5ZF:O5[D_9YGSG(5&D&7CY^8$
M+BD+V7)F=5 FI=8%GD<3VP'>C@?)8@J)/1-H;BN'MO[,]59U1B=JFR_.-8=:
M7 ;1^E0;Y4A/&V<VMNZ+< *Y4WL/3PW/%E+KTU3[$>/ZVHS9/O"_K7U)%O-%
M^7DQ_UA][OI389[K?Z[_Z6BK[>0U&QAP;??=R):KZUR;C5?HUBIS'XP$7QO_
M*I\+D&M2()7$F.(L&I$;ZX;[*3E50=9/?;UI<WS=V\Z68ISF&9(W" I9S5[Q
MY/R4[)VJ/91%ZYG6]Y Q[7W;0.YWM=JIK.[@.KV]A<W3I/7.DT,<(!=#EF]]
MM' N68BUL;I57B?3.G?C>RJFQ\I)@GT0* =SN3N<_!H^[]JQ*Z8CXZE 8;S6
M/<H$L3I+*0B59<3DY1AZ\SY:>L+,X3)^$#)',KP#X+Q<S+\BW?ATA'Y=K'&7
M^KA[T-22\Z(,L(3D?&17Y_*1@9>X=%(GJ75L'4I]D*">('2LS+^OV&DD@*F?
M_JIE^/,BS+>D6]JW\\*"X87\$2'I#B]*@.18@M2",WS42K[G<Z=UNYI"X%2N
M=: ^;O/C^MT@!#1>!0E,HJPYT0J\L1;0,:]TT25AZ[E?>TCI"2^M+97C^-T=
M;%Z&Y?+;;/YQ^_:#*A/LO0:FZ[7,38: @K96;$#),";3ND7&0_3T=.<<*? '
M070"]R=M1G<5";L1I[BJ-JM96\H%"+IV^Q#!0+3H(9(&C298PT3KZIE[R.A)
M];1!SJF\/K4W[X=VN6\W=G*CWYGT-BJ!%ASR6A2--0^0:4"=!$^B)O&-"9Q>
M6L^-C9TC.=YG'=5F0PVJJ.[]G$9AWB>IH-H3PO.Q)"UC AU$!%6,@"#)UV8\
ML^"0K.;<NECVZ4*W200G'"K0UFE0$B,XI>E8*,NTLL%8T?K-ZKF$;@^1^Y#0
M[2&L[L#&K?INO=5W=3[B)N2DZ3+$.O?#U6)E192!BRE"1*:8Y :=;WT6[J-C
M>KR<)-Q[;I:3.-TA6K9AA:!+ECXB,!'K$'"D,\1\ H,L6AM-]*%UOL;]E$R<
MC'&RA!^!S!'L[@ T#\<.4?OD&1TIINO#?'(98F(<$K-HB^1%XU\H>-M"X@>%
M;@]A?P=8NN=]1*&P).("UC%;VVO4_%LI@(Z61!]Y?2/IXZ7Q2>-WIUQ5)W*Y
M.YS<B( [KUV23H)4HK;!* 5B\04*CX'$K'P8.>3;\4OC03(>^M)X",.G?AOZ
M_W"Y>+N8S=?O:QO-5^2(OL5EJM'':QWZ'N>SQ;)JTA\OD+CE=G- D_**9P6<
MDPY52@9B7IV!D(N*AEP)=G=&P)Z'I!.(Z E1QT)@,8$\IL;=FSD>NDV]W29#
MSXHV!KRIP_1*8. ,L9K,SAQB]L7=397> [OC:>CI[FN!NB>2QM2@>X<9/V\*
MJ=Z4#Y\VN[AK*NYL1,F3JZT372T35RI:"%+4-_Z<Z< %:=S0=LP#E^PIKMP"
M4N/P>FH$W4D*B%8&#-D#5YD1^+F%F'4$BSG5^7=1ECP()D>D4HS6Q*T]%D[@
MVM0"O_,DNT%P'<U3MW39D$8QKFIK@:(R69",/ ]/1B,DJ8-RY%,6[P9!X+&5
M>E(0Q_M;[9G:,T*V!R>E@+K.1&$ER)J#Q,'YH,&48$UFQN@\+./J\;6FL8='
MD.I0O!S!XIX10Y;8SK"24O,4,QA=1^O*R"$PM,!+3)++**,?=K<,6JY3W!PC
MW:'(.8[5/8/GP^^+G4W%)"GGJ"!PEH#TL0-?K 1K"YU!P7VRY63P7"TWC3LT
M*7B.8W77X"$<[ Z$]5)[7C@86[O8!$4'0@9#%GH1WF@;A1H6V1FXX#2VS;0
M.I+=/4/HU>)BN=T2YP)=)%\AUA$JBA4$S[4 YF/,T=8:Z6$-^X>M-XW'-"F
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MV-R8L'96LN.VVGI,1W)'2TITEC)YDL6)@-9'GD8<8->337.D./=/KSN(MQW
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MMG5;N %D]63HML%4:UET *_?YN&RLO[2U7N]6EW4"/E/?WS!^0K/$L]%J*!
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MB6%YQ@+/B7%R2$Q1H+A4-:HF@%LR(XW"+$3KQCZGTCQ]#GPK_#P S=&%^;S
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M!/)V7)VK*"%L1LDZ83(7K)[54=_*^BVM.43N0TIK#F%U!S?:/5F90@234=1
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M8+X\3S-<O;Q85CZ?26V0HZ3;&KFKG?4$G2$1@7OZFDF=<O-6+7M(&00H_YP
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M\ Z LZ_46[G@:[@!O&6U;U\RX$/@=+!2W:'56;5^Q7]>]?4'R7E@??TA3.\
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M?MB\RT/0]"A5$S^XM1'_75"UE<74=]7;BW@^2Y=/@(66G\T_[IY>?%1D^'O
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M0)M4PH0:J:'O(.( *S$$#M,UH3LJG2;W"$ZT#YO/'EH.)DHR9&V@9L(M1QG
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M]&8"QM7, H]0B;;C*D6&I1$,)"2W=IM8YXV91-J07B)FS^V,$C-6;8)[OK-
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MZSERI(&4VO4'=X_\9U:>&+QV3R ?5YT1$H] ;3HL])==&X@TEY9=B !7PGH
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M<%HJZZIBS4U*\MSX?K/Z9GJ$#D*X7X_0(>(.'6!V=3),4L,Q(J[G$8,NE#&
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MH1?G*.-9(IR7F.K$3;E+@#UL.8#&=<8PV@TEGEEKAG1Z>+6'U<,Q[MG-88C
MX]2;;:8GEUBE/ <ZM6O ;F0U1:D!$G'"*6<*,M^=AM]8-X=!4/?NYC!$[O$I
MT+8!)DNH];D2 !EWS9>E>T8K*;">/C/V'Y%AWW<R;ZJ;PR"0>W5S&"+Q"-3F
M@Q;MY](>WLO5"YQ5<Q24:DY$"A*#W0JHNUZ@*1 DRU0.LRP3_B?+[W,1.&_J
M^Y2:*.;H%.4KO]UUY\88FR1/0)JZABA$N]>Q"@'K[AE&[2]3ZGLTY"%>PEJ9
MJ1@?59F1 @]]5W=FL<O>5^6]KMO"O0RI6MUL.RKGF669"0"5Z^&6"&M[,V9
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M8<W8@I<;AC_?WM5<MG8!HE@4[8,?WVW<%\/5!'A2BF&2C2<"\^GB'2$;KH3
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M7PGV?M(KSD?D-[]%W_S"_2%XH__K/_X/4$L#!!0    ( 'TW"%D:R3&?M!0
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MO^+/0M[P%)^#[L"N];D<MWY3W!M!,Z"XEJ+@W]3R(Z!B+"SZ5E'NX"%8\[1
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M4X')U"GNC6H?1/M;S= D*<J9#>;7?.0X%.1FU7+"B:4H2:/Q&3NY G!XL,!
M[O!RT+DXDZN$Z2ZBF$WZ^(8XY3X2\).#+6<'Q!*3!LGM>%I[]H5^]K%^=I 1
ME=+^V@U<LM&\&;Y'3CLUS+ZC>]#S2&3IC1M/FW@[WNUQY=4<_ZN[V]:7M=_@
M>+L[N[NX+/N-U?C.?((;(\''FR/!7^[L[N$Z'(&M=$DV[WDIRFJ]OI"H&XWL
M>,ARI3%%3^83-@:%X<IH,4^E,>3PTC>9R&/DIFQUIUFZ;2X%A1/46OS)L7$M
M_7-R4K#UY[/A'#-+\L)Q_2S08Y&;A6FHE&]5&SUZ8LJ%9U^VOH$R8 *1AAJ
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M>N8/'K!G?G.%_>&]$?8#2F+;&*NH"^Q!Y]59/SMFIU6I 3!@;(U94(W>CI2
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MGR-\WE94TDWLHN4B?5Y:^DJVYGEUEL6R$E-N<>,CZDBSUFL2<%^SB]]VM6_
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M(VX2:+8\//N0E%N,MZBYV9"2TKFZ@L'#4(WSGNL7BL]RQ7UW/"PQFB"-[[$
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M@^J 425IN@7!&9=0&\:/%'XWU;"UA0 . <8 =JEYCKCOACL*9SH!ZH7'B&J
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M+^T#;AE7,,'093#B%Y'4,:;ZL:7!K<!-63(> NM=HA2QOUDG&>T0:C=.NHN
MW-T(GC9!,</Z"/<DN5J6J6]ME)+"$TRV!?XW)*TC::],WH;27ZJ"S%79;@24
MP0YQ=3]W14&EAY>QT]XUF)6)5O2XE_2"EQ[XD7=$S#GH:\"^J3L1Z"9@1BR%
M\Z>41?GL=\^5:PS6H-$M<>ES;8E/F' 3+0S781PHTO7::SCF+2Y[)6K-T;]A
M<1V+>X3&HWK4Y\ZQAY1]Q>PI[K 6,R^]4=D*2'M]@DU/JB4R-4O"N1P<80@_
M"P VSVXTR)>E FXU'!HD!-%#95]^ S!WXP3G@7=5=)<+04IJ;@8OJ6S=X'0L
MVR 9]J)^C]RWL$DOPR:5\]MU;[E7<E^,%Y2X##]. &\7;-PML:\[!P-(!C^-
M\6J?,A'_6]+=PPFV.-X[7%$& L)^I;[8X60H_=XRJQPANG)HJ9:AZ#EJ,BQ+
M!XT;5AW+Q2VY>X\5C7J6-N8NAG$U_Y.RR&1A\$8B[/>?DVO6\:2R>5$]HQ_^
MJUI'H>D'\["(&DCTQMD0GDR2M "61%J"SWUF& *FB2E=P[!/TTK9%*N7@?5=
MI_&UB_(T7685]G'F&!8'22[I(RO0TT[\>1U 8=UQ*F;*3+#[DU&IF<C$YJ+P
MC6EIK$/I&E"Y2]-@'Y+,UEMIG]NWN2YEX[E&"TW!SU[(1C$[UO9=;19SO\3<
M5(^ZC0JM>0O#YRXBSU==>;19%@BB#0 /+NU^!:73M/-<XICK1L9HF:+E'"_]
M>WTDF,MY&? MW2D)6K;EEN&:9:8S]DV+(G&2"N#(>$W<D&K(O<K\/97DM6J<
MOD@#UPJCMN?I(L$001V:BBD6>=E^@%L'B7FZH!W1:6EW^9.'*;%#&!9UO%BA
M7$;7\^_6 <;SK!S7]88L C3"RE5^\^)6?5_[[L6]143]XZ%,K]TUM3\D2:W\
M@@\/?RV%A\0102M$G+ \)-9_%"4WJQ.O90.YO,(ZG%@&MEV5I39*ZL_8<<8I
M? "38^WH3)O-%=-"_9?(]=3 D@#X.6OHM#B<T9-)Q2+;%#R6R16&>P+NUHC\
M!;3CP+(R=,ZIC6['-N4CHF +*1A4[5'F(EU+<L4Y1H/HAJ5R$3,R"E81<_)M
MW8KQN+TCAPB[0G#/EMV/C+&PZ._3D_YI)/R+&5F]T<EZEE"]2B=K:&0=W2[+
M1OT<7]5)(.<RH :?3GUK:6TU\F+J^::T][8K^3T1Q#?P:K>NEH6)G#O1V?+K
MLW+IOM:>+\'*^OS+:?/F27)$MG)UG%N_;0\4U#>S49VSRDE$@Y-J'A746*3L
MGU#=V\FN>0<4-IB@WKE&X<7%&-]RTI\BP"#@<9+2;&/M07[B&S!FI?]?\6V&
M91MY+B2GENDS/TC@W;QCLY+ :." 6YF@9&.MG?91'?JR3P95*7$7F-4)45PE
M0.&X.BC4S"4L6(>!D[!NU=:M(+!L##+J&+CF.E#^H;?1ZH\#]K8V6N5]&]O[
M1_[E,^MMCW=91UOJ-.<7L-Q<([)J3:2Q)AP'M]X^JJ^^^;ITOT %6RL!)Z&.
M$NW;YQV8Y)_F/!$T\:]3S1YIL 6L2>J(WR6BX94*\M.0YU)\'S?8#3(F7P53
M^:I5W=!,L'F/2ZN3WK!VEZ7MR<OQ>N32Q)U6= 6N'"@VAZ256^9Q0/1/V"X#
MQ JGJ<DW*0DBI'HW6/\<<"7%L&\6&#WFO;Y$/RW>*CO9$BAF7AZ*T1:N?W,T
M&&\,]KCPI@&_;UU4R1(N$^%N.\ZIQIR@0Z?&7<.=WM#5!K0;V99EX@0"$-D>
M#@T<OB^^/IX>HZ/^Q!MN8Z1G*?<BYV K)V"%WM46:UP(V*C (J;68X'8Y?P
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M:8="5OM[G(9+^&>:S^(W_P]02P,$%     @ ?3<(62=HK@7W-P  \6P! !<
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M6 T8I2["F;DH%+B@N/1)FL-.+>!,:+@:%I?L(W@(,#Y+]/N?@1:WE::O/)H
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M9J: >3A%/C>):H(=WQ5C!%ANL"@RT(UDBPML*T_NTV_DY(;=.;E&6H_2'(^
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MEM(N$:6+"LJA3U$]*GN3-C R1Y H]*(!@UX4H'.'0%R(SVF$PACC5T:3+S.
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M)KL^BC+Z,FG5E3/<7H0VS$@*&VS&4&C9<ZB+)OW&/ A+N!)I/&6$2N0L)>S
M"[-1>F9';X4S7ENN\#Z*T8,7_/? R4*L+56FJ+7<UNJ&H@MN6;=GS)1[E<]Q
M:!9MSW\D82AE:6(0&CT$Q&LE JQ2CW<-;?FW.8+ M"*O$PQ9M4QF&)CSN\'
MWN!^8P9PSR9%X,KB%^:IXZ4A#'2 CANW6PV(UJ4D/\ZKLT[TRGRVLFWCX59V
M&CC<GDX#HY1[S7!2$"<O1WZK-&1YW%/ =AD[=2C@FV;RFOWX)F\6;9F5)8$;
M0/'[VBNRIN?A5OE$NX=F##K-S 3*D ?;\%.KPD &&^+&F[K.C&%S&;D8#"K!
M,HK:%35:E*$<OP2AJ2(E,N/(LDW^ZNVX4R\1;DW;,C_]SDO#YG2@57U-Z[K
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M+A:X(MK+"5LWHD_H7/O5#^?)-A;R'QUL$4L)!A$=H@N'?$@DMEFV<DX&[-R
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M4SH(B=91U4VS?.-1F2]V7,ML%9OAY425-?$\)F+%&;7WHP^%6:?,KE-5A^&
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ME]2>PN^24_T;3#--?P>7(A/!2SR@4B7=G]GI3,D).=,X>^/M!#0V><?&S?[
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M(O68U<0QP%5Q&D', 3(3J@SW. QIT+_UDY8FT$I-H0LT8'$2R:GM-^$F7+)
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MG^ZJHV=%J#L&<9MN*]7_#ZG\34CE;&U?226OZ]I5>Y8D;1Z(7U3-EK>0LW/
M/*5>,[6Z.LT?0O6K%:H;SL8>4*C;*-(&*M(9MT*6-9';X-,2P:*AJ*00O#8+
MDQ(D?\R_0F8'&A%UD -^/JQ!($U!5,Z3_3:!5]TL0K^#O'U8K/"Z";DF_5B
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MMV4((;)W*HP?-#@/4!\BC8>+, 4+C%<M\FF2 @6!+D^D<1A5F2'@QX^R&;6
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M[^%D5A1I##,U-X60)">V<!-72;R:<F3+R/-.:V-4E>!Z$3]?T3RN$EHD$A%
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MYI3@6E3SK'BH%7J[V$Y;Z*ZP@O0GC$BG=L0, X$NTR2WUL-J7DF6QQE56?-
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M)1U$36.WN;KFLW71-=^(A.RG6(4#5UM?@$6@6L9)MG2<QI??*[3SF1P33[O
M.1XD.N!N77.$*!P@^M(@KQ(S0&6E@?&!^ [%]7L;8Y.%EF?"REC$$+%="S0]
M.@MMC&:AXN-:V[1?2_DAQ4-,8-3BM2K;O([=VN74909+*ZXH3QR+9ER<%/ %
MD]>M&?\58<S#*[HZ/YJ.,)@&%DT4';)'(>L/"%\LX)X.FF6QU+TGNTY4LP>D
M6%4D'QT]KBIMCP&GVEU3^O9,JX^M:>9&DDKXF)52(N- %MYM+:POZVY;F3/E
M^;J<*97BFDO-GV4MG,BM%L%T%I7=?#1-;VFLCH]6>U6IU5E5W:<T# MPA%S)
METS7CI-'0Y;Y$$Y',6K1D11S!-4;8DIH/2!C#XE: =513IF/U (.IA&F*IZ)
MW*82II(X#Z=*&.B\X2I,G$.UH_2U<S0AL7CJP.B=(J<$GU8IYVAM[+H;K,ZZ
MPS% <\C0U=M\/4YOA;4A:X)GK>*-1W0P^W0P'<$-C#6DM&WL= Y79SI%C'P&
MD@XDC!4JFSU=_NI,EQ'YCI?U,Z:.'1JNP"\DNV,CQD4&-LEQPODG,]BPC-/!
M+&UVW;MWF8.C,+(JM9WK#A;L1M$F>@N:G\43C 588=IH?2 :.#;NUS1 3GM9
MIP=!-@EF8!:[Z!4QM(J,XBJ6?[/7O5Z==>]H.\[2=V(][4YO&SIC'B#\>*O"
MO( W*_PVT0S<AK6"/T3(<A8R/P6>:]HO)V^3FW*:(_N9S2.DJ!)'\S=[78Q6
M9EWT>MW]GED8HG>4)W<!=AU/L#Q"4X;(2TQPB5D;."O I *"S$,\D.8T;^,*
MRS;\W%LFGJSAW L>,*5"W@)[/:&R''#TT7HHU5TNY0_3SXP&V-B)G*S<1+KN
M!!,&3JM26V0Z?^_,MTG!QJ_M;B?7IZP-/+?M$B!X:6TYD,DYT":89T/15+]I
MPY=#L#++ >3W4R+(AHTX#%4PI1.WG-%?/7=]-25J%58858*S1MYW.(-'.J S
MH.P+J7KIRUCZ>]3#'7.T"TC[;J*R--8,-:E!LTOHZPK0!J]QH=L"VA;H- <H
M",>G7(-X ?DAOA A&1$LKRPW?AL:1C5&GK/L0=KR9A]B?ZS>8F]03JV33-]R
M&,XB=PJKS1"3%3XZ=Z?@3X7E8EAEB:?.0N]'G!]0@]_;"^IH(6Q3A;?) IR+
M6!LIXBB "Y9,C#>!$9<(^QL1+Z3YE%Z"ZI6P]AB8?\146P2ZY_@B[ D,X6'8
M+6=;-!_(0J>>=)IB>NRYE")E;M!+XHM&77 S0"U#S\;N@8\KLP?H_(^^"/JB
M#E?"*1^%2,;'$M04H&QDTR,;?IC# HV&<[L/B?K<QZHP28'IDM!T2=VHKW]#
MH./G-0K7,GU4*_!-DFT:& \;#5V7% HOVH8R/R^4V;)[E[172W#,AR AA0'(
M+F6['X@X(W)R00M@8@L:HGU=%OFL'#?O&*)->9?=I+"KD'22*3?\]L0N<[94
MP@ U!GB[8:UYSNP=YGV8'\Y!K$% 0.(-8$\_OR#B]+,/5Y?OS_H7R*!^>;&6
M-1A<(4@&',&])6B\D":4)QCK<\$B[6#E UD:HE<L!GNX90H:"*^"J11W,.I
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M+DVM95B&T5#C.KQ>N*['L($38L_?>9!@V 7K!"/T?%8X^ACBF9Q'RS.F<12
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M$7#X"4MRP_\FV33\Y?\#4$L#!!0    ( 'TW"%DMVYW#^*(  )CP!P 6
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M9D&H<%45DY2,5/J4HCI;3C00*<),59@M@ >8FA 60_[G,=4(P:#<T+VQ@2S
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M^I)D3->\L)_"QA1UML5G\# %L2,B94ITK=)L^"6N*R5A6AM%O3]8;&E?'&I
MJKHW3B9!I#FHR0;[2=@N/1X+APN#Q:9S*'X-NE3TJKU940H)9(BD][HYKF\]
MV/Y@<:SD(2#A!EB18"\-84L^?KZ"'S?"_$L<FL$B/>G0#!9IQ.<'CXWX_XP+
M(L^</C"YY?79*8/%)@;S/;#-@?^P, -IX95I1P(("MNOIUM""8C>.;CN1#G0
MI@<D(YY#YU4+E^-'I[:J;5.&WF&#;]7R>3S[]'0$!O?%NQ;>;WWV_6!AF+[@
M&=BVI]R-)Q+YWV%*TMD:Q=!MC:-5SJOA^;1Y76PU<<_<<@MH_+9?YK3K>#]/
M[IB133*5SCBMS P5@Y! W(G4$'+^<1BM0\2&2%F#GUT$@1U%T?LY 2<1:TE=
M<4TY-;T('QO"_\+J-G-LT[9%F :Z7VQ<PBRM"!&Q.5=?R(:/UB8.O3]8;%QP
M5(>@I*1W:0C7M1S(+?;)3KBT6D!ZNDY[:;"PN7<(XA[$)OH45.7!:'>==L=@
MR<%,.T(+F'YT.^49[)2UV2>#S>:?:VP>,H2]8=(")8V(^VEC[0SB3RB0CQ7U
MU#=I8BH+I%+,D@HPU;RJ#,$<-K6NM"GN:G?B!H-4E8FMHS$W2AHVV1&+DE_9
MLC=#$(YW\7^_:>]ID7%/.U.Q0<9MD'$#E\R#Q:SX"/KA :T,;E\Z.7L-#18U
M==[ZN-UJMZQC#&/$B T$Y6^0@"W,,OW+UF#$%K9/O1@\ED;?M4+AOW6W#3+\
MS>$AL=:Z\:V-37$P6.!!WPX8T-8E(^&*@E]Q1'S'<<06 NSG+>RO$QN  972
M@/0W7U-3QU+M]/W<<B53Q5M5T6[&+XZ*)I^DV2).98GOG;S!I]EZWSY,8IK?
M%-D-<PFY_N9X7[G'58DE.6RC+*BQZ0$QP:<MT&YP8.P( SQQ^Q1+3UT!!IL:
M*1/+I**@ !:)KQ?IE-Z5.EBNS[D<+/#".Y?G'J!F0$>3X;M&D_2A?GIDBRV4
MD3)\@]$--BGK"^Z8(IY#6V-TC\;:JH[!PAS.W_XRK.UH:S"IS]@"#E8/Y-VM
MY:2TD\I5HM9G_PP6_(!YN"%LH$\)=.WNK5&DZV"P^( EW5Z'L&-8Y%#/KJH9
M[R@96J3J&CXS-:!IY2*Z0B(_S)RFF=H5M_JMFAD<H/1WVU+"61>]'0MM-S7;
M/M2K=D/B;M?V[\U"XR),R&-?^9SL8ZH.Z-:Q;Z78[7V!:AE%T:MV;Y6P'S%V
M8Y&>Q 4R9?7>IK/G*;]'8TI ?CSX&G\"X7$/>;'.OH57NL  ZO('X6L)U9%'
MA1K+(G =8BZT8*Y:R^.BP>&5$;S=%'P0V'K<HB8\03QC)18H&G"XM_"Y91T3
M.$(21R"'K^W4DWRGN4]L_Q(8[BT:I8AT6!NA/MB$^N5U6B;L0 Y'B%-:0I<5
M5R#X!84I<U*@@(C->9.\A<4?4>M&<8P%G\2__"0;03[",J[A;Z_!YMB][=6E
MH!K.AF/Q9Z4:Y8 H3$0U</4MUK+UMWVC'980QT0+[(&>[XPJZ=;'-AULMC[P
M&(>TKSK$1-/H$,PAL  L_R5F5<',J46;I^+RS@OD&B2E_;D;Z!LE,_NWR^'Y
MY>G1ZY/H]!MU KU_TSP=/:$]@TFXG][^X^3\[/#LZ(1QG7][>WIV&5U<GIR<
MGY[]%!V]??/F]!+^6I.C>SH:3E#U^>C9"YR)13QW7Q;>A.B!%<WZEMH>RJ3O
M[8V>T$2\X3:5U^E\Q5C92\\#0\M_[#EA39TB3)+$Y]\NCA[4!H)DIJYJ\*S2
MZKI5 NLH"?>74&)N$S9Z T<Q<)1GG:G8P%$V<)0A$37I$M%HTNN4@PTJ0Q;E
M.5A-,#$9)[=<U'BLL^(6I,]ABW=B0:])(X X&HW]>J5HHKY&4;6UOPT/FR-K
M,S%"WL"S*$I"44C.RK*D:_]*1!#>>V&Q#(9C'E'QQ?%*[6T;Y>4H$DS[B5T#
M63ZF#:< 00YKM[MM+._VX@C5R:38F5RKM#21"+MDX<TQS@9WR!0R@M<4X$/#
M!H:"J]M9^+)]7[\@JN'"'@1@4H00 V$U^)XY=GG1)C=;?)VD_RHMI?%P+*7=
MT?Y3G(CSEA09@+W4$6R>&.%<1BL\RQM_K+G;Q*?LE6!.T',9\NY)O]'NN9^?
M=>]@].Q[G @XJDE:39JJT\N)VG_<8FT>,:OI*T>,UL7_]'90)H]U?1=S0*L)
MLN!9:S4IM]5>N,KTJ37 RH4K&::V"-;5VA_VYH&!@C6EXL3 =H_4N+C1Z[X/
MAK,1=E^,GNS+1IBJ"8I?*DR^IH09ESFTBB/\L+'Q<Z5A#F;(+#.31U:,I@N)
M\35?V)LAK:L5US9VX#6ML0=<3Z?I)!656@I"U%_N'I9+F\[NG'L..:[M @]G
M?6W8"XGSKY4 #8PHQS5QK1+9EZ06HGVVE,_EC>>X:.HH2V=I;8&ZEE:W5]33
M=DC%0?DW..4W@Y+>]I33+HCM%F!=76 5&PKT/J&-HB&O$*1"64)RP&YT2=PD
MW+4IT3,B9&X#5X(.F"W,.&RMF69+[M/"W8]L$PQH%SQUQMP$&R>3V38Q60?K
M]J,SA3[]%.;/$^O4 [5*2_++IVU$$?[7VT<6 ^-I=VGV1*IA4LRUY[Q9(=1V
M\-9=1 QI>^PY$\\T9/&E1 (K*LUB#"4[GF]K-7#KF@G%"2EH+VU>J',,)W1M
MCPENCJ/2G()/IHBVCQ[7( Q\,!R%"M^O]]9(/PYG8WC:HV]CI-CGR#&2STO"
M(,V+# U&?WVK@BG_=9*J=F,2HVP\>8'8/8W;I&:NI= <6>_E'\[J^Q8DJOU*
MZ[;;1O7LOB)A[9+TFI&616I]UVY ,MT[NB971-0#'$&?-OE$0,M5<'C1RV]*
M(3G6F$F>%Y4)MP8!5D5%+L7$G.6T]O"KIK97#O<R7,._76[Y^8+\\2:WO,DM
M#U2P38:3H]H;/<=Y^*E)R;)X5Z;Y) 4S9 A)*I<O-R*7<ZRMU!5VP4@BB9S,
M[0N@C+W"1H13!?X26EJP%S1U+9J738+_(JN+?E-12(X=+?C,=FK^M4FNI% B
M'!'5&Q1YQG)Y7MR"0L?&2+#=8##Z(^9JJ^Q.)+FOO[$T QR_/889997V6KJ'
M82)3 ..>BHAUKG1 7#L^E.HF$!P<F_H1\!5N%:;^R35(%X:A1@%P2DT^Y,5M
MII,KGA5!4!%2?LH5%1AIP.?"!#-\ :;P+@AT! YHD6EI!]5:+S.81= KZC*P
M\.I[$I487&/0Q$29@$DK3KZX%+E5>]^; I5.5]CTV")%XGM\\7NG(GA.L6AR
MW![ '@JP$J ;.'((_J(MO.!'XFGJOW_0DA3Y1\$=K=AV:=D?-KZX+MB 9#AR
MUV #<!^_T<0.X9MUJY"Z%*Z2H=A\/VR"+&%D$<)')+)E"]X:Y+_/#. R;-(U
M;FJ$I& S.#A[MP@[P1;G=]&=5F6TI3)A\X!]2 <6^6P9R"*CL+)%1;0Q,3I>
M:63']#B#25CU?\\A$*'RP!/#QGJ%Z)XF<^5B1<>\AK,=#H6+X& Z2+0FINB-
MZMG@O2;4A-VR]7*3H\[M"?#SB^DZC$*4CCL+C!Y<E_9P1[J\H5R1%;2QN![+
MKZ.*1 3^).Y-%%8^Y3LW!?.3C/'>J+VV3&D=>S:]OR'E,_$:R%.68@RG7=E2
M/[J:'V^+ >T^4)26AIN*SU-?@S_41M#YXFH;3H4Y(+[PMQM46ZP;J6/D)C8/
M,^BL<(Y:4P0/DV]QGW#I9#I77#;8Q7Z-/?!,IIGKSI5>%+?89FZ.@KMB2F3O
M=B;DYA^TD;4K;E.^.R&Z> .KGI%+ 9K > K'NN0CP>Q0*9B<W^A<2^!04Z-J
MF*%9=TYC.K+]]Z*%SPL?'"E&#Q)-L[89Z[N"]#<N*<D-V?B\4RTLO[UG^5#
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MH)EFZH-NI5&H9 ,NF5KXM@D/K<D>&E[ZVO=K;+1XG8W?I0NTVEC(VS^4EGA
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M4D2HR!);52=A2QJ9=!1LC8\B0<N.<1B)X4#GXMNE51 D>:C\:9UKV>^CZ#2
MCM!Y:W(3Z B035;[D]VQY'VVPM!+OR00#T2:Z*7Y=G]<C,0RZX6@8&&LP2*H
M0!I<@5$O,7!FKUJ^&6+>I\*)=6.0-%/7F75_]*+'Q!&YC/FDM>GQ!X;*<#JW
M&D/%[I2?./.4W:W8.KEH; 6;=WX6]%5GD66=Z)B=:Y./]'W0,%A/>(%^A=67
M,;$EG(8?P9;7C,WT64YF-LXE[T8(Z%;F3:0RGT;P!]!.L=B0I><<[[)*_)'I
MV-<G8$B3#Z"M&B)X)#D:3#I+5IL;=5P5WB;K?;%8%J97JG9M.0\IPPJDH@#_
MFB $!U@4XY]@NT+?"*:WJ&1Q*7""DS?\[6U1?@")<:5)U?HLL&%:.C4$"!0R
M*Q7RR98?G(O/5@MEQ_-<-"M+J/PND'&1Z9%*^PL$$/TJR,1V11JY(Z]@6Z-$
M)8EH@B<D&$GFAH*XE1&U@K7[@S,];K"35QG]##]":)ZX$GPE-^))-!I#A/XP
M]!!;S+MB4X=J@BE78TA9AHB%(Z*1F["LU02P'@EQ]OHYWZRX*OR_G=ZX5N5,
MT?>LB&B2_OS=[O.#EV"^3:YSV'%7=^%=Y><*7BI)B94E!FF4_M9HGODH5S/=
MR2B;"3PNFRO0@(:?PF][1HV+M@7MT)U63-X5N4=,L6@B/F%<"X8E8U"Z+*HB
MBZZU2KJ/WV2O3/9J]\DF?;5)7PTY?=4G*BQ'VB?("P-L%A% +4J,*+$"0LQM
MID.CZ#8\LB:42Y0WB'^+;6-<!CZX;YRISI#Q:>HQR'T!Y00O\ JS=FVZ3^/-
M[H\.8D/4(6&T )(WONL+&("!&D<#,>Y#23X @U[Z)$LT@G R,%.$<@/G*,'A
MTDY3%4$^:F/3=/VXV%?BA!UIY3VM8>5"&^T[))J<,=@CY-H1'K)6=5,Y"I^N
M(=4/Q(ND50#%Q^#J;D.@MN/88GSF0 [5-2V%'7;CW7ZGHGF)!4YT 8>;)L6.
M'3DZX1,\F533&QZ9KHFQP'WVL4&&[1R9NVA!^WUT"E)-!=$F2%*Z-1F[T_N'
MXL/>%FP'NM*[7S=2[7WZ*D586N]=EXT#%B= L6)(4X*J@<UMPQ8> : 7UH.-
M@'F%'?,SM/).&&.H?!#PDLH6[W:<J<&A$&41AXZ=!-O=CKN#;BH&+V"HMD"D
M[G4!;DNIYM<5LX3 O_ XZGGJ<*O= (M!$H9]5;X=CG UD-,U<?X'6&+:.K/&
M_2<A'[B]YWI27.7D&*PXOAD<K>71 3*!.L#Z9;$ *R*7Q0-ZQ*!QL(WV6!11
MM8I!TA)]J$R7T+DN;I$8DC,[F/[47(9MW7G.?WCIE$X1&=T*><C,ZO7)%0=H
M<@F:GL"QR\_<AXR(0A+8RH6D%\:A#;S*0H6-G9S:[ <-U4[G J/ 5\FB63QS
MVOK;_(UG^6Y5VQZN"_G\<#FK6O<]9?2IVB/N0\U_EC[HAM;_3;'E:Z(4AE<S
M3COU@KF?SS5BHV@'CE:;UV^='^&FQB/$9[DR"#-K%@?A6I(!4M-C)5>/,)?T
MN ]3ZUPR[P&0MJ$^:P0.>SJ4#6ISKF:Q+M@96C4<S.[,&%W25CEY+/G*#D Q
M+  )2^X\*BS\?(9]K#!!9G:>\0(G:JXL<0ONT]!;:*=;'2J"DZR!PKH')7%/
M<\:P+Q>V8'=_<LH6%%Q&)LN48-LUM_KTFG?=JA(.*1RX2:;26=_[X.%$JX8O
MKJ*FZM;*BKGP/B?'[**V9;(_:6P]:?S.(LMVID3-305CO9>-_$3HLL2R,47"
MAWJ& 7]@PUC6VB'=YJWUPN9F"]^*''VK(Q5.X@R-VKR:XCJ S0"F+A@7N>'B
M)DI:S]0SA;+>@V&::4[11F4C$C:IQ;LM:*L6K *3#BULXK9)7=C413<8ODE=
M;%(7 TI=?,N&BU:.<=$,.A@2:97. MPA,@GZ!GB&H4\@"4Y-6\G<HRT#,/4T
M+:NZ#=/M]]KO53DQYCNJ1N665MQR6 9%FUW4XS*E(V9%IYP_OPOOVO)*=72A
MIAJT[+&J%;JQW%K=0[2^,M0X9-XR\!)GS $6?.LD.LFO>,KGFCC*N"7#1-MI
M%]QSDU.6BT>);2DR5WE1$(<#@KNM)KL!-Y+F(&%^C!SK;3/7@ @,D)*F3";9
MI,:631E"<MUT$'VSQ]K_:;:5H:UH^>.?':P<!G?./P9CZX^>'!CJG'>'_WIS
M<G9YL28NU3\&19C#_-=8-K%Z?L$U">D,$>2'93'5:D,XGJ)^T^XTUE\]J$PX
ME^([0X'O\EP.(+._'>KV%;:$I9,'QAF6R:#_1>A@_)6SGK\1*=LBV>+Q 7H=
M_:1HBW8>;[);=*<]N*1ON6&<KYQ5<+3R*XPAH)>M.#:Z)I)K@!G*8\]&7*W\
M^OQ>)@L[%X;8$K_5I*OENE:5S[<<J2C7->&>D>8DF)W3:1]E@<NM&<^+C&R#
M86GQ=Z&\+2KA@Z:^1TT-__R=O3F%R!!"E%VY8>1!4#%L?<=^F^JX(=V&W6%6
M*H#@>'%_[NK82CDQF1JZ+3)J& F/6H<^AL?V.;DN$%"W)@=W>%FD(*7W6 ]N
M;+Q/B0#/XC:AE;5<)*/L" \DI"Z%B\:6"3.=\"&[O?C+\*N4* 'I&(=?("X!
M]G#P82SMU25N$$L-IY?$2AW;N[#QM6Y0L_.>Y@)9@U&W'MQ"?>(=G0;D1'1G
M5!RC<&UG;4OBUCS [UH;I@<G&H#R!F (!B,>@#TH2,_N7I):NWOF').<CO2P
M0KA$:SD179-.D9:@LU?OO1:_NV\ E 7J&^M6_[[9[KD'5W0@3<Z8"[:IT1_3
MO@W?2CY<;>G?VD18AD3FPQ&6T_RF&$*,Q0&7'*H^L,U,'_9_G/91^WI.?$IO
M9./[MUBG3E^'![+KUK>CX:>(3%-9]*XI)]>H)=Z6"2>1Z=K@TRJL<'89[189
M1\_00V0<$NW#?^$,IM6\87('>A\'! Q'+23LQJ*E<CG=F]DW4.#GHX-^@--$
M@0N9J-)G"Z#(/]?@"5$7]BFS-!2FDZ@H0AGKX@/[[Y=)W=MD4C>9U,>FIX9$
MO"69 '6'0F<0/6(>N5,^P#S 45-B7=K=:+6M< ZY_S?7R)$?/0!W[KC(,E4.
M(;"/IL\ )F254_"_5O[^NR]7>D38ET=;+]-7R $K)]=8@"VD8C3((W72E,7F
M0'D!HQ?[SPX&%"I:O+UPY7XO<LVE/,3-<<.^2(L/)47@?4)^T90K0]!+@OLT
M=94*(T:(C()?':E<)8JS'_;)C N^\^C+QCP.TV/+1"^-XR<INW[T+3I-_)C0
MO37.V<%HE^OG*:1%+VBP4-36!.:!GDV])5@SQ"Y\*6%C[+)&K>;Q"J;BY\S+
MN6X0^!Q'K^MD9$>887,SO[HE2F=$L%]KZD #/IY%S7DH,.-H$X7G4++@IS*H
M8QR4A9&=PU\#V-[;,>[+:_B$XPA9<6LJ-7#Z</-WE[L;GK>(0#X2MF'=\9 6
MHC6L 2Y%D/TKAAZ"/5GE;,51)^'S'[B!,8@=;_K&VX?7AA23^7ZMNE ).H',
M"\A,<DP?]TG0LL!UPOC D)W,]!LYF;W'*70R#T;/OL>)Z-6G"&-(\PD6E+**
MI+Q,E]CZ/Y;3_3UD;5:$E/_S=[O/T,9[Z/_W;%_]6X/LT@(2;V:HEK;^N>WO
M] 6VS);:AJT0,RT+T[.DVYVT\#QKJFCK7]M!134^X_#+/6/69'4*?_(J;_W(
M=U8SRBC;%]SZR)__UA0,TL=1J&W)!RPR+2+8":8 8&N\W:>6@]_'U L57OEN
MNY-?_O%.C&"D#C5=C&3K+KLG6A;MW+F=.OCN?W5SFO>\5.\-6;SEL#7YSHY"
M=<;IBK:$:SWW_XNV6I]\C+:V6BGK@^<O6PE5PM2 ZQM^O(U?/-MM/V1QH.X3
MCFE_?'YMQ/. Y//NB(/="^4S&$8;^;Q,/B,"M"7(B,$MG1I"R;&N;S4<WB\I
MM:E=T%"$=BA3G'CM^_W7%_#K+\=W^N1XYR?WR?5!"? !B^L! J E(1==WLWU
MBK$CAPR<X+K"$,41P)W[ 12NAZM*;0]5>&4LDH^RE-RVHE,">2_2X7%ML.$!
M=7^1#B'"2G6I5M]@29 Z6*YI^Y=02Q2[^9)&6YH"UCI5$#^60MU;[]UJ]=&R
MP?@-23)U*\AULR^)JU%])*BPI;RZ;06@I<*8Q].F)3.\6W:(B%ZWC8"28M)(
MFU8"+97"DT0&!&$@A;9)XTUR1A4G>E;DS"@N#&/V3;G+N_KH4Y^IK"JZP[#T
M.*9]M[1K417RA##P*">N)J%](L1N6GD-$H-^1M+AEFZ.9;Y(W %*6,_F=&=:
M,QI=:R$,>45AZ"BPLV[#&:P&OC OU5X_Y!6A9RCZ$ZS5)*V7E-S^^Z&@]CMS
ML4%!;5!0@U:)R7!4HK&Y7J.4%<-KQ<IPE1FFU6*$D&G-Z'M4[=CGG/OL@:^-
MM6]@ ^ _N16-U-&4FLK$2)43(AE_M26,XA;JZ]J-!M5OV]9&54C^"2('"0L#
M=W9>(MLT:6%5!2E?_/:(@,IO5'Z-7>7RZ$>5?XAI0OY5E,&_Q-"EE*YO2J!U
M D.64*W*?8:*5G)2EQ/B)0[#,]OX172';S!1&;9O].QJIKJDPD%$'G<>C,R:
MOS5>Q>(,S*!9,S.>O4(_E5^WU;\^Y"^35HU(7HKWI?0K-;7PJ-X/1OMP]#NE
M?6R?('E)0C61E@=$C)CUJ5$84B\SQGZ>%W<JPU+48=C_#JE/!F9I1A>XGJ9<
MX9E)X7>*;!_0';BW-!=#9/"OI%4%;AOO[8UVNV4&CYO_93#T+T_9-T5;Y_SD
MI_>O#R_?GO]K/4[^D.A?7HSVB67')WFVKN"&#.8Q@< ?D/\Q(/#+3C\+$P[0
M;3: (BK&Q#R*H0-_EP@+<XLUO=6>/FC(9CY<2G*.0A=9PM_^TNH!9]D!Z)95
M,YVF$THK9-@<BUJ ,!^=(+:$!\'T=)6>R2[H0:$)?$3<(91'LC*,OU!\ E_+
ML<!E=WYH1$\QX4(#SE233_JHT/M8W8+>S4&S.\?7;F>:XB38"@W[2</-L,T(
MOP+',5P9>X=4ARF2.XOB-7'Q>@89JYJL6DOZW4,GT6K_ZX?25#];/.T00[-B
MNB,'+!$V*W*ML_FTR9@D/)JFF:&;77!O"DJ#WLPIHI/=4>:'7M?CR$\EYF??
M*HAAP9S7&-.CJ_Z>%[<[/Q>W/+F\!;ASGVQS?Y+[9A:?/\<'UYY;< ^=?IL<
M'KN;>)0=,_5!? 1_]0/#N+\G$O@[);P9O/"6'EV-HIM4P33.%)':P]QJ0>Q:
M^FQ<RANL3:Q=C!)VZ(*6 @_8HO@-\0RV]VK[D"S9=2:X.)@])YTA"/7LB $Q
M_ FO@"(43Y.=#IIG,3*/3NR\ND[9X/5D6 IJ)CR4"$XR6W;'-&<.!^[E@$^#
M#6F("KVF-]ZG\KO#*;X=PJ.W:>KRWFY:=YW5:G'[AAMB$"/LL##ZA$_!P<)?
MLX])7S(ZM<"]&FS!>8F\%GQFL=N/J$ &P3^@:P&>-4N]'$N&U^Q8' HS:&"D
M7]H6A1A[9M5 N57#\<]Y/]/^RI?N^Z5+M[C!5  'V#3<^2K8&VZX0[J(:QYJ
M:F  6R&=*T];&'$E35]Z"A^"2H?8)V7QI#+<\]J+KIAV*E@.,5=T7I_N/MGZ
ML(W=669I174,</^CX_.?2:J!4PT_DUIT]P@J" '9K)*0O*KOE9@>6">>0$6J
MX&S3O-3+V!QL,C:;C,V0&<"Q.Y9F3XI5!#M08A"#"S%.<_[,@-.VO)9^H:K9
M-IH.;43*TM,HJ6GF8<_=V^TC.<HO0J1_8&36F8[RR@C&&=P +C'65DJ/F*G:
M\(:074FL62(5O5NN2<AY2*PX+O"4SL9-67&@=C"QI\^-D)3!Z]@N5ZT8B:>O
M%[76W*I"CAORND!%=]G<F:B^0A4FNMH$J)\2^).+'+?[+&(/'N*L8B^^(3PW
MC50W?D9(XE,"#[TG_IZ+NE#9Q7ZDPDP".EQ%4V+G=]/$!N]:%F !<1.#?,J=
MCQ4122XBV4>$C7/J,W6+?O*ZB(GAD)(8,;&\9<&*A<4O?=Z@Q^P4VM<+_#84
M$6^L/C/A5>-V7H'QFULJR=Y.@'UMBLFN[;H0$@REF\7"^!A5/,4)3K&M#% V
MAW:%_7-M>\N^'\/A2[ >VGBQG!LGKL:^;D\P\V L&@B;^85WT-JRA"5F;"3G
M(?5M*J@S1=?.B+:(<U*M%#TA!;K+-^\02G371W0-)Z?N+!SLG[/)I3VF7-JG
M-%;P+)Q'M,B/JX9N.&$\4^+<9TO/YAC]Z@\S^['>+79B)0C<G^'LV!/4[F@;
MLTL+8^)@0? 365=3E@',U"LB5[E6-_CL7YLRK1)NZ&K,8TK]4#:#4F74KBGG
M5ET12R\#I_<W.[(!=RP+3JCVI. PDXHP/0QF+[UM=%-D8)BH$A9RM%+MO=IN
MMWXOLK&&XYM[7</)@.,Y;'40H,065@L(N3]^*9-MNC%B@M(E-S#;9+8NFZMC
MS>VV8!MC.:"!XIO'23(D+\3,PS2I4*M(A8#-SF%RE5*A? <^"+*WB-7?W1=_
M.].Z7I J#5N%M\]6RYN5^5CX*-FTSLUUQ0\]#=_]*U45NI3W/6JMA?* I+(I
M;#X5P>-7^%"&VY=#FFI"V^?(.%6AB*LMIS'OL:K(D*F)?9=P:X +,M;2\;Q*
MQY)<!]TE4=**_!S6#KA--%S0P,L+'H;*<_%7F NOBDE*&2$;'H)IS617<HV/
M4 ,3C,7>JN\EL*^]%TSRQLP/IN+BU#V]P!XB\TQ-[%YNW<UO!.R_&HYI;C[D
M6[![UQZ-J?RC=8"7M,/_-#?DD9V6X1P7<$V>[#,EN9=TMFB)=G/+2K:+$%_[
MFSXI8(287(1MWV2R&U6HS^$06*R5;=B"*2*XC6G',H8U4PSN=X!^B0=>E04H
MK5Q?P6\XPEE2B!\1&S/0<F*J&"R.:0+?AA.@:$_9U-GD'FWN\>DF][C)/7ZF
M;%U1-A)D0EJB74E9!Q0(+"[Z.V[]3\-Q?/>%M*-2:+)5:,Q1?2W\]-7QH7.A
M>ATLJJD5PZ+RLSBD^+%)[@T;'*41F%,11VQMBCWA]WZG2B.C12LBV%AJ)=RM
MT$CX?0@FPII$L@;(,Q'J_4%5 +5B*VSC>^"YE09%VFD81(>B]?'@\$?+X/(#
M(-$W#00$D_Y(7)W6Y/TQ3Z>]E)\HQ<++[W%UHD_N2N?R^@<@/^(6)MK4LU9!
M_,5S=OU-UYZVMF'/]GSU2 SZ/V@2^/#[]JSR1!!6&=^YK3?[)T,Z]+FQRC?4
MF\P%N+8?,FLD3QXX95]P1JQ=HC_.J2Z2#XN:?%!7IJ:FM8<,MPHH6FH.U6[2
MN7!6['B]5IWV*NQ%JCEY3@@0.!-%)AV1S-GM(DUXH*Y:J'.VOZ@AL=*,Y].A
M&!(VXWFLN39K@GHX25=-H!!H-=#X;.USRUC<L:8?+$IW./Q2N\!^ @Z?3N!$
M(7:+:8+D%Z81&/Y&"QC:%33 $2J*#Y7IW0661&5%&N=_;'$.EQH1OQ[HIGY\
MR Z#DB@BG]CYC5M-<VFCNZ]9&=@Z)A^HA932&+A/L83/]1IVMROL\175:4!8
MI+V5O=K(L#0/9>"]LD< &M$W[372?XC<AEWE3A4@2+O>ZN$[%C5EN&&3SHXU
MO\$-BS+<5!W%QBJ,H^JNJO5,/DB:4L>.=-+M&MXTUY01014IG? B[_!O#6QQ
M61H-8XD?-4G Z6!4SNC)@:$)>'-X]O[5X='E^_.3Z/#L.+IX_^[=ZW]%;U^)
M:7#^]OC]T>7%FJC]TP&1"!CVD&6EL2L.)W@IO*!*&OYNAYYZR4+"1J*]-K/D
MI;W\M00'+T#T@N*>B&6/!L%2[IREB%+KA83,MJ'S3Y%%DA0,[JQOT1L>HZ=9
M<Q&[5^AK(9Y5M%7DFB,=-]*0]/T%J7WIHV.J!SF@8D#MYV]_V6[!0P7C:*QU
M42UH%$U^>O,NCGZ3R6-58Z#E.#VQW+PRLR%5_:**F&Y@9I>071%3ZFX>[U6?
MX)^;?(_-]SS;Y'LV^9XAUYKU@;M#NM:ELO/?%C"&L[  +Q5-8$7A"247&9@*
M.%_N#Z"+55>?#@,8_W[.U'EIB;RVDP8%_B(+P#)*(/G?Y)JYW8?=[.K5JAG%
M<VPTD5C[R N:]YM/Y'9.BB9+F"V?0B8<Y.841X>BJ%5Q!T>@*V0Z=60FT$'>
MMQ?ML"4N_$C#XJAO=%;,33'+8MZ%F6=\VA*V,,L@ME&,D9M4C5/YHQC#*29Z
M"1@:IA"8GQ)NUBXI+ P7YBW.$MM3MVFEY5WR!>_0BN82=R:%$&QBYI,FT,*:
M6X6,8J.:V*]ANG:%1G,OX06'+L5^#HXP91%M5#HU+X A"8$D$:=V8MFOO8SA
M P@\*. ]T>G<IB)L;$N0VV"V@LZQR2-_&U=AJM].1H(O22/BQ: MJI.>&XQ:
MM%"< .40'DWDWRZ.3!90L+!^7J)SINRQH5JRJ$PYG,DD67BP9!O,87VHDT:>
M[$BB33*H%5'Q9S<<Z9$M8$/V6":]+E5$IP,JE#;.]:L"0275RCWI"W><33[R
MV6B_EZ7D-$_1W8S,T.,O4 _9G_7MK9)$H'I>1$3\VVUC!"<DKZ^K0-P$9"RO
MJ*[ZR%*_11>*NE$$U9-&L(,70J]&Y/D@P4OX XXK<^<G[*?B RYU.8LQAIMI
M; 7;X^"/]93[+FE*%N-)Q#CY!)UU,''-S>-^4BY.+^!:8)#8E:G'/M[=R%RX
MZ%=>0C !QV6!-$,)!I;!RN;C#6*LVP3G3(^;##9-&?T,?U:ZKK;-LOCS5Q<(
MM&"*!F/ "Y=SFS8-UYK?4F8U#5023!J,&+?'$ Q5LYN'8)[&O.'"->ILN@YM
M= K;PF\\S.14-GC3VFJD-YEV@^BB[:[!]!*<XT8G(R),F,K,P.+_AF2YEMBK
MU0;&9S"@93=3*NS=H"=2@D3$/M$"ZJD9)?YMDDH@*BA$J(3#JGG<_)*S(*,A
M4X2: ?%%+6RL+.TH9MEQ1QX+ (@QFS8+E/(#F2'I)QA*K'!B=YHY47O=\.2@
MW"EA!Z2.DW("ZTR\"D+?:&[!0D@^M'VH6SEV]V:R8N;]/%($_1'F(\W;E(YK
MQ*T-"GPX% 9&@1MM^*XI)\02_Y;!999 <""A\K/"+^GJT5"!QM0*'$HDR?=%
MO^4](79[J9/J1^<A =";P\-/XCFX1_.UX$IS,]^.KU$9^=1#C@JC33$F+4SY
MDJ7^5CVK[^FXWK>#AJ"'.B2V,)?D^>UXE"U3ZSA6"^P(HF)D=Y^=#-^*#-]Z
M!(8H::3@$8[M;HRD+&.=&?]5H9Q--)HCE .G#(\'MAN7@L+C#DM7=Q%LP33S
M:5AEAYF4?$@FFA@>J6E:SGCPQM?$V]-8!+?I7.E%\\#JU (?$Z\__3T32)D;
MENP,>NJ=/-LB"GEMN3&41Z,,3UJ6>#*CZ7KNXD'VOVO_B)EH$#D_M)VK*>B_
M"H-G;F%[T))D;B*S$94;NZI,;^*=>E/<20/)_&?"\[5X:P5LO#(V[9L3!I7:
MMHVK<!@T0OO(WK 0B:3[MGI_L"*1& 5C4&V<@E;=/E68K-PH-JDPFPI[ODF%
M;5)A0TZ%L0 RM*U\SHUX62!CPTAR1]K&D07PQL)L!NI.I-J4X\JL>\!5!Q>!
MA*C*? [8I0IES$IKOHC#8KDB$>7)<5XGNS]#JX#8>R7@!'53I(EY@:1HQG7L
MQ8IMK4=]W2OAC>0.7^,/B'(ONO-%]6C;*%:2ZR.'G?MFW;."RG?,X<%$@8_Q
M;8J?X3BO-869/UG%,QBD:M7"C7HU.L[.54'[TY"(Y&!<L2/-H)+@^<W<5>SX
M>\8\*=,WV+6GGW2_&Z&W<7;+X\AC,% 7KQ<7@2_AO"'KL:.I)T P/=F4#22@
M0RF@9?=38*1*W$%YI0 MG*PMS2"0</]=1$@DW"=4JH[@IJ]4FF&JZ>2&C0&?
MR:#&C=@IWJO$[N66HM15HS)D+EF*>:.^:[QF9K:Q)ZU38=-V14!Q8Y>J76_A
M-1@+^15C8]GA6?'D5F73.X%?NC!Z2ZBFT<5(2/P)2M64Q5R#@?@^I^1NBPN]
MLU%= [,]8X+VM/"P59[$B6_:&"]HC>SE!=UF\IM.+;/FY1"P#>BY(>K^8Q_[
MU'E.=N %9L 4K:_]7@R6F_<3S%4;5/1X$7TI:+H\KT\*:3A,="8"==&,N>"Y
M;@>A5AIR6I.*W@'V>?+%/<>-0ZECBSR6=\@3D<*JK^JJ*&-+]MXB#+]5GC@Q
M<MNI[2T?K;G"0%OK= PDPL:4<WUVM_$1O, EKYH)<\9&>]]9E4Q5^L223OG3
ML&5/$'K::C>IHMB'0%461%&#*)[N&?B2Q&R?ANC3:FR'M.SK.Z&@DX:O#OPB
M43JT0SQ;S:]Q6@0MR8O>1WG5.:H5JPLLD<[+M=)M1@,:!6Z&MU1OAPL"YT[/
M:T:S]V07EB7CN.<:6H)M7O$9&K@X*'@KFZ"SAK"SS<A(Y*1B[.*DGY0B,^.'
MBZ=ISTM0A760KC*C[G7,^O.0UA_R!AQ.8]AYZP$0(2[SGZ@<S7!BKPN]]'!7
MF+D+[KA@Z_$;3L5\]YI@39N,IHC>)!S;4K^BKP1O&/2*CUSM#[#%4(!5JU36
MTZC.%>4OPND]3/73#W#+X2D&O[?WJJHV+:B)[+,GV&Y':X,A)!%,W$:U9:\E
M]3#EBS0&;4IB,"F#(6\6L:&IHC^2K $/LI@J#GOT"/?N ^!$@]C"Q$05Z#Y/
MM294B".J;^)H(@+P"\Y-0HTIG2+S(DWA,FW"]39<_V(3KM^$ZX<<KI< L&#:
M7:20\-W(DU/50KF1I""H2LI#]HE+:5W$MC,)IU 4563YH 0?$YBG!'N$3*M?
MJ<1[7?SIR7 4ZQXW(S]OJFOCQG90.T'#X5 G4'O))8":;C2L3R5M%1)^5\LR
M#-M$PDQQZ2!:?0UKKRO"[V*"N/.-LP,T%B!80.P$00X+@MU;5"9*(6^,@A)R
MK[1SQ"1+VU'2:!O =-^N#])L./PK)LYW!)>E>2..^05%?CPFZE4(QTNO.AG9
M4*YRN-@4)=C1&L]S81_K;N <>VDBW&,B7;9L'QDE%WMMZAR&DNI6EE?J=+B\
M6EW!V/'GH$)A6MI9O[Y/KK=IO)Z-GA+K>9JG,YX-*LOX0)E*(G7RYH4+1,*)
M,8PL/#_K(O<'V..##Q13!K[+5+YBA.9;HN\!F=OT5A#<C\_L3X[UHBU7&2*(
M5]N!P<+]O#9Y)EP.@B(I06^+].*M@3!SKF7(*X>^]\XQS/!BV=:2:SXU-[G
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MH?^&[QTO;"WGJ#/[Q;6JJF*24LJ7'L54EF9J+4F\_<1FV[Z2F/]\YW/PYVZ
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MW4IX<E1[OSCTY0EG9$$G]"V%OCSGS (D0 (D0 (D0 *D,D%:Q^I4KK3N3%>
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M  F0P!.8+D "I%)" D\ $B !$G@"D  )D, 3>S5=@ 1(X E,%R !4BDA@2<
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M42H9B=+3#YN;+P#*1MMKK1;@@DB4??#-(Q(%D2C[ QR1*/#9 S$05P\Q+,*
M!$B !)X )$ ")/#$7DT7( $2> +3!4B 5$I(B$0!9F &YDI@1B0*(E$0B8)(
M%$2B(!(%D2B(1$$D"GSV0 S$0 R+," !$B"!)P )D #IU8VMZ'F)GI<;NKAO
MN^<ES.@PHV_1C+[3AP0@ 1(@(50'X0S #,S C%"=Y:$Z:+6%5EMOX.I&JZW<
MBVM=[[Q"IWMV'VZM>!5<ZX;9UCNMWN9'^SI"H-&V5[N]ESBL;-M.:0 &8  N
M-6!$B@$Q$ /Q#B.&0P*0  F0P!. !$B !)[8J^D")$ "3V"Z  F02@D)/ %(
M@ 1(X E  B1  D_LU70!$B"!)S!=@ 1(I82$1"U@!F9@K@1F)&J5)D'HC1Z$
MTBTHW;(9292F=$M5DQBU \=U/EA_3><+GVW.]TAJ1%(CDAJ1U(A:^:B5CUKY
MJ)7_NL!1*Q^Y8D ,Q-5##$\?( $2(($G  F0  D\L5?3!4B !)[ = $2()42
M$G@"D  )D!")C&A-8 ;FO<",2.05@O%XU&%F6A'WB[A?Q/TNW1MO#OZW;\//
MPTOM9,6-W3HLT>"'#MOJQEP;67>>Y;.1<([P-7>F!3>6]L_Q\1IT5;K ZW^Z
M-AO..+#8@YUK[=B]O;4#]E>9,.63W45_-.0QX*DP<<,QM>><)LWVUJ ,S\;?
M!R<"S(;0;'%B?OVE<5C_E/UOP9F$@WK'#FJ2LVW^XYU]V&HVC?;1K#MKU-O3
M5MN83'H]LVU.FT>MSM'A[(]&_1U.][TYW0?/RZ'9TMCEPI_-K"E1B79B!)8V
M^&MZ8SC7EC:*!_H^">?-B58,/GE2#*Y&[*0X;*3/PZMQL=H%=MUE=FV!73?$
MKJ6A(TFE7U:!N=61_L^"#2)XU/K7GF7=4N[F1F9F\UMT9:65<>:EJTTLS2!(
MIA:P/Q[Y%>_"\ *;_93M: \>(SQV3R*UW @"8WK#/GEC>1;[--]O_ NI4\7P
M-=\*M)GK!3?TD#&]Z3K:H=[0E^OTX.==YN=#\'-E^#FIZGY=FY^7WW++@N]R
M-+P8:Q>>[7I$[C^,8'JCG=I^L"ER+]G7-B??)QT^S6*'#X:+X6*X&"Z&B^$6
M#W<;MZ+XJ5H:0>S8O.WZ<'$'W>4[: ]WT/WQP'S;Q?B*2\\P+3:^G\46Q-3H
MZ\1$\=IEK08592A#G3NQF2DT0?M.D-8M4I> U6QN"U8^1S5T[5FQ"&L#0TA
M90^D9A,'TJL5^BP)>^23H@ARBM&BMIY8=J8*9:.E-WO%;S^W &-/[S4W7RV2
M+<^CP\T_MMW0FZWBKSY[M#V]V5WML:NE XF=DDT>>';=.GI@)LJ=+ZQW3VQ>
M^0K]9&8OM_16)_8:YS7UXJOK<;V5MO?W_NA?:^@#Y4?+'_C1#MB/35? ?_[@
MQ"HB"L9^,GN%P\VK*+;ANHFWMFG.K;=>&.)L/CZ_.KL<_;YZ2L_FA;+FIBSQ
MHERZ!/L7%Z?#X_[E\/SLUU_:1RL6?MX!8*/!U^'X<L21/??.L0,PS\YU$$B6
M0+Z>GY^,-T<?8N8W>>:73V3CR_[E55)F&].'5BB J='_VWKKZ&D:+E/2Y8MW
M&D0#T4 T;\C3U14=Z!H;#Z*!:'9&-*!KT#4V'D0#T>R$:$#7H.NM;[P<Y_2^
MBP2K!:L%] QZQH8KI4BP6B :T#1HNDP;#S2-U0+1@*8W4AA_B11!Y"^4'38O
MA ?A54EX.%B*FQ0@3:]T:7K(N-M8&3+DI2$O;;MY:=4]5W -AF@@FK*(!CHN
MZ!H;#Z*!:'9"-*!KT#4V'D0#T>R$:$#7H&ML/(AF!T6S3W%'H&G0]-8W'$0#
MT4 TH&O0-38>1 /15$8TH&O0]=8WWCY=9[%:L%I SZ#G,JPN;#C0,T0#F@9-
MEWIU@:;!11 -:!K)Z-L78CE2@JM$]<BCW@7A8<7A($'R.9+/D7R.Y',DGR/Y
MO'1WNSW48Z 70S0PDL"6O4NK"S0-+H)H0-.@Z5*O+M TN BK!?0,>B[EZL*&
M SU#-*!IT'2I5Q=H&EP$T8"F0=.E7EV@:7 15@OH&?1<RM6%#0=ZAFA TZ#I
M4J\NT#2X"*(!38.F2[VZ0-/@(JP6T#.2R$NZ_I#26V:A8<5!>$@FW_2!@F1R
M)),CF1S)Y$@F1S)Y&>YX>ZA!0\6#:& L@2U[EU87:!I<A-4">@8]EW)U8<.!
MGK%:0,^@YU*N+FPXT#-$ YH&39=Z=8&FP440#6@:-%WJU06:!A=AM8">0<^E
M7%W8<*!GB 8T#9HN]>H"38.+(!K0-&BZU*L+- TNPFH!/2.)O*3K#RF]$!Z$
MMX?"P\&"9'(DDR.9',GD2"9',GDI[GH0#40#T<!X MOV3JPN6"O!15@MH&?0
M<RE7%S8<Z!FB 4V#IDN]ND#3X"*(!C0-FB[UZ@)-@XNP6D#/H.=2KBYL.- S
M1 .:?LMXZV(A@<=?)CH0_39DAO4&V6U4=CA+$&*]0R'6)&?;_,<[^[#5;!KM
MHUEWUJBWIZVV,9GT>F;;G#:/6IVCP]D?S<X[Q&5O)BX[&4=]2+M!['[!+HV&
MWNS$7A24HEZ-_?+4<IC,WUQ,<IG]]FWX>7BI#0ME5 F8%YX]M;3G8FPVB>JW
M-/2&KO'1%PX^,=161Z]W<I7(-T\:Z/7T3J/WG)R!=EMO'[U"O'Q'[]:[FW_L
M$5OK1YM_;%>O'[8W'=W?6*8M9M]4^DR=M)EWJZA>+_F5N-;4TH\VK34]<UOF
M:T]\3_K:S/6TE]@S(*D72TJ>.!#D&W'!+HF,9&49TQMMX3!=T)TE!:=ALZ8%
M]A];(+--'2Z;((*G9D9H..^*%;"F?I15A\6+;S^ES<)[_BL-A#_QHQTP84U7
MN*3]+77% H&!P#9*8'^#A#(2&BP\ERVCQF']D_KOJT@,=)QOF%HN_G(1M/9L
M@I:6@L+IWY?=MIS UW9I[+T\_^.Y!R $F*#_;0@1)T)E%/1"[V#2&GVX-:'^
M35C--=N9SA<F>VX^[Y9U^(G1ZL6>BW4\6(4[@KLW\ET&V_!X-/7G3%:GG1\[
MPU^R'=-R@H\?&MTM^''$C/;UE-87_?>5]_SZY+-92:^Q%,L^B9_U;<Y5X0):
M;1*+G+'+YP?A'J4+]_C[Q#4?V?]N@MOY?_\_4$L#!!0    ( 'TW"%EL?871
M>P<  )0C   6    :6YS;2TR,#(T,#8S,&5X,S$Q+FAT;>5::V\;MQ+]?G\%
MKX,V-B#9DFS%MNP82),4-7!Q'VV ]%M![<Y*A+GDEN1*5G_]/4.NWG(B(\W#
MK3_(VN60G,?AF2&IZW$H]<WUF&1^\X_K?[;;XHW-ZI),$)DC&2@7M5=F)-[G
MY.]$N]U(O;;5S*G1.(A>IW<FWEMWIR8RM0<5--W,Q[D^2<_7)W&2ZZ'-9S?7
MN9H(E;\\4*?#RQ>=R_[Y15_VSJB;2=F162\ONO*\<W%ZGOW6/4!7B*<^/LPT
MO3PHE6F/B><?G/6.S_M5N)JJ/(P'W4[GNX,H>G-=6!,PGT/_]#4-LS58H/O0
MEEJ-S"":=)"ZSILSJZT;/.O$ORMN:1>R5'HV>/Y.E>3%OVDJ?K:E-,];7AK?
M]N14D02]^H.@$]2+C].D\CG&T<K0W(1NCY5^^^M/MS_<OOO^6?=%Y^JT>]Q=
M5WMATN?3ZVRG7DFA+65V>"]#N,E])??]0EE0UC3NZ_3$:W)!%2J3_/K;]N6Z
M,D.9W8V<K4W>;O0JXM_5E]+RMB7>*ZV5+,5/Q^)?-%6^)5Z/%17B[3UE=5 3
M$O\IX%MRPA;BUO@21'%K,NLJZY@U6B*+[I^),);A^V?]BX>LWK%"OSV/'':/
MQ*T82]CM:*)H"G/#6'GQ>RT=,*]G> _3@[!&_&A=*;J=]O\>\ V\<?FTO=$[
M$C](#[-@;3D3=\9.->4C:B6G-*[(+:8T%ID$(TIEA#0S49O@:H(I\$1,,_"1
M%"6>G)):%#+#*Z"J5$$$F^2V! QEY+UT,Q8IY1UAWI4Q/=[E4 93ZIBC, <+
M9,HA)T',H#LTR0'?Z5AE8^%K_ECVGY*C9A VH%1>(WEQ'IRJ,(:!O@+=\.P\
M;@75; XS)^B6B^%LU0U//]JG'X@VB4(9^)-#L_1?"Z&&.)K=2KLR!59&I&-\
MSW2=8TS$:,59+<17\6JJX&)&!Z-&ZV7X&\_[C:F!L%SQP"V6J#4$$'.+P,3I
M?-0GDWXL"FVG?@X(1R/E@Y.82/++I#>T;*W$U<^5V=+VZ8?V[$B\6_/#<]^$
MK:%OAKQMF)Y]<RNDHQ@%>%4--;&W!"'T0ZW\F,59K,1RYR7/S[GRF;:^1C\F
M F=U"D?E;$8Y7GMQ"._GA' F%[^]S\;2C$B\PAK[N=:0Z)[*=K=_2$>Q:[>?
MIZ?TJ+CL, D&/+[@A;B"CA0MUF7OB8JUB0I,Q'9N8@82G!,>G][6BB<%(C)A
M</JBVBP]OSY Y)%X0Q[%'1P62?+CT6PQ?V>R]OMW82(=$B+3S)2HV=8. V 1
M3I2/2QM29.(X7%0L26&56!QI&4/=</,R7*V&=+A1@2"@B[=:Y7&3X^NA5[F2
M3K$!*F602'6&1ZH]LWI<&3ZF@$@$UA,4PO8F=JI0":BLUI+Y"V9%)9;9 3U2
MKEE-D?@V)!8$Q:#_0[7!1^#RQ#$VW,38WNMY"VK[,\'>B -*)RIG($EOC63*
MDQX@Y"*"T25=/H\TL*?D4&D59IQA=DW+N(^@B/%.D%T372E"(K/>-P95-<I'
M#Z]S1LQ03.91@5B.C,@@T6G #BU4,9Y9!*56@A9PKRJ0V]\17-F1>#N1NHZK
MG#U/1<$[Q0E\YG<4 DB >_!5>MQ=%404H2.XQJ?:8VCK\/#<^S"J7$@3%U;%
MQ\M.,9R7;'%A4/)!W" #!#S!WPP(.5@F>7H[8KPQ:2J!V+(!B$>P"N<EFV6U
MXXBL)(&U\4KK ][P<0E&\1F&:/:1XG!+N "<L,8WY!HU4=)2W$'QYLK4"UV.
MDB9CZ1=9DMDAPH\WYV"6:'U#:3/LD^Y(-]NI#?G6)SCD3P;;MX:I_N/+YWB&
MD,^!V%HN4V:-56 L5RP'^!$I<:OP@5(294^PSB_R3WR!P4KLLP/13AX<6N0V
M;LD5=(K=#P$<T(YG6L-_+KOF"*??:P65(Z9K$\_B_-%?NS)^A9TIUP_QE!&Z
M\<XB4X2(-"EB4:%.2=XQYZ?\'5D_5A[QJ&.^2WU4G)MB,NW&=BQCF:.CI\4J
MWH&)IE*!,,*+@J*54HY'OO%U6:(6_H.B&0U+[MS)/[S"GWB4N_VF-GV%Y% X
M+)@6?$YQ=2-J\5BH"6\KL:TR$ZLGQ)1KY*@YW7(-(5!9:3LCM$['-K& 7 ,/
M@OV)V>?X<Y#L)WOZ<B]'OX$K(UFD$_+U<_(O?%(?%7I5CVH?DAX7K7C+]4VZ
M]\^\>/C\L8ZZB"_XMVYWB-NW.;F \L@QL6A9>1K,OUPA.U=:S@;*1-UCIRO0
MX4B9]M"&8,L!7SA..,6C)FLNOR((4G-S%WEV>7S1/^7KR  <A'P^<7-3>1QO
M*D]"OMUV>7%\V7FXN7/<7;2=Q+'3^+# 5]*\/#@]V#!24P'O5X@TGWB(>8B;
M5I>"\U!SL-6.QDKFO/$=]*I[@=:KE7M GFW3/<DSG_UN< MQG83^L_,K'S^W
M;K86:V)_;SY]AWR*$YZ2G:_'4J7*^X'KR[^JX8?_3:<^J ^V;#[:-OHDDMS7
MN-W?+V5\,'U]*,]^N/S<^ E)97V\1!JD0^0);?VH9$D$,0UTEEWD$&Q0A^TN
M'_D=2O.9?A5S$G^-\W]02P,$%     @ ?3<(6?F T#A>!P  Z"(  !8   !I
M;G-M+3(P,C0P-C,P97@S,3(N:'1MY5K;<MLX$GW?K\ ZM1.K2K(E67)LV7&5
M<YE:O^QE)E6S;UL@V111)@$. $K1?/V<!JB[G#B;G22>^$$6B0;0EX/3#4#7
MA:_*F^N"9';SE^N_]GKBC4F;BK07J27I*1.-4WHJ?LG(W8M>KY5Z;>J%5=/"
MBV%_.!*_&'NO9C*V>^5+NEF.<WT:GZ]/PR37B<D6-]>9F@F5O3Q2\O)LE.;C
M\?GXXGQ$1,D975P,S^7@19)1/QW]=W"$KA"/?9Q?E/3RJ%*Z5Q#//QD-3UZ,
M:W\U5YDO)H-^_V]'0?3F.C?:8SZ+_O%K'&9O,$_O?4^6:JHGP:2CV'79G)K2
MV,FS?OB[XI9>+BM5+B;/WZF*G/@'S<5/II+Z>==)[7J.K,JCH%._$72">N%Q
M'E5^@7%*I6EIPF#(2K_]S]_O7MV]^^'9X+Q_=38X&6ZKO3+IC]-K=%"OJ-">
M,@>\ER+<9+^2^WZFU"NC6_?UA^(U6:]RE4I^_6W[<EN91*;W4VL:G?5:O?+P
M=_6EM+SKBI^EE>*5T<Z3TEWQNE"4BQ^5ECI5LA3_S.%8LL+DXDZ["BQQIU-C
M:V.9,KHB#;Y?"%](_\.S\<5#)A]8GM^>.XX''7$G"CDC86FF: YS?:&<^+61
M%H O%W@/T[TP6OQH;"4&_=Z_'_ -O''YM+TQ[(A7TL$L6%LMQ+TV\Y*R*76C
M4UI79 93:H,T@A&ETD+JA6BTMPW!%'@BY!CX2(H*3Y91E<L4KX"J2GGA393;
M$]"4DG/2+EBDDO>$>3?&='B701E,688$A3E8(%46"0EB&MVA20;XS@N5%L(U
M_+'N/R=+[2!L0*5<B<S%27"N? $#70VNX=EYW!JJF0QFSM M$\EBTPU//]IG
M'X@VB7S%"&O_=1%JB*/9;K0KG6-E!"[&][1L,HR)&&TXJXOX*EY--5S,Z&#4
ME.4Z_*WGW<[40%BF>. N2S0E!!!S@\"$Z5S0)Y6N$'EIYFX)"$M3Y;R5F$CR
MRZ@WM.QNQ-4ME=G3]NF'=M01[[;\\-RU86OIFR%O6J9GW]P):2E$ 5Y524GL
M+4$(?5(J5[ XBU58[KSD^3E3+BV-:]"/B<":,H:CMB:E#*^=.(;W,T(XHXO?
MOD\+J:<D;K'&?FI*2 S.9&\P/J9.Z#H89_$I/BJN.72$ 8\O>"%NH"-&BW5Y
M]$3YUD0Y)F([=S$#"<X)A]/;5G6D0#;:3\[.ZV5M>1@@'^GT[2!'=L0;<BCY
MX,G GA\/<Y>)/96->WP79MB$$+)VILC9IK$8 *MSIEQ8\Y B'<;A:F/-%IN,
M8ZF4 0,M::_CV&W9B!L5F .Z.%.J+&Q]7),XE2EI%1N@8FH)'*AYI,8QW8<E
MXT)N" QA'$$A;'I"IQHE@DJ;4C*QP:R@Q#IMH$=,0INY$]\28D%P#_H_5#3\
MN3&6[&+LT0M]#VJ/IXA'(PXHG:F,@22=T9*Y4#J D*L+1I>TV3+2P)Z2B2J5
M7W#J.30MXSZ (L0[0G9+=*,Z"93[OC6H;E!7.GB=4V6**C,+"H0Z94H:&; $
M[-!"->.915"#16@!]ZH&ZWV/X$H[XNU,EDU8Y>QYRG/>/\[@,W>@0D!F? 1?
MQ<?#Y4) $3J":UPL2A+3^(?G?@RCRI4T<<65?[P>%<FRE@L+@Z(/PK89(. )
MOC,@9&"9Z.G]B/&.I2T10LL.(#Z!53@OF31M+$=D(PELC5<9Y_&&#U$PBDLQ
M1+O!%,=[PCG@A#6^(]>JB5J7PM:*=UVZ6>G2B9H4TJVR)+-#@!_OVL$LP?J6
MTA;80-U3V>ZS=N2[G^&0A\'VE,KG\:>7S^$,(5OBK;M>C4P.F_%?+TR.XR=D
MOKWZ!DI)5#?>6+=*,^$%!JNPS_9$!^DN,4AAW)(IZ!2Z'P,?8!?'[(7_7%TM
M@4R_-@HJ!^@V.AS$N<YW6AG?8LO*]4,X>X1NO.5(%2%4;8I85:ASDO?,^3%_
M!]8/E4<X UEN7S\) &TQ&;=I!Y:QS-#1T6H5'P!+6ZE &'%'0=&-*<<AW[BF
MJE +_T;!C)8E#V[QO]=T@J+U%EDCMUAB702# A\@G.$@J8U[-]*PTC-3SHBY
M6,MI>QYF6PJAJB[-@M Z+TSD#;F%*J#@,]/2R?\G-E_G(/T-?!GX)9ZHQ\_;
M9MHX'[]?=,/-U#=T;?$9-P)?2AGQA_\M#?5AR[1<MZ 9LKQF2UD[FBR_7"%5
MUJ5<3)0.NH9.5Z"@J=*]Q'AOJ@E?_<TXWZ(.:N,90AN;VUO!T>7)Q?B,+P8]
M$.RSY<3MG>%)N#,\]=E^V^7%R67_X>;^R6#5=AK&CN/# E=+_?+H[&C'R))R
M>+M&:/F402QCVK;:&(R'FKVI#S36,N/-YF18OQ=HO=J -L^VZY[HF2\/]WZ$
M^^C%E0N?VW=,JQ7P>%<^?6_\SQYX2D8^<'?X9S7W^%_Q9 66KFWF>NEV??C2
MNJ"S[X/3P'%?/1%\,"M]N$;;^5E&;5RXFYG$(]@9[?U08[VJ Z'WUUUD@J7=
M^/TN'_EM1_L9?VER&G[A\CM02P,$%     @ ?3<(6>[L=#I$!0  /!@  !8
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M8#.$S+'OEF9WR&?>45;__1O3 _>F]B]02P,$%     @ ?3<(68[&IA>5$
MGH(  !<   !I;G-M,#(Y,C0P-C,P97@Q,#4Q+FAT;>U=ZU/;2!+_?G_%'+G+
M0LI6_ !L'DN5 \[&V>510(Z[^W(UDL9X$EG2:D88[U]_W3,C6;(M8PC!@K!5
M"[&E>?7SUST]P_Y #KV#_0&C[L'?]O]>K9*CP(F'S)?$B1B5S"6QX/XUN7*9
M^$:J5?/681".(WX]D*11:VR2JR#ZQF^H?BZY]-A!TL_^>_UY_[T:9-\.W/'!
MOLMO"'=_7>-VPVXVZXV6L[7=V*S5[1UWA]7:E-KM+>ILUAK_JZ]!4WA=MQ%R
M[+%?UX;<KPX8CK];K]>L=CN4>R/NRL%NO5;[YYIZ]V"_'\ R3 LG\()H]TU-
M_;>'3ZI].N3>>/>72SYD@IRP$3D/AM3_I2*H+ZJ"1;RO7Q3\+P8=PQCJXT@/
MW()^/.ZS="(-'/DLCD1,85P9D)YD0[)=JZ_;&^OUVL8ZO]D@09^<L^O8HY('
M/KFH_EXA3N#WN0NDXM0CW.\'T5 _7>>^RQW%!'M,WK[9J>^]>_<.?C?W-LB
M"F(SYI-@R"6^TH^"(>G>#KC-)0&B;%EU>,&AL6 $OEGG&X0+X@>20/>P.!B,
M^BY\KQ_( 2-R'#*<8782^/UA, RI/R9V( ?$B84$.D5 .]4!=61,/?@@46 $
M@7F%$0B#A*ZBW.*L_?=(P P_-8] ***#F6<)YR2[E57J\6M_5TG<VF,SMK$4
M8_.4S<]V5CYI= TB"O0"4NUNP0#F&QF$ZF-F40X0AT4K6E7GN'MR!/]?DI-3
MB]21$9>GY/#T^+A[?MCK_-'[;^>R=WI".K^==[OJO0_=RZMN]P3?[)U<''>/
M2._D\/3\[/2\<PD?.B='Y*QSWB-GGSKGQQWRV_&'3X6LO0^9OH+8\?Y8?P6*
M 53;;6Z'/UX<-N<2[G( .M/GD9"$@IESE<E<?_NFW6C4]I(%KX2CZ6Q. N3H
MDTQE/HT4->I@JUB_SQS);QAIU,GG&&Q%HU9OE9%<I)M.]0@L6"FH!Y[$&.$A
MBQRPH_PO;9H[UQ%C:NZN<A)HC2>DQC;M'[* EM5>8@5[82 XSG,W8NCN;M@>
MJG5UT\+UW[!(@F_SC';;5##L8.U #E9)=/1^B8!NDG6D81F$-&%T*>319G*$
MP$.;^0$%I$!^&]J?*@1^,_CD@]>/PB#24CKB !HH8@+?X2&@CM"CCH(9-D)+
M)@ R2'(<!$+(B I *\T*.:JV&\WZ#KF0-/)M%EU73-?C4E@-7'HI>($JW_/%
MD.&OA.K,15;\BZ,KY?0!S*C7R$=TL9'/2.>&^3&KD \Q]UR,!.HU^!!Q]YJ-
M$$=6R,GGMV_JV[4]4FNW:ZUJL[F]50HF:;J4@4T5!-@*Y@&?N \&/:=#$R9:
M9/H;(@8 KN%]$K$^B[ #: X+\+291Q"NP7L)*'Y&P:@S40*26^0E@LZK3]WS
M;N>BHOAMB T1W8A <,XCAI*AP*@.YL!>"B5)$(.YRA,+5'1\-D$.T 0$"X6)
M.."2*?<GEL#E H(]H1HF IL9>3:<FR)Q^0EZ<GI5(9=(U8^GYUU04W1=OH"
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M'U!+ 0(4 Q0    ( 'TW"%E,22Q8*L ! ,-"%@ 1              "  0
M  !I;G-M+3(P,C0P-C,P+FAT;5!+ 0(4 Q0    ( 'TW"%E@NX&HOA,  #+6
M   1              "  5G  0!I;G-M+3(P,C0P-C,P+GAS9%!+ 0(4 Q0
M   ( 'TW"%G>TJ3.RAX  /4F 0 5              "  4;4 0!I;G-M+3(P
M,C0P-C,P7V-A;"YX;6Q02P$"% ,4    " !]-PA9_XU6]@U_   7I@4 %0
M            @ %#\P$ :6YS;2TR,#(T,#8S,%]D968N>&UL4$L! A0#%
M  @ ?3<(6?FC OYE&0$ FL8* !4              ( !@W(" &EN<VTM,C R
M-# V,S!?;&%B+GAM;%!+ 0(4 Q0    ( 'TW"%F*W(E2!+T  #FR"  5
M          "  1N, P!I;G-M+3(P,C0P-C,P7W!R92YX;6Q02P$"% ,4
M" !]-PA9&LDQG[04  !R?   %P              @ %2200 :6YS;2TR,#(T
M,#8S,&5X,3 Q,2YH=&U02P$"% ,4    " !]-PA9;\D(FDLT  "U30$ %P
M            @ $[7@0 :6YS;2TR,#(T,#8S,&5X,3 Q,BYH=&U02P$"% ,4
M    " !]-PA9R'H$?4\<  !:J0  %P              @ &[D@0 :6YS;2TR
M,#(T,#8S,&5X,3 Q,RYH=&U02P$"% ,4    " !]-PA9)VBN!?<W  #Q; $
M%P              @ $_KP0 :6YS;2TR,#(T,#8S,&5X,3 Q-"YH=&U02P$"
M% ,4    " !]-PA9!]PM6CH(  #M-@  %@              @ %KYP0 :6YS
M;2TR,#(T,#8S,&5X,3 R+FAT;5!+ 0(4 Q0    ( 'TW"%E],NS3%",  #('
M 0 6              "  =GO! !I;G-M+3(P,C0P-C,P97@Q,#,N:'1M4$L!
M A0#%     @ ?3<(6<E*#JQX1P  /04" !8              ( !(1,% &EN
M<VTM,C R-# V,S!E>#$P-"YH=&U02P$"% ,4    " !]-PA9+=N=P_BB  "8
M\ < %@              @ '-6@4 :6YS;2TR,#(T,#8S,&5X,3 U+FAT;5!+
M 0(4 Q0    ( 'TW"%EL?871>P<  )0C   6              "  ?G]!0!I
M;G-M+3(P,C0P-C,P97@S,3$N:'1M4$L! A0#%     @ ?3<(6?F T#A>!P
MZ"(  !8              ( !J 4& &EN<VTM,C R-# V,S!E>#,Q,BYH=&U0
M2P$"% ,4    " !]-PA9[NQT.D0%   \&   %@              @ $Z#08
M:6YS;2TR,#(T,#8S,&5X,S(Q+FAT;5!+ 0(4 Q0    ( 'TW"%E ?EWJ$P4
M + 5   6              "  ;(2!@!I;G-M+3(P,C0P-C,P97@S,C(N:'1M
M4$L! A0#%     @ ?3<(68[&IA>5$   GH(  !<              ( !^1<&
M &EN<VTP,CDR-# V,S!E>#$P-3$N:'1M4$L%!@     3 !,  P4  ,,H!@
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>insm-20240630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:insm="http://www.insmed.com/20240630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="insm-20240630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2024-08-02</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">insm:VertuisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">insm:VertuisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">insm:AdrestiaTherapeuticsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">insm:AdrestiaTherapeuticsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:AlgaeneXIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-04</startDate>
            <endDate>2021-08-04</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">insm:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">insm:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">insm:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:PriorityReviewVoucherMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:PriorityReviewVoucherMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">insm:MeasurementInputProbabilityOfSuccessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">insm:PriorityReviewVoucherMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">insm:ARIKAYCEGlobalNetSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-01</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">insm:ARIKAYCEGlobalNetSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-01</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">insm:BrensocatibGlobalNetSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:EuropeAndTheRestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:EuropeAndTheRestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:EuropeAndTheRestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:EuropeAndTheRestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">insm:AcquiredResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:DebtInstrumentConversionTermFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:RedemptionOfThe2025ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:ZeroPointSevenFivePercentConvertibleSeniorNoteDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:AdrestiaTherapeuticsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:VertuisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:VertuisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:A2019IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-12</startDate>
            <endDate>2020-05-12</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:A2019IncentivePlanThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-15</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:EmployeeStockPurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-15</startDate>
            <endDate>2018-05-15</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">insm:AdrestiaTherapeuticsLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">insm:VertuisBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">insm:VertuisBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:TriggeringEventAxis">insm:MilestoneEvent1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">insm:VertuisBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:TriggeringEventAxis">insm:MilestoneEvent2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-04</startDate>
            <endDate>2021-08-04</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:AlgaeneXIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:AlgaeneXIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2021-05-24</startDate>
            <endDate>2021-05-24</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">insm:MotusBiosciencesIncAndAlgaeneXIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:A2025ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-07</startDate>
            <endDate>2024-08-07</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:A2025ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-07</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:A2028ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-01</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:A2028ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-02</startDate>
            <endDate>2024-08-02</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">insm:VertuisBioIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:A2028ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-01</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">insm:S.NicoleSchaefferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">insm:S.NicoleSchaefferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">insm:S.NicoleSchaeffer2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">insm:S.NicoleSchaeffer2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">insm:MartinaFlammerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">insm:MartinaFlammerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">insm:MichaelSmithMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">insm:MichaelSmithMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="reportingunit">
        <measure>insm:reportingUnit</measure>
    </unit>
    <unit id="sale">
        <measure>insm:sale</measure>
    </unit>
    <unit id="day">
        <measure>insm:day</measure>
    </unit>
    <unit id="days">
        <measure>insm:days</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001104506</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-26">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-27">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-28">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-29">Q2</dei:DocumentFiscalPeriodFocus>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-5" id="f-100">http://fasb.org/us-gaap/2024#ProductMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-1" id="f-101">http://fasb.org/us-gaap/2024#ProductMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-6" id="f-102">http://fasb.org/us-gaap/2024#ProductMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-7" id="f-103">http://fasb.org/us-gaap/2024#ProductMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="c-5" id="f-108">http://fasb.org/us-gaap/2024#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="c-6" id="f-109">http://fasb.org/us-gaap/2024#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="c-1" id="f-110">http://fasb.org/us-gaap/2024#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="c-7" id="f-111">http://fasb.org/us-gaap/2024#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="c-222" decimals="4" id="f-847" unitRef="number">25.5384</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="c-223" decimals="7" id="f-848" unitRef="number">0.0255384</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="c-224" decimals="7" id="f-849" unitRef="number">0.0307692</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="c-289"
      decimals="INF"
      id="f-999"
      unitRef="number">0.0255384</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="c-294"
      decimals="INF"
      id="f-1000"
      unitRef="number">0.0307692</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <ecd:TrdArrDuration contextRef="c-295" id="f-1027">P352D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-297" id="f-1028">P203D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-299" id="f-1029">P357D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-301" id="f-1030">P250D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-30739</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">INSMED INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">VA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">54-1972729</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">700 US Highway 202/206</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Bridgewater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">08807</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">977-9900</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">INSM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">171849103</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">1246799000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">482374000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">298073000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">40300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">41189000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">90063000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">83248000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">41022000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">24179000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">1418184000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">929063000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">72777000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">65384000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">19629000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">20985000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">16406000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">18017000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">61178000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">63704000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">136110000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">136110000</us-gaap:Goodwill>
    <us-gaap:OtherAssets contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">85834000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">96574000</us-gaap:OtherAssets>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">1810118000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">1329837000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">290844000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">214987000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">224448000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">2782000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">2610000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">6077000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">8032000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-64" unitRef="usd">524151000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">225629000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-3" id="f-66" unitRef="usd">946825000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">1155313000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-3" decimals="-3" id="f-68" unitRef="usd">158377000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">155034000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-70" unitRef="usd">101500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">84600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-72" unitRef="usd">25588000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">27026000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-74" unitRef="usd">11666000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">11013000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">3193000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">3145000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-78" unitRef="usd">1771300000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">1661760000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-80"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-81"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-82" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-83" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-84" unitRef="shares">166666599</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-85" unitRef="shares">166666599</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-86" unitRef="shares">147977960</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-87" unitRef="shares">147977960</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-88" unitRef="usd">1667000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-89" unitRef="usd">1480000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-90" unitRef="usd">3943826000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-91" unitRef="usd">3113487000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-92" unitRef="usd">-3903845000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-93" unitRef="usd">-3446145000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-94" unitRef="usd">-2830000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-95" unitRef="usd">-745000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-96" unitRef="usd">38818000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-97" unitRef="usd">-331923000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-98" unitRef="usd">1810118000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-99" unitRef="usd">1329837000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-104" unitRef="usd">90340000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-105" unitRef="usd">77229000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">165840000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-107" unitRef="usd">142443000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-5" decimals="-3" id="f-112" unitRef="usd">20964000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-6" decimals="-3" id="f-113" unitRef="usd">16594000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-114" unitRef="usd">38421000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-7" decimals="-3" id="f-115" unitRef="usd">30424000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-116" unitRef="usd">146748000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-117" unitRef="usd">196969000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">267831000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-119" unitRef="usd">324834000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-120" unitRef="usd">106569000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-121" unitRef="usd">84431000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">199671000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-123" unitRef="usd">164345000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-5" decimals="-3" id="f-124" unitRef="usd">1263000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-6" decimals="-3" id="f-125" unitRef="usd">1263000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">2526000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-7" decimals="-3" id="f-127" unitRef="usd">2526000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-5" decimals="-3" id="f-128" unitRef="usd">103700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-6" decimals="-3" id="f-129" unitRef="usd">13500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">91800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-7" decimals="-3" id="f-131" unitRef="usd">4000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:CostsAndExpenses contextRef="c-5" decimals="-3" id="f-132" unitRef="usd">379244000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-6" decimals="-3" id="f-133" unitRef="usd">312757000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-134" unitRef="usd">600249000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-7" decimals="-3" id="f-135" unitRef="usd">526129000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-136" unitRef="usd">-288904000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-137" unitRef="usd">-235528000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">-434409000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-139" unitRef="usd">-383686000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNonoperating contextRef="c-5" decimals="-3" id="f-140" unitRef="usd">10285000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating contextRef="c-6" decimals="-3" id="f-141" unitRef="usd">11172000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">19068000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating contextRef="c-7" decimals="-3" id="f-143" unitRef="usd">21696000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-5" decimals="-3" id="f-144" unitRef="usd">21267000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-6" decimals="-3" id="f-145" unitRef="usd">20619000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-146" unitRef="usd">42309000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-7" decimals="-3" id="f-147" unitRef="usd">40622000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-5" decimals="-3" id="f-148" unitRef="usd">384000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-6" decimals="-3" id="f-149" unitRef="usd">1184000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">2746000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-7" decimals="-3" id="f-151" unitRef="usd">-349000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-152" unitRef="usd">-269000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-153" unitRef="usd">-488000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">-1369000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-155" unitRef="usd">-599000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-156" unitRef="usd">-299771000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-157" unitRef="usd">-244279000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">-456273000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-159" unitRef="usd">-403560000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-160" unitRef="usd">838000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-161" unitRef="usd">530000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-162" unitRef="usd">1427000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-163" unitRef="usd">1013000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-164" unitRef="usd">-300609000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-165" unitRef="usd">-244809000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">-457700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-167" unitRef="usd">-404573000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-168"
      unitRef="usdPerShare">-1.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-169"
      unitRef="usdPerShare">-1.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-170"
      unitRef="usdPerShare">-1.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-171"
      unitRef="usdPerShare">-1.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-172"
      unitRef="usdPerShare">-3.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-173"
      unitRef="usdPerShare">-3.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-174"
      unitRef="usdPerShare">-2.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-175"
      unitRef="usdPerShare">-2.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-176" unitRef="shares">154702000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-177" unitRef="shares">154702000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-178" unitRef="shares">137553000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-3" id="f-179" unitRef="shares">137553000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-180" unitRef="shares">151579000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-181" unitRef="shares">151579000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-182" unitRef="shares">136957000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-183" unitRef="shares">136957000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-5" decimals="-3" id="f-184" unitRef="usd">-300609000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-5" decimals="-3" id="f-185" unitRef="usd">-300609000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-6" decimals="-3" id="f-186" unitRef="usd">-244809000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-6" decimals="-3" id="f-187" unitRef="usd">-244809000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">-457700000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">-457700000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-7" decimals="-3" id="f-190" unitRef="usd">-404573000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-7" decimals="-3" id="f-191" unitRef="usd">-404573000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-192" unitRef="usd">-1194000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-193" unitRef="usd">-2202000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-194" unitRef="usd">-2049000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-195" unitRef="usd">-2373000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-196" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-197" unitRef="usd">-132000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-198" unitRef="usd">-36000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-199" unitRef="usd">366000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-200" unitRef="usd">-301803000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-6" decimals="-3" id="f-201" unitRef="usd">-247143000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">-459785000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="-3" id="f-203" unitRef="usd">-406580000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding contextRef="c-8" decimals="-3" id="f-204" unitRef="shares">136429000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-205" unitRef="usd">1364000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-206" unitRef="usd">2809242000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-207" unitRef="usd">-2856342000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-208" unitRef="usd">1083000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-209" unitRef="usd">-44653000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-210" unitRef="usd">-244809000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-211" unitRef="usd">-244809000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-14" decimals="-3" id="f-212" unitRef="usd">-2334000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-213" unitRef="usd">-2334000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-15" decimals="-3" id="f-214" unitRef="shares">513000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-15" decimals="-3" id="f-215" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-16" decimals="-3" id="f-216" unitRef="usd">7278000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-6" decimals="-3" id="f-217" unitRef="usd">7283000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-15" decimals="-3" id="f-218" unitRef="shares">2028000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-15" decimals="-3" id="f-219" unitRef="usd">20000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-16" decimals="-3" id="f-220" unitRef="usd">37994000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-6" decimals="-3" id="f-221" unitRef="usd">38014000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-15" decimals="-3" id="f-222" unitRef="shares">349000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-15" decimals="-3" id="f-223" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-6" decimals="-3" id="f-224" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c-15" decimals="-3" id="f-225" unitRef="shares">3431000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-15" decimals="-3" id="f-226" unitRef="usd">34000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-16" decimals="-3" id="f-227" unitRef="usd">72356000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-6" decimals="-3" id="f-228" unitRef="usd">72390000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-16" decimals="-3" id="f-229" unitRef="usd">18359000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-230" unitRef="usd">18359000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding contextRef="c-17" decimals="-3" id="f-231" unitRef="shares">142750000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-232" unitRef="usd">1428000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-233" unitRef="usd">2945229000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-234" unitRef="usd">-3101151000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-235" unitRef="usd">-1251000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-236" unitRef="usd">-155745000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c-22" decimals="-3" id="f-237" unitRef="shares">148561000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-238" unitRef="usd">1486000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-239" unitRef="usd">3138578000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-240" unitRef="usd">-3603236000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-241" unitRef="usd">-1636000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-242" unitRef="usd">-464808000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-27" decimals="-3" id="f-243" unitRef="usd">-300609000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-244" unitRef="usd">-300609000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-28" decimals="-3" id="f-245" unitRef="usd">-1194000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-246" unitRef="usd">-1194000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-29" decimals="-3" id="f-247" unitRef="shares">3062000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-29" decimals="-3" id="f-248" unitRef="usd">31000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-30" decimals="-3" id="f-249" unitRef="usd">68540000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-5" decimals="-3" id="f-250" unitRef="usd">68571000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-29" decimals="-3" id="f-251" unitRef="shares">14515000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-29" decimals="-3" id="f-252" unitRef="usd">145000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-30" decimals="-3" id="f-253" unitRef="usd">713422000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-5" decimals="-3" id="f-254" unitRef="usd">713567000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-29" decimals="-3" id="f-255" unitRef="shares">529000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-29" decimals="-3" id="f-256" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-5" decimals="-3" id="f-257" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-30" decimals="-3" id="f-258" unitRef="usd">23286000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-259" unitRef="usd">23286000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding contextRef="c-31" decimals="-3" id="f-260" unitRef="shares">166667000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-261" unitRef="usd">1667000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-262" unitRef="usd">3943826000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-263" unitRef="usd">-3903845000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-264" unitRef="usd">-2830000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-265" unitRef="usd">38818000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c-35" decimals="-3" id="f-266" unitRef="shares">135654000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-267" unitRef="usd">1357000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-268" unitRef="usd">2782416000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-269" unitRef="usd">-2696578000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-270" unitRef="usd">756000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-271" unitRef="usd">87951000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-40" decimals="-3" id="f-272" unitRef="usd">-404573000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-273" unitRef="usd">-404573000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-41" decimals="-3" id="f-274" unitRef="usd">-2007000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-275" unitRef="usd">-2007000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-42" decimals="-3" id="f-276" unitRef="shares">595000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-42" decimals="-3" id="f-277" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-43" decimals="-3" id="f-278" unitRef="usd">8416000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-7" decimals="-3" id="f-279" unitRef="usd">8422000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-42" decimals="-3" id="f-280" unitRef="shares">2028000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-42" decimals="-3" id="f-281" unitRef="usd">20000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-43" decimals="-3" id="f-282" unitRef="usd">37994000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-7" decimals="-3" id="f-283" unitRef="usd">38014000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-42" decimals="-3" id="f-284" unitRef="shares">542000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-42" decimals="-3" id="f-285" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-7" decimals="-3" id="f-286" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="c-42" decimals="-3" id="f-287" unitRef="shares">3931000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-42" decimals="-3" id="f-288" unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-43" decimals="-3" id="f-289" unitRef="usd">81601000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-7" decimals="-3" id="f-290" unitRef="usd">81640000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-43" decimals="-3" id="f-291" unitRef="usd">34802000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-7" decimals="-3" id="f-292" unitRef="usd">34802000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding contextRef="c-17" decimals="-3" id="f-293" unitRef="shares">142750000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-294" unitRef="usd">1428000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-295" unitRef="usd">2945229000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-296" unitRef="usd">-3101151000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-297" unitRef="usd">-1251000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-298" unitRef="usd">-155745000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c-44" decimals="-3" id="f-299" unitRef="shares">147978000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-300" unitRef="usd">1480000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-301" unitRef="usd">3113487000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-302" unitRef="usd">-3446145000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-303" unitRef="usd">-745000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-304" unitRef="usd">-331923000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-48" decimals="-3" id="f-305" unitRef="usd">-457700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-306" unitRef="usd">-457700000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-49" decimals="-3" id="f-307" unitRef="usd">-2085000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">-2085000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-50" decimals="-3" id="f-309" unitRef="shares">3279000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-50" decimals="-3" id="f-310" unitRef="usd">33000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-51" decimals="-3" id="f-311" unitRef="usd">72590000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">72623000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-50" decimals="-3" id="f-313" unitRef="shares">14515000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-50" decimals="-3" id="f-314" unitRef="usd">145000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-51" decimals="-3" id="f-315" unitRef="usd">713013000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-316" unitRef="usd">713158000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-50" decimals="-3" id="f-317" unitRef="shares">895000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-50" decimals="-3" id="f-318" unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-1" decimals="-3" id="f-319" unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-51" decimals="-3" id="f-320" unitRef="usd">44736000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">44736000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding contextRef="c-31" decimals="-3" id="f-322" unitRef="shares">166667000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-323" unitRef="usd">1667000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-324" unitRef="usd">3943826000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-325" unitRef="usd">-3903845000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-326" unitRef="usd">-2830000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-327" unitRef="usd">38818000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-328" unitRef="usd">-457700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-329" unitRef="usd">-404573000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">3024000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-7" decimals="-3" id="f-331" unitRef="usd">2559000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-332" unitRef="usd">2526000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-7" decimals="-3" id="f-333" unitRef="usd">2526000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-334" unitRef="usd">44736000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-335" unitRef="usd">34802000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">3651000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-7" decimals="-3" id="f-337" unitRef="usd">3728000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:PaidInKindInterest contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">12571000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-7" decimals="-3" id="f-339" unitRef="usd">11201000</us-gaap:PaidInKindInterest>
    <us-gaap:OtherNoncashExpense contextRef="c-1" decimals="-3" id="f-340" unitRef="usd">9715000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense contextRef="c-7" decimals="-3" id="f-341" unitRef="usd">3846000</us-gaap:OtherNoncashExpense>
    <insm:AccretionOfDebtDiscountMarketableSecurities contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">1963000</insm:AccretionOfDebtDiscountMarketableSecurities>
    <insm:AccretionOfDebtDiscountMarketableSecurities contextRef="c-7" decimals="-3" id="f-343" unitRef="usd">0</insm:AccretionOfDebtDiscountMarketableSecurities>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">1356000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-7" decimals="-3" id="f-345" unitRef="usd">1356000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <insm:NoncashOperatingLeaseExpense contextRef="c-1" decimals="-3" id="f-346" unitRef="usd">1611000</insm:NoncashOperatingLeaseExpense>
    <insm:NoncashOperatingLeaseExpense contextRef="c-7" decimals="-3" id="f-347" unitRef="usd">7299000</insm:NoncashOperatingLeaseExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-3" id="f-348" unitRef="usd">91800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-7" decimals="-3" id="f-349" unitRef="usd">4000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">2746000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-7" decimals="-3" id="f-351" unitRef="usd">-349000</us-gaap:UnrealizedGainLossOnDerivatives>
    <insm:NoncashAcquisitionRelatedExpense contextRef="c-52" decimals="-3" id="f-352" unitRef="usd">0</insm:NoncashAcquisitionRelatedExpense>
    <insm:NoncashAcquisitionRelatedExpense contextRef="c-53" decimals="-3" id="f-353" unitRef="usd">10250000</insm:NoncashAcquisitionRelatedExpense>
    <insm:NoncashAcquisitionRelatedExpense contextRef="c-54" decimals="-3" id="f-354" unitRef="usd">0</insm:NoncashAcquisitionRelatedExpense>
    <insm:NoncashAcquisitionRelatedExpense contextRef="c-55" decimals="-3" id="f-355" unitRef="usd">76481000</insm:NoncashAcquisitionRelatedExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-356" unitRef="usd">1080000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-7" decimals="-3" id="f-357" unitRef="usd">2291000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-358" unitRef="usd">8353000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-7" decimals="-3" id="f-359" unitRef="usd">8081000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-360" unitRef="usd">17823000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-3" id="f-361" unitRef="usd">155000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-1" decimals="-3" id="f-362" unitRef="usd">-15699000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c-7" decimals="-3" id="f-363" unitRef="usd">7458000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-364" unitRef="usd">2737000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-7" decimals="-3" id="f-365" unitRef="usd">224000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-366" unitRef="usd">-6748000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-7" decimals="-3" id="f-367" unitRef="usd">-5158000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-368" unitRef="usd">-306987000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-369" unitRef="usd">-269095000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-370" unitRef="usd">11462000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-371" unitRef="usd">8281000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-3" id="f-372" unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-7" decimals="-3" id="f-373" unitRef="usd">292690000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <insm:ProceedsFromCashAcquiredInAssetAcquisition contextRef="c-1" decimals="-3" id="f-374" unitRef="usd">0</insm:ProceedsFromCashAcquiredInAssetAcquisition>
    <insm:ProceedsFromCashAcquiredInAssetAcquisition contextRef="c-7" decimals="-3" id="f-375" unitRef="usd">3417000</insm:ProceedsFromCashAcquiredInAssetAcquisition>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-1" decimals="-3" id="f-376" unitRef="usd">300000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-7" decimals="-3" id="f-377" unitRef="usd">65000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-378" unitRef="usd">288538000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-379" unitRef="usd">-232554000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-380" unitRef="usd">72623000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-7" decimals="-3" id="f-381" unitRef="usd">8422000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-382" unitRef="usd">713158000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-7" decimals="-3" id="f-383" unitRef="usd">38014000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-384" unitRef="usd">1266000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-7" decimals="-3" id="f-385" unitRef="usd">1291000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-386" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-7" decimals="-3" id="f-387" unitRef="usd">1218000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-388" unitRef="usd">784515000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-389" unitRef="usd">43927000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-390" unitRef="usd">-1641000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-391" unitRef="usd">-3432000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-392" unitRef="usd">764425000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-393" unitRef="usd">-461154000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-394" unitRef="usd">482374000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-39" decimals="-3" id="f-395" unitRef="usd">1074036000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-396" unitRef="usd">1246799000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-21" decimals="-3" id="f-397" unitRef="usd">612882000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-398" unitRef="usd">16695000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-7" decimals="-3" id="f-399" unitRef="usd">19491000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-400" unitRef="usd">1562000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-7" decimals="-3" id="f-401" unitRef="usd">1362000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-402">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;1.      The Company and Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company's first commercial product, ARIKAYCE, is approved in the United States (US) as ARIKAYCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mycobacterium avium complex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis (CF). In March 2021, Japan's Ministry of Health, Labour and Welfare (MHLW) approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. NTM lung disease caused by MAC (which the Company refers to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's pipeline includes clinical-stage programs, brensocatib and treprostinil palmitil inhalation powder (TPIP), as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP) and hidradenitis suppurativa (HS). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH). The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, artificial intelligence-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was incorporated in the Commonwealth of Virginia on November&#160;29, 1999 and its principal executive offices are located in Bridgewater, New Jersey. The Company has legal entities in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom (UK), and Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements have been prepared pursuant to the rules&#160;and regulations for reporting on Form&#160;10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the US (GAAP) for complete consolidated financial statements are not included herein. The unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000110450624000008/insm-20231231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Annual Report on Form&#160;10-K for the year ended December&#160;31, 20&lt;/a&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Any references in these notes to applicable accounting guidance are meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. The unaudited interim consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;The Company had $1,246.8 million in cash and cash equivalents as of June&#160;30, 2024 and reported a net loss of $457.7 million for the six months ended June&#160;30, 2024. The Company has funded its operations through public offerings of equity securities, de&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;bt financings and revenue interest financings. The Company expects to continue to incur consolidated operating losses, including losses in its US and certain international entities, while funding research and development (R&amp;amp;D) activities for ARIKAYCE, brensocatib, TPIP and its other pipeline programs, continuing commercialization and regulatory activities for ARIKAYCE and pre-commercial, regulatory and, if approved, commercialization activities for brensocatib, and funding other general and administrative activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects its future cash requirements to be substantial. While the Company currently has sufficient funds to meet its financial needs for at least the next 12 months, the Company may raise additional capital in the future to fund its operations, its ongoing commercialization and clinical trial activities, and its future product candidates, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company&#x2019;s commercial, regulatory and development activities. Any future financing will also be contingent upon market &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;conditions. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiarie&lt;/span&gt;s,  Adrestia Therapeutics Inc., Celtrix Pharmaceuticals,&#160;Inc., Insmed France SAS, Insmed Gene Therapy LLC, Insmed Germany&#160;GmbH, Insmed Godo Kaisha, Insmed Holdings Limited, Insmed Innovation UK Limited, Insmed Ireland Limited, Insmed Italy S.R.L., Insmed Limited, Insmed Netherlands&#160;B.V., Insmed Netherlands Holdings B.V., and Insmed Switzerland GmbH.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-403" unitRef="usd">1246800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-404" unitRef="usd">-457700000</us-gaap:NetIncomeLoss>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-405">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2.      Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Company&#x2019;s complete listing of significant accounting policies is set forth in Note 2 of the notes to the consolidated financial statements in the Company's &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001104506/000110450624000008/insm-20231231.htm" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;. Selected significant accounting policies are discussed in detail below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, acquisition related intangibles including in process research and development (IPR&amp;amp;D) and goodwill, fair value of contingent consideration, and accounting for research and development costs. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for uncollectible trade receivables. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the six months ended June&#160;30, 2024 and their respective percentages for the six months ended June&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.116%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.913%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.934%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.717%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturers, or an adverse change in their business, could materially impact future operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finite-lived Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Finite-lived intangible assets are measured at their respective fair values on the date they were recorded. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6 - Intangibles, Net and Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment Assessment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing the carrying value of the assets to the fair value of the assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations and Asset Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration for the Company&#x2019;s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets&#x2019; carrying amounts on the acquiring entity&#x2019;s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. If the in-licensed agreement for IPR&amp;amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as acquired IPR&amp;amp;D expense in its consolidated statements of comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable, unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. None of the Company's contingent consideration met the definition of a derivative as of June&#160;30, 2024. Upon recognition of a contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indefinite-lived Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Indefinite-lived intangible assets consist of IPR&amp;amp;D. IPR&amp;amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&amp;amp;D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&amp;amp;D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#x2019;s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company&#x2019;s outlook and market performance of the Company&#x2019;s industry and recent and forecasted financial performance. The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#x2019;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. As of June&#160;30, 2024 and December&#160;31, 2023, the Company continues to operate as one reporting unit. The Company performs an impairment test for goodwill annually as of October 1. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6 - Intangibles, Net and Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9 - Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Unamortized debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the UK, and Japan. The results of the Company's non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in total s&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hareholders' equity (deficit),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as a component of accumulated other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company realizes foreign currency transaction gains and losses in the normal course of business based on movements in the applicable exchange rates. These gains and losses are included as a component of other expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;In the normal course of business, the Company is exposed to the effects of interest rate changes. The Company may enter into derivative instruments, including interest rate swaps and caps, to manage or hedge interest rate risk. Derivative instruments are recorded at fair value on the balance sheet date. The Company has not elected hedge accounting treatment for the changes in the fair value of derivatives. Changes in the fair value of derivatives are recorded each period and are included in change in fair value of interest rate swap in the consolidated statements of comprehensive loss and consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory and Cost of Product Revenues (excluding amortization of intangible assets)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Inventory is stated at the lower of cost and net realizable value. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. Inventory used for clinical development purposes is expensed to R&amp;amp;D expense when consumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&#160;Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock (RS), restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three and six months ended June&#160;30, 2024 and 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(300,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(404,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares used in calculation of basic net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RS and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of June&#160;30, 2024 and 2023, respectively, as their effect would have been anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.833%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.559%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.555%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RS and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements (Not Yet Adopted)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;In December 2023, the FASB issued ASU 2023-09, Income Taxes&#x2014;Improvements to Income Tax Disclosures, in order to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires greater disaggregation of income tax disclosures related to the income tax rate &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reconciliation and income taxes paid. ASU 2023-09 will be effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of adoption of ASU 2023-09 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-406">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, acquisition related intangibles including in process research and development (IPR&amp;amp;D) and goodwill, fair value of contingent consideration, and accounting for research and development costs. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-407">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.&lt;/span&gt;&lt;/div&gt;The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The Company uses an expected loss methodology to calculate allowances for trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company does not currently have a material allowance for uncollectible trade receivables.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-408">The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the six months ended June&#160;30, 2024 and their respective percentages for the six months ended June&#160;30, 2023.&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.116%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.913%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.934%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.717%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.936%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-56" decimals="2" id="f-409" unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-57" decimals="2" id="f-410" unitRef="number">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-58" decimals="2" id="f-411" unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-59" decimals="2" id="f-412" unitRef="number">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-60" decimals="2" id="f-413" unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-61" decimals="2" id="f-414" unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c-1" id="f-415">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finite-lived Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Finite-lived intangible assets are measured at their respective fair values on the date they were recorded. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6 - Intangibles, Net and Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment Assessment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing the carrying value of the assets to the fair value of the assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <insm:BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock contextRef="c-1" id="f-416">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations and Asset Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the date of acquisition. In accordance with ASC 805, Business Combinations, the Company recognizes and measures goodwill as of the acquisition date, as the excess of the fair value of the consideration paid over the fair value of the identified net assets acquired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration for the Company&#x2019;s business acquisitions may include future payments that are contingent upon the occurrence of a particular event or events. The obligations for such contingent consideration payments are recorded at fair value on the acquisition date. The contingent consideration obligations are then evaluated each reporting period. Changes in the fair value of contingent consideration, other than changes due to payments, are recognized as a gain or loss and recorded within change in the fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If determined to be an asset acquisition, the Company accounts for the transaction under ASC 805-50, which requires the acquiring entity in an asset acquisition to recognize assets acquired and liabilities assumed based on the cost to the acquiring entity on a relative fair value basis, which includes transaction costs in addition to consideration given. No gain or loss is recognized as of the date of acquisition unless the fair value of non-cash assets given as consideration differs from the assets&#x2019; carrying amounts on the acquiring entity&#x2019;s books. Consideration transferred that is non-cash will be measured based on either the cost (which shall be measured based on the fair value of the consideration given) or the fair value of the assets acquired and liabilities assumed, whichever is more reliably measurable. Goodwill is not recognized in an asset acquisition and any excess consideration transferred over the fair value of the net assets acquired is allocated to the identifiable assets based on relative fair values. If the in-licensed agreement for IPR&amp;amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as acquired IPR&amp;amp;D expense in its consolidated statements of comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable, unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired. None of the Company's contingent consideration met the definition of a derivative as of June&#160;30, 2024. Upon recognition of a contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.&lt;/span&gt;&lt;/div&gt;</insm:BusinessCombinationsAndAssetAcquisitionsPolicyPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="c-1" id="f-417">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indefinite-lived Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Indefinite-lived intangible assets consist of IPR&amp;amp;D. IPR&amp;amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise, they are expensed. The fair values of IPR&amp;amp;D project assets acquired in business combinations are capitalized. The Company generally utilizes the Multi-Period Excess Earning Method to determine the estimated fair value of the IPR&amp;amp;D assets acquired in a business combination. The projections used in this valuation approach are based on many factors, such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#x2019;s fair value is less than its carrying amount. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company&#x2019;s outlook and market performance of the Company&#x2019;s industry and recent and forecasted financial performance. The Company performs a qualitative test for its indefinite-lived intangible assets annually as of October 1.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-418">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&#x2014;Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company&#x2019;s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. As of June&#160;30, 2024 and December&#160;31, 2023, the Company continues to operate as one reporting unit. The Company performs an impairment test for goodwill annually as of October 1.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfReportingUnits
      contextRef="c-1"
      decimals="INF"
      id="f-419"
      unitRef="reportingunit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:NumberOfReportingUnits
      contextRef="c-62"
      decimals="INF"
      id="f-420"
      unitRef="reportingunit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-421">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes right-of-use (ROU) assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the consolidated statements of comprehensive loss in the same line item as expenses arising from fixed lease payments.&lt;/span&gt;&lt;/div&gt;Leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="c-1" id="f-422">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Unamortized debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-423">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the UK, and Japan. The results of the Company's non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in total s&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hareholders' equity (deficit),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as a component of accumulated other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company realizes foreign currency transaction gains and losses in the normal course of business based on movements in the applicable exchange rates. These gains and losses are included as a component of other expense, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c-1" id="f-424">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;In the normal course of business, the Company is exposed to the effects of interest rate changes. The Company may enter into derivative instruments, including interest rate swaps and caps, to manage or hedge interest rate risk. Derivative instruments are recorded at fair value on the balance sheet date. The Company has not elected hedge accounting treatment for the changes in the fair value of derivatives. Changes in the fair value of derivatives are recorded each period and are included in change in fair value of interest rate swap in the consolidated statements of comprehensive loss and consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <insm:InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock contextRef="c-1" id="f-425">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory and Cost of Product Revenues (excluding amortization of intangible assets)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Inventory is stated at the lower of cost and net realizable value. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. Inventory used for clinical development purposes is expensed to R&amp;amp;D expense when consumed.&lt;/span&gt;&lt;/div&gt;</insm:InventoryAndCostOfProductRevenuesExcludingAmortizationOfIntangibleAssetsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-426">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period.&#160;Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options, restricted stock (RS), restricted stock units (RSUs), performance stock units (PSUs) and convertible debt securities would be anti-dilutive as the Company incurred a net loss. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options and from the assumed conversion of the Company's convertible notes are determined based on the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="c-1" id="f-427">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the reconciliation of the weighted average number of common shares used to compute basic and diluted net loss per share for the three and six months ended June&#160;30, 2024 and 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(300,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244,809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(404,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares used in calculation of basic net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RS and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding used&#160;in calculation of diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-428" unitRef="usd">-300609000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-429" unitRef="usd">-244809000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-430" unitRef="usd">-457700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-431" unitRef="usd">-404573000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-432" unitRef="shares">154702000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-433" unitRef="shares">137553000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-434" unitRef="shares">151579000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-435" unitRef="shares">136957000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-63" decimals="-3" id="f-436" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-64" decimals="-3" id="f-437" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-65" decimals="-3" id="f-438" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-66" decimals="-3" id="f-439" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-67" decimals="-3" id="f-440" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-68" decimals="-3" id="f-441" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-69" decimals="-3" id="f-442" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-70" decimals="-3" id="f-443" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-71" decimals="-3" id="f-444" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-72" decimals="-3" id="f-445" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-73" decimals="-3" id="f-446" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-74" decimals="-3" id="f-447" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="c-5" decimals="-3" id="f-448" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="c-6" decimals="-3" id="f-449" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="c-1" decimals="-3" id="f-450" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities contextRef="c-7" decimals="-3" id="f-451" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-452" unitRef="shares">154702000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-3" id="f-453" unitRef="shares">137553000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-454" unitRef="shares">151579000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-455" unitRef="shares">136957000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-456"
      unitRef="usdPerShare">-1.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-457"
      unitRef="usdPerShare">-1.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-458"
      unitRef="usdPerShare">-1.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-459"
      unitRef="usdPerShare">-1.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-460"
      unitRef="usdPerShare">-3.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-461"
      unitRef="usdPerShare">-3.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-462"
      unitRef="usdPerShare">-2.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-463"
      unitRef="usdPerShare">-2.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-464">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of June&#160;30, 2024 and 2023, respectively, as their effect would have been anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.833%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.553%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.559%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.555%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RS and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-75" decimals="-3" id="f-465" unitRef="shares">23430000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-76" decimals="-3" id="f-466" unitRef="shares">21999000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-77" decimals="-3" id="f-467" unitRef="shares">3425000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-78" decimals="-3" id="f-468" unitRef="shares">2828000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-79" decimals="-3" id="f-469" unitRef="shares">665000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-80" decimals="-3" id="f-470" unitRef="shares">666000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-81" decimals="-3" id="f-471" unitRef="shares">23438000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-82" decimals="-3" id="f-472" unitRef="shares">23438000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-473">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements (Not Yet Adopted)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;In December 2023, the FASB issued ASU 2023-09, Income Taxes&#x2014;Improvements to Income Tax Disclosures, in order to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 requires greater disaggregation of income tax disclosures related to the income tax rate &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reconciliation and income taxes paid. ASU 2023-09 will be effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of adoption of ASU 2023-09 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-474">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;3.      Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&#x2014;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#x2019;s anticipated life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&#x2014;Inputs reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of June&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2024, $300.0&#160;million of marketable securities, consisting of US Treasury Notes, matured. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. The collateral for interest rate swap and the interest rate swap are recorded in other assets and accounts payable and accrued liabilities, respectively, in the consolidated balance sheet as of June&#160;30, 2024 and December&#160;31, 2023. The collateral for interest rate swap is cash, a Level 1 asset. The interest rate swap is a Level 2 liability as it uses observable inputs other than quoted market prices in an active market. There were no transfers in or out of Level 1, Level 2 or Level 3 during the six months ended June&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, the Company held no available-for-sale securities. Marketable securities maturing in one year or less are classified as current assets and marketable securities maturing in more than one year are classified as non-current assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2) whether the security was rated below investment grade; (3) failure of the issuer to make scheduled interest or principal payments; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover. The Company has determined that there were no other-than-temporary impairments during the six months ended June 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The deferred consideration arose from the acquisition of Motus Biosciences, Inc. (Motus) in August 2021. The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company&#x2019;s common stock on each of the first, second and third anniversaries of the closing date, subject to certain reductions. During August 2022 and August 2023, the Company fulfilled the payments due on the first and second anniversaries of the closing date by issuing 171,427 shares and 177,203 shares of the Company's common stock, respectively, after certain reductions. A valuation of the deferred consideration is performed quarterly with gains and losses included within change in fair value of deferred and contingent consideration liabilities in the consolidated statements of comprehensive loss. As the deferred consideration is settled in shares, there is no discount rate applied in the fair value calculation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The deferred consideration has been classified as a Level 2 recurring liability as its valuation utilizes an input, the Insmed share price, which is a directly observable input at the measurement date and for the duration of the liabilities' anticipated lives. Deferred consideration expected to be settled within twelve months or less is classified as a current liability within accounts payable and accrued liabilities. As of June&#160;30, 2024, the fair value of deferred consideration included in accounts payable and accrued liabilities was $12.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following observable input was used in the valuation of the deferred consideration as of June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.111%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value as of June&#160;30, 2024 (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Observable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$12.4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insmed share price as of June&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$67.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liabilities arose from the acquisitions of Motus and AlgaeneX, Inc. (AlgaeneX) (together, the Business Acquisition) in August 2021 (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16 - Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). The contingent consideration liabilities consist of developmental and regulatory milestones, a priority review voucher milestone and net sales milestones. Upon the achievement of certain development and regulatory milestone events, the Company is obligated to issue to Motus equityholders up to 5,348,572 shares in the aggregate and AlgaeneX equityholders up to 368,867 shares in the aggregate. The fair value of the development and regulatory milestones are estimated utilizing a probability-adjusted approach. At June&#160;30, 2024, the weighted average probability of success was 42%. The development and regulatory milestones will be settled in shares of the Company's common stock. As such, there is no discount rate applied in the fair value calculation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company were to receive a priority review voucher, the Company is obligated to pay to the Motus equityholders a portion of the value of the priority review voucher, subject to certain reductions. The potential payout will be either 50% of the after tax net proceeds received by the Company from a sale of the priority review voucher or 50% of the average of the sales prices for the last three publicly disclosed priority review voucher sales, less certain adjustments. The fair value of the priority review voucher milestone is estimated utilizing a probability-adjusted discounted cash flow approach. This obligation will be settled in cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liabilities for net sales milestones were valued using an option pricing model with Monte Carlo simulation. As of June&#160;30, 2024, the fair value of these net sales milestones were deemed immaterial to the overall fair value of the contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration liabilities have been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the inputs to the valuation approach, the estimated fair value could be significantly different than the fair value the Company determined. Contingent consideration expected to be settled within twelve months or less is classified as a current liability within accounts payable and accrued liabilities. Contingent consideration expected to be settled in more than twelve months is classified as a non-current liability. As of June&#160;30, 2024, the fair value of the current and non-current contingent consideration was $68.2&#160;million and $101.5&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation of the contingent consideration liabilities is performed quarterly with gains and losses included within change in fair value of contingent consideration liabilities in the consolidated statements of comprehensive loss. The following significant unobservable inputs were used in the valuation of the development and regulatory milestones and the priority review voucher milestone as of June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.586%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.290%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value as of June&#160;30, 2024 (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$161.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability-adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probabilities of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14% - 97%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Priority review voucher milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability-adjusted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the six months ended June 30, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.143%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.383%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred&lt;br/&gt;&#160;Consideration &lt;br/&gt;(Level 2 Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent Consideration&lt;br/&gt;&#160;(Level 3 Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the convertible notes, which differs from their carrying value, is influenced by interest rates, the Company's stock price and stock price volatility (collectively, the Current Market Factors), and is determined by prices for the convertible notes observed in market trading which are Level 2 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the Company's 0.75% convertible senior notes due 2028 (the 2028 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of June&#160;30, 2024 was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.2 billion, deter&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;mined using Current Market Factors and the ability of the Company to obtain debt on comparable terms to the 2028 Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the Company's 1.75% convertible senior notes due 2025 (the 2025 Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of June&#160;30, 2024 wa&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s $384.5 million, determined using Current Market Factors, and the ability of the Company to obtain debt on comparable terms to the 202&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 Convertible Notes. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 10 - Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Synthetic Royalty Financing Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, the Company entered into a revenue interest purchase agreement (the Royalty Financing Agreement) with OrbiMed Royalty &amp;amp; Credit Opportunities IV, LP (OrbiMed). Under the Royalty Financing Agreement, OrbiMed paid the Company &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$150 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% of ARIKAYCE global net sales on or after September 1, 2025, as well as 0.75% of brensocatib global net sales, if approved (the Revenue Interest Payments). In the event that OrbiMed has not received aggregate Revenue Interest Payments of at least &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$150 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on or prior to March 31, 2028, the Company must make a one-time payment to OrbiMed for the difference between the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$150 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the aggregated Revenue Interest Payments that have been paid. In addition, the royalty rate for ARIKAYCE will be increased beginning March 31, 2028 to the rate which would have resulted in aggregate Revenue Interest Payments as of March 31, 2028 equaling &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$150 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The total Revenue Interest Payments payable by the Company to OrbiMed are capped at 1.8x of the purchase price or up to a maximum of 1.9x of the purchase price under certain conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company&#x2019;s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective interest method over the life of the arrangement, in accordance with ASC 470, Debt and ASC 835, Interest. The Company will utilize the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and will update the effective interest rate on a quarterly basis. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11 - Royalty Financing Agreement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-475">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&#x2014;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&#x2014;Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#x2019;s anticipated life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&#x2014;Inputs reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets. The Company's cash and cash equivalents permit daily redemption and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-476">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of June&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.300%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-83" decimals="-5" id="f-477" unitRef="usd">1246800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-84" decimals="-5" id="f-478" unitRef="usd">1246800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-85" decimals="-5" id="f-479" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-86" decimals="-5" id="f-480" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DerivativeAssets contextRef="c-83" decimals="-5" id="f-481" unitRef="usd">6000000.0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-84" decimals="-5" id="f-482" unitRef="usd">6000000.0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-85" decimals="-5" id="f-483" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-86" decimals="-5" id="f-484" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue contextRef="c-83" decimals="-5" id="f-485" unitRef="usd">1500000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue contextRef="c-84" decimals="-5" id="f-486" unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue contextRef="c-85" decimals="-5" id="f-487" unitRef="usd">1500000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue contextRef="c-86" decimals="-5" id="f-488" unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <insm:BusinessCombinationDeferredLiability contextRef="c-83" decimals="-5" id="f-489" unitRef="usd">12400000</insm:BusinessCombinationDeferredLiability>
    <insm:BusinessCombinationDeferredLiability contextRef="c-84" decimals="-5" id="f-490" unitRef="usd">0</insm:BusinessCombinationDeferredLiability>
    <insm:BusinessCombinationDeferredLiability contextRef="c-85" decimals="-5" id="f-491" unitRef="usd">12400000</insm:BusinessCombinationDeferredLiability>
    <insm:BusinessCombinationDeferredLiability contextRef="c-86" decimals="-5" id="f-492" unitRef="usd">0</insm:BusinessCombinationDeferredLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-83" decimals="-5" id="f-493" unitRef="usd">169700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-84" decimals="-5" id="f-494" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-85" decimals="-5" id="f-495" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-86" decimals="-5" id="f-496" unitRef="usd">169700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-87" decimals="-5" id="f-497" unitRef="usd">482400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-88" decimals="-5" id="f-498" unitRef="usd">482400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-89" decimals="-5" id="f-499" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-90" decimals="-5" id="f-500" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:MarketableSecurities contextRef="c-87" decimals="-5" id="f-501" unitRef="usd">298100000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="c-88" decimals="-5" id="f-502" unitRef="usd">298100000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="c-89" decimals="-5" id="f-503" unitRef="usd">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="c-90" decimals="-5" id="f-504" unitRef="usd">0</us-gaap:MarketableSecurities>
    <us-gaap:DerivativeAssets contextRef="c-87" decimals="-5" id="f-505" unitRef="usd">6000000.0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-88" decimals="-5" id="f-506" unitRef="usd">6000000.0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-89" decimals="-5" id="f-507" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-90" decimals="-5" id="f-508" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue contextRef="c-87" decimals="-5" id="f-509" unitRef="usd">1200000</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue contextRef="c-88" decimals="-5" id="f-510" unitRef="usd">0</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue contextRef="c-89" decimals="-5" id="f-511" unitRef="usd">1200000</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue contextRef="c-90" decimals="-5" id="f-512" unitRef="usd">0</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <insm:BusinessCombinationDeferredLiability contextRef="c-87" decimals="-5" id="f-513" unitRef="usd">5700000</insm:BusinessCombinationDeferredLiability>
    <insm:BusinessCombinationDeferredLiability contextRef="c-88" decimals="-5" id="f-514" unitRef="usd">0</insm:BusinessCombinationDeferredLiability>
    <insm:BusinessCombinationDeferredLiability contextRef="c-89" decimals="-5" id="f-515" unitRef="usd">5700000</insm:BusinessCombinationDeferredLiability>
    <insm:BusinessCombinationDeferredLiability contextRef="c-90" decimals="-5" id="f-516" unitRef="usd">0</insm:BusinessCombinationDeferredLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-87" decimals="-5" id="f-517" unitRef="usd">84600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-88" decimals="-5" id="f-518" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-89" decimals="-5" id="f-519" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-90" decimals="-5" id="f-520" unitRef="usd">84600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c-1" decimals="-5" id="f-521" unitRef="usd">300000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:MarketableSecurities contextRef="c-83" decimals="INF" id="f-522" unitRef="usd">0</us-gaap:MarketableSecurities>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-91"
      decimals="INF"
      id="f-523"
      unitRef="shares">184433</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-92"
      decimals="INF"
      id="f-524"
      unitRef="shares">184433</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-93"
      decimals="INF"
      id="f-525"
      unitRef="shares">184433</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-94"
      decimals="INF"
      id="f-526"
      unitRef="shares">171427</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-95"
      decimals="INF"
      id="f-527"
      unitRef="shares">177203</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <insm:BusinessCombinationDeferredLiability contextRef="c-96" decimals="-5" id="f-528" unitRef="usd">12400000</insm:BusinessCombinationDeferredLiability>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-529">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following observable input was used in the valuation of the deferred consideration as of June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.111%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.159%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value as of June&#160;30, 2024 (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Observable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$12.4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insmed share price as of June&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$67.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following significant unobservable inputs were used in the valuation of the development and regulatory milestones and the priority review voucher milestone as of June&#160;30, 2024:&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.586%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.290%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value as of June&#160;30, 2024 (in millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Values&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$161.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability-adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probabilities of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14% - 97%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Priority review voucher milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability-adjusted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of success&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the changes in the fair value of the Company's valuations for the deferred and contingent consideration liabilities for the six months ended June 30, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.143%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.383%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred&lt;br/&gt;&#160;Consideration &lt;br/&gt;(Level 2 Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent Consideration&lt;br/&gt;&#160;(Level 3 Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <insm:BusinessCombinationDeferredLiability contextRef="c-3" decimals="-5" id="f-530" unitRef="usd">12400000</insm:BusinessCombinationDeferredLiability>
    <insm:BusinessCombinationDeferredConsiderationLiabilityMeasurementInput
      contextRef="c-97"
      decimals="2"
      id="f-531"
      unitRef="usdPerShare">67.00</insm:BusinessCombinationDeferredConsiderationLiabilityMeasurementInput>
    <insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares
      contextRef="c-98"
      decimals="INF"
      id="f-532"
      unitRef="shares">5348572</insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares>
    <insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares
      contextRef="c-99"
      decimals="INF"
      id="f-533"
      unitRef="shares">368867</insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-100" decimals="2" id="f-534" unitRef="number">0.42</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <insm:ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage contextRef="c-101" decimals="2" id="f-535" unitRef="number">0.50</insm:ProceedsOfSaleOfPriorityReviewVoucherObligatedToPayToEquityHoldersPercentage>
    <insm:AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage contextRef="c-101" decimals="2" id="f-536" unitRef="number">0.50</insm:AverageSalesPricesOfPubliclyDisclosedPriorityReviewVoucherSalesObligatedToPayEquityHoldersPercentage>
    <insm:NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders contextRef="c-102" decimals="INF" id="f-537" unitRef="sale">3</insm:NumberOfPubliclyDisclosedSalesUsedToDetermineAverageSalesPriceOwedToEquityHolders>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-103" decimals="-5" id="f-538" unitRef="usd">68200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-103" decimals="-5" id="f-539" unitRef="usd">101500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-104" decimals="-5" id="f-540" unitRef="usd">161800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-105" decimals="2" id="f-541" unitRef="number">0.14</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-106" decimals="2" id="f-542" unitRef="number">0.97</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-107" decimals="-5" id="f-543" unitRef="usd">5200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-108" decimals="3" id="f-544" unitRef="number">0.164</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-109" decimals="3" id="f-545" unitRef="number">0.164</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-110" decimals="-3" id="f-546" unitRef="usd">7400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-111" decimals="-3" id="f-547" unitRef="usd">58100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueAdjustment contextRef="c-112" decimals="-3" id="f-548" unitRef="usd">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment contextRef="c-113" decimals="-3" id="f-549" unitRef="usd">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions contextRef="c-112" decimals="-3" id="f-550" unitRef="usd">-400000</us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions>
    <us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions contextRef="c-113" decimals="-3" id="f-551" unitRef="usd">-3600000</us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions>
    <insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments contextRef="c-112" decimals="-3" id="f-552" unitRef="usd">0</insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments>
    <insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments contextRef="c-113" decimals="-3" id="f-553" unitRef="usd">0</insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-114" decimals="-3" id="f-554" unitRef="usd">7800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-115" decimals="-3" id="f-555" unitRef="usd">61700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-116" decimals="-3" id="f-556" unitRef="usd">5700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-117" decimals="-3" id="f-557" unitRef="usd">84600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueAdjustment contextRef="c-118" decimals="-3" id="f-558" unitRef="usd">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment contextRef="c-119" decimals="-3" id="f-559" unitRef="usd">0</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions contextRef="c-118" decimals="-3" id="f-560" unitRef="usd">-6700000</us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions>
    <us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions contextRef="c-119" decimals="-3" id="f-561" unitRef="usd">-85100000</us-gaap:AssetAtFairValueChangesInFairValueResultingFromChangesInAssumptions>
    <insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments contextRef="c-118" decimals="-3" id="f-562" unitRef="usd">0</insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments>
    <insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments contextRef="c-119" decimals="-3" id="f-563" unitRef="usd">0</insm:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAdjustments>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-120" decimals="-3" id="f-564" unitRef="usd">12400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-121" decimals="-3" id="f-565" unitRef="usd">169700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-122"
      decimals="INF"
      id="f-566"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-123" decimals="-8" id="f-567" unitRef="usd">1200000000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-124"
      decimals="INF"
      id="f-568"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-125" decimals="-5" id="f-569" unitRef="usd">384500000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <insm:ProceedsFromRoyaltyFinancing contextRef="c-126" decimals="-6" id="f-570" unitRef="usd">150000000</insm:ProceedsFromRoyaltyFinancing>
    <insm:DebtInstrumentRoyaltyStatedPercentage contextRef="c-127" decimals="2" id="f-571" unitRef="number">0.04</insm:DebtInstrumentRoyaltyStatedPercentage>
    <insm:DebtInstrumentRoyaltyStatedPercentage contextRef="c-128" decimals="3" id="f-572" unitRef="number">0.045</insm:DebtInstrumentRoyaltyStatedPercentage>
    <insm:DebtInstrumentRoyaltyStatedPercentage contextRef="c-129" decimals="4" id="f-573" unitRef="number">0.75</insm:DebtInstrumentRoyaltyStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-130" decimals="-6" id="f-574" unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-126" decimals="-6" id="f-575" unitRef="usd">150000000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <insm:ProceedsFromRoyaltyFinancing contextRef="c-126" decimals="-6" id="f-576" unitRef="usd">150000000</insm:ProceedsFromRoyaltyFinancing>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-577">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;4.      Product Revenues, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract to determine which are performance obligations and to assess whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenues, net consist of net sales of ARIKAYCE. The Company's customers in the US include specialty pharmacies and specialty distributors. In December 2020, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Europe. In July 2021, the Company began recognizing product revenue from commercial sales of ARIKAYCE in Japan. Globally, product revenues are recognized once the Company performs and satisfies all five steps of the revenue recognition criteria mentioned above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a geographic summary of the Company's product revenues, net, for the three and six months ended June&#160;30, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.014%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.170%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe and rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total product revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer credits: Certain of the Company's customers are offered various forms of consideration, including prompt payment discounts. The payment terms for sales to specialty pharmacies and specialty distributors for prompt payment discounts are based on contractual rates agreed with the respective specialty pharmacies and distributors. The Company anticipates that its customers will earn these discounts and, therefore, deducts the full amount of these discounts from total gross product revenues at the time such revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates: The Company contracts with certain government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accounts payable and accrued liabilities on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;The Company also recognizes revenue related to various early access programs (EAPs) in Europe. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-578">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a geographic summary of the Company's product revenues, net, for the three and six months ended June&#160;30, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.014%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.164%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.170%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe and rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total product revenues, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-131" decimals="-3" id="f-579" unitRef="usd">63793000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-132" decimals="-3" id="f-580" unitRef="usd">57665000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-133" decimals="-3" id="f-581" unitRef="usd">120142000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-134" decimals="-3" id="f-582" unitRef="usd">106732000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-135" decimals="-3" id="f-583" unitRef="usd">21111000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-136" decimals="-3" id="f-584" unitRef="usd">15593000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-137" decimals="-3" id="f-585" unitRef="usd">36002000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-138" decimals="-3" id="f-586" unitRef="usd">28749000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-139" decimals="-3" id="f-587" unitRef="usd">5436000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-140" decimals="-3" id="f-588" unitRef="usd">3971000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-141" decimals="-3" id="f-589" unitRef="usd">9696000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-142" decimals="-3" id="f-590" unitRef="usd">6962000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-591" unitRef="usd">90340000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-592" unitRef="usd">77229000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-593" unitRef="usd">165840000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-594" unitRef="usd">142443000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-595">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;5.      Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's inventory balance consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.266%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.258%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company has not recorded any significant inventory write-downs. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-596">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's inventory balance consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.824%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.266%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.258%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-3" decimals="-3" id="f-597" unitRef="usd">24898000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-4" decimals="-3" id="f-598" unitRef="usd">24562000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-3" decimals="-3" id="f-599" unitRef="usd">36494000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-4" decimals="-3" id="f-600" unitRef="usd">33480000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-3" decimals="-3" id="f-601" unitRef="usd">28671000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-4" decimals="-3" id="f-602" unitRef="usd">25206000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-603" unitRef="usd">90063000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-604" unitRef="usd">83248000</us-gaap:InventoryNet>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-605">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;6.      Intangibles, Net and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangibles, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Finite-lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, the Company's finite-lived intangible assets consisted of acquired ARIKAYCE R&amp;amp;D and the milestones paid to PARI for the license to use the Lamira&#xae; Nebulizer System (Lamira) for the delivery of ARIKAYCE to patients as a result of the US Food and Drug Administration (FDA) and EC approvals of ARIKAYCE in September 2018 and October 2020, respectively. The Company began amortizing its acquired ARIKAYCE R&amp;amp;D and PARI milestone-related intangible assets in October 2018, over ARIKAYCE's initial regulatory exclusivity period of 12 years. Amortization of these assets during each of the next five years is estimated to be approximately $5.1 million per year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indefinite-lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, the Company's indefinite-lived intangible assets consisted of acquired IPR&amp;amp;D from the Business Acquisition (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16 - Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). Indefinite-lived intangible assets are not amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A rollforward of the Company's intangible assets for the six months ended June 30, 2024 and June&#160;30, 2023 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.210%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired ARIKAYCE R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PARI milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired ARIKAYCE R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PARI milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's goodwill balance of $136.1 million as of June&#160;30, 2024 and December&#160;31, 2023, resulted from the August 2021 Business Acquisition. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16 - Acquisitions &lt;/span&gt;for further details.</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-3" id="f-606">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-3" decimals="-5" id="f-607" unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-3" decimals="-5" id="f-608" unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-3" decimals="-5" id="f-609" unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-3" decimals="-5" id="f-610" unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-3" decimals="-5" id="f-611" unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-612">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A rollforward of the Company's intangible assets for the six months ended June 30, 2024 and June&#160;30, 2023 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.130%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.492%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.210%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired ARIKAYCE R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PARI milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired ARIKAYCE R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PARI milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-143" decimals="-3" id="f-613" unitRef="usd">32738000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-144" decimals="-3" id="f-614" unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-144" decimals="-3" id="f-615" unitRef="usd">2425000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-145" decimals="-3" id="f-616" unitRef="usd">30313000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-146" decimals="-3" id="f-617" unitRef="usd">29600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-147" decimals="-3" id="f-618" unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-147" decimals="-3" id="f-619" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-148" decimals="-3" id="f-620" unitRef="usd">29600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-149" decimals="-3" id="f-621" unitRef="usd">1366000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-150" decimals="-3" id="f-622" unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-150" decimals="-3" id="f-623" unitRef="usd">101000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-151" decimals="-3" id="f-624" unitRef="usd">1265000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-4" decimals="-3" id="f-625" unitRef="usd">63704000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-1" decimals="-3" id="f-626" unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-627" unitRef="usd">2526000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-628" unitRef="usd">61178000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-152" decimals="-3" id="f-629" unitRef="usd">37588000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-153" decimals="-3" id="f-630" unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-153" decimals="-3" id="f-631" unitRef="usd">2425000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-154" decimals="-3" id="f-632" unitRef="usd">35163000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-155" decimals="-3" id="f-633" unitRef="usd">29600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-156" decimals="-3" id="f-634" unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-156" decimals="-3" id="f-635" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-157" decimals="-3" id="f-636" unitRef="usd">29600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-158" decimals="-3" id="f-637" unitRef="usd">1568000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-159" decimals="-3" id="f-638" unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-159" decimals="-3" id="f-639" unitRef="usd">101000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-160" decimals="-3" id="f-640" unitRef="usd">1467000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-39" decimals="-3" id="f-641" unitRef="usd">68756000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-7" decimals="-3" id="f-642" unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-7" decimals="-3" id="f-643" unitRef="usd">2526000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-21" decimals="-3" id="f-644" unitRef="usd">66230000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill contextRef="c-4" decimals="-5" id="f-645" unitRef="usd">136100000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-3" decimals="-5" id="f-646" unitRef="usd">136100000</us-gaap:Goodwill>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-647">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;7.      Fixed Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.916%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Useful Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-648">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.916%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.398%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Useful Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3-5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-161" id="f-649">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-161" decimals="-3" id="f-650" unitRef="usd">24476000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-162" decimals="-3" id="f-651" unitRef="usd">22660000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-163" id="f-652">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-163" decimals="-3" id="f-653" unitRef="usd">6428000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-164" decimals="-3" id="f-654" unitRef="usd">6428000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-165" id="f-655">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-166" id="f-656">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-167" decimals="-3" id="f-657" unitRef="usd">6252000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-168" decimals="-3" id="f-658" unitRef="usd">6001000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-169" id="f-659">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-169" decimals="-3" id="f-660" unitRef="usd">89000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-170" decimals="-3" id="f-661" unitRef="usd">89000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-171" id="f-662">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-171" decimals="-3" id="f-663" unitRef="usd">1336000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-172" decimals="-3" id="f-664" unitRef="usd">1336000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-173" id="f-665">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-174" id="f-666">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-175" decimals="-3" id="f-667" unitRef="usd">37922000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-176" decimals="-3" id="f-668" unitRef="usd">38049000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-177" decimals="-3" id="f-669" unitRef="usd">43616000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-178" decimals="-3" id="f-670" unitRef="usd">35449000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-3" id="f-671" unitRef="usd">120119000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-672" unitRef="usd">110012000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-673" unitRef="usd">47342000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-674" unitRef="usd">44628000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-675" unitRef="usd">72777000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-676" unitRef="usd">65384000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-677">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;8.      Accounts Payable and Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.207%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accrued operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued technical operation expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalty and milestones payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue Interest Payments payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales allowances and related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued France ATU reimbursement payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred and contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued milestone payment to AstraZeneca&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2024, a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$12.5 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; milestone commitment became payable to AstraZeneca upon the Company's release of an official public statement that it intends to file a new drug application (NDA) for brensocatib.&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-678">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.207%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.569%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accrued operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued technical operation expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalty and milestones payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue Interest Payments payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales allowances and related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued France ATU reimbursement payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred and contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued milestone payment to AstraZeneca&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;290,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-679" unitRef="usd">51363000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-680" unitRef="usd">65393000</us-gaap:AccountsPayableCurrent>
    <insm:AccruedClinicalTrialExpenses contextRef="c-3" decimals="-3" id="f-681" unitRef="usd">22581000</insm:AccruedClinicalTrialExpenses>
    <insm:AccruedClinicalTrialExpenses contextRef="c-4" decimals="-3" id="f-682" unitRef="usd">23711000</insm:AccruedClinicalTrialExpenses>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent contextRef="c-3" decimals="-3" id="f-683" unitRef="usd">16114000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-684" unitRef="usd">13885000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <insm:AccruedTechnicalOperationExpenses contextRef="c-3" decimals="-3" id="f-685" unitRef="usd">11097000</insm:AccruedTechnicalOperationExpenses>
    <insm:AccruedTechnicalOperationExpenses contextRef="c-4" decimals="-3" id="f-686" unitRef="usd">9187000</insm:AccruedTechnicalOperationExpenses>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-687" unitRef="usd">42198000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-688" unitRef="usd">48933000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-3" decimals="-3" id="f-689" unitRef="usd">7288000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-4" decimals="-3" id="f-690" unitRef="usd">5674000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-3" decimals="-3" id="f-691" unitRef="usd">2175000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="c-4" decimals="-3" id="f-692" unitRef="usd">2175000</us-gaap:InterestPayableCurrent>
    <insm:RevenueInterestPaymentsPayable contextRef="c-3" decimals="-3" id="f-693" unitRef="usd">3613000</insm:RevenueInterestPaymentsPayable>
    <insm:RevenueInterestPaymentsPayable contextRef="c-4" decimals="-3" id="f-694" unitRef="usd">3347000</insm:RevenueInterestPaymentsPayable>
    <insm:AccruedSalesAllowancesAndRelatedCosts contextRef="c-3" decimals="-3" id="f-695" unitRef="usd">14479000</insm:AccruedSalesAllowancesAndRelatedCosts>
    <insm:AccruedSalesAllowancesAndRelatedCosts contextRef="c-4" decimals="-3" id="f-696" unitRef="usd">10937000</insm:AccruedSalesAllowancesAndRelatedCosts>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent contextRef="c-3" decimals="-3" id="f-697" unitRef="usd">17188000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <us-gaap:ContractWithCustomerRefundLiabilityCurrent contextRef="c-4" decimals="-3" id="f-698" unitRef="usd">14685000</us-gaap:ContractWithCustomerRefundLiabilityCurrent>
    <insm:BusinessCombinationDeferredPaymentsCurrent contextRef="c-3" decimals="-3" id="f-699" unitRef="usd">81600000</insm:BusinessCombinationDeferredPaymentsCurrent>
    <insm:BusinessCombinationDeferredPaymentsCurrent contextRef="c-4" decimals="-3" id="f-700" unitRef="usd">6700000</insm:BusinessCombinationDeferredPaymentsCurrent>
    <insm:AccruedMilestonePaymentCurrent contextRef="c-3" decimals="-3" id="f-701" unitRef="usd">12500000</insm:AccruedMilestonePaymentCurrent>
    <insm:AccruedMilestonePaymentCurrent contextRef="c-4" decimals="-3" id="f-702" unitRef="usd">0</insm:AccruedMilestonePaymentCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-703" unitRef="usd">8648000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-704" unitRef="usd">10360000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-705" unitRef="usd">290844000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-706" unitRef="usd">214987000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LesseeFinanceLeasesTextBlock contextRef="c-1" id="f-708">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;9.      Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $3.2 million and $4.1 million for the three months ended June&#160;30, 2024 and 2023, respectively, and $8.1 million and $4.2 million for the six months ended June&#160;30, 2024 and 2023, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.728%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance right-of-use assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating right-of-use assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f $54.4 million and $49.1 million incurred by the Company under these additional agreements have been classified within&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;other assets in the Company's &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consolidated balance sheet as of June&#160;30, 2024 and December&#160;31, 2023, respectively. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-707">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;9.      Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease portfolio consists primarily of office and laboratory space, manufacturing facilities, research equipment and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's leases of its corporate headquarters and a research facility in San Diego, which are classified as finance leases. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, the Company has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $3.2 million and $4.1 million for the three months ended June&#160;30, 2024 and 2023, respectively, and $8.1 million and $4.2 million for the six months ended June&#160;30, 2024 and 2023, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.728%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance right-of-use assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating right-of-use assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon UK Limited (Patheon) related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs o&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f $54.4 million and $49.1 million incurred by the Company under these additional agreements have been classified within&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;other assets in the Company's &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consolidated balance sheet as of June&#160;30, 2024 and December&#160;31, 2023, respectively. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <insm:LeaseRemainingLeaseTerm contextRef="c-179" id="f-709">P1Y</insm:LeaseRemainingLeaseTerm>
    <insm:LeaseRemainingLeaseTerm contextRef="c-180" id="f-710">P10Y10M</insm:LeaseRemainingLeaseTerm>
    <us-gaap:VariableLeaseCost contextRef="c-5" decimals="-5" id="f-711" unitRef="usd">3200000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-6" decimals="-5" id="f-712" unitRef="usd">4100000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-5" id="f-713" unitRef="usd">8100000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-7" decimals="-5" id="f-714" unitRef="usd">4200000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-715">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the supplemental non-cash disclosures of the Company's leases included in its consolidated financial statements (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.728%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance right-of-use assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating right-of-use assets obtained in exchange for lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-5" decimals="-3" id="f-716" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-6" decimals="-3" id="f-717" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-1" decimals="-3" id="f-718" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-7" decimals="-3" id="f-719" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-720" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-721" unitRef="usd">130000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-722" unitRef="usd">5656000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-723" unitRef="usd">1881000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount contextRef="c-3" decimals="-5" id="f-724" unitRef="usd">54400000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount contextRef="c-4" decimals="-5" id="f-725" unitRef="usd">49100000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-726">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;10.      Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of long-term debt and debt, long-term consists of the following commitments as of June&#160;30, 2024 and December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.608%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.800%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.090%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.136%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.135%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.139%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224,448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt, long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,155,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company completed an underwritten public offering of $575.0 million aggregate principal amount of the 2028 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $75.0 million in aggregate principal amount of 2028 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $15.7&#160;million, were approximately $559.3 million. The 2028 Convertible Notes bear interest payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2021. The 2028 Convertible Notes mature on June 1, 2028, unless earlier converted, redeemed, or repurchased. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, the Company completed an underwritten public offering of $450.0 million aggregate principal amount of the 2025 Convertible Notes, including the exercise in full of the underwriters' option to purchase an additional $50.0 million in aggregate principal amount of 2025 Convertible Notes. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $14.2 million, were approximately $435.8 million. The 2025 Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The 2025 Convertible Notes would have matured on January 15, 2025 but, on June 27, 2024, the Company called the outstanding 2025 Convertible Notes for redemption, with a redemption date of August 9, 2024. See &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redemption of the 2025 Convertible Notes &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;below for further details.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A portion of the net proceeds from the 2028 Convertible Notes was used to repurchase $225.0 million of the Company's outstanding 2025 Convertible Notes. The Company recorded a loss on early extinguishment of debt of $17.7 million, primarily related to the premium paid on extinguishment of a portion the 2025 Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after March 1, 2028, until the close of business on the second scheduled trading day immediately preceding June 1, 2028, holders may convert their 2028 Convertible Notes at any time. The initial conversion rate for the 2028 Convertible Notes is 30.7692 shares of common stock per $1,000 principal amount of 2028 Convertible Notes (equivalent to an initial conversion price of approximately $32.50 per share of common stock). Upon conversion of either the 2025 Convertible Notes or the 2028 Convertible Notes, holders may receive cash, shares of the Company's common stock or a combination of cash and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares of the Company's common stock, at the Company's option. The conversion rates will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their 2028 Convertible Notes prior to March 1, 2028, only under the following circumstances, subject to the conditions set forth in the indenture: (i) during the five business day period immediately after any five consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of the 2028 Convertible Notes, as determined following a request by a holder of such notes, for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than 45 days from the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company's assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding 10% of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the 2028 Convertible Notes may be surrendered by a holder for conversion at any time from or after the date that is 30 scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on June 30, 2021 (and only during such calendar quarter), the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day (each, a Stock Price Convertibility Trigger), or (v) if the Company sends a notice of redemption, a holder may surrender all or any portion of its 2028 Convertible Notes to which the notice of redemption relates for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a)&#160;the second business day immediately preceding the related redemption date or (b)&#160;if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid. As of June&#160;30, 2024, there have not been any holder-initiated conversion requests for either series of convertible notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each series of convertible notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in both series of convertible notes are not required to be separately accounted for as a derivative. However, since the convertible notes are within the scope of the accounting guidance for cash convertible instruments, the Company is required to separate each series of convertible notes into liability and equity components. The carrying amount of the liability component of each series of convertible notes as of the date of issuance was calculated by measuring the fair value of a similar liability that did not have an associated equity component. The fair value was based on data from readily available pricing sources which utilize market observable inputs and other characteristics for similar types of instruments. The carrying amount of the equity component representing the embedded conversion option for each series of convertible notes was determined by deducting the fair value of the liability component from the gross proceeds of the applicable convertible notes. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in the accounting guidance for contracts in an entity&#x2019;s own equity. The fair value of the liability component of the 2025 Convertible Notes on the date of issuance was estimated at $309.1&#160;million using an effective interest rate of 7.6% and, accordingly, the residual equity component on the date of issuance was $140.9&#160;million. The fair value of the liability component of the 2028 Convertible Notes on the date of issuance was estimated at $371.6&#160;million using an effective interest rate of 7.1% and, accordingly, the residual equity component on the date of issuance was $203.4&#160;million. The respective discounts were amortized to interest expense over the term of the applicable series of convertible notes through December&#160;31, 2022, prior to the adoption of ASU 2020-06. The 2028 Convertible Notes have a remaining term of approximately 3.92 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $566.1 million carrying value of the 2028 Convertible Notes as of June&#160;30, 2024 is net of $8.9 million of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;unamortized debt issuance costs. The $224.4 million carrying value of the 2025 Convertible Notes as of June&#160;30, 2024 is net of $0.6 million of unamortized debt issuance costs. The 2028 Convertible Notes and 2025 Convertible Notes are long-term and current liabilities, respectively, as of June&#160;30, 2024. The following table presents the carrying value of the Company's convertible notes balance (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.753%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.755%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Face value of outstanding convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,091)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224,448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redemption of the 2025 Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 27, 2024, the Company issued a redemption notice for its 2025 Convertible Notes with a redemption date of August 9, 2024 (the Redemption Date). All then outstanding 2025 Convertible Notes will be redeemed at a redemption price equal to 100% of the principal amount of the 2025 Convertible Notes, plus accrued and unpaid interest on the 2025 Convertible Notes to, but excluding, the Redemption Date (the Redemption Price). For each $1,000 principal amount of 2025 Convertible Notes, the Redemption Price will be equal to approximately $1,001.17. The Company has elected to settle any conversions of the 2025 Convertible Notes that occur on or before the business day prior to the Redemption Date in shares of common stock. As of June&#160;30, 2024, none of the 2025 Convertible Notes converted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Secured Senior Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2022, the Company entered into a $350&#160;million senior secured term loan agreement with Pharmakon Advisors LP (Pharmakon), manager of the BioPharma Credit funds (the Term Loan). The Term Loan matures on October 19, 2027 and bears interest at a rate based upon the secured overnight financing rate (SOFR), subject to a SOFR floor of 2.5%, in addition to a margin of 7.75% per annum. Up to 50% of the interest payable during the first 24 months from the closing of the Term Loan may be paid-in-kind at the Company's election. If elected, paid-in-kind interest will be capitalized and added to the principal amount of the Term Loan. The Term Loan, including the paid-in-kind interest, will be repaid in eight equal quarterly payments starting in the 13th quarter following the closing of the Term Loan (i.e., the quarter ending March 31, 2026), except that the repayment start date may be extended at the Company's option for an additional four quarters, so that repayments start in the 17th quarter following the closing of the Term Loan, subject to the achievement of specified ARIKAYCE data thresholds and certain other conditions. Net proceeds from the Term Loan, after deducting the lenders' fees and deal expenses of $15.2 million, were $334.8&#160;million. During the six months ended June 30, 2024, paid-in-kind interest capitalized was $12.6&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the carrying value of the Company&#x2019;s Term Loan balance as of June&#160;30, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.169%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.103%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.276%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.103%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.277%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Original Term Loan balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid-in-kind interest capitalized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan issuance costs, unamortized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, future principal repayments of debt for each of the years through maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.543%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;redemption notice the Company issued for its 2025 Convertible Notes, the principal balance of the 2025 Convertible Notes was reclassified to due within the current year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense related to debt and finance leases for the three and six months ended June&#160;30, 2024 and 2023 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.934%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.797%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty Financing Agreement interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Swap interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total debt interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-727">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current portion of long-term debt and debt, long-term consists of the following commitments as of June&#160;30, 2024 and December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.608%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.800%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.090%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.136%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.135%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.139%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224,448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt, long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;946,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,155,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-181" decimals="-3" id="f-728" unitRef="usd">790553000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-182" decimals="-3" id="f-729" unitRef="usd">788909000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-183" decimals="-3" id="f-730" unitRef="usd">380720000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-184" decimals="-3" id="f-731" unitRef="usd">366404000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent contextRef="c-3" decimals="-3" id="f-732" unitRef="usd">224448000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-4" decimals="-3" id="f-733" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-3" decimals="-3" id="f-734" unitRef="usd">946825000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-735" unitRef="usd">1155313000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-185" decimals="-5" id="f-736" unitRef="usd">575000000.0</us-gaap:DebtInstrumentFaceAmount>
    <insm:DebtInstrumentOptionToPurchaseAdditionalDebt contextRef="c-185" decimals="-5" id="f-737" unitRef="usd">75000000.0</insm:DebtInstrumentOptionToPurchaseAdditionalDebt>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-185" decimals="-5" id="f-738" unitRef="usd">15700000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-186" decimals="-5" id="f-739" unitRef="usd">559300000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-187" decimals="-5" id="f-740" unitRef="usd">450000000.0</us-gaap:DebtInstrumentFaceAmount>
    <insm:DebtInstrumentOptionToPurchaseAdditionalDebt contextRef="c-187" decimals="-5" id="f-741" unitRef="usd">50000000.0</insm:DebtInstrumentOptionToPurchaseAdditionalDebt>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-187" decimals="-5" id="f-742" unitRef="usd">14200000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c-188" decimals="-5" id="f-743" unitRef="usd">435800000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c-189" decimals="-5" id="f-744" unitRef="usd">225000000.0</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-190" decimals="-5" id="f-745" unitRef="usd">-17700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-185"
      decimals="2"
      id="f-746"
      unitRef="usdPerShare">32.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="c-191" decimals="INF" id="f-747" unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="c-192" decimals="INF" id="f-748" unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-191" decimals="INF" id="f-749" unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-192" decimals="INF" id="f-750" unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c-192"
      decimals="INF"
      id="f-751"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c-191"
      decimals="INF"
      id="f-752"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="c-193" decimals="INF" id="f-753" unitRef="day">45</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="c-194" decimals="INF" id="f-754" unitRef="day">45</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-193" decimals="INF" id="f-755" unitRef="day">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-194" decimals="INF" id="f-756" unitRef="day">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c-193"
      decimals="INF"
      id="f-757"
      unitRef="number">0.10</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c-194"
      decimals="INF"
      id="f-758"
      unitRef="number">0.10</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange contextRef="c-195" decimals="INF" id="f-759" unitRef="day">30</insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange>
    <insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange contextRef="c-196" decimals="INF" id="f-760" unitRef="day">30</insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="c-197" decimals="INF" id="f-761" unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="c-198" decimals="INF" id="f-762" unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-198" decimals="INF" id="f-763" unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-197" decimals="INF" id="f-764" unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c-197"
      decimals="INF"
      id="f-765"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c-198"
      decimals="INF"
      id="f-766"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-187" decimals="-5" id="f-767" unitRef="usd">309100000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-187" decimals="3" id="f-768" unitRef="number">0.076</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="c-187" decimals="-5" id="f-769" unitRef="usd">140900000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-185" decimals="-5" id="f-770" unitRef="usd">371600000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-185" decimals="3" id="f-771" unitRef="number">0.071</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="c-185" decimals="-5" id="f-772" unitRef="usd">203400000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <insm:ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining contextRef="c-199" id="f-773">P3Y11M1D</insm:ConvertibleDebtInstrumentDiscountAmortizationPeriodRemaining>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-200" decimals="-5" id="f-774" unitRef="usd">566100000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-122" decimals="-5" id="f-775" unitRef="usd">8900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-201" decimals="-5" id="f-776" unitRef="usd">224400000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-124" decimals="-5" id="f-777" unitRef="usd">600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c-1" id="f-778">The following table presents the carrying value of the Company's convertible notes balance (in thousands):&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.753%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.755%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Face value of outstanding convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,091)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224,448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity within the liability account for the six-month period ended June&#160;30, 2024 and year ended December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended &lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty financing agreement liability - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue Interest Payments paid and payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty financing agreement liability - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty financing issuance costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty issuance costs, unamortized - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred issuance costs, unamortized - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,866)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Royalty Financing Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:SecuredDebt contextRef="c-202" decimals="-3" id="f-779" unitRef="usd">800000000</us-gaap:SecuredDebt>
    <us-gaap:SecuredDebt contextRef="c-203" decimals="-3" id="f-780" unitRef="usd">800000000</us-gaap:SecuredDebt>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-202" decimals="-3" id="f-781" unitRef="usd">9447000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-203" decimals="-3" id="f-782" unitRef="usd">11091000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebtCurrent contextRef="c-202" decimals="-3" id="f-783" unitRef="usd">224448000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-203" decimals="-3" id="f-784" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-202" decimals="-3" id="f-785" unitRef="usd">566105000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-203" decimals="-3" id="f-786" unitRef="usd">788909000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c-204"
      decimals="INF"
      id="f-787"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <insm:DebtInstrumentRedemptionPricePerShare
      contextRef="c-204"
      decimals="INF"
      id="f-788"
      unitRef="usdPerShare">1001.17</insm:DebtInstrumentRedemptionPricePerShare>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-205" decimals="-6" id="f-789" unitRef="usd">350000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-206" decimals="3" id="f-790" unitRef="number">0.025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-207" decimals="4" id="f-791" unitRef="number">0.0775</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <insm:DebtInstrumentPercentOfInterestPayable contextRef="c-207" decimals="2" id="f-792" unitRef="number">0.50</insm:DebtInstrumentPercentOfInterestPayable>
    <us-gaap:DebtInstrumentTerm contextRef="c-207" id="f-793">P24M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-205" decimals="-5" id="f-794" unitRef="usd">15200000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromLoans contextRef="c-207" decimals="-5" id="f-795" unitRef="usd">334800000</us-gaap:ProceedsFromLoans>
    <us-gaap:PaidInKindInterest contextRef="c-1" decimals="-5" id="f-796" unitRef="usd">12600000</us-gaap:PaidInKindInterest>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="c-1" id="f-797">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the carrying value of the Company&#x2019;s Term Loan balance as of June&#160;30, 2024 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.169%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.541%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.103%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.276%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.103%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.277%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Original Term Loan balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid-in-kind interest capitalized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan issuance costs, unamortized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-208" decimals="-3" id="f-798" unitRef="usd">350000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-209" decimals="-3" id="f-799" unitRef="usd">350000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:AccumulatedCapitalizedInterestCosts contextRef="c-208" decimals="-3" id="f-800" unitRef="usd">40108000</us-gaap:AccumulatedCapitalizedInterestCosts>
    <us-gaap:AccumulatedCapitalizedInterestCosts contextRef="c-209" decimals="-3" id="f-801" unitRef="usd">27537000</us-gaap:AccumulatedCapitalizedInterestCosts>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-208" decimals="-3" id="f-802" unitRef="usd">9388000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-209" decimals="-3" id="f-803" unitRef="usd">11133000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-208" decimals="-3" id="f-804" unitRef="usd">380720000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-209" decimals="-3" id="f-805" unitRef="usd">366404000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-806">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, future principal repayments of debt for each of the years through maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.543%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-807" unitRef="usd">225000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-3" decimals="-3" id="f-808" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-3" decimals="-3" id="f-809" unitRef="usd">195054000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-3" decimals="-3" id="f-810" unitRef="usd">195054000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-3" decimals="-3" id="f-811" unitRef="usd">575000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <insm:LongTermDebtMaturityAfterYearFourAndThereafter contextRef="c-3" decimals="-3" id="f-812" unitRef="usd">0</insm:LongTermDebtMaturityAfterYearFourAndThereafter>
    <us-gaap:LongTermDebt contextRef="c-3" decimals="-3" id="f-813" unitRef="usd">1190108000</us-gaap:LongTermDebt>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock contextRef="c-1" id="f-814">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense related to debt and finance leases for the three and six months ended June&#160;30, 2024 and 2023 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.934%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.797%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty Financing Agreement interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Swap interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total debt interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebt contextRef="c-210" decimals="-3" id="f-815" unitRef="usd">2062000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-211" decimals="-3" id="f-816" unitRef="usd">2062000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-212" decimals="-3" id="f-817" unitRef="usd">4125000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-213" decimals="-3" id="f-818" unitRef="usd">4125000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-214" decimals="-3" id="f-819" unitRef="usd">12658000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-215" decimals="-3" id="f-820" unitRef="usd">11490000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-216" decimals="-3" id="f-821" unitRef="usd">25141000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-217" decimals="-3" id="f-822" unitRef="usd">22401000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-218" decimals="-3" id="f-823" unitRef="usd">4893000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-219" decimals="-3" id="f-824" unitRef="usd">4805000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-220" decimals="-3" id="f-825" unitRef="usd">9715000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-221" decimals="-3" id="f-826" unitRef="usd">9569000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-5" decimals="-3" id="f-827" unitRef="usd">1800000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-6" decimals="-3" id="f-828" unitRef="usd">2004000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-1" decimals="-3" id="f-829" unitRef="usd">3651000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-7" decimals="-3" id="f-830" unitRef="usd">3728000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestIncomeOther contextRef="c-5" decimals="-3" id="f-831" unitRef="usd">710000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c-6" decimals="-3" id="f-832" unitRef="usd">354000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c-1" decimals="-3" id="f-833" unitRef="usd">1464000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c-7" decimals="-3" id="f-834" unitRef="usd">427000</us-gaap:InterestIncomeOther>
    <insm:InterestExpenseExcludingFinanceLeaseInterestExpense contextRef="c-5" decimals="-3" id="f-835" unitRef="usd">20703000</insm:InterestExpenseExcludingFinanceLeaseInterestExpense>
    <insm:InterestExpenseExcludingFinanceLeaseInterestExpense contextRef="c-6" decimals="-3" id="f-836" unitRef="usd">20007000</insm:InterestExpenseExcludingFinanceLeaseInterestExpense>
    <insm:InterestExpenseExcludingFinanceLeaseInterestExpense contextRef="c-1" decimals="-3" id="f-837" unitRef="usd">41168000</insm:InterestExpenseExcludingFinanceLeaseInterestExpense>
    <insm:InterestExpenseExcludingFinanceLeaseInterestExpense contextRef="c-7" decimals="-3" id="f-838" unitRef="usd">39396000</insm:InterestExpenseExcludingFinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-5" decimals="-3" id="f-839" unitRef="usd">564000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-6" decimals="-3" id="f-840" unitRef="usd">612000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-1" decimals="-3" id="f-841" unitRef="usd">1141000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-7" decimals="-3" id="f-842" unitRef="usd">1226000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:InterestExpense contextRef="c-5" decimals="-3" id="f-843" unitRef="usd">21267000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-6" decimals="-3" id="f-844" unitRef="usd">20619000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-845" unitRef="usd">42309000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-7" decimals="-3" id="f-846" unitRef="usd">40622000</us-gaap:InterestExpense>
    <us-gaap:RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock contextRef="c-1" id="f-850">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;11.      Royalty Financing Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In October 2022, the Company entered into the Royalty Financing Agreement with OrbiMed. Under the Royalty Financing Agreement, OrbiMed paid the Company $150&#160;million in exchange for the right to receive, on a quarterly basis, royalties in an amount equal to 4% of ARIKAYCE global net sales prior to September 1, 2025 and 4.5% of ARIKAYCE global net sales on or after September 1, 2025, as well as 0.75% of brensocatib global net sales, if approved. In the event that OrbiMed has not received aggregate Revenue Interest Payments of at least $150&#160;million on or prior to March 31, 2028, the Company must make a one-time payment to OrbiMed for the difference between the $150&#160;million and the aggregated Revenue Interest Payments that have been paid. In addition, the royalty rate for ARIKAYCE will be increased beginning March 31, 2028 to the rate which would have resulted in aggregate Revenue Interest Payments as of March 31, 2028 equaling $150&#160;million. The total Revenue Interest Payments payable by the Company to OrbiMed are capped at 1.8x of the purchase price or up to a maximum of 1.9x of the purchase price under certain conditions. Net proceeds from the Royalty Financing Agreement, after deducting the lenders' fees and deal expenses of $3.8&#160;million were, $146.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Royalty Financing Agreement at the time of the transaction was based on the Company&#x2019;s estimates of future royalties expected to be paid to OrbiMed over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. This liability is being amortized using the effective interest method over the life of the arrangement, in accordance ASC 470, Debt and ASC 835, Interest. The initial annual effective interest rate was determined to be&#160;12.4%. The Company is utilizing the prospective method to account for subsequent changes in the estimated future payments to be made to OrbiMed and updates the effective interest rate on a quarterly basis.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the activity within the liability account for the six-month period ended June&#160;30, 2024 and year ended December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended &lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty financing agreement liability - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue Interest Payments paid and payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty financing agreement liability - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty financing issuance costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty issuance costs, unamortized - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred issuance costs, unamortized - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,866)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Royalty Financing Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Revenue Interest Payments payable in connection with the royalty financing agreement were $3.6 million and $3.3 million as of June&#160;30, 2024 and December&#160;31, 2023, respectively, which were recorded within accounts payable and accrued expenses on the consolidated balance sheet. Non-cash interest expense is recorded within interest expense in the consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:RepurchaseAgreementsResaleAgreementsSecuritiesBorrowedAndSecuritiesLoanedDisclosureTextBlock>
    <insm:ProceedsFromRoyaltyFinancing contextRef="c-126" decimals="-6" id="f-851" unitRef="usd">150000000</insm:ProceedsFromRoyaltyFinancing>
    <insm:DebtInstrumentRoyaltyStatedPercentage contextRef="c-127" decimals="2" id="f-852" unitRef="number">0.04</insm:DebtInstrumentRoyaltyStatedPercentage>
    <insm:DebtInstrumentRoyaltyStatedPercentage contextRef="c-128" decimals="3" id="f-853" unitRef="number">0.045</insm:DebtInstrumentRoyaltyStatedPercentage>
    <insm:DebtInstrumentRoyaltyStatedPercentage contextRef="c-129" decimals="4" id="f-854" unitRef="number">0.75</insm:DebtInstrumentRoyaltyStatedPercentage>
    <insm:ProceedsFromRoyaltyFinancing contextRef="c-126" decimals="-6" id="f-855" unitRef="usd">150000000</insm:ProceedsFromRoyaltyFinancing>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-130" decimals="-6" id="f-856" unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-126" decimals="-6" id="f-857" unitRef="usd">150000000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <insm:DebtInstrumentRoyaltyPayableMaximum
      contextRef="c-225"
      decimals="INF"
      id="f-858"
      unitRef="number">1.8</insm:DebtInstrumentRoyaltyPayableMaximum>
    <insm:DebtInstrumentRoyaltyPayableMaximum
      contextRef="c-226"
      decimals="INF"
      id="f-859"
      unitRef="number">1.9</insm:DebtInstrumentRoyaltyPayableMaximum>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c-130" decimals="-5" id="f-860" unitRef="usd">3800000</us-gaap:DebtInstrumentFeeAmount>
    <insm:ProceedsFromRoyaltyFinancingAgreementNet contextRef="c-126" decimals="-5" id="f-861" unitRef="usd">146200000</insm:ProceedsFromRoyaltyFinancingAgreementNet>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-130" decimals="3" id="f-862" unitRef="number">0.124</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-227" decimals="-3" id="f-863" unitRef="usd">158162000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-228" decimals="-3" id="f-864" unitRef="usd">151538000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:PaymentsForRoyalties contextRef="c-229" decimals="-3" id="f-865" unitRef="usd">6634000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties contextRef="c-230" decimals="-3" id="f-866" unitRef="usd">12222000</us-gaap:PaymentsForRoyalties>
    <us-gaap:InterestExpenseDebt contextRef="c-229" decimals="-3" id="f-867" unitRef="usd">9715000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-230" decimals="-3" id="f-868" unitRef="usd">18846000</us-gaap:InterestExpenseDebt>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-231" decimals="-3" id="f-869" unitRef="usd">161243000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-227" decimals="-3" id="f-870" unitRef="usd">158162000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-227" decimals="-3" id="f-871" unitRef="usd">3128000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-228" decimals="-3" id="f-872" unitRef="usd">3523000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-232" decimals="-3" id="f-873" unitRef="usd">262000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-233" decimals="-3" id="f-874" unitRef="usd">521000</us-gaap:AmortizationOfFinancingCosts>
    <insm:DebtIssuanceCostsOther contextRef="c-229" decimals="-3" id="f-875" unitRef="usd">0</insm:DebtIssuanceCostsOther>
    <insm:DebtIssuanceCostsOther contextRef="c-230" decimals="-3" id="f-876" unitRef="usd">126000</insm:DebtIssuanceCostsOther>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-231" decimals="-3" id="f-877" unitRef="usd">2866000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-227" decimals="-3" id="f-878" unitRef="usd">3128000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-3" decimals="-3" id="f-879" unitRef="usd">158377000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-880" unitRef="usd">155034000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-234" decimals="-5" id="f-881" unitRef="usd">3600000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-235" decimals="-5" id="f-882" unitRef="usd">3300000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-883">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;12.      Shareholders' Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;As of June&#160;30, 2024, the Company had 500,000,000 shares of common stock authorized with a par value of $0.01 per share and 166,666,599 shares of common stock issued and outstanding. In addition, as of June&#160;30, 2024, the Company had reserved 23,430,187 shares of common stock for issuance upon the exercise of outstanding stock options, 3,425,045 shares of common stock for issuance upon the vesting of RSUs and 664,724 shares for issuance upon the vesting of PSUs. The Company has also reserved 23,438,430 shares of common stock in the aggregate for issuance upon conversion of the 2025 Convertible Notes and 2028 Convertible Notes, subject to adjustment in accordance with the applicable indentures. In connection with the Business Acquisition, the Company reserved 9,406,112 shares of the Company&#x2019;s common stock, subject to certain closing-related reductions. The shares of the Company&#x2019;s common stock reserved in connection with the Motus acquisition were partly issued as acquisition consideration at closing and on the first and second anniversaries of the closing date of the acquisition, and will also be issued upon the third anniversary of the closing date of the acquisition and upon the achievement of certain development and regulatory milestone events, subject to certain reductions. The shares of the Company&#x2019;s common stock reserved in connection with the AlgaeneX acquisition will be issued upon the achievement of a development milestone event, subject to certain reductions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Of the 9,406,112 shares reserved, subject to certain closing-related reductions, the Company issued 2,889,367 shares of the Company's common stock in connection with the Business Acquisition (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 16 - Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;) in the third quarter of 2021, after certain closing-related deductions. In the third quarter of 2022, the Company issued 171,427 shares of the Company's common stock to fulfill the payment required to Motus equityholders on the first anniversary of the Business Acquisition. In the third quarter of 2023, the Company issued 177,203 shares of the Company's common stock to fulfill the payment required to Motus equityholders on the second anniversary of the Business Acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the second quarter of 2023, in connection with the Company's acquisition of Adrestia Therapeutics Ltd. (Adrestia), the Company issued 3,430,867 shares of the Company's common stock as consideration at closing. See &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 16 - Acquisitions&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the Company&#x2019;s acquisition of Vertuis Bio, Inc. (Vertuis), the Company reserved &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;550,000&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; shares of the Company&#x2019;s common stock, subject to future adjustment. An aggregate of 500,000 of the reserved shares were issued as acquisition consideration at closing. See &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 16 - Acquisitions&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 17 - Subsequent Events&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; for further details. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2022, the Company completed an underwritten offering of 13,750,000 shares of the Company's common stock at a public offering price of $20.00 per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and offering expense of $16.2&#160;million, were $258.8&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the first quarter of 2021, the Company entered into a sales agreement with SVB Leerink LLC (now known as Leerink Partners LLC) (Leerink), to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $250.0&#160;million, from time to time, through an &#x201c;at the market&#x201d; equity offering program (the ATM program), under which Leerink acted as sales agent. In&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; 2023, the Company issued and sold an aggregate of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;6,503,041&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; shares of common stock through the ATM program at a weighted-average public offering price of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$24.12&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; per share and received net proceeds of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$152.2 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the first quarter of 2024, the Company entered into a new sales agreement with Leerink to sell shares of the Company's common stock, with aggregate gross sales proceeds of up to $500.0 million, from time to time, through a new &#x201c;at the market&#x201d; equity offering program (the new ATM program), under which Leerink acts as sales agent. In connection with entering into the new ATM program, the Company terminated the ATM program. The Company has not issued any shares under the new ATM program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2024, the Company completed an underwritten offering of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;14,514,562&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; shares of the Company's common stock at a public offering price of $51.50 per share. 1,893,203 of the shares of common stock were issued pursuant to the exercise in full of the underwriters' option to purchase additional shares. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and estimated offering expenses of $34.3&#160;million, were $713.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;As of June&#160;30, 2024, the Company had 200,000,000 shares of preferred stock authorized with a par value of $0.01 per share and no shares of preferred stock were issued and outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-884" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-885"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-886" unitRef="shares">166666599</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-887" unitRef="shares">166666599</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-236"
      decimals="INF"
      id="f-888"
      unitRef="shares">23430187</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-237"
      decimals="INF"
      id="f-889"
      unitRef="shares">3425045</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-238"
      decimals="INF"
      id="f-890"
      unitRef="shares">664724</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-202"
      decimals="INF"
      id="f-891"
      unitRef="shares">23438430</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-239"
      decimals="INF"
      id="f-892"
      unitRef="shares">9406112</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-240"
      decimals="INF"
      id="f-893"
      unitRef="shares">9406112</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-241"
      decimals="INF"
      id="f-894"
      unitRef="shares">2889367</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-242"
      decimals="INF"
      id="f-895"
      unitRef="shares">171427</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-243"
      decimals="INF"
      id="f-896"
      unitRef="shares">177203</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-244"
      decimals="INF"
      id="f-897"
      unitRef="shares">3430867</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-245"
      decimals="INF"
      id="f-898"
      unitRef="shares">550000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-246"
      decimals="INF"
      id="f-899"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-247"
      decimals="INF"
      id="f-900"
      unitRef="shares">13750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-248"
      decimals="2"
      id="f-901"
      unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-249" decimals="-5" id="f-902" unitRef="usd">16200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-247" decimals="-5" id="f-903" unitRef="usd">258800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <insm:CommonStockAuthorizedAggregateGrossSalesProceeds contextRef="c-250" decimals="-5" id="f-904" unitRef="usd">250000000</insm:CommonStockAuthorizedAggregateGrossSalesProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-251"
      decimals="INF"
      id="f-905"
      unitRef="shares">6503041</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-252"
      decimals="INF"
      id="f-906"
      unitRef="usdPerShare">24.12</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-251" decimals="-5" id="f-907" unitRef="usd">152200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <insm:CommonStockAuthorizedAggregateGrossSalesProceeds contextRef="c-253" decimals="-5" id="f-908" unitRef="usd">500000000.0</insm:CommonStockAuthorizedAggregateGrossSalesProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-254"
      decimals="INF"
      id="f-909"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-255"
      decimals="INF"
      id="f-910"
      unitRef="shares">14514562</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-256"
      decimals="2"
      id="f-911"
      unitRef="usdPerShare">51.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-257"
      decimals="INF"
      id="f-912"
      unitRef="shares">1893203</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-258" decimals="-5" id="f-913" unitRef="usd">34300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-255" decimals="-5" id="f-914" unitRef="usd">713200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-915" unitRef="shares">200000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-916"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-917" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-918" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-919">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;13.      Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company's current equity compensation plan, the Insmed Incorporated Amended and Restated 2019 Incentive Plan (the 2019 Incentive Plan), was approved by shareholders at the Company's Annual Meeting of Shareholders on May&#160;13, 2024.&#160;The 2019 Incentive Plan replaced the Insmed Incorporated 2019 Incentive Plan. The 2019 Incentive Plan is administered by the Compensation Committee of the Board of Directors of the Company.&#160;Under the terms of the 2019 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards to eligible employees and non-employee directors.&#160;At the May 2024 Annual Meeting of Shareholders, the Company's shareholders approved Amendment No. 1 to the 2019 Incentive Plan, which provides for the issuance of an additional 3,000,000 shares under the plan. As of June&#160;30, 2024, 4,780,711 shares remain available for future issuance under the 2019 Incentive Plan. The 2019 Incentive Plan will terminate on April 3, 2029 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options to new hires, which awards are made pursuant to the Nasdaq's inducement grant exception to the shareholder approval requirement for grants of equity compensation. During the six months ended June&#160;30, 2024, the Company granted inducement stock options covering 899,330 shares of the Company's common stock to new employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 15, 2018, the 2018 Employee Stock Purchase Plan (ESPP) was approved by shareholders at the Company's 2018 Annual Meeting of Shareholders. The Company has reserved the following for issuance under the ESPP: (i) 1,000,000 shares of common stock,&#160;plus&#160;(ii)&#160;commencing on January&#160;1, 2019 and ending on December&#160;31, 2023, an additional number of shares to be added on the first day of each calendar year equal to the lesser of (A) 1,200,000 shares of common stock, (B) 2% of the number of outstanding shares of common stock on such date and (C)&#160;an amount determined by the administrator.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;As of June&#160;30, 2024, there was $168.6&#160;million of unrecognized compensation expense related to unvested stock options. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, the Company had performance-conditioned options totaling 114,780 shares outstanding which had not yet met the recognition criteria. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;As of June&#160;30, 2024, there was $72.8&#160;million of unrecognized compensation expense related to unvested RSU awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Performance Stock Units&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;As of June&#160;30, 2024, there were 265,887 unvested PSUs outstanding with an unrecognized compensation expense of $10.4 million. The PSUs are subject to two performance conditions based on brensocatib milestones. As of June 30, 2024, the Company achieved the first performance condition by issuing a press release announcing certain topline results from the ASPEN trial by June 30, 2024. The potential payout of the awards ranges from 0% to 250% of the target, dependent on a market condition that is based on the Company's total shareholder return compared to the NASDAQ Biotechnology Index, subject to certain adjustments (the Peer Group). During the second quarter of 2024, the Company's total shareholder return was compared to the Company's Peer Group and the potential payout of the awards was determined to be 250% of the target, pending the achievement of the second performance condition, the acceptance of an NDA by the FDA for brensocatib, and satisfaction of the remaining service condition to such awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options, RSUs and the ESPP during the three and six months ended June&#160;30, 2024 and 2023 (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.805%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.448%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to PSUs during the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended June&#160;30, 2024 or June&#160;30, 2023, as the second performance condition associated with the PSU awards was not probable as of either date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-259"
      decimals="INF"
      id="f-920"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-260"
      decimals="INF"
      id="f-921"
      unitRef="shares">4780711</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-922" unitRef="shares">899330</insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-261"
      decimals="INF"
      id="f-923"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-262"
      decimals="INF"
      id="f-924"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c-262"
      decimals="INF"
      id="f-925"
      unitRef="number">0.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-236" decimals="-5" id="f-926" unitRef="usd">168600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-236"
      decimals="INF"
      id="f-927"
      unitRef="shares">114780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-237" decimals="-5" id="f-928" unitRef="usd">72800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-238"
      decimals="INF"
      id="f-929"
      unitRef="shares">265887</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-238" decimals="-5" id="f-930" unitRef="usd">10400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-263"
      decimals="INF"
      id="f-931"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-264"
      decimals="INF"
      id="f-932"
      unitRef="number">2.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="c-71" decimals="2" id="f-933" unitRef="number">2.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-934">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate stock-based compensation expense recorded in the consolidated statements of comprehensive loss related to stock options, RSUs and the ESPP during the three and six months ended June&#160;30, 2024 and 2023 (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.805%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.390%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.538%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.448%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-265" decimals="-3" id="f-935" unitRef="usd">11301000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-266" decimals="-3" id="f-936" unitRef="usd">8787000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-267" decimals="-3" id="f-937" unitRef="usd">21636000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-268" decimals="-3" id="f-938" unitRef="usd">16686000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-269" decimals="-3" id="f-939" unitRef="usd">11985000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-270" decimals="-3" id="f-940" unitRef="usd">9571000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-271" decimals="-3" id="f-941" unitRef="usd">23100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-272" decimals="-3" id="f-942" unitRef="usd">18116000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-273" decimals="-3" id="f-943" unitRef="usd">23286000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-274" decimals="-3" id="f-944" unitRef="usd">18358000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-275" decimals="-3" id="f-945" unitRef="usd">44736000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-276" decimals="-3" id="f-946" unitRef="usd">34802000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-74" decimals="INF" id="f-947" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-73" decimals="INF" id="f-948" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-949">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;14.      Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded a provision for income taxes of $0.8 million and $0.5 million for the three months ended June 30, 2024 and 2023, respectively, and $1.4 million and $1.0 million for the six months ended June 30, 2024 and 2023, respectively. The provisions recorded for the three and six months ended June&#160;30, 2024 and 2023 are primarily a result of certain of the Company's international subsidiaries, which had taxable income during the periods. Additionally, the Company is impacted by certain state taxes which effectively impose income tax on modified gross revenues. In jurisdictions where the Company has net losses, there was a full valuation allowance recorded against the Company's deferred tax assets and therefore no tax benefit was recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to US federal, state and international income taxes and the statute of limitations for tax audit is open for the Company&#x2019;s federal tax returns for the years ended 2020 and later, generally open for certain states for the years 2019 and later, and generally open for international jurisdictions for the years 2018 and later. The Company has incurred net operating losses since inception, except for the year ended December&#160;31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin. As of June&#160;30, 2024 and December&#160;31, 2023, the Company had recorded reserves for unrecognized income tax benefits against certain deferred tax assets in the US.&#160;However, given the Company&#x2019;s valuation allowance position, these reserves do not have an impact on the balance sheet as of June&#160;30, 2024 and December&#160;31, 2023 or the consolidated statements of comprehensive loss for the three and six months ended June&#160;30, 2024 and 2023.&#160;The Company has not recorded any accrued interest or penalties related to uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Organisation for Economic Co-operation and Development (OECD) recently published a framework to implement a global corporate minimum income tax rate of 15% on income arising in low-tax jurisdictions (Pillar Two). The Pillar Two proposed legislation is applicable to multinational corporations with global revenue exceeding &#x20ac;750 million for at least two years of the preceding four years. Over 140 countries have agreed in principle to implement Pillar Two and many have, or are in the process of, enacting related legislation. The Pillar Two legislation is not anticipated to be effective for the Company until the Company&#x2019;s annual global revenues have exceeded the &#x20ac;750 million threshold. The Company is still evaluating the potential consequences of Pillar Two on its longer-term financial position.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-5" id="f-950" unitRef="usd">800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-5" id="f-951" unitRef="usd">500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-952" unitRef="usd">1400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-5" id="f-953" unitRef="usd">1000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="INF" id="f-954" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-3" decimals="INF" id="f-955" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-956">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;15.      Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense charged to operations was $2.8 million and $2.1 million for the three months ended June 30, 2024 and 2023, respectively, and $5.9 million and $4.3 million for the six months ended June 30, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-5" decimals="-5" id="f-957" unitRef="usd">2800000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-6" decimals="-5" id="f-958" unitRef="usd">2100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-959" unitRef="usd">5900000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-7" decimals="-5" id="f-960" unitRef="usd">4300000</us-gaap:OperatingLeaseCost>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-961">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;16.      Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Asset Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Adrestia Therapeutics Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, the Company acquired all of the issued and outstanding share capital of Adrestia, a privately held, preclinical stage company. At the closing of the transaction, the Company issued an aggregate of 3,430,867 shares of the Company&#x2019;s common stock to Adrestia&#x2019;s former shareholders (collectively, the Adrestia shareholders). The closing share price on the date of the transaction was $21.10, resulting in a purchase price of $72.4 million. The Adrestia shareholders may also become entitled to receive contingent payments up to an aggregate of $326.5 million in cash upon the achievement of certain development, regulatory and commercial milestone events, as well as royalty payments based upon a low single-digit percentage of net sales of certain products, both subject to the terms and conditions of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The shares of the Company&#x2019;s common stock issued to the Adrestia shareholders were issued pursuant to Section 4(a)(2) of the Securities Act of 1933 (and, with respect to certain Adrestia shareholders, in reliance on Regulation S promulgated under the Securities Act of 1933). The Company did not receive any net proceeds from the issuance of common stock to the Adrestia shareholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the acquisition under ASC 805 and ASU 2017-01 and concluded that substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets and accounted for the transaction as an asset acquisition. The Company determined that the IPR&amp;amp;D acquired did not have any future alternative use and, in accordance with ASC 730, Research and Development, expensed the assets within research and development in the consolidated statement of comprehensive loss as of the date of the acquisition. The Company recognized $76.5 million as IPR&amp;amp;D expense, after adjusting for working capital assumed in connection with the asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vertuis Bio, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, the Company acquired Vertuis, a privately held, preclinical stage company. At the closing of the transaction, the Company issued an aggregate of 500,000 shares of the Company&#x2019;s common stock to Vertuis&#x2019; former stockholders and an individual who are entitled to receive a portion of the acquisition consideration (collectively, the Vertuis equityholders). The closing share price on the date of the transaction was $18.50. The Company is obligated to pay the Vertuis equityholders up to an aggregate of $23.0&#160;million in cash upon the achievement of certain development and regulatory milestone events, and up to an aggregate of $63.8&#160;million in cash upon the achievement&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of certain net sales-based milestone events, in each case, subject to certain reductions. See &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 17 - Subsequent Events&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The shares of the Company&#x2019;s common stock issued to the Vertuis equityholders were issued pursuant to Section 4(a)(2) of the Securities Act of 1933.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the purchase price (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.543%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.276%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of Insmed common stock issued on closing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of Insmed common stock issued in July 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the acquisition under ASC 805 and ASU 2017-01 and concluded that substantially all of the fair value of the gross assets acquired are concentrated in a single identifiable asset or a group of similar identifiable assets and accounted for the transaction as an asset acquisition. The Company determined that the assets acquired did not have any future alternative use and, in accordance with ASC 730, Research and Development, expensed the assets within research and development in the consolidated statement of comprehensive loss as of the date of the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Combination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 4, 2021, the Company acquired all of the equity interests of Motus and AlgaeneX, each a privately held, preclinical stage company. In connection with the closing of the Company&#x2019;s acquisition of Motus, the Company issued an aggregate of 2,889,367 shares of the Company&#x2019;s common stock, following certain closing-related reductions, to Motus&#x2019;s former stockholders and option holders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, Motus equityholders), subject to certain adjustments&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company is obligated to issue to Motus equityholders an aggregate of 184,433 shares of the Company&#x2019;s common stock on each of the first, second and third anniversaries of the closing date and up to 5,348,572 shares in the aggregate upon the achievement of certain development and regulatory milestone &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;events, and to pay to the Motus equityholders an aggregate of $35&#160;million upon the achievement of certain net sales-based milestones and a portion of the value of a priority review voucher (to the extent issued to the Company), in each case, subject to certain reductions. During August 2022 and August 2023, the Company fulfilled the payments due on the first and second anniversaries of the closing date by issuing 171,427 shares and 177,203 shares of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company's common stock, respectively, after certain reductions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing of the Company&#x2019;s acquisition of AlgaeneX, the Company paid $1.5&#160;million in cash to AlgaeneX&#x2019;s former stockholders and certain individuals who are entitled to receive a portion of the acquisition consideration (collectively, the AlgaeneX equityholders). The Company is obligated to issue to the AlgaeneX equityholders an aggregate of 368,867 shares of the Company&#x2019;s common stock upon the achievement of a development milestone event and pay to the AlgaeneX equityholders a mid-single digits licensing fee on certain future payments received by the Company in licensing transactions for AlgaeneX&#x2019;s manufacturing technology, in each case, subject to certain reductions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The shares of the Company&#x2019;s common stock issued to the Motus equityholders and the AlgaeneX equityholders were issued, and the shares issuable in the future will be issued, pursuant to Section 4(a)(2) of the Securities Act of 1933, and the numbers of such issued and issuable shares was calculated based on a per share value of $27.11, which was the weighted average price per share of the Company's common stock preceding the closing of the Business Acquisition for the 45 consecutive trading day period beginning on May 24, 2021. The Company will not receive any proceeds from the issuance of common stock to the Motus equityholders or the AlgaeneX equityholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Business Acquisition under ASC 805 and ASU 2017-01. The Company concluded that substantially all of the fair value of the gross assets acquired is not concentrated in a single identifiable asset or a group of similar identifiable assets. The transaction does not pass the screen test and thus management performed a full assessment to determine if the acquired entities met the definition of a business. For the full assessment, management considered whether it has acquired (a) inputs, (b) substantive processes, and (c) outputs. Under ASC 805, to be considered a business, a set of activities and assets is required to have only the first two of the three elements, which together are or will be used in the future to create outputs. Management determined that the acquired entities met the definition of a business since the Company acquired inputs and substantive processes capable of producing outputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Therefore, the transaction has been accounted for under the acquisition method of accounting. Under the acquisition method, the total purchase price of the acquisition is allocated to the net tangible and identifiable intangible assets acquired and liabilities assumed based on the fair values as of the date of the acquisition. The fair value of the consideration totaled approximately $165.5&#160;million. The results of Motus's and AlgaeneX's operations have been included in the Company's consolidated statements of comprehensive loss beginning on the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of IPR&amp;amp;D was capitalized as of the acquisition date and accounted for as indefinite-lived intangible assets until completion or disposition of the assets or abandonment of the associated research and development efforts. Upon successful completion of the development efforts, the useful lives of the IPR&amp;amp;D assets will be determined based on the anticipated period of regulatory exclusivity and will be amortized within operating expenses. Until that time, the IPR&amp;amp;D assets will be subject to impairment testing and will not be amortized. The goodwill recorded related to the acquisition is the excess of the fair value of the consideration transferred by the acquirer over the fair value of the net identifiable assets acquired and liabilities assumed at the date of acquisition. The goodwill recorded is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <insm:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="c-277"
      decimals="INF"
      id="f-962"
      unitRef="shares">3430867</insm:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <us-gaap:SharePrice
      contextRef="c-21"
      decimals="2"
      id="f-963"
      unitRef="usdPerShare">21.10</us-gaap:SharePrice>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-277" decimals="-5" id="f-964" unitRef="usd">72400000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration contextRef="c-277" decimals="-5" id="f-965" unitRef="usd">326500000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff contextRef="c-54" decimals="-5" id="f-966" unitRef="usd">76500000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <insm:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="c-278"
      decimals="INF"
      id="f-967"
      unitRef="shares">500000</insm:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <us-gaap:SharePrice
      contextRef="c-279"
      decimals="2"
      id="f-968"
      unitRef="usdPerShare">18.50</us-gaap:SharePrice>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration contextRef="c-280" decimals="-5" id="f-969" unitRef="usd">23000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration contextRef="c-281" decimals="-5" id="f-970" unitRef="usd">63800000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionTableTextBlock contextRef="c-1" id="f-971">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the purchase price (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.543%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.276%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.146%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of Insmed common stock issued on closing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of Insmed common stock issued in July 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable contextRef="c-278" decimals="-4" id="f-972" unitRef="usd">9250000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration contextRef="c-278" decimals="-4" id="f-973" unitRef="usd">1000000.00</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-278" decimals="-4" id="f-974" unitRef="usd">10250000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-282"
      decimals="INF"
      id="f-975"
      unitRef="shares">2889367</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-91"
      decimals="INF"
      id="f-976"
      unitRef="shares">184433</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-92"
      decimals="INF"
      id="f-977"
      unitRef="shares">184433</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-93"
      decimals="INF"
      id="f-978"
      unitRef="shares">184433</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares
      contextRef="c-98"
      decimals="INF"
      id="f-979"
      unitRef="shares">5348572</insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-283" decimals="-6" id="f-980" unitRef="usd">35000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-94"
      decimals="INF"
      id="f-981"
      unitRef="shares">171427</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-95"
      decimals="INF"
      id="f-982"
      unitRef="shares">177203</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-284" decimals="-5" id="f-983" unitRef="usd">1500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares
      contextRef="c-99"
      decimals="INF"
      id="f-984"
      unitRef="shares">368867</insm:BusinessCombinationContingentConsiderationEquityInterestIssuedAndIssuableNumberOfShares>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="c-285"
      decimals="2"
      id="f-985"
      unitRef="usdPerShare">27.11</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="c-286"
      decimals="2"
      id="f-986"
      unitRef="usdPerShare">27.11</us-gaap:BusinessAcquisitionSharePrice>
    <insm:BusinessAcquisitionConsecutiveTradingDayPeriod contextRef="c-287" decimals="INF" id="f-987" unitRef="days">45</insm:BusinessAcquisitionConsecutiveTradingDayPeriod>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-288" decimals="-5" id="f-988" unitRef="usd">165500000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-989">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;17.      Subsequent Events&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Conversions of 2025 Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of August 7, 2024, holders of $224.7&#160;million aggregate principal amount of the outstanding 2025 Convertible Notes elected to convert their notes into shares of the Company's&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; common stock at a conversion rate of 25.5384 shares of common stock per $1,000 principal amount of 2025 Convertible Notes (equivalent to an initial conversion price of approximately $39.16 per share of common stock). These conversions will result in the issuance of an aggregate of 5,739,433 shares of the Company&#x2019;s common stock. Unless earlier converted, on the Redemption Date, the remaining $0.3&#160;million aggregate principal amount of 2025 Convertible Notes outstanding will be redeemed by the Company at the Redemption Price. See&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Note 10 - Debt&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Conversions of 2028 Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 1, 2024, the 2028 Convertible Notes became convertible by the holders of such notes due to the satisfaction of the Stock Price Convertibility Trigger applicable to such notes. The current conversion rate for the 2028 Convertible Notes is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.7692 shares of common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $32.50 per share of comm&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on stock). The Company has elected to settle any conversions of the 2028 Convertible Notes in shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of August 2, 20&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;24, holders of nine thousand dollars of aggregate principal amount of 2028 Convertible Notes elected to convert their notes, resulting in an issuance of an aggregate of 276 shares of the Company&#x2019;s common stock. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The 2028 Convertible Notes will only be convertible during the third quarter of 2024 unless another triggering event occurs. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;See&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; Note 10 - Debt &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Vertuis Deferred Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2024, the Company issued the Vertuis equityholders an additional $1.0&#160;million of shares of the Company's common stock, or 14,773 shares of common stock, based on the closing share price on June 28, 2024. See Note 16 &#x2013; Acquisitions for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c-289" decimals="-5" id="f-990" unitRef="usd">224700000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-290"
      decimals="2"
      id="f-991"
      unitRef="usdPerShare">39.16</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c-289"
      decimals="INF"
      id="f-992"
      unitRef="shares">5739433</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockAmountIssued1 contextRef="c-289" decimals="-5" id="f-993" unitRef="usd">300000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-291"
      decimals="2"
      id="f-994"
      unitRef="usdPerShare">32.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ConversionOfStockAmountIssued1 contextRef="c-292" decimals="-3" id="f-995" unitRef="usd">9000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c-292"
      decimals="INF"
      id="f-996"
      unitRef="shares">276</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration contextRef="c-293" decimals="-5" id="f-997" unitRef="usd">1000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <insm:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="c-293"
      decimals="INF"
      id="f-998"
      unitRef="shares">14773</insm:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-1" id="f-1001">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our policy governing transactions in our securities by our directors, officers and employees permits our directors, officers and employees to enter into trading plans complying with Rule 10b5-1 under the Exchange Act. The following table describes the written plans for the sale of our securities adopted, modified or terminated by our executive officers and directors during the second quarter of 2024, each of which was entered into during an open trading window and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (each, a Trading Plan).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.062%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.769%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.850%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.433%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Name and Title&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Date of Adoption of Trading Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Scheduled Start Date of Trading Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Scheduled Expiration Date of Trading Plan (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maximum Shares Subject to Trading Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Date Plan Terminated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;S. Nicole Schaeffer&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chief People Strategy Officer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2/27/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/03/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5/21/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,734&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;06/07/2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/11/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9/10/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;04/01/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,309&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Martina Flammer&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chief Medical Officer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/07/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9/06/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;08/29/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370,536&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Michael Smith&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Chief Legal Officer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6/13/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9/13/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;05/21/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,871&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan&#x2019;s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-5" id="f-1002">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-5" id="f-1003">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:TrdArrIndName contextRef="c-295" id="f-1004">S. Nicole Schaeffer</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-295" id="f-1005">Chief People Strategy Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-295" id="f-1006">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-295" id="f-1007">2/27/2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-296"
      decimals="INF"
      id="f-1008"
      unitRef="shares">63734</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrTerminationDate contextRef="c-295" id="f-1009">06/07/2024</ecd:TrdArrTerminationDate>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-295" id="f-1010">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-297" id="f-1011">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-297" id="f-1012">6/11/2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-297" id="f-1013">04/01/2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-298"
      decimals="INF"
      id="f-1014"
      unitRef="shares">46309</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-299" id="f-1015">Martina Flammer</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-299" id="f-1016">Chief Medical Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-299" id="f-1017">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-299" id="f-1018">6/07/2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrExpirationDate contextRef="c-299" id="f-1019">08/29/2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-300"
      decimals="INF"
      id="f-1020"
      unitRef="shares">370536</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-301" id="f-1021">Michael Smith</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-301" id="f-1022">Chief Legal Officer</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate contextRef="c-301" id="f-1023">6/13/2024</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-301" id="f-1024">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrExpirationDate contextRef="c-301" id="f-1025">05/21/2025</ecd:TrdArrExpirationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-302"
      decimals="INF"
      id="f-1026"
      unitRef="shares">27871</ecd:TrdArrSecuritiesAggAvailAmt>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
